WO2006124875A2 - Diarylsulfone sulfonamides and use therof - Google Patents

Diarylsulfone sulfonamides and use therof Download PDF

Info

Publication number
WO2006124875A2
WO2006124875A2 PCT/US2006/018886 US2006018886W WO2006124875A2 WO 2006124875 A2 WO2006124875 A2 WO 2006124875A2 US 2006018886 W US2006018886 W US 2006018886W WO 2006124875 A2 WO2006124875 A2 WO 2006124875A2
Authority
WO
WIPO (PCT)
Prior art keywords
benzenesulfonamide
phenylsulfonyl
sulfonyl
methyl
trifluoromethyl
Prior art date
Application number
PCT/US2006/018886
Other languages
French (fr)
Other versions
WO2006124875A3 (en
Inventor
Ariamala Gopalsamy
William Jay Moore
Jeffery Curtis Kern
Albert John Molinari
Mengxiao Shi
Gregory Scott Welmaker
Matthew Allan Wilson
Girija Krishnamurthy
Thomas Joseph Commons
Michael Byron Webb
Richard P. Woodworth
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Priority to JP2008511473A priority Critical patent/JP2008540579A/en
Priority to BRPI0610009-0A priority patent/BRPI0610009A2/en
Priority to CA002607326A priority patent/CA2607326A1/en
Priority to AU2006247334A priority patent/AU2006247334A1/en
Priority to EP06770422A priority patent/EP1879859A2/en
Publication of WO2006124875A2 publication Critical patent/WO2006124875A2/en
Publication of WO2006124875A3 publication Critical patent/WO2006124875A3/en
Priority to IL187269A priority patent/IL187269A0/en
Priority to NO20075781A priority patent/NO20075781L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3882—Arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/20—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4056—Esters of arylalkanephosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Definitions

  • the present invention relates to novel diarylsulfone sulfonamides that act, for example, as modulators of secreted frizzled-related protein- 1.
  • the present invention also relates to processes for the preparation of diarylsulfone sulfonamides and to their use in treating various diseases and disorders.
  • Bone remodeling the process by which the adult human skeleton is continuously renewed, is carried out by osteoclasts and osteoblasts, two specialized cell types that originate from hematopoietic and mesenchymal progenitors of the bone marrow, respectively.
  • a continuous and orderly supply of these cells is believed to be essential for skeletal homeostasis, as increased or decreased production of osteoclasts or osteoblasts and/or changes in the rate of their apoptosis are largely responsible for the imbalance between bone resorption and formation that underlies several systemic or localized bone diseases.
  • enhanced osteoclast activity has been found to play a major role in the pathogenesis of postmenopausal osteoporosis, Paget's disease, lytic bone metastases, multiple myeloma, hyperparathyroidism, rheumatoid arthritis, periodontitis, and hypercalcemia of malignancy.
  • Wnt proteins have been identified as a family of growth factors consisting of more than a dozen structurally related molecules that are involved in the regulation of fundamental biological processes such as apoptosis, embryogenesis, organogenesis, morphogenesis and tumorigenesis (Nusse and Varmus, Cell 1992, 69:1073-1087).
  • Wnt polypeptides are multipotent factors and have biological activities similar to those of other secretory proteins such as transforming growth factor (TGF)- ⁇ , fibroblast growth factors (FGFs), nerve growth factor (NGF), and bone morphogenetic proteins (BMPs).
  • TGF transforming growth factor
  • FGFs fibroblast growth factors
  • NGF nerve growth factor
  • BMPs bone morphogenetic proteins
  • Frizzled proteins contain an amino terminal signal sequence for secretion, a cysteine-rich domain (CRD) that is thought to bind Wnt, seven putative transmembrane domains that resemble a G-protein coupled receptor, and a cytoplasmic carboxyl terminus.
  • CCD cysteine-rich domain
  • LDL low-density lipoprotein
  • LRP low-density lipoprotein receptor-related proteins
  • the first secreted frizzled-related protein was named "Frzb” (for "frizzled motif in bone development") and was purified and cloned from bovine articular cartilage extracts based on its ability to stimulate in vivo chondrogenic activity in rats (Hoang et al, J. Biol Chem. 1996, 271 :26131-26137; Jones & Jomary, Bioessays 2002, 24:811-820). The human homologue of the bovine gene has also been cloned. Unlike the frizzled proteins, however, Frzb does not contain a serpentine transmembrane domain, and appears to be a secreted receptor for Wnt.
  • Frzb does not contain a serpentine transmembrane domain, and appears to be a secreted receptor for Wnt.
  • the Frzb cDNA encodes a 325 amino acid/36,000 dalton protein and is predominantly expressed in the appendicular skeleton. The highest level of expression is in developing long bones and corresponds to epiphyseal chondroblasts; expression declines and disappeares toward the ossification center. [0007] Studies indicate that SFRPs participate in apoptosis. Some SFRPs have thus been identified as "SARPs" for secreted apoptosis related proteins. Additional members of the SFRP family have been identified, and have been shown to be antagonists of Wnt action.
  • SFRP/SARP genes There are currently at least five known human SFRP/SARP genes: SFRP-l/FrzA/FRP-l/SARP-2, SFRP-2/SDF-5/SARP-1, SFRP-3/Frzb-l/FrzB/Fritz, SFRP-4 and SFRP-5/SARP-3 (Leiffle et ah, Mechanisms of Development 1998, 75:29-42).
  • Secreted frizzled related protein-1 (SFRP- 1) is a Wnt antagonist and is expressed in osteoblasts and osteocytes. Although the precise role that SARPs/SFRPs play in apoptosis is not yet clear, these proteins appear to either suppress or enhance the programmed cell death process.
  • the present invention relates to certain diarylsulfone sulfonamides and to their use, for example, in medical treatment.
  • the invention relates to diarylsulfone sulfonamides that act as modulators of secreted frizzled related protein-1.
  • the compounds can be used, for example, to treat bone disorders such as osteoporosis.
  • the present invention is directed to compounds of Formula
  • R 1 is and each R 1 group is optionally substituted with up to three R 8 groups;
  • Y is O, S, or NR 9 ;
  • R 8 is alkyl, arylalkyl, perfluoroalkyl, alkenyl, arylalkenyl, alkynyl, arylalkynyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, aryl, alkylaryl, heteroaryl, alkoxy, perfluoroalkoxy, arylalkoxy, alkylcarbonyl, arylcarbonyl, halogen, cyano, azido, hydroxyl, carboxy, alkoxycarbonyl, alkylamino, dialkylamino, alkylaminocarbonyl, dialkylaniinocarbonyl, alkylcarbonylamino, alkylcarbonylalkylamino, hydroxyalkylamino, nitro, alkylcarbonyloxime, alkylsulfonyl, alkylsulfinyl, alkylthio,
  • R 9 is hydrogen, alkyl, aryl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, or spirocycloalkyl;
  • X is oxygen or an electron pair
  • R 2 is hydrogen, alkyl, alkoxy, cycloalkyl, perfluoroalkyl, perfluoroalkylalkyl, perfluoroalkoxy, dialkylamino, or halogen;
  • R 4 is hydrogen, halogen, alkyl, cycloalkyl, alkoxy, perfluoroalkyl, or perfluoroalkoxy; or R 2 and R 4 , together with the carbon atoms to which they are attached, form a cycloalkyl ring of 5 to 7 carbon atoms that is optionally substituted with 1 to 3 R groups; each R is, independently, hydrogen, alkyl, arylalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, spirocycloalkyl, aryl, arylalkyl, or alkoxyalkyl;
  • R 5 , and R 6 are, independently, hydrogen, alkyl, aryl, alkoxy, halogen, or perfluoroalkyl;
  • R 3 and R 7 are each, independently, hydrogen or an optionally substituted alkyl, cycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, heteroarylalkyl, alkylaryl, alkylheteroaryl, alkenyl, alkynyl, fused cycloalkylaryl, fused heterocycloalkylaryl, cycloalkylcarbonyl, or heterocycloalkylcarbonyl group; or Ra and R 7 , together with the nitrogen atom to which they are attached, form a five or six membered heterocycloalkyl ring optionally substituted with 1 to 5 substituents selected from alkyl, aryl, heterocycloalkyl, heterocycloalkylalkyl, alkylamino, dialkylamino, alkoxycarbonyl, alkylcarbonyl, alkylaminocarbonylalkyl, and heterocycloalkylcarbonylalkyl.
  • the invention relates to compositions comprising at least one compound of Formula 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents, or carriers.
  • the present invention also provides methods for treating patients suffering from osteoporosis, arthritis, chronic obstructive pulmonary disease, cartilage defects, bone fractures, or leiomyoma that comprise administering to the patients a therapeutically effective amount of at least one compound of Formula 1.
  • alkyl refers to an optionally substituted aliphatic hydrocarbon chain having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, and more preferably 1 to 4 carbon atoms.
  • alkyl includes straight and branched chains. Straight chain alkyl groups have 1 to 8 carbon atoms and branched chain alkyl groups have 3 to 12 carbon atoms.
  • alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, and isohexyl groups.
  • hydroxyalkyl refers to the group -alkyl-OH where alkyl is an alkyl group as previously defined.
  • carboxyalkyl refers to the group -alkyl-C(O)OH where alkyl is an alkyl group as previously defined.
  • haloalkyl refers to the group -alkyl-halo where halo is a halogen atom and alkyl is an alkyl group as previously defined.
  • perfluoroalkyl refers to an optionally substituted straight or branched aliphatic hydrocarbon chain of 1 to 8 carbon atoms and preferably 1 to 3 carbon atoms, in which all hydrogens are replaced with fluorine.
  • perfluoroalkylalkyl refers to the group -alkyl- perfluoroalkyl where alkyl and perfluoroalkyl are as previously defined.
  • alkenyl refers to an optionally substituted aliphatic straight or branched hydrocarbon chain having 2 to 12 carbon atoms that contain 1 to 3 double bonds.
  • Straight chain alkenyl groups have 2 to 8 carbon atoms and branched chain alkenyl groups have 3 to 12 carbon atoms.
  • alkenyl groups include, but are not limited to, vinyl, prop-1-enyl, allyl, but-1-enyl, but-2-enyl, but-3-enyl, 3,3-dimethylbut-l-enyl, or 2- methylvinyl.
  • alkynyl refers to an optionally substituted aliphatic straight or branched hydrocarbon chain having 2 to 8 carbon atoms that contains 1 to 3 triple bonds.
  • Straight chain alkynyl groups have 2 to 8 carbon atoms and branched chain alkynyl groups have 5 to 12 carbon atoms.
  • cycloalkyl refers to an optionally substituted hydrocarbon ring containing 3 to 12 carbon atoms and preferably 3 to 6 carbon atoms. Cycloalkyl groups may be monocyclic or bicyclic, and may be saturated or partially saturated. The term “bicycloalkyl,” as used herein, refers to a bicyclic cycloalkyl group of 8 to 12 ring carbon atoms. “Bridged" cycloalkyl groups contain at least one carbon-carbon bond between two non-adjacent carbon atoms of the cycloalkyl ring.
  • alkylcycloalkyl refers to the group -cycloalkyl- (alkyl)n in which n is 1 to 3, cycloalkyl is a cycloalkyl group as previously defined, and alkyl is an alkyl group as previously defined.
  • cycloalkylalkyl refers to the group -alkyl-cycloalkyl in which alkyl is an alkyl group as previously defined and cycloalkyl is a cycloalkyl group as previously defined.
  • spirocycloalkyl refers to two optionally substituted cycloalkyl groups as previously defined that are joined by a single sp3 carbon atom that is the only common member of the two joined rings.
  • heterocycloalkyl refers to a 3 to 12 membered, and more preferably 5 to 7 membered optionally substituted cycloalkyl group in which one to three carbon atoms of the cycloalkyl group are replaced with a heteroatom independently selected from oxygen, nitrogen, and sulfur, including sulfoxide and sulfonyl.
  • the heterocycloalkyl group may be saturated or partially saturated, and may be monocyclic or bicyclic.
  • heterocycloalkyl refers to the bicyclic structure formed when a heterocycloalkyl group is fused to another heterocycloalkyl group, to a cycloalkyl group, to an aryl group, or to a heteroaryl group. Heterobicycloalkyl groups have 8 to 12 ring atoms. "Bridged" heterocycloalkyl groups contain at least one carbon-carbon bond between non-adjacent carbon atoms of the heterocycloalkyl ring.
  • alkylheterocycloalkyl refers to the group -heterocycloalkyl-(alkyl) n in which n is 1 to 3, heterocycloalkyl is a heterocycloalkyl group as previously defined, and alkyl is an alkyl group as previously defined.
  • heterocycloalkylalkyl refers to the group -R'-heterocycloalkyl where R' is an alkyl group as previously defined and heterocycloalkyl is a heterocycloalkyl group as previously defined.
  • aryl refers to an optionally substituted carbocyclic aromatic ring.
  • Aryl groups may be monocyclic or bicyclic.
  • Exemplary aryl groups include phenyl and naphthyl.
  • carboxyaryl refers to the group -aryl-C(O)OH, where aryl is an aryl group as previously defined.
  • heteroaryl refers to an optionally substituted 5 to 10 membered monocyclic or bicyclic carbon containing aromatic ring having 1 to 3 of its ring members independently selected from nitrogen, sulfur and oxygen.
  • Monocyclic rings preferably have 5 to 6 members and bicyclic rings preferably have 8 to 10 membered ring structures.
  • heteroaryls include, but are not limited to, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzofuranyl, isobenzofuranyl, benzothienyl, isobenzothienyl, quinolyl, isoquinolyl, quinoxalinyl, and quinazolinyl.
  • alkylheteroaryl refers to the group -heteroaryl-alkyl wherein heteroaryl is a heteroaryl group as previously defined and alkyl is an alkyl group as previously defined.
  • arylcarbonylalkyl refers to the group R'-C(O)-aryl where R' is an alkyl group as previously defined and aryl is an aryl group as previously defined.
  • fused cycloalkylaryl refers to a cycloalkyl group as previously defined fused to an aryl group of five or six carbon atoms as previously defined or fused to a heteroaryl group of five or six atoms as previously defined. The point of attachment can occur at any generally acceptable position.
  • fused cycloalkylarylaminocarbonyl refers to the group -C(O)-NH-fused cycloalkylaryl where fused cycloalkylaryl is a fused cycloalkylaryl group as previously defined.
  • fused hetercycloalkylaryl refers to a heterocycloalkyl group as previously defined fused to an aryl group of five or six carbon atoms as previously defined or fused to a heteroaryl group of five or six atoms as previously defined. The point of attachment can occur at any generally acceptable position.
  • fused hetercycloalkylarylcarbonyl refers to the group -C(O)- fused hetercycloalkylaryl where fused hetercycloalkylaryl is a fused hetercycloalkylaryl group as previously defined.
  • alkylcarbonyl refers to the group -C(O)R' where R' is an alkyl group as previously defined.
  • alkylthioalkylcarbonyl refers to the group -C(O)-R' -S-R' where R' is an alkyl group as previously defined.
  • alkylcarbonylamino refers to the group -NHC(O)R' where R' is an alkyl group as previously defined.
  • alkoxycarbonylamino refers to the group -NHC(O)OR' where R' is an alkyl group as previously defined.
  • alkylcarbonylalkylamino refers to the group -NH-R' -C(O)R' where R' is an alkyl group as previously defined.
  • alkylsulfonylamino refers to the group -NH 2 -S(O) 2 -R' where R' is an alkyl group as previously defined.
  • carboxyarylsulfonylamino refers to the group -NH 2 -S(O) 2 -aryl-C(O)OH where aryl is an aryl group as previously defined.
  • alkoxy refers to the group -O-R' where R' is an alkyl group as previously defined.
  • perfluoroalkoxy refers to the group -O-R" where R" is a perfluoroalkyl group as previously defined.
  • amino alkylamino
  • dialkylamino dialkylamino
  • aminoalkyl refers to the group -R 5 NH 2 where R' is an alkyl group as previously defined.
  • alkylcarbinol refers to an alkyl group as previously defined substituted with a hydroxy 1 group.
  • carbonyl refers to a bivalent carbon atom that is further bonded to an oxygen atom through a double bond.
  • thiocarbonyl refers to a bivalent carbon atom that is further bonded to a sulfur atom through a double bond.
  • halogen or halo, refer to chlorine, bromine, fluorine or iodine.
  • cyano or "cyanoalkyl,” as used herein, refers to the group -CN or -R'-CN where R' is an alkyl group as previously defined.
  • alkoxyalkyl refers to the group -R'-alkoxy where R' is an alkyl group as previously defined and alkoxy is an alkoxy group as previously defined.
  • arylalkyl refers to the group -R'-aryl where aryl is an aryl group as previously defined, and R' is an alkyl group as previously defined.
  • heteroarylalkyl refers to the group -R'-heteroaryl where heteroaryl is a heteroaryl group as previously defined, and R' is an alkyl group as previously defined.
  • arylalkenyl refers to the group -alkenyl-aryl where aryl is an aryl group as previously defined, and alkenyl is an alkenyl group as previously defined.
  • arylalkynyl refers to the group -alkynyl-aryl where aryl is an aryl group as previously defined, and alkynyl is an alkynyl group as previously defined.
  • arylalkoxy refers to the group -alkoxy-aryl where aryl is an aryl group as previously defined and alkoxy is an alkoxy group as previously defined.
  • benzoxy refers to the group -O-CH 2 -phenyl.
  • aminocarbonylalkoxy refers to the group -alkoxy- C(O)NH 2 where alkoxy is an alkoxy group as previously defined.
  • alkoxycarbonylalokxy refers to the group -alkoxy- C(O)-alkoxy where alkoxy is an alkoxy group as previously defined.
  • carboxyalkoxy refers to the group -alkoxy-C(O)OH where alkoxy is an alkoxy group as previously defined.
  • arylalkylcarbonyl refers to the group -alkylcarbonyl- aryl wherein alkylcarbonyl is an alkylcarbonyl group as previously defined and aryl is an aryl group as previously defined.
  • arylcarbonyl refers to the group -C(O)-aryl, where aryl is an aryl group of 6 to 10 carbon atoms as previously defined.
  • dialkylaminoarylcarbonyl refers to the group -arylcarbonyl-N(R')(R') where arylcarbonyl is an arylcarbonyl group as previously defined.
  • arylthio refers to the group -S-aryl where aryl is an aryl group as previously defined.
  • arylthiol refers to the group HS-aryl where aryl is an aryl group as previously defined.
  • arylsulfonyl refers to the group -S(O)2-aryl where aryl is an aryl group as previously defined.
  • arylsulfonylarylsulfonyl refers to the group -S(O) 2 -aryl-S(O) 2 -aryl where aryl is an aryl group as previously defined.
  • carboxyarylsulfonyl refers to the group -S(O) 2 -aryl-C(O)OH where aryl is an aryl group as previously defined.
  • aminosulfonyl refers to the group -S(O) 2 -NH 2 .
  • heteroarylsulfonyl refers to the group -S(O) 2 -heteroaryl where heteroaryl is a heteroaryl group as previously defined.
  • arylester refers to the group -C(O)O-aryl where aryl , is an aryl group as previously defined.
  • alkylcarbonyl refers to the group -C(O)R' where R' is an alkyl group as previously defined.
  • alkylthiocarbonyl refers to the group -C(S)R' where R' is an alkyl group as previously defined.
  • alkylaminoalkylcarbonyl refers to the group -C(O)R 5 NH(R') where R' is an alkyl group as previously defined.
  • dialkylaminoalkylcarbonyl refers to the group -C(O)R'N(R')(R') where R' is an alkyl group as previously defined.
  • perfluoroalkylcarbonyl refers to the group -C(O)R" where R" is a perfluoroalkyl group as previously defined.
  • carboxyalkylcarbonyl refers to the group -C(O)R 5 C(O)OH where R' is an alkyl group as previously defined.
  • alkoxycarbonyl refers to the group -C(O)OR 5 where R 5 is an alkyl group as previously defined.
  • alkoxythiocarbonyl refers to the group -C(S)OR 5 where R 5 is an alkyl group as previously defined.
  • alkoxycarbonylalkyl refers to the group -R 5 C(O)OR 5 where R 5 is an alkyl group as previously defined.
  • arylcarbonyl, 55 refers to the group -C(O)-aryl where aryl is an aryl group as previously defined.
  • heteroarylcarbonyl, 55 refers to the group -C(O)-heteroaryl where heteroaryl is a heteroaryl group as previously defined.
  • heteroarylalkylcarbonyl, 55 refers to the group -C(O)-R 5 -heteroaryl where heteroaryl is a heteroaryl group as previously defined and R 5 is an alkyl group as previously defined.
  • heterocycloalkylalkylcarbonyl, 55 refers to the group -C(O)-R'-heterocycloalkyl where heterocycloalkyl is a heterocycloalkyl group as previously defined and R 5 is an alkyl group as previously defined.
  • heterocycloalkylalkylaminothiocarbonyl refers to the group -C(O)-S-NH-R' -heterocycloalkyl where heterocycloalkyl is a heterocycloalkyl group as previously defined and R 5 is an alkyl group as previously defined.
  • aryloxycarbonyl refers to the group -C(O)-O-aryl where aryl is an aryl group as previously defined.
  • aryloxythiocarbonyl refers to the group -C(S)-O-aryl where aryl is an aryl group as previously defined.
  • cyanoarylcarbonyl, 55 refers to the group -C(O)-aryl-CN where aryl is an aryl group as previously defined.
  • arylalkylcarbonyl refers to the group -C(O)-R'-aryl where R' is an alkyl group as previously defined and aryl is an aryl group as previously defined.
  • cycloalkylcarbonyl refers to the group -C(O)-cycloalkyl where cycloalkyl is a cycloalkyl group as previously defined.
  • heterocycloalkylcarbonyl refers to the group -C(O)-heterocycloalkyl where heterocycloalkyl is a heterocycloalkyl group as previously defined.
  • heterocycloalkylthiocarbonyl refers to the group -C(S)-heterocycloalkyl where heterocycloalkyl is a heterocycloalkyl group as previously defined.
  • aminoalkylcarbonyl refers to the group -C(O)-R' -NH 2 where R' is an alkyl group as previously defined.
  • alkoxycarbonylaminothiocarbonyl refers to the group -C(O)-S-NH-C(O)-O-R' where R' is an alkyl group as previously defined.
  • alkoxycarbonylalkylaminothiocarbonyl refers to the group -C(O)-S-NH-R'-C(O)-O-R' where R' is an alkyl group as previously defined.
  • alkylthiocarbonylalkylcarbonyl refers to the group -C(O)-R' -C(O)-S-R' where R' is an alkyl group as previously defined.
  • cyanoalkoxycarbonyl refers to the group -C(O)-alkoxy-CN where alkoxy refers to an alkoxy group as previously defined.
  • alkylaryl refers to the group -aryl-R' where R' is an alkyl group as previously defined, and aryl is an aryl group as previously defined.
  • alkylester refers to the group -C(O)OR' wherein R' is an alkyl group as previously defined.
  • aminocarbonyl refers to the group -C(O)NH 2 .
  • alkylaminocarbonyl and “dialkylaminocarbonyl,” as used herein, refer to the groups -C(O)NHR' and -C(0)N(R') 2 , respectively, where each R' is, independently, an alkyl group as previously defined.
  • heterocycloalkylaminocarbonyl refers to the group -C(O)NH-heterocycloalkyl where heterocycloalkyl is a heterocycloalkyl group as previously defined.
  • carboxyalkylcarbonylheterocycloalkylaminocarbonyl refers to the group -heterocycloalkylaminocarbonyl-C(O)-R'-C(O)OH where heterocycloalkylaminocarbonyl is a heterocycloalkylaminocarbonyl group as previously defined and R' is an alkyl group as previously defined.
  • carboxyalkylaminocarbonyl refers to the group -alkylaminocarbonyl-carboxy where carboxy is a carboxy group as previously defined and alkylaminocarbonyl is an alkylaminocarbonyl group as previously defined.
  • alkoxycarbonylalkylaminocarbonyl refers to the group -alkylaminocarbonyl -carbonyl-alkoxy where alkoxy is an alkoxy group as previously defined, carbonyl is a carbonyl group as previously defined, and alkylaminocarbonyl is an alkylaminocarbonyl group as previously defined.
  • aminocarbonylalkyl refers to the group -R 5 C(O)NH 2 where R' is an alkyl group as previously defined.
  • alkylaminocarbonylalkyl and “dialkylaminocarbonylalkyl,” as used herein, refer to the groups -R 3 C(O)NHR' and -R' C(O)N(R' ) 2 , respectively, where each R' is, independently, an alkyl group as previously defined.
  • alkylaminothiocarbonyl and “dialkylaminothiocarbonyl,” as used herein, refer to the groups -C(S)NHR' and -C(S)N(R')2, respectively, where each R' is, independently, an alkyl group as previously defined.
  • heterocycloalkylcarbonylalkyl refers to the group -R'C(O)heterocycloalkyl where R' is an alkyl group as previously defined and heterocycloalkyl is a heterocycloalkyl group as previously defined.
  • arylaminocarbonyl refers to the group - C(O)NH(aryl), where aryl is an aryl group as previously defined.
  • heteroarylaminocarbonyl refers to the group -C(O)NH(heteroaryl), where heteroaryl is a heteroaryl group as previously defined.
  • heteroarylaminothiocarbonyl refers to the group -C(S)NH(heteroaryl), where heteroaryl is a heteroaryl group as previously defined.
  • arylaminothiocarbonyl refers to the group -C(S)NH(aryl), where aryl is an aryl group as previously defined.
  • cycloalkylaminocarbonyl refers to an alkylaminocarbonyl or dialkylaminocarbonyl group as previously defined in which at least one alkyl group is replaced by a cycloalkyl group.
  • alkylsulfonyl refers to the group -S(O) 2 -R' where R' is an alkyl group as previously defined.
  • alkylsulfmyl refers to the group -S(O)-R' where R' is an alkyl group as previously defined.
  • alkylthio refers to the group -S-R' where R' is an alkyl group as previously defined.
  • perfluoroalkylthio refers to the group -S-R" where R" is a perfluoroalkyl group as previously defined.
  • tertiary alkylcarbinol refers to the group -C(R') 2 OH where R' is an alkyl group as previously defined.
  • tertiary cycloalkylcarbinol refers to the group -C(cycloalkyl) 2 OH where cycloalkyl refers to a cycloalkyl group as previously defined.
  • tertiary alkylcycloalkylcarbinol refers to the group -C(R')(cycloalkyl)OH where R' refers to an alkyl group as previously defined, and cycloalkyl refers to a cycloalkyl group as previously defined.
  • tertiary arylcarbinol refers to the group -C(aryl)2 ⁇ H where each "aryl” independently refers to an aryl group as previously defined.
  • tertiary arylalkylcarbinol refers to the group -C(R')(aryl)OH where R' is an alkyl group as previously defined, and aryl is an aryl group as previously defined.
  • phosphonic acid alkyl refers to the group -R'-P(O)(OH) 2 where R' is an alkyl group as previously defined.
  • dimethylphosphonatealkyl refers to the group -R'-P(O)(OCH 3 )2 where R' is an alkyl group as previously defined.
  • partially saturated refers to a nonaromatic cycloalkyl or heterocycloalkyl group containing at least one double bond and preferably one or two double bonds.
  • terapéuticaally effective amount refers to the amount of a compound of formula 1 that, when administered to a patient, is effective to at least partially treat a condition from which the patient is suffering or is suspected to suffer. Such conditions include, but are not limited to, osteoporosis, arthritis, chronic obstructive pulmonary disease, cartilage defects, bone fractures, and leiomyoma.
  • pharmaceutically acceptable salts or “pharmaceutically acceptable salt” includes acid addition salts, namely salts derived from treating a compound of formula 1 with an organic or inorganic acids or bases.
  • the compound having formula I has an acidic function, for instance where R 3 is carboxyalkyl or R 8 is carboxy or phenolic hydroxyl
  • pharmaceutically acceptable salts or “pharmaceutically acceptable salt” includes salts derived from bases, for instance, sodium salts.
  • patient refers to a mammal.
  • administer refers to either directly administering a compound or composition to a patient, or administering a prodrug derivative or analog of the compound to the patient, which will form an equivalent amount of the active compound or substance within the patient's body.
  • treat and “treating,” as used herein, refer to partially or completely alleviating, inhibiting, preventing, ameliorating and/or relieving a condition from which a patient is suspected to suffer.
  • shocker and “suffering,” as used herein, refer to one or more conditions with which a patient has been diagnosed, or is suspected to have.
  • R 1 is and each R 1 group is optionally substituted with up to three R 8 groups;
  • Y is O, S, or NR 9 ;
  • R 8 is alkyl, arylalkyl, perfluoroalkyl, alkenyl, arylalkenyl, alkynyl, arylallcynyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, aryl, alkylaryl, heteroaryl, alkoxy, perfluoroalkoxy, arylalkoxy, alkylcarbonyl, arylcarbonyl, halogen, cyano, azido, hydroxyl, carboxy, alkoxycarbonyl, alkylamino, dialkylamino, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, alkylcarbonylalkylamino, hydroxyalkylamino, nitro, alkylcarbonyloxime, alkylsulfonyl, alkylsulfinyl, alkylthio,
  • R 9 is hydrogen, alkyl, aryl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, or spirocycloalkyl;
  • X is oxygen or an electron pair
  • R 2 is hydrogen, alkyl, alkoxy, cycloalkyl, perfluoroalkyl, perfluoroalkylalkyl, perfluoroalkoxy, dialkylamino, or halogen;
  • R 4 is hydrogen, halogen, alkyl, cycloalkyl, alkoxy, perfluoroalkyl, or perfluoroalkoxy; or R 2 and R 4 , together with the carbon atoms to which they are attached, form a cycloalkyl ring of 5 to 7 carbon atoms that is optionally substituted with 1 to 3 R groups; each R is, independently, hydrogen, alkyl, arylalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, spirocycloalkyl, aryl, arylalkyl, or alkoxyalkyl;
  • R 5 , and R 6 are, independently, hydrogen, alkyl, aryl, alkoxy, halogen, or perfluoroalkyl;
  • R 3 and R 7 are each, independently, hydrogen or an optionally substituted alkyl, cycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, heteroarylalkyl, alkylaryl, alkylheteroaryl, alkenyl, alkynyl, fused cycloalkylaryl, fused heterocycloalkylaryl, cycloalkylcarbonyl, or heterocycloalkylcarbonyl group; or R 3 and R 7 , together with the nitrogen atom to which they are attached, form a five or six membered heterocycloalkyl ring optionally substituted with 1 to 5 substituents selected from alkyl, aryl, heterocycloalkyl, heterocycloalkylalkyl, alkylamino, dialkylamino, alkoxycarbonyl, alkylcarbonyl, allcylaminocarbonylalkyl, and heterocycloalkylcarbonylalkyl; provided that the compound is
  • Any carbon or nitrogen atom in R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 , as defined herein, may be optionally substituted with one or more substituents understood by those skilled in the art to be suitable substituents. The following lists provide examples of such substituents.
  • alkyl, cycloalkyl, alkylheterocycloalkyl, heteroarylalkyl, alkylaryl, alkylheteroaryl, alkenyl, alkynyl, fused cycloalkylaryl, fused heterocycloalkylaryl, cycloalkylcarbonyl, and heterocycloalkylcarbonyl groups of R 3 and R 7 may each be, independently, optionally substituted with 1 to 5 substituents selected from alkyl, perfluoroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, fused cycloalkylaryl, alkoxy, aminocarbonylalkoxy, alkoxycarbonylalkoxy, carboxyalkoxy, cycloalkyloxy, aryloxy, amino, alkylamino, dialkylamino, alkoxycarbonylamino, carboxy, cyano, halogen, oxo, hydroxyl, al
  • the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl substituents on the alkyl groups ofR 3 and R 7 may be, independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, spirocycloalkyl, perfluoroalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, dimethylphosphonatealkyl, phosphonic acid alkyl, arylalkyl, cycloalkylallcyl, alkoxy, perfluoroalkoxy, arylalkoxy, benzoxy, aryl, heteroaryl, carboxyaryl, arylcarbonyl, alkylcarbonyl, perfluoroalkylcarbonyl, alkoxycarbonyl, carboxyalkylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, aryloxythiocarbonyl,
  • the heterocycloalkyl groups of R 3 and R 7 may be independently, optionally substituted with 1 to 5 substituents selected from alkyl, hydroxyalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heterocycloalkylcarbonylalkyl, arylalkyl, heteroarylalkyl, arylcarbonylalkyl, alkylcarbonyl, cyano, alkylester, alkylamide, cycloalkylamide, aryl, arylester, alkylcarbonyl, perfluoroalkylcarbonyl, aminocarbonyl, arylaminocarbonyl, arylaminothiocarbonyl, cyanoalkoxycarbonyl, cycl
  • the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl substituents on the heterocycloalkyl groups of R 3 and R 7 may be independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, spirocycloalkyl, perfluoroalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, dimethylphosphonatealkyl, phosphonic acid alkyl, arylalkyl, cycloalkylalkyl, alkoxy, perfluoroalkoxy, arylalkoxy, benzoxy, aryl, heteroaryl, carboxyaryl, arylcarbonyl, alkylcarbonyl, perfluoroalkylcarbonyl, alkoxycarbonyl, carboxyalkylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, aryloxythiocarbonyl
  • the amino substituents on the alkyl groups of R 3 and R 7 may be, independently, optionally substituted with 1 or 2 substituents selected from alkyl, hydroxyalkyl, carboxyalkyl, cycloalkyl, alkoxycarbonylalkyl, aryl, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl, cycloalkylcarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, alkoxy carbonylalkylaminocarbonyl, carboxyalkylcarbonyl, carboxyalkylaminocarbonyl, carboxyalkylcarbonylheterocycloalkylaminocarbonyl, arylaminocarbonyl, arylcarbonyl, heteroarylaminocarbonyl, heterocycloalkyl
  • the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl substituents on the amino substituents on the alkyl groups of R 3 and R 7 may be, independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, spirocycloalkyl, perfluoroalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, dimethylphosphonatealkyl, phosphonic acid alkyl, arylalkyl, cycloalkylalkyl, alkoxy, perfluoroalkoxy, arylalkoxy, benzoxy, aryl, heteroaryl, carboxyaryl, arylcarbonyl, alkylcarbonyl, perfluoroalkylcarbonyl, alkoxycarbonyl, carboxyalkylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, aryloxythi
  • the alkyl group substituents on the heterocycloalkyl ring formed from R 3 and R 7 , together with the nitrogen atom to which they are attached may each be, independently, optionally substituted with 1 to 5 substituents selected from aryl, heteroaryl optionally substituted with one to three alkyl groups, aminoalkyl, heterocycloalkyl, fused heterocycloalkylaryl, and heterocycloalkylcarbonyl.
  • R 1 of Formula 1 is aryl.
  • R 1 of Formula 1 is
  • each R 8 is, independently, alkyl, alkylaryl, alkylheteroaryl, alkylamino, dialkylamino, carboxy, alkylcarbonyl, alkoxy, perfluoroalkoxy, halogen, or cyano.
  • Additional embodiments of the invention relate to compounds of Formula 1 in which R 4 , R 5 , and R 6 are each hydrogen.
  • Alternative embodiments of the invention relate to compounds of Formula 1 in which R 4 is methyl and R 5 and R 6 are each hydrogen, or R 5 is methyl and R 4 and R 6 are each hydrogen, or R 6 is methyl and R 4 and R 5 are each hydrogen.
  • R 4 is halogen, alkyl, cycloalkyl, alkoxy, perfluoroalkyl, or perfluoroalkoxy.
  • R 5 , and R 6 are, independently, alkyl, alkoxy, halogen, or perfluoroalkyl.
  • Certain embodiments of the invention are directed to compounds of Formula 1 in which R 2 is methyl, ethyl, isopropyl, propyl, Cl, methoxy, trifluoromethyl, or trifluoromethoxy.
  • R 2 is methyl, isopropyl, trifluoromethyl, or trifluoromethoxy.
  • R 2 is isopropyl or trifluoromethyl.
  • Still further embodiments of the invention relate to compounds of Formula I in which R 2 is hydrogen, alkoxy, cycloalkyl, perfluoroalkyl, perfluoroalkylalkyl , perfluoroalkoxy, dialkylamino, or halogen.
  • R 3 and R 7 together with the nitrogen atoms to which they are attached, form an optionally substituted 5 or 6 membered heterocycloalkyl group.
  • R 3 and R 7 together with the nitrogen atoms to which they are attached, form an optionally substituted piperazinyl group.
  • R 3 and R 7 are each, independently, alkyl, heterocycloalkyl, heterocycloalkylalkyl, alkylheterocycloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, fused cycloalkylaryl, fused heterocycloalkylaryl, cycloalkylcarbonyl, alkoxyalkyl, alkoxycarbonylalkyl, cyanoalkyl, aminoalkyl, dialkylaminocarbonylalkyl, or alkylalkylaminocarbonylalkyl.
  • each alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group are optionally substituted with up to four R 13 groups;
  • R 13 is hydrogen, F, Cl, Br, alkyl, alkoxy, aryl, nitro, aminosulfonyl, arylalkoxy, perfluoroalkyl, perfluoroalkoxy, amino, alkylamino, dialkylamino, hydroxy, carboxy, cycloalkyl, carboxyalkyl, carboxyalkoxy, alkoxycarbonyl, aminocarbonylalkyl, alkoxycarbonylalkoxy,ammocarbonylalkoxy, alkylaminocarbonylallcyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, heterocycloalkylcarbonyl, heterocycloalkylaminocarbonyl, alkylaminocarbonylalkoxy, dialkylaminocarbonylalkyl, dialkylaminocarbonylalkoxy, heterocycloalkylcarbonylalkyl, dialkylaminocarbonylalkoxy, heterocycloal
  • R 15 is hydrogen, alkyl, aryl, cycloalkyl, alley lcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, heterocycloalkylcarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, heterocycloalkylthiocarbonyl, heterocycloalkylalkylaminothiocarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, arylthiocarbonyl, alkoxythiocarbonyl, or aryloxythiocarbonyl;
  • R 16 , R 17 and R 18 are each, independently, hydrogen, alkyl, aryl or cycloalkyl; m is 0, I, or 2; p is 0, 1, or 2; q is 1 or 2; s is 1 or 2; and
  • W is NR 9 , O, or S.
  • the alkyl, aryl and cycloalkyl groups of R 13 , R 14 and R 15 may each be, independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, perfluoroalkyl, aryl, heteroaryl, alkoxy, aryloxy, cycloalkyloxy, amino, alkylamino, dialkylamino, carboxy, cyano, oxo, hydroxyl, alkylcarbonyl, alkoxycarbonyl, arylcarbonyl, alkoxycarbonylamino, alkylcarbonylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthio, alkyloxothio, and alkoxycarbonylalkylamino.
  • the arylsulfonyl, arylcarbonyl and heteroarylcarbonyl groups of R 13 , R 14 and R 15 may be each, independently, optionally substituted with 1 to 5 substituents selected from hydrogen, halogen, hydroxyl, alkyl, cycloalkyl, perfluoroalkyl, aryl, alkoxy, heterocycloalkyl, heteroaryl, cycloalkyloxy, aryloxy, amino, alkylamino, dialkylamino, alkylthio, alkyloxothio, carboxy, cyano, oxo, alkylcarbonyl, arylcarbonyl,alkoxycarbonyl, alkylcarbonylamino, aminocarbonyl, alkylaminocarbonyl, and dialkylaminocarbonyl.
  • the heterocycloalkyl groups OfR 13 , R 14 and R 15 may each be, independently, optionally substituted with 1 to 5 substituents selected from hydrogen, hydroxyl, alkyl, cycloalkyl, perfluoroalkyl, aryl, heterocycloalkyl, heteroaryl, heteroarylcarbonyl, heteroarylalkylcarbonyl, alkylcarbonyl, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, arylcarbonyl, heteroarylcarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, heterocycloalkylcarbonylalkyl, carboxyalkylcarbonyl, and arylaminocarbony 1.
  • alkylcarbonyl groups of R 13 , R 14 and R 15 may each be, independently, optionally substituted with 1 to 5 substituents selected from amino, alkylamino, dialkylamino, cycloalkyl, heterocycloalkyl, perfluoroalkyl, aryl, heteroaryl, alkoxy, aryloxy, cycloalkyloxy, carboxy, cyano, oxo, hydroxyl, alkylcarbonyl, alkoxycarbonyl, arylcarbonyl, and alkoxy carbony lamino .
  • the amino groups of the alkylamino and hetercycloalkylamino groups OfR 13 , R 14 and R 15 may each be, independently, optionally substituted with a substituent selected from hydrogen, alkyl, cycloalkyl, and aryl.
  • Particular embodiments of the invention relate to compounds of Formula 1 in which R 7 is hydrogen and R 3 is heteroarylethyl, heteroarylpropyl, arylethyl, heterocycloalkyl, heterocycloalkylethyl, heterocycloalkylpropyl, heterocycloalkylmethyl, heterocyclalkylamino, cycloalkyl, fused cycloalkylaryl, aminoalkyl, or alkoxyalkyl.
  • R 7 is hydrogen and R 3 is heteroarylethyl, heteroarylpropyl, heterocyclalkylamino, fused cycloalkylaryl, or phenylethyl.
  • R 7 is hydrogen and R 3 is pyridinylethyl, imidazolylethyl, imidazolylpropyl, heterocyclalkylamino, fused cycloalkylaryl, or phenylethyl.
  • representative compounds of Formula 1 include: ⁇ /-(2-phenylethyl)-3-(phenylsulfonyl)benzenesulfonamide; iV-[2-(2-chlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N- [2-(3 -methoxypheny l)ethy 1] -3 -(phenylsulfony l)benzenesulfonamide ; ⁇ /-[2-(3,4-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; jV-[2-(4-bromophenyl)ethyl]-3-(phenylsulfonyl)benzenes
  • JV 3 - ⁇ [3-(phenylsulfonyl)phenyl]sulfonyl ⁇ -beta-alaninamide; methyl JV- ⁇ [3-(phenylsulfonyl)phenyl]sulfonyl ⁇ -beta-alaninate;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

Compounds of Formula (I), or pharmaceutically acceptable salts thereof, are provided, which are modulators of secreted frizzled related protein-1. The compounds, and compositions containing the compounds, can be used to treat a variety of disorders, including osteoporosis.

Description

DIARYLSULFONE SULFONAMIDES AND USE THEREOF
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. application serial number
60/681,080, filed May 13, 2005, and U.S. application serial number , filed May
10, 2006, which are incorporated herein in their entireties.
FIELD OF THE INVENTION
[0002] The present invention relates to novel diarylsulfone sulfonamides that act, for example, as modulators of secreted frizzled-related protein- 1. The present invention also relates to processes for the preparation of diarylsulfone sulfonamides and to their use in treating various diseases and disorders.
BACKGROUND OF THE INVENTION
[0003] Bone remodeling, the process by which the adult human skeleton is continuously renewed, is carried out by osteoclasts and osteoblasts, two specialized cell types that originate from hematopoietic and mesenchymal progenitors of the bone marrow, respectively. A continuous and orderly supply of these cells is believed to be essential for skeletal homeostasis, as increased or decreased production of osteoclasts or osteoblasts and/or changes in the rate of their apoptosis are largely responsible for the imbalance between bone resorption and formation that underlies several systemic or localized bone diseases. For example, enhanced osteoclast activity has been found to play a major role in the pathogenesis of postmenopausal osteoporosis, Paget's disease, lytic bone metastases, multiple myeloma, hyperparathyroidism, rheumatoid arthritis, periodontitis, and hypercalcemia of malignancy.
[0004] Numerous genes and gene families (and the polypeptides encoded by them) that participate in the regulation of bone cell production and apoptosis have been identified. Wnt proteins have been identified as a family of growth factors consisting of more than a dozen structurally related molecules that are involved in the regulation of fundamental biological processes such as apoptosis, embryogenesis, organogenesis, morphogenesis and tumorigenesis (Nusse and Varmus, Cell 1992, 69:1073-1087). Wnt polypeptides are multipotent factors and have biological activities similar to those of other secretory proteins such as transforming growth factor (TGF)-β, fibroblast growth factors (FGFs), nerve growth factor (NGF), and bone morphogenetic proteins (BMPs).
[0005] Studies indicate that certain Wnt proteins interact with a family of proteins named "frizzled" that act as receptors for Wnt proteins or as components of a Wnt receptor complex (in Moon et al, Cell 1997, 88:725-728; Barth et al, Curr. Opin. Cell Biol. 1997, 9:683- 690). Frizzled proteins contain an amino terminal signal sequence for secretion, a cysteine-rich domain (CRD) that is thought to bind Wnt, seven putative transmembrane domains that resemble a G-protein coupled receptor, and a cytoplasmic carboxyl terminus. The Frizzled receptors form a signaling complex with another family of membrane receptors known as the low-density lipoprotein (LDL) receptor-related proteins (LRP) (in Logan & Nusse, Annual Review of Cell & Developmental Biology 2004, 20:781-810; Moon et al, Nature Reviews Genetics 2004, 5:691- 701).
[0006] The first secreted frizzled-related protein (SFRP) was named "Frzb" (for "frizzled motif in bone development") and was purified and cloned from bovine articular cartilage extracts based on its ability to stimulate in vivo chondrogenic activity in rats (Hoang et al, J. Biol Chem. 1996, 271 :26131-26137; Jones & Jomary, Bioessays 2002, 24:811-820). The human homologue of the bovine gene has also been cloned. Unlike the frizzled proteins, however, Frzb does not contain a serpentine transmembrane domain, and appears to be a secreted receptor for Wnt. The Frzb cDNA encodes a 325 amino acid/36,000 dalton protein and is predominantly expressed in the appendicular skeleton. The highest level of expression is in developing long bones and corresponds to epiphyseal chondroblasts; expression declines and disappeares toward the ossification center. [0007] Studies indicate that SFRPs participate in apoptosis. Some SFRPs have thus been identified as "SARPs" for secreted apoptosis related proteins. Additional members of the SFRP family have been identified, and have been shown to be antagonists of Wnt action. There are currently at least five known human SFRP/SARP genes: SFRP-l/FrzA/FRP-l/SARP-2, SFRP-2/SDF-5/SARP-1, SFRP-3/Frzb-l/FrzB/Fritz, SFRP-4 and SFRP-5/SARP-3 (Leimeister et ah, Mechanisms of Development 1998, 75:29-42). Secreted frizzled related protein-1 (SFRP- 1) is a Wnt antagonist and is expressed in osteoblasts and osteocytes. Although the precise role that SARPs/SFRPs play in apoptosis is not yet clear, these proteins appear to either suppress or enhance the programmed cell death process. Deletion of SFRP-I in mice has been shown to lead to decreased osteoblast/osteocyte apoptosis and to increased bone formation. (Bodine, P.V.N, et al, MoL Endocrinol, 2004, 18(5) 1222-1237.)
[0008] A need exists in the art for the identification of modulators of SFRP-I that can be used as novel agents for the treatment of bone disorders, including bone resorption disorders such as osteoporosis, and for regulation of bone formation in humans.
SUMMARY OF THE INVENTION
[0009] The present invention relates to certain diarylsulfone sulfonamides and to their use, for example, in medical treatment. In one aspect, the invention relates to diarylsulfone sulfonamides that act as modulators of secreted frizzled related protein-1. The compounds can be used, for example, to treat bone disorders such as osteoporosis.
[0010] In certain aspects, the present invention is directed to compounds of Formula
(1):
Figure imgf000004_0001
(1) or a pharmaceutically acceptable salt thereof, wherein
R1 is
Figure imgf000005_0001
and each R1 group is optionally substituted with up to three R8 groups;
Y is O, S, or NR9;
R8 is alkyl, arylalkyl, perfluoroalkyl, alkenyl, arylalkenyl, alkynyl, arylalkynyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, aryl, alkylaryl, heteroaryl, alkoxy, perfluoroalkoxy, arylalkoxy, alkylcarbonyl, arylcarbonyl, halogen, cyano, azido, hydroxyl, carboxy, alkoxycarbonyl, alkylamino, dialkylamino, alkylaminocarbonyl, dialkylaniinocarbonyl, alkylcarbonylamino, alkylcarbonylalkylamino, hydroxyalkylamino, nitro, alkylcarbonyloxime, alkylsulfonyl, alkylsulfinyl, alkylthio, perfluoroalkylthio, arylthio, tertiary alkylcarbinol, tertiary alkylcycloalkylcarbinol, or tertiary arylalkylcarbinol;
R9 is hydrogen, alkyl, aryl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, or spirocycloalkyl;
X is oxygen or an electron pair;
R2 is hydrogen, alkyl, alkoxy, cycloalkyl, perfluoroalkyl, perfluoroalkylalkyl, perfluoroalkoxy, dialkylamino, or halogen;
R4 is hydrogen, halogen, alkyl, cycloalkyl, alkoxy, perfluoroalkyl, or perfluoroalkoxy; or R2 and R4, together with the carbon atoms to which they are attached, form a cycloalkyl ring of 5 to 7 carbon atoms that is optionally substituted with 1 to 3 R groups; each R is, independently, hydrogen, alkyl, arylalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, spirocycloalkyl, aryl, arylalkyl, or alkoxyalkyl;
R5, and R6 are, independently, hydrogen, alkyl, aryl, alkoxy, halogen, or perfluoroalkyl;
R3 and R7 are each, independently, hydrogen or an optionally substituted alkyl, cycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, heteroarylalkyl, alkylaryl, alkylheteroaryl, alkenyl, alkynyl, fused cycloalkylaryl, fused heterocycloalkylaryl, cycloalkylcarbonyl, or heterocycloalkylcarbonyl group; or Ra and R7, together with the nitrogen atom to which they are attached, form a five or six membered heterocycloalkyl ring optionally substituted with 1 to 5 substituents selected from alkyl, aryl, heterocycloalkyl, heterocycloalkylalkyl, alkylamino, dialkylamino, alkoxycarbonyl, alkylcarbonyl, alkylaminocarbonylalkyl, and heterocycloalkylcarbonylalkyl.
[0011] In other embodiments, the invention relates to compositions comprising at least one compound of Formula 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents, or carriers.
[0012] The present invention also provides methods for treating patients suffering from osteoporosis, arthritis, chronic obstructive pulmonary disease, cartilage defects, bone fractures, or leiomyoma that comprise administering to the patients a therapeutically effective amount of at least one compound of Formula 1.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0013] The term "alkyl," as used herein, refers to an optionally substituted aliphatic hydrocarbon chain having 1 to 12 carbon atoms, preferably 1 to 8 carbon atoms, and more preferably 1 to 4 carbon atoms. The term "alkyl" includes straight and branched chains. Straight chain alkyl groups have 1 to 8 carbon atoms and branched chain alkyl groups have 3 to 12 carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, and isohexyl groups.
[0014] The term "hydroxyalkyl," as used herein, refers to the group -alkyl-OH where alkyl is an alkyl group as previously defined.
[0015] The term "carboxyalkyl," as used herein, refers to the group -alkyl-C(O)OH where alkyl is an alkyl group as previously defined.
[0016] The term "haloalkyl," as used herein, refers to the group -alkyl-halo where halo is a halogen atom and alkyl is an alkyl group as previously defined.
[0017] The term "perfluoroalkyl," as used herein, refers to an optionally substituted straight or branched aliphatic hydrocarbon chain of 1 to 8 carbon atoms and preferably 1 to 3 carbon atoms, in which all hydrogens are replaced with fluorine.
[0018] The term "perfluoroalkylalkyl," as used herein, refers to the group -alkyl- perfluoroalkyl where alkyl and perfluoroalkyl are as previously defined.
[0019] The term "alkenyl," as used herein, refers to an optionally substituted aliphatic straight or branched hydrocarbon chain having 2 to 12 carbon atoms that contain 1 to 3 double bonds. Straight chain alkenyl groups have 2 to 8 carbon atoms and branched chain alkenyl groups have 3 to 12 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl, prop-1-enyl, allyl, but-1-enyl, but-2-enyl, but-3-enyl, 3,3-dimethylbut-l-enyl, or 2- methylvinyl.
[0020] The term "alkynyl," as used herein, refers to an optionally substituted aliphatic straight or branched hydrocarbon chain having 2 to 8 carbon atoms that contains 1 to 3 triple bonds. Straight chain alkynyl groups have 2 to 8 carbon atoms and branched chain alkynyl groups have 5 to 12 carbon atoms.
[0021] The term "cycloalkyl," as used herein, refers to an optionally substituted hydrocarbon ring containing 3 to 12 carbon atoms and preferably 3 to 6 carbon atoms. Cycloalkyl groups may be monocyclic or bicyclic, and may be saturated or partially saturated. The term "bicycloalkyl," as used herein, refers to a bicyclic cycloalkyl group of 8 to 12 ring carbon atoms. "Bridged" cycloalkyl groups contain at least one carbon-carbon bond between two non-adjacent carbon atoms of the cycloalkyl ring.
[0022] The term "alkylcycloalkyl," as used herein, refers to the group -cycloalkyl- (alkyl)n in which n is 1 to 3, cycloalkyl is a cycloalkyl group as previously defined, and alkyl is an alkyl group as previously defined.
[0023] The term "cycloalkylalkyl," as used herein, refers to the group -alkyl-cycloalkyl in which alkyl is an alkyl group as previously defined and cycloalkyl is a cycloalkyl group as previously defined.
[0024] The term "spirocycloalkyl," as used herein, refers to two optionally substituted cycloalkyl groups as previously defined that are joined by a single sp3 carbon atom that is the only common member of the two joined rings.
[0025] The term "heterocycloalkyl," as used herein, refers to a 3 to 12 membered, and more preferably 5 to 7 membered optionally substituted cycloalkyl group in which one to three carbon atoms of the cycloalkyl group are replaced with a heteroatom independently selected from oxygen, nitrogen, and sulfur, including sulfoxide and sulfonyl. The heterocycloalkyl group may be saturated or partially saturated, and may be monocyclic or bicyclic. The term "heterobicycloalkyl" refers to the bicyclic structure formed when a heterocycloalkyl group is fused to another heterocycloalkyl group, to a cycloalkyl group, to an aryl group, or to a heteroaryl group. Heterobicycloalkyl groups have 8 to 12 ring atoms. "Bridged" heterocycloalkyl groups contain at least one carbon-carbon bond between non-adjacent carbon atoms of the heterocycloalkyl ring.
[0026] The term "alkylheterocycloalkyl," as used herein, refers to the group -heterocycloalkyl-(alkyl)n in which n is 1 to 3, heterocycloalkyl is a heterocycloalkyl group as previously defined, and alkyl is an alkyl group as previously defined.
[0027] The term "heterocycloalkylalkyl," as used herein, refers to the group -R'-heterocycloalkyl where R' is an alkyl group as previously defined and heterocycloalkyl is a heterocycloalkyl group as previously defined.
[0028] The term "aryl," as used herein refers to an optionally substituted carbocyclic aromatic ring. Aryl groups may be monocyclic or bicyclic. Exemplary aryl groups include phenyl and naphthyl.
[0029] The term "carboxyaryl," as used herein, refers to the group -aryl-C(O)OH, where aryl is an aryl group as previously defined.
[0030] The term "heteroaryl," as used herein refers to an optionally substituted 5 to 10 membered monocyclic or bicyclic carbon containing aromatic ring having 1 to 3 of its ring members independently selected from nitrogen, sulfur and oxygen. Monocyclic rings preferably have 5 to 6 members and bicyclic rings preferably have 8 to 10 membered ring structures. Examples of heteroaryls include, but are not limited to, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, indazolyl, benzofuranyl, isobenzofuranyl, benzothienyl, isobenzothienyl, quinolyl, isoquinolyl, quinoxalinyl, and quinazolinyl.
[0031] The term "alkylheteroaryl," as used herein, refers to the group -heteroaryl-alkyl wherein heteroaryl is a heteroaryl group as previously defined and alkyl is an alkyl group as previously defined.
[0032] The term "arylcarbonylalkyl," as used herein, refers to the group R'-C(O)-aryl where R' is an alkyl group as previously defined and aryl is an aryl group as previously defined.
[0033] The term, "fused cycloalkylaryl," as used herein, refers to a cycloalkyl group as previously defined fused to an aryl group of five or six carbon atoms as previously defined or fused to a heteroaryl group of five or six atoms as previously defined. The point of attachment can occur at any generally acceptable position. [0034] The term, "fused cycloalkylarylaminocarbonyl," as used herein, refers to the group -C(O)-NH-fused cycloalkylaryl where fused cycloalkylaryl is a fused cycloalkylaryl group as previously defined.
[0035] The term, "fused hetercycloalkylaryl," as used herein, refers to a heterocycloalkyl group as previously defined fused to an aryl group of five or six carbon atoms as previously defined or fused to a heteroaryl group of five or six atoms as previously defined. The point of attachment can occur at any generally acceptable position.
[0036] The term "fused hetercycloalkylarylcarbonyl," as used herein, refers to the group -C(O)- fused hetercycloalkylaryl where fused hetercycloalkylaryl is a fused hetercycloalkylaryl group as previously defined.
[0037] The term "alkylcarbonyl," as used herein, refers to the group -C(O)R' where R' is an alkyl group as previously defined.
[0038] The term "alkylthioalkylcarbonyl," as used herein, refers to the group -C(O)-R' -S-R' where R' is an alkyl group as previously defined.
[0039] The term "alkylcarbonylamino," as used herein, refers to the group -NHC(O)R' where R' is an alkyl group as previously defined.
[0040] The term "alkoxycarbonylamino," as used herein, refers to the group -NHC(O)OR' where R' is an alkyl group as previously defined.
[0041] The term "alkylcarbonylalkylamino," as used herein, refers to the group -NH-R' -C(O)R' where R' is an alkyl group as previously defined.
[0042] The term "alkylsulfonylamino," as used herein, refers to the group -NH2-S(O)2-R' where R' is an alkyl group as previously defined.
[0043] The term "carboxyarylsulfonylamino," as used herein, refers to the group -NH2-S(O)2-aryl-C(O)OH where aryl is an aryl group as previously defined.
[0044] The term "alkylcarbonyloxime," as used herein, refers to the group -C(N=OR' )R' where R' is an alkyl group as previously defined.
[0045] The term "alkoxy," as used herein, refers to the group -O-R' where R' is an alkyl group as previously defined.
[0046] The term "perfluoroalkoxy," as used herein, refers to the group -O-R" where R" is a perfluoroalkyl group as previously defined. [0047] The terms "amino," "alkylamino," "dialkylamino," and "imino," as used herein, refer to the groups -NH2, -NHR', -N(R')2, and -C=NH, respectively, where each R' is, independently, an alkyl group as previously defined.
[0048] The term "aminoalkyl," as used herein, refers to the group -R5NH2 where R' is an alkyl group as previously defined.
[0049] The term "alkylcarbinol," as used herein, refers to an alkyl group as previously defined substituted with a hydroxy 1 group.
[0050] The term "carboxy," as used herein, refers to the group -COOH.
[0051] The term "carbonyl," as used herein, refers to a bivalent carbon atom that is further bonded to an oxygen atom through a double bond.
[0052] The term "thiocarbonyl," as used herein, refers to a bivalent carbon atom that is further bonded to a sulfur atom through a double bond.
[0053] The terms "halogen" or "halo," as used herein, refer to chlorine, bromine, fluorine or iodine.
[0054] The term "cyano" or "cyanoalkyl," as used herein, refers to the group -CN or -R'-CN where R' is an alkyl group as previously defined.
[0055] The term "alkoxyalkyl," as used herein, refers to the group -R'-alkoxy where R' is an alkyl group as previously defined and alkoxy is an alkoxy group as previously defined.
[0056] The term "arylalkyl," as used herein, refers to the group -R'-aryl where aryl is an aryl group as previously defined, and R' is an alkyl group as previously defined.
[0057] The term "heteroarylalkyl," as used herein, refers to the group -R'-heteroaryl where heteroaryl is a heteroaryl group as previously defined, and R' is an alkyl group as previously defined.
[0058] The term "arylalkenyl," as used herein, refers to the group -alkenyl-aryl where aryl is an aryl group as previously defined, and alkenyl is an alkenyl group as previously defined.
[0059] The term "arylalkynyl," as used herein, refers to the group -alkynyl-aryl where aryl is an aryl group as previously defined, and alkynyl is an alkynyl group as previously defined.
[0060] The term "arylalkoxy," as used herein, refers to the group -alkoxy-aryl where aryl is an aryl group as previously defined and alkoxy is an alkoxy group as previously defined. The term "benzoxy" refers to the group -O-CH2-phenyl. [0061] The term "aminocarbonylalkoxy," as used herein, refers to the group -alkoxy- C(O)NH2 where alkoxy is an alkoxy group as previously defined.
[0062] The term "alkoxycarbonylalokxy," as used herein, refers to the group -alkoxy- C(O)-alkoxy where alkoxy is an alkoxy group as previously defined.
[0063] The term "carboxyalkoxy," as used herein, refers to the group -alkoxy-C(O)OH where alkoxy is an alkoxy group as previously defined.
[0064] The term "arylalkylcarbonyl," as used herein, refers to the group -alkylcarbonyl- aryl wherein alkylcarbonyl is an alkylcarbonyl group as previously defined and aryl is an aryl group as previously defined.
[0065] The term "arylcarbonyl," as used herein, refers to the group -C(O)-aryl, where aryl is an aryl group of 6 to 10 carbon atoms as previously defined.
[0066] The term "dialkylaminoarylcarbonyl," as used herein, refers to the group -arylcarbonyl-N(R')(R') where arylcarbonyl is an arylcarbonyl group as previously defined.
[0067] The term "arylthio," as used herein, refers to the group -S-aryl where aryl is an aryl group as previously defined.
[0068] The term "arylthiol," as used herein, refers to the group HS-aryl where aryl is an aryl group as previously defined.
[0069] The term "arylsulfonyl," as used herein, refers to the group -S(O)2-aryl where aryl is an aryl group as previously defined.
[0070] The term "arylsulfonylarylsulfonyl," as used herein, refers to the group -S(O)2-aryl-S(O)2-aryl where aryl is an aryl group as previously defined.
[0071] The term "carboxyarylsulfonyl," as used herein, refers to the group -S(O)2-aryl-C(O)OH where aryl is an aryl group as previously defined.
[0072] The term "aminosulfonyl," as used herein, refers to the group -S(O)2-NH2.
[0073] The term "heteroarylsulfonyl," as used herein, refers to the group -S(O)2-heteroaryl where heteroaryl is a heteroaryl group as previously defined.
[0074] The term "arylester," as used herein, refers to the group -C(O)O-aryl where aryl , is an aryl group as previously defined.
[0075] The term "alkylcarbonyl," as used herein, refers to the group -C(O)R' where R' is an alkyl group as previously defined.
[0076] The term "alkylthiocarbonyl," as used herein, refers to the group -C(S)R' where R' is an alkyl group as previously defined. [0077] The term "alkylaminoalkylcarbonyl," as used herein, refers to the group -C(O)R5NH(R') where R' is an alkyl group as previously defined.
[0078] The term "dialkylaminoalkylcarbonyl," as used herein, refers to the group -C(O)R'N(R')(R') where R' is an alkyl group as previously defined.
[0079] The term "perfluoroalkylcarbonyl," as used herein, refers to the group -C(O)R" where R" is a perfluoroalkyl group as previously defined.
[0080] The term "carboxyalkylcarbonyl," as used herein, refers to the group -C(O)R5C(O)OH where R' is an alkyl group as previously defined.
[0081] The term "alkoxycarbonyl," as used herein, refers to the group -C(O)OR5 where R5 is an alkyl group as previously defined.
[0082] The term "alkoxythiocarbonyl," as used herein, refers to the group -C(S)OR5 where R5 is an alkyl group as previously defined.
[0083] The term "alkoxycarbonylalkyl," as used herein, refers to the group -R5C(O)OR5 where R5 is an alkyl group as previously defined.
[0084] The term "arylcarbonyl,55 as used herein, refers to the group -C(O)-aryl where aryl is an aryl group as previously defined.
[0085] The term "heteroarylcarbonyl,55 as used herein, refers to the group -C(O)-heteroaryl where heteroaryl is a heteroaryl group as previously defined.
[0086] The term "heteroarylalkylcarbonyl,55 as used herein, refers to the group -C(O)-R5 -heteroaryl where heteroaryl is a heteroaryl group as previously defined and R5 is an alkyl group as previously defined.
[0087] The term "heterocycloalkylalkylcarbonyl,55 as used herein, refers to the group -C(O)-R'-heterocycloalkyl where heterocycloalkyl is a heterocycloalkyl group as previously defined and R5 is an alkyl group as previously defined.
[0088] The term "heterocycloalkylalkylaminothiocarbonyl," as used herein, refers to the group -C(O)-S-NH-R' -heterocycloalkyl where heterocycloalkyl is a heterocycloalkyl group as previously defined and R5 is an alkyl group as previously defined.
[0089] The term "aryloxycarbonyl," as used herein, refers to the group -C(O)-O-aryl where aryl is an aryl group as previously defined.
[0090] The term "aryloxythiocarbonyl," as used herein, refers to the group -C(S)-O-aryl where aryl is an aryl group as previously defined.
[0091] The term "cyanoarylcarbonyl,55 as used herein, refers to the group -C(O)-aryl-CN where aryl is an aryl group as previously defined.
[0092] The term "arylalkylcarbonyl," as used herein, refers to the group -C(O)-R'-aryl where R' is an alkyl group as previously defined and aryl is an aryl group as previously defined.
[0093] The term "cycloalkylcarbonyl," as used herein, refers to the group -C(O)-cycloalkyl where cycloalkyl is a cycloalkyl group as previously defined.
[0094] The term "heterocycloalkylcarbonyl," as used herein, refers to the group -C(O)-heterocycloalkyl where heterocycloalkyl is a heterocycloalkyl group as previously defined.
[0095] The term "heterocycloalkylthiocarbonyl," as used herein, refers to the group -C(S)-heterocycloalkyl where heterocycloalkyl is a heterocycloalkyl group as previously defined.
[0096] The term "aminoalkylcarbonyl," as used herein, refers to the group -C(O)-R' -NH2 where R' is an alkyl group as previously defined.
[0097] The term "alkoxycarbonylaminothiocarbonyl," as used herein, refers to the group -C(O)-S-NH-C(O)-O-R' where R' is an alkyl group as previously defined.
[0098] The term "alkoxycarbonylalkylaminothiocarbonyl," as used herein, refers to the group -C(O)-S-NH-R'-C(O)-O-R' where R' is an alkyl group as previously defined.
[0099] The term "alkylthiocarbonylalkylcarbonyl," as used herein, refers to the group -C(O)-R' -C(O)-S-R' where R' is an alkyl group as previously defined.
[0100] The term "cyanoalkoxycarbonyl," as used herein, refers to the group -C(O)-alkoxy-CN where alkoxy refers to an alkoxy group as previously defined.
[0101] The term "alkylaryl," as used herein, refers to the group -aryl-R' where R' is an alkyl group as previously defined, and aryl is an aryl group as previously defined.
[0102] The term "alkylester," as used herein, refers to the group -C(O)OR' wherein R' is an alkyl group as previously defined.
[0103] The term "aminocarbonyl," as used herein, refers to the group -C(O)NH2.
[0104] The terms "alkylaminocarbonyl," and "dialkylaminocarbonyl," as used herein, refer to the groups -C(O)NHR' and -C(0)N(R')2, respectively, where each R' is, independently, an alkyl group as previously defined.
[0105] The term "heterocycloalkylaminocarbonyl," as used herein, refers to the group -C(O)NH-heterocycloalkyl where heterocycloalkyl is a heterocycloalkyl group as previously defined. [0106] The term "carboxyalkylcarbonylheterocycloalkylaminocarbonyl," as used herein, refers to the group -heterocycloalkylaminocarbonyl-C(O)-R'-C(O)OH where heterocycloalkylaminocarbonyl is a heterocycloalkylaminocarbonyl group as previously defined and R' is an alkyl group as previously defined.
[0107] The term "carboxyalkylaminocarbonyl," as used herein, refers to the group -alkylaminocarbonyl-carboxy where carboxy is a carboxy group as previously defined and alkylaminocarbonyl is an alkylaminocarbonyl group as previously defined.
[0108] The term "alkoxycarbonylalkylaminocarbonyl," as used herein, refers to the group -alkylaminocarbonyl -carbonyl-alkoxy where alkoxy is an alkoxy group as previously defined, carbonyl is a carbonyl group as previously defined, and alkylaminocarbonyl is an alkylaminocarbonyl group as previously defined.
[0109] The term "aminocarbonylalkyl," as used herein, refers to the group -R5C(O)NH2 where R' is an alkyl group as previously defined.
[0110] The terms "alkylaminocarbonylalkyl," and "dialkylaminocarbonylalkyl," as used herein, refer to the groups -R3C(O)NHR' and -R' C(O)N(R' )2, respectively, where each R' is, independently, an alkyl group as previously defined.
[0111] The terms "alkylaminothiocarbonyl," and "dialkylaminothiocarbonyl," as used herein, refer to the groups -C(S)NHR' and -C(S)N(R')2, respectively, where each R' is, independently, an alkyl group as previously defined.
[0112] The term "heterocycloalkylcarbonylalkyl," as used herein, refers to the group -R'C(O)heterocycloalkyl where R' is an alkyl group as previously defined and heterocycloalkyl is a heterocycloalkyl group as previously defined.
[0113] The term "arylaminocarbonyl," as used herein, refers to the group - C(O)NH(aryl), where aryl is an aryl group as previously defined.
[0114] The term "heteroarylaminocarbonyl," as used herein, refers to the group -C(O)NH(heteroaryl), where heteroaryl is a heteroaryl group as previously defined.
[0115] The term "heteroarylaminothiocarbonyl," as used herein, refers to the group -C(S)NH(heteroaryl), where heteroaryl is a heteroaryl group as previously defined.
[0116] The term "arylaminothiocarbonyl," as used herein, refers to the group -C(S)NH(aryl), where aryl is an aryl group as previously defined. [0117] The term "cycloalkylaminocarbonyl," as used herein, refers to an alkylaminocarbonyl or dialkylaminocarbonyl group as previously defined in which at least one alkyl group is replaced by a cycloalkyl group.
[0118] The term "alkylsulfonyl," as used herein, refers to the group -S(O)2-R' where R' is an alkyl group as previously defined.
[0119] The term "alkylsulfmyl," as used herein, refers to the group -S(O)-R' where R' is an alkyl group as previously defined.
[0120] The term "alkylthio," as used herein, refers to the group -S-R' where R' is an alkyl group as previously defined.
[0121] The term "perfluoroalkylthio," as used herein, refers to the group -S-R" where R" is a perfluoroalkyl group as previously defined.
[0122] The term "tertiary alkylcarbinol," as used herein, refers to the group -C(R')2OH where R' is an alkyl group as previously defined.
[0123] The term "tertiary cycloalkylcarbinol," as used herein, refers to the group -C(cycloalkyl)2OH where cycloalkyl refers to a cycloalkyl group as previously defined.
[0124] The term "tertiary alkylcycloalkylcarbinol," as used herein, refers to the group -C(R')(cycloalkyl)OH where R' refers to an alkyl group as previously defined, and cycloalkyl refers to a cycloalkyl group as previously defined.
[0125] The term "tertiary arylcarbinol," as used herein, refers to the group -C(aryl)2θH where each "aryl" independently refers to an aryl group as previously defined.
[0126] The term "tertiary arylalkylcarbinol," as used herein, refers to the group -C(R')(aryl)OH where R' is an alkyl group as previously defined, and aryl is an aryl group as previously defined.
[0127] The term "phosphonic acid alkyl," as used herein, refers to the group -R'-P(O)(OH)2 where R' is an alkyl group as previously defined.
[0128] The term "dimethylphosphonatealkyl," as used herein, refers to the group -R'-P(O)(OCH3)2 where R' is an alkyl group as previously defined.
[0129] The term "partially saturated," as used herein, refers to a nonaromatic cycloalkyl or heterocycloalkyl group containing at least one double bond and preferably one or two double bonds.
[0130] The term "therapeutically effective amount," as used herein, refers to the amount of a compound of formula 1 that, when administered to a patient, is effective to at least partially treat a condition from which the patient is suffering or is suspected to suffer. Such conditions include, but are not limited to, osteoporosis, arthritis, chronic obstructive pulmonary disease, cartilage defects, bone fractures, and leiomyoma.
[0131] The term "pharmaceutically acceptable salts" or "pharmaceutically acceptable salt" includes acid addition salts, namely salts derived from treating a compound of formula 1 with an organic or inorganic acids or bases. Where the compound having formula I has an acidic function, for instance where R3 is carboxyalkyl or R8 is carboxy or phenolic hydroxyl, the term "pharmaceutically acceptable salts" or "pharmaceutically acceptable salt" includes salts derived from bases, for instance, sodium salts.
[0132] The term "patient," as used herein, refers to a mammal.
[0133] The terms "administer," "administering," or "administration," as used herein, refer to either directly administering a compound or composition to a patient, or administering a prodrug derivative or analog of the compound to the patient, which will form an equivalent amount of the active compound or substance within the patient's body.
[0134] The terms "treat" and "treating," as used herein, refer to partially or completely alleviating, inhibiting, preventing, ameliorating and/or relieving a condition from which a patient is suspected to suffer.
[0135] The terms "suffer" and "suffering," as used herein, refer to one or more conditions with which a patient has been diagnosed, or is suspected to have.
[0136] Certain embodiments of the invention relate to compounds of Formula (1):
Figure imgf000016_0001
or a pharmaceutically acceptable salt thereof, wherein
R1 is
Figure imgf000017_0001
and each R1 group is optionally substituted with up to three R8 groups;
Y is O, S, or NR9;
R8 is alkyl, arylalkyl, perfluoroalkyl, alkenyl, arylalkenyl, alkynyl, arylallcynyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, aryl, alkylaryl, heteroaryl, alkoxy, perfluoroalkoxy, arylalkoxy, alkylcarbonyl, arylcarbonyl, halogen, cyano, azido, hydroxyl, carboxy, alkoxycarbonyl, alkylamino, dialkylamino, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, alkylcarbonylalkylamino, hydroxyalkylamino, nitro, alkylcarbonyloxime, alkylsulfonyl, alkylsulfinyl, alkylthio, perfluoroalkylthio, arylthio, tertiary alkylcarbinol, tertiary alkylcycloalkylcarbinol, or tertiary arylalkylcarbinol;
R9 is hydrogen, alkyl, aryl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, or spirocycloalkyl;
X is oxygen or an electron pair;
R2 is hydrogen, alkyl, alkoxy, cycloalkyl, perfluoroalkyl, perfluoroalkylalkyl, perfluoroalkoxy, dialkylamino, or halogen;
R4 is hydrogen, halogen, alkyl, cycloalkyl, alkoxy, perfluoroalkyl, or perfluoroalkoxy; or R2 and R4, together with the carbon atoms to which they are attached, form a cycloalkyl ring of 5 to 7 carbon atoms that is optionally substituted with 1 to 3 R groups; each R is, independently, hydrogen, alkyl, arylalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, spirocycloalkyl, aryl, arylalkyl, or alkoxyalkyl;
R5, and R6 are, independently, hydrogen, alkyl, aryl, alkoxy, halogen, or perfluoroalkyl;
R3 and R7 are each, independently, hydrogen or an optionally substituted alkyl, cycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, heteroarylalkyl, alkylaryl, alkylheteroaryl, alkenyl, alkynyl, fused cycloalkylaryl, fused heterocycloalkylaryl, cycloalkylcarbonyl, or heterocycloalkylcarbonyl group; or R3 and R7, together with the nitrogen atom to which they are attached, form a five or six membered heterocycloalkyl ring optionally substituted with 1 to 5 substituents selected from alkyl, aryl, heterocycloalkyl, heterocycloalkylalkyl, alkylamino, dialkylamino, alkoxycarbonyl, alkylcarbonyl, allcylaminocarbonylalkyl, and heterocycloalkylcarbonylalkyl; provided that the compound is not
2-methyl-N-(2-phenylethyl)-5-(phenylsulfonyl)-benzenesulfonamide;
2-methyl-N-(2-phenylmethyl)-5-(phenylsulfonyl)-benzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-cyclohexyl-2-methylbenzenesulfonamide;
N-benzyl-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-(2-furylmethyl)-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-benzenesulfonamide;
5 - [(4-bromopheny l)sulfonyl] -2-methylbenzenesulfonamide ;
2-methyl-5-[(4-nitrophenyl)sulfonyl]-benzenesulfonamide;
5-[(2,4-dinitrophenyl)sulfonyl]-2-methyl-benzenesulfonamide; or
5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(3-pyridinylmethyl)-benzenesulfonamide.
[0137] Any carbon or nitrogen atom in R1, R2, R3, R4, R5, R6, and R7, as defined herein, may be optionally substituted with one or more substituents understood by those skilled in the art to be suitable substituents. The following lists provide exemples of such substituents.
[0138] The alkyl, cycloalkyl, alkylheterocycloalkyl, heteroarylalkyl, alkylaryl, alkylheteroaryl, alkenyl, alkynyl, fused cycloalkylaryl, fused heterocycloalkylaryl, cycloalkylcarbonyl, and heterocycloalkylcarbonyl groups of R3 and R7 may each be, independently, optionally substituted with 1 to 5 substituents selected from alkyl, perfluoroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, fused cycloalkylaryl, alkoxy, aminocarbonylalkoxy, alkoxycarbonylalkoxy, carboxyalkoxy, cycloalkyloxy, aryloxy, amino, alkylamino, dialkylamino, alkoxycarbonylamino, carboxy, cyano, halogen, oxo, hydroxyl, alkylcarbonyl, carboxyalkylcarbonyl, arylaminocarbonyl, heterocycloalkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, fused cycloalkylarylaminocarbonyl, and fused heterocycloalkylarylcarbonyl.
[0139] The cycloalkyl, heterocycloalkyl, aryl, and heteroaryl substituents on the alkyl groups ofR3 and R7 may be, independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, spirocycloalkyl, perfluoroalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, dimethylphosphonatealkyl, phosphonic acid alkyl, arylalkyl, cycloalkylallcyl, alkoxy, perfluoroalkoxy, arylalkoxy, benzoxy, aryl, heteroaryl, carboxyaryl, arylcarbonyl, alkylcarbonyl, perfluoroalkylcarbonyl, alkoxycarbonyl, carboxyalkylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, aryloxythiocarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocycloalkylcarbonyl, heterocycloalkylthiocarbonyl, arylthiocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, dialkylaminoarylcarbonyl, dialkylaminoalkylcarbonyl, alkylthiocarbonyl, arylaminocarbonyl, heteroarylcarbonyl, heteroarylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, arylsulfonylarylsulfonyl, carboxyarylsulfonyl, nitro, amino, dialkylamino, alkylcarbonylamino, alkylsulfonylamino, carboxyarylsulfonylamino, hydroxy, carboxy, sulfonamide, alkylthio, halogen, cyano, guanidine, and oxo, and the nitrogen atoms in the heteroaryl substituents may be optionally substituted with an oxygen atom.
[0140] The heterocycloalkyl groups of R3 and R7 may be independently, optionally substituted with 1 to 5 substituents selected from alkyl, hydroxyalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heterocycloalkylcarbonylalkyl, arylalkyl, heteroarylalkyl, arylcarbonylalkyl, alkylcarbonyl, cyano, alkylester, alkylamide, cycloalkylamide, aryl, arylester, alkylcarbonyl, perfluoroalkylcarbonyl, aminocarbonyl, arylaminocarbonyl, arylaminothiocarbonyl, cyanoalkoxycarbonyl, cycloalkylcarbonyl, arylcarbonyl, arylthiocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, heteroarylcarbonyl, heterocycloalkylcarbonyl, cyanoarylcarbonyl, arylalkylcarbonyl, alkoxycarbonyl, alkoxyalkylcarbonyl, alkylthioalkylcarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocycloalkylalkylcarbonyl, heterocycloalkylalkylaminothiocarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, heteroarylalkylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylaminothiocarbonyl, alkoxycarbonylalkylaminothiocarbonyl, alkylthiocarbonylalkylcarbonyl, alkylsulfonyl, arylsulfonyl, alkylaminoarylsulfonyl, and heteroarylsulfonyl.
[0141] The cycloalkyl, heterocycloalkyl, aryl, and heteroaryl substituents on the heterocycloalkyl groups of R3 and R7 may be independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, spirocycloalkyl, perfluoroalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, dimethylphosphonatealkyl, phosphonic acid alkyl, arylalkyl, cycloalkylalkyl, alkoxy, perfluoroalkoxy, arylalkoxy, benzoxy, aryl, heteroaryl, carboxyaryl, arylcarbonyl, alkylcarbonyl, perfluoroalkylcarbonyl, alkoxycarbonyl, carboxyalkylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, aryloxythiocarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocycloalkylcarbonyl, heterocycloalkylthiocarbonyl, arylthiocarbonyl, alkylaminocarbonyl, diallcylaminocarbonyl, dialkylaminoarylcarbonyl, dialkylaminoalkylcarbonyl, alkylthiocarbonyl, arylaminocarbonyl, heteroarylcarbonyl, heteroarylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, arylsulfonylarylsulfonyl, carboxyarylsulfonyl, nitro, amino, dialkylamino, alkylcarbonylamino, alkylsulfonylamino, carboxyarylsulfonylamino, hydroxy, carboxy, sulfonamide, alkylthio, halogen, cyano, guanidine, and oxo, and the nitrogen atoms in the heteroaryl substituents may be optionally substituted with an oxygen atom.
[0142] The amino substituents on the alkyl groups of R3 and R7 may be, independently, optionally substituted with 1 or 2 substituents selected from alkyl, hydroxyalkyl, carboxyalkyl, cycloalkyl, alkoxycarbonylalkyl, aryl, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl, cycloalkylcarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, alkoxy carbonylalkylaminocarbonyl, carboxyalkylcarbonyl, carboxyalkylaminocarbonyl, carboxyalkylcarbonylheterocycloalkylaminocarbonyl, arylaminocarbonyl, arylcarbonyl, heteroarylaminocarbonyl, heterocycloalkylcarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, heterocycloalkylaminocarbonyl, heterocycloalkylthiocarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, and aryloxythiocarbonyl.
[0143] The cycloalkyl, heterocycloalkyl, aryl, and heteroaryl substituents on the amino substituents on the alkyl groups of R3 and R7 may be, independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, spirocycloalkyl, perfluoroalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, dimethylphosphonatealkyl, phosphonic acid alkyl, arylalkyl, cycloalkylalkyl, alkoxy, perfluoroalkoxy, arylalkoxy, benzoxy, aryl, heteroaryl, carboxyaryl, arylcarbonyl, alkylcarbonyl, perfluoroalkylcarbonyl, alkoxycarbonyl, carboxyalkylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, aryloxythiocarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocycloalkylcarbonyl, heterocycloalkylthiocarbonyl, arylthiocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, dialkylaminoarylcarbonyl, dialkylaminoalkylcarbonyl, alkylthiocarbonyl, arylaminocarbonyl, heteroarylcarbonyl, heteroarylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, arylsulfonylarylsulfonyl, carboxyarylsulfonyl, nitro, amino, dialkylamino, alkylcarbonylamino, alkylsulfonylamino, carboxyarylsulfonylamino, hydroxy, carboxy, sulfonamide, alkylthio, halogen, cyano, guanidine, and oxo, and the nitrogen atoms in the heteroaryl substituents may be optionally substituted with an oxygen atom.
[0144] The alkyl group substituents on the heterocycloalkyl ring formed from R3 and R7, together with the nitrogen atom to which they are attached may each be, independently, optionally substituted with 1 to 5 substituents selected from aryl, heteroaryl optionally substituted with one to three alkyl groups, aminoalkyl, heterocycloalkyl, fused heterocycloalkylaryl, and heterocycloalkylcarbonyl.
[0145] In preferred embodiments of the invention R1 of Formula 1 is aryl.
[0146] In other embodiments of the invention, R1 of Formula 1 is
Figure imgf000021_0001
[0147] Certain aspects of the invention relate to compounds of Formula 1 wherein each R8 is, independently, alkyl, alkylaryl, alkylheteroaryl, alkylamino, dialkylamino, carboxy, alkylcarbonyl, alkoxy, perfluoroalkoxy, halogen, or cyano.
[0148] Other aspects of the invention are directed to compounds of Formula 1 in which X is oxygen.
[0149] Additional embodiments of the invention relate to compounds of Formula 1 in which R4, R5, and R6 are each hydrogen. Alternative embodiments of the invention relate to compounds of Formula 1 in which R4 is methyl and R5 and R6 are each hydrogen, or R5 is methyl and R4 and R6 are each hydrogen, or R6 is methyl and R4 and R5 are each hydrogen.
[0150] Further embodiments of the invention are directed to compounds of Formula I in which R4 is halogen, alkyl, cycloalkyl, alkoxy, perfluoroalkyl, or perfluoroalkoxy. [0151] Other aspects of the invention are directed to compounds of Formula I in which R5, and R6 are, independently, alkyl, alkoxy, halogen, or perfluoroalkyl.
[0152] Certain embodiments of the invention are directed to compounds of Formula 1 in which R2 is methyl, ethyl, isopropyl, propyl, Cl, methoxy, trifluoromethyl, or trifluoromethoxy. In preferred embodiments, R2 is methyl, isopropyl, trifluoromethyl, or trifluoromethoxy. In particularly preferred embodiments, R2 is isopropyl or trifluoromethyl.
[0153] Still further embodiments of the invention relate to compounds of Formula I in which R2 is hydrogen, alkoxy, cycloalkyl, perfluoroalkyl, perfluoroalkylalkyl , perfluoroalkoxy, dialkylamino, or halogen.
[0154] Other aspects of the invention relate to compounds of Formula 1 in which R3 and R7, together with the nitrogen atoms to which they are attached, form an optionally substituted 5 or 6 membered heterocycloalkyl group. In preferred aspects, R3 and R7, together with the nitrogen atoms to which they are attached, form an optionally substituted piperazinyl group.
[0155] Additional embodiments of the invention relate to compounds of Formula I in which R3 and R7 are each, independently, alkyl, heterocycloalkyl, heterocycloalkylalkyl, alkylheterocycloalkyl, arylalkyl, heteroarylalkyl, alkenyl, alkynyl, fused cycloalkylaryl, fused heterocycloalkylaryl, cycloalkylcarbonyl, alkoxyalkyl, alkoxycarbonylalkyl, cyanoalkyl, aminoalkyl, dialkylaminocarbonylalkyl, or alkylalkylaminocarbonylalkyl.
[0156] Further embodiments of the invention are directed to compounds of Formula 1 in which R7 is hydrogen and R3 is alkyl, cycloalkyl,
Figure imgf000023_0001
wherein the carbon atoms of each alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group are optionally substituted with up to four R13 groups;
R13 is hydrogen, F, Cl, Br, alkyl, alkoxy, aryl, nitro, aminosulfonyl, arylalkoxy, perfluoroalkyl, perfluoroalkoxy, amino, alkylamino, dialkylamino, hydroxy, carboxy, cycloalkyl, carboxyalkyl, carboxyalkoxy, alkoxycarbonyl, aminocarbonylalkyl, alkoxycarbonylalkoxy,ammocarbonylalkoxy, alkylaminocarbonylallcyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, heterocycloalkylcarbonyl, heterocycloalkylaminocarbonyl, alkylaminocarbonylalkoxy, dialkylaminocarbonylalkyl, dialkylaminocarbonylalkoxy, heterocycloalkylcarbonylalkyl, heterocycloalkylaminocarbonylalkoxy, heterocycloalkylcarbonylalkoxy, cycloalkylaminoalkyl, heterocycloalkylaminoalkyl, aminoalkylaminoalkylarylamionalkyl, heteroarylaminoalkylarylalkylaminoallcyl, heteroarylalkylaminoalkyl, alkylaminoalkylamino, dialkylaminoalkylaminoarylamino, heteroarylaminoarylalkylamino, heteroarylalkylamino, or cyano; each R12 is alkyl, aryl, alkylamino, dialkylamino, alkoxy, hydroxyl, amino, arylamino, diarylamino, aryl(alkyl)amino, or aryloxy; each R14 is hydrogen, alkyl, aryl, cycloalkyl, alkylcarbonyl, arylcarbonyl, aryloxycarbonyl, alkylsulfonyl, arylsulfonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, heterocycloalkylcarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, heterocycloalkylthiocarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, alkoxycarbonylaminothiocarbonyl, cycloalkylcarbonyl, aminocarbonyl, alkoxycarbonyl, cycloalkylaminocarbonyl, heterocycloalkylaminocarbonyl, cycloalkylsulfonyl, heterocycloalkylsulfonyl, heteroarylsulfonyl, or aryloxythiocarbonyl;
R15 is hydrogen, alkyl, aryl, cycloalkyl, alley lcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, heterocycloalkylcarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, heterocycloalkylthiocarbonyl, heterocycloalkylalkylaminothiocarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, arylthiocarbonyl, alkoxythiocarbonyl, or aryloxythiocarbonyl;
R16, R17 and R18 are each, independently, hydrogen, alkyl, aryl or cycloalkyl; m is 0, I, or 2; p is 0, 1, or 2; q is 1 or 2; s is 1 or 2; and
W is NR9, O, or S.
[0157] The alkyl, aryl and cycloalkyl groups of R13, R14 and R15 may each be, independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, perfluoroalkyl, aryl, heteroaryl, alkoxy, aryloxy, cycloalkyloxy, amino, alkylamino, dialkylamino, carboxy, cyano, oxo, hydroxyl, alkylcarbonyl, alkoxycarbonyl, arylcarbonyl, alkoxycarbonylamino, alkylcarbonylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthio, alkyloxothio, and alkoxycarbonylalkylamino.
[0158] The arylsulfonyl, arylcarbonyl and heteroarylcarbonyl groups of R13, R14 and R15 may be each, independently, optionally substituted with 1 to 5 substituents selected from hydrogen, halogen, hydroxyl, alkyl, cycloalkyl, perfluoroalkyl, aryl, alkoxy, heterocycloalkyl, heteroaryl, cycloalkyloxy, aryloxy, amino, alkylamino, dialkylamino, alkylthio, alkyloxothio, carboxy, cyano, oxo, alkylcarbonyl, arylcarbonyl,alkoxycarbonyl, alkylcarbonylamino, aminocarbonyl, alkylaminocarbonyl, and dialkylaminocarbonyl.
[0159] The heterocycloalkyl groups OfR13, R14 and R15 may each be, independently, optionally substituted with 1 to 5 substituents selected from hydrogen, hydroxyl, alkyl, cycloalkyl, perfluoroalkyl, aryl, heterocycloalkyl, heteroaryl, heteroarylcarbonyl, heteroarylalkylcarbonyl, alkylcarbonyl, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, arylcarbonyl, heteroarylcarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, heterocycloalkylcarbonylalkyl, carboxyalkylcarbonyl, and arylaminocarbony 1.
[0160] In addition, the alkylcarbonyl groups of R13, R14 and R15 may each be, independently, optionally substituted with 1 to 5 substituents selected from amino, alkylamino, dialkylamino, cycloalkyl, heterocycloalkyl, perfluoroalkyl, aryl, heteroaryl, alkoxy, aryloxy, cycloalkyloxy, carboxy, cyano, oxo, hydroxyl, alkylcarbonyl, alkoxycarbonyl, arylcarbonyl, and alkoxy carbony lamino .
[0161] The amino groups of the alkylamino and hetercycloalkylamino groups OfR13, R14 and R15 may each be, independently, optionally substituted with a substituent selected from hydrogen, alkyl, cycloalkyl, and aryl.
[0162] Particular embodiments of the invention relate to compounds of Formula 1 in which R7 is hydrogen and R3 is heteroarylethyl, heteroarylpropyl, arylethyl, heterocycloalkyl, heterocycloalkylethyl, heterocycloalkylpropyl, heterocycloalkylmethyl, heterocyclalkylamino, cycloalkyl, fused cycloalkylaryl, aminoalkyl, or alkoxyalkyl. In preferred embodiments R7 is hydrogen and R3 is heteroarylethyl, heteroarylpropyl, heterocyclalkylamino, fused cycloalkylaryl, or phenylethyl. In particularly preferred embodiments R7 is hydrogen and R3 is pyridinylethyl, imidazolylethyl, imidazolylpropyl, heterocyclalkylamino, fused cycloalkylaryl, or phenylethyl.
[0163] Specific, representative compounds of Formula 1 include: Λ/-(2-phenylethyl)-3-(phenylsulfonyl)benzenesulfonamide; iV-[2-(2-chlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N- [2-(3 -methoxypheny l)ethy 1] -3 -(phenylsulfony l)benzenesulfonamide ; Λ/-[2-(3,4-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; jV-[2-(4-bromophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; iV-[2-(4-fluorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(4-chlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonaniide;
Λ/-[2-(4-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
JV- [2-(4-methy lpheny l)ethyl] -3 -(pheny lsulfony l)benzenesulfonamide ;
N-{2-[4-(aminosulfonyl)phenyl]ethyl}-3-(phenylsulfonyl)benzenesulfonamide;
JV- { 2- [3 ,4-bis(benzyloxy )pheny 1] ethyl } -3 -(pheny lsulfony l)benzenesulfonamide;
7V-[2-(4-nitrophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
JV- [2-( 1 ,3 -benzodioxol-5 -y l)ethy 1] -3 -(pheny lsulfony l)benzenesulfonamide ;
3 -(pheny lsulfony Y)-N- { 2- [3 -(trifluoromethyl)pheny 1] ethyl } benzenesulfonamide;
JV-[2-(3-chlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
JV- [2-(2,4-dichloropheny l)ethy 1] -3 -(phenylsulfony l)benzenesulfonamide ;
JV-[2-(2,6-dichlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
JV-[2-(2,5-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
JV-[2-(3,4-dichlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; iV-[2-(3,5-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonaniide;
JV- [2-(4-ethoxypheny l)ethy l]-3 -(phenylsulfony l)benzenesulfonamide ;
JV-[2-(3-fluorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(2-fluorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
JV-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
JV- [2-(4-ethoxy-3 -methoxyphenyl)ethyl] -3 -(pheny lsulfony l)benzenesulfonamide;
JV-(4-methoxybenzyl)-3-(phenylsulfonyl)benzenesulfonamide;
JV-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
JV-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
JV3-{[3-(phenylsulfonyl)phenyl]sulfonyl}-beta-alaninamide; methyl JV- { [3-(phenylsulfonyl)phenyl]sulfonyl} -beta-alaninate;
JV-(2-cyanoethyl)-3-(phenylsulfonyl)benzenesulfonamide;
3-(phenylsulfonyl)-JV-(2-pyridin-2-ylethyl)benzenesulfonamide;
JV-(3 -morpholin-4-y lpropyl)-3 -(pheny lsulfony l)benzenesulfonamide ;
JV- [2-( 1 -methy lpyrrolidin-2-y l)ethyl] -3 -(phenylsulfony l)benzenesulfonamide ;
3 -(pheny lsulfony l)-JV-(2-pyridin-4-ylethyl)benzenesulfonamide ; AlYJLJLU JLOO3 - 26 -
3-(phenylsulfonyl)-iV-(2-piperidin-l-ylethyl)benzenesulfonamide;
N-[2-(lH-imidazol-4-yl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-({[3-(phenylsulfon.yl)phenyl]sulfonyl}amino)ethyl]acetatnide; iV-(2-morpholin-4-ylethyl)-3-(phenylsulfonyl)benzenesulfonamide; iV-[3-(2-oxopyrrolidin-l-yl)propyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(diethylamino)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; iV-[2-(diinethylamino)ethyl]-3-(pb-enylsulfoiiyl)benzenesulfonamide;
JV-(3 -methoxypropy l)-3 -(pheny lsulfony l)benzenesulfonamide ;
N-[3-(dimeth.ylamino)propyl]-3-(pb.enylsulfonyl)benzenesulfonamide;
N-(2-methoxy ethyl)-3 -(pheny lsulfony l)benzenesulfonamide ;
N-[3-(diethylamino)propyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-3-(phenylsulfonyl)benzenesulfonamide;
3-(phenylsulfonyl)-N-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide;
N-[3-(4-methylpiperazin-l-yl)propyl]-3-(phenylsulfonyl)benzenesulfonamide;
N- { [3 -(pheny lsulfony l)pheny 1] sulf ony 1} -beta-alanine ;
N-2,3-dihydro-lH-inden-2-yl-3-(phenylsulfonyl)benzenesulfonamide;
^[(lS^^^-phenylcyclopropylj-S-φhenylsulfony^benzenesulfonamide;
N-[(2i?)-2-phenylpropyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[(25)-2-phenylpropyl]-3-(phenylsulfonyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-iV-(2-phenylethyl)benzenesulfonamide;
N-[2-(2-chlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-ΛT-[2-(2-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-iV-[2-(3-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide;
N-[2-(3,4-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; iV-[2-(4-broniophenyl)ethyl]-5-[(4-fluoroρhenyl)sulfonyl]-2-niethylbenzenesulfonamide;
JV-[2-(4-fiuorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
Λr-[2-(4-chlorophenyl)ethyl]-5-[(4-fluoroρhenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-[2-(4-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[2-(4-methylphenyl)ethyl]benzenesulfonamide;
7V-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide; iV-{2-[3,4-bis(benzyloxy)phenyl]ethyl}-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-iV-[2-(4-nitrophenyl)ethyl]benzenesulfonamide;
N-[2-(l,3-benzodioxol-5-yl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-{2-[3-
(trifluoromethy l)pheny 1] ethyl} benzenesulfonamide ;
Λ/-[2-(3-chlorophenyl)ethyl]-5-[(4-fluoropb.enyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[2-(2,4-dichlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[2-(2,6-dichlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; iV-[2-(2,5-dimethoxyphenyl)ethyl]-5-[(4-fluoroplienyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[2-(3,4-dichlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[2-(3,5-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N- [2-(4-ethoxyphenyl)ethy 1] -5- [(4-fluoropheny l)sulfony 1] -2-methy lbenzenesulfonamide ;
N-[2-(3-fluorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
J/V-[2-(2-fluorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N- [2-(3 -ethoxy-4-methoxypheny l)etliy 1] -5 - [(4-fluoropheny l)sulfonyl] -2- methylbenzenesulfonamide; iV-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-iV-(4-methoxybenzyl)-2-methylbenzenesulfonaniide;
Λ/-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
7V-[2-(5-bromo-2-methoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
2-Methyl-N- (2-phenylethyl)-5-(phenylsulfonyl) benzene sulfonamide; iV-[2-(2-chlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(2-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
Λ/-[2-(3-methoxyphenyl)ethyl]-2-raethyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(4-bromophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
Λ/-[2-(4-fluorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(4-chlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(4-methoxyphenyl)ethyl]-2-metliyl-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[2-(4-methylphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-{2-[3,4-bis(benzyloxy)phenyl]ethyl}-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[2-(4-nitrophenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(l,3-benzodioxol-5-yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-{2-[3-(trifluoromethyl)phenyl]ethyl}benzenesulfonamide; iV-[2-(3-chloropb.enyl)ethyl]-2-metb.yl-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(2,4-dichlorophenyl)etliyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(2,6-dichlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(2,5-dimethoxyplienyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3,4-dichlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3,5-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(4-ethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3-fluorophenyl)ethyl]-2-methyl-5-(phen.ylsulfonyl)benzenesulfonamide;
N-[2-(2-fluorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-(4-methoxybenzyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(5-bromo-2-methoxyphenyl)ethyl]-2-methyl-5-φhenylsulfonyl)beiizenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-iV-(2-phenylethyl)benzenesulfonamide;
N-[2-(2-chlorophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5 - [(4-chloropheny l)sulfony I]-N- [2-(2-methoxypheny l)ethy 1] -2-methy lbenzenesulfonamide ;
5-[(4-chlorophenyl)sulfonyl]-N-[2-(3-methoxyphenyl)ethyl]-2-methylberizenesulfonamide;
5-[(4-cMorophenyl)sulfonyl]-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-methylbenzenesulfonamide;
N-[2-(4-bromophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-[2-(4-fluorophenyl)ethyl]-2-methylbenzenesulfonamide;
N-[2-(4-cliloropb.enyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5- [(4-chloropheny l)sulfonyl] -N- [2-(4-methoxypheny l)ethy 1] -2-methy lbenzenesulfonamide ;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[2-(4-methylphenyl)ethyl]benzenesulfonamide; N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-[(4-chlorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[2-(4-nitrophenyl)ethyl]benzenesulfonamide;
N-[2-(l,3-benzodioxol-5-yl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-JV-{2-[3-
(trifluoromethyl)pheny 1] ethyl} benzenesulfonamide ;
N- [2-(3 -chloropheny l)ethy 1] -5 - [(4-chlorophenyl)sulfony 1] -2-methylbenzenesulfonamide ;
5-[(4-chlorophenyl)sulfonyl]-iV-[2-(2,4-dichlorophenyl)ethyl]-2-niethylbenzenesulfonamide;
5 - [(4-chloropheny l)sulfony 1] -N- [2-(2,6-dichlorophenyl)ethy 1] -2-methylbenzenesulfonamide ;
5-[(4-chlorophenyl)sulfonyl]-N-[2-(2,5-dimethoxyphenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-iV-[2-(354-dichlorophenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-iV-[2-(3,5-dimethoxyphenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-[2-(4-ethoxyphenyl)etliyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-[2-(3-fluorophenyl)ethyl]-2-methylbenzenesulfonamide;
5- [(4-chloropheny l)sulfonyl] -JV- [2-(2-fluoropheny l)ethyl] -2-methylbenzenesulfonamide ;
5-[(4-chlorophenyl)sulfonyl]-JV-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-2- methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-JV-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-2- methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-JV-(4-methoxybenzyl)-2-methylbenzenesulfonamide;
JV-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
JV-[2-(5-bromo-2-methoxyphenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
2-methyl-5-[(4-methylphenyl)sulfonyl]-N-(2-phenylethyl)benzenesulfonamide;
N-[2-(2-chlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
JV-[2-(2-methoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
JV-[2-(3-methoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
7V-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
JV-[2-(4-bromophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
JV-[2-(4-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(4-chlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]beixzenesulfonamide; N-[2-(4-methoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
2-methyl-N-[2-(4-methylphenyl)ethyl]-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-methyl-5-[(4- methylphenyl)sulfonyl]beiizenesulfonamide;
2-methyl-5-[(4-methylphenyl)sulfonyl]-N-[2-(4-nitrophenyl)ethyl]benzenesulfonamide;
N-[2-(l,3-benzodioxol-5-yl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
2-methyl-5-[(4-methylphenyl)sulfonyl]-N-{2-[3-
(trifluoromethyl)phenyl]ethyl}benzenesulfonamide; iV-[2-(3-chlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(2,4-dichlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(2,6-dichlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(2,5-dimethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; iV-[2-(3,4-dichlorophenyl)ethyl]-2-methyl-5-[(4-methylpb.enyl)sulfonyl]benzenesulfonaniide;
N-[2-(3,5-dimethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(4-ethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(3-fluorophenyl)ethyl]-2-meώyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(2-fluorophenyl)etb.yl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-2-methyl-5-[(4- methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(5-bromo-2-methoxyphenyl)ethyl]-2-methyl-5-[(4- methylphenyl)sulfonyl]benzenesulfonamide;
2-ethyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-7V-[2-(2-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-iV-[2-(3-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(3,4-dimethoxyphenyl)ethyl]-2-etb.yl-5-(phenylsulfonyl)benzenesulfonamide;
N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-etb.yl-5-(phenylsulfonyl)benzenesulfonamide;
2-etb.yl-N-[2-(3-fluorophenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-iV-[2-(2-fluoiOphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(3-ethoxy-4-metb.oxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide;
2-methoxy-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-methoxy-N-[2-(2-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; 2-methoxy-N-[2-(3-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3,4-dimethoxyphenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonaniide;
N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3-fluorophenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(2-fluoroplienyl)ethyl]-2-methoxy-5-(pb.enylsulfonyl)benzenesulfonamide;
N-[2-(3-ethoxy-4-metb.oxyphenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfoiiamide;
N-[2-(4-ethoxy-3-methoxypb.enyl)etb.yl]-2-metb.oxy-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-N-(3-phenylpropyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-iV-(3-phenylpropyl)-5-(phenylsulfonyl)benzenesulfonaniide;
N-2,3-dihydro-lH-inden-2-yl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-iV-[(15',2i?)-2-phenylcyclopropyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-iV-[(2i?)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-2,3-dihydro-li7-inden-2-yl-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-metb.yl-N-[(15',2i?)-2-phenylcyclopropyl]benzenesulfonaniide;
5 - [(4-fluoropheny l)sulfonyl] -2-methy 1-N- [(2i?)-2-pheny lpropy l]benzenesulfonamide ;
N-2,3-dihydro-lH-inden-2-yl-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
2-methyl-5-[(4-methylphenyl)sulfonyl]-N-[(15',2i?)-2-phenylcyclopropyl]benzenesulfonamide;
2-methyl-5-[(4-methylphenyl)sulfonyl]-N-[(2i?)-2-phenylpropyl]benzenesulfonamide;
5-[(4-cUorophenyl)sulfonyl]-N-2,3-dihydro-lH-inden-2-yl-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-iV-[(l)S',2JR)-2-phenylcyclopropyl]benzenesulfonamide;
5 - [(4-chloropheny l)sulfony 1] -2-methy 1-N- [(2i?)-2-pheny lpropy l]benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[(2)S)-2-phenylpropyl]benzenesulfonamide;
2-methyl-N-[(2iS)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-[(4-methylphenyl)sulfonyl]-iV-[(25)-2-phenylpropyl]ben2;enesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[(2)S)-2-phenylpropyl]benzenesulfonamide;
N-2,3-dihydro-lH-inden-2-yl-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-N-[(liS',2i?)-2-phenylcyclopropyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-N-[(2i?)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-2,3-dihydro-lif-inden-2-yl-2-methoxy-5-(pb.enylsulfonyl)benzenesulfonamide;
2-methoxy-N-[(15',2i?)-2-phenylcyclopropyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-methoxy-N-[(2i?)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-isopropyl-iV-(2-pb.enylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-A/-(2-phenylethyl)-3-(phenylsulfonyl)benzenesulfonamide;
2-chloro-iV-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-(2-hydroxy-2-methylpropyl)-N-(2-phenylethyl)-5- (phenylsulfonyl)benzenesulfonamide;
N- { [2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl} -L-phenylalaninamide; methyl N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-D-phenylalaninate;
N-(2,3 -dihydro- 1 H-inden- 1 -yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(2-fluorophenyl)ethyl]-3-[(4-metb.ylphenyl)sulfonyl]-53657,8-tetrahydronaphthalene-l- sulfonamide;
5-[(4-fluoropb.enyl)sulfonyl]-2-isopropyl-iV-[(2i?)-2-phenylpropyl]benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[(25)-2-phenylpropyl]benzenesulfonamide;
N-(2-phenylethyl)-5-(phenylsulfonyl)-2-propylbenzenesulfonamide;
5-(phenylsulfonyl)-2-propylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-iV-(2-phenyletb.yl)-2-propylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-propylbenzenesulfonamide;
N-(2-phenylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)-benzenesulfonamide;
2,4-diisopropyl-7V-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide; iV-(2,3-dihydro-lH-inden-2-yl)-2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-Λ/-(2-phenyleth.yl)benzenesulfonamide; iV-(2,3-dihydro-lH-inden-2-yl)-5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropy lbenzenesulfonamide ;
N-(2-hydroxy-2-phenylethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-phenylethyl)-2-methylbenzenesulfonamide;
2-ethyl-5-[(4-fluorophenyl)sulfonyl]-7V-(2-hydroxy-2-phenylethyl)benzenesulfonamide;
N-(2-hydroxy-2-phenylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; trans-iV-(2-hydroxy-l-methyl-2-plienylethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-iV-[trans-2-hydroxy-l-metliyl-2-phenylethyl]-2- methylbenzenesulfonamide;
2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-[(trans)-2-hydroxy-l-methyl-2- phenylethyl]benzenesulfonamide; iV-[(trans)-2-hydroxy-l-methyl-2-pb.enylethyl]-2,4-dimethyl-5-
(phenylsulfonyl)benzenesulfonamide;
N-[(1S*,2S* )-2-hy droxycy clohexyl] -2-methy 1-5 -(pheny lsulfony l)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxyethyl)-2-isopropylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(3-moφholin-4-ylpropyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-iV-(2-pyridin-4-ylethyl)benzenesulfonamide;
2-ethyl-5-(phenylsulfonyl)-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-methoxy-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-methoxy-5-(phenylsulfonyl)-Λ/'-(2-pyridin-4-ylet]iyl)benzenesulfonamide;
5-[(4-chloropb.enyl)sulfonyl]-2-methyl-N-(2-pyridin-2-yletb.yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2,4-dimethyl-5-(pb.enylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2,3-dimethyl-5-(phenylsulfonyl)-iV-(2-pyridin-2-ylethyl)benzenesulfonaniide;
2-me1iιyl-5-{[4-(methylamino)phenyl]sulfonyl}-iV-(2-pyridin-2-yletb.yl)benzenesulfonamide;
2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-iV-(2-pyridin-2-ylethyl)benzenesulfonaniide;
5- { [4-( 1 -cyclohexy 1- 1 -hydroxy ethy l)phenyl] sulfony 1 } -2-methy l-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
5 - { [4-( 1 -hydroxy- 1 -pheny lethyl)pheny 1] sulfony 1} -2-methy l-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
5- { [4-( 1 -hydroxy- 1 -methyl-2-phenylethyl)phenyl] sulfonyl} -2-methyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide;
5 - [(3 -cyanopheny l)sulfonyl] -2-methy l-N-(2-pyridin-2-y lethy l)benzenesulfonamide ;
2-methyl-5-(l-naphthylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-hydroxyphenyl)sulfonyl]-2-methyl-iV-(2-pyridm-2-ylethyl)benzenesulfonamide;
5-[(3,5-difluorophenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4-ethylphenyl)sulfonyl]-2-methyl-7V-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-acetylphenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(2-ethoxyphenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(2,5-dimethoxyphenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(2,3-dimethoxyphenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(2,4-dimethoxyphenyl)sulfonyl]-2-methyl-7V-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-methyl-N-(2-pyridin-2-ylethyl)-5-(pyridin-3-ylsulfonyl)benzenesulfonamide;
5-(lH-indol-5-ylsulfonyl)-2-methyl-Λ/'-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4-cyanophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-{[3-(etb.ylsulfonyl)phenyl]sulfonyl}-2-methyl-Λ/-(2-pyridin-2-ylethyl)beiizenesulfonamide;
2-methy 1-5 - [(2-methy lpheny l)sulfony 1] -/V-(2-pyridin-2-y lethy l)benzenesulfonamide ;
5-[(2-ethylphenyl)sulfonyl]-2-metb.yl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-(biphenyl-2-ylsulfonyl)-2-metb.yl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-(biphenyl-4-ylsulfonyl)-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-(biphenyl-3-ylsulfonyl)-2-methyl-iV-(2-pyridm-2-ylethyl)benzenesulfonamide;
5-[(4-tert-butylphenyl)sulfonyl]-2-isopropyl-Ν-(2-pyridin-2- ylethyl)benzenesulfonamide;
5-[(4-tert-butylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
5-[(3,5-dimethylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-chlorophenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-yletliyl)benzenesulfonamide;
2-isopropyl-5-[(3-methoxyphenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-isopropyl-5-[(2-methoxyphenyl)sulfonyl]-Λ/-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3,5-difluorophenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-cyclohexyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-cyclohexyl-5-[(4-fluorophenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-tert-butyl-5-(phenylsulfonyl)-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
2,6-dimethyl-3-(phenylsulfonyl)-Λ/-(2-pyridin-2-ylethyl)benzenesulfonamide;
5- { [5-(dimethylamino)- 1 -naphthyljsulfonyl} -2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
5-[(3-chloro-5-cyanopb.enyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide
2-methyl-3-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3,5-dichlorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-isopropyl-iV-(2-pyridin-2-ylethyl)-5-{[3-
(trifluoromethoxy)phenyl]sulfonyl}benzenesulfonamide;
5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide;
2-isopropyl-iV-(2-pyridin-2-ylethyl)-5-{[3-
(trifluoromethy l)pheny 1] sulfony 1} benzenesulfonamide ; 5-[(5-chloro-2-methoxyphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
2-isopropyl-N-(2-pyridin-2-ylethyl)-5-(quinolin-8-ylsulfonyl)benzenesulfonamide;
5-[(2,5-dichloro-3-thienyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(5-chloro-l,3-dimethyl-lH-pyrazol-4-yl)sulfonyl]-2-isopropyl-N-(2-pyridin-2- ylethy l)benzenesulfonamide ;
2-isopropyl-5-[(l-methyl-lH-imidazol-4-yl)sulfonyl]-N-(2-pyridin-2- y lethy l)benzenesulfonamide ;
5-[(3-chloro-2-metb.ylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4,4-dimethyl-2-oxo-l,4-dihydro-2H-3,l-benzoxazin-6-yl)sulfonyl]-2-isopropyl-N-(2-pyridin-
2-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-4- ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-3- ylethyl)benzenesulfonamide;
5-[(3-cyanophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-(lH-indol-5-ylsulfonyl)-2-isopropyl-iV:-(2-pyridin-2-yleth.yl)beiizenesulfonamide;
5-(phenylsulfonyl)-2-propyl-iV-(2-pyridin-2-ylethyl)benzenesulfonaniide;
5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide;
2-isopropyl-5-(phenylsulfinyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-bromo-2-methylphenyl)sulfonyl]-2-isopropyl-iV"-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(2-chloro-6-methylphenyl)sulfonyl]-2-isopropyl-iVr-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-isopropyl-5-[(3-methylphenyl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-isopropyl-5-[(i?)-phenylsulfinyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-isopropyl-5-[(5)-phenylsulfinyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-bromo-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-cyano-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-acetyl-2-methylphenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-chloro-4-fluorophenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4-fluoro-2-methylphenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-yletb.yl)benzenesulfonamide;
2-isopropyl-5-[(l-methyl-lH-indol-5-yl)sulfonyl]-iV-(2-pyridm-2-yletliyl)benzenesulfonamide;
2-isopropyl-5-{[2-methyl-4-(methylamino)phenyl]sulfonyl}-iV-(2-pyridin-2- ylethyl)benzenesulfonamide; 5-{[3-chloro-4-(methylamino)phenyl]sulfonyl}-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide;
2,4-diisopropyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2,4-diisopropyl-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide;
2,4-diisopropyl-5-(phenylsulfonyl)-Λ/'-(2-pyridin-4-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-iV-(2-pyridm-2-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-iV-(2-pyridin-3-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-iV-(2-pyridin-4-ylethyl)benzenesulfonamide;
2-chloro-5-(phenylsulfonyl)-iV-(2-pyridin-3-ylethyl)benzenesulfonamide;
2-chloro-5-(phenylsulfonyl)-iV-(2-pyridin-4-ylethyl)benzenesulfonamide;
5 - [(4-fluorophenyl)sulfony 1] -2-isopropy 1-N- [2-( 1 -oxidopyridin-3 - yl)ethy l]benzenesulfonamide ;
5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH"-imidazol-4-yl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-iV-[3-(lH"-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
N- [2-( 1 H-imidazol-4-y l)ethy 1] -2-methy l-5-(phenylsulfony l)benzenesulfonamide ;
N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-N-[2-(lH-imidazol-4-yl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-N-[3-(lH-imidazol-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(l/f-imidazol-4-yl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide;
N- [3-( 1 H-imidazol- 1 -yl)propyl]-2-methoxy-5-(phenylsulfony l)benzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
5-[(4-azidophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-metb.ylbenzenesulfonamide;
Ν-[2-(lΗ-indol-3-yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(lH"-imidazol-l-yl)propyl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH"-irnidazol-l-yl)ethyl]benzenesulfonamide;
2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]benzenesulfonamide;
5-({4-[ethyl(methyl)amino]phenyl}sulfonyl)-N-[3-(l/f-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide;
N-[3-(l/f-imidazol-l-yl)propyl]-2-methyl-5-[(4-pyrrolidin-l- ylphenyl)sulfonyl]benzenesulfonamide;
N-[3-(li/-imidazol-l-yl)propyl]-4-methyl-3-(phenylsulfinyl)benzenesulfonamide;
5 - [(4-fluorophenyl)sulfony 1] -N- [2-( 1 H-imidazol- 1 -y l)ethy 1] -2-methy lbenzenesulfonamide; N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-{[4-
(methylamino)phenyl]sulfonyl}benzenesulfonamide;
5- { [4-(ethylamino)phenyl]sulfonyl} -N- [3 -( lH-imidazol- 1 -yl)propyl] -2- methylbenzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -2-methy 1-5 - [(4-piperidin- 1 - ylphenyl)sulfonyl]benzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-[(4-moφholin-4- ylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(lH-imidazol-l-yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-5-[(4-methoxyphenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-5-[(2-methoxyphenyl)sulfonyl]-2-methylbenzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -yl)propy 1] -4-methy 1-3 -(phenylsulfony l)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-[3-(li/-imidazol-l-yl)propyl]-2-isopropylbenzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -yl)propy 1] -5- [(3 -methoxypheny l)sulfony 1] -2-methy lbenzenesulfonamide;
N-[2-(lH-imidazol-l-yl)ethyl]-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -2,4-dimethyl-5-(phenylsulfony l)benzenesulfonamide ;
5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2,4-dimethylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2,4-dimethylbenzenesulfonamide;
2-chloro-iV-[3-(lH-imidazol-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-5-[(4-isopropylphenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-(2-naphthylsulfonyl)benzenesulfonamide;
5- [(3 ,4-dichloropheny l)sulfony 1] -N- [3 -( 1 H-imidazol- 1 -y l)propyl] -2-methy lbenzenesulfonamide ;
5- [(3 -chloropheny l)sulfony 1] -N- [3 -( 1 H-imidazol- 1 -y l)propyl] -2-methy lbenzenesulfonamide;
5-[(3,5-dimethylphenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
5- [(3 ,5 -dichloropheny l)sulfony 1] -N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -2-methy lbenzenesulfonamide;
5- [(2,5 -dichloropheny l)sulfonyl] -N- [3 -( lH-imidazol- 1 -y l)propy 1] -2-methy lbenzenesulfonamide ;
N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-(phenylsulfinyl)benzenesulfonamide;
N- [2-( 1 H-imidazol- 1 -y l)ethy 1] -2,3 -dimethy 1-5 -(phenylsulfony l)benzenesulfonamide ;
N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -2,3 -dimethy l-5-(pheny lsulfony l)benzenesulfonamide ;
5- { [4-(cyclohexy lamino)pheny 1] sulfony 1 } -N- [3 -( 1 H-imidazol- 1 -yl)propy 1] -2- methy lbenzenesulfonamide ; 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide ;
5-[(4-{[(lS,2S)-l-(hydroxymethyl)-2-methylbutyl]amino}ρhenyl)sulfonyl]-N-[3-(lH-imidazol- l-yl)propyl]-2-methylbenzenesulfonamide;
7V-[3-(l/f-imidazol-l-yl)propyl]-2-methyl-5-({4-[(l- phenylethy l)amino]pheny 1 } sulfony l)benzenesulfonamide ;
5 - [(2,3 -dichloropheny l)sulfony 1] -N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -2-methy lbenzenesulfonamide ;
Λ/-[3-(l/f-imidazol-l-yl)propyl]-2-methyl-5-(2-tb.ienylsulfonyl)benzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-2-nαethyl-5-[(2-methyl-3-furyl)sulfonyl]benzenesulfonamide; iV-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-{[4-(tetrahydro-2H-pyran-4- ylamino)phenyl]sulfonyl}benzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -yl)propy 1] -5 -( {4- [(3 -isopropoxypropyl)amino]pheny 1 } sulfony l)-2- methylbenzenesulfonamide;
5-( {4- [(cy clopropylmethy l)amino]pheny 1 } sulfony I)-N- [3 -( 1 H-imidazol- 1 -yl)propy 1] -2- methylbenzenesulfonamide;
5-({4-[(li?,2i?,45)-bicyclo[2.2.1]hept-2-ylamino]phenyl}sulfonyl)-N-[3-(l/f-imidazol-l- yl)propyl]-2-methylbenzenesulfonamide;
5-{[4-(benzylamino)phenyl]sulfonyl}-N-[3-(lH"-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide;
5-[(4-{[(15)-l-cyclohexylethyl]amino}phenyl)sulfonyl]-N-[3-(lH'-imidazol-l-yl)propyl]-2- methy lbenzenesulfonamide ;
5- [(4- { [( 1 R)- 1 -cy clohexy lethyl] amino} pheny l)sulfony I]-N- [3 -( 1 H-imidazol- 1 -y l)propyl] -2- methylbenzenesulfonamide;
5 -( {4- [(2-hy droxybuty l)amino]phenyl } sulfony I)-N- [3 -( 1 H-imidazol- 1 -y l)propyl] -2- methylbenzenesulfonamide;
N-[3-(lH"-imidazol-l-yl)propyl]-2-methyl-5-[(4-{[4-
(trifluoromethy l)benzy 1] amino } pheny l)sulfonyl]benzenesulfonamide;
5-[(2-chlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
Ν-(tert-butyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
5-[(4-tert-butylphenyl)sulfonyl]-N-[3-(lΗ-imidazol-l-yl)propyl]-2- isopropylbenzenesulfonamide;
5-[(4-tert-butylphenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide; 5- [(4-fluoropheny l)sulfony 1] -N- [2-( 1 H-imidazol-4-yl)ethy 1] -2-isopropy lbenzenesulfonamide;
5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-iV-[2-(lH-imidazol-l-yl)ethyl]-2- isopropylbenzenesulfonamide; iV-[2-(lH-imidazol-l-yl)ethyl]-2-isopropyl-5-{[4-
(methylamino)phenyl]sulfonyl}benzenesulfonamide;
5-({4-[(2-hydroxybutyl)amino]phenyl}sulfonyl)-iV'-[2-(lH"-imidazol-l-yl)ethyl]-2- isopropylbenzenesulfonamide;
5-[(4-{[(25)-l-(hydroxymethyl)-2-methylbu1yl]amino}phenyl)sulfonyl]-N-[2-(lH-imidazol-l- yl)ethyl]-2-isopropylbenzenesulfonamide;
N-[S-(I H-imidazol- 1 -y l)propyl] -2-methy 1-3 -(pheny lsulfony l)benzenesulfonamide ;
N-[3-(lH-Imidazol-l-yl)propyl]-5-(phenylsulfonyl)-2-propylbenzenesulfonamide;
5-[(4-Fluorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-propylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[2-(2-methyl-lH-imidazol-l- yl)ethyl]benzenesulfonamide;
N-[2-(2-ethyl-l/i-imidazol-l-yl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-iV-[2-(2-isopropyl-lH-iniidazol-l- yl)ethyl]benzenesulfonamide;
N-[3-(lH-Imidazol-l-yl)propyl]-2,4-diisopropyl-5-(plienylsulfonyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[2-(l-methylpyrrolidin-2-yl)ethyl]benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-iV-(2-piperidin-l-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-me1iiyl-iV-(2-morpholin-4-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-metb.yl-N-[3-(2-oxopyrrolidin-l-yl)propyl]benzenesulfonamide;
N-[3-(dimetb.ylamino)propyl]-5-[(4-fluorophenyl)sulfonyl]-2-metliylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-(2-methoxyethyl)-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-iV-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide;
5- [(4-fluorophenyl)sulfony l]-2-methyl-N- [3 -(4-methy lpiperazin- 1 - yl)propyl]benzenesulfonamide;
2-methyl-iV-(3-morpholin-4-ylpropyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-iV-[2-(l-methylpyrrolidin-2-yl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-Λ'-(2-piperidin-l-ylethyl)benzenesulfonaniide;
2-methyl-iV-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[3-(2-oxopyrrolidin-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-iV-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide;
2-methy l-N-[3 -(4-methy lpiperazin- 1 -y l)propy 1] -5 -(pheny lsulfony l)benzenesulfonamide ;
2-ethyl-N-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-5-(phenylsulfonyl)-A/"-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide;
2-methoxy-N-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-methoxy-5-(plienylsulfonyl)-iV-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2-moφb.olin-4-ylethyl)beiizenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-tetrahydro-2i7-pyran-4-ylbenzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-(2-tetrahydro-2H"-pyran-4-ylethyl)benzenesulfonamide;
2-ethyl-5-(phenylsulfonyl)-iV-tetrahydro-2H-pyran-4-ylbenzenesulfonaniide;
2-ethyl-5-(phenylsulfonyl)-N-(2-tetrahydro-2/i-pyran-4-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-iV-tetraliydro-2H-pyran-4-ylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-tetrahydro-2/i'-pyran-4-ylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-tetrahydro-2/f-pyran-4- ylethyl)benzenesulfonamide;
2,4-dimethyl-5-(phenylsulfonyl)-N-tetrahydro-2/f-pyran-4-ylbenzenesulfonamide;
2,4-dimethyl-5-(phenylsulfonyl)-N-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-iV-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-iV"-[2-(tetrahydro-2H-pyran-4- yl)ethyl]benzenesulfonamide;
2-chloro-iV-(2-morpholin-4-yleth.yl)-5-(phenylsulfonyl)benzenesulfonamide;
2,3-dimethyl-5-(phenylsulfonyl)-N-(tetrahydro-2i:f-pyran-4-yl)benzenesulfonamide;
2,3-dimethyl-5-(phenylsulfonyl)-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzenesulfonatnide;
2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-Λ/-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-[2-(tetrahydro-2H-pyran-4- yl)ethyl]benzenesulfonamide;
2-chloro-5-(phenylsulfonyl)-N-(tetrahydro-2iϊ-pyran-4-yl)benzenesulfonamide;
5-[(4-bromophenyl)sulfonyl]-2-methyl-N-(tetrahydro-2i/-pyran-4-yl)benzenesulfonamide;
5-[(4-cyanophenyl)sulfonyl]-2-methyl-7V-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; N-[3-(lH"-imidazol-l-yl)propyl]-2-methyl-5-(pyridin-2-ylsulfonyl)benzenesulfonamide;
5 - [(2,4-dichloropheny l)sulfony 1] -N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -2-methy lbenzenesulfonamide ;
5-[(4-acetylphenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
5-[(4-bromophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-(te1xahydro-2H-pyran-4-ylmethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide;
2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide;
2,4-dimethyl-5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide;
Ν-(2,2-dimethylpropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
5-({4-[(lE)-N-hydroxyethanimidoyl]phenyl}sulfonyl)-2-methyl-N-(tetrahydro-2H-pyran-4- y l)benzenesulfonamide ;
5-[(4-acetylphenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5- { [4-( 1 -hydroxy- 1 -methylethyl)phenyl] sulfony 1 } -2-methy l-iV-(2-pyridm-2- ylethyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)benzenesulfonamide;
N-(l-benzylpiperidin-4-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-(l-benzylpyrrolidin-3-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; ethyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate;
5-[(4-tert-butylphenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
5-[(4-tert-butylphenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide; tert-butyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate;
2-methy 1-5 -(pheny lsulfony l)-N-piperidin-4-y lbenzenesulfonamide ;
2-methyl-5-(phenylsulfonyl)-N-[l-(phenylsulfonyl)piperidin-4- yl]benzenesulfonamide;
N- [ 1 -(2-furoy l)piperidin-4-y 1] -2-methy l-5-(pheny lsulfony l)benzenesulfonamide ;
N-[l-(2-methoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
N- [ 1 -(3 -methoxybenzoy l)piperidin-4-yl] -2-methy 1-5 - (phenylsulfony l)benzenesulfonamide;
N-[l-(3,4-dimethoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-{l-[3-(trifluoromethyl)benzoyl]piperidin-4- yl}benzenesulfonamide;
N-[l-(4-chlorobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; N-[l-(4-methoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[l-(4-methylbenzoyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide;
N-[l-(methoxyacetyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[l-(phenylacetyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
N-[l-(cyclohexylcarbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
2,6-dimethyl-3-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
N-[l-(cyclopropylcarbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
N-[l-(4-cyanobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
N-[l-(3-cyanobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[l-(methylsulfonyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide;;
N-(l-acetylpiperidin-4-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide
N-(4- { [4-( { [2-methyl-5-(phenylsulfonyl)phenyl] sulfonyl} amino)piperidin- 1 - y 1] carbony 1 } pheny l)acetamide;
2-methyl-N- { 1 -[( 1 -methyl- 1 H-imidazol-4-yl)sulfonyl]piperidin-4-yl} -5-
(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-[l-(2-thienylsulfonyl)piperidin-4- yl]benzenesulfonamide;
N-( 1 - { [5 -(dimethylamino)- 1 -naphthy 1] sulfonyl } piperidin-4-y l)-2-methyl-5 -
(phenylsulfonyl)benzenesulfonamide;
N-[I-(1 ,3-benzodioxol-5-ylcarbonyl)piperidin-4-yl]-2-methyl-5-
(phenylsulfonyl)benzenesulfonamide;
N-[l-(isoxazol-5-ylcarbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
N-[l-(N,N-dimethylglycyl)piperidm-4-yl]-2-methyl-5- (phenylsulfonyl)beiizenesulfonamide; prop-2-yn-l-yl 4-({[2-metb.yl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine- 1- carboxylate; methyl 4-( { [2-methyl-5-(phenylsulfonyl)phenyl] sulfonyl } amino)piperidme- 1 - carboxylate;
2-methoxyphenyl 4-({ [2-methyl-5- (phenylsulfonyl)phenyl] sulfonyl} amino)piperidine- 1 - carboxylate;
N-(tert-buty l)-4-( { [2-methy 1-5 -(pheny lsulfony l)pheny 1] sulfonyl } amino)piperidine- 1 - carboxamide;
N-cyclohexyl-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxamide;
2-methyl-iV-(2-morpholin-4-ylethyl)-3-(phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[l-(2-naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-[l-(2-thienylcarbonyl)piperidin-4- yl]benzenesulfonamide; isobutyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate;
N- { 1 -[4-(dimethylamino)benzoyl]piperidin-4-yl}-2-methyl-5-
(pheny lsulfony l)benzenesulfonamide ; ;
4-fluorophenyl 4-({ [2-methyl-5-(pb.enylsulfonyl)phenyl]sulfonyl}amino)piperidine- 1 - carboxylate
N-ethyl-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxamide;
2-methyl-N-[l-(morpholin-4-ylcarbonyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide;
N,N-dimethy l-4-( { [2-methy 1-5 -(pheny lsulfony l)pheny 1] sulfony 1 } amino)piperidine- 1 - carboxamide;
N-[l-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-[l-(pyridin-3-ylcarbonyl)piperidm-4- yl]benzenesulfonamide; tert-butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidine-l- carboxylate;
N-(l-{[5-(dimethylamino)-l-naphthyl]sulfonyl}piperidin-4-yl)-5-[(4- fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide;
5- [(4-fluoropheny l)sulfonyl] -2-isopropy 1-N- [ 1 -(methoxyacety l)piperidin-4- yljbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide;
N-(l-benzylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; ethyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl} sulfony l)amino]piperidine-l- carboxylate;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-l- ylethyl)benzenesulfonamide; tert-butyl 4-{[(2-isopropyl-5-{[4-
(methylamino)phenyl]sulfonyl}phenyl)sulfonyl]amino}piperidine-l-carboxylate;
N-(l-acetylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide;
N-[l-(cyclopropylcarbonyl)piperidin-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide;
N-[I -(4-cyanobenzoy l)piperidin-4-y 1] -5 - [(4-fluoropheny l)sulfony 1] -2- isopropylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydrofuran-2- yhnethyl)benzenesulfonamide; 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2H'-pyran-4- yl)benzenesulfbnamide;
5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2H"-pyran-4- ylmethyl)benzenesulfonamide;
5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-2-isopropyl-iV-[2-(tetrahydro-2H'-pyran-4- yl)ethyl]benzenesulfonamide;
N-(3',6'-dihydroxy-3-oxo-3H-spiro[2-benzofuran-l59'-xanthen]-5-yl)-4-[({5-[(4- fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidine-l- carbothioamide;
2-isopropyl-5-[(2-methylphenyl)sulfonyl]-N-(tetraliydro-2H'-pyran-4-yl)benzenesulfonamide;
5-[(3-chloro-2-methylphenyl)sulfonyl]-2-isopropyl-iV-(tetrahydro-2i/-pyran-4- yl)benzenesulfonamide;
2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-(tetrahydro-2/i-pyran-4- ylmethyl)benzenesulfonamide;
5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-Λ/-(tetrahydro-2i7-pyran-4- yl)benzenesulfonamide;
5- { [4-(dimethylamino)phenyl]sulfonyl} -2-isopropyl-N-(tetrahydro-2i7-pyran-4- ylmethyl)benzenesulfonamide;
5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-N-[2-(tetrahydro-2H-pyran-4- yl)ethyl]benzenesulfonamide;
2-isopropyl-5- { [4-(4-methylpiperazin- 1 -yl)phenyl] sulfonyl} -iV-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
2-isopropyl-5- { [4-(4-methylpiperazin- 1 -yl)phenyl] sulfonyl} -iV-(tetrahy dro-2H-pyran-4- ylmethyl)benzenesulfonamide ;
2-isopropyl-5- { [4-(4-methylpiperazin- 1 -y l)pheny 1] sulfonyl } -N-[2-(tetrahydro-2H-pyran-4- yl)ethyl]benzenesulfonamide;
5-(phenylsulfonyl)-2-propyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
5-(phenylsulfonyl)-2-propyl-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide;
5-(phenylsulfonyl)-2-propyl-N-[2-(tetrahydro-2/i'-pyran-4-yl)ethyl]benzenesulfonaniide; tert-butyl 4-({[5-(phenylsulfonyl)-2-propylphenyl]sulfonyl}amino)piperidine-l-carboxylate;
5 - [(4-fluoropheny l)sulfony 1] -2-propyl-Λ/-(tetrahy dro-2H-pyran-4-y l)benzenesulfonamide ;
5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-[2-(tetrahydro-2uf-pyran-4- yl)ethyl]benzenesulfonamide; tert-Butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2-propylphenyl}sulfonyl)amino]piperidine-l- carboxylate;
2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-Ν-piperidin-4- ylbenzenesulfonamide;
5-[(5-chloro-l,3-dimethyl-lH-pyrazol-4-yl)sulfonyl]-2-isopropyl-N-(tetrahydro-2/i-pyran-4- yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[l-(morpholin-4-ylcarbonyl)piperidin- 4- yl]benzenesulfonamide;
4- [( { 5- [(4-fluoropheny l)sulfonyl] -2-isopropy lpheny 1 } sulfony l)amino] -N,N- dimethy lpiperidine-
1-carboxamide;
N-(l-benzylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-piperidin-4-ylbenzenesulfonamide;
5 -( { 4- [(2-cy anoethy l)(methy l)amino]pheny 1 } sulfony l)-2-isopropyl-iV-(tetrahydro-27f-pyran-4- yl)benzenesulfonamide;
5-({4-[(2-cyanoethyl)(methyl)amino]phenyl}sulfonyl)-2-isopropyl-iV-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide;
N-(l-acetylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
N-[I -(4-cy anobenzoy l)piperidin-4-y 1] -5 - [(4-fluoropheny l)sulfony 1] -2- methylbenzenesulfonamide;
4-[({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)amino]-N,N- dimethylpiperidine-l- carboxaniide;
5-[(4-fluorophenyl)sulfonyl]-N-[l-(methoxyacetyl)piperidin-4-yl]-2- methylbenzenesulfonamide;
2-isopropyl-5-[(3-methoxyphenyl)sulfonyl]-N-(tetrahydro-2//-pyran-4-yl)benzenesulfonamide;
5- { [4-(dimethy lamino)-2-methy lpheny 1] sulfony 1} -2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
2-(dimethylamino)-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5- [(4-fluoropheny l)sulfonyl] -2-methy 1-Ν- [ 1 -(morpholin-4-y lcarbonyl)piperidin-4- yljbenzenesulfonamide;
2-chloro-5-[(3-methylphenyl)sulfonyl]-iV-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
2-chloro-5-[(3-methoxyphenyl)sulfonyl]-Λ/-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 2-chloro-5-[(l-methyl-lH-indol-5-yl)sulfonyl]-iV-(tetrahydro-2i-7-pyran-4- yl)benzenesulfonamide;
5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide;
2,4-diisopropyl-5-(phenylsulfonyl)-N-(tetrahydro-2i7-pyran-4-yl)benzenesulfonaniide;
2,4-diisopropyl-5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide;
2,4-diisopropyl-5-(phenylsulfonyl)-N-[2-(tetrahydro-2//-pyran-4-yl)ethyl]benzenesulfonamide;
5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(te1xahydro-2H-pyran-4-yl)benzenesulfonamide;
2-chloro-5-[(4-fluorophenyl)sulfonyl]-N-(tetrahydro-2/f-pyran-4-yl)benzenesulfonamide; tert-butyl 4-({[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate
2-chloro-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide;; tert-butyl 4-[4-({4-isopropyl-3-[(tetrahydro-2/i-pyran-4- ylamino)sulfonyl]phenyl} sulfonyl)phenyl]piperazine- 1 -carboxylate
5-({4-cw-3,5-dimethylpiperazin-l-ylphenyl}sulfonyl)-2-isopropyl-iV-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
5-({4-trα«ji-2,5-dimethylpiperazin-l-ylphenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2i:/-pyran-4- yl)benzenesulfonamide;
2-isopropyl-5-[(4-piperazin-l-ylphenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-iV-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide ;
5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-[2-(tetrahydro-2H-pyran-4- y l)ethy l]benzenesulfonamide ;
2-chloro-iV-[3-(4-metliylpiperazm-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide; l-{[2-chloro-5-(phenylsulfonyl)plienyl]sulfonyl}-iV,N-diethylpyrrolidin-3-amine; ethyl l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperidine-3-carboxylate;
2-chloro-5-(phenylsulfonyl)-Λ/-[l-(trifluoroacetyl)piperidm-4-yl]benzenesulfonamide;
2-chloro-iVr-[l-(2,2-dimethylpropanoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
N-(tert-butyl)-4-({[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxamide;
2-chloro-N-[l-(morpholin-4-ylcarbonyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
2-chloro-iV-(l-cyanopiperidin-4-yl)-5-(phenylsulfonyl)benzenesulfonamide;
N3-({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)-beta-alaninamide; methyl N-( { 5- [(4-fluoropheny l)sulfony 1] -2-methylpheny 1 } sulfony l)-beta-alaninate;
N-(2-cyanoethyl)-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; iV-{2-[({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)amino]ethyl}acetamide;
N-[2-(diethylamino)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[2-(dimethylamino)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-(3-methoxypropyl)-2-methylbenzenesulfonamide;
N- [3 -(diethy lamino)propyl] -5 - [(4-fluoropheny l)sulfony 1] -2-methy lbenzenesulfonamide ;
N- ({5-[(4-fluorophenyl) sulfony 1] -2-methy lphenyl} sulfonyl)-beta-alanine; iV3-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-alaninamide; methyl N- { [2-methyl-5-(phenylsulfonyl)phenyl] sulfonyl} -beta-alaninate;
N-[2-(diethylamino)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(dimethylamino)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; iV-(3-methoxypropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N- [3 -(dimethy lamino)propy 1] -2-methy 1-5 -(pheny lsulfony l)benzenesulfonamide;
N-(2-methoxyethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(diethylamino)propyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; methyl N- { [2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl} -beta-alaninate;
2-ethyl-N-(3-methoxypropyl)-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(dimethylamino)propyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-N-(2-methoxyethyl)-5-(phenylsulfonyl)benzenesulfonamide;
Ν- [3 -(diethy lamino) propyl]-2-ethyl-5- (phenylsulfonyl) benzene sulfonamide; methyl N-{[2-methoxy-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-alaninate;
2-methoxy-N-(3-methoxypropyl)-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(dimethylamino)propyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide;
2-methoxy-N-(2-methoxyethyl)-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(diethylamino)propyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-Ν-propylbenzenesulfonamide;
N-(l-ethylpropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-cyclobutyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-cyclopentyl-2-methy 1-5 -(pheny lsulfony l)benzenesulfonamide ;
N-cyclohexyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide; N-(2-hydroxy- 1 , 1 -dimethy lethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-cyclopropyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-cyclopropyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide;
N-cyclobutyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide;
N-cy clopentyl-5 - [(4-fluoropheny l)sulfony 1] -2-isopropylbenzenesulfonamide ;
N-cyclohexyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide;
N-cyclopentyl-5-(phenylsulfonyl)-2-propylbenzenesulfonamide;
N-cyclopentyl-5-[(4-fluorophenyl)sulfonyl]-2-propylbenzenesulfonamide;
N-cyclopentyl-2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide;
N-cyclopentyl-5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropylbenzenesulfonamide;
2-chloro-N-(2-cyanoethyl)-5-(phenylsulfonyl)berizenesulfonamide; methyl N-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}-2-methylalaninate;
N-[2-(3,4-dimethoxyphenyl)ethyl]-N,2-dimethyl-5-(phenylsulfonyl)benzenesulfonamide;
N-allyl-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N- [2-(3 ,4-dimethoxyphenyl)ethyl] -2-methyl-5-(phenylsulfonyl)-N-prop-2- ynylbenzenesulfonamide;
N-[2-(2-fluorophenyl)ethyl]-N,2-dimethyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
Ν-allyl-Ν- [2-(2 -fluorophenyl) ethyl] -2-methy 1-5- [(4-methylphenyl) sulfonyl] benzene sulfonamide;
N-[2-(2-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]-N-prop-2- ynylbenzenesulfonamide;
N,2-dimethyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
1 -{ [2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-4-(2-oxo-2-pyrrolidin-l -ylethyl)piperazine;
N,N-diethyl-N-[2-(4-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]amine;
4-[2-(4-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]morpholine;
1 - { [2-methy l-5-(phenylsulfonyl)phenyl] sulfonyl} -4-(2-pyrrolidin- 1 -ylethy l)piperazine;
4-[3-(4-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)propyl]morpholine;
2-ethyl-N-methyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
1 - { [2-ethyl-5-(phenylsulfonyl)phenyl] sulfonyl} -4-(2-oxo-2-pyrrolidin- 1 -ylethyl)piperazine;
N,N-diethyl-N-[2-(4-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]amine;
4-[2-(4-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]morpholine;
1 - { [2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl} -4-(2-pyrrolidin-l -ylethyl)piperazine; 4-[3-(4-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)propyl]morpholine; N-[I -(cy clopropylcarbony l)piperidin-4-y 1] -N~( { 5 -[(4-fluoropheny l)sulfony 1] -2- methylphenyljsulfonytycyclopropanecarboxamide;
1 - { [2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl} -4-pyrrolidin-l -ylpiperidine; 4-[2-(4-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]morpholine; 1 -(1 ,3-benzodioxol-5-ylmethyl)-4-{ [2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperazine; tert-buty^l-IP-chloro-S-φhenylsulfony^phenyysulfony^pyrrolidin-S-y^carbamate; tert-butyl (l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperidin-4-yl)carbamate; 2-chloro-iV-methyl-5-(phenylsulfonyl)-iV-(2-pyridin-2-ylethyl)benzenesulfonamide; 1 - { [2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl} -4-[(2,5-dimethyl-lH-pyrrol- 1 - y l)methy l]piperidine ;
2-chloro-N-(2-hydroxy-l,l-dimethylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-iV-(cyanomethyl)-5-(phenylsulfonyl)benzenesulfonamide; iV-(2-cyanoethyl)-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide; 2-methyl-N-(3-oxo-3-pyrτolidin-l-ylpropyl)-5-(phenylsulfonyl)benzenesulfonamide; N-(ter^butyl)-Λ^-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-β-alaninamide; N3- { [2-methy l-5-(ρheny lsulfonyl)pheny 1] sulfony 1 } -N-( 1,2,3 ,4-tetrahy dronaphthalen- 1 -y I)- β - alaninamide;
N-methyl-Λ^-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-N-phenyl-β-alaninamide; 2-methyl-N-[3-(6-methyl-3,4-dihydroquinolin-l(2H)-yl)-3-oxopropyl]-5- (phenylsulfonyl)benzenesulfonamide;
2-chloro-N-(2-hydroxyethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-N-(2-hydroxy-l-methylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-iV- [2-hydroxy- 1 -(hy droxymethy l)ethy 1] -5 -(pheny lsulfony l)benzenesulfonamide ; iV-(2-cyanoethyl)-5-(pb.enylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-(2-hydroxyethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-(2-hydroxy-l-methylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[(l-S)-2-hydroxy-l-methylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[(li?)-2-hydroxy-l-methylethyl]-5-φhenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-iV-(2-hydroxy-l-methylethyl)-2-isopropylbenzenesulfonamide; 5- [(4-fluoropheny l)sulfonyl] -N- [ 1 -(hy droxymethy l)-2-methy lpropy 1] -2- isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxybutyl)-2-isopropylbenzenesulfonamide;
N-(2-cyanoethyl)-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide;
5-[(3-chlorophenyl)sulfonyl]-iV-(2-cyanoethyl)-2-(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-ylmetliyl)-2-(trifluoromethyl)benzenesulfonamide;
N-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-(3-morpholin-4-ylpropyl)-5-(plienylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-(3-methoxypropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[l-(hydroxymethyl)-2-methylpropyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[(lR)-l-(hydroxymethyl)propyl]-5-(plienylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-(2-hydroxy ethyl)-5 - [(3 -methoxypheny l)sulfony 1] -2-(trifluoromethy l)benzenesulfonamide ;
N-(2-cyanoethyl)-5-[(4-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide;
N-(2-cyanoethyl)-5-[(4-hydroxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide;
N-[(l-hydroxycyclohexyl)methyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-3- ylethyl)benzenesulfonamide;
N-{[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}-β-alanine;
4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)butanoic acid; tert-bu1yl 4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidine-
1-carboxylate;
5-(phenylsulfonyl)-N-(piperidin-4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide; tert-butyl [trans-A-{{ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexyl]carbamate;
4-oxo-4-{4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}aniino)methyl]piperidin- l-yl}butanoic acid;
5-oxo-5-{4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin- l-yl}pentanoic acid;
3-({4-[({[5-(pb.enylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin-l- yl}sulfonyl)benzoic acid; tert-butyl 2-[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l-carboxylate;
5-(phenylsulfonyl)-iV-(2-pyrrolidin-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide;
{2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}ammo)ethyl]pyrrolidin-l- yl} acetic acid;
4-oxo-4-{2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin- l-yl}butanoic acid;
3-({2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-l- yl}sulfonyl)benzoic acid; ter^utyl 4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}ammo)ethyl]piperidine-
1-carboxylate; methyl 3 -( { [2-isopropyl-5-(phenylsulfonyl)phenyl] sulfony 1} amino)cyclohexanecarboxylate; methyl 4-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate; methyl trans-A-[{{ [2-isopropyl-5-
(phenylsulfony^pheny^sulfonyljamino^ethyycyclohexanecarboxylate;
5-(phenylsulfonyl)-N-(2-piperidin-4-ylethyl)-2-(trifluoromethyl)benzenesulfonamide;
{4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin-l- yl} acetic acid;
{4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidin-l- yl} acetic acid; methyl 3-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate; methyl 4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfonyl } amino)cyclohexanecarboxy late; methyl trans A-[({ [5-(phenylsulfonyl)-2-
(trifluoromethy^phenyljsulfonyljamino^ethyljcyclohexanecarboxylate;
3-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid;
4-( { [2-isopropyl-5-(phenylsulfonyl)phenyl] sulfonyl} amino)cyclohexanecarboxylic acid; trans-4-[({ [2-isopropyl-5-
(pheny lsulfonyl)phenyl] sulfonyl } amino)methy 1] cyclohexanecarboxy lie acid;
3-{4-[({[5 -(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfonyl} amino)methy l]piperidin- 1 - yl} benzoic acid;
3-{4-[2-({ [5-(pheny lsulfony l)-2-(trifluoromethyl)phenyl] sulfonyl } amino)ethy ljpiperidin- 1 - yl}benzoic acid;
N-(trαrø-4-aminocyclohexyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid; 4-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)cyclohexanecarboxylic acid; rra;w-4-[({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)methyl]cyclohexanecarboxy lie acid;
N-(trβ77j'-4-hydroxycyclohexyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; tert-butyl 4-[({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)carbonyl]piperidine-l-carboxylate;
N- { [5 -(phenylsulfony l)-2-(trifluoromethy l)pheny 1] sulfonyl } piperidine-4-carboxaniide ;
5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethoxy)benzenesulfonamide;
2-isopropyl-5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide;
2-Methoxy-5-(phenylsulfonyl)-iV-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
5-[(3-metlioxyphenyl)sulfonyl]-Λ/'-(tetraliydro-2H'-pyran-4-yl)-2-
(trifluoromethyl)benzenesulfonamide;
5-[(3-hydroxyphenyl)sulfonyl]-iV-(tetrahydro-2H-pyran-4-yl)-2-
(trifluoromethyl)benzenesulfonamide;
5- [(3 -chloropheny l)sulfony 1] -iV-(tetrahy dro-2H-pyran-4-y l)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-[(3S)-piperidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-[(3i?)-piperidin-3-yl]-2-(trifluorometliyl)benzenesulfonamide;
5-[(l,2-dimethyl-lH-indol-5-yl)sulfonyl]-Λ/-piperidin-4-yl-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-[(35)-pyrrolidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-[(3i?)-pyrrolidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-(tetrahydro-2Η-thiopyran-4-yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-thiopyran-4- yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)-2-
(trifluoromethyl)benzenesulfonamide;
5-[(2-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-pyrrolidin-3-yl-2-(trifluoromethyl)benzenesulfonamide;
N-[(2R*,4S*,6S*)-2,6-dimethyltetrahydro-2H-pyran-4-yl]-5-[(4- fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide ; 5- { [4-(methylamino)pheny 1] sulfonyl} -N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide;
5-{[4-(dimethylamino)phenyl]sulfonyl}-N-ρiρeridin-4-yl-2-
(trifluoromethyl)benzenesulfonamide;
5-({4-[(2-hydroxyethyl)amino]phenyl}sulfonyl)-iV-piperidm-4-yl-2-
(trifluoromethyl)benzenesulfonamide;
N-(l,l-dioxidotetrahydro-2H-thiopyran-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide ;
5 - { [2-(methy lamino)pheny 1] sulfonyl } -N-piperidin-4-yl-2-(trifluoromethy l)benzenesulfonamide ;
5-{[2-(dimethylamino)phenyl]sulfonyl}-iV-piperidm-4-yl-2-
(trifluoromethyl)benzenesulfonamide;
5-({2-[(2-h.ydroxyethyl)amino]phenyl}sulfonyl)-Λ/-piperidin-4-yl-2-
(trifluoromethyl)benzenesulfonamide;
2-ethyl-5-(phenylsulfonyl)-7V-piperidin-4-ylbenzenesulfonamide;
2,3-dimethyl-5-(phenylsulfonyl)-iV-piperidin-4-ylbenzenesulfonamide;
2,4-dimethyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide;
2-isopropyl-5-(phenylsulfonyl)-Λ/'-piperidin-4-ylbenzenesulfonamide;
5-(phenylsulfonyl)-N-piperidin-4-yl-2-propylbenzenesulfonamide;
2-isopropyl-5-(phenylsulfonyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-(2,2,6,6-tetramethylpiperidin-4-yl)-2-
(trifluoromethyl)benzenesulfonamide;
5-[(4-methoxyphenyl)sulfonyl]-N-piperidin-4-yl-2-(trifluorometh.yl)benzenesulfonamide;
5-[(3-bromophenyl)sulfonyl]-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide;
2-chloro-iV- [ 1 -(4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
2-chloro-iV-[l-(4-cyanobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
2-chloro-5-(phenylsulfonyl)-iV-{l-[4-(trifluoromethyl)benzoyl]piperidin-4- y 1 } benzenesulfonamide ;
5-(phenylsulfonyl)-2-(trifluoromethyl)-iV-{l-[4-(trifluoromethyl)benzoyl]piperidin-4- y 1 } benzenesulfonamide; iV-[l-(2-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(2-niethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; TV-[I -(3-chloroben2;oyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
TV-[I -(3 ,4-difluorobenzoyl)piperidin-4-yl] -5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
TV-[I -(3 ,5-difluorobenzoyl)piperidin-4-yl] -5-(pheny lsulfony l)-2-
(trifluoromethyl)beiizenesulfonamide;
7V-[l-(2,6-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
/V-[l-(2,4-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-{l-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}-2-
(trifluoromethyl)benzenesulfonamide;
7V-{l-[2-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
7V-{l-[3-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
TV- [ 1 -(3 ,4-dichlorobenzoy l)piperidin-4-yl] -5 -(pheny lsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
TV-[l-(4-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
TV-(l-isonicotinoylpiperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
TV-[l-(2-chloro-6-methoxyisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
TV-[l-(2-chloro-4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-TV-[l-(2,4,6-trifluorobenzoyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide;
TV-[I -(4-tert-butylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
TV-(4-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- y 1] carbony 1 } pheny l)acetamide;
5-(pheny lsulfony l)-2-(trifluoromethy I)-TV-(I -{ [4- (trifluoromethyl)phenyl]carbonothioyl}piperidin-4-yl)benzenesulfonamide; iV-[l-(4-te7Y-butylbenzoyl)piperidin-4-yl]-5-[(3-methoxyphenyl)sulfonyl]-2-
(trifluoromethyl)benzenesulfonamide; iV-[l-(4-tert-butylbenzoyl)piperidin-4-yl]-5-[(3-chlorophenyl)sulfonyl]-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-{l-[2-(trifluoromethoxy)benzoyl]piperidin-4-yl}-2-
(trifluoromethyl)benzenesulfonamide; iV-(l-benzoylpiperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N- [ 1 -(4-tert-buty lbenzoy l)pyrrolidin-3 -y 1] -5-(pheny lsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
N-[I -(4-tert-buty lbenzoy l)piperidin-4-y 1] -5 - [(3 -hydroxypheny l)sulfony 1] -2-
(trifluoromethyl)benzenesulfonamide;
N- [ 1 -(4-benzoy lbenzoy l)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; iV-[l-(3-benzoylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; l-Isopropyl-4-(phenylsulfonyl)benzene;
2-Isopropyl-Λ/-[l-(2-methoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
N-[l-(3-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; iV-[l-(4-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-(plienylsulfonyl)benzenesulfonamide;
7V-[l-(2-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
2-Isopropyl-5-(phenylsulfonyl)-7V-{l-[4-(trifluoromethyl)benzoyl]piperidin-4- y 1 } benzenesulfonamide ;
2-Isopropyl-7V-[l-(l-naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
2-Isopropyl-N-[l-(2-naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
N-[l-(3-Cyanobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[l-(4-Cyanobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; jV-[l-(4-tert-Butylbenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[l-(2-Ethoxy-l-naphthoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[l-(2-chloro-6-methylisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; N-[l-(2,6-dichloroisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{l-[4-(dimethylamino)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{l-[(6-chloropyridin-3-yl)carbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonaniide;
N-(I -[(2,5-dichloropyridin-3-yl)carbonyl]piperidin-4-yl} -5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(2-chloroisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfony I)-N- { 1 -[(6-pyrrolidin- 1 -ylpyridin-3 -yl)carbony l]piperidin-4-yl } -2-
(trifluoromethyl)benzenesulfonamide;
N-(l-{[6-(dimethylamino)pyridin-3-yl]carbonyl}piperidin-4-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{1- [(6-oxo- 1 - { [5-(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1 } - 1 ,6-dihy dropyridin-3 - yl)carbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-{l-[(6-phenylpyridin-3-yl)carbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{l-[(6-morpholin-4-ylpyridin-3-yl)carbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-[l-(2-pyrrolidin-l-ylisonicotinoyl)piperidin-4-yl]-2-
(trifluorometb.yl)benzenesulfonamide;
N-{1- [(6-oxo- 1 ,6-dihy dropyridin-3 -yl)carbony l]piperidin-4-y 1} -5 -(pheny lsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-[l-(pyridin-3-ylcarbonyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-[l-(pyridin-2-ylcarbonyl)piperidm-4-yl]-2-
(trifluoromethyl)benzenesulfonamide;
N-{l-[4-(methylthio)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-2-(trifluoromethyl)-N-(l-{[6-(trifluoroniethyl)pyridin-3- yl]carbonyl}piperidin-4-yl)benzenesulfonamide; N- {1 -[4-(methylsulfinyl)benzoyl]piperidin-4-yl} -5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-[l-(l,3-thiazol-4-ylcarbonyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl 4-({ [5-(phenylsulfonyl)-2-(trifluorometliyl)phenyl]sulfonyl}amino)piperidine-l - carboxylate; tert-butyl (3S)-3-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)piperidine- 1 - carboxylate; tert-butyl (3i?)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate; tert-butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2- methylphenyl}sulfonyl)amino]piperidine-l- carboxylate; tert-butyl (3<S)-3 -( { [5-(phenylsulfony l)-2-(trifluoromethy l)pheny 1] sulfonyl } amino)pyrrolidine- 1 - carboxylate; tert-butyl (3i?)-3 -( { [5-(phenylsulfony l)-2-(trifluoromethy l)pheny 1] sulfonyl } amino)pyrrolidine- 1 - carboxylate; tert-butyl 4-({ [5-[(4-fluoroρhenyl)sulfonyl]-2-
(trifluoromethy l)phenyl] sulfonyl } amino)piperidine- 1 -carboxylate; tert-butyl 4-( { [2-ethyl-5-(phenylsulfonyl)phenyl] sulfonyl} amino)piperidine- 1 -carboxylate; tert-butyl 4-({[2,3-dimethyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate; tert-butyl 4-({[2,4-dimethyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate; tert-butyl 4-( { [2-isopropy 1-5 -(pheny lsulfonyl)pheny 1] sulfonyl } ammo)piperidine- 1 -carboxylate;
4- { [3 -( { [ 1 -(tert-butoxy carbony l)piperidin-4-yl] amino } sulfony l)-4-
(trifluoromethyl)phenyl] sulfonyl } benzoic acid;
4-oxo-4-[4-({[5-(pb.enylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yljbutanoic acid;
4-oxo-4-[3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l- yl]butanoic acid;
5-oxo-5-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yljpentanoic acid;
5-oxo-5-[3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l- yl]pentanoic acid; N-[I -(N,N-dimethy lgly cy l)piperidin-4-y 1] -5 -(phenylsulfony l)-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl 4-{2-oxo-2-[4-({[5-(ρhenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl} amino)piperidin- 1 -yl] ethyl }piperidine- 1 -carboxylate;
5-(phenylsulfonyl)-N-[l-(piperidin-4-ylacetyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(N-methylglycyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-[l-(pyrrolidin-l-ylacetyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(morpholin-4-ylacetyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-[l-(piperazin-l-ylacetyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide;
N-{l-[3-(methylthio)propanoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{l-[3-(methylsulfϊnyl)propanoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[I-(I H-imidazol- 1 -y lacetyl)piperidin-4-yl]-5 -(phenylsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
4- [( { 5- [(4-fluoropheny l)sulfonyl] -2-isopropy lphenyl } sulfony l)amino] -Ν- 1 - naphthy lpiperidine-
1 -carbothioamide;
Ν-(2-fluorophenyl)-4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropy lphenyl} sulfonyl)amino]piperidine- 1 -carbothioamide;
4- [( { 5 - [(4-fluoropheny l)sulfonyl] -2-isopropy lphenyl} sulfony l)amino] -N-(2- methylphenyl)piperidine-l-carbothioamide; ethyl ({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-l- y 1 } carbonothioy l)carbamate ;
N-butyl-4- [( { 5- [(4-fluoropheny l)sulfony 1] -2- isopropy lphenyl } sulfony l)amino]piperidine- 1 - carbothioamide;
4- [( { 5- [(4-fluoropheny l)sulfonyl] -2-isopropy lphenyl } sulfony l)amino] -N-(4- methoxypheny l)piperidine- 1 -carbothioamide ; methyl 4-[({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-l- yl} carbonothioyl)amino]benzoate; methyl N-({4-[({ 5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl} sulfonyl)amino]piperidin- 1 - yl} carbonothioyl)glycinate;
4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(2- morpholin-4- ylethyl)piperidine- 1 -carbothioamide;
4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(3- nitrophenyl)piperidine- 1 -carbothioamide;
3- [({4- [({5- [(4-fluoropheny l)sulfony 1] -2- isopropylphenyl } sulfony l)amino]piperidin- 1 - yl} carbonothioyl)amino]benzoic acid;
4-[({5-[(4-fluorophenyl)sulfonyl]-2 -isopropylphenyl} sulfony l)ammo]-N-pyridin-3- ylpiperidine-
1 -carbothioamide;
4- [( { 5- [(4-fluoropheny l)sulfonyl] -2 -isopropylphenyl } sulfony l)amino] -N- [4-
(trifluoromethy l)pheny l]piperidine- 1 -carbothioamide ; iV-(4-tert-butylphenyl)-4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxamide;
3 -( { [4-( { [5-(pheny lsulfonyl)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)piperidin- 1 - yl]carbonothioyl}amino)benzoic acid; tert-butyl 4-{ [4-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l - yl] carbony 1 } piperidine- 1 -carboxy late ;
5-(phenylsulfonyl)-N-[l-(piperidin-4-ylcarbonyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl (2S)-2-{ [4-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-
1 -yl] carbonyl}pyrrolidine- 1 -carboxylate;
5-(phenylsulfonyl)-iV-(l-L-prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide; tert-butyl (2i?)-2-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-
1 -yl] carbonyl}pyrrolidine- 1 -carboxylate;
5-(phenylsulfonyl)-N-(l-D-prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide;
N-[I -(I -acetyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl (55)-2-oxo-5-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l -carboxylate; N-[l-(5-oxo-L-prolyl)piperidin-4-yl]-5-(plienylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[I -(I -methyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; fe^butyl (4i?)-4-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-
1 -y 1] carbony 1 } - 1 ,3 -thiazolidine-3 -carboxy late ;
5-(phenylsulfonyl)-N-{l-[(4i?)-l,3-thiazolidin-4-ylcarbonyl]piperidin-4-yl}-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl (3i?)-3-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-
1 -yl]carbonyl} pyrrolidine- 1 -carboxylate; tert-butyl (35)-3-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-
1 -yl]carbonyl} pyrrolidine- 1 -carboxylate;
5-(phenylsulfonyl)-N-{l-[(3i?)-pyrrolidin-3-ylcarbonyl]piperidin-4-yl}-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-{l-[(35)-pyrrolidin-3-ylcarbonyl]piperidin-4-yl}-2-
(trifluoromethy l)benzenesulfonamide ; tert-butyl (4i?)-4-{ [4-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-
1 -y 1] carbony 1 } - 1 ,3 -thiazolidine-3 -carboxylate 1 -oxide;
N-( 1 - { [(3R)- 1 -acety lpyrrolidin-3 -yl] carbonyl } piperidin-4-y l)-5-(pheny lsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
N-(I -{ [(3S)-I -acetylpyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(l-isobutyryl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(I-[I -(2,2-dimethylpropanoyl)-L-prolyl]piperidin-4-yl} -5-(pheny lsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{l-[l-(3,3-dimethylbutanoyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{l-[l-(cyclohexylcarbonyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(I-[I -(morpholin-4-ylcarbonyl)-L-proly l]piperidin-4-y 1 } -5-(pheny lsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
(2S)-N-(tert-butyl)-2-([4-(([5-(phenylsulfonyl)-2- (Mfluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxamide;
(25)-N-phenyl-2-{[4-({[5-(phenylsulfonyl)-2-(trifluorometliyl)phenyl]sulfonyl}amino)piperidin- l-yl]carbonyl}pyrrolidine-l-carboxamide; iV-{l-[l-(methylsulfonyl)-L-prolyl]piperidin-4-yl}-5-(pb.enylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(l-benzoyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(I -{ 1 -[4-(dimethylamino)benzoyl]-L-prolyl}piperidin-4-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[I-(I -isonicotinoy 1-L-proly l)piperidin-4-yl] -5 -(pheny lsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(I-(I- [(6-chloropyridin-3 -y l)carbony 1] -L-proly 1 } piperidin-4-y l)~5-(pheny lsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
4- [((2S)-2- { [4-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)piperidin- 1 - yl]carbonyl}pyrrolidin-l -yl)sulfonyl]benzoic acid;
N-[l-(N,N-dimethylglycyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[I-(I -benzyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{l-[l-(cyclohexylmethyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{1 -[I -(3,3-dimethylbutyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
(25)-N-ethyl-2-{[4-(([5-(phenylsulfonyl)-2-(trifluorometb.yl)phenyl]sulfonyl}amino)piperidin-l- y^carbonyllpyrrolidine-l-carboxamide;
(25)-NΛ-dimethyl-2-( [4-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxamide; tert-butyl (25)-2- { [4-( ( [5-[(3-cyanoρhenyl)sulfonyl]-2-
(1xifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxylate;
N-[l-(2-hydroxy-2-methylpropyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-2-(trifluoromethyl)-N- ( 1 - [4-(trifluoromethyl)benzyl]piperidin-4- yl}benzenesulfonamide;
N-[l-(cyanomethyl)piperidin-4-yl]-5-φhenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
Λ/-[l-(2-oxo-2-phenylethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-2-(trifluoromethyl)-N-{l-[4-(trifluoroniethyl)phenyl]piperidin-4- yl}benzenesulfonamide;
Λ/-[l-(2-hydroxyethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
2-Isopropyl-N-[(li?*,55'*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-5-
(phenylsulfonyl)benzenesulfonamide monohydrochloride;
[4-( { [5 -(pheny lsulfony l)-2-(trifluorometliy l)pheny 1] sulfony 1} amino)piperidin- 1 -y 1] acetic acid;
2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide;
5-(phenylsulfonyl)-iV-[l-(2H-tetrazol-5-ylmeth.yl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide;
3-[4-({[5 -(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)piperidin- 1 -yl]propanoic acid;
3 - [4-( { [5 -(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)piperidin- 1 -y ljbenzoic acid;
4- [4-( { [5-(pheny lsulfonyl)-2-(trifluoromethy l)pheny 1] sulfony 1 } amino)piperidin- 1 -yljbenzoic acid;
-Y-[l-(3-cyanophenyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
2- [4-( { [5 -(pheny lsulfony l)-2-(trifluoromethyl)pheny 1] sulfony 1} amino)piperidin- 1 - yljpropanamide;
N-[l-(2-morpholin-4-ylethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[(1R*, SS^-δ-Methyl-δ-azabicycloP^.lJoctO-ylJ-S^henylsulfonyl)^-
(trifluoromethyl)benzenesulfonamide;
(2i?)-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yljpropanamide;
(2jS)-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]propanamide ; methyl [4-( { [5-(pheny lsulfony l)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin- 1 - yl]acetate;
N-methy 1-2- [4-( { [5-(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1 } amino)piperidin- 1 - yl]acetamide;
ΛζN-dimethy 1-2- [4-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)piperidin- 1 - yljacetamide; iV-isopropyl-2-[4-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)piperidin- 1 - yl]acetamide;
N-[l-(2-morpholin-4-yl-2-oxoethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide;
7V-{l-[(4-tert-butylphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-[l-(phenylsulfonyl)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonamide; 3-{[4-({[5 -(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfonyl } amino)piperidin- 1 - yl]sulfonyl}benzoic acid;
4- { [4-( { [5 -(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfonyl} amino)piperidin- 1 - yl] sulfonyl} benzoic acid;
N- { 1 - [(4-hydroxypheny l)sulfonyl]piperidin-4-y 1 } -5 -(pheny lsulfony l)-2- (trifluoromethyl)benzenesulfonamide; methyl 3-{ [4-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l - y 1] sulfonyl } benzoate;
N-{l-[(3-cyanophenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-(l-{[3-(2H"-tetrazol-5-yl)phenyl]sulfonyl}piperidin-4-yl)-2- (trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-(2-pyridin-3-ylethyl)-2-(trifluoromethoxy)benzenesulfonamide; 2-isopropyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonainide; 2-isopropyl-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; l-Methoxy-4-(phenylsulfonyl)benzene;
Λ/"-[2-(l-oxidopyridin-3-yl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-iV-(2-hydroxy-2-pyridin-2-ylethyl)-2- isopropylbenzenesulfonamide; N-(2-hydroxy-2-pyridin-2-ylethyl)-2-isopropyl-5-(phenylsulfonyl)benzene-sulfonamide;
N-(2-hydroxy-2-pyridin-2-ylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-iV-(2-hydroxy-2-pyridin-3-ylethyl)-2- isopropylbenzenesulfonamide;
N-(2-hydroxy-2-pyridin-3-ylethyl)-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
N-(2-hydroxy-2-pyridin-3-yleth.yl)-2,4-dimetliyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(l/f-Imidazol-l-yl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-3-ylethyl)-2-methylbenzenesulfonaniide;
N-(2-hydroxy-2-pyridin-3-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
5-[(3-methoxyphenyl)sulfonyl]-iV-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide;
5-[(3-chlorophenyl)sulfonyl]-N-(2-pyridin-3-ylethyl)-2-(1xifluorometb.yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-2-yleth.yl)-2-methylbenzenesulfonamide;
N-(2-hydroxy-2-pyridin-2-ylethyl)-5-(phenylsulfonyl)-2-(trifluorometb.yl)benzenesulfonamide;
5-(phenylsulfonyl)-Ν-(2-pyridin-4-ylethyl)-2-(trifluorometliyl)benzenesulfonaniide;
5-[(4-hydroxyphenyl)sulfonyl]-N-(2-pyridm-3-ylethyl)-2-(trifluorometliyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2-
(trifluoromethyl)benzenesulfonamide;
5-[(2-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2-
(trifluoromethyl)benzenesulfonamide ;
5-(Phenylsulfonyl)-2-propyl-iV-(2-pyridin-4-ylethyl)benzenesulfonaniide;
5-(phenylsulfonyl)-N-[2-(2H-tetrazol-5-yl)ethyl]-2-(trifluoromethyl)benzenesulfonamide;
5-[(4-Fluorophenyl)sulfonyl]-2-propyl-iV-(2-pyridin-3-ylethyl)benzenesulfonamide;
5-[(4-Fluorophenyl)sulfonyl]-2-propyl-iV-(2-pyridin-4-ylethyl)benzenesulfonamide;
5-(Phenylsulfonyl)-2-propyl-iV-(2-pyridin-3-ylethyl)benzenesulfonaniide;
2-isopropyl-5-(phenylsulfonyl)-iV-(pyridin-4-ylmethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-(pyridin-4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[(6-chloropyridin-3-yl)methyl]-5-(phenylsulfonyl)-2-(trifluoroniethyl)benzenesulfonamide;
5-(phenylsulfonyl)-A/-[(6-pyrrolidin-l-ylpyridin-3-yl)methyl]-2-
(trifluoromethyl)benzenesulfonamide;
N-[(6-morpholin-4-ylpyridin-3-yl)methyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; 2-chloro-iV-[(li?:1:,2i?*)-2-hydroxy-l-methyl-2-phenylethyl]-5-
(phenylsulfonyl)benzenesulfonamide;
N-(2-hydroxy-2-phenyletiiyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; iV-[(li?:i:,2i2:1:)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N- [( 15',2i?)-2-hydroxy- 1 -methyl-2-phenylethyl] -5-(phenylsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
N-[(li?525)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[(l(S)-l-benzyl-2-hydroxyethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[(15)-2-hydroxy-l-(l/f-indol-3-ylmethyl)etb.yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-phenylethyl)-2-isopropylbenzenesulfonamide;
JV-(2-hydroxy-2-phenylethyl)-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[(2R)-2-hydroxy-2-phenylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[(2S)-2-hydroxy-2-phenylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
4- [2-( { [5 -(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)ethy l]benzoic acid;
N-[2-(4-aminophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[2-(4-methoxyphenyl)etih.yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-(4-aminobenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonaniide;
N-[2-(4-hydroxyphenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoroniethyl)benzenesulfonamide; methyl 4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]benzoate; methyl 4-[({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)methyl]benzoate; iV-[2-(4-bromophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
3-[({4-[({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)methyl]phenyl}amino)sulfonyl]benzoic acid;
N-(4-bromobenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[2-(4-cyanophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; methyl 4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzoate;
4'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-3- carboxylic acid; 4'-[({[5-(phenylsulfonyl)-2-(trifluorome1iiyl)phenyl]sulfonyl}amino)methyl]biphenyl-4- carboxylic acid;
5-(phenylsulfonyl)-N-{2-[4-(2H'-tetrazol-5-yl)phenyl]ethyl}-2-
(trifluoromethyl)benzenesulfonamide;
Λ/-(2-{4-[(methylsulfonyl)amino]phenyl}ethyl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; iV-(3-bromobenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
3 '- [( { [5-(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1 } amino)methy l]bipheny 1-3 - carboxylic acid;
3'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-4- carboxylic acid;
N- [2-(4- { [amino(imino)methy 1] amino } pheny l)ethy 1] -5-(pheny lsulfony l)-2-
(trifluoromethyl)benzenesulfonamide; iV-[4-(dimethylamino)benzyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; iV-(2,4-dimethoxybenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; tert-Butyl [2-({[5-(phenylsulfonyl)-2-(1rifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate;
N-(2-Aminoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride;
N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
4-Methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
4-tert-Butyl-N- [2-( { [5-(pheny lsulfony l)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
4-Fluoro-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
4-Chloro-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
4-Bromo-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfony 1 } amino)ethyl]benzamide ;
4-Methoxy-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfony 1 } amino)ethy l]benzamide ;
N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4-
(trifluoromethy l)benzamide ; N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4-
(trifluoromethoxy)benzamide ;
N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]isonicotinamide; tert-Butyl methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl] sulfonyl} amino)ethyl]carbamate;
N-[2-(Methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride;
N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfonyl} amino)ethyl]benzamide;
4-Methoxy-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfonyl} amino)ethyl]benzamide;
N-{2-[(anilinocarbonyl)(methyl)amino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(2- {methyl [(pyridin-3 -ylamino)carbony 1] amino } ethyl)-5 -(pheny lsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
N- { 2- [ { [(2,4-dimethoxypheny l)amino]carbony 1 } (methy l)amino] ethyl} -5 -(pheny lsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
N-{2-[[(tert-butylamino)carbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{2-[{[(4-methoxyphenyl)amino]carbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;;
N- {2- [ [(butylamino)carbony 1] (methy l)amino] ethyl} -5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide
N-{2-[{[(2,4-difluorophenyl)amino]carbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l-carboxamide;
N-{2-[[(diethylamino)carbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]moφholine-4-carboxamide; N- [2-(methy 1 { [methyl(pheny l)amino] carbony 1 } amino)ethy 1] -5 -(pheny lsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-Methyl-N- [2-( { [5 -(pheny lsulfony l)-2-(trifluoromethy l)phenyl] sulfony 1 } amino)ethy 1] -2- furamide;
4-tert-Butyl-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-2-
(trifluoromethoxy)benzamide;
N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfonyl } amino)ethy 1] cy clohexanecarboxamide ;
3-Fluoro-N-methyl-N-[2-( { [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4-(trifluoromethyl)benzamide;
Methyl 4-({methyl[2-( { [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)benzoate;
N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-
(txifluoromethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide;
N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfonyl } amino)ethyl] isonicotinamide ;
2-Chloro-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide;
N,2,2-trimethyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfonyl } amino)ethyl]propanamide;
2-ethyl-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]butanamide; butyl methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate; tert-butyl 4-[({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}aniino)ethyl]amino}carbonyl)amino]piperidine-l-carboxylate;
2,2-dimethylpropyl methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate; isobutyl methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfonyl } amino)ethyl] carbamate ; 3-(trifluoromethyl)phenyl methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfony 1} amino)ethy 1] carbamate ;
4-fluorophenyl methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate;
4-bromophenyl methyl [2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate;
Λ/"-(2-{methyl[(piperidin-4-ylamino)carbonyl]amino}ethyl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; ethyl N-({methyl[2-( { [5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfonyl } amino)ethy 1] amino } carbonyl)gly cinate;
3-({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfonyl } amino)ethy 1] amino } sulfony l)benzoic acid; tert-butyl 4-({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)piperazine-l-carboxylate;
N-({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)glycine;
4-{methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}-4- oxobutanoic acid;
N-methyl-iV-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperazine-l-carboxamide; iV-{2-[(2-hydroxyethyl)(methyl)amino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; methyl N-methyl-N-[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycinate; ethyl iV-methyl-iV- [2-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl } amino)ethyl]- D - alaninate; tert-butyl (35)-3-[({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl] sulfonyl} amino)ethyl]amino} carbonyl)amino]pyrrolidine- 1 -carboxylate; tert-butyl methyl[3-( { [5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfonyl} amino)propyl] carbamate ;
N-[3-(methylamino)propyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N-[2-(methyl{[(35)-pyrrolidin-3-ylamino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl 4-[({methyl[3-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)propyl]amino}carbonyl)amino]piperidine-l- carboxylate; tert-butyl N-methyl-N-[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfony 1 } amino)ethy 1] - β -alaninate ; tert-butyl N-methyl-JV-[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycinate;
N-(3-{methyl[(piperidm-4-ylamino)carbonyl]amino}propyl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl 4-({methyl[3-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl] sulfony 1} amino)propyl]amino} carbonyl)piperazine- 1 -carboxylate;
N-methyl-N-[3-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl] sulfony 1 } amino)propyl]piperazine- 1 -carboxamide;
4-{4-[({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfonyl } amino)ethy 1] amino } carbonyl)amino]piperidin- 1 -y 1 } -A- oxobutanoic acid;
N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycine;
N-methyl-iV-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-β- alanine;
4-(bromomethyl)-iV-metb.yl-iV-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfonyl } amino)ethyl]benzamide ; tert-butyl [3-({[5-(phenylsulfonyl)-2-(trifluorometb.yl)pb.enyl]sulfonyl}amino)propyl]carbamate; tert-butyl 4-[methyl({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl] sulfonyl } amino)ethyl] amino } carbonyl)amino]piperidine- 1 -carboxylate; tert-butyl (3i?)-3-[({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfonyl } amino)ethy 1] amino } carbony l)amino]pyrrolidine- 1 -carboxylate;
4-{methyl[3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)propyl]amino}-4- oxobutanoic acid;
N-(3-aminopropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; dimethyl [4-({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]aniino}carbonyl)benzyl]phosphonate;
N-[2-(methyl{[methylφiperidin-4-yl)amino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[2-(methyl{[(3i-)-pyπ.Olidin-3-ylamino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl (3i?)-3-[({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfony 1 } amino)ethy 1] amino } carbony l)amino]piperidine- 1 -carboxy late; tert-butyl (3^-3-[({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfony 1} amino)ethy 1] amino } carbony l)amino]piperidine- 1 -carboxy late ;
N-[2-(methyl{[(3i?)-piperidin-3-ylamino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[2-(methyl{[(35)-piperidin-3-ylaniino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide ;
[4-({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfony 1 } amino)ethy 1] amino } carbony l)benzyl]phosphonic acid; tert-butyl 4-[methyl({ [2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l-carboxylate; tert-butyl 4-[({[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfonyl } amino)ethyl] amino } carbony l)amino]piperidine- 1 -carboxy late ;
N-(2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-(2-hydroxy-2,3-dihydro- 1 H-inden- 1 -yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(l-hydroxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(5-methoxy-2,3 -dihydro- 1 H-inden-2-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(5-hydroxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; methyl {[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)-2,3-dihydro-lH- inden-5-yl]oxy}acetate; {[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)-2,3-dihydro-lH-inden-5- yl]oxy}acetic acid; methyl 2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)indane-5-carboxylate;
N-(l-hydroxy-6-methoxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
2-{[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)-2,3-dihydro-lH-inden-
5-yl]oxy } acetamide;
2-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)indane-5-carboxylic acid; or
N-(5-bromo-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide.
[0164] In certain embodiments of the invention, when R1 of Formula I is phenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I are each H; then R3 of Formula I is not methylphenyl, ethylphenyl, or hydrogen. In other embodiments, when R1 of Formula I is phenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I are each H; then R3 of Formula I is not alkylphenyl or hydrogen. In still further embodiments, when R1 of Formula I is phenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I are each H; then R3 of Formula I is not alkylaryl or hydrogen.
[0165] In further embodiments of the invention, when R1 of Formula I is chlorophenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I are each H; then R3 of Formula I is not cyclohexyl, methylphenyl, methylfuranyl, methylpyridyl, or hydrogen. In other embodiments, when R1 of Formula I is chlorophenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I are each H; then R3 of Formula I is not cycloalkyl, alkylphenyl, alkylfuranyl, alkylpyridyl, or hydrogen. In additional embodiments, when R1 of Formula I is chlorophenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I are each H; then R3 of Formula I is not cycloalkyl, alkylaryl, alkylheteroaryl, or hydrogen.
[0166] In certain embodiments of the invention, when R1 of Formula I is bromophenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I are each H; then R3 of Formula I is not hydrogen.
[0167] In certain other embodiments of the invention, when Ri of Formula I is nitrophenyl or dinitrophenyl; X of Formula I is O; R2 of Formula I is CH3; and R4, R5, R6, and R7 of Formula I are each H; then R3 of Formula I is not hydrogen. [0168] Compounds of Formula 1 may be used to modulate the activity of secreted frizzled related protein- 1. Such compounds are of interest for the treatment of bone fractures as well as bone disorders, including osteoporosis, and for the treatment of arthritis, chronic obstructive pulmonary disease, cartilage defects, prostate cancer and leiomyoma.
[0169] In certain embodiments, the present invention therefore provides methods of treating, preventing, inhibiting, or alleviating each of the maladies listed above in a mammal, preferably in a human, comprising administering a therapeutically effective amount of a compound of Formula 1 or a pharmaceutically acceptable salt thereof to a patient suspected to suffer from such a malady.
[0170] In other embodiments, the invention relates to compositions comprising at least one compound of Formula 1, or a steroisomer or pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such compositions include pharmaceutical compositions for treating or controlling disease states or conditions of the bone. In certain embodiments, the compositions comprise mixtures of one or more compounds of Formula 1.
[0171] Certain of the compounds of Formula 1 contain stereogenic carbon atoms or other chiral elements and thus give rise to stereoisomers, including enantiomers and diastereomers. The invention generally relates to all stereoisomers of the compounds of Formula 1, as well as to mixtures of the stereoisomers. Throughout this application, the name of a compound without indication as to the absolute configuration of an asymmetric center is intended to embrace the individual stereoisomers as well as mixtures of stereoisomers. Reference to optical rotation [(+), (-) and (±)] is utilized to distinguish the enantiomers from one another and from the racemate. Furthermore, throughout this application, the designations R* and S* are used to indicate relative stereochemistry, employing the Chemical Abstracts convention which automatically assigns R* to the lowest numbered asymmetric center.
[0172] An enantiomer can, in some embodiments of the invention, be provided substantially free of the corresponding enantiomer. Thus, reference to an enantiomer as being substantially free of the corresponding enantiomer indicates that it is isolated or separated via separation techniques or prepared so as to be substantially free of the corresponding enantiomer. "Substantially free," as used herein, means that a significantly lesser proportion of the corresponding enantiomer is present. In preferred embodiments, less than about 90 % by weight of the corresponding enantiomer is present relative to desired enantiomer, more preferably less than about 1% by weight. Preferred enantiomers can be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC), and the formation and crystallization of chiral salts, or preferred enantiomers, can be prepared by methods described herein. Methods for the preparation of enantiomers are described, for example, in Jacques, et ah, Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al, Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972), each of which is hereby incorporated by reference in its entirety.
[0173] The following synthetic schemes are designed to illustrate, but not limit, general procedures for the preparation of compounds of Formula 1. The reagents used can be either commercially obtained or can be prepared by standard procedures described in the literature.
Scheme 1:
Figure imgf000075_0001
2b (X = O) 1 i. AICI3, aryl; ii. Chlorosulfonic acid, heat; iii. Amine, TEA, DCM or Amine, Na2CO3, ACN/water
[0174] In Scheme 1, step i, a suitably substituted aryl sulfonyl chloride (5), either commercially available, known in the literature, or prepared according to methods known and established for the preparation of sulfonyl chlorides, including procedures exemplified in the experimental section of this document, wherein, R2, R4, R5, R6 and R1 are as previously defined, is reacted with an unsubstituted or suitably substituted aryl group, either commercially available, known in the literature, or prepared according to methods known and established for the preparation of substituted benzenes, with or without a Lewis acid catalyst such as aluminum chloride, either using the substituted aryl in excess as the solvent, or using another suitably acceptable solvent. The diaryl sulfone product is then treated with chlorosulfonic acid with or without solvent, step ii, at room temperature or with heating for several hours or longer where appropriate to provide a sulfonyl chloride (2b), which is used directly or purified according to established procedures. The sulfonyl chloride (T) is reacted in step iii with an amine (R7R3NH), either commercially available, known in the literature, or prepared according to methods known and established for the preparation of primary and secondary amines, in a suitable solvent, such as dichloromethane or acetonitrile, in the presence of an acid scavenger, such as triethylamine, at room temperature to afford the desired product (1).
Scheme 2:
Figure imgf000076_0001
9a (X = LP) or
9b (X = O) iv. arylthiol, K2CO3, DMF; v. m-CPBA or oxone, DCM; vi. SnCl2, or H2/Pd; vii. NaNO2, HCl, AcOH; viii. SO2(g), CuCl2;
[0175] In Scheme 2, step iv, a suitably substituted 3-fluoro nitrobenzene derivative, either commercially available, known in the literature, or prepared according to methods known and established for the preparation of such nitrobenzenes, is reacted with an appropriately substituted arylthiol, either commercially available, known in the literature, or prepared according to methods known and established for the preparation of such arylthiols, in the presence of an acid scavenger, such as potassium carbonate, in a suitable solvent, such as dimethylformamide or dimethylacetamide, at an elevated temperature for several hours to provide diaryl sulfide (7). The diaryl sulfide (7) is oxidized, step v, using established procedures, or as known in the literature, in an acceptable solvent such as dichloromethane, with a suitable oxidant, such as meta-chloroperoxybenzoic acid or oxone, to afford either the sulfoxide (8a) or sulfone (8b). The sulfoxide or sulfone is subjected to reducing conditions, such as stannous chloride, step vi, or reagents that are commonly used to effect the reduction of a nitro group, known in the literature, to afford aniline (9a or 9b). Diazotization, step vii, of the anilinium hydrochloride salt under acidic conditions with sodium nitrite, followed by sulfonylation, step viii, with sulfur dioxide and hydrogen chloride in the presence of an organic metal catalyst, such as copper (II) chloride, according to procedures described in the literature, results in the formation of sulfonyl chloride (2), which may be transformed into the sulfonamide (1) as previously described, step iii.
Scheme 3
Figure imgf000077_0001
LP or O)
Figure imgf000077_0002
12 ix. BuLi, -78 0C, THF; x. SO2(g); xi. NCS, DCM; xii. NBS, H2SO4; xiii. thiophenol, NiBr2, Zn, Dppf, K2CO3, NMP, microwave, 160 0C, 10 min
[0176] In Scheme 3, an appropriately substituted sulfonyl chloride (11), wherein R2 is as previously defined for alkyl, either commercially available, known in the literature, or prepared according to methods known and established for the preparation of such sulfonyl chlorides, including procedures exemplified in the experimental section, such as from aryl bromide (10), either commercially available, known in the literature, or prepared according to methods known and established for the preparation of such aryl bromides, is transmetalated, step ix, at reduced temperature and in a suitable solvent such as tetrahydrofuran, using an acceptable organometallic reagent that is known to effect such transformations, such as n-butyl lithium, and the resulting metalated species is treated with sulfur dioxide, step x, to afford a sulfinic acid intermediate that is isolated or immediately oxidized, step xi, to a sulfonyl chloride (11). The sulfonyl chloride (11) is then transformed into a sulfonamide, step iii, and brominated, step xii, using N-bromosuccinimide in concentrated sulfuric acid, or other brominating conditions that are commonly used to brominate aryl sulfonamides, to afford an aryl bromosulfonamide (3). The aryl bromosulfonamide (3) is then reacted with an arylthiol, either commercially available, known in the literature, or prepared according to methods known and established for the preparation of thiophenols, using a catalytic system comprised of nickel (II) bromide and zinc metal, with a suitable ligand such as Dppf, step xiii, in the presence of an inorganic base, such as potassium carbonate, and a polar aprotic solvent, such as l-methyl-2-pyrrolidinone, at elevated temperatures to afford a sulfide (12), which is oxidized, step v, using a suitable oxidant such as meta-chloroperoxybenzoic acid or oxone, or by established procedures, as known in the literature, in an acceptable solvent, such as dichloromethane, for the oxidation of sulfides, including procedures exemplified in the experimental section, to afford a diarylsulfone sulfonamide (1).
Scheme 4
(where X = O)
Figure imgf000078_0001
xiv. MeMgBr, -78 to 0 0C, THF; xv. K2CO3, Cu(OAc)2, DMSO, arylboronic acid
[0177] Alternatively, as depicted in Scheme 4, intermediate 3 is exposed to methyl magnesium bromide, step xiv, followed by a metal halogen exchange reagent, such as butyl lithium, step ix, at reduced temperature and in a suitable solvent, such as tetrahydrofuran, to afford a lithiated species that is quenched with sulfur dioxide, step x, to afford a sulfϊnic acid that is isolated as the sodium salt (4), as exemplified in the experimental section. The sodium sulfinate (4) is then reacted with an appropriately substituted aryl boronic acid, step xv, either commercially available, known in the literature, or prepared according to methods known and established for the preparation of aryl boronic acids, in a cross coupling reaction that is promoted by a copper salt, such as copper (II) acetate, in an appropriate polar aprotic solvent, such as dimethylsulfoxide or dimethylforamide, in the presence of an acid scavenger, such as triethylamine or potassium carbonate, and a desiccant, such as molecular sieves, at ambient or elevated temperatures, or as exemplified in the experimental section, to provide compounds of Formula 1.
Scheme 5 xiv, ix, xvi 3 — — — *- 1 xvi. arylsulfonyl fluoride [0178] Alternatively, as depicted in Scheme 5, the lithiated intermediate from 3, Scheme 4, is quenched with an appropriately substituted aryl sulfonyl fluoride, step xvi, either commercially available, known in the literature, or prepared according to methods known and established for the preparation of aryl sulfonyl fluorides, as exemplified in the experimental section, to provide compounds of Formula 1.
Scheme 6
Figure imgf000079_0001
R6
[0179] In Scheme 6, an appropriately substituted aryl sulfonyl chloride, either commercially available, known in the literature, or prepared according to methods known and established for the preparation of aryl sulfonyl chlorides, is elaborated as described in Scheme 1, step i, to provide 8, and then, according to Scheme 2, steps vi, vii and viii, to provide sulfonyl chloride (T), which is transformed to compounds of Formula 1 as previously described.
Scheme 7
Figure imgf000079_0002
14 15
[0180] Alternatively, as depicted in Scheme 7, intermediate 3 is prepared from an appropriately substituted bromoaniline (14), either commercially available, known in the literature, or prepared according to methods known and established for the preparation of bromoanilines, according to the protocol followed in Scheme 2, steps vii and viii, to afford a sulfonyl chloride (15), which is converted into a sulfonamide (3), step iii, as outlined in the previous schemes. Intermediate 3 is elaborated to compounds of Formula 1 using methods previously described in Schemes 3, 4 or 5, as appropriate. ' .1SBiEiMEi
AM101865 - 79 -
Scheme 8
Figure imgf000080_0001
16 xvii. Amine, DMA, K2CO3, microwave, 180 0C;
[0181] In Scheme 8, an aryl fluoride (16), either prepared according to procedures previously described, exemplified in the experimental section, commercially available, or known in the literature, is reacted with an appropriately substituted primary or secondary amine, either commercially available or known in the literature, using a suitable polar solvent, such as dimethylacetamide, in the presence of an acid scavenger, such as potassium carbonate, at elevated temperatures to afford the desired product.
Scheme 9
Figure imgf000080_0002
17
xviii. Electrophile, base, DCM
[0182] The piperidinyl sulfonamide (17), shown in Scheme 9, either prepared according to procedures exemplified in the experimental section, commercially available, or known in the literature, is reacted with an appropriately substituted electrophile such as, but not limited to, an acid chloride, sulfonyl chloride, alkyl halide, isothiocyanate, isocyanate, or epoxide, in the presence of an acid scavenger, such as morpholinomethyl-polystyrene or triethylamine where appropriate, in a suitable solvent, such as dichloromethane, to provide the desired product of Formula 1. 3. /X 888 B
AM101865 - 80 -
Scheme 10
Figure imgf000081_0001
xix. NaH, DMF, propynylchloride
[0183] Compounds of Formula 1, in which R7 is H and R3 is as previously described, are further alkylated by deprotonating using an alkali base, such as sodium hydride, in an appropriate solvent, such as dimethylformamide, and subsequently treating with an alkylating agent, such as propynyl chloride, to yield a tertiary sulfonamide.
Scheme 11
Figure imgf000081_0002
xx. Cu powder, CF2Br2, activated carbon, DMF, 100 0C
[0184] In Scheme 11 , an aryl sulfonyl chloride (5), either prepared according to procedures previously described, commercially available, or known in the literature, is reacted as described in Scheme 1, step i, to afford an intermediate diarylsulfone (18). Reaction of 18 with an in situ derived copper trifluoromethylating agent, step xx, also known in the literature as Burton's reagent, which is generated by the reaction of copper metal and dibromodifluoromethane in a polar aprotic solvent such as dimethylformamide, and heating for several hours, provides the trifluoromethyl intermediate 19. The conversion of 19 to aniline 20 and then to the subsequent sulfonyl chloride proceeds as previously described using steps vi - vm. Scheme 12
Figure imgf000082_0001
Vl VIl, VIII III
19 20 2b 1 xxi. sodium arylsulfmate, DMA, 100 0C
[0185] Alternatively, in Scheme 12, the nitro benzene (21) can be converted to the trifluoromethyl intermediate (22) in an analogous manner used to prepared 19, employing step xx. Further elaboration of 22 to a diaryl sulfide (7), step iv, in an analogous fashion as outlined in Scheme 2. The sulfide can than be oxidized to the diaryl sulfone (19) using procedures that were previously discussed in Scheme 2, step v. Diaryl sulfone (19) can also be directly prepared by reacting 22 with an aryl sulfinate, step xxi, either commercially available, or known in the literature, in a polar aprotic solvent such as dimethylacetamide with heating for several hours. Intermediate 19 can be further transformed to aniline 20, step vi, using previously estabilished procedures. The aniline (20) can then be converted into the sulfonyl chloride, step vii - viii, using previously established procedures, and subsequently reacted with an amine, step iii, to afford compounds of formula 1.
[0186] In certain embodiments, the invention relates to compositions comprising at least one compound of Formula 1, or a stereoisomer or pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such compositions are prepared in accordance with general pharmaceutical formulation procedures, such as, for example, those described in Remingtons Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985), which is incorporated herein by reference in its entirety. Pharmaceutically acceptable carriers are those carriers that are compatible with the other ingredients in the formulation and are biologically acceptable.
[0187] The compounds of Formula 1 can be administered orally or parenterally, neat, or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances that can also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders, tablet-disintegrating agents, or encapsulating materials. In powders, the carrier is a finely divided solid that is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99 % of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
[0188] Liquid carriers can be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both, or a pharmaceutically acceptable oil or fat. The liquid carrier can contain other suitable pharmaceutical additives such as, for example, solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.
[0189] Liquid pharmaceutical compositions that are sterile solutions or suspensions can be administered by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Compositions for oral administration can be in either liquid or solid form.
[0190] The compounds of Formula 1 can be administered rectally or vaginally in the form of a conventional suppository. For administration by intranasal or intrabronchial inhalation or insufflation, the compounds of Formula 1 can be formulated into an aqueous or partially aqueous solution, which can then be utilized in the form of an aerosol. The compounds of Formula 1 can also be administered transdermally through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non-toxic to the sldn, and allows delivery of the agent for systemic absorption into the blood stream via the skin. The carrier can take any number of forms such as creams and ointments, pastes, gels, and occlusive devices. The creams and ointments can be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient can also be suitable. A variety of occlusive devices can be used to release the active ingredient into the blood stream such as a semipermeable membrane covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature.
[0191] Preferably the pharmaceutical composition is in unit dosage form, e.g. as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefϊlled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
[0192] The amount provided to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, and the state of the patient, the manner of administration, and the like. In therapeutic applications, compounds of Formula 1 are provided to a patient already suffering from a disease in an amount sufficient to cure or at least partially ameliorate the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective amount." The dosage to be used in the treatment of a specific case must be subjectively determined by the attending physician. The variables involved include the specific condition and the size, age, and response pattern of the patient. The compounds can be administered orally, rectally, parenterally, or topically to the skin and mucosa. The usual daily dose depends on the specific compound, method of treatment and condition treated. The usual daily dose is 0.01 - 1000 mg/kg for oral application, preferably 0.5 - 500 mg/kg, and 0.1 - 100 mg/kg for parenteral application, preferably 0.5 - 50 mg/kg.
[0193] In certain embodiments, the present invention is directed to prodrugs of compounds of Formula 1. The term "prodrug," as used herein, means a compound that is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of Formula 1. Various forms of prodrugs are known in the art such as those discussed in, for example, Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991), Bundgaard, et ah, Journal of Drug Delivery Reviews, 8:1-38(1992), Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq. (1988); and Higuchi and Stella (eds.) Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975), each of which is hereby incorporated by reference in its entirety.
[0194] The following examples are illustrative of certain embodiments of the invention and should not be considered to limit the scope of the invention. ACD NamePro software was employed to generate IUPAC names for the following examples. The IUPAC names of the following examples are indicative of the neutral or free base forms. Compounds were either isolated as a free base or the corresponding hydrochloride salt as indicated in the experimental procedure.
E,ample 1 : 2-Me
Figure imgf000085_0001
[0195] Step 1 : To phenyl-4-tolyl sulfone (2.32 g, 10.0 mmol) was added chloro sulfonic acid (6.7 mL, 100 mmol) and the reaction mixture was stirred at 50 0C for 5 hours and then cooled to room temperature. The reaction mixture was slowly poured into ice (200 g) and a white solid precipitated. The resulting suspension was extracted with ethyl acetate (150 mL x 3) and the organic layers were combined and washed with brine (200 mL) and collected. The collected organic layer was dried over sodium sulfate and concentrated to give 5- Benzenesulfonyl-2-methyl-benzenesulfonyl chloride (3.30 g, 100 % yield). The product was used without further purification.
[0196] Step 2: The mixture of 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride (66 mg, 0.20 mmol), phenethylamine (36 mg, 0.30 mmol) and triethyl amine (30 mg, 0.30 mmol) in methylene chloride (2 mL) was stirred at 37 0C for 12 hours. Then the reaction mixture was concentrated and purified by reverse phase chromatography to give 2-Methyl-N- (2- phenylethyl)-5-(phenylsulfonyl) benzene sulfonamide (68 mg, 82% yield).
[0197] LC/MS conditions: Aquasil C18; Mobile Phase A: 100% (0.1% Formic Acid) in water (by volume), B: 100% (0.1% Formic Acid) in CAN; Flow Rate: 0.800 mL/min.
[0198] Column Temperature: 40 0C; Injection Volume: 5 μL, UV: monitor 215, 230, 254, 280, and 300 run; Purity is reported at 254 run unless otherwise noted.
[0199] Gradient Table:
Time (min) %B
0 0
2.5 100
4.0 100
4.1 0
5.5 0
MS Conditions (Same for both LC conditions)
Instrument: Agilent MSD
Ionization Mode: API-ES
Gas Temperature: 350 0C
Drying Gas : 13.0 L/min.
Nebulizer Pressure: 55 psig
Polarity: 50% positive, 50% negative
VCap: 3000V (positive), 2500V (negative)
Fragmentor: 120 (positive), 120 (negative)
Mass Range: 100 - 1000 m/z
Threshold: 150
Step size: 0.15
Gain: 1
Peak width: 0.15 min
HPLC: Rt = 3.1 min; MS 416 (M+H).
[0200] 1HNMR (CDCl3) δ 8.48 (IH, d), 7.97 (IH, dd), 7.94 (2H, dd), 7.58 (dd, IH), 7.51 (2H, dd), 7.39 (IH, dd), 7.30 (2H, dd), 7.05 (2H, dd), 4.44 (IH, t), 3.27 (2H, m), 2.78 (2H, t), 2.46 (3H, s).
Figure imgf000087_0001
Examples 2 to 30
[0201] The compounds of Examples 2 to 30 were prepared generally according to the procedures described in Example 1.
Figure imgf000087_0002
.•" -B- «..!■ IUi 'U1 IU!
- 87 -
Figure imgf000088_0001
Examples 31 to 179
[0202] The compounds of Examples 31 to 179 were prepared generally according to the procedures described in Example 1.
Figure imgf000088_0002
Figure imgf000089_0001
Figure imgf000090_0001
-Jb, ιu.« IU' ImIt
-90-
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0002
Example 180: N- ({5-[(4-fluorophenyl) sulfonyl]-2-methylphenyl} sulfonyl)-beta-alanine
Figure imgf000094_0001
[0203] To methyl N- ({5-[(4-fluorophenyl) sulfonyl]-2-methylphenyl} sulfonyl)-beta- alaninate (Example 160) (30 mg, 0.07 mmol) in methanol (1 mL) was added 2.0 M of lithium hydroxide aqueous solution (1 niL, 2 mmol). The reaction mixture was stirred at room temperature for 5 hours and purified by reverse phase column to yield N- ({5-[(4-fluoro- phenyl) sulfonyl]-2-methylphenyl} sulfonyl)-beta-alanine (25 mg, 86 % yield). [0204] HPLC (Method 1): Rt = 2.56 min; MS 402.04 [M+H]
Examples 181-202
[0205] The compounds of Examples 181 to 201 were prepared generally according to the procedures described in Example 1.
Figure imgf000095_0001
Example 202: iV-{[3-(phenylsulfonyl)phenyl]sulfonyl}-beta-alanine
[0206] The compound of Example 202 was prepared generally according to the procedures described in Example 180. Examples 203-221
[0207] The compounds of Examples 203 to 221 were prepared generally according to the procedures described in Example 1.
Figure imgf000096_0001
Examples 222, 223, and 225 to 229
[0208] The compounds of Examples 222, 223, and 225 to 229 were prepared generally according to the procedures described in Example 230.
Figure imgf000097_0002
Example 230: N- [3-(diethylamino) propyl] -2-ethyl-5- (phenylsulfonyl) benzene sulfonamide
Figure imgf000097_0001
[0209] Step 1 : To 4-Ethyl-benzenesulfonyl chloride (4.12 g, 20.0 mmol) and aluminum chloride (3.20 g, 24.0 mmol) was added benzene (10 niL). The reaction mixture was stirred at room temperature over night and then poured into water. The resulting solution was diluted with ethyl acetate (200 niL) and the organic layer was washed with IM aqueous sodium hydroxide solution (100 mL) and brine (100 niL). The organic layer was dried over sodium sulfate, filtered and concentrated to give l-Benzenesulfonyl-4-ethyl-benzene (4.58 g, 92.1% yield) as a white solid.
[0210] 1HNMR (CDCl3) δ 8.09 (2H, dd), 7.89 (2H, dd), 7.94 (2H, dd), 7.51 (m, 2H), 7.29 (IH, m), 7.00 (2H, dd), 2.86 (2H3 qt), 1.22 (3H, t). [0211] Step 2: Following the same procedure described in Example 1 (step 1), 5- Benzenesulfonyl-2-ethyl-benzenesulfonyl chloride was made quanitively.
[0212] Step 3: Following the same procedure described in Example 1 (step 2), a 0.1 mmol scale reaction was set up and N- [3-(diethylamino) propyl]-2-ethyl-5- (phenylsulfonyl) benzene sulfonamide (38 mg, 86% yield) was synthesized.
[0213] HPLC (Method 2): Rt = 2.8 min; MS 439.2 [M+H]
Examples 231-243
[0214] The compounds of Examples 231 to 243 were prepared generally according to the procedures described in Example 230.
Figure imgf000098_0001
Examples 244-265
[0215] The compounds of Examples 244 to 265 were prepared generally according to the procedures described in Example 1.
Figure imgf000099_0001
Figure imgf000100_0001
Examples 266-271
[0216] The compounds of Examples 266 to 271 were prepared generally according to the procedures described in Example 230.
Figure imgf000100_0002
Examples 272-275
[0217] The compounds of Examples 272 to 275 were prepared generally according to the procedures described in Example 276.
Figure imgf000100_0003
Example 276: N-allyl-N- [2-(2-fluorophenyl) ethyl]-2-methyl-5- [(4-methylphenyI) sulfonyl] benzene sulfonamide
Figure imgf000101_0001
[0218] To N- [2-(2-fluoroρhenyl) ethyl]-2-methyl-5- [(4-methylphenyl) sulfonyl] benzene sulfonamide (Example 138) (22 mg, 0.05 mmol) in DMF (1 mL) was added sodium hydride (4 mg, 0.1 mmol). The reaction mixture was stirred at room temperature for 20 minutes, and then allyl bromide (12 mg, 0.1 mmol) was added. The reaction mixture was stirred at room temperature for another 2 hours and purified by a reverse phase column to yield N-allyl-N- [2-(2- fluorophenyl) ethyl]-2-methyl-5- [(4-methylphenyl) sulfonyl] benzene sulfonamide (8.2 mg, 34% yield).
Examples 277: Λ/-[2-(2-fluorophenyl)ethyl]-2-methyl-5-[(4-metliylphenyl)sulfonyl]-Λ/-prop- 2-ynylbenzenesuIfonamide
[0219] The compound of Example 277 was prepared generally according to the procedures described in Example 276.
Examples 278-283
[0220] The compounds of Examples 278 to 283 were prepared generally according to the procedures described in Example 1.
Figure imgf000101_0002
Figure imgf000102_0001
Examples 284-289
[0221] The compounds of Examples 284 to 289 were prepared generally according to the procedures described in Example 230.
Figure imgf000102_0002
[0222] The following table provides the HPLC retention time and mass spec data for the compounds of Examples 1 to 289.
Figure imgf000102_0003
V/ :!L ElBSiB
-102-
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
/'1,SBlBiEi1
AIVUUlOOS -105-
Figure imgf000106_0001
1.8!3SiB
AM101865 -106-
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Example 290 : 5- [(4-chlorophenyl)sulfonyl] -2-methyl-iV-(2-morpholin-4- ylethyl)benzenesulfonamide
[0223] The title compound was prepared in a manner similar to that described in Example 1.
[0224] Step 1 : 4-chlorophenyl-4-tolyl sulfone and clilorosulfonic acid were used to prepare 5-(4-chlorophenyl)sulfonyl-2-methylbenzenesulfonyl chloride.
[0225] Step 2: 5-(4-chlorophenyl)sulfonyl-2-methylbenzenesulfonyl chloride and 4-(2- aminoethyl)-morpholine were used to prepare 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2- moφholin-4-ylethyl)benzenesulfonamide. MS (ES-) m/z 456.8; HRMS: calcd for C19H23ClN2O5S2 + H+, 459.08097; found (ESI, [M+H]+), 459.0798.
Example 291 : 5- [(4-chlorophenyI)suIfonyl] -2-methyl-iV-(2-py ridin-2- ylethyl)benzenesulfonamide
[0226] In an analogous manner to Example 290, 2-(2-aminoethyl)-pyridine was used to prepare 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES-) m/z 448.8; HRMS: calcd for C20H19ClN2O4S2 + H+, 451.05475; found (ESI, [M+H]+), 451.0546.
Example 292: 5-[(4-chlorophenyl)sulfonyl]-AL[3-(lJH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide
[0227] In an analogous manner to Example 290, l-(3-aminopropyl)-imidazole was used to prepare 5-[(4-chlorophenyl)sulfonyll-N-[3-(lH-imidazol-l-vDpropyl]-2- methylbenzenesulfonamide. MS (ES-) m/z 451.8;HRMS: calcd for C19H20ClN3O4S2 + H+, 454.06565; found (ESI, [M+H]+), 454.0644.
Example 293: 5-[(4-azidophenyI)suIfonyl]-Λ43-(lif-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide
[0228] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3- (lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and sodium azide in DMF were used to prepare 5- r(4-azidophenyl)sulfonyl~|-./V'- ["3 -( 1 H-imidazol- 1 -yl)propyl]-2- methylbenzenesulfonamide. MS (ES-) m/z 458.8; HRMS: calcd for C19H20N6O4S2 + H+, 461.10602; found (ESI, [M+H]+), 461.1066.
Example 294: N-[2-(lH-indol-3-yl)ethyl]-2-methyl-5-(phenylsulfonyI)benzenesuIfonamide
[0229] To a solution of 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride (0.36 g, 1.1 mmol) in DMF (10 mL) was added pyridine (0.13 mL, 1.6 mmol) and tryptamine (0.21 g, 1.3 mmol). The reaction was stirred at room temperature overnight and then diluted with ethyl acetate and washed with saturated ammonium chloride, saturated sodium bicarbonate, and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified using automated flash chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N- \2-( 1 H-indol- S-yDethyli^-methyl-S-CphenylsulfonvDbenzenesulfonamide. MS (ES-) m/z 452.8.
Example 295: 2-isopropyl-Λr-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide
[0230] The title compound was prepared in a manner similar to that described in Example 230.
[0231] Step 1 : 4-isopropylbenzene sulfonyl chloride and benzene were used to prepare l-benzenesulfonyl-4-isopropylbenzene, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane).
[0232] Step 2: l-Benzenesulfonyl-4-isopropylbenzene and chlorosulfonic acid were used to prepare 5-benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride, which was purified via Biotage Horizon (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane). [0233] Step 3: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and phenethyl amine were used to prepare 2-isopropyl-iV-(2-phenylethyl)-5-
(phenylsulfonyl)benzenesulfonamide, which was purified using a via Biotage Horizon™ (FLASH 25 M, silica, gradient from 10% hexane to 50% EtOAc/hexane gradient). MS (ES-) m/z 441.9; HRMS: calcd for C23H25NO4S2 + H+, 444.12978; found (ESI, [M+H]+), 444.1297.
Example 296: Λ'-[3-(lJHr-imidazol-l-yl)propyl]-2-isopr()pyl-5- (phenyϊsulfonyl)benzenesulfonamide
[0234] In an analogous manner to Example 295:
[0235] Step 3: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 3-(1Ji"- imidazol-l-yl)propylamine were used to prepare N-[3-(lH~-imidazol-l-yl)propyl]-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 445.9; HRMS: calcd for C21H25N3O4S2 + H+, 448.13592; found (ESI, [M+H]+), 448.1364.
Example 297: 2-ethyl-5-[(4-fluorophenyl)suIfonyI]-Λ^-[2-(lH-imidazol-l- yl)ethyl] benzenesulfonamide
[0236] In an analogous manner to Example 295:
[0237] Step 1 : 4-ethylbenzene sulfonyl chloride and fluorobenzene were used to prepare 1 -ethyl-4-[(4-fluorophenyl)sulfonyl]benzene.
[0238] Step 2: l-Ethyl-4-[(4-fluorophenyl)sulfonyl]benzene and chlorosulfonic acid were used to prepare 2-ethyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride.
[0239] Step 3: 2-Ethyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2- (liT-imidazol-l-yl)ethylamine were used to prepare 2-ethyl-5-[(4-fluorophenyDsulfonyl1-JV-[2- (lH-imidazol-l-yl)ethyl]benzenesulfonamide. MS (ES-) m/z 435.9; HRMS: calcd for C19H20FN3O4S2 + H+, 438.09520; found (ESI, [M+H]+), 438.0945.
Example 298: 2-methyI-5-(phenyIsulfonyl)-iV-tetrahydro-2jEr-pyran-4- ylbenzenesulfonamide
[0240] In an analogous manner to Example 1 : - Ill -
[0241] Step 2: 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride and tetrahydro- pyran-4-ylamine were used to prepare 2-methyl-5-fphenylsulfonylVN-tetrahvdro-2iy-pyran-4- ylbenzenesulfonamide, which was purified using a via Biotage Horizon™ (FLASH 25 M, silica, gradient from 10% EtOAc/hexane to 50% EtOAc/hexane gradient. MS (ESI+) m/z 396; MS (ESI-) m/z 394; HRMS: calcd for C18H21NO5S2 + H+, 396.09339; found (ESI, [M+H]+), 396.0932.
Example 299: 2-methyI-5-(phenylsulfonyl)-iV-(2-tetrahydro-2iy-pyraii-4- ylethyl)benzenesulfonamide
[0242] In an analogous manner to Example 298:
[0243] Step 2: 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride and 2- (tetrahydro-pyran-4-yl)-ethylamine were used to prepare 2-methyl-5-(phenylsulfonyl)-N-(2- tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide. MS (ESI+) m/z 424; MS (ESI-) m/z All; HRMS: calcd for C20H25NO5S2 + H+, 424.12469; found (ESI, [M+H]+), 424.1237.
Example 300 : 2-ethyl-5-(phenylsulfonyl)-Λ'-tetrahydro-2Jϊ-pyran-4-ylbenzenesulfonamide
[0244] In an analogous manner to Example 295 :
[0245] Step 3: 5-benzenesulfonyl-2-ethyl-benzenesulfonyl chloride and tetrahydro- pyran-4-ylamine were used to prepare 2-ethyl-5-(phenylsulfonyl')-./V-tetrahvdro-2i:7-pyran-4- ylbenzenesulfonamide. MS (ESI+) rø/z 410; MS (ESI-) m/z 408; HRMS: calcd for C19H23NO5S2 + H+, 410.10904; found (ESI, [M+H]+), 410.11.
Example 301 : 2-ethyI-5-(phenylsulfonyl)-iV-(2-tetrahydro-2jHr-pyran-4- ylethyl)benzenesulfonamide
[0246] In an analogous manner to Example 295: [0247] Step 3: 5-benzenesulfonyl-2-ethyl-benzenesulfonyl chloride and 2-(tetrahydro- pyran-4-yl)-ethylamine were used to prepare 2-ethyl-5-fphenylsulfonyl)-N-(2-tetrahvdro-2//- pyran-4-ylethyl)benzenesulfonamide. MS (ESI+) m/z 438; MS (ESI-) m/z 436; HRMS: calcd for C2IH27NO5S2 + H+, 438.14034; found (ESI, [M+H]+), 438.1385.
Example 302: 2-methyI-Λr-(2-phenyIethyl)-3-(phenylsulfonyl)benzenesulfonamide
[0248] To a stirred solution of 2-fluoro-6-riitrotoluene (5.O g, 32.2 mmol) in DMF (80 mL) was added benzenethiol (4.0 niL, 38.8 mmol) and potassium carbonate (8.9 g, 64.4 mmol). The resulting solution was heated to 100 °C overnight and concentrated. The residue was taken up in ethyl acetate and washed with ammonium chloride solution (sat) and brine. The organic phase was dried over magnesium sulfate, concentrated and flash column separated using 3% ethyl acetate/ hexane. The recovered material was dissolved in methylene chloride (70 mL) and m-chloroperbenzoic acid (8.0 g, 46.3 mmol) was added portionwise over 1 hour. The mixture was stirred an additional 30 minutes, washed with sodium bicarbonate solution (sat), dried over magnesium sulfate and concentrated. The residue was flash column separated using 20 % ethyl acetate/ hexane. The resulting material was added to methanol (30 mL), chilled to 0 °C and 10 % palladium on carbon (120 mg) was added. Sodium borohydride (0.84 g, 22.2 mmol) was then added portionwise and stirred for 1 hour. The reaction was quenched with ammonium chloride solution (sat) and extracted several times with ethyl acetate. The organic layer was filtered through celite, washed with brine, dried over magnesium sulfate, and concentrated. The resulting material was dissolved in acetonitrile (16 mL), chilled to 0 °C and concentrated acetic acid (1.6 mL) and concentrated hydrochloric acid (1.6 mL) were added. Sodium nitrite (0.17 g, 2.42 mmol) dissolved in D.I. water (0.5 mL) was added dropwise and the solution was stirred 20 minutes. Sulfur dioxide was then bubbled into the solution over 20 minutes. Copper chloride dihydrate (0.34 g, 2.02 mmol) dissolved in D.I. water (0.5 mL) was added to the solution, the ice bath was removed and the solution was stirred at room temperature for 3.5 hours. The mixture was concentrated, taken up in ethyl acetate and washed with brine. The organic layer was dried over magnesium sulfate, and concentrated. The resulting material was dissolved in THF (4 mL), triethylamine (0.4 mL, 2.86 mmol) and phenethylamine (0.1 mL, 0.79 mmol) were added and the mixture was stirred at room temperature for 30 minutes. The solution was treated with sodium bicarbonate solution (sat) and extracted several times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and concentrated to give 2-methyl-N-f2-phenylethylV
3-(phenylsulfonyl)benzenesulfonamide (0.05 g, 5%).
MS (ES-) m/z 413.9;
HRMS: calcd for C21H2iNO4S2 + H+, 416.09848; found (ESI5 [M+H]+), 416.0975.
Example 303: 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-iV-[3-(lflr-imidazol-l- yl)propyl]benzenesulfonamide
[0249] In an analogous manner to Example 295 :
[0250] Step 3: 2-Ethyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 3- (Ii7-imidazol-l-yl)propylamine were used to prepare 2-ethyl-5 - [(4-fluorophenyl)sulfonyl1 -N- ]2- ( 1 H-imidazol- 1 -y Dpropy 1] benzenesulfonamide .
Example 304: 5-({4-[ethyl(methyl)amino]phenyl}sulfonyl)-Λ'-[3-(lJH-imidazol-l-yl)propyl]- 2-methylbenzenesulfonamide
[0251] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-iV-[3- (lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and N-ethylmethylamine were used to prepare 5-((4-[ethyl('methyl')amino1phenvUsulfonylVA/-['3-riH-imidazol-l-yl)propyl1-2- methy lbenzenesulfonamide . MS (ES-) m/z 474.9; HRMS: calcd for C22H28N4O4S2 + H+, 477.16247; found (ESI, [M+H]+), 477.1625.
Example 305: iV-[3-(lJHr-imidazol-l-yl)propyl]-2-methyl-5-[(4-pyrrolidin-l- ylphenyl)sulfonyl]benzenesulfonamide
[0252] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-iV-[3- (lH-imidazol-l-yl)propyl]-2-methy lbenzenesulfonamide and pyrrolidine were used to prepare Nz [3-d/i"-imidazol-l-yl)propyl1-2-methyl-5-r(4-pyrrolidin-l- ylphenyDsulfonyllbenzenesulfonamide. MS (ES-) m/z 486.9; HRMS: calcd for C23H28N4O4S2 + H+, 489.16247; found (ESI, [M+H]+), 489.1643. Example 306: JV-[3-(l#-imidazol-l-yl)propyl]-4-methyl-3- (phenylsulfinyl)benzenesulfonamide
[0253] In an analogous manner to Example 302, 2-fluoro-4-nitrotoluene and 1 equivalent of m-chloroperbenzoic acid were used to prepare N- \3 -( 1 i7-imidazol- 1 -vDpropyl] -4- methyl-3-fphenylsulfinyl)benzenesulfonamide. MS (ESI+) m/z 404; HRMS: calcd for C19H21N3O3S2 + H+, 404.10971; found (ESI, [M+H]+), 404.1116.
Example 307: 5-[(4-fluorophenyl)sulfonyl]-^-[2-(lH-imidazol-l-yl)ethyl]-2- methylbenzenesulfonamide
[0254] In an analogous manner to Example 298:
[0255] Step 2: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2- (lH-imidazol-l-yl)ethylamine were used to prepare 5-[f4-fluorophenyl)sulfonyll-iV-[2-('lH'- imidazol- 1 -yl)ethyll-2-methylbenzenesulfonamide. MS (ES+) w/z 424; MS (ES-) m/z 422; HRMS: calcd for C18H18FN3O4S2 + H+, 424.07955; found (ESI, [M+H]+), 424.0798.
Example 308: 5-[(4-fluorophenyl)sulfonyl]-2-methyl-Λf-tetrahydro-2#-pyran-4- ylbenzenesulfonamide
[0256] In an analogous manner to Example 298:
[0257] Step 2: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepare 5-["(4-fluorophenyl)sulfonyl1-2-methyl-iV- tetrahydro-2H-pyran-4-ylbenzenesulfonamide. MS (ES+) w/z 414; MS (ES-) m/z AU; HRMS: calcd for C18H20FNO5S2 + H+, 414.08397; found (ESI, [M+H]+), 414.0843.
Example 309: 5-[(4-fluorophenyl)sulfonyl]-2-methyl-Λ'-(2-tetrahydro-2iϊ-pyran-4- ylethyl)benzenesulfonamide
[0258] In an analogous manner to Example 298: [0259] Step 2: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2- (tetrahydro-pyran-4-yl)-ethylamine were used to prepare 5-[(4-fluorophenyl)sulfonyl]-2-methyl- N-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide. MS (ES+) m/z 442; MS (ES-) m/z 440; HRMS: calcd for C20H24FNO5S2 + H+, 442.11527; found (ESI, [M+H]+), 442.1167.
Example 310: iV-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-{[4- (methylamino)phenyl]sulfonyl}benzenesulfonamide
[0260] In an analogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyi]-N-[3- (li7-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and methylamine were used to prepare N-r3-qH-imidazol-l -vnpropyll-2-methyl-5-f f4- (methylamino)phenyl]sulfonyUbenzenesulfonamide. MS (ES-) m/z 446.9; HRMS: calcd for C20H24N4O4S2 + H+, 449.13117; found (ESI, [M+H]+), 449.1319.
Example 311: 5- { [4-(ethy lamino)phenyl] sulf onyl} -N- [3-(ljHr-imidazol-l -yl)propy 1] -2- methylbenzenesulfonamide
[0261] In an analogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-N-[3- (lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and ethylamine (70% aqueous solution) were used to prepare 5- { [4-f ethylamino*)phenyl]sulfonyl| -N- f 3 -( 1 H-imidazol- 1 -yDpropyl] -2- methylbenzenesulfonamide. MS (ES-) m/z 460.9; HRMS: calcd for C21H26N4O4S2 + H+, 463.14682; found (ESI, [M+H]+), 463.1487.
Example 312: JV-[3-(l#-imidazol-l-yl)propyl]-2-methyl-5-[(4-piperidin-l- ylphenyl)sulfonyl]benzenesulfonamide
[0262] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3- (lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and piperidine were used to prepare N- [3 -( 1 i/-imidazol- 1 -yDpropy 1] -2-methyl-5- ["(4-piperidin- 1 - ylphenyDsulfonynbenzenesulfonamide. MS (ES+) m/z 503; MS (ES-) m/z 501; HRMS: calcd for C24H30N4O4S2 + H+, 503.17812; found (ESI, [M+H]+), 503.1782.
Example 313: iV-[3-(liϊ-imid[azol-l-yl)propyl]-2-methyl-5-[(4-morpholin-4- ylphenyl)sulfonyl]benzenesulfonamide
[0263] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-JV-[3- (lH"-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and morpholine were used to prepare iV-|[3-(l/i-imidazol-l-yl)propyl]-2-methyl-5-r(4-morpholm-4- ylphenyl)sulfonyl"|benzenesulfonamide. MS (ES+) m/z 505; MS (ES-) m/z 503; HRMS: calcd for C23H28N4O5S2 + H+, 505.15739; found (ESI, [M+H]+), 505.1587.
Example 314: Λ42-(llϊ-imidazoI-l-yl)ethyl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0264] In an analogous manner to Example 298:
[0265] Step 2: 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride and 2-(IH- imidazol-l-yl)ethylamine were used to prepare N- \2-( 1 H-imidazol- 1 -y Dethy 1] -2-methy 1-5 - (phenylsulfonyDbenzenesulfonamide. MS (ES-) m/z 403.8; HRMS: calcd for C18H19N3O4S2 + H+, 406.08897; found (ESI, [M+H]+), 406.0878.
Example 315: iV-[3-(lH-imidazol-l-yl)propyl]-5-[(4-methoxyphenyl)sulfonyl]-2- methylbenzenesulfonamide
[0266] Step 1: To a stirred solution of 5-bromo-2-methylaniline (1.49 g, 8.01 mmol) in acetonitrile (65 mL) at O0C was added glacial acetic acid (6.5 mL) and concentrated HCl (6.5 mL). A solution of sodium nitrite (0.66 g, 9.61 mmol) dissolved in D.I water (2 mL) was added dropwise. The resulting solution was stirred 20 minutes. Sulfur dioxide was then bubbled into the solution for 20 minutes. A solution of copper (II) chloride dihydrate (1.37 g, 8.01 mmol) dissolved in D.I. water (2 mL) was added, the ice bath was removed and the solution was allowed to stir overnight at room temperature. The reaction volume was concentrated to one third and extracted several times with ethyl acetate. The organic layers were combined, washed with water and sat. sodium bicarbonate solution, dried over magnesium sulfate and concentrated. The crude was dissolved in THF (22 mL) and triethylamine (1.8 mL, 12.91 mmol) was added. l-(3-aminopropyl)-imidazole (1.0 mL, 8.38 mmol) was added dropwise and the resulting solution was stirred 30 minutes at room temperature. The solution was partitioned between an aqueous ammonium chloride solution and ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated to give 5-bromo-N- [3 -( 1 i/-imidazol- 1 -y Dpropy 1] -2- methylbenzenesulfonamide (1.41 g, 49%). MS (ES) m/z 355.8; HRMS: calcd for C13H16BrN3O2S + H+, 358.02193; found (ESI, [M+H]+), 358.0211.
[0267] Step 2: A solution of nickel (II) bromide (0.03 g, 0.11 mmol), zinc powder (0.03 g, 0.45 mmol), l,r-bis(diphenylphosphino)-ferrocene (0.12 g, 0.22 mmol), and potassium carbonate (0.31 g, 2.24 mmol) in NMP (10 mL) was stirred at room temperature for 1 hour. 5- bromo-N-[3-(li7-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide (0.70 g, 1.95 mmol) and 4- methoxybenzenethiol (0.2 mL, 1.61 mmol) were added and the resulting solution was heated overnight at 80°C. The solution was partitioned between an aqueous ammonium chloride solution and ethyl acetate. The organic layer was concentrated and HPLC separated. The resulting solid was dissolved in methylene chloride (5 mL). M-chloroperbenzoic acid (0.29 g, 77%, 1.29 mmol) was added and the solution was stirred 1 hour at room temperature, concentrated and HPLC separated to give N-["3-(lH-imidazol-l-yl)propyl]-5-[(4- methoxyphenyDsulfonyll-2-methylbenzenesulfonamide (0.11 g, 13%). MS (ES-) m/z 447.9; ΗRMS: calcd for C20H23N3O5S2 + H+, 450.11519; found (ESI, [M+H]+), 450.1148.
Example 316: N- [3-(lϋT-imidazol-l -y l)propy 1] -5- [(2-methoxypheny l)sulf ony 1] -2- methylbenzenesulfonamide
[0268] In an analogous manner to Example 315:
[0269] Step 2: 2-methoxybenzenethiol was used to prepare JV-P-dϋf-imidazol- 1 - yl)propyl1-5-["(2-methoxyphenyl)sulfonvn-2-methylbenzenesulfonamide. MS (ES+) m/z 450; MS (ES-) m/z 448; HRMS: calcd for C20H23N3O5S2 + H+, 450.11519; found (ESI, [M+H]+), 450.1148. Example 317: iV-[3-(li?-imidazol-l-yl)propyl]-4-methyl-3- (phenylsulfonyl)benzenesulfonamide
[0270] To a stirred solution of N-[3-(lH-imidazol-l-yl)propyl]-4-methyl-3- (phenylsulfinyl)benzenesulfonamide (0.13 g, 0.32 mmol) in methylene chloride (7 mL) was added m-chloroperbenzoic acid (0.05 g, 0.32 mmol). The solution was then concentrated and HPLC separated to give N- \3 -( 1 H-imidazol- 1 -y Dpropy 1] -4-methy 1-3 - (phenylsulfonyl)benzenesulfonamide. (0.004 g, 3%). MS (ES+) w/_: 420;
Figure imgf000119_0001
Example 318: 5-[(4-fluorophenyl)sulfonyl]-Λ'-[2-(liϊ-imidazol-l-yI)ethyl]-2- isopropylbenzenesulfonamide
[0271] In an analogous manner to Example 295 :
[0272] Step 1 : 4-isopropylbenzene sulfonyl chloride and fluorobenzene were used to prepare l-isopropyl-4-[(4-fluorophenyl)sulfonyl]benzene, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane).
[0273] Step 2: l-Isopropyl-4-[(4-fluorophenyl)sulfonyl]benzene and chlorosulfonic acid were used to prepare 2- isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane).
[0274] Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-(li7-imidazol-l-yl)ethylamine were used to prepare 5- [(4-fluorophenyr)sulfony 1] -N- \2-( 1 H- imidazol- 1 -y Dethy 1] -2-isopropylbenzenesulfonamide . MS (ES-) m/z 449.8; HRMS: calcd for C20H22FN3O4S2 + H+, 452.11085; found (ESI, [M+H]+), 452.1094.
Example 319: 5-[(4-fluorophenyl)sulfonyl]-7V-[3-(li7-imidazol-l-yl)propyI]-2- isopropylbenzenesulfonamide
[0275] In an analogous manner to Example 295:
[0276] Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 3-(l/f-imidazol-l-yl)propylamine were used to prepare 5- [(4-fluorophenvDsulfonyl]-iV- ["3 \-( 1 H- imidazol- 1 -yl)τ>ropyll-2-isopropylbenzenesulfonamide. MS (ES-) m/z 463.8;
HRMS: calcd for C2IH24FN3O4S2 + H+, 466.12650; found (ESI, [M+H]+), 466.1253.
Example 320 ; 5-[(4-fluorophenyl)suIfonyl]-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0277] In an analogous manner to Example 295 :
[0278] Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-pyridin-2-yl-ethylamine were used to prepare 5-[f4-fluorophenyl)sulfonyl]-2-isopropyl-iV-f2- pyridin-2-ylethyl)benzenesulfonamide. MS (ES-) m/z 460.8; HRMS: calcd for C22H23FN2O4S2 + H+, 463.11560; found (ESI5 [M+H]+)5 463.115.
Example 321 : 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-iV-tetrahydro-2/7-pyran-4- ylbenzenesulfonamide
[0279] In an analogous manner to Example 295 :
[0280] Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepare 5-[(4-fluorophenyl')sulfonyl1-2-isopropyl-JV- tetrahydro-2H-pyran-4-ylbenzenesulfonamide. MS (ES-) m/z 439.9; HRMS: calcd for C20H24FNO5S2 + H+, 442.11527; found (ESI, [M+H]+), 442.1174.
Example 322: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-7V-(2-tetrahydro-2JfiT-pyran-4- ylethyl)benzenesulfonamide
[0281 ] In an analogous manner to Example 295 :
[0282] Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-(tetrahydro-pyran-4-yl)-ethylamine were used to prepare 5 - t"(4-fluorophenyl)sulfony 1] -2- isopropyl-7V-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide. MS (ES-) m/z 467.9; HRMS: calcd for C22H28FNO5S2 + H+, 470.14657; found (ESI3 [M+H]+), 470.1471;
Example 323: Λr-[3-(lJHr-imidazol-l-yl)propyl]-5-[(3-methoxyphenyl)sulfonyl]-2- methylbenzenesulfonamide [0283] In an analogous manner to Example 315:
[0284] Step2: 3-methoxybenzenethiol was used to prepare TV- [3 -( 1 H-imidazol- 1 - vDpropyll -5- \(3 -methoxyphenvDsulfonyfl -2-methylbenzenesulfonamide . MS (ES-) m/z 447.9; HRMS: calcd for C20H23N3O5S2 + H+, 450.11519; found (ESI, [M+H]+), 450.1154.
Example 324: JV-[2-(liy-imidazol-l~yl)ethyl]-2,4-dimethyl-5- (phenylsulfonyl)benzenesulfonamide
[0285] In an analogous manner to Example 295 :
[0286] Step 1 : Benzene sulfonyl chloride and meta xylene were used to prepare 1- benzenesulfonyl-2,4-dimethyl-benzene, which was purified via Biotage Horizon™ (FLASH 40 M5 silica, gradient from 100% hexane to 20% EtOAc/hexane).
[0287] Step 2: l-Benzenesulfonyl-2,4-dimethyl-benzene and chlorosulfonic acid were used to prepare 5-benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtO Ac/hexane) .
[0288] Step 3: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 2-(IH- imidazol-l-yl)ethylamine were used to prepare N-[2-(lH-imidazol-l-yl)ethyll-2,4-dimethyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ESI+) m/z 420; MS (ESI-) m/z 418; HRMS: calcd for C19H21N3O4S2 + H+, 420.10462; found (ESI, [M+H]+), 420.1051.
Example 325: JV-[3-(l#-imidazol-l-yl)pr(>pyl]-2,4-dimethyl-5- (phenylsulfbnyl)benzenesulfonamide
[0289] In an analogous manner to Example 298:
[0290] Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 3-(17f- imidazol-l-yl)propylamine were used to prepare JV- [3-( 1 H-imidazol- 1 -yl)propyl]-2,4-dimethyl- 5-(phenylsulfonyl)benzenesulfonamide. MS (ESI+) m/z 434; MS (ESI-) m/z 432; HRMS: calcd for C20H23N3O4S2 + H+, 434.12027; found (ESI, [M+H]+), 434.1186.
Example 326: 2,4-dimethyl-5-(phenylsulfonyl)-iV-(2-pyridin-2-ylethyl)benzenesulfonamide
[0291] In an analogous manner to Example 298:
[0292] Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 2- pyridin-2-yl-ethylamine were used to prepare 2,4-dimethyl-5-(plienylsulfonyl)-iV-(2-pyridin-2- ylethyDbenzenesulfonamide. MS (ES-) m/z 428.9; HRMS: calcd for C21H22N2O4S2 + H+, 431.10937; found (ESI, [M+H]+), 431.1079.
Example 327: 2,4-dimethyl-5-(phenylsuIfonyl)-ΛLtetrahydro-2Jff-pyran-4- ylbenzenesulfonamide
[0293] In an analogous manner to Example 298:
[0294] Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepare 2,4-dimethyl-5-(phenylsulfonyl)-iV-tetrahydro- 2/i-pyran-4-ylbenzenesulfonamide. MS (ES-) m/z 407.9; HRMS: calcd for C19H23NO5S2 + H+, 410.10904; found (ESI, [M+H]+), 410.1096.
Example 328: 2,4-dimethyl-5-(phenylsulfonyl)-Λ'-(2-tetrahydro-2JHr-pyran-4- ylethyl)benzenesulfbnamide
[0295] In an analogous manner to Example 298:
[0296] Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 2- (tetrahydro-pyran-4-yl)-ethylamine were used to prepare 2,4-dimethyl-5-(phenylsulfonyl)-A/-(2- tetrahydro-2i:f-pyran-4-ylethyl)benzenesulfonamide. MS (ES-) m/z 435.9; HRMS: calcd for C21H27NO5S2 + H+, 438.14034; found (ESI, [M+H]+), 438.141.
Example 329: 5-[(4-fluorophenyl)suIfonyl]-iV-[2-(l^-imidazol-l-yl)ethyl]-2,4- dimethylbenzenesulfonamide
[0297] In an analogous manner to Example 295: [0298] Step 1 : 4-Fluorobenzene sulfonyl chloride and meta xylene were used to prepare l-(4-fluoro-benzenesulfonyl)-2,4-dimethyl-benzene, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane).
[0299] Step 2: l-(4-Fluoro-benzenesulfonyl)-2,4-dimethyl-benzene and chlorosulfonic acid were used to prepare 5-(4-fluoro-benzenesulfonyl)-2,4-dimethyl-benzenesulfonyl chloride, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane).
[0300] Step 3: 5-(4-Fluoro-benzenesulfonyl)-2,4-dimethyl-benzenesulfonyl chloride and 2-(lH-imidazol-l-yl)ethylamine were used to prepare 5-[(4-fluorophenvπsulfonyl]-N-[2- ( 1 H~-imidazol- 1 -y Dethy 1] -2 ,4-dimethylbenzenesulfonamide . MS (ESI+) m/z 438; MS (ESI-) m/z 436; ΗRMS: calcd for C19H20FN3O4S2 + H+, 438.09520; found (ESI5 [M+H]+), 438.0945.
Example 330: S-IC^fluorophenyOsulfonylJ-iV-tS-Clfl-imidazol-l-y^propyl]^^- dimethylbenzenesulfonamide
[0301] In an analogous manner to Example 298 :
[0302] Step 2: 5-(4-Fluoro-benzenesulfonyl)-2,4-dimethyl-benzenesulfonyl chloride and 3-(l/f-imidazol-l-yl)propylamine were used to prepare 5-[(4-fluorophenyl)sulfonyl]-N-f3- ( 1 H~-imidazol- 1 -vDpropy 1] -2,4-dimethylbenzenesulfonamide .
Figure imgf000123_0001
MS (ESI-) m/z 450; HRMS: calcd for C20H22FN3O4S2 + H+, 452.11085; found (ESI5 [M+H]+), 452.1115.
Example 331 : 5-[(4-fluorophenyI)suIfonyl]-2,4-dimethyl-JV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0303] In an analogous manner to Example 298:
[0304] Step 2: 5-(4-Fluoro-benzenesulfonyl)-2,4-dimethyl-benzenesulfonyl chloride and 2-pyridin-2-yl-ethylamine were used to prepare 5 - [(4-fluoropheny Dsulfony 11 -2,4-dimethy 1- iV-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI+) w/z 449; MS (ESI-) m/z AAl; HRMS: calcd for C21H21FN2O4S2 + H+, 449.09995; found (ESI, [MH-H]+), 449.0979.
Example 332: 5-[(4-fluorophenyl)sulfonyl]-2,4-dimethyI-Λ'-(tetrahydro-2Jfi?-pyran-4- yl)benzenesulfonamide
[0305] In an analogous manner to Example 298:
[0306] Step 2: 5-(4-Fluoro-benzenesulfonyl)-2,4-dimethyl-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepare 5-[(4-fluorophenyl)sulfonyl1-2,4-dimethyl- A/"-ftetrahydro-2H'-pyran-4-yl)benzenesulfonamide. MS (ESI+) m/z 428; MS (ESI-) m/z 426; HRMS: calcd for C19H22FNO5S2 + H+, 428.09962; found (ESI, [M+H]+), 428.0981.
Example 333: 5-[(4-jπuorophenyl)sulfonyl]-2,4-dimethyl-Λr-[2-(tetrahydro-2Hr-pyran-4- yl)ethyl] benzenesulfonamide
[0307] In an analogous manner to Example 298:
[0308] Step 2: 5-(4-Fluoro-benzenesulfonyl)-2,4-dimethyl-benzenesulfonyl chloride and 2-(tetrahydro-pyran-4-yl)-ethylamine were used to prepare 5-[(4-fluorophenyl)sulfonyl]-2,4- dimethyl-iV-r2-rtetrahvdro-2H'-pyran-4-yDethyl]benzenesulfonamide. MS (ESI+) w/z456; MS (ESI-) m/z 454; HRMS: calcd for C21H26FNO5S2 + H+, 456.13092; found (ESI, [M+H]+), 456.1321.
Example 334: 2-chloro-iV-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide
[0309] Step 1: 3-nitro-4-chlorobenzenesulfonylchloride (5.0 g, 19.5 mmol) was added portionwise to a stirred solution of aluminum chloride (3.12 g, 23.4 mmol) in benzene (10 mL) and stirred overnight at room temperature. The solution was poured over ice and extracted several times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and concentrated. The crude solid was dissolved in methanol (100 mL) and water (3 mL). Tin (II) chloride (11.0 g, 58.0 mmol) was added and the resulting solution was heated to 70 °C overnight The solution was concentrated and partitioned between ethyl acetate and a saturated sodium bicarbonate solution. The organic layer was dried over magnesium sulfate and concentrated to give [2-chloro-5-fphenylsulfonyl)phenyl'|amine (2.59 g, 36%). MS (ESI+) rø/z 268;
HRMS: calcd for C12H10ClNO2S + H+, 268.01935; found (ESI, [M+H]+), 268.0202;
[0310] Step 2: To a stirred solution of [2-chloro-5-(phenylsulfonyl)phenyl]amine (2.5 g, 9.34 mmol) in acetonitrile (75 niL) at 0 °C was added glacial acetic acid (7.5 mL) and concentrated HCl (7.5 mL). A solution of sodium nitrite (0.77 g, 11.21 mmol) dissolved in D.I water (3 mL) was added dropwise. The resulting solution was stirred 20 minutes. Sulfur dioxide was then bubbled into the solution for 20 minutes. A solution of copper (II) chloride dihydrate (1.59 g, 9.34 mmol) dissolved in D.I. water (3 mL) was added, the ice bath was removed and the solution was allowed to stir overnight at room temperature. The reaction volume was concentrated to one third and extracted several times with ethyl acetate. The organic layers were combined, washed with water and sat. sodium bicarbonate solution, dried over magnesium sulfate and concentrated. The crude material was carried on without further purification.
[0311] Step 3: Following the same procedure described in Example 1 (step 2), 5- benzenesulfonyl-2-chlorobenzenesulfonyl chloride and phenethylamine were used to prepare 2z chloro-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 433.8; HRMS: calcd for C20H18ClNO4S2 + H+, 436.04385; found (ESI, [M+H]+), 436.0475.
Example 335: 2-chloro-iV-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide
[0312] In an analogous manner to Example 334:
[0313] Step 3 : 4-(2-aminoethyl)-morpholine was used to prepare 2-chloro-7V-r2- morpholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 442.8; HRMS: calcd for C18H21ClN2O5S2 + H+, 445.06532; found (ESI3 [M+H]+)5 445.0679.
Example 336: 2-chloro-JV-[3-(l//-imidazol-l-yI)propyl]-5- (phenylsulfonyl)benzenesulfonamide
[0314] In an analogous manner to Example 334:
[0315] Step 3: l-(3-aminopropyl)-imidazole was used to prepare 2-chloro-iV- \3-(lH- imidazol-l-yl)propyl]-5-fphenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 437.8; HRMS: calcd for C18H18ClN3O4S2 + H+, 440.05000; found (ESI, [M+H]+), 440.0482.
Example 337: 2-chloro-5-(phenylsulfonyl)-iV-(2-pyridin-2-ylethyl)benzenesuIfonamide
[0316] In an analogous manner to Example 334:
[0317] Step 3: 2-(2-aminoethyl)-pyridine was used to prepare 2-chloro-5- (phenylsulfonyl*)-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES-) m/z 434.8; HRMS: calcd for C19H17ClN2O4S2 + H+, 437.03910; found (ESI, [M+H]+), 437.042.
Example 338: iV-[3-(ljH-imidazol-l-yl)propyl]-5-[(4-isopropylphenyI)su!fonyl]-2- methylbenzenesulfonamide
[0318] In an analogous manner to Example 315:
[0319] Step 2: 4-isopropylbenzenethiol was used to prepare
A/-r3-dH-imidazol-l-yl')propyl]-5-r(4-isopropylphenyl)sulfonyl]-2- methylbenzenesulfonamide .
MS (ES-) m/z 460.0;
HRMS: calcd for C22H27N3O4S2 + H+, 462.15157; found (ESI, [M+H]+), 462.1525.
Example 339: iV-[3-(liϊ~imidazol-l-yl)propyl]-2-methyl-5-(2- naphthylsulfonyl)benzenesulfonamide
[0320] In an analogous manner to Example 315:
[0321] Step 2: 2-naphthlyene was used to prepare TV- [3 -( 1 H-imidazol- 1 -vDpropyl] -2- methyl-5-(2-naphthylsulfonyl)benzenesulfonamide. MS (ES-) m/z 467.9; HRMS: calcd for C23H23N3O4S2 + H+, 470.12027; found (ESI, [M+H]+), 470.1189.
Example 340: 5-[(3,4-dichlorophenyl)sulfonyl]-iV-[3-(lJfir-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide
[0322] Step 1 : In an analogous manner to Example 315, step 1.
[0323] Step 2: A solution of nickel (II) bromide (0.03 g, 0.11 mmol), zinc powder (0.03 g, 0.45 mmol), 1,1 '-bis(diphenylphosphino)-ferrocene (0.12 g, 0.22 mmol), and potassium carbonate (0.31 g, 2.24 mmol) in NMP (8 mL) was stirred at room temperature for 1 hour. 5- bromo-iV-[3-(lH:-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide (0.70 g, 1.95 mmol) and 3,4-dichlorobenzenethiol (0.2 mL,1.57 mmol) were added and the resulting solution was heated in the microwave at 160 °C for 10 minutes. The solution was partitioned between a saturated aqueous ammonium chloride solution and ethyl acetate. The organic layer was concentrated and HPLC separated. The resulting solid was dissolved in methylene chloride (5 niL). M- chloroperbenzoic acid (0.22 g, 77%, 0.99 mmol) was added and the solution was stirred 1 hour at room temperature, washed with a saturated aqueous sodium dithionite solution, a saturated aqueous sodium bicarbonate solution, concentrated and HPLC separated to give 5-[(3,4- dichlorophenyl)sulfonyll-N-[3-(lH-imidazol-l-yl)propyl1-2-methylbenzenesulfonamide (0.08 g,
'%>.
MS (ES-) m/z 485.8;
HRMS: calcd for C19H19Cl2N3O4S2 + H+, 488.02668; found (ESI5 [M+H]+), 488.03.
Example 341: 2-(2-hydroxy-2-methylpropyl)-N-(2-phenylethyl)-5- (phenylsulfonyl)benzenesulfonamide
[0324] To a solution of 2-methyl-N-(2-phenylethyl)-5-
(phenylsulfonyl)benzenesulfonamide(l .0 g 2.4 mmol) in tetrahydrofuran (20 mL) was added butyllithiurn (6.0 mL of 2.5 M in hexanes) dropwise at -78 0C. The solution was allowed to stir at —78 0C for twenty minutes and then acetone (0.18 mL, 2.4 mmol) was added dropwise. The reaction was stirred at —78 0C for one hour and then poured onto ice/water and extracted with ethyl acetate (3 x 75 mL). The combined organics were dried with magnesium sulfate and concentrated down. The crude residue was purified using automated flash chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 2-(2- hydroxy-2-memylpropyl)-N-(2-phenylethyr)-5- (phenylsulfonyl)benzenesulfonamide (0.12 g, 11%).
MS (ES+) m/z AlA; MS (ES-) m/z All; HRMS: calcd. for C24H27NO5S2 + H+, 474.1409: found (ESI, [m+H]+), 474.1397.
Example 342: 5-[(3-chlorophenyl)sulfonyl]-iV-[3-(lJΪ-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide
[0325] In an analogous manner to Example 340: [0326] Step 2: 3-chlorobenzenethiol was used to prepare 5 - [(3 -chlorophenyl) sulfony 1] - JV-f3-(l /f-imidazol- 1 -y Dpropyl] -2-methylbenzenesulfonamide . HRMS: calcd for C19H20ClN3O4S2 + H+, 454.06565; found (ESI, [M+H]+), 454.0649.
Example 343: 5-[(3,5-dimethylphenyl)suIfonyl]-iV-[3-(lJfr-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide
[0327] In an analogous manner to Example 340:
[0328] Step 2: 3,5-dimethylbenzenethiol was used to prepare 5-[Y3,5- dimethylpheny Dsulfony 1] -JV- [3 -( 1 /f-imidazol- 1 -vDpropyH -2-methylbenzenesulfonamide.
MS (ESI+) m/z 448;
HRMS: calcd for C21H25N3O4S2 + H+, 448.13592; found (ESI, [M+H]+), 448.1387.
Example 344: 5-[(3,5-dichlorophenyI)sulfonyl]-JV-[3-(lJy-imidazol-l-yI)propyl]-2- methylbenzenesulfonamide
[0329] In an analogous manner to Example 340:
[0330] Step2: 3,5-dichlorobenzenethiol was used to prepare 5-[(3,5- dichlorophenypsulfonyll -JV- [3 -( 1 /f-imidazol- 1 -yDpropyl] -2-methylbenzenesulfonamide .
HRMS: calcd for C19H19Cl2N3O4S2 + H+, 488.02668; found (ESI, [M+H]+), 488.0278.
Example 345: 5-[(2,5-dichlorophenyl)sulfonyl]-JV-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide
[0331] In an analogous manner to Example 377:
[0332] Step 2: 2,5-dichlorobenzenethiol was used to prepare 5-[(2,5- dichloropheny Psulfonyl] -JV- [3 -( 1 /f-imidazol- 1 -yDpropyl] -2-methylbenzenesulfonamide.
MS (ES-) m/z 485.8;
HRMS: calcd for C19H19Cl2N3O4S2 + H+, 488.02668; found (ESI, [M+H]+), 488.0279.
Example 346: JV-[3-(liϊ-imidazol-l-yl)propyl]-2-methyl-5- (phenylsulfinyl)benzenesulfonamide
[0333] In an analogous manner to Example 340:
[0334] Step 2: benzenethiol and 1 equivalent of m-chloroperbenzoic acid were used to prepare JV-[3-(li/-imidazol-l-yl)propyl]-2-methyl-5-(phenylsulfinyl)benzenesulfonamide. MS (ES-) m/z 402.0;
HRMS: calcd for C19H21N3O3S2 + H+, 404.10971; found (ESI, [M+H]+), 404.1118.
Example 347: Λφ-(l#-imidazol-l-yl)ethyl]-2,3-dimethyl-5- (phenylsulfonyl)benzenesulfonamide
[0335] In an analogous manner to Example 295 :
[0336] Step 1 : Benzene sulfonyl chloride and ortho xylene were used to prepare A- Benzenesulfonyl-l,2-dimethyl-benzene, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtOAc/hexane).
[0337] Step 2: 4-Benzenesulfonyl-l,2-dimethyl-benzene and chlorosulfonic acid were used to prepare 5-benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride, which was purified via Biotage Horizon™ (FLASH 40 M, silica, gradient from 100% hexane to 20% EtO Ac/hexane) .
[0338] Step 3: 5-Benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride and 2-(1H- imidazol-l-yl)ethylamine were used to prepare N-[2-πH-imidazol-l-yl)ethyl]-2,3-dimethyl-5- (phenylsulfonyl)benzenesulfonamide. ΗRMS: calcd for C19H21N3O4S2 + H+, 420.10462; found (ESI, [M+H]+), 420.1036.
Example 348: A^-[3-(li?-imidazol-l-yl)propyl]-2,3-dimethyl-5- (phenylsulfonyl)benzenesulfonamide
[0339] In an analogous manner to Example 298:
[0340] Step 2: 5-Benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride and 3-(1H- imidazol-l-yl)propylamine were used to prepare N-[3-(lH-imidazol-l-yl)propyl1-2,3-dirnethyl- 5-fphenylsulfonyl)benzenesulfonamide. ΗRMS: calcd for C20H23N3O4S2 + H+, 434.12027; found (ESI, [M+H]+), 434.1187.
Example 349 : 2,3-dimethyl-5-(phenylsulfonyl)-iV-(2-py ridin-2-ylethyl)benzenesulfonamide
[0341] In an analogous manner to Example 298:
[0342] Step 2: 5-Benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride and 2- pyridin-2-yl-ethylamine were used to prepare 2,3-dimethyl-5-(phenylsulfonyl)-A/'-(2-pyridin-2- ylethvDbenzenesulfonamide . HRMS: calcd for C21H22N2O4S2 + H+, 431.10937; found (ESI, [M+H]+), 431.1085.
Example 350: 2,3-dimethyl-5-(phenylsulfonyl)-iV-(tetrahydro-2iϊ-pyran-4- yl)benzenesulfonamide
[0343] In an analogous manner to Example 298 :
[0344] Step 2: 5-Benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepare 2,3-dimethyl-5-(phenylsulfonyl)-iV-(tetrahvdro- 2H-pyran-4-yDbenzenesulfonamide. HRMS: calcd for C19H23NO5S2 + H+, 410.1096; found (ESI, [M+H]+), 410.1114.
Example 351 : 2,3-dimethyl-5-(phenylsulfonyl)-Λ'-[2-(tetrahydro-2jHr-pyran-4- yl)ethyl] benzenesulfonamide
[0345] In an analogous manner to Example 298:
[0346] Step 2: 5-Benzenesulfonyl-2,3-dimethyl-benzenesulfonyl chloride and 2- (tetrahydro-pyran-4-yl)-ethylamine were used to prepare 2,3-dimethyl-5-(phenylsulfonyl)-A/-[2- (tetrahydro-2H-pyran-4-yDemyl]benzenesulfonamide.
[0347] HRMS: calcd for C21H27NO5S2 + H+, 438.14034; found (ESI, [M+H]+), 438.1413.
Example 352: 5-{[4-(cyclohexylamino)phenyl]sulfonyl}-iV-[3-(liϊ-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide
[0348] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-iV-[3- (lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and cyclohexylamine were used to prepare 5- { [4-(cy clohexy lamino^pheny 1] sulfonyl } -N- [3 -( 1 H-imidazol- 1 -yPpropy 1] -2- methylbenzenesulfonamide. MS (ES-) m/z 515.0; HRMS: calcd for C25H32N4O4S2 + H+, 517.19377; found (ESI, [M+H]+), 517.1782.
Example 353: 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-N-[3-(lH-imidazol-l- yl)propyl]-2-methylbenzenesulfonamide
[0349] To a solution of 5-[(4-fluorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]- 2-methylbenzenesulfonamide (75 mg, 0.17 mmol) in N,N-dimethylacetamide (0.5 mL) was added 3-aminopropionitrile (67 mg, 0.96 mmol). The solution was heated with stirring using microwave irradiation (180 0C) for 65 minutes. Upon cooling, the reaction mixture was diluted with water (10 niL) and the aqueous phase was extracted with ethyl acetate (3 x 10 mL). The combined organic phases were concentrated and the resulting crude residue was purified using automated flash column chromatography with a graduated mobile phase consisting of dichloromethane and methanol resulting in the isolation of 5-({4-[(2- cyanoethyl)ammo1phenyUsulfonyl)-N-[3-(lH-imidazol-l-yl)propyr|-2- methylbenzenesulfonamide (38 mg, 45%).
MS (ES+) m/z 488.0
MS (ES-) m/z 485.9
HRMS: calcd for C22H25N5O4S2 + H+, 488.1426; found (ESI, [M+HJ+), 488.1440.
Example 354: 5-[(4-{[(lS,2S)-l-(hydroxymethyl)-2-methylbutyl]amino}phenyI)sulfonyl]-Λ'- [3-(l/f-imidazoI-l-yI)propyl]-2-methylbenzenesulfonamide
[0350] In an analogous manner to Example 353, 5-[(4~fluorophenyl)sulfonyl]-iV-[3- ( 1 H-imidazol- 1 -y l)propyl] -2-methy lbenzenesulfonamide and ( 1 S, 2S)- 1 -(hy droxymethyl)-2- methylbutyl] amine were used to prepare 5- |Y4- { [( 1 SJ.S)- 1 -(hy droxymethy P)-2- methy lbutyl] amino } phenyDsulfonyl] -N- [3 -( lif-imidazol- 1 -yDpropyll -2- methy lbenzenesulfonamide . MS (ES-) m/z 533.0; HRMS: calcd for C25H34N4O5S2 + H+, 535.20434; found (ESI, PSdH-H]+), 535.2024.
Example 355: Λ^3-(lif-imidazol-l-yl)propyl]-2-methyl-5-({4-[(l- phenylethyl)amino]phenyl}sulfonyl)benzenesulfonamide
[0351] In an analogous manner to Example 353, 5-[(4-fmorophenyl)sulfonyl]-N-[3- (lH"-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and 2-phenylethylamine were used to prepare N- [3 -( 1 H-imidazol- 1 -y Dpropy 1] -2-methyl-5-( { 4- F( 1 - phenylethvDaminolphenyUsulfonyDbenzenesulfonamide. MS (ES-) m/z 536.9; HRMS: calcd for C27H30N4O4S2 + H+, 539.17812; found (ESI, [M+H]+), 539.1788. Example 356: 2-methyl-5-{[4-(methylamino)phenyl]sulfonyl}-iV~(2-pyridin-2- ylethyl)benzenesulfonamide
[0352] To a solution of 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2- ylethyl)benzene-sulfonamide (75 mg, 0.17 mmol) in N,N-dimethylacetamide (0.5 mL) was added an ethanolic solution containing methyl amine (33%, 0.5 mL). The solution was heated with stirring using microwave irradiation (180 0C) for 20 minutes. Upon cooling, the reaction mixture was diluted with water (10 mL) and the aqueous phase was extracted with ethyl acetate (3 x 10 mL). The combined organic phases were concentrated and the resulting crude residue was purified using automated flash column chromatography with a graduated mobile phase consisting of dichloromethane and methanol resulting in the isolation of 2-methyl-5-{ [4- (methylamino)phenyl1sulfonyl}-N-(2-pyridin-2-ylethyl)-benzenesulfonamide (92 mg, 81%). MS (ES-) m/z 446; HRMS: calcd for C21H23N3O4S2 + H+, 446.12027; found (ESI, [M+H]+), 446.1209.
Example 357: 2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-iV-(2-pyridm-2- ylethyl)benzenesulfonamide
[0353] In an analogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide and methylamine were used to prepare JV^ Ϊ3 -( lH-imidazol- 1 -yl")propyn-2-methyl-5-f T4- (methylamino)phenyllsulfonyllbenzenesulfonamide. MS (ES+) w/z 474; MS (ES-) m/z 472; HRMS: calcd for C23H27N3O4S2 + H+, 474.15157; found (ESI, [M+H]+), 474.1511.
Example 358: 2-isopropyl-5-{[4-(methylamino)phenyl]suIfonyl}-iV-(tetrahydro-2iϊ-pyran- 4-yl)benzenesulfonamide
[0354] In an analogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-tetrahydro-2H"-pyran-4-ylbenzenesulfonamide and methylamine were used to prepare 2-isopropyl-5- { [4-(methylamino)phenyl] sulfonyl } -N-ftetrahydro-2H"-pyran-4- yDbenzenesulfonamide.
Figure imgf000133_0001
MS (ES-) m/z 451;
HRMS: calcd for C21H28N2O5S2 + H+, 453.15124; found (ESI5 [M+H]+), 453.1505.
Example 359: 2-isopropyl-5-{[4-(methylamino)phenyI]sulfonyl}-AL[2-(tetrahydro-2JHr- pyran-4-yl)ethyI]benzenesulfonamide
[0355] In an analogous manner to Example 356, 5-["(4-fluorophenyl)sulfonyl]-2- isopropyl-N-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide and methylamine were used to prepare 2-isopropyl-5-{r4-(methylamino)phenvπsulfonyl>-JV-r2-('tetrahvdro-2/j'-pyran-4- yl)ethyl]benzenesulfonamide. MS (ES+) w/z 481; MS (ES-) m/z 479; HRMS: calcd for C23H32N2O5S2 + H+, 481.18254; found (ESI, [M+H]+), 481.1837.
Example 360: 5-[(2,3-dichlorophenyl)sulfonyI]-iV-[3-(lJΪ-imidazol-l-yl)propyI]-2- methylbenzenesulfonamide
[0356] In an analogous manner to Example 340:
[0357] Step 2: 2,3-dichlorobenzenethiol was used to prepare 5-|"(2,3- dichlorophenyl)sulfonyl]-A/-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide.
MS (ESI+) m/z 488;
MS (ESI-) m/z 486;
HRMS: calcd for C19H19Cl2N3O4S2 + H+, 488.02668; found (ESI, [M+H]+), 488.0269.
Example 361 : 2-chloro-5-(phenylsulfonyl)-iV-(tetrahy dro-2JΪ-py ran-4- yl)benzenesulfonamide
[0358] In an analogous manner to Example 334:
[0359] Step 3: tetrahydropyran-4-ylamine was used to prepare 2-chloro-5- (phenylsulfonylVA/"-(tetrahydro-2/f-pyran-4-yl)benzenesulfonamide. MS (ESI-) m/z 414; HRMS: calcd for C17H18ClNO5S2 + H+, 416.03877; found (ESI, [M+H]+), 416.0392. Example 362: iV-[3-(ljy-imidazol-l-yl)propyl]-2-methyl-5-(2- thienylsulfonyl)benzenesulfonamide
[0360] In an analogous manner to Example 340:
[0361] Step 2: thiopliene-2-thiol was used to prepare N- [3 -(I H-imidazol- 1 -yDpropy 1] - 2-methyl-5-f2-thienylsulfonyl*)benzenesulfonamide. MS (ESI+) m/z 426; HRMS: calcd for C17H19N3O4S3 + H+, 426.06104; found (ESI, [M+H]+)3 426.062.
Example 363: A'-[3-(lHr-imidazoH-yl)propyI]-2-methyl-5-[(2-inethyl-3- furyl)sulfonyl]benzenesulfonamide
[0362] In an analogous manner to Example 340:
[0363] Step 2: 2-methylfuran-3 -thiol was used to prepare A/-[3-ri//-imidazol-l- yl')propyl]-2-methyl-5-r(2-methyl-3-furvDsulfonyl]benzenesulfonamide. MS (ESI+) m/z 424; MS (ESI-) m/z 422; HRMS: calcd for C18H2IN3O5S2 + H+, 424.09954; found (ESI, [M+H]+)5 424.0983.
Example 364 : N- { [2-methy l-5-(phenylsulfonyl)phenyl] sulf onyl} -L-pheny lalaninamide
[0364] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, diisopropylethylamine, and L-phenylalaninamide in dichloromethane were used to prepare N-f[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl>-L-phenylalaninamide. MS (ESI+) m/z 459 MS (ESI-) m/z 457.
Example 365: methyl N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-D-phenylalaninate
[0365] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, diisopropylethylamine, and D-phenylalanine methyl ester in dichloromethane were used to prepare methyl N-{[2-methyl-5- (phenylsulfonyDphenyl]sulfonyl}-D-phenylalaninate. MS (ESI+) m/z 474; MS (ESI-) m/z 472. Example 366: iV-[3-(l/-r-imidazol-l-yI)propyl]-2-methyI-5-{[4-(tetrahydro-2iϊ-pyran-4- ylamino)phenyl]sulfonyl}benzenesulfonamide
[0366] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-iV-[3- (lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and 4-aminotetrahydropyran were used to prepare N-["3-(l/jr-imidazol-l-vπpropyll-2-methyl-5-{[4-ftetrahvdro-2H-pyran-4- ylaminotphenyl] sulfony 1 } benzenesulfonamide . MS (ESI+) rø/z 519; MS (ESI-) m/z 517; HRMS: calcd for C24H30N4O5S2 + H+, 519.17304; found (ESI, [M+H]+), 519.1755.
Example 367: iV-[3-(liϊ-imidazol-l-yl)propyl]-5-({4-[(3- isopropoxypropyl)amino]phenyl}suIfonyl)-2-methyIbenzenesulfonamide
[0367] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-iV-[3- (lH"-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and 3-isopropoxypropyl)amine were used to prepare N- \3 -( 1 H-imidazol- 1 -y Dpropy 1] -5 -( { 4- [(3 - isopropoxypropy l)amino]pheny 1 } sulfonyl V2-methylbenzenesulfonamide . MS (ESI+) m/z 535; MS (ESI-) m/z 533; HRMS: calcd for C25H34N4O5S2 + H+, 535.20434; found (ESI, [M+H]+), 535.2054.
Example 368: 5-({4-[(cycIopropylmethyl)amino]phenyl}sulfonyI)-iV-[3-(liϊ-imidazol-l- yl)propyl]-2-methyIbenzenesulfonamide
[0368] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-iV-[3- (lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and cyclopropylmethylamine were used to prepare 5-( {4- [(cyclopropy lmethvDaminolphenyl } sulfonvD-N- F3 -( 1 H-imidazol- 1 -yDpropyl] - 2-methylbenzenesulfonamide. MS (ESI+) m/z 489; MS (ESI-) m/z 487; ΗRMS: calcd for C23H28N4O4S2 + H+, 489.16247; found (ESI, [M+H]+), 489.1653.
Example 369: 5-({4-[(lR,2if,45)-bicyclo[2.2.1]hept-2-ylamino]phenyl}sulfonyl)-iV-[3-(lJΪ- imidazol-l-yl)propyl]-2-methylbenzenesulfonamide [0369] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3- ( 1 H-imidazol- 1 -y l)propyl] -2-methy lbenzenesulfonamide and ( 1 i?,2i?,45)-bicyclo [2.2.1 ]hept~2- ylamine were used to prepare 5-({4-r(li?,2i?,4lSr)-bicvclo[2.2.1]hept-2-ylamino1phenyl|sulfonyl)- N-r3-(lH"-imidazol-l-yl)propyl1-2-methylbenzenesulfonamide. MS (ESI+) m/z 529; MS (ESI-) m/z 527; HRMS: calcd for C26H32N4O4S2 + H+, 529.19377; found (ESI, [M+H]+), 529.1946.
Example 370: 5-{[4-(benzylamino)phenyl]sulfonyl}-iV-[3-(lJϊ-imidazoI-l-yl)propyl]-2- methylbenzenesulfonamide
[0370] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3- (lH-imidazol-l-yl)propyl]-2-methylberizenesulfonamide and benzylamine were used to prepare 5-{ [~4-(benzylamino)pheny 1] sulfony 1 > -N- [3-d H-imidazol- 1 -y Dpropyl] -2- methylbenzenesulfonamide. MS (ESI+) m/z 525; MS (ESI-) m/z 523.
Example 371 : 5-[(4-{[(lS)-l-cyclohexylethyl]amino}phenyl)sulfonyl]-iV-[3-(lHr-iinidazol-l- yl)propyl]-2-methylbenzenesulfonamide
[0371] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3- (lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and (15)-l-cyclohexylethylamine were used to prepare 5-1"(4-1 [YIISVI -cyclohexylethyl] amino } pheny Dsulfonyl] -N- ["3-(I H-imidazol- 1 - yl)propyl]-2-methylbenzenesulfonamide. MS (ESI+) m/z 545; ΗRMS: calcd for C27H36N4O4S2 + H+, 545.22507; found (ESI, [M+H]+), 545.2244.
Example 372: 5-[(4-{[(lR)-l-cyclohexylethyl]amino}phenyl)sulfonyl]-iV-[3-(lH-imidazol-l- yl)propyl]-2-methylbenzenesulfonamide
[0372] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3- (lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and (li?)-l-cyclohexylethylamine were used to prepare 5 - [(4- { [( 1 R)- 1 -cyclohexy lethyl] amino 1 pheny Dsulfonyl] -N- [3 -( 1 H-imidazol- 1 - vDpropyll -2-methy lbenzenesulfonamide . MS (ESI+) m/z 545; MS (ESI-) m/z 543; HRMS: calcd for C27H36N4O4S2 + H+, 545.22507; found (ESI, [M+H]+), 545.2255.
Example 373: 5-({4-[(2-hydroxybutyl)amino]phenyl}sulfonyl)-iV-[3-(lJHr-imidazol-l- yl)propyl]-2-methylbenzenesulfonamide
[0373] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-JV-[3- (lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide and 2-hydroxybutylamine were used to prepare 5-( (4- r(2-hydroxybutyl)amino1phenyl j sulfonylViV- f3-(l H-imidazol- 1 -yl)propyl]-2- methylbenzenesulfonamide. MS (ESI+) m/z 507; MS (ESI-) m/z 505; HRMS: calcd for C23H30N4O5S2 + H+, 507.17304; found (ESI, [M+H]+), 507.1738.
Example 374: iV-[3-(lZT-imidazol-l-yl)propyl]-2-methyl-5-[(4-{[4- (trifluoromethyl)benzyl]amino}phenyl)sulfonyl]benzenesulfonamide
[0374] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[3- ( 1 i/-imidazol- 1 -yl)propy 1] -2-methylbenzenesulfonamide and 4-(trifluoromethyl)benzylamine were used to prepare N-\3-(l H-imidazol- 1 -y Dpropyl] -2-methyl-5- |~f 4- { [4- (trifluoromethvDbenzyllaminolphenylisulfonylibenzenesulfonamide. MS (ESI+) m/z 593; HRMS: calcd for C27H27F3N4O4S2 + H+, 593.14986; found (ESI, [M+H]+), 593.1508.
Example 375: 5-[(4-bromophenyl)sulfonyl]-2-methyl-Λ'-(tetrahydro-2JHr-pyraii-4- yl)benzenesulfonamide
[0375] In an analogous manner to Example 230:
[0376] Step 1: p-toluene sulfonyl chloride and bromobenzene were used to prepare 1- bromo-4-[(4-methylphenyl)sulfonyl]benzene.
[0377] Step 2: Following the same procedure described in Example 1 (step 1), 1- bromo-4-[(4-methylphenyl)sulfonyl]benzene and chlorosulfonic acid was used to prepare 5-(4- bromobenzenesulfonyl)-2-rnethylbenzenesulfonyl chloride. [0378] Step 3: Following the same procedure described in Example 1 (step 2), 5-(4- bromobenzenesulfonyl)-2-methylbenzenesulfonyl chloride and tetrahydropyran-4-ylamine were used to prepare 5-[(4-bromophenγl)sulfonvn-2-methyl-iV-('tetrahvdro-2/j'-pyran-4- vDbenzenesulfonamide. MS (ESI-) m/z 472;
Example 376: 5-[(4-cyanophenyl)sulfonyl]-2~methyl-iV-(tetrahydro-217-pyran-4- yl)benzenesulfonamide
[0379] To a stirred solution of 5-[(4-bromophenyl)sulfonyl]-2-methyl-A^tetrahydro- 2H-pyran-4-yl)benzenesulfonamide (0.30 g, 0.63 mmol) in DMF (3 mL) was added zinc cyanide (0.05 g, 0.38 mmol), tris(dibenzylideneacetone) dipalladium(O) (0.03 g, 0.03 mmol), and 1,1'- bis(diphenylphosphino)-ferrocene (0.04 g, 0.06 mmol). The resulting solution was heated to reflux for 1 hour. The solution was concentrated. Flash column separation with 10%-60% ethyl acetate/ hexane followed by trituration gave 5-[(4-cyanophenyDsulfonyl]-2-methyl-iV- (tetrahvdro-2H"-pyran-4-yπbenzenesulfonamide (0.11 g, 42%). MS (ESI-) m/z 419.
Example 377: 5-[(2-chlorophenyl)sulfonyl]-iV-[3-(lJHr-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide
[0380] Step 1 : In an analogous manner to Example 315, step 1.
[0381] Step 2: A solution of nickel (II) bromide (0.03 g, 0.11 mmol), zinc powder (0.03 g, 0.45 mmol), l,l'-bis(diphenylphosphino)-ferrocene (0.12 g, 0.22 mmol), and potassium carbonate (0.31 g, 2.24 mmol) in NMP (8 mL) was stirred at room temperature for 1 hour. 5- bromo-iV-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide (0.70 g, 1.95 mmol) and 2- chlorobenzenethiol (0.18 niL,1.57 mmol) were added and the resulting solution was heated in the microwave at 160 °C for 10 minutes. The solution was partitioned between a saturated aqueous ammonium chloride solution and ethyl acetate. The organic layer was concentrated and FfPLC separated. The resulting solid was dissolved in methylene chloride (5 mL). Oxone (0.68 g, 1.10 mmol) was added and the solution was stirred 2 days at room temperature, washed with a saturated aqueous ammonium chloride solution, dried over magnesium sulfate and concentrated to give 5-[f2-chlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide (0.04 g, 4%). MS (ESI+) m/z 454;
MS (ESI-) m/z 452;
HRMS: calcd for C19H20ClN3O4S2 + H+, 454.06565; found (ESI, [M+H]+), 454.0683.
Example 378: Λ43-(l#-imidazol-l~yI)propyl]-2-methyI-5-(pyridin-2- ylsulfonyl)benzenesulfonamide
[0382] In an analogous manner to Example 340:
[0383] Step 2: 2-mercaptopyridine was used to prepare N-[3-( Ii7-imidazol- 1 - yl)propyl]-2-methyl-5-(pyridin-2-ylsulfonyl)benzenesulfonamide. MS (ESI+) rø/z 421; HRMS: calcd for C18H20N4O4S2 + H+, 421.09987; found (ESI, [M+H]+), 421.0989.
Example 379: 5-[(2,4-dichlorophenyl)sulfonyl]-iV-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide
[0384] In an analogous manner to Example 377:
[0385] Step 2: 2,4-dichlorobenzenethiol was used to prepare 5-|Y2,4- dichlorophenvDsulfony 11 -N- [3 -( 1 ff-imidazol- 1 -vDpropyl] -2-methy lbenzenesulfonamide .
MS (ESI+) m/z 488;
MS (ESI-) m/z 486;
HRMS: calcd for C19H19Cl2N3O4S2 + H+, 488.02668; found (ESI, [M+H]+), 488.0299.
Example 380: 5-[(4-acetylphenyl)sulfonyl]-2-methyl-iV-(tetrahydro-2Jϊ-pyran-4- yl)benzenesulfonamide
[0386] To a stirred mixture of 5-[(4-bromophenyl)sulfonyl]-2-methyl-N-(tetrahydro- 2H-pyran-4-yi)benzenesulfonamide (0.70 g, 1.46 mmol) in toluene (10 niL) was added tetrakis(triphenylphosphine) palladium(O) (0.01 g, 0.07 mmol), and tributyl(l-ethoxyvinyl)tin (0.5 mL, 1.48 mmol). The resulting solution was heated at 100 0C overnight and partitioned between a saturated aqueous ammonium chloride solution and ethyl acetate. The organic layer was concentrated, taken up in THF (10 mL) and 2Ν HCl (5 mL) was added. The resulting solution was stirred at room temperature for 2 hours and extracted several times with ethyl acetate. The combined organic layers were filtered through celite and concentrated. Trituration with ether gave 5-[f4-acetylphenyl)sulfonyl1-2-methyl-N-('tetrahvdro-2H-pyran-4- vDbenzenesulfonamide (0.54 g, 85%).
MS (ESI+) rø/z 438;
MS (ESI-) m/z 436;
HRMS: calcd for C20H23NO6S2 + H+, 438.10396; found (ESI, [M+H]+), 438.1023.
Example 381 : 5-[(4-bromophenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0387] In an analogous manner to Example 375 :
[0388] Step 3: 2-(2-aminoethyl)-pyridine was used to prepare 5-[(4- bromophenyl')sulfonyl]-2-methyl-iV-(2-pyridm-2-ylethyl)benzenesulfonamide.
MS (ESI+) m/z 495;
HRMS: calcd for C20Hi9BrN2O4S2 + H+, 495.00424; found (ESI, [M+H]+), 495.0048.
Example 382 : 2-methyl-5-(phenylsulfonyl)-iV-(tetrahy dro-2/7-py ran-4- ylmethyl)benzenesulfonamide
[0389] In an analogous manner to Example 298:
[0390] Step 2: 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride and 2- (tetrahydro-pyran-4-yl)-methylamine were used to prepare 2-methyl-5 -("phenylsulfonyD-iV- (tetrahydro-2H-pyran-4-ylmethyDbenzenesulfonamide. MS (ESI+) rø/z 410; MS (ESI-) m/z 408; HRMS: calcd for C19H23NO5S2 + H+, 410.10904; found (ESI, [M+H]+), 410.111.
Example 383 : 5- [(4-fluorophenyl)sulfony 1] -2-methyl-Λr-(tetrahy dro-2/Z-py ran-4- ylmethyl)benzenesulfonamide
[0391] In an analogous manner to Example 298:
[0392] Step 2: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and tetrahydro-pyran-4-yl-methylamine were used to prepare 5-[(4-fluorophenyl)sulfonyl1-2-methyl- N-(tetrahydro-2//-pyran-4-ylmethyl)benzenesulfonamide. MS (ESI+) m/z 428; MS (ESI-) m/z 426; HRMS: calcd for C19H22FNO5S2 + H+, 428.09962; found (ESI, [M+H]4), 428.1015. Example 384: 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-Ar-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide
[0393] In an analogous manner to Example 298:
[0394] Step 2: 2-Ethyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and tetrahydro-pyran-4-yl-metliylamine were used to prepare 2-ethyl-5-[f4-fluorophenyl)sulfonyri-iV- (tetrahvdro-2H"-pyran-4-ylmethyl)benzenesulfonamide. MS (ESI+) m/z 442; MS (ESI-) m/z 440; HRMS: calcd for C20H24FNO5S2 + H+, 442.11527; found (ESI, [MH-H]+), 442.1144.
Example 385: 2,4-dimethyl-5-(phenyIsulfonyl)-Λr-(tetrahydro-2JfiT-pyran-4- ylmethyl)benzenesulfonamide
[0395] In an analogous manner to Example 298 :
[0396] Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and tetrahydro-pyran-4-yl-mthylamine were used to prepare 2,4-dimethyl-5-fphenylsulfonyiyN- (tetrahydro-2H-pyran-4-ylmethvDbenzenesulfonamide. MS (ESI+) m/z 424; MS (ESI-) m/z 422; HRMS: calcd for C20H25NO5S2 + H+, 424.12469; found (ESI, [M+H]+), 424.124.
Example 386: JV-(2-hydroxy-2-phenylethyl)-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0397] In an analogous manner to Example 298:
[0398] Step 2: 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride and 2-amino-l- phenyl-ethanol were used to prepare N-(2-hvdroxy-2-phenylethylV2-methyl-5- (phenylsulfonyDbenzenesulfonamide. MS (ESI-) m/z 430; HRMS: calcd for C21H21NO5S2 + NH4 +, 449.11994; found (ESI, [M+NH4]+), 449.119.
Example 387: 5-[(4-fluorophenyl)suIfonyl]-iV-(2-hydroxy-2-phenylethyl)-2- methylbenzenesulfonamide
[0399] In an analogous manner to Example 298: [0400] Step 2: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2- amino-1-phenyl-ethanol were used to prepare 5-[(4-fluorophenyl)sulfonyl1-N-(2-hydroxy-2- phenylethyl)-2-methylbenzenesulfonamide. MS (ESI-) m/z 448; HRMS: calcd for C21H20FNO5S2 + NH4 +, 467.11052; found (ESI, [M+NH4]+), 467.1105.
Example 388: 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-iV-(2-hydroxy-2- phenylethyl)benzenesulfonamide
[0401] In an analogous manner to Example 298:
[0402] Step 2: 2-Ethyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2- amino-1-phenyl-ethanol were used to prepare 2-ethyl-5-[(4-fluorophenyl)sulfonyll-N-(2- hydroxy-2-phenylethyl)benzenesulfonamide. MS (ESI-) m/z 462.
Example 389: Λr-(2-hydroxy-2-phenylethyl)-2,4-dimethyl-5- (phenylsulfonyl)benzenesulfonamide
[0403] In an analogous manner to Example 298:
[0404] Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 2-amino- 1-phenyl-ethanol were used to prepare N-('2-hvdroxy-2-phenylethyl')-2,4-dimethyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ESI-) m/z 444; HRMS: calcd for C22H23NO5S2 + NH4 +, 463.13559; found (ESI, [M+NH4]+), 463.1356.
Example 390: trans-iV-(2-hydroxy-l-methyl-2-phenylethyl)-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0405] In an analogous manner to Example 298:
[0406] Step 2: 5-Benzenesulfonyl-2-methyl-benzenesulfonyl chloride and norephedrine hydrochloride were used to prepare trans-A/'-(2-hydroxy- 1 -methyl-2-phenylethyl V2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ESI-) m/z 444; HRMS: calcd for C22H23NO5S2 + NH4 +, 463.13559; found (ESI, [M+NH4]+), 463.1376. Example 391 : 5-[(4-fluorophenyl)sulfonyI]-Λr-[trans-2-hydroxy-l-methyl-2-phenylethyl]-2- methylbenzenesulfonamide
[0407] In an analogous manner to Example 298:
[0408] Step 2: 2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and norephedrine hydrochloride were used to prepare 5 - [f4-fluorophenyl)sulfbnyl] -N- [trans-2- hydroxy- 1 -methy 1-2-pheny lethy 1] -2-methy lbenzenesulfonamide . MS (ESI-) m/z 462; HRMS: calcd for C22H22FNO5S2 + NH4 +, 481.12617; found (ESI, [M+NH4]+), 481.1258.
Example 392: 2-ethyI-5-[(4-fluorophenyl)sulfonyl]-Λr-[(trans)-2-hydroxy-l-methyI-2- phenylethyl]benzenesulfonamide
[0409] In an analogous manner to Example 298:
[0410] Step 2: 2-Ethyl-5-(4-fiuoro-benzenesulfonyl)-benzenesulfonyl chloride and norephedrine hydrochloride were used to prepare 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-iV- [(trans)-2-hydroxy-l-methyl-2-phenylethyl]benzenesulfonamide. MS (ESI-) m/z Al 6; HRMS: calcd for C23H24FNO5S2 + NH4 +, 495.14182; found (ESI, [M+NH4]"1"), 495.1408.
Example 393: iV-[(trans)-2-hydroxy-l-methyl-2-phenylethyl]-2,4-dimethyl-5- (phenylsulfonyl)benzenesulfonamide
[0411] In an analogous manner to Example 298:
[0412] Step 2: 5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and norephedrine hydrochloride were used to prepare N-[ftrans)-2-hydroxy-l-methyl-2-phenylethyl~|- 2,4-dimethyl-5-fphenylsulfonyl)benzenesulfonamide. HRMS: calcd for C23H25NO5S2 + NH4 +, 477.15124; found (ESI, [M+NH4]+), 477.1517.
Example 394: 2-methyl-5-(phenylsulfonyl)-N-propylbenzenesulfonamide
[0413] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and propylamine hydrochloride in dichloromethane were used to prepare 2-methyl-5-(phenylsulfonylVN-propylbenzenesulfonamide. MS (ES-) m/z 352.0. Example 395: N-(tert-butyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide
[0414] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and tert-butylamine in dichloromethane were used to prepare N-ftert-butyl)-2-methyl-5-(phenylsulfonyl')benzenesulfonamide. MS (ESI-) m/z 366.
Example 396: N-(2,2-dimethylpropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide
[0415] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and røeø-pentylamine in dichloromethane were used to prepare N-(2,2-dimethylpropyl)-2-methyl-5-(phenylsulfonvDbenzenesulfonamide. MS (ES-) m/z 380.0.
Example 397: N-(l-ethylpropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide [0416] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and 3-aminopentane in dichloromethane were used to prepare N-(l-ethylpropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 380.0.
Example 398: N-cyclobutyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide
[0417] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and cyclobutylamine in dichloromethane were used to prepare N-cyclobutyl-2-methyl-5-fphenylsulfonyl)benzenesulfonamide. MS (ESI-) m/z 364.
Example 399: N-cyclopentyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide
[0418] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and cyclopentylamine in dichloromethane were used to prepare N-cyclopentyl^-methyl-S-fphenylsulfonyDbenzenesulfonamide. MS (ESI-) m/z 378.
Example 400: N-cyclohexyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide [0419] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and cyclohexylamine in dichloromethane were used to prepare N-cvclohexyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide. MS (ESI-) m/z 392.
Example 401 : 2-methyl-5-(phenylsulfonyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide
[0420] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and 2,2,2 -trifluoroethylamine in dichloromethane were used to prepare 2-methyl-5-(phenylsulfonyl)-N-(2,2,2-trifluoroethyl')benzenesulfonamide. MS (ES-) m/z 391.9.
Example 402: 5-({4-[(l£)-iV-hydroxyethanimidoyl]phenyl}sulfonyl)-2-methyl-iV- (tetrahydro-2i?-pyran-4-yl)benzenesulfonamide
[0421] To a stirred mixture of 5-[(4-acetylphenyl)sulfonyl]-2-methyl-iV-(tetrahydro-2H'- pyran-4-yl)benzenesulfonamide (0.2Og, 0.46mmol) in ethanol (2mL) and D.I. water (0.5mL) was> added sodium acetate (0.05g, 0.55mmol) and hydroxylamine hydrochloride (0.04g, 0.50mmol). The resulting mixture was heated to reflux for 2.5 hours. The solution was concentrated and filtered to give 5-({4-[(l E)-N-hy droxyethanimidoy rjphenyl ) sulfony IV 2-methy l-JV"-(tetrahvdro- 2H-pyran-4-yDbenzenesulfonamide (0.11 g, 55%). MS (ES1+) tn/z 453; HRMS: calcd for C20H24N2O6S2, 452.10758; found (ESI, [H+M]+), 453.1131.
Example 403: 5-[(4-acetylphenyl)sulfonyl]-2-methyl-JV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0422] In an analogous manner to Example 380, 5-[(4-bromophenyl)sulfonyl]-2- methyl-Λ/"-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepare 5-[(4- acetylphenyl')sulfonyl]-2-methyl-JV-(2-pyridin-2-ylethyl')benzenesulfonamide. MS (ESI+) rø/z 459; HRMS: calcd for C22H22N2O5S2 + H+, 459.10429; found (ESI, [M+H]+), 459.1054.
Example 404: N-(2-hydroxy-l,l-dimethylethyl)-2-methyl-5- (phenylsulfonyl)benzenesulfonamide [0423] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and 2-amino-2 -methyl- 1-propanol in dichloromethane were used to prepare N-f2 -hydroxy- 1 , 1 -dimethylethyl)-2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ESI-) m/z 382.
Example 405: 5-{[4-(l-hydroxy-l-methylethyl)phenyl]sulfonyl}-2-methyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0424] To a stirred mixture of 5-[(4-acetylphenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide (0.15 g, 0.33 mmol) in THF (3 mL) was added methyl magnesium bromide 1.4M in 75% toluene/THF (0.75 mL, 1.0 mmol) at 0 °C. The resulting mixture was stirred 2 hours, quenched with a saturated aqueous ammonium chloride solution, and extracted several times with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, and concentrated. HPLC separation gave 5- {[4-d -hydroxy- 1- methylethyDphenyl]sulfonyl>-2-methyl-A/-('2-pyridin-2-ylethyl)benzenesulfonamide (0.02 g,
%).
MS (ES+) m/z 475;
HRMS: calcd for C23H26N2O5S2, 474.12831; found (ESI, [H+M]+), 475.1382.
Example 406 : 5-{ [4-(l -cy clohexyl-1 -hydroxy ethyl)phenyl] sulfonyl} -2-methyl-iV-(2-py ridin- 2-ylethyl)benzenesulfonamid
[0425] In an analogous manner to Example 405, cyclohexyl magnesium chloride was used to prepare 5 - { \4-( 1 -cyclohexyl- 1 -hy droxy ethy Pphenyl] sulfonyl } -2-methyl-JV"-(2-pyridin-2- ylethyPbenzenesulfonamide. MS (ES-) m/z 541.0; HRMS: calcd for C28H34N2O5S2 + H+, 543.19819; found (ESI, [M+H]+), 543.1959.
Example 407: 5-{[4-(l-hydroxy-l-phenylethyl)phenyl]sulfonyl}-2-methyl-Λ'-(2-pyridin-2- ylethyl)benzenesulfonamide
[0426] In an analogous manner to Example 405, phenyl magnesium bromide was used to prepare 5-{[4-(l-hydroxy-l-phenylethyl)phenyl1sulfonyl}-2-methyl-N-r2-pyridin-2- ylethyDbenzenesulfonamide. MS (ES-) m/z 535.0;
HRMS: calcd for C28H28N2O5S2 + H+, 537.15124; found (ESI, [M+H]+), 537.1492.
Example 408: 5-{[4-(l-hydroxy-l-methyI-2-phenylethyI)phenyl]sulfonyl}-2-methyl-iV-(2- pyridin-2-yIethyI)benzenesulfonamide
[0427] In an analogous manner to Example 405, benzyl magnesium chloride was used to prepare 5-{r4-(l-hvdroxy-l-methyl-2-phenylethyl)plienyllsulfonyl}-2-methyl-A/'-(2-pyridin-2- ylethvDbenzenesulfonamide . MS (ES-) m/z 549.0; HRMS: calcd for C29H30N2O5S2 + H+, 551.16689; found (ESI, [M+H]+), 551.1655.
Example 409: 5-[(3-cyanophenyl)sulfonyl]-2-methyl-Λ'-(2-pyridin-2- ylethyl)benzenesulfonamide
[0428] Step 1 : Following the same procedure described in Example 315 (step 1), 2-(2- aminoethyl)-pyridine was used to prepare 5-bromo-2-methyl-JV-(2-pyridin-2- ylethyl)benzenesulfonamide . MS (ES) m/z 352.9;
[0429] Step 2: To a stirred solution of 5-bromo-2-methyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide (10.0 g, 28.15 mmol) in THF (200 niL) at -78°C was added methyl magnesium bromide 1.4M in 75% toluene/THF (24.0 mL, 33.6 mmol). The reaction was stirred 10 minutes and n-butyl lithium 2.5M in hexane (14.0 mL, 35.0 mmol) was added dropwise. The reaction was stirred an additional 10 minutes. Sulfur dioxide was bubbled into the reaction for 20 minutes and was then allowed to warm to room temperature over a period of 2 hours. The reaction was quenched with D.I. water (200 mL) and extracted with ethyl acetate. Sodium hydroxide 2.5M was added to the aqueous layer to a pH of 11 and extracted again with ethyl acetate. The aqueous layer was concentrated and the resulting solid was triturated with methanol to give 4-methyl-3-{[(2-pyridin-2-ylethyl)amino]sulfonyl}benzenesulfinic acid (10.6 g, 103% contains undetermined quantity of inorganic salts.) MS (ESI) m/z 341;
[0430] Step 3 : To a stirred solution of 4-methyl-3- { [(2-pyridin-
2ylethyl)amino]sulfonyl}benzenesulfϊnic acid (0.30 g, 0.83 mmol) in DMSO (4 mL) was added 3-cyanophenylboronic acid (0.12 g, 0.83 mmol), potassium carbonate (0.46 g, 3.31 mmol), and copper (II) acetate (0.16 g, 0.91 mmol). The resulting solution was stirred overnight at room temperature under a drying tube. The reaction was partitioned between ammonium chloride solution (sat) and ethyl acetate. The organic layer was concentrated. HPLC separation gave 5^ r(3-cyanophenyl)sulfoiiyl]-2-methyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide (0.0 2g, 5%). MS (ES+) m/z 442.0; MS (ES-) m/z 440.0.
Example 410: 2-methyl-5-(l-naphthyIsulfonyl)-Λ'-(2-pyridin-2-ylethyl)benzenesuIfonamide
[0431] In an analogous manner to Example 409,
[0432] Step 3: 1-naphthylene boronic acid was used to prepare 2-methyl-5-(l- naphthylsulfonylVN-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES-) m/z 465.0; HRMS: calcd for C24H22N2O4S2 + H+, 467.10937; found (ESI, [M+H]+), 467.1113.
Example 411: 2-methyl-5-(phenylsulfonyl)-N-(2,2,6,6-tetramethylpiperidin-4- yl)benzenesulfonamide
[0433] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and 4-amino-2,2,4,4-tetramethylpiperidine in dichloromethane were used to prepare 2-methyl-5-(phenylsulfonyl)-N-(2,2,6,6- tetramethylpiperidin-4-yl)benzenesulfonamide. MS (ESI+) m/z 451; MS (ESI-) m/z 449.
Example 412: N-[(lS%2S*)-2-hydroxycyclohexyl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0434] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and frαw-2-aminocyclohexanol hydrochloride in dichloromethane were used to prepare N- \( 1 S * ,2S * )-2-hydroxy cyclohexyl] -2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ESI+) m/z 410; MS (ESI-) m/z 408. Example 413: N-(l-benzylpiperidin-4-yI)-2-methyI-5-(phenylsulfonyl)benzenesulfonamide
[0435] In an analogous manner to Example 294, 5-benzenesulfonyl-2~methyl- benzenesulfonyl chloride, triethylamine, and 4-amino-l-benzylpiperidine in dichloromethane were used to prepare N-d-benzylpiperidin-4-yl)-2-methyl-5- (phenylsulfonyDbenzenesulfonamide. MS (ESI+) m/z 485; MS (ESI-) m/z 483.
Example 414: N-(l-benzylpyrrolidin-3-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide
[0436] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and l-benzyl-3-aminopyrrolidine in dichloromethane were used to prepare N-(l-benzylpyrrolidin-3-yl>2-methyl-5- (phenylsulfonvDbenzenesulfonamide. MS (ESI+) m/z 471; MS (ESI-) m/z 469.
Example 415: N-(2,3-dihydro-lH-inden-l-yl)-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0437] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and 1-aminoindane in dichloromethane were used to prepare N-(2,3-dihvdro-lH-inden-l-yl)-2-methyl-5-(phenylsulfonyDbenzenesulfonamide. MS (ESI-) m/z 426.
Example 416: 5- [(3-hy droxyphenyl)sulfonyl] -2-methy l-iV-(2-py ridin-2- ylethyl)benzenesulfonamide
[0438] In an analogous manner to Example 409,
[0439] Step 3 :3-hydroxyphenyl boronic acid was used to prepare 5-[(3- hydroxyphenyl)sulfonyl]-2-methyl-7V-f2-pyridin-2-ylethyl)benzenesulfonamide.
HRMS: calcd for C20H20N2O5S2 + H+, 433.08864; found (ESI, [M+H]+), 433.0912.
Example 417: 5-[(3,5-difluorophenyI)suIfonyl]-2-methyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide [0440] In an analogous manner to Example 409,
[0441] Step 3: 3,5-difluorophenyl boronic acid was used to prepare 5-r(3,5- difluorophenyl)sulfonyll-2-methyl-iV-(2-pyridin-2-yleth.yl)benzenesulfonamide. MS (ES-) m/z 451.0; HRMS: calcd for C20H18F2N2O4S2 + H+, 453.07488; found (ESI, [M+H]+)5 453.0736.
Example 418: 5-[(4-ethylphenyI)sulfonyl]-2-methyI-JV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0442] In an analogous manner to Example 409,
[0443] Step 3: 4-ethylphenyl boronic acid was used to prepare 5-[(4- ethylphenyl)sulfonyll-2-methyl-A/'-(2-pyridin-2-ylethyl)benzenesulfonamide.
MS (ES-) m/z 443.0;
HRMS: calcd for C22H24N2O4S2 + H+, 445.12502; found (ESI, [M+H]+), 445.1262.
Example 419: 5- [(3-acetylphenyl)sulf ony 1] -2-methyl-iV-(2-py ridin-2- ylethyl)benzenesulfonamide
[0444] In an analogous manner to Example 409,
[0445] Step 3: 2-acetylphenyl boronic acid was used to prepare 5-[(3- acetylphenvDsulfonvn-2-meth.yl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide.
MS (ES-) m/z 457.0;
HRMS: calcd for C22H22N2O5S2 + H+, 459.10429; found (ESI, [M+H]+), 459.1059.
Example 420: 5-[(2-ethoxyphenyl)sulfonyl]-2-methyl-JV~(2~pyridin-2- ylethyl)benzenesulfonamide
[0446] In an analogous manner to Example 409,
[0447] Step 3: 2-ethyoxyphenyl boronic acid was used to prepare 5-[(2- ethoxyphenvDsulfonvn-Σ-methyl-N-C∑-pyridin-Σ-ylethYDbenzenesulfonamide. MS (ES-) m/z 459.0; HRMS: calcd for C22H24N2O5S2 + H+, 461.11994; found (ESI, [M+H]+), 461.1215.
Example 421 : 5-[(2,5-dimethoxyphenyl)sulfonyI]-2-methyl-iV-(2-pyridm-2- ylethyl)benzenesulfonamide [0448] In an analogous manner to Example 409,
[0449] Step 3: 2,5-dimethoxyphenyl boronic acid was used to prepare 5-[(2,5- dimethoxyphenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES-) m/z 475.0; HRMS: calcd for C22H24N2O6S2 + H+, 477.11485; found (ESI, [M+H]+), 477.1174.
Example 422: 5-[(2,3-dimethoxyphenyl)sulfonyI]-2-methyl--V-(2-pyridm-2- ylethyl)benzenesulfonamide
[0450] In an analogous manner to Example 409,
[0451] Step 3: 2,3-dimethoxyphenyl boronic acid was used to prepare 5-[(2,3- dimetlioxyphenyl)sulfonyl1-2-methyl-iV-('2-pyridin-2-yletlivπbenzenesulfonamide. MS (ES-) m/z 475.0; HRMS: calcd for C22H24N2O6S2 + H+, 477.11485; found (ESI, [M+H]+), 477.1169.
Example 423: 5-[(2,4-dimethoxyphenyl)sulfonyI]-2-methyI-ΛL(2-pyridin-2- ylethyl)benzenesulfonamide
[0452] In an analogous manner to Example 409,
[0453] Step 3 : 2,4-dimethoxyphenyl boronic acid was used to prepare 5-|"(2,4- dimethoxyphenyl)sulfonyll-2-methyl-iV-(2-pyridin-2-ylethvπbenzenesulfonamide. MS (ES-) m/z 475.0; HRMS: calcd for C22H24N2O6S2 + H+, 477.11485; found (ESI, [M+H]+), 477.1144.
Example 424: N-cyclopropyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide
[0454] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and cyclopropylamine in dichloromethane were used to prepare N-cyclopropyl-2-metriyl-5-(phenylsulfonyDbenzenesulfonamide. MS (ES-) m/z 350.0.
Example 425: ethyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate
[0455] In an analogous manner to Example 294, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride, triethylamine, and ethyl 4-amino-l-piperidine carboxylate in dichloromethane were used to prepare ethyl 4-({|~2-methyl-5- (phenylsulfonyl)phenyllsulfonyl}amino)piperidine-l-carboxylate. MS (ES-) m/z 465.0.
Example 426: 2-methyl-iV-(2-pyridin~2-ylethyl)-5-(pyridin-3- ylsulfonyl)benzenesulfonamide
[0456] In an analogous manner to Example 409,
[0457] Step 3: pyridine-3-boronic acid was used to prepare 2-methyl-JV-(2-pyridin-2- ylethyl)-5-(pyridm-3-ylsulfonvDbenzenesulfonamide. MS (ESI+) m/z 418.
Example 427: 5-(lH-indol-5-yIsulfonyl)-2-methyl-JV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0458] In an analogous manner to Example 409,
[0459] Step 3: 5-indole boronic acid was used to prepare 5-( 1 ϋ/-indol-5-ylsulfonylV2- methyl-iy-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES+) m/z 456.1.
Example 428: 5-[(4-cyanophenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0460] In an analogous manner to Example 409,
[0461] Step 3: 4-cyanophenyl boronic acid was used to prepare 5-[(4- cvanophenyl)sulfonyll-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide.
MS (ESI+) m/z 442.
Example 429: 5-{[3-(ethyIsulfonyl)phenyl]sulfonyl}-2-methyl-iV-(2-pyridiii-2- ylethyl)benzenesulfonamide
[0462] In an analogous manner to Example 409,
[0463] Step 3: 3-(ethylsulfonyl)phenyl boronic acid was used to prepare 5-{|~3- ('ethylsulfonyl)phenyl]sulfonyl}-2-metb.yl-iV-(2-pyridin-2-ylethyl')benzenesulfonamide. MS (ES+) m/z 509.0. Example 430: 2-methyl-5-[(2-methylphenyl)sulfonyI]-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0464] In an analogous manner to Example 409,
[0465] Step 3: 2-methylphenyl boronic acid was used to prepare 2-methyl-5-rf2- methylphenyl')sulfonyll-./V-('2-pyridin-2-ylethyl>)benzenesulfonamide. MS (ESl+) m/z 431.
Example 431 : 5-[(2-ethylphenyl)sulfonyl]-2-methyl-iV-(2-pyridm-2- ylethyl)benzenesulfonamide
[0466] In an analogous manner to Example 409,
[0467] Step 3: 2-ethylphenyl boronic acid was used to prepare 5-|"(2- ethylphenyl")sulfonyl1-2-metliyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide.
MS (ESI+) w/z 445.
Example 432: 5-(biphenyl-2-ylsulfonyl)-2-methyI-7V-(2-pyridin-2- ylethyl)benzenesulfonamide
[0468] In an analogous manner to Example 409,
[0469] Step 3: 2-biphenyl boronic acid was used to prepare 5 -(biphenyl-2-y lsulfony I)- 2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI+) m/z 493.
Example 433: 5-(biphenyl-4-ylsulfonyl)-2-methyI-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0470] In an analogous manner to Example 409,
[0471] Step 3: 4-biphenyl boronic acid was used to prepare 5-(biphenyl-4-ylsulfonyl)- 2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI+) m/z 493.
Example 434: 5-(biphenyl-3-ylsulfonyl)-2-methyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0472] In an analogous manner to Example 409, [0473 J Step 3 : 3-biphenyl boronic acid was used to prepare 5-(biphenyl-3 -ylsulfonyl)- 2-methyl-N-f2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI+) rø/z 493.
Example 435: 5-[(4-tert-butylphenyl)sulfonyl]-2-isopropyI-N-(2-pyridin-2- ylethyl)benzenesulfonamide
[0474] In an analogous manner to Example 230,
[0475] Step 1 : 4-Isopropylbenzenesulfonyl chloride and tert-butylbenzene were used to prepare 1 -tert-butyl-4-[(4-isopropylphenyl)sulfonyl]benzene.
[0476] Step 2: l-tert-Butyl-4-[(4-isopropylphenyl)sulfonyl]benzene and chlorosulfonic acid were used to prepare 5-(4-tert-butyl-benzenesulfonyl)-2-isopropyl-benzenesulfonyl chloride.
[0477] Step 3: To a solution of 5-(4-tert-Butyl-benzenesulfonyl)-2-isopropyl- benzenesulfonyl chloride (150 mg, 0.36 mmol) in dichloromethane (4.0 mL) was added pyridine (73 mg, 0.72 mmol) and 2-(2-aminoethyl)pyridine (44 mg, 0.36 mmol). The reaction was stirred at room temperature overnight and then extracted with saturated sodium bicarbonate (2 x 10 mL), followed by saturated ammonium chloride (2 x 10 mL). The organic layer was dried with magnesium sulfate and concentrated down under vacuum. The crude residue was purified using automated flash chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 5-[(4-tert-butylphenyl)sulfonyl]-2-isopropyl-N-(2- pyridin-2-ylethyl)benzenesulfonamide (178 mg, 98%).
Figure imgf000154_0001
Example 436: 5-[(4-tert-butylphenyl)sulfonyl]-N-[3-(lH-imidazoI-l-yl)propyl]-2- isopropylbenzenesulfonamide
[0478] In an analogous manner to Example 435, 5-(4-tert-Butyl-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and l-(3-aminopropyl)imidazole were used to prepare 5-[(4- tert-butylphenyl)sulfonyl]-N-[3-(lH-imida2ol-l-yl)propyl]-2- isopropylbenzenesulfonamide. MS (ES+) m/z 504; HRMS: calcd. for C25H33N3O4S2 + H+, 504.1991 : found (ESI, [m+H]*), 504.2007. Example 437: 5-[(4-tert-butylphenyI)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide
[0479] In an analogous manner to Example 435, 5-(4-tert-Butyl-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and 4-aminotetrahydropyran were used to prepare 5-[("4-tert- butylphenyl)sulfonyl]-2-isopropyl-N-('tetrahvdro-2H-pyran-4- vDbenzenesulfonamide. MS (ES+) m/z 480.
Example 438: 5-[(4-tert-butyIphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide
[0480] In an analogous manner to Example 230,
[0481] Step 1 : p-Toluenesulfonyl chloride and tert-butylbenzene were used to prepare l-tert-butyl-4-[(4-methylphenyl)sulfonyl]benzene.
[0482] Step 2: l-tert-Butyl-4-[(4-methylphenyl)sulfonyl]benzene and chlorosulfonic acid were used to prepare 5-(4-tert-butyl-benzenesulfonyl)-2-methyl-benzenesulfonyl chloride.
[0483] Step 3 : In an analogous manner to Example 435, 5-(4-tert-Butyl- benzenesulfonyl)-2-methyl-benzenesulfonyl chloride and 2-(2-aminoethyl)pyridine were used to prepare 5-[(4-tert-butylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide. MS (ES+) m/z 473; HRMS: calcd. for C24H28N2O4S2 + H+, 473.1569; found (ESI3 [m+H]+), 473.1551.
Example 439: 5-[(4-tert-butylphenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide
[0484] In an analogous manner to Example 435, 5-(4-tert-Butyl-benzenesulfonyl)-2- methyl-benzenesulfonyl chloride and l-(3-aminopropyl)imidazole were used to prepare 5-[(4- tert-butylpheny Dsulfony H -N- [3 -( 1 H-imidazol- 1 -vDpropy 11 -2- methy lbenzenesulfonamide . MS (ES+) m/z 476; HRMS: calcd. for C23H29N3O4S2 + H+, 476.1678; found (ESI, [m+H]+), 476.1662.
Example 440: 5-[(4-tert-butylphenyl)sulfonyI]-2-methyI-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide [0485] In an analogous manner to Example 435, 5-(4-tert-Butyl~benzenesulfonyl)-2- methyl-benzenesulfonyl chloride and 4-aminotetrahydropyran were used to prepare 5-[(4-tert- butylphenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4- vDbenzenesulfonamide. MS (ES+) m/z 452.
Example 441 : iV-[2-(2-Fluorophenyl)ethyl]-3-[(4-methylphenyI)sulfonyl]-5,6,7,8- tetrahydronaphthalene-l-sulfonamide
[0486] Step a: A stirred solution of 1 ,2,3,4-tetrahydronaphthalene (10.0 niL, 74 mmol) and p-toluenesulfonyl chloride (3.81 g, 20 mmol) was cooled to 0 0C and treated slowly under nitrogen with solid anhydrous aluminum chloride (3.20 g, 24 mmol). After stirring neat for 4 hours at room temperature, the mixture was slowly poured into ice water and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and filtered through a short column of silica gel. The filtrate was evaporated in vacuo to yield a crude oil containing a mixture of isomers in approximately a 6:1 ratio. The crude oil was recrystallized twice from diethyl ether-hexane to yield 4-methylphenyl 5,6,7,8-tetrahvdronaphthalen-2-yl sulfone (3.04 g, 53%) as a homogeneous, colorless, crystalline solid, m.p. 130-132 °C; MS(EI) m/z 286; HRMS: calcd for C17H18O2S, 286.10275; found (EI, M+.), 286.1022.
[0487] Step b: 4-Methylphenyl 5,6,7,8-tetrahydronaphthalen-2-yl sulfone (0.29 g, 1.0 mmol) was heated with stirring at 60 °C for one hour under nitrogen with chlorosulfonic acid (0.67mL, 1.17 g, 10.0 mmol). The mixture was cooled to room temperature, poured slowly into a cold solution of IN hydrochloric acid, and extracted with ethyl acetate (2x.). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated in vacuo to an oil. The oil was dissolved in dichloromethane and treated dropwise under nitrogen with a solution of 2-fluorophenethylamine (0.28 g, 2.0 mmol) in dichloromethane. After stirring for one hour at room temperature, the reaction mixture was concentrated in vacuo and diluted with ethyl acetate. The organic phase was washed sequentially with IN hydrochloric acid and a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered through a short column of silica gel, and the filtrate concentrated to a crude oil. The crude oil was purified by preparative liquid chromatography on a Biotage® 40 Mi column of pre-packed silica gel (90 g) eluting with a gradient of 25% - 50% methyl fert-butyl ether in hexane at a flow rate of 50 niL/min to afford, after evaporation of the solvent under vacuum, N- [2-(2-fluorophenyl)ethy 11 -3 - ["(4- methylphenyl)sulfonvn-5,6.,7,8-tetralivdronaphthalene-l-sulfonamide (0.12 g, 25%) as a colorless, homogeneous, amorphous foam, m.p. 55-60 °C; MS (ES-) m/z 486.1; MS (ES+) m/z 488.1.
Example 442: 5-[(4-fluorophenyl)sulfonyl]-Λ'-[2-(lJHr-imidazol-4-yl)ethyI]-2- isopropylbenzenesulfonamide
[0488] In an analogous manner to Example 298 :
[0489] Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-(lH-imidazol-4-yl)-ethylarnine were used to prepare 5- [(4-fluoropheny Dsulfonyll -N- \2-( 1 H- imidazol-4-yl)ethyl]-2-isopropylbenzenesulfonamide. MS (ES+) m/z 452.0; MS (ES-) m/z 450.0.
Example 443: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-iV-[(2R)-2- phenylpropyl] benzenesulfonamide
[0490] In an analogous manner to Example 298:
[0491] Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-(R)-phenylpropyl-l -amine were used to prepare 5 - r(4-fluorophenv0sulfonyl1 -2-isopropyl-N- r(2J?V2-phenylpropyllbenzenesulfonamide. MS (ES+) m/z 476.1; MS (ES-) m/z 474.1.
Example 444: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-iV-[(2S)-2- phenylpropyl] benzenesulfonamide
[0492] In an analogous manner to Example 298:
[0493] Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-(S)-phenylpropyl-l -amine were used to prepare 5-[f4-fluorophenyl)sulfonyl~|-2-isopropyl-N- r(2iSV2-phenylpropyπberizenesulfonamide. MS (ES-) m/z Al AA. Example 445: 5-[(4-fluorophenyl)suIfonyl]-2-isopropyl-Λr-(tetrahydro-2iϊ-pyran-4- ylmethyl)benzenesulfonamide
[0494] In an analogous manner to Example 298:
[0495] Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and tetrahydro-pyran-4-yl-methylamine were used to prepare 5 - Ff 4-fluorophenyl)sulfbnyl] -2- isopropyl-A/-(tetrahydro-2H'-pyran-4-ylmethyl')benzenesulfonamide. MS (ES+) m/z 456.1; MS (ES-) m/z 454.1.
Example 446: tert-butyl 4-({[2-methyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate
[0496] In an analogous manner to Example 435, 5-benzenesulfonyl-2-methyl- benzenesulfonyl chloride and 4-amino-l-Boc-piperidine were used to prepare tert-butyl 4-({[2- methyl-5-(phenylsulfony Dphenyll sulfonylj aminolpiperidine- 1 - carboxylate. MS (ES-) m/z 493.
Example 447: 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide
[0497] To a solution of 25% trifluoroacetic acid/dichloromethane was added tert-butyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate (2.0 g, 4.04 mmol) and the solution was stirred at room temperature for two hours. The reaction was then extracted with saturated sodium bicarbonate, dried with magnesium sulfate, and concentrated down under vacuum to give 2-methyl-5-(phenylsulfonylVN-piperidin-4-ylbenzenesulfonamide (1.5g, 94%). MS (ES+) m/z 495 MS (ES-) m/z 493.
Example 448: 2-methyl-5-(phenylsulfonyl)-N-[l-(phenylsulfonyl)piperidin-4- yljbenzenesulfonamide
[0498] To a solution of 2-methyl-5-(phenylsulfonyl)-N-piperidin-4- ylbenzenesulfonamide (125 mg, 0.32 mmol) and pyridine (48 mg, 0.48 mmol) in dichloromethane (4 mL) was added benzenesulfonyl chloride (59 mg, 0.33 mmol). The reaction was stirred at room temperature for three hours and then extracted with saturate sodium bicarbonate. The aqueous phase was washed with dichloromethane (2 x 10 mL). The combined organic phases were dried with magnesium sulfate and concentrated down under vacuum. The crude residue was purified using automated flash chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 2-methyl-5-(phenylsulfonyl)- N-[I -fphenylsulfonyP)piperidin-4- ylibenzenesulfonamide (95 mg, 56%). MS (ES+) m/z 535 MS (ES-) m/z 533.
Example 449: N-[l-(2-furoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0499] To a slurry of 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide (75 mg, 0.19 mmol), morphlinomethyl-polystyrene (170 mg, 62 mmol), and dimethylaminopyridine-polystyrene (70 mg, 0.14 mmol) in dichloromethane (8 mL) was added 2-furoyl chloride (50 mg, 0.38 mmol). The reaction was rotated on an orbital shaker for four hours. Then aminomethylated-polystyrene (150 mg, 0.33 mmol) was added to the reaction and it was rotated for an addition two and one-half hours. The reaction was then filtered and the resin was washed alternately with dichloromethane (3 x 5 mL) and methanol (3 x 5 mL) and concentrated down under vacuum. The crude residue was purified using automated flash chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation ofN-[l-r2-furoyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyπbenzenesulfonamide (68 mg, 73 %). MS (ES+) m/z 489.
Example 450: 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-iV-[2-(lH-imidazol-l-yl)ethyl]- 2-isopropylbenzenesulfonamide
[0500] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-N-[2- (lH-imidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide and 3-aminopropionitrile were used to prepare 5-( { 4- [(2-cyanoethy Daminojpheny 1 ) sulfony IViV- \2-( 1 H-imidazol- 1 -vDethyll -2- isopropylbenzenesulfonamide. MS (ESI+) m/z 502; MS (ESI-) m/z 500. Example 451: iV-[2-(lJϊ-imidazol-l-yl)ethyl]-2-isopropyI-5-{[4- (methylamino)phenyl]sulfonyl}benzenesulfonamide
[0501] In an analogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-iV-[2- (lH"-imidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide and methylamine were used to prepare JV-r2-flH"-imidazol-l-yl^ethvn-2-isopropyl-5-(r4- (methy laminolpheny 1] sulfony 1 } benzenesulfonamide . MS (ESI+) m/z 463; MS (ESI-) m/z 461.
Example 452: 5-({4-[(2-hydroxybutyl)amino]phenyl}sulfonyl)-iV-[2-(lHr-imidazol-l- yl)ethyl]-2-isopropylbenzenesuIfonamide
[0502] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfbnyl]-JV-[2- (l/f-imidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide and 2-hydroxybutylamine were used to prepare 5 -( {4- [(2-hydroxybutyl)ammo]pheny 1 } sulfony \)-N-\2-( 1 if-imidazol- 1 -vDethyl] -2- isopropylbenzenesulfonamide . MS (ESI+) rø/z 521; MS (ESI-) m/z 519.
Example 453: 5-[(4-{[(2S)-l-(hydroxymethyl)-2-methylbutyl]amino}phenyl)sulfonyl]-Λ'-[2- (lJϊ-imidazol-l-y^etliyll^-isopropylbenzenesulfonamide
[0503] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-iV-[2- (lH-imidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide and L-isoleucinol were used to prepare 5-r(4-(r(2^-l-(hvdroxymethylV2-methylbutyllamino)phenyl)sulfonyll-N-r2-αH-imidazol-l- yl1ethyl]-2-isopropylbenzenesulfonamide. MS (ESI+) m/z 549; MS (ESI-) m/z 547.
Example 454: 5-[(3,5-dimethylphenyl)sulfonyl]-2-isopropyl-ΛL(2-pyridin-2- ylethyl)benzenesulfonamide
[0504] Step 1 : Following the procedure described in Example 409 (Step 2), 5-bromo-2- isopropyl-7V-(2-pyridin-2-ylethyl)benzenesulfonamide (Example 474 Steps 1 and 2) was used to prepare 4-isopropyl-3-{r(2-pyridin-2-ylethyl)aminolsulfonyl)benzenesulfinic acid. [0505] Step 2: Following the procedure described in Example 409 (Step 3), 4- isopropyl-3-{[(2-pyridin-2-ylethyl)amino]sulfonyl}benzenesulfinic acid and 3,5-dimethylphenyl boronic acid were used to prepare 5-[f3,5-dimethylphenyl)sulfonyll-2-isopropyl-N-(2-pyridin-2- ylethy Dbenzenesulfonamide . MS (ESI+) rø/z 473; MS (ESI-) m/z 471.
Example 455: 5-[(3-chlorophenyl)suIfonyl]-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0506] In an analogous manner to Example 454,
[0507] Step 2: 3-chlorophenyl boronic acid was used to prepare 5-[(3- chlorophenyπsulfonvn-2-isopropyl-iV-f2-pyridin-2-ylethyl)benzenesulfonamide.
MS (ESI+) rø/z 479;
MS (ESI-) m/z 477.
Example 456: 2-isopropyl-5-[(3-methoxyphenyl)sulfonyl]-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0508] In an analogous manner to Example 454,
[0509] Step 2: 3 -methyoxy phenyl boronic acid was used to prepare 2-isopropyl-5-[(3- methoxyphenyl')sulfonyl]-iV-(2-pyridin-2-ylethyl')benzenesulfonamide. MS (ESI+) m/z 475; MS (ESI-) m/z 473.
Example 457: 2-isopropyl-5-[(2-methoxyphenyI)sulfonyl]-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0510] In an analogous manner to Example 454,
[0511] Step 2: 2-methoxyphenyl boronic acid was used to prepare 2-isopropyl-5-IY2- methoxyphenyl)sulfonyll-A/-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI+) m/z ; MS (ESI-) m/z. Example 458: 5-[(3,5-difluorophenyl)sulfonyl]-2-isopropyI-JV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0512] In an analogous manner to Example 454,
[0513] Step 2: 3,5-difluorophenyl boronic acid was used to prepare 5-|"(3,5- difluoroplienyl)sulfonyl]-2-isopropyl-iV:-(2-pyridin-2-ylethyl')benzenesulfonamide. MS (ESI+) m/z 481; MS (ESI-) m/z 479.
Example 459 : 2-cyclohexyl-5-(phenylsulfonyl)-iV-(2-pyridin-2-ylethyl)benzenesulfonamide
[0514] Step 1 : Following the same procedure described in Example 474 (Step 1), 2- cyclohexylbromobenzene was used to prepare 2-cyclohexyl-N-(2-pyridin-2- ylethyDbenzenesulfonamide.
MS (ESI+) m/z 345; MS (ESI-) m/z 343.
[0515] Step 2: Following the same procedure described in Example 474 (Step 2), 2- cyclohexyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepare 5-bromo-2- cyclohexyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI+) m/z 423; MS (ESI-) m/z 421.
[0516] Step 3: Following the same procedure described in Example 409 (Step 2), 5- bromo-2-cyclohexyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepare 4^ cyclohexyl-3 - { |Y2-pyridin-2-y lethy Dammo] sulfonyl } benzenesulfinic acid.
[0517] Step 4: Following the same procedure in Example 409 (Step 3), 4-cyclohexyl-3- {[(2-pyridin-2-ylethyl)amino]sulfonyl}benzenesulfinic acid and phenyl boronic acid was used to prepare 2-cyclohexyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI+) m/z 485; MS (ESI-) m/z 483.
Example 460: 2-cyclohexyl-5-[(4-fluorophenyl)sulfonyl]-Λ/-(2-pyridin-2- ylethyl)benzenesulfonamide
[0518] In an analogous manner to Example 459, [0519] Step 4: 4-fluorophenyl boronic acid was used to prepare 2-cyclohexyl-5-[(4- fluorophenyl)sulfonyl1-A/-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI+) m/z 503; MS (ESI-) m/z 501.
Example 461 : 2-fer/-butyl-5-(phenylsulfonyI)-iV-(2-py ridin-2-ylethyl)benzenesuIfonamide
[0520] Step 1 : To a stirred solution of 2-tertbutylbenzenethiol (4.72 g, 28.4 mmol) in concentrated sulfuric acid (90 niL) at 0 °C was added 6% sodium hypochlorite solution (426 niL) dropwise. The resulting mixture was extracted with methylene chloride. Triethylamine (10.0 mL, 71.7 mmol) and 2-(2-aminoethyl)pyridine (4.0 mL, 33.4 mmol) were added and the mixture was stirred 30 minutes, washed with a saturated aqueous ammonium chloride solution and concentrated. Flash column separation with 50% ethyl acetate/ hexane gave 2-fert-butyl-iV- (2-pyridin-2-ylethvDbenzenesulfonamide (3.29 g, 36%). MS (ESI+) m/z 319; MS (ESI-) m/z 317.
[0521] Step 2: Following the same procedure described in Example 474 (Step T), 2- tert-butyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepare 5-bromo-2-fert-butyl- N-(2-pyridin-2-ylethyl)benzenesulfonamide.
[0522] Step 3: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-tert-butyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide and phenyl sulfonyl fluoride were used to prepare 2-fert-butyl-5-(phenylsulfonyl)-.A/-('2-pyridin-2- ylethvDbenzenesulfonamide. MS (ESI+) m/z 459.
Example 462: N-[l-(2-methoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0523] To a slurry of 2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide (50 mg, 0.13 mmol) and moφhlinomethyl-polystyrene (170 mg, 62 mmol) in dichloromethane (8 mL) was added 2-anisolyl chloride (65 mg, 0.38 mmol). The reaction was rotated on an orbital shaker overnight. Then aminomethylated-polystyrene (150 mg, 0.33 mmol) was added to the reaction and it was rotated for addition four hours. The reaction was then filtered and the resin was washed alternately with 10% dichloromethane/methanol (3 x 6 mL). The crude residue was purified using automated flash chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N- F 1 -(2-methoxybenzoyl)piperidin-4-yH-2- methyl-5- (phenylsulfonyl)benzenesulfonamide (52 mg, 78 %). MS (ES+) m/z 529.
Example 463: N-[l-(3-methoxybenzoyl)piperidin-4-yl]-2-methyI-5- (phenylsulfonyl)benzenesulfonamide
[0524] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 3- anisolyl chloride were used to prepare N-[I -(3- methoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 529.
Example 464: N-[l-(3,4-dimethoxybenzoyl)piperidin-4-yI]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0525] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 3,4-dimethoxybenzene-l-carbonyl chloride were used to prepare N-[l-(3,4-dimethoxybenzoyl)piperidm-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 559.
Example 465: 2-methyl-5-(phenylsulfonyI)-N-{l-[3-(trifluoromethyl)benzo^l]piperidin-4- yl}benzenesulfonamide
[0526] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidm-4-ylbenzenesulfonamide and 3-(trifluoromethyl)benzoyl chloride were used to prepare 2-methyl-5-(phenylsulfonyl)-N-π-r3-('trifluoromethyl)benzoyllpiperidm-4- yl} benzenesulfonamide. MS (ES+) m/z 567.
Example 466: N-[l-(4-chlorobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide [0527] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 4-chlorobenzoic acid chloride were used to prepare N-[I- (4-chlorobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 533.
Example 467: N-[l-(4-methoxybenzoyl)piperidin-4-yI]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0528] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 4-anisoyl chloride were used to prepare N-Fl -(4- methoxybenzoyl')piperidin-4-vn-2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 529.
Example 468: 2-methyl-N-[l-(4-methylbenzoyI)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide
[0529] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 4-methylbenzoyl chloride were used to prepare 2-methyl- N-["l-(4-methylbenzovDpiperidin-4-yll-5- (phenylsulfonyDbenzenesulfonamide. MS (ES+) m/z 513.
Example 469: N-[l-(methoxyacetyl)piperidm-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0530] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and methoxyacetic acid chloride were used to prepare N-[I- (methoxyacetyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl*)benzenesulfonamide. MS (ES+) m/z 467.
Example 470: 2-methyl-N-[l-(phenylacetyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide
[0531] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and α-toluyl chloride were used to prepare 2-methyl-N-[l- (phenylacetyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 513. Example 471 : N-[l-(cyclohexyIcarbonyl)piperidin-4-yI]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0532] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and cyclohexanecarbonyl chloride were used to prepare N-[I- rcvclohexylcarbonyl)piperidin-4-vn-2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 505.
Example 472: 2,6-dimethyl-3-(phenylsulfonyI)-N-(2-pyridin-2-ylethyl)benzenesuIfonamide [0533] Step 1 : Following the same procedure described in Example 1 (Step 1), 2- bromo- 1,3 -dimethyl benzene was used to prepare 3-bromo-2,4-dimethylbenzenesulfonyl chloride.
[0534] Step 2: Following the same procedure described in Example 230 (Step 1), 3- bromo-2,4-dimethylbenzenesulfonyl chloride was used to prepare 2-bromo- 1 ,3-dimethyl-4-
(phenylsulfonvDbenzene.
[0535] Step 3: Following the same procedure described in Example 474 (Step 1), 2- bromo-l,3-dimethyl-4-(phenylsulfonyl)benzene was used to prepare 2,6-dimethyl-3-
(phenylsulfonyD-A/-(2-pyridin-2-ylethyDbenzenesulfonamide.
MS (ESI+) m/z 431;
MS (ESI-) m/z 429.
Example 473: 2,6-dimethyl-3-(phenylsulfonyl)-iV-(tetrahydro-2i/-pyraii-4- yl)benzenesulfbnamide
[0536] In an analogous manner to Example 472,
[0537] Step 3: tetrahydropyran-4-ylamine was used to prepare 2,6-dimethyl-3- (phenylsulfonyl)-iV-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide. MS (ESI+) w/z 410; MS (ESI-) m/z 408.
Example 474: 5-{[5-(dimethylamino)-l-naphthyl]sulfonyl}-2-isopropyl-Λ'-(2-pyridin-2- ylethyl)benzenesulfonamide
[0538] Step 1 : To a stirred solution of 2-bromoisopropylbenzene (10.0 g, 50.2 mmol) in THF (350 mL) at -78°C was added n-butyl lithium 2.5 M in hexane (14.0 niL, 35.0 mmol) dropwise. After 10 minutes, sulfur dioxide was bubbled in over a period of 30 minutes. The solution was allowed to warm to room temperature and stirred for 2 hours. The solution was concentrated and taken up in methylene chloride (300 mL). N-chlorosuccinimide (8.1 g, 60.6 mmol) was added and the solution was stirred 1.5 hours at room temperature. 2-(2- aminoethyl)pyridine (7.2 mL, 60.2 mmol) was added and the solution was stirred an additional 45 minutes at room temperature, washed with a saturated aqueous ammonium chloride solution. The organic layer was dried over magnesium sulfate and concentrated. Trituration with ether gave 2-isopropyl-iV-(2-pyridm-2-ylethyl)benzenesulfonamide (8.67 g, 56%). MS (ESI) m/z 305.
[0539] Step 2: To a stirred solution of 2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide (10.0g, 32.8mmol) in 90% concentrated sulfuric acid (110 mL) was added N-bromosuccinimide (5.85 g, 32.8 mmol) at room temperature and the solution was stirred 15 minutes. The solution was chilled in an ice bath and 25% sodium hydroxide was slowly added to pH 9. The solution was extracted several times with ethyl acetate. The organic layers were combined, dried over magnesium sulfate, and concentrated. Trituration with ether gave 5^ bromo-2-isopropyl-N-(2-pyridin-2-ylethvDbenzenesulfonamide (6.0 g, 48%). MS (ESI+) m/z 383; MS (ESI-) m/z 381.
[0540] Step 3: To a stirred solution of dansyl chloride (1.0 g, 3.70 mmol) in acetonitrile (3 mL), was added potassium fluoride (0.86 g, 14.8 mmol) and 18-crown-6 (0.05 g, 0.19 mmol). The resulting solution was stirred overnight at room temperature. The solution was diluted with D.I. water and extracted several times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and concentrated to give dansyl fluoride (0.50 g, 53%).
[0541] Step 4: To a stirred solution of 5-bromo-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide (0.30 g, 0.78 mmol) in THF (3 mL) at 0 °C was added methyl magnesium bromide 1.4 M in 75% toluene/THF (0.6 mL, 0.84 mmol). The reaction was stirred 10 minutes, then cooled to -78 °C and n-butyl lithium 2.5 M in hexane (0.35 mL, 0.87 mmol) was added dropwise. The reaction was stirred an additional 10 minutes. The reaction was warmed to 0 °C and dansyl fluoride (0.20 g, 0.79 mmol) was added. The reaction was stirred overnight at room temperature, partitioned between ammonium chloride solution and ethyl acetate. The organic layer was concentrated and HPLC separated to give 5-{[5- ( dimethylamino)- 1 -naphthyll sulfony 1 > -2-isopropyl-N-f 2-pyridin-2-ylethvDbenzenesulfonamide (0.05 g, 12%).
MS (ESI+) m/z 538;
MS (ESI-) m/z 536.
Example 475: N-[l-(cyclopropylcarbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0542] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and cyclopropanecarbonyl chloride were used to prepare N- [l-fcyclopropylcarbonyl)piperidin-4-yll-2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 463.
Example 476: N-[l-(4-cyanobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0543] In an analogous manner to Example 462, 2-methy 1-5 -(phenylsulfony I)-N- piperidin-4-ylbenzenesulfonamide and 4-(chlorocarbonyl)benzonitrile were used to prepare N- [l-(4-cyanoben2oyDpiperidin-4-yl]-2-methyl-5- (phenylsulfonvDben2enesulfonamide. MS (ES+) m/z 524.
Example 477: N-[l-(3-cyanobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0544] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 3-cyanobenzoyl chloride were used to prepare N-[I -(3- cyanobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 524.
Example 478: 2-methyl-N-[l-(methylsulfonyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide
[0545] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and methanesulfonyl chloride were used to prepare 2-methyl- N-[l-(methylsulfonyl)piperidin-4-yll-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) rø/z 473. Example 479: N-(l-acetylpiperidin-4-yl)-2-methyI-5-(phenylsulfonyl)benzenesulfonamide
[0546] In an analogous manner to Example 462, 2-methy 1-5 -(phenylsulfony I)-N- piperidin-4-ylbenzenesulfonamide and acetyl chloride were used to prepare N-(I -acetylpiperidin- 4-yl)-2-methyl-5-(phenylsulfonyDbenzenesulfonamide. MS (ES+) m/z ASl.
Example 480: N-(4-{[4-({[2-methyI-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidin-l- yl]carbonyl}phenyl)acetamide
[0547] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 4-acetamidobenzoyl chloride were used to prepare N-(4- { \4-( { r2-methyl-5-(phenylsulfonvDphenyl] sulfonyl } amino)piperidm- 1 - yl") carbonyl } phenvDacetamide . MS (ES+) m/z 556.
Example 481 : 2-methyI-N-{l-[(l-methyl-lH-imidazoI-4-yI)sulfonyl]piperidin-4-yl}-5- (phenylsulfonyl)benzenesulfonamide
[0548] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and l-methylimidazole-4-sulfonyl chloride were used to prepare 2-methy 1-N- { 1 - [( 1 -methyl- 1 H-imidazol-4-vDsulfony llpiperidin-4-yl > -5- CphenylsulfonyDbenzenesulfonamide. MS (ES+) m/z 539.
Example 482 : 2-methyl-5-(phenylsulfonyl)-N- [l-(2-thienylsulfonyl)piperidin-4- yl]benzenesulfonamide
[0549] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 2-thiophenesulfonyl chloride were used to prepare 2z methyl-5-(phenylsulfonyl')-N-['l-('2-thienylsulfonyl)piperidin-4- yllbenzenesulfonamide.
MS (ES+) m/z 541.
Example 483: N-(l-{[5-(dimethyIamino)-l-naphthyl]sulfonyl}piperidin-4-yl)-2-methyl-5- (phenylsulfonyl)benzenesulfonamide [0550] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and dansyl chloride were used to prepare N-(I-I [5- (dimethylaminoVl-naphthyl1sulfonyl)piperidin-4-yl)-2-methyl-5- (phenylsulfonyl)benzenesulfonamide.
MS (ES+) m/z 628.
Example 484: N-[l-(l,3-benzodioxoI-5-ylcarbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0551] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 1 ,3-benzodioxole-5-carbonyl chloride were used to prepare N-[I -(1 ,3-benzodioxol-5-ylcarbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyDbenzenesulfonamide. MS (ES+) m/z 543 MS (ES-) m/z 541.
Example 485: N-[l-(isoxazol-5-ylcarbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0552] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 5-isoxazolecarbonyl chloride were used to prepare N-[I- (isoxazol-5-ylcarbonvDpiperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 490.
Example 486: N-[l-(N,N-dimethylglycyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0553] In an analogous manner to Example 462, 2-methy 1-5 -(phenylsulfony I)-N- piperidin-4-ylbenzenesulfonamide and dimethylaminoacetyl chloride hydrochloride were used to prepare N-[I -(TSf ,N-dimethylgly cy l)piperidin-4-yl1 -2-methyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 480.
Example 487: prop-2-yn-l-yl 4-({[2-methyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine- 1-carboxylate [0554] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and propargylchloroformate were used to prepare prop-2-yn- 1 -y 1 4-( { r2-methy 1-5 -(phenylsulfonvDphenyl] sulfony 11 amino)piperidine- 1 -carboxy late . MS (ES+) m/z All MS (ES-) m/z 475.
Example 488: methyl 4-({[2-methyl-5-(phenylsuIfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate
[0555] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfbnyl)-N- piperidin-4-ylbenzenesulfonamide and methylchloroforrnate were used to prepare methyl 4-(([2- methyl-5-(phenylsulfonyl)plienyl1sulfonyl}ammo)piperidine-l- carboxylate. MS (ES+) m/z 453 MS (ES-) m/z 451.
Example 489: 2-methoxyphenyl 4-({[2-methyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate
[0556] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 2-methoxyphenylchloroformate were used to prepare 2z methoxyphenyl 4-f { [2-methy 1-5 - (pheny lsulfonyDpheny 1] sulfonyl > amino)piperidine- 1 - carboxylate. MS (ES+) m/z 545 MS (ES-) m/z 543.
Example 490: N-(tert-butyl)-4-({[2-methyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine- 1-carboxamide
[0557] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and t-butylisocyanate were used to prepare N-(tert-butyl>4- ({ β-methyl-S-fphenylsulfonyDphenv^sulfonyllamino^piperidine- 1 -carboxamide. MS (ES+) m/z 494 MS (ES-) m/z 492. Example 491: N-cyclohexyl-4-({[2-methyI-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxamide
[0558] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and cyclohexylisocyanate were used to prepare N-cyclohexyl- 4-( { [2-methyl-5 -(phenylsulfony Dpheny 1] sulfonyl } amino)piperidine- 1 - carboxamide . MS (ES+) m/z 520; MS (ES-) m/z 518.
Example 492: 5-[(3-chloro-5-cyanophenyl)sulfonyl]-2-methyI-JV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0559] In an analogous manner to Example 409,
[0560] Step 3: 3-chloro-5-cyanophenyl boronic acid was used to prepare 5-r(3-chloro- 5-cyanopb.enyl)sulfonyl1-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES-) m/z 474.0.
Example 493: JV-[3-(l#-imidazol-l-yl)propyl]-2-methyl-3- (phenylsulfonyl)benzenesulfonamide
[0561] In an analogous manner to Example 302, l-(3-aminopropyl)-imidazole was used to prepare N- [3 -( 1 H-imidazol- 1 -yDpropyll -2-methyl-3 -(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z All.9; HRMS: calcd for C19H21N3O4S2 + H+, 420.10462; found (ESI, [M+H]+), 420.1049.
Example 494: 2-methyl-3-(phenylsulfonyl)-iV-(2-pyridm-2-ylethyl)benzenesulfonamide
[0562] In an analogous manner to Example 302, 2-(2-aminoethyl)-pyridine was used to prepare 2-methyl-3-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES-) m/z 414.9; HRMS: calcd for C20H20N2O4S2 + H+, 417.09372; found (ESI, [M+H]+), 417.0934.
Example 495: 2-methyl-ΛL(2-morpholin-4-yIethyl)-3-(phenylsulfonyl)benzenesulfonamide
[0563] In an analogous manner to Example 302, 1-ethylaminomorpholine was used to prepare 2-methyl-N-(2-moφholin-4-ylethyl)-3-(phenylsulfonyl)benzenesulfonamide (0.28g,
>%). MS (ES-) m/z 422.9;
HRMS: calcd for C19H24N2O5S2 + H+, 425.11994; found (ESI, [M+H]+), 425.1211.
Example 496: 2-methyl-N-[l-(2-naphthoyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide
[0564] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 2-naphthalenecarbonyl chloride were used to prepare 2; methyl-N-[l-(2-naphthoyl)piperidin-4-yll-5-(phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 549 MS (ES-) m/z 547 HRMS: calcd. for C29H28N2O5S2 + H+, 549.15124: found (ESI, [m+H]*), 549.15026.
Example 497: 2-methyl-5-(phenylsulfonyl)-N-[l-(2-thienylcarbonyl)piperidin-4- yl] benzenes ulfonamide
[0565] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 2-thenoyl chloride were used to prepare 2-methyl-5- (phenylsulfonyl)-N-[l-(2-thienylcarbonyl)piperidin-4- yl1benzenesulfonamide. MS (ES+) m/z 505 MS (ES-) m/z 503 HRMS: calcd. for C23H24N2O5S3 + H+, 505.092564: found (ESI, [m+H]+), 505.0947.
Example 498: isobutyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine- 1- carboxylate
[0566] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and isobutyl chloroformate were used to prepare isobutyl 4- d[2-methyl-5-(phenylsulfonyl)phenvnsulfonyl}amino)piperidine-l- carboxylate. MS (ES+) m/z 495 MS (ES-) m/z 493 HRMS: calcd. for C23H30N2O6S2 + H+, 495.16181: found (ESI, [m+H]+), 495.16266.
Example 499 : N- {1 - [4-(dimethy lamino)benzoyl] piperidin-4-y 1} -2-methy 1-5- (phenylsulfonyl)benzenesulfonamide [0567] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N~ piperidin-4-ylbenzenesulfonamide and 4-dimethylaminobenzoyl chloride were used to prepare N-(I -[4-f dimethylamino)benzoyHpiperidin-4-yU -2-methyl-5- (phenylsulfonypbenzenesulfonamide. MS (ES+) m/z 542 MS (ES-) m/z 540 HRMS: calcd. for C27H31N3O5S2 + H+, 542.17779: found (ESI, [m+H]+), 542.17725.
Example 500: 4-fluorophenyl 4-({[2-methyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine- l-carboxylate
[0568] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 4-fluorophenylchloroformate were used to prepare 4; fluorophenyl 4-(([2-methyl-5-(phenylsulfonyl)phenyl1sulfonyl}amino)piperidine- l-carboxylate. MS (ES+) m/z 533 MS (ES-) m/z 531 HRMS: calcd. for C25H25FN2O6S2 + H+, 533.12109: found (ESI, [m+H]+), 533.12157.
Example 501: N-ethyl-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine- 1- carboxamide
[0569] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and ethylisocyanate were used to prepare N-ethyl-4-C-f|~2- methyl-5-f phenylsulfonyDphenyll sulfony 1 } amino)piperidine- 1 - carboxamide . MS (ES+) m/z 466 MS (ES-) m/z 464 HRMS: calcd. for C21H27N3O5S2 + H+, 466.14649: found (ESI, [m+H]+), 466.14684.
Example 502: 2-methyl-N-[l-(morpholin-4-yIcarbonyl)piperidin-4-yI]-5- (plienylsulfonyl)benzenesulfonamide
[0570] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 4-morpholinecarbonyl chloride were used to prepare 2a methyl-N-[l-(moφholin-4-ylcarbonyl')piperidin-4-yll-5- ('phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 508 MS (ES-) m/z 506
HRMS: calcd. for C23H29N3O6S2 + H+, 508.15706: found (ESI, [m+H]+)5 508.15678.
Example 503: N,N-dimethyl-4-({[2-methyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxamide
[0571] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-n- piperidin-4-ylbenzenesulfonamide and dimethylcarbamyl chloride were used to prepare N,N- dimethyl-4-r{r2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxamide. MS (ES+) m/z 466 MS (ES-) m/z 464 HRMS: calcd. for C21H27N3O5S2 + H+, 466.14649: found (ESI, [m+H]+), 466.14672.
Example 504: N-[l-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide
[0572] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-n- piperidin-4-ylbenzenesulfonamide and t-butylacetyl chloride were used to prepare N-[I -(3,3- dimethylbutanoyl)piperidin-4-yl]-2-methyl-5- fphenylsulfonvDbenzenesulfonamide. MS (ES+) rø/z 493 MS (ES-) m/z 491 HRMS: calcd. for C24H32N2O5S2 + H+, 493.183092: found (ESI, [m+H]+), 493.1813.
Example 505: 5-[(3,5-dichlorophenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0573] Step 1 : Following the same procedure described in Example 474 (Step 3), 3,5- dichlorobenzene sulfonyl chloride was used to prepare 3,5-dichlorobenzene sulfonyl fluoride.
[0574] Step 2: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide and 3,5-dichlorobenzene sulfonyl fluoride were used to prepare 5 - [Y3 , 5-dichlorophenyl)sulfonyl] -2-isopropyl-./V-(2- pyridin-2-ylethyDbenzenesulfonamide. MS (ESI) m/z 513; MS (ESI) m/z 511; HRMS: calcd for C22H22Cl2N2O4S2 + H+, 513.04708; found (ESI-FTMS, [M+H]1+), 513.04709. Example 506: 2-isopropyI-iV-(2-pyridin-2-yIethyl)-5-{[3- (trifluo romethoxy)pheny 1] sulf ony 1} benzenesulf onamide
[0575] In an analogous manner to Example 454,
[0576] Step 2: 3 -trifluoromethoxy phenyl boronic acid was used to prepare 2-isopropyl- N-(2-pyridin-2-ylethylV5-(r3-(trifluoromethoxy)phenyl]sulfonyl'}benzenesulfonamide. MS (ESI) m/z 529; MS (ESI) m/z 527; HRMS: calcd for C23H23F3N2O5S2 + H+, 529.10732; found (ESI-FTMS, [M+H]1+), 529.10719.
Example 507: 5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0577] In an analogous manner to Example 454,
[0578] Step 2: 4-dimethylaminophenyl boronic acid was used to prepare 5-{[4- (dimethylamino)phenyl1sulfonyl}-2-isopropyl-N-(2-pyridin-2-ylethyDbenzenesulfonamide. MS (ESI) m/z 488; MS (ESI) m/z 486; HRMS: calcd for C24H29N3O4S2 + H+, 488.16722; found (ESI-FTMS, [M+H]1+), 488.16721.
Example 508: 2~isopropyl-iV-(2-pyridin-2-ylethyl)-5-{[3- (trifluoromethyl)phenyl]sulfonyl}benzenesulfbnamide
[0579] Step 1 : Following the same procedure described in Example 474 (Step 3), 3- trifluoromethylbenzene sulfonyl chloride was used to prepare 3-trifluoromethylbenzene sulfonyl fluoride.
[0580] Step 2: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide and 3-trifluoromethylbenzene sulfonyl fluoride were used to prepare 2-isopropyl-iV-(2-pyridin-2-ylethyl')-5- { [3 - (trifluoromethyl)phenyl] sulfonyl} benzenesulfonamide. MS (ESI) m/z 513; MS (ESI) m/z 511; HRMS: calcd for C23H23F3N2O4S2 + H+, 513.11241; found (ESI-FTMS, [M+H]1+), 513.11169. Examle 509: 5-[(5-chIoro-2-methoxyphenyl)suIfonyI]-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0581] Step 1 : Following the same procedure described in Example 474, (Step 3), 5- chloro-2-methoxybenzene sulfonyl chloride was used to prepare 5-chloro-2-methoxybenzene sulfonyl fluoride.
[0582] Step 2: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide and 5-chloro-2-methoxybenzene sulfonyl fluoride were used to prepare 5-[f5-chloro-2-methoxyphenyl)sulfonyl1-2-isopropyl-iV- (2-pyridin-2-ylethyl)benzenesulfbnamide. MS (ESI) m/z 509; MS (ESI) m/z 507; HRMS: calcd for C23H25ClN2O5S2 + H+, 509.09662; found (ESI-FTMS, [M+H]1+), 509.0966.
Example 510: 2-isopropyI-Λ?-(2-pyridiii-2-ylethyI)-5-(quinolra-8- ylsulfonyl)benzenesulfonamide
[0583] Step 1 : Following the same procedure described in Example 474, (Step 3), quinolin-8 -sulfonyl chloride was used to prepare quinolin-8-sulfonyl fluoride.
[0584] Step 2: Following the same procedure described in Example 474, (Step 4), 5- bromo-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide and quinolin-8-sulfonyl fluoride were used to prepare 2-isopropyl-iV-(2-pyridin-2-ylethylV5-('quinolin-8- ylsulfonvDbenzenesulfonamide. MS (ESI) m/z 496; MS (ESI) m/z 494; HRMS: calcd for C25H25N3O4S2 + H+, 496.13592; found (ESI-FTMS, [M+H]1+), 496.13588.
Example 511: 5-[(2,5-dichloro-3-thienyl)sulfonyl]-2-isopropyl~iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0585] Step 1 : Following the same procedure described in Example 474, (Step 3), 2,5- dichlorothiophene-3 -sulfonyl chloride was used to prepare 2,5-dichlorothiophene-3-sulfonyl fluoride.
[0586] Step 2: Following the same procedure described in Example 474, (Step 4), 5- bromo-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide and 2,5-dichlorothiophene-3- sulfonyl fluoride were used to prepare 5-[(2,5-dichloro-3-thienvDsulfonyl"|-2-isopropyl-iV'-('2- pyridin-2-ylethyl)benzenesulfonamide.
MS (ESI) m/z 519;
MS (ESI) m/z 517;
HRMS: calcd for C20H20Cl2N2O4S3 + H+, 519.00350; found (ESI-FTMS, [M+H]1+), 519.00298.
Example 512: 5-[(5-chloro-l,3-dimethyl-lJϊr-pyrazoI-4-yl)suIfonyl]-2-isopropyl-Λ':-(2- pyridin-2-yIethyl)benzenesulfonamide
[0587] Step 1 : Following the same procedure described in Example 474, (Step 3), 5- chloro-l,3-dimethyl-lH-pyrazole-4-sulfonyl chloride was used to prepare 5-chloro-l ,3-dimethyl- lH-pyrazole-4-sulfonyl fluoride.
[0588] Step 2: Following the same procedure described in Example 474, (Step 4), 5- bromo-2-isopropyl-N-(2-pyridm-2-ylethyl)benzenesulfonamide and 5-chloro-l ,3-dimethyl-lH- pyrazole-4-sulfonyl fluoride were used to prepare 5 - [Y5-chloro- 1 ,3 -dimethyl- 1 H-pyrazol-4- yDsulfonyl]-2-isopropyl-N-f2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI) m/z 497; MS (ESI) m/z 495; HRMS: calcd for C21H25ClN4O4S2 + H+, 497.10785; found (ESI, [M+H]+), 497.1062.
Example 513: 2-isopropyl-5-[(l-methyl-ljHr-imidazol-4-yl)suIfonyl]-Λ'-(2-pyridin-2- ylethyl)benzenesulfonamide
[0589] Step 1 : Following the same procedure described in Example 474, (Step 3), 1- methyl-lH-imidazole-4-sulfonyl chloride was used to prepare 1 -methyl- 1 H-imidazole-4-sulfony 1 fluoride.
[0590] Step 2: Following the same procedure described in Example 474, (Step 4), 5- bromo-2-isopropy l-iV-(2-pyridin-2-y lethy l)benzenesulfonamide and 1 -methyl- 1 H-imidazole-4- sulfonyl fluoride were used to prepare 2-isopropyl-5-r(l-methyl-lH-imidazol-4-yl)sulfonyl1-iV- (2-pyridin-2-ylethyDbenzenesulfonamide. MS (ESI) m/z 449; MS (ESI) m/z 441; HRMS: calcd for C20H24N4O4S2 + H+, 449.13117; found (ESI, [M+H]+), 449.133. Exaraple 514: 5-[(3-chloro~2-methyIphenyl)suIfonyl]-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0591] Step 1 : Following the same procedure described in Example 474, (Step 3), 3- chloro-2-methylbenzene sulfonyl chloride was used to prepare 3 -chloro-2-methylbenzene sulfonyl fluoride.
[0592] Step 2: Following the same procedure described in Example 474, (Step 4), 5- bromo-2-isopropy l-iV-(2-pyridin-2-ylethy l)benzenesulfonamide and 3 -chloro-2-methylbenzene sulfonyl fluoride were used to prepare 5-[(3-chloro-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2- pyridin-2-ylethyl)benzenesulfonamide. MS (ESI) m/z 493; MS (ESI) m/z 491; HRMS: calcd for C23H25ClN2O4S2 + H+, 493.10170; found (ESI, [M+H]+), 493.1028.
Example 515: 5-[(4,4-dimethyl-2-oxo-l,4-dihydro-2Hr-3,l-benzoxazin-6-yI)sulfonyl]-2- isopropyl-iV-(2-pyridin-2-yIethyl)benzenesulfonainide
[0593] In an analogous manner to Example 454,
[0594] Step 2: 4,4-dimethyl-2-oxo-l,4-dihydro-2/J-3,l-berizoxazin-6-boronic acid was used to prepare 5-[(4,4-dimethyl-2-oxo-l,4-dihydro-2H-3,l-benzoxazin-6-yl')sulfonyll-2- isopropyl-N-(2-pyridm-2-ylethyl)benzenesulfonamide. MS (ES) m/z 542.0; HRMS: calcd for C26H29N3O6S2 + H+, 544.15705; found (ESI-FT/MS, [M+H]1+), 544.1574;
Example 516: 2-metb.yl-5-(phenylsulfonyl)-N-[l-(pyridin-3-ylcarbonyl)piperidin-4- yl] benzenesulfonamide
[0595] In an analogous manner to Example 462, 2-methyl-5-(phenylsulfonyl)-n- piperidin-4-ylbenzenesulfonamide and 3-pyridinecarbonyl chloride were used to prepare 2z methyl-5-("phenylsulfonyl)-N-ri-(pyridm-3-ylcarbonyl)piperidin-4- yl]benzenesulfonamide. MS (ES+) m/z 500 MS (ES-) m/z 498 HRMS: calcd. for C24H25N3O5S2 + H+, 500.131391: found (ESI, [m+H]^, 500.1339. Example 517: tert-butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidine-l-carboxylate
[0596] In an analogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and 4-amino-l-boc-piperidine were used to prepare tert-butyl 4- IY ( 5- |"(4-fluorophenyl)sulfonyl]-2- isopropy lphenyl 1 sulfonyl)amino"jpiperidine- 1 -carboxy late. MS (ES-) m/z 539.
Example 518: N-(l-{[5-(dimethylamino)-l-naphthyI]sulfonyl}piperidin-4-yl)-5-[(4- fluorophenyl)suIfonyl]-2-isopropylbenzenesulfonamide
[0597] In an analogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n- piperidin-4-ylbenzenesulfonamide and dansyl chloride were used to prepare N-(I -{["5- (dimethylaminoVl-naphtliyllsulfonyl}piperidin-4-yl)-5-r(4- fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide. MS (ES+) m/z 61 A MS (ES-) m/z 672.
Example 519: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[l-(methoxyacetyl)piperidin-4- yl] benzenesulfonamide
[0598] In an analogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n- piperidin-4-ylbenzenesulfonamide and methoxyacetic chloride were used to prepare 5-[(4- fluorophenvDsulfonyll -2-isopropy 1-N- [" 1 -(methoxy acetyDpiperidin-4- yl]benzenesulfonamide . MS (ES+) w/z 513 MS (ES-) m/z 511 HRMS: calcd. for C23H29FN2O6S2 + H+, 513.1524: found (ESI, [m+H]+), 513.1525.
Example 520: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4- ylbenzenesulfonamide
[0599] tert-Butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidine-l -carboxy late (0.5 mg, 0.92 mmol) was added to 3 mL of 4 M hydrochloric acid in dioxane and the precipitate was filtered giving the desired 5-[(4- fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide. MS (ES-) m/z 539 HRMS: calcd. for C25H33FN2O6S2 + H+, 558.2102: found (ESI, [m+H]+), 558.211.
Example 521 : N-cyclopropyI-5-[(4-fluorophenyI)sulfonyl]-2-isopropylbenzenesulfonamide
[0600] In an analogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and cyclopropylamine were used to prepare N-cyclopropyl- 5-[(4-fluorophenyl)sulfonyll-2-isopropylbenzenesulfonamide. MS (ES+) rø/_r 398 MS (ES-) m/z 396 HRMS: calcd. for C18H20FNO4S2 + H+, 398.0891: found (ESI, [m+H]+), 398.091.
Example 522: N-cyclobutyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide
[0601] In an analogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and cyclobutylamine were used to prepare N-cyclobutyl-5- [(4-fluorophenyl)sulfonyll-2-isopropylbenzenesulfonamide.
MS (ES+) m/z 412 MS (ES-) m/z 410 HRMS: calcd. for C19H22FNO4S2 + H+, 412.1047: found (ESI, [m+H]+), 412.1059.
Example 523 : N-cyclopentyl-5- [(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide
[0602] In an analogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and cyclopentylamine were used to prepare N-cyclopentyl-5- r(4-fluorophenvDsulfonyll-2-isopropylbenzenesulfonamide. MS (ES+) m/z 426 MS (ES-) m/z 424 HRMS: calcd. for C20H24FNO4S2 + H+, 426.1204: found (ESI, [m+H]+), 426.1211.
Example 524 : N-cy clohexyl-5- [(4-fluorophenyl)sulf onyl] -2-is opropylbenzenesulf onamide
[0603] In an analogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and cyclohexylamine were used to prepare N-cyclohexyl-5- [(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide. MS (ES+) m/z 440 MS (ES-) rø/z 438 HRMS: calcd. for C21H26FNO4S2 + H+, 440.136: found (ESI5 [m+H]+), 440.1373.
Example 525: N-(l-benzylpiperidin-4-yl)-5-[(4-fluorophenyl)suIfonyl]-2- isopropylbenzenesulfonamide
[0604] In an analogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and 4-amino-l-benzylpiperidine were used to prepare N-(I- benzylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl"j-2- isopropylbenzenesulfonamide. MS (ES+) m/z 531 MS (ES-) m/z 529 HRMS: calcd. for C27H31FN2O4S2 + H+, 531.1782: found (ESI, [m+H]+), 531.1785.
Example 526: ethyl 4-[({5-[(4-fluorophenyl)suIfonyl]~2- isopropylphenyl}sulfonyl)amino]piperidine-l-carboxylate
[0605] In an analogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and ethyl 4-amino-l-piperidine carboxylate were used to prepare ethyl 4-[({5-['('4-fluorophenyl)sulfonyl]-2- isopropylphenyl|sulfonyl)aminolpiperidine-l- carboxylate. MS (ES+) m/z 513 MS (ES-) m/z 511 HRMS: calcd. for C23H29FN2O6S2 + H+, 513.1524: found (ESI, [m+H]+), 513.1536.
Example 527: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-l- ylethyl)benzenesulfonamide
[0606] In an analogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and l-(2-aminoethyl)piperidine were used to prepare 5-IY4- fluorophenyl)sulfonyrj-2-isopropyl-N-f 2-piperidin- 1 - ylethvDbenzenesulfonamide. MS (ES+) m/z 469 MS (ES-) m/z 467 HRMS: calcd. for C22H29FN2O4S2 + H+, 469.1626: found (ESI, [m+H]+), 469.1632.
Example 528: tert-bufyl 4-{[(2-isopropyl-5-{[4- (methylamino)phenyl]sulfonyl}phenyl)sulfonyl]amino}piperidine-l-carboxylate [0607] To a solution of methylamine in ethanol (2.0 mL, 2.0 M) was added tert-butyl 4- [({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidine-l-carboxylate (350 mg, 0.64 mmol) and the reaction was heated to 130 0C for 30 minutes in the microwave. The reaction mixture was concentrated and purified by automated flash chromatography using a gradient of 20% to 100% ethyl acetate/hexane resulting in the isolation of 353 mg of tert-butyl 4- { [(2-isopropyl-5-{ [4- (methylamino)phenyl]sulfonyl}phenyl)sulfonyl]amino}piperidine-l - carboxylate. MS (ES-) m/z 550.
Example 529: N-(l-acetylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyI]-2- isopropylbenzenesulfonamide
[0608] In an analogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n- piperidin-4-ylbenzenesulfonamide and acetyl chloride were used to prepare N-(I -acetylpiperidin- 4-yl)-5-[(4-fluorophenyDsulfonyl]-2- isopropylbenzenesulfonamide. MS (ES+) m/z 483 MS (ES-) m/z 481 HRMS: calcd. for C22H27FN2O5S2 + H+, 483.142370: found (ESI, [m+H]+), 483.143.
Example 530: N-[l-(cyclopropylcarbonyl)piperidin-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide
[0609] In an analogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n- piperidin-4-ylbenzenesulfonamide and cyclopropylcarbonyl chloride were used to prepare N-[I- (cyclopropylcarbonyl')piperidin-4-yl]-5-[(4-fluorophenyl')sulfonyl]-2- isopropylbenzenesulfonamide. MS (ES+) m/z 509 MS (ES-) m/z 507 HRMS: calcd. for C24H29FN2O5S2 + H+, 509.158019: found (ESI, [m+H]+), 509.1589.
Example 531 : N-[l-(4-cyanobenzoyl)piperidin-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide [0610] In an analogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 4-cyanobenzoyl chloride were used to prepare N- [1 -(4- cvanobenzovπpiperidin-4-yl1-5-[r4-fluorophenyl)sulfonyl1-2- isopropylbenzenesulfonamide. MS (ES+) m/z 570 MS (ES-) m/z 568.
Example 532: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydrofuran-2- ylmethyl)benzenesulfonamide
[0611] In an analogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and tetrahydrofurfurylamine were used to prepare 5-[C4- fluorophenvDsulfonyll^-isopropyl-N-Ctetrahydrofuran^- ylmethvDbenzenesulfonamide. MS (ES+) m/z 442 MS (ES-) m/z 440.
Example 533: 5-[(4-fluorophenyI)sulfonyl]-2-isopropyl-N-(2-pyridin-4- ylethyl)benzenesulfonamide
[0612] In an analogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and 4-(2-aminoethyl)pyridine were used to prepare 5-[(4- fluorophenyl)sulfonyl'|-2-isopropyl-N-r2-pyridm-4- ylethyDbenzenesulfonamide. MS (ES+) w/z 463
Figure imgf000184_0001
Example 534: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-3- ylethyl)benzenesulfonamide
[0613] In an analogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and 3-(2-aminoethyl)pyridine were used to prepare 5-|"(4- fluorophenyl')sulfonyll-2-isopropyl-N-(2-pyridin-3- ylethyl)benzenesulfonamide. MS (ES+) m/z 463 MS (ES-) m/z 461 HRMS: calcd. for C22H23FN2O4S2 + H+, 463.116155: found (ESI, [m+H]+), 463.1174. Example 535: 5-({4-[(2-cyanoethyI)amino]phenyI}sulfonyl)-2-isopropyl-iV-(tetrahydro-2JHr- pyran-4-yI)benzenesulfonamide
[0614] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-iV-tetrahydro-2H-pyran-4-ylbenzenesulfonamide and 3-aminopropionitrile in DMA were used to prepare 5-({4-rf2-cvanoethyl)amino]phenyllsulfonyl')-2-isopropyl-N-rtetrahydro- 2ijr-pyran-4-yl)benzenesulfonamide. MS (ES) m/z 490.1;
HPLC purity 96.7% at 210-370 urn, 8.3 min.; 96.9% at 304 ran, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H29N3O5S2 + H+, 492.16214; found (ESI, [M+H]+), 492.1638.
Example 536: 5-({4-[(2-cyanoethyI)amino]phenyl}sulfonyl)-2-isopropyl-iV-(tetrahydro-2JHr- pyran-4-yImethyl)benzenesulfonamide
[0615] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-tetrahydro-2/i-pyran-4-ylmethyl)benzenesulfonamide and 3-aminopropionitrile in DMA were used to prepare 5-({4-[(2-cyanoethyl)amino1phenyUsulfonyl)-2-isopropyl-N- (tetrahydro-2iir-pyran-4-ylmethyl')benzenesulfonamide. MS (ES) m/z 504.1;
HPLC purity 96.7% at 210-370 ran, 8.5 min.; 97.0% at 304 nm, 8.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H31N3O5S2 + H+, 506.17779; found (ESI, [M+H]+), 506.1786.
Example 537: 5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-2-isopropyl-iV-[2-(tetrahydro- 2/f-pyran-4-yl)ethyl]benzenesulfonamide
[0616] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-iV-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide and 3-aminopropionitrile in DMA were used to prepare 5-( {4- [(2-cyanoethyDaminolphenyl} sulfonyl)-2-isopropyl-N- [2- ftetrahydro-2H-pyran-4-yl)ethyl1benzenesulfonamide. MS (ES) m/z 518.2; ΗPLC purity 97.4% at 210-370 nm, 8.7 min.; 97.6% at 304 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C25H33N3O5S2 + H+, 520.19344; found (ESI, [M+H]+), 520.1949.
Example 538: N-(3',6'-dihydroxy-3-oxo-3H-spiro[2-benzofuran-l,9'-xanthen]-5-yl)-4-[({5- [(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]piperidine-l- carbothioamide
[0617] In an analogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n- piperidin-4-ylbenzenesulfonamide and fluorescein isothiocyanate were used to prepare N-(3',6'- dihydroxy-3-oxo-3H-spiro[2-benzofuran-l,9'-xanthenl-5-yl)-4-r({5-r(4-fluorophenyl)sulfonyll- 2-isopropylphenyl} sulfonyl)ammo]piperidine- 1 - carbothioamide. MS (ES+) m/z 830.
Example 539: 5-[(3-cyanophenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0618] In an analogous manner to Example 454,
[0619] Step 2: 3-cyanophenylboronic acid was used to prepare 5-[(3- cyanophenyl)sulfonyl1-2-isopropyl-N-(2-pyridin-2-ylethvDbenzenesulfonamide.
MS (ES) m/z 468.1;
HRMS: calcd for C23H23N3O4S2 + H+, 470.12027; found (ESI, [M+H]+)5 470.1223.
Example 540: 5-(l/Z-indoI-5-ylsulfonyI)-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0620] In an analogous manner to Example 454,
[0621] Step 2: indole-5-boronic acid was used to prepare 5-riϋ/-indol-5-ylsulfonyl)-2- isopropyl-iV-(2-pyridm-2-ylethyl)benzenesulfonamide. MS (ES) m/z 482.1; HRMS: calcd for C24H25N3O4S2 + H+, 484.13592; found (ESI, [M+H]+), 484.1382.
Example 541 : 2-isopropyl-5-[(2-methylphenyl)sulfonyl]-Λr-(tetrahydro-2Jϊ-pyran-4- yl)benzenesulfonamide
[0622] In an analogous manner to Example 474, [0623] Step 1 : 4-amino tetrahydropyran was used to prepare 2-isopropyl-N-(tetrahvdro- 2H-pyran-4-yl)benzenesulfonamide.
[0624] Step 2: 2-isopropyl-N-(tetrahydro-2H"-pyran-4-yl)benzenesulfonamide was used to prepare 5-bromo-2-isopropyl-N-(tetrahvdro-2H-pyran-4-yl)ben2enesulfonamide.
[0625] Step 3: 2-methylphenyl sulfonyl fluoride and 5-bromo-2-isopropyl-iV- (tetrahydro-2/f-pyran-4-yl)benzenesulfonamide were used to prepare 2-isopropyl-5-|"f2- methylphenyl)sulfonyl1-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide. MS (ES) m/z 436.1; HRMS: calcd for C21H27NO5S2 + H+, 438.14034; found (ESI, [M+H]+), 438.1409.
Example 542: 5-[(3-chloro-2-methylphenyl)suIfonyl]-2-isopropyl-iV-(tetrahydro-2/?-pyran- 4-yl)benzenesuIfonamide
[0626] In an analogous manner to Example 541 ,
[0627] Step 3: 5-bromo-2-isopropyl-iV-(tetraliydro-2H-pyran-4-yl)benzenesulfonamide and 3-chloro-2-methylphenyl sulfonyl fluoride were used to prepare 5-[(3-chloro-2- methylphenyl)sulfonyll-2-isopropyl-iV-rtetrahydro-2H-pyran-4-yl)benzenesulfonamide. MS (ES) m/z 470.1; HRMS: calcd for C21H26ClNO5S2 + H+, 472.10137; found (ESI-FTMS, [MH-H]1+), 472.1024.
Example 543: 2-isopropyl-5-{[4-(methylamino)phenyl]suIfonyI}-iV-(tetrahydro-2i3r-pyran- 4-ylmethyl)benzenesulfonamide
[0628] In an analogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-iV-(2-tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide and methylamine were used to prepare 2-isopropyl-5- { [4-(methylamino)phenyl] sulfonyl} -N-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide. MS (ES) m/z 465.2;
HPLC purity 96.6% at 210-370 nm, 9.0 min.; 98.2% at 310 nni, 9.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H30N2O5S2 + H+, 467.16689; found (ESI, [M+H]+), 467.1691. .. H! IH fell ifcii
AM101865 - 187 -
Example 544: 5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-Λr-(tetrahydro-2flr- pyran-4-yl)benzenesulfonamide
[0629] In an analogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N~tetrahydro-2H-pyran-4-ylbenzenesulfonamide and a dimethylamine solution in THF were used to prepare 5-{[4-(dimethylammo)phenyllsulfonyl>-2-isoproρyl-7V-(tetrahydro-2H"- py ran-4-yDbenzenesulfonamide . MS (ES) m/z 465.1;
HPLC purity 96.2% at 210-370 nm, 9.2 min.; 96.2% at 318 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H30N2O5S2 + H+, 467.16689; found (ESI, [M+H]+), 467.1694.
Example 545: 5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-iV-(tetrahydro-2JEr- pyran-4-ylmethyl)benzenesulfonamide
[0630J In an analogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-Λ/-(2-tetrahydro-2ϋ/-pyran-4-ylmethyl)benzenesulfonamide and a dimethylamine solution in THF were used to prepare 5 - { [4-(dimethylamino)pheny 1] sulfony 1} -2-isopropyl-JV- (tetrahydro-2/f-pyran-4-ylmethyl)benzenesulfonamide. MS (ES) m/z 479.2;
HPLC purity 96.3% at 210-370 nm, 9.4 min.; 96.6% at 318 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H32N2O5S2 + H+, 481.18254; found (ESI, (M+H]+), 481.1829.
Example 546: 5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-iV-[2-(tetrahydro-2iϊ- pyran-4-yl)ethyl]benzenesulfonamide
[0631] In an analogous manner to Example 356, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-iV-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide and a dimethylamine solution in THF were used to prepare 5-{[4-(dimethylammo)phenyl]sulfonyl|-2-isopropyl-iV-[2- (tetrahydro-2H-pyran-4-yl)ethyl]benzenesulfonamide. MS (ES) m/z 493.2; HPLC purity 100% at 210-370 nm, 9.6 min.; 99.2% at 318 nm, 9.6 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C24H34N2O5S2 + H+, 495.19819; found (ESI, [M+H]+), 495.1986.
Example 547: 2-isopropyl-5-{[4-(4-methyIpiperazin-l-yl)phenyl]sulfonyl}-iV-(tetrahydro- 2iϊ-pyran-4-yI)benzenesulf6namide
[0632] To a solution of 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-tetrahydro-2H"- pyran-4-ylbenzenesulfonamide (88 mg, 0.2 mmol) in acetonitrile (0.5 mL) was added N- methylpiperazine (101 mg, 0.99 mmol). The solution was heated with stirring using microwave irradiation (150 0C) for 60 minutes. Upon cooling, the reaction mixture was diluted with water (10 mL) and the aqueous phase was extracted with ethyl acetate (3 x 10 mL). The combined organic phases were concentrated and the resulting crude residue was purified using automated flash column chromatography with a graduated mobile phase consisting of dichloromethane and methanol resulting in the isolation of 2-isopropyl-5-f [4-(4-methylpiperazin- 1 - yl)phenyl1sulfonvU-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide (100 mg, 97%). MS (ES) m/z 520.2;
HPLC purity 93.9% at 210-370 nm, 6.7 min.; 95.8% at 300 mn, 6.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H35N3O5S2 + H+, 522.20909; found (ESI, [MH-H]+), 522.2094.
Example 548: 2-isopropyl-5-{[4-(4-methylpiperazin-l-yl)phenyl]sulfonyl}-iV-(tetrahydro- 2/2r-pyran-4-ylmethyl)benzenesulfonamide
[0633] In an analogous manner to Example 547, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-tetrahydro-2/f-pyran-4-ylmethyl)benzenesulfonamide and N-methylpiperazine were used to prepare 2-isopropyl-5-{[4-r4-methylpiperazin-l-yl)phenyl]sulfonyU-N-(tetrahydro-2H- pyran-4-ylmethyl)benzenesulfonamide. MS (ES) m/z 534.2;
HPLC purity 94.8% at 210-370 nm, 7.0 min.; 95.2% at 300 nm, 7.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H37N3O5S2 + H+, 536.22474; found (ESI, [MH-H]+), 536.2244. Example 549: 2-isopropyl-5-{[4-(4-methyIpiperazin-l-yl)phenyl]sulfonyl}-iV-[2- (tetrahydro-2JfiT-pyran-4-yl)ethyl]benzenesulfonamide
[0634] In an analogous manner to Example 547, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-tetrahydro-2H-pyran-4-ylethyl)berizenesulfonamide and N-methylpiperazine were used to prepare 2-isopropyl-5-{[4-(4-methylpiperazin-l-vDphenyl]sulfonyl|-N-['2-('tetrahydro- 2H-pyran-4-yl)ethyl1benzenesulfonamide. MS (ES) m/z 548.2;
HPLC purity 96.1% at 210-370 nm, 7.3 min.; 96.2% at 300 nm, 7.3 min.; Xten-a RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for 10min3 hold 4min. HRMS: calcd for C27H39N3O5S2 + H+, 550.24039; found (ESI, [M+H]+), 550.2411.
Example 550: iV-(2-phenyIethyl)-5-(phenylsulfonyl)-2-propylbenzenesuIfonamide
[0635] Step a) l-(Phenylsulfonyl)-4-propylbenzene
[0636] A stirred solution of n-propylbenzene (2.40 g, 20 mmol) and benzenesulfonyl chloride (3.52 g, 20 mmol) was cooled to -40 °C and treated slowly under nitrogen with solid anhydrous aluminum chloride (3.20 g, 24 mmol). After stirring neat for 4 hours at room temperature, the mixture was slowly poured into ice water and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and filtered through a short column of silica gel. The filtrate was evaporated in vacuo to yield a crude oil, which was crystallized from diethyl ether-hexane to yield 1 -(phenylsulfonyl) 4-propylbenzene (4.57 g, 88%) as a homogeneous, colorless, crystalline solid, m.p. 83-85 °C; MS (+ESI), m/z: 261 [M+H]+; MS (-ESI), m/z: 259 [M-H]";
HRMS: calcd for C15H16O2S, 260.08710; found (EI, M+.), 260.0876; HPLC purity 100% at 210-370 nm, 9.8 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
[0637] Step b) 5-Benzenesulfonyl-2-propyl-benzenesulfonyl chloride
[0638] 1 -(Phenylsulfonyl) 4-propylbenzene (2.60 g, 10 mmol) was heated with stirring at 60 °C for one hour under nitrogen with chlorosulfonic acid (6.7 mL, 11.7 g, 100 mmol). The mixture was cooled to room temperature, poured slowly into a cold solution of IN hydrochloric acid, and extracted with ethyl acetate (2x.). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated in vacuo to a crude oil. The crude oil was crystallized from diethyl ether-hexane to afford 5-benzenesulfonyl-2-propyl-benzenesulfonyl chloride (3.51 g, 98%) as a homogeneous, colorless, crystalline solid, which was utilized in subsequent reactions.
[0639] Step c) N-(2-Phenylethyl)-5-(phenylsulfonyl)-2-propylbenzenesulfonamide [0640] A stirred solution of 5-benzenesulfonyl-2-propyl-benzenesulfonyl chloride (0.18 g, 0.5 mmol) in dichloromethane (10 niL) was treated dropwise under nitrogen with a solution of phenethylamine (0.12 g, 1.0 mmol) in dichloromethane. After stirring for one hour at room temperature, or until the reaction was complete, the mixture was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min. After evaporation of the solvent under vacuum, the title compound, N-(2-phenylethyl)-5- (phenylsulfonyl>2-propylbenzenesulfonamide (0.17 g, 77%), was obtained as a homogeneous, clear oil;
MS (-ESI), m/z: 442.1 [M-H]";
HRMS: calcd for C23H25NO4S2 + H+, 444.12978; found (ESI, [M+H]+), 444.1323; HPLC purity 100% at 210-370 rnn, 10.3 min; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 551 : 5-(PhenyIsuIfonyl)-2-propyl-iV-(tetrahydro-2iϊ-pyran-4- yl)benzenesulfonamide
[0641] The title compound was prepared from 5-benzenesulfonyl-2-propyl- benzenesulfonyl chloride (0.18 g, 0.5 mmol) and tetrahydro-pyran-4-ylamine (0.10 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 550, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford 5-(phenylsulfonyl)-2-propyl-iV-('tetrahydro-2H'- pyran-4-yl)benzenesulfonamide (0.15 g, 71%), as a homogeneous, colorless, crystalline solid, m.p. 131-133 °C; MS (-ESI), m/z: 422.1 [M-H]"; HRMS: calcd for C20H25NO5S2 + H+, 424.12469; found (ESI, [M+H]+), 424.1262; HPLC purity 100% at 210-370 nm, 9.0 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 552 : 5-(Phenylsulfonyl)-2-propyl-iV-(tetrahy dro-2i/-py ran-4- ylmethyl)benzenesulfonamide
[0642] The title compound was prepared from 5-benzenesulfonyl-2-propyl- benzenesulfonyl chloride (0.18 g, 0.5 mmol) and (tetrahydro-pyran-4-yl)methylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 550, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford S-fphenylsulfonyD-Σ-propyl-iV- ftetrahydro-2H-pyran-4-ylmethyl)benzenesulfonaim'de (0.21 g, 98%), as a homogeneous, clear oil;
MS (-ESI), m/z: 436.1 [M-H]";
HRMS: calcd for C21H27NO5S2 + H+, 438.14034; found (ESI, [M+H]+), 438.1419; HPLC purity 100% at 210-370 nm, 9.2 min; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 553: 5-(PhenyIsulfonyl)-2-propyl-Λr-[2-(tetrahydro-2iϊ-pyran-4- yl)ethyl]benzenesulfonamide
[0643] The title compound was prepared from 5-benzenesulfonyl-2-propyl- benzenesulfonyl chloride (0.18 g, 0.5 mmol) and 2-(tetrahydro-pyran-4-yl)ethylamine (0.13 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 550, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford 5-(ρhenylsulfonyl)-2-propyl-iV-[2- ftetrahydro-2i/-pyran-4-yl)emyl]benzenesulfonamide (0.16 g, 72%), as a glass; MS (-ESI), m/z: 450.1 [M-H]";
HRMS: calcd for C22H29NO5S2 + H+, 452.15599; found (ESI, [M+H]+), 452.1551; HPLC purity 100% at 210-370 nm, 9.4 min; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 554: iV-Cyclopentyl-5-(phenylsulfonyI)-2-propylbenzenesulfonamide
[0644] The title compound was prepared from 5-benzenesulfonyl-2-propyl- benzenesulfonyl chloride (0.18 g, 0.5 mmol) and cyclopentylamine (0.09 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 550, step c. The crude product was purified by preparative liquid chromatography on a Biotage" 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford A/-cyclopentyl-5-(phenylsulfonyl)-2-propylbenzenesulfonamide (0.14 g, 67%), as a glass; MS (-ESI), m/z: 406.1 [M-H]";
HRMS: calcd for C20H25NO4S2 + H+, 408.12978; found (ESI, [M+H]+), 408.1322; HPLC purity 100% at 210-370 nm, 10.1 min; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 555: 5-(Phenylsulfonyl)-2-propyI-iV-(2-pyridin-2-ylethyl)benzenesulfonamide
[0645] The title compound was prepared from 5-benzenesulfonyl-2-propyl- benzenesulfonyl chloride (0.18 g, 0.5 mmol) and 2-pyridin-2-yl-ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 550, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford 5-(phenylsulfonyl>2-propyl-N-(2-pyridin-2- ylethvDbenzenesulfonamide (0.17 g, 75%), as a homogeneous, colorless, crystalline solid, m.p. 100-102 °C;
MS (+ESI), m/z: 445 [M+H]+; MS (-ESI), m/z: 443 [M-H]";
HRMS: calcd for C22H24N2O4S2 + H+, 445.12502; found (ESI, [M+H]+), 445.1255; HPLC purity 100% at 210-370 nm, 9.0 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 556: J/V-[3-(liϊ-Imidazol-l-yl)propyl]-5-(phenylsulfonyl)-2- propylbenzenesulfonamide
[0646] The title compound was prepared from 5-benzenesulfonyl-2-propyl- benzenesulfonyl chloride (0.18 g, 0.5 mmol) and 3-imidazol-l-yl-propylamine (0.13 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 550, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-4% methanol in dichloromethane at a flow rate of 50 mL/min, to afford N-[3-flH-imidazol-l-yl)propyr|-5- (phenylsulfonyl)-2-propylbenzenesulfonamide (0.03 g, 14%), as a homogeneous, off-white, amorphous solid, m.p. 143-146 0C; MS (-ESI), m/z: 443 [M-H]";
HRMS: calcd for C21H25N3O4S2 + H+, 448.13592; found (ESI, [M+H]+), 448.1381; HPLC purity 100% at 210-370 nm, 7.3 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 557: 5-(PhenylsuIfonyl)-2-propylbenzenesuIfonamide
[0647] The title compound was prepared from 5-benzenesulfonyl-2-propyl- benzenesulfonyl chloride (0.18 g, 0.5 mmol) and 3-miidazol-l-yl-propylamine (0.13 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 550, step c. The crude product was purified by preparative liquid chromatography on a Biotage 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-4% methanol in dichloromethane at a flow rate of 50 mL/min, to afford 5-(phenylsulfonyl)-2- propylbenzenesulfonamide (0.06 g, 34%), as a clear, tan oil; MS (-ESI), m/z: 338.1 [M-H]";
HRMS: calcd for C15H17NO4S2 + NH4 +, 357.09372; found (ESI, [M+NH4]"1"), 357.0938; HPLC purity 89.5% at 210-370 nm; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 558: tert-Bntyl 4-({[5-(phenylsulfonyl)-2- propylphenyl]sulfonyl}amino)piperidine-l-carboxylate
[0648] The title compound was prepared from 5-benzenesulfonyl-2-propyl- benzenesulfonyl chloride (0.36 g, 1.0 mmol) and 4-amino-piperidine-l-carboxylic acid, tert- butyl ester (0.40 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 550, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 15%-50% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford tert-butyl 4-(fr5- fphenylsulfonvD^-propyrphenyl] sulfonyl} amino)piperidine- 1 -carboxylate (0.40 g, 77%), as homogeneous, colorless, crystalline solid, m.p. 128-130 °C;
MS (-ESI), m/z: 521.1 [M-H]-;
HRMS: calcd for C25H34N2O6S2 + NH4 +, 540.21965; found (ESI, [M+NH4]+), 540.2227;
HPLC purity 100% at 210-370 nm, 10.3 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 559: 5-[(4-fluorophenyl)sulfonyl]-iV-(2-phenylethyl)-2-propyIbenzenesulfonamide [0649] Step a) l-Fluoro-4-[(4-propylphenyl)sulfonyl]benzene [0650] A stirred solution of n-propylbenzene (2.40 g, 20 mmol) and 4- fluorobenzenesulfonyl chloride (3.88 g, 20 mmol) was cooled to -40 °C and treated slowly under nitrogen with solid anhydrous aluminum chloride (3.20 g, 24 mmol). After stirring neat for 4 hours at room temperature, the mixture was poured slowly into ice water and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and filtered through a short column of silica gel. The filtrate was evaporated in vacuo to yield an oil, l-fluoro-4-r(4-propylphenyl)sulfonyl]benzene (5.56 g, 100%) as a homogeneous, clear, pale, yellow oil; MS (+ESI), m/z: 279.1 [M+H]+;
HRMS: calcd for C15H15FO2S, 278.07768; found (EI, M+.), 278.0774;
HPLC purity 98.8% at 242 nm, 9.9 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
[0651] Step b) 5-[(4-Fluorophenyl)sulfonyl]-2-propylbenzenesulfonyl chloride [0652] l-Fluoro-4-[(4-propylphenyl)sulfonyl]benzene (2.78 g, 10 mmol) was heated with stirring at 60 0C for one hour under nitrogen with chlorosulfonic acid (6.7mL, 11.7 g, 100 mmol). The mixture was cooled to room temperature, poured slowly into a cold solution of IN hydrochloric acid, and extracted with ethyl acetate (2x.). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated in vacuo to a homogeneous, clear, tan oil, 5-[(4-fluorophenyl)sulfonyl1- 2-propylbenzenesulfonyl chloride (3.74 g, 99%), which solidified on standing and was utilized in subsequent reactions.
[0653] Step c) 5-[(4-Fluorophenyl)sulfonyl]-N-(2-phenylethyl)-2- propylbenzenesulfonamide SB E B AM101865 - 195 -
[0654] A stirred solution of 5-[(4-fluorophenyl)sulfonyl]-2-propylbenzenesulfonyl chloride (0.19 g, 0.5 mmol) in dichloromethane (10 mL) was treated dropwise under nitrogen with a solution of phenethylamine (0.12 g, 1.0 mmol) in dichloromethane. After stirring for one hour at room temperature or until the reaction was complete, the mixture was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min. After evaporation of the solvent under vacuum, the title compound, 5-r(4-fluorophenyl)sulfonyl1- A/-(2-phenylethylV2-propylbenzenesulfonamide (0.22 g, 93%), was obtained as a homogeneous, clear, colorless oil; MS (-ESI), m/z: 460.1 [M-H]";
HRMS: calcd for C23H24FNO4S2 + H+, 462.12035; found (ESI, [M+H]+), 462.1214; HPLC purity 100% at 210-370 nm, 10.4 min.; 100% at 242 nm, 10.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 560: 5-[(4-Fluorophenyl)sulfonyl]-2-propyl-iV-(tetrahydro-2iϊ-pyran-4- yl)benzenesulfonamide
[0655] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2- propylbenzenesulfonyl chloride (0.19 g, 0.5 mmol) and tetrahydro-pyran-4-ylamine (0.10 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 559, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert-hυtyl ether in hexane at a flow rate of 50 mL/min, to afford 5-[f4-fluorophenyl)sulfonyl]-2-propyl-N- (tetrahvdro-2H-pyran-4-yl)benzenesulfonamide (0.18 g, 80%), as a homogeneous, colorless, crystalline solid, m.p. 131-133 °C; MS (-ESI), m/z: 440.1 [M-H]";
HRMS: calcd for C20H24FNO5S2 + H+, 442.11527; found (ESI, [M+H]+), 442.1644; HPLC purity 100% at 210-370 nm, 9.2 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 561 : 5-[(4-Fluorophenyl)sulf onyl]-2-propyl-Λ'-(tetrahydro-2jHr-pyran-4- ylmethyl)benzenesulfonamide [0656] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2- propylbenzenesulfonyl chloride (0.19 g, 0.5 mmol) and (tetrahydro-pyran-4-yl)methylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 559, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert- butyl ether in hexane at a flow rate of 50 rnL/min, to afford 5-|'(4-fluorophenyl')sulfonyl]-2- propyl-N-(tetrahvdro-2/f-pyran-4-γlmethyl)benzenesulfonamide (0.20 g, 87%), as a glass; MS (-ESI), m/z: 454.1 [M-H]";
HRMS: calcd for C21H26FNO5S2 + H+, 456.13092; found (ESI, [M+H]"1"), 299.19; HPLC purity 100% at 210-370 ran, 9.4 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 562: 5-[(4-Fluorophenyl)sulfonyl]-2-propyl-Λ'-[2-(tetrahydro-2J£r-pyran-4- yl)ethyl] benzenesulf onamide
[0657] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2- propylbenzenesulfonyl chloride (0.19 g, 0.5 mmol) and 2-(tetrahydro-pyran-4-yl)ethylamine (0.13 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 559, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert- butyl ether in hexane at a flow rate of 50 mL/min, to afford 5-|"(4-fluorophenyDsulfonyll-2- propyl-N-r2-rtetrahydro-2H-pyran-4-yl)ethyllbenzenesulfonamide (0.14 g, 58%), as a glass; MS (-ESI), m/z: 468.1 [M-Hp;
HRMS: calcd for C22H28FNO5S2 + H+, 470.14657; found (ESI, [M+H]+), 470.1467; HPLC purity 100% at 210-370 nm, 9.6 min; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 563: ΛLCyclopentyl-5-[(4-fluorophenyl)sulfonyl]-2-propyIbenzenesulfonamide
[0658] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2- propylbenzenesulfonyl chloride (0.19 g, 0.5 mmol) and cyclopentylamine (0.09 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 559, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford N-cvclopentΛd-5-r("4-fluorophenyl)sulfbnyl]-2- propylbenzenesulfonamide (0.15 g, 71%), as a glass;
MS (-ESI)3 m/z: 424.1 [M-H]";
HRMS: calcd for C20H24FNO4S2 + H+, 426.12035; found (ESI, [M+H]+), 426.1199;
HPLC purity 99.1% at 210-370 nm, 10.2 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 564: 5~[(4-Fluorophenyl)sulfonyl]-2-propyl-JV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0659] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2- propylbenzenesulfonyl chloride (0.19 g, 0.5 mmol) and 2-(pyridin-2-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 559, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%- 100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford 5-[(4-fluorophenyl)sulfonyl]-2-propyl-iV- (2-pyridin-2-ylethyl)benzenesulfonamide (0.18 g, 78%), as a homogeneous, colorless, crystalline solid, m.p. 113-115 °C; MS (+ESI)5 m/z: 463 [M+H]+; MS (-ESI), m/z: 461 [M-H]-;
HRMS: calcd for C22H23FN2O4S2 + H+, 463.11560; found (ESI, [M+H]+), 463.1176; HPLC purity 100% at 210-370 nm, 9.2 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 565: 5-[(4-Fluorophenyl)sulfonyl]-iV-[3-(lJfir-imidazol-l-yl)propyl]-2- propylbenzenesulfonamide
[0660] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2- propylbenzenesulfonyl chloride (0.38 g, 1.0 mmol) and 3-(lH-imidazol-lyl)propylamine (0.25 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 559, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-4% methanol in dichloromethane at a flow rate of 50 mL/min, to afford 5 - [(4-fluoropheny Dsulf onyl] - JV- [3 - ( 1 H- imidazol- 1 -yl)propyl]-2-propylbenzenesulfonamide (0.12 g, 25%), as a foam; MS (-ESI), m/z: 464.1 [M-H]";
HRMS: calcd for C21H24FN3O4S2 + H+, 466.12650; found (ESI, [M+H]+), 466.125; HPLC purity 100% at 210-370 nm, 7.6 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 566: 5-[(4-FIuorophenyl)sulfonyI]-2-propylbenzenesuIfonamide
[0661] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2- propylbenzenesulfonyl chloride (0.38 g, 1.0 mmol) and 3-(l/f-imidazol-lyl)propylamine (0.25 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 559, step c. The crude product was purified by preparative liquid chromatography on a Biotage ' 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-4% methanol in dichloromethane at a flow rate of 50 mL/min, to afford 5 - [f 4-fluorophenyl)sulfonyl] -2- propylbenzenesulfonamide (0.23 g, 50%), as a tan foam; MS (-ESI), m/z: 356.1 [M-H]";
HRMS: calcd for C15H16FNO4S2 + H+, 358.05775; found (ESI, [M+H]+), 409.0887; HPLC purity 79.8% at 210-370 nm, 8.5 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 567: fert-Butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2- propylphenyl}sulfonyl)amino]piperidine~l-carboxylate
[0662] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2- propylbenzenesulfonyl chloride (0.38 g, 1.0 mmol) and 4-amino-piperidine-l-carboxylic acid, fert-butyl ester (0.40 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 559, step c. The crude product was purified by preparative liquid chromatography on a Biotage 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 15%-50% methyl fert-butyl ether in hexane at a flow rate of 50 mL/min, to afford fert-butyl 4- [( { 5 -[^-fluorophenylisulfonyl] -2-propylphenyl > sulfonvDaminolpiperidine- 1 - carboxylate (0.46 g, 85%), as a homogeneous, colorless, crystalline solid, m.p. 151-153 0C; MS (-ESI), m/z: 539.1 [M-H]";
HRMS: calcd for C25H33FN2O6S2 + NH4 +, 558.21023; found (ESI, [M+NH4]+), 558.208; HPLC purity 100% at 210-370 nm, 10.4 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 568: 2-isopropyl-5-{[4-(methylamino)phenyI]sulfonyl}-N-piperidin-4- ylbenzenesulfonamide
[0663] 100 mg of tert-butyl 4-{[(2-isopropyl-5-{[4-
(methylamino)phenyl]sulfonyl}phenyl)sulfonyl]aniino}piperidine-l-carboxylate was added to 2 niL of 4M hydrochloric acid in dioxane and the precipitate was filtered giving the desired 2^ isopropyl-5- { [4-("methylamino)phenyl]sulfonyl| -N-piperidin-4- ylbenzenesulfonamide. MS (ES+) m/z 452 MS (ES-) m/z 450 HRMS: calcd. for C21H29N3O4S2 + H+, 452.167776: found (ESI3 [m+H]+), 452.166.
Example 569: 5-[(5-chIoro-l,3-dimethyl-lHr-pyrazol-4-yl)sulfonyl]-2-isopropyl-Λ'- (tetrahydro-2JfiT-pyran-4-yl)benzenesulfonamide
[0664] In an analogous manner to Example 541,
[0665] Step 3: 5-bromo-2-isopropyl-iV-(tetrahydro-2H"-pyran-4-yl)benzenesulfonamide and 5-chloro-l,3-dimethyl-lH'-pyrazole-4-sulfonyl fluoride were used to prepare 5-[(5-chloro- l,3-dimethyl-li7-pyrazol-4-yl')sulfonyl1-2-isopropγl-N-(tetrahvdro-2H"-pyran-4- vDbenzenesulfbnamide. MS (ES) m/z Al AA; ΗRMS: calcd for C19H26ClN3O5S2 + H+, 476.10752; found (ESI, [M+H]+), 476.1059.
Example 570: N-Cl-Phenylethy^-S-φhenylsulfony^^-Ctrifluoromethyl)- benzenesulfonamide
[0666] Step 1: l-Benzenesulfonyl-2-nitro-4-trifluomethyl-benzene: A mixture of 4- bromo-3-nitrobenzotriflluoride (10 mL, 65 mmol) and benzenesulfinic acid, sodium salt (10.77 g, 66 mmol) in 100 mL of DMF was stirred under nitrogen overnight at 80 0C. After cooling to room temperature the reaction was partitioned with water and methylene chloride. The organic layer was separated and the aqueous layer was extracted three times with methylene chloride. The combined extracts were dried (anhydrous MgSO4), filtered and the solvent was removed under reduced pressure to give l-benzenesulfonyl-2-nitro-4-trifluomethyl-benzene (21.52 g, 99%) as a white solid, mp 148-150°C.
[0667] Step 2: 2-Benzenesulfonyl-5-trifluoromethyl-phenylamine. A mixture of 1- benzenesulfonyl-2-nitro-4-trifluomethyl-benzene (10.21 g, 31 mmol), prepared in the previous step and Tin(II) chloride (29.22 g, 160 mol) in 100 niL of methanol and 5 mL of water was stirred at reflux under nitrogen for three days. The methanol was removed under reduced pressure and then the residue was partitioned between methylene chloride and 2 N HCl. The organic layer was separated and the aqueous layer extracted three times with methylene chloride. The combined extracts were dried (anhydrous MgSO4), filtered and the solvent removed under reduced pressure to give 2-benzenesulfonyl-5-trifluoromethyl-phenylamine (8.87g, 95%) as a white solid, mp 142-143 °C.
[0668] Step 3: [4-bromo-2-(phenylsulfonyl)-5-(trifluoromethyl)phenyl] amine. A mixture of 2-benzenesulfonyl-5-trifluoromethyl-phenylamine (3.87 g, 13 mmol), prepared in the previous step, benzyltrimethylammonium tribromide (5.02g, 13 mmol), and calcium carbonate (3.86 g, 40 mmol) in 100 mL methylene chloride and 50 mL of methanol was stirred under nitrogen overnight at room temperature. The solvent was removed under reduced pressure and then the residue was partitioned between methylene chloride and 2 N HCl. The organic layer was separated and the aqueous layer extracted three times with methylene chloride. The combined extracts were dried (anhydrous MgSO4), filtered and the solvent removed under reduced pressure to produce 4.97 g of a yellow solid. The solid was taken up in methylene chloride and purified on a Horizon™ Flash Collector (Column: Biotage Si 40+M) using a linear gradient of 5% ethyl acetate-hexane to 100% ethyl acetate as the eluent. Isolation of the main component [4-bromo- 2-(phenylsulfonyl)-5-(trifluoromethyl)phenyl]amine (4.87g, 94%) as a light yellow solid, mp 169-171 0C; MS (ESI) m/z 380; MS (ESI) m/z 378;
[0669] Step 4: 4-Benzenesulfonyl-2-bromo-l-trifluoromethyl-benzene. A solution of Sodium Nitrite (918.9 mg, 13.3 mmol) in 20 mL of water was added under nitrogen at ice bath temperature drop wise over 15 minutes to a solution of [4-bromo-2-(phenylsulfonyl)-5- (trifluoromethyl)phenyl] amine (4.22 g, 11.1 mmol) prepared in the previous step in 200 mL of acetonitrile and 20 mL of concentrated sulfuric acid. After the addition the reaction was stirred at ice bath temperature for thirty minutes. 50% Hypophosphorous acid- water (11.5 mL, 110 mmol) was then added under nitrogen at ice bath temperature drop wise over 20 minutes to the stirring reaction and then was immediately capped and placed into the refrigerator overnight. The reaction was then partitioned between ethyl acetate and water. The ethyl acetate layer was separated, washed four times with water, dried (anhydrous MgSO4) and the solvent removed under reduced pressure to give 4-benzenesulfonyl-2-bromo-l-trifluoromethyl-benzene (3.20 g, 79%) as a yellow solid. [0670] Step 5: S-Benzenesulfonyl^-trifluoromethyl-benzenesulfinic acid. Butyllithium (2.5 M solution in hexanes; 1.6 niL, 4.0 mmol) was added under nitrogen over approximately two minutes to a solution of 4-benzenesulfonyl-2-bromo-l-trifluoromethyl-benzene (1.0 g, 2.7 mmol) in 10 mL of anhydrous tetrahydrofuran at dry ice-acetone temperature. After the addition the reaction was stirred at dry ice-acetone temperature for one hour. After that time SO2 gas was bubbled into the reaction flask for approximately five minutes at dry ice-acetone bath temperature. After warming to room temperature the solvent and the excess SO2 were removed under reduced pressure and then the residue was partitioned between methylene chloride and 2 N HCl. The organic layer was separated and the aqueous layer extracted three times with methylene chloride. The combined extracts were dried (anhydrous MgSO4), filtered and the solvent removed under reduced pressure to produce 0.77 g of brown solid.
[0671] Step 6: N-(2-phenylethyl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide. A mixture of 5-benzenesulfonyl-2-trifluoromethyl- benzenesulfϊnic acid (0.58 g, 1.6 mmol), prepared in the previous step, N-Chlorosuccinimide (0.26 g, 1.98 mmol), and triethylamine (0.7 mL, 5 mmol) in 30 mL methylene chloride was stirred under nitrogen for thirty minutes at room temperature. Phenethylamine (0.25 mL, 2 mmol) was slowly syringed into the flask and the reaction was stirred under nitrogen overnight at room temperature. The solvent was removed under reduced pressure and then the residue was partitioned between methylene chloride and 2 N HCl. The organic layer was separated and the aqueous layer extracted three times with methylene chloride. The combined extracts were dried (anhydrous MgSO4), filtered and the solvent removed under reduced pressure to produce 0.82 g of brown solid. The solid was taken up in methylene chloride and purified on a Horizon™ Flash Collector (Column: Biotage Si 25+M) using a linear gradient of 5% methylene chloride-hexane to 100% methylene chloride as the eluent. Additional purification was done on 0.20 g of product with a Luna Cl 8 (50 x 250 mm) reverse phase column on a Varian HPLC system using 70% methanol / water mobile phase isocraticly at 100 ml/min. Isolation of the main component gave the title compound N-(2-phenylethyl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide (0.23 g, 35.4%), as a white solid mp 151-153 °C. MS (ES) m/z 468.1.
Example 571: 5-(Phenylsulfonyl)-N-(2-pyridin-2-ylethyl)-2- (trifluoromethyl)benzenesulfonamide [0672] A mixture of 5-benzenesulfonyl-2-trifluoromethyl-benzenesulfinic acid (0.59 g, 1.7 mmol), prepared in the same manner as described in step 5 of Example 570, N- Chlorosuccinimide (0.27 g, 2.0 mmol), and triethylamine (0.7 mL, 5 mmol) in 30 ml methylene chloride was stirred under nitrogen for thirty minutes at room temperature. 2-(2- pyridyl)ethylamine (0.24 mL, 2 mmol) was slowly syringed into the flask and the reaction was stirred under nitrogen overnight at room temperature. The solvent was removed under reduced pressure and then the residue was partitioned between methylene chloride and 2 N HCl. The organic layer was separated and the aqueous layer extracted three times with methylene chloride. The combined extracts were dried (anhydrous MgSO4), filtered and the solvent was removed under reduced pressure to produce 0.67 g of a dark brown solid. The solid was taken up in methylene chloride and purified on a Horizon™ Flash Collector (Column: Biotage Si 25+M) using a linear gradient of 5% methylene chloride-hexane to 100% methylene chloride as the eluent. Isolation of the main component gave the title compound 5-(phenylsulfonyl)-N-(2- pyridin-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide (75.5 mg, 9.6%) as a white solid, mp 149-151 °C; MS (ES) m/z 469.0.
Example 572: 5-[(4-fluorophenyI)suIfonyl]-2-isopropyl-N-[l-(morpholin-4- ylcarbonyl)piperidin- 4-yI]benzenesulfonamide
[0673] In an analogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n- piperidin-4-ylbenzenesulfonamide and 4-morpholinecarbonyl chloride were used to prepare 5^ [(4-fluorophenyDsulfonyll-2-isopropyl-N-[l-rmorpholin-4-ylcarbonyπpiperidin- 4- ylibenzenesulfonamide. MS (ES+) m/z 554 MS (ES-) m/z 552 HRMS: calcd. for C25H32FN3O6S2 + H+, 554.179484: found (ESI, [m+H]+), 554.1799.
Example 573 : 4- [({5- [(4-fluorophenyl)sulfonyl] -2-isopropy lphenyl} sulfony l)amino] -N,N- dimethylpiperidine-1-carboxamide
[0674] In an analogous manner to Example 462, 2-isopropyl-5-(phenylsulfonyl)-n- piperidin-4-ylbenzenesulfonamide and dimethylcarbamyl chloride were used to prepare 4- [({5- r(4-fluorophenyl)sulfonyll-2-isopropylphenyl>sulfonyl)amino]-N,N- dimethylpiperidine-l- carboxamide.
MS (ES+) w/z 512
MS (ES-) m/z 510
HRMS: calcd. for C23H30FN3O5S2 + H+, 512.168919: found (ESI, [m+H]+), 512.1692.
Example 574: N-(l~benzylpiperidin-4-yI)-5-[(4-fluorophenyl)suIfonyl]-2- methylbenzenesulfonamide
[0675] In an analogous manner to Example 435, 5-(4-fluoro-benzenesulfonyl)-2- methyl-benzenesulfonyl chloride and 4-amino-l-benzylpiperidine were used to prepare N-(I- benzylpiperidm-4-yl)-5-|"(4-fluorophenγl)sulfonyll-2- methylbenzenesulfonamide. MS (ES+) m/z 503 MS (ES-) m/z 501 HRMS: calcd. for C25H27FN2O4S2 + H+, 503.147455: found (ESI, [m+H]+), 503.1489.
Example 575: 2-isopropyl-5-(phenylsulfinyl)-iV-(2-pyridiii-2-ylethyl)benzenesulfonamide
[0676] Step 1 : Following the same procedure as described in Example 474 (Stepl), 2- bromoisopropylbenzene was used to prepare 2-isopropyl-iV-(2-pyridin-2- ylethyPbenzenesulfonamide .
[0677] Step 2: Following the same procedure as described in Example 474 (Step2), 2- isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepare 5-bromo-2-isopropyl- N-(2-pyridin-2-ylethyl)benzenesulfonamide.
[0678] Step 3: Following the same procedure as described in Example 346, 5-bromo-2- isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide, and benzenethiol were used to prepare 2^ isopropyl-5-(phenylsulfinyl)-JV-f2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES) m/z 427.1; HRMS: calcd for C22H24N2O3S2 + H+5 429.13011; found (ESI, [M+H]+), 429.1309.
Example 576: 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-piperidin-4-yIbenzenesulfonamide [0679] 200 mg of palladium on carbon were wetted with 30 mL of ethanol and 1.5 g of N-(l-benzylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide hydrochloride was added. The reaction was mixed on a Parr shaker at 45 psi overnight. The reaction mixture was filtered through Celite® and the filtrate was concentrated down giving the desired 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-piperidin-4-ylbenzenesulfonamide.
MS (ES+) rø/z 413
MS (ES-) m/z 411
HRMS: calcd. for C18H21FN2O4S2 + H+, 413.100505: found (ESI, [m+H]+), 413.0997.
Example 577: 5-[(3-bromo-2-methyIphenyl)suIfonyl]-2-isopropyI-AL(2-pyridin-2- ylethyl)benzenesulfonamide
[0680] Step 1 : Following the same procedure described in Example 334, 2-methyl-3- bromoaniline was used to prepare 2-methyl-3-bromobenzenesulfonyl chloride.
[0681] Step 2: Following the same procedure described in Example 474, 2-methyl-3- bromobenzenesulfonyl chloride was used to prepare 2-methyl-3-bromobenzenesulfonyl fluoride.
[0682] Step 4: Following the same procedure described in Example 474, 5-bromo-2- isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide and 3-bromo-2-methylbenzene sulfonyl fluoride were used to prepare 5-[(3-bromo-2-methylphenyl)sulfonyll-2-isopropyl-A/-('2-pyridm- 2-ylethyl)benzenesulfonamide. MS (ESI) m/z 537; HRMS: calcd for C23H25BrN2O4S2 + H+, 537.05119; found (ESI, M+H), 537.0517.
Example 578: 5-[(2-chloro-6-methylphenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0683] Step 1 : Following the same procedure described in Example 474 (Step 3), 2- chloro-6-methylbenzene sulfonyl chloride was used to prepare 2-chloro-6-methylbenzene sulfonyl fluoride.
[0684] Step 2: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide and 2-chloro-6-methylbenzene sulfonyl fluoride were used to prepare 5 - [(2-chloro-6-methylphenyl)sulfonyl1 -2-isopropyl-iV-(2- pyridin-2-ylethyl)benzenesulfonamide. MS (ESI) m/z 493; HRMS: calcd for C23H25ClN2O4S2 + H+, 493.10170; found (ESI, M+H), 493.1023. Example 579: 2-isopropyl-5~[(3-methylphenyl)sulfonyl]-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0685] Step 1 : Following the same procedure described in Example 474 (Step 3), 3- methylbenzene sulfonyl chloride was used to prepare 3-methylbenzene sulfonyl fluoride.
[0686] Step 2: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-isopropyl-N-(2~pyridin-2-ylethyl)benzenesulfonamide and 3-methylbenzene sulfonyl fluoride were used to prepare 2-isopropyl-5-r(3-memylphenyl)sulfonyl"|-N-(2-pyridin-2- ylethyl)benzenesulfonamide . MS (ESI) m/z 459; FIRMS: calcd for C23H26N2O4S2 + H+, 459.14067; found (ESI, M+H), 459.1412.
Example 580: 5-({4-[(2-cyanoethyl)(methyl)amino]phenyI}sulfonyI)-2-isopropyI-iV- (tetrahydro-2Jϊ-pyran-4-yI)benzenesulfonamide
[0687] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-tetrahydro-2H-pyran-4-ylbenzenesulfonamide and 3-(methylamino)propionitrile in DMA were used to prepare 5 -( { 4- [(2-cyanoethy l)(methyDamino]pheny 1 } sulfony l)-2-isopropyl- Ν-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide. MS (ESI) m/z 506;
HPLC purity 96.0% at 210-370 nm, 8.6 min.; 95.8% at 312 nm, 8.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H31N3O5S2 + H+, 506.17779; found (ESI, [M+H]+), 506.1783.
Example 581: 5-({4-[(2-cyanoethyl)(methyl)amino]phenyl}sulfonyl)-2-isopropyl-Λ'- (tetrahydro-2jHr-pyran-4-ylmethyl)benzenesuIfonamide
[0688] In an analogous manner to Example 353, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide and 3- (methylamino)propionitrile in DMA were used to prepare 5-({4-[(2- cvanoethyl)(methyl)amino]phenyl}sulfonyl)-2-isopropyl-Ν-(tetrahydro-2H-pyran-4- ylmethvDbenzenesulfonamide. MS (ESI) m/z 520; HPLC purity 96.3% at 210-370 nm, 8.8 min.; 96.0% at 312 nm, 8.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C25H33N3O5S2 + H+, 520.19344; found (ESI, [M+H]+), 520.194.
Example 582: 5-[(4-fluorophenyl)sulfonyl]-iV-(2-hydroxyethyl)-2- isopropylbenzenesulfonamide
[0689] In an analogous manner to Example 230:
[0690] Step 3: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-aminoethanol were used to prepare 5-r(4-fluorophenyl)sulfonyl]-N-(2-hydroxyethyl)-2- isopropylbenzenesulfonamide. MS (ESI +) m/z 402; MS (ESI -) m/z 400;
HPLC purity 100% at 210-370 nm, 8.3 min.; 100% at 242 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C17H20FNO5S2 + H+, 402.08397; found (ESI, [M+H]+), 402.0845.
Example 583: 5-[(4-fluorophenyI)suIfonyl]-2-isopropyl-iV-[2-(2-methyI-liϊ-imidazol-l- yl)ethyl]benzenesulfonamide
[0691] Step 1 : To a stirred solution of 5-[(4-fluorophenyl)sulfonyl]-N-(2- hydroxyethyl)-2-isopropylbenzenesulfonamide (0.6 mg, 1.5 mmol), triethylamine (2.2 mmol) and a catalytic amount of N,Ndimethylaminopyridine in dichloromethane was added 4- methylbenzenesulfonyl chloride (1.8 mmol) and after 4 hours an additional 1.8 mmol of 4- methylbenzene sulfonyl chloride was added. The reaction was concentrated and then purified by flash column chromatography using an ethyl acetate-hexane gradient affording predominately the N,O-bistosyl intermediate.
[0692] Step 2: 2-Methylimidazole (164 mg, 2 mmol) was dissolved in anhydrous tetrahydrofuran (1 mL) and sodium hydride (60% mineral oil dispersion, 24 mg, 1 mmol) was added. After 30 minutes, a solution of the intermediate bistosylate (stepl, 0.14 mmol) in tetrahydrofuran was added and the reaction was allowed to stir at room temperature for 30 additional minutes. The mixture was quenched upon the addition of water. The mixture was extracted with ethyl acetate (3 x 2 mL). The combined organic phases were concentrated and the resulting crude residue was purified by automated flash column chromatography resulting in the recovery of 56 mg (85%) of 5-[(4-fluorophenyl)sulfonvn-2-isopropyl-N-[2-('2-methyl-lH- imidazol- 1 -yl)ethyl]benzenesulfonamide.
MS (ESI +) m/z 466;
MS (ESI -) w/z 464;
HPLC purity 100% at 210-370 nm, 7.5 min.; 100% at 244 nm, 7.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C21H24FN3O4S2 + H+, 466.12650; found (ESI, [M+H]+), 466.1271.
Example 584: 7V-[2-(2-ethyl-lHr-imidazol-l-yl)ethyI]-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide
[0693] In an analogous manner to Example 583 :
[0694] Step 2: 2- The bistosylate and 2-ethylimidazole were used to prepare N-["2-(2- ethy 1- 1 H-imidazol- 1 -y Dethyl] -5 - [f 4-fluoropheny Dsulfonyl] -2-isopropy lbenzenesulfonamide. MS (ESI +) m/z 480; MS (ESI -) m/z 478;
HPLC purity 100% at 210-370 nm, 7.7 min.; 100% at 244 nm, 7.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H26FN3O4S2 + H+, 480.14215; found (ESI, [M+H]+), 480.1427.
Example 585: N-(l-acetylpiperidm-4-yl)-5-[(4-fluorophenyl)sulfbnyl]-2- methylbenzenesulfonamide
[0695] In an analogous manner to Example 462, 5-[(4-fluorophenyl)sulfonyl]-2- methyl-N-piperidin-4-ylbenzenesulfonamide and acetic anhydride were used to prepare N-Cl- acetylpiperidin-4-yl)-5-["(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide. MS (ES+) rø/z 455 MS (ES-) m/z 453.
Example 586: N-[l-(4-cyanobenzoyl)piperidin-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide [0696] In an analogous manner to Example 462, 5-[(4-fluorophenyl)sulfonyl]-2- methyl-N-piperidin-4-ylbenzenesulfonamide and 4-cyanobenzoyl chloride were used to prepare N- r 1 -f 4-cyanobenzoyl)piperidm-4-y 1] -5 - |"(4-fluorophenyl)sulfony 1] -2- methylbenzenesulfonamide. MS (ES+) m/z 542 MS (ES-) m/z 540.
Example 587: 4-[({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyI}sulfonyI)amino]-N,N- dimethylpiperidine-1-carboxamide
[0697] In an analogous manner to Example 462, 5-[(4-fluorophenyl)sulfonyl]-2- methyl-N-piperidin-4-ylbenzenesulfonamide and dimethylcarbamyl chloride were used to prepare 4-[({5-r(4-fluorophenyl)sulfonyll-2-methylphenyl>sulfonyl')amino]-N,N- dimethy lpiperidine- 1 -carboxamide . MS (ES+) m/z 484 MS (ES-) m/z 482.
Example 588: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-7V-[2-(2-isopropyl-ljH-imidazol-l- yl)ethyl]benzenesulfonamide
[0698] In an analogous manner to Example 583 :
[0699] Step 2: 2- The bistosylate and 2-isopropylimidazole were used to prepare 5-[(4- fluorophenylisulfonyll-Σ-isopropyl-N-β-^-isopropyl-lH-imidazol-l- yDethyl]benzenesulfonamide . MS (ESI +) m/z 494; MS (ESI -) m/z 492;
HPLC purity 91.6% at 210-370 ran, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H28FN3O4S2 + H+, 494.15780; found (ESI, M+H), 494.1584.
Example 589: 5-[(4-fluorophenyl)sulfonyl]-N-[l-(methoxyacetyl)piperidin-4-yl]-2- methylbenzenesulfonamide [0700] In an analogous manner to Example 462, 5-[(4-fluorophenyl)sulfonyl]-2- methyl-N-piperidin-4-ylbenzenesulfonamide and methoxyacetyl chloride were used to prepare 5^ r(4-fluorophenyl)sulfonyl1-N-[l-(methoxyacetyl)piperidin-4-yl]-2- methylbenzenesulfonamide. MS (ES+) m/z 4S5 MS (ES-) m/z 483 HRMS: calcd. for C21H25FN2O6S2 + H+, 485.121634: found (ESI, [m+H]+), 485.1216.
Example 590: 2-isopropyl-5-[(i?)-phenylsulfϊnyl]-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0701] Chiral separation of 2-isopropyl-5-(phenylsulfinyl)-iV-(2-pyridin-2- ylethyl)benzenesulfonamide using a prep chiral SFC column AD-H 35%methanol/65% CO2 at 50mL/min yielded
Figure imgf000210_0001
ylethvDbenzenesulfonamide. MS (ES) m/z 426.9.
Example 591: 2-isopropyl-5-[(S)-phenylsulfinyl]-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0702] Chiral separation of 2-isopropy l-5-(phenylsulfmyl)-Λ/-(2-pyridin-2- ylethyl)benzenesulfonamide using a prep chiral SFC column AD-H 35%methanol/65% CO2 at 50mL/min yielded 2-isopropyl-5-[6SVphenylsulfinyl]-N-(2-pyridin-2- ylethyPbenzenesulfonamide. MS (ES) m/z 426.9.
Example 592: 2-bromo-5-(phenylsulfonyl)-iV-(2-pyridiii-2-ylethyl)benzenesulfonamide
[0703] Step 1: Following the same procedure described in Example 1 (Step 1), 4- nitrobromobenzene and chlorosulfonic acid were used to prepare 2-bromo-5- nitrobenzenesulfonyl chloride.
[0704] Step 2: Following the same procedure described in Example 1 (Step 2), 2-(2- ethylamino)pyridine and 2-bromo-5-nitrobenzenesulfonyl chloride were used to prepare 2c bromo-5-nitro-N-(2-pyridin-2-ylethyl)benzenesulfonamide.
[0705] Step 3: 2-bromo-5-nitro-N-(2-pyridin-2-ylethyl)benzenesulfonamide (1.5 g, 3.88 mmol) was dissolved in methanol (25 mL) and water (1 mL). Tin (II) chloride (3.68 g, 19.4 mmol) was added and the resulting solution was heated to 70 °C overnight. The solution was concentrated and partitioned between ethyl acetate and a saturated aqueous sodium bicarbonate solution. The organic layer was dried over magnesium sulfate and concentrated to give 2- bromo-5-amino-N-(2-pyridin-2-ylethyl)benzenesulfonamide (1.2 g, 87%).
[0706] Step 4: Following the same procedure described in Example 334 (Step 2), 2- bromo-5-amino-iV-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepare 4-bromo-3-(2- pyridin-2-yl-ethylsulfamoyl)-benzenesulfonyl chloride.
[0707] Step 5: To a stirred solution of aluminum chloride (1.82 g, 13.64 mmol) in nitrobenzene (40 mL), was added benzene (3 mL), and 4-bromo-3-(2-pyridin-2-yl- ethylsulfamoyl)-benzenesulfonyl chloride (1.0 g, 2.27 mmol) at 80 0C. The resulting mixture was stirred 4 days at 80 0C with daily addition of benzene (2 mL). The reaction was then cooled to room temperature, poured over ice and extracted with dichloromethane. The organic phase was concentrated and flash column separated with 50% ethyl acetate/ hexane to give 2-bromo-5- ('phenylsulfonyl)-7V-('2-pyridin-2-ylethyDbenzenesulfonamide (0.23 g, 21%). MS (ES) m/z 478.8; HRMS: calcd for C19H17BrN2O4S2 + H+, 480.98859; found (ESI, M+H), 480.9891.
Example 593: 5-[(3-cyano-2-methylphenyI)sulfonyl]-2-isopropyl-Λ'-(2-pyridin-2- ylethyl)benzenesulfonamide
[0708] In an analogous manner to Example 376, 5-[(3-bromo-2- methylphenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepare 5-r(3-cyano-2-methylphenyl)sulfonyl]-2-isopropyl-iV-('2-pyridin-2- ylethypbenzenesulfonamide. MS (ES) m/z 481.9.
Example 594: 5-[(3-acetyl-2-methylphenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0709] In an analogous manner to Example 380, 5-[(3-bromo-2- methylphenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepare 5-r("3-acetyl-2-methylphenyDsulfonyl]-2-isopropyl-iV-(2-pyridin-2- ylethvDbenzenesulfonamide. MS (ES) m/z 499.0; HRMS: calcd for C25H28N2O5S2 + H+, 501.15124; found (ESI5 M+H), 501.1518.
Example 595: 5-[(3-chloro-4-fluorophenyI)sulfonyI]-2-isopropyl-iV-(2~pyridin-2- ylethyl)benzenesulfonamide
[0710] Step 1 : Following the same procedure described in Example 474 (Step 3), 3- chloro-4-fluorobenzene sulfonyl fluoride was used to prepare 3-chloro-4-fluorobenzene sulfonyl fluoride.
[0711] Step 2: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide and 3-chloro-4-fiuorobenzene sulfonyl fluoride were used to prepare 5 - \(3 -chloro-4-fluorophenyl)sulfony 1] -2-isopropy l-iV-(2- pyridin-2-ylethyDbenzenesulfonamide. MS (ESI) m/z 497; MS (ESI) m/z 495.
Example 596: 5-[(4-fluoro-2-methylphenyl)suIfonyl]-2-isopropyl-JV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0712] Step 1 : Following the same procedure described in Example 474 (Step 3), 2- methyl-4-fluorobenzene sulfonyl chloride was used to prepare 2-methyl-4-fluorobenzene sulfonyl fluoride.
[0713] Step 2: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide and 2-methyl-4-fluorobenzene sulfonyl fluoride were used to prepare 5-[f4-fluoro-2-methylphenyDsulfonyl]-2-isopropyl-N-(2- pyridin-2-ylethyl)benzenesulfonamide. MS (ES) m/z 474.9; HRMS: calcd for C23H25FN2O4S2 + H+, 477.13125; found (ESI, M+H), 477.1318.
Example 597: 2-isopropyl-5-[(l-methyl-lHr-indol-5-yl)sulfonyl]-Λ^-(2-pyridin-2- ylethyl)benzenesulfonamide
[0714] Step 1 : To a stirred solution of 5-bromoindole (2.0 g, 10.2 mmol) in DMF (25 mL) at 0 °C was added sodium hydride (0.45 g, 60%, 11.22 mmol) and the resulting solution was stirred for 5 minutes. Methyl iodide (1.3 mL, 20.8 mmol) was added and the reaction was allowed to warm to room temperature. After 1 hr the reaction was quenched with a saturated aqueous ammonium chloride solution and extracted several times with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, and concentrated to give crude l-methyl-5-bromoindole. This material was dissolved in THF (20 niL) and chilled to -78 0C. n-Butyl lithium 2.5 M in hexane (3.8 mL, 9.5 mmol) was added dropwise. After 10 minutes sulfur dioxide was bubbled into the reaction mixture for 5 minutes. The mixture was allowed to warm to room temperature and concentrated. The crude mixture was taken up in methylene chloride (20 mL) and N-bromosuccinimide (1.25 g, 9.36 mmol) was added and the resulting solution was stirred for 1 hr. The solution was washed with a saturated aqueous ammonium chloride solution, dried over magnesium sulfate, and concentrated. The mixture was flash column separated using 20% ethyl acetate/ hexane to give 1 -methylindole-5 - sulfonyl chloride (0.64 g, 27%).
[0715] Step 2: Following the same procedure described in Example 474 (Step 3), 1- methylindole-5-sulfonyl chloride was used to prepare 1 -methylindole-5-sulfonyl fluoride.
[0716] Step 3: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide and 1 -methylindole-5-sulfonyl fluoride were used to prepare 5-[r4-fluoro-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2- ylethypbenzenesulfonamide . MS (ESI) m/z 498; MS (ESI) m/z 496.
Example 598: 2-isopropyl-5-[(3-methoxyphenyl)sulfonyl]-iV-(tetrahydro-2Jϊ-pyran-4- yl)benzenesulfonamide
[0717] Step 1 : Following the same procedure described in Example 474 (Step 3), 3- methoxybenzene sulfonyl chloride was used to prepare 3-methoxybenzenesulfonyl fluoride.
[0718] Step 2: 3-methoxybenzenesulfonyl fluoride and 5-bromo-2-isopropyl-N- (tetrahydro-2H"-pyran-4-yl)benzenesulfonamide were used to prepare 2-isopropyl-5-[(3- methoxyphenyl)sulfonyl1-7V-rtetrahydro-2H-pyran-4-yl)benzenesulfonamide. MS (ESI) m/z 454; MS (ESI) m/z 452.
Example 599: 2-isopropyl-5-{[2-methyl-4-(methylamino)phenyl]sulfonyI}-7V-(2-pyridin-2- ylethyl)benzenesulfonamide [0719] In an analogous manner to Example 356, 5-[(4-fluoro-2- methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepare 2-isopropyl-5-{[2-methyl-4-('methylamino)phenyl1sulfonyl}-iV-r2-pyridin-2- ylethvDbenzenesulfonamide . MS (ESI) m/z 488; MS (ESI) m/z 486.
Example 600: 5-{[4-(dimethylamino)-2-methyIphenyl]sulfonyl}-2-isopropyl-iV-(2-pyridin- 2-ylethyl)benzenesulfonamide
[0720] In an analogous manner to Example 353, 5-[(4-fluoro-2- methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepare 5-{[4-(dimethylammoV2-methylphenyllsulfonyl|-2-isopropyl-N-(2-pyridin-2- ylethyDbenzenesulfonamide. MS (ES) m/z 500.1; HRMS: calcd for C25H31N3O4S2 + H+, 502.18287; found (ESI-FTMS, [M+H]1+), 502.18264.
Example 601 : 2-(dimethylamino)-5-(phenylsulfonyI)-iV-(2-pyridm-2- ylethyl)benzenesulfonamide
[0721] Step 1 : Following the same procedure described in Example 1 (Step 1), A- nitrobromobenzene and chlorosulfonic acid were used to prepare 2-bromo-5- nitrobenzenesulfonyl chloride.
[0722] Step 2: Following the same procedure described in Example 1 (Step T), 2-(2- ethylamino)pyridine and 2-bromo-5-nitrobenzenesulfonyl chloride were used to prepare 2^ bromo-5-nitro-iV-(2-pyridin-2-ylethyl)benzenesulfonamide.
[0723] Step 3 : 2-bromo-5-nitro-N-(2-pyridin-2-ylethyl)benzenesulfonamide ( 1.5 g, 3.88 mmol) was dissolved in dimethylamine 2.0 M in THF (10 mL) and the resulting solution was microwave heated for 10 mintues at 160 °C. The solution was diluted with ethyl acetate and washed with a saturated aquous ammonium chloride solution. The organic layer was dried over magnesium sulfate, filtered, and concentrated to give 2-dimethylamino-5-m'tro-iV-f2-pyridin-2- ylethvDbenzenesulfonamide (1.3 g, 95%). [0724] Step 4: Following the same procedure described in Example 592 (Step 3), 2- dimethylamino-5-nitro-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepare 2_r dimethylamino-5-ammo-7V-(2-pyridin-2-ylethyl)benzenesulfonamide.
[0725] Step 5: To a stirred solution of 2-dimethylamino-5-amino-N-(2-pyridin-2- ylethyl)benzenesulfonamide (0.60 g, 1.87 mmol) in acetonitrile (15 mL) and hydrobromic acid 48% (1.5 mL) at 0 0C was added sodium nitrite (0.16 g, 2.2 mmol) dissolved in a minimum amount of water dropwise. The resulting solution was stirred 20 minutes and copper I bromide (0.36 g, 2.5 mmol) was added and stirred 1 hr. The solution was diluted with water, neutralized with sodium hydroxide and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and concentrated to give 2-dimethylamino-5-bromo-N-(2-pyridin-2- ylethvDbenzenesulfonamide (0.49 g, 81%).
[0726] Step 6: Following the same procedure described in Example 474 (Step 4), 2- dimethylamino-5-bromo-iV-(2-pyridin-2-ylethyl)benzenesulfonamide and benzene sulfonyl fluoride were used to prepare 2-(dimethylamino)-5-Cphenylsulfonyl)-N-(2-pyridin-2- ylethyDbenzenesulfonamide. MS (ES) m/z 444.1; HRMS: calcd for C21H23N3O4S2 + H+, 446.12027; found (ESI-FTMS, [M+H]1+), 446.1205
Example 602: N-[l-(cycIopropyIcarbonyl)piperidin-4-yl]-N-({5-[(4-fluorophenyl)sulfonyl]- 2- methylphenyl}sulfonyl)cyclopropanecarboxamide
[0727] In an analogous manner to Example 462, 5-[(4-fluorophenyl)sulfonyl]-2- methyl-N-piperidin-4-ylbenzenesulfonamide and cyclopropylcarbonyl chloride were used to prepare N-[l-(cvclopropylcarbonyl)piperidin-4-yl1-N-({5-|T4-fluorophenyl')sulfonyl]-2- methylphenyllsulfonvDcyclopropanecarboxamide. MS (ES+) m/z 549.
Example 603: 5-[(4-fluorophenyl)sulfonyl]-2-methyI-N-[l-(morpholin-4- ylcarbonyl)piperidin-4- yl] benzenesulfonamide
[0728] In an analogous manner to Example 462, 5-[(4-fluorophenyl)sulfonyl]-2- methyl-N-piperidin-4-ylbenzenesulfonamide and 4-morpholinecarbonyl chloride were used to prepare 5-r(4-fluorophenyl)sulfonyl]-2-methyl-N-[l-('morpholin-4-ylcarbonyl')piperidin-4- yllbenzenesulfonamide. MS (ES+) m/z 526 MS (ES-) m/z 524.
Example 604: 2-chIoro-5-[(3-methylphenyl)sulfonyl]-iV-(tetrahydro-2i-r-pyran-4- yl)benzenesulfonamide
[0729] Step 1 : Following the same procedure described in Example 1 (Step 2), 4- aminotetrahydropyran and 2-chloro-5-nitiObenzenesulfonyl chloride were used to prepare 5^ nitro-2-chloro-iV-(tetrahydro-2/j'-pyran-4-yl)benzenesulfonamide.
[0730] Step 2: Following the same procedure described in Example 592 (Step 3), 5- nitro-2-chloro-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide was used to prepare 5-amino-2- chloro-N-rtetrahvdro-2H-pyran-4-yl)benzenesulfonamide.
[0731] Step 3: Following the same procedure described in Example 601 (Step 5), 5- amino-2-chloro-iV-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide was used to prepare 5-bromo- 2-chloro-iV-(tetrahydro-2H'-pyran-4-yDbenzenesulfonamide.
[0732] Step 4: Following the same procedure described in Example 474 (Step 3), 3- methylbenzene sulfonyl chloride was used to prepare 3 -methylbenzenesulfony 1 fluoride.
[0733] Step 5: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-chloro-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide and 3-methylbenzene sulfonyl fluoride were used to prepare 2-chloro-5-[(3-methylphenvπsulfonyl1-7V"-(tetrahydro-2H- pyran-4-vDbenzenesulfonamide. MS (ES) m/z 428.0.
Example 605 : 5- { [3-chloro-4-(methylamino)phenyl] sulfonyl} -2-isopropyl-iV-(2-py ridin-2- ylethyl)benzenesulfonamide
[0734] In an analogous manner to Example 356, 5-[(3-chloro-4-fluorophenyl)sulfonyl]- 2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide was used to prepare 5-{|"3-chloro-4- (methylamino)phenyllsulfonyl}-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ES) m/z 506.1.
Example 606: 2-chloro-5-[(3-methoxyphenyl)sulfonyl]-Λ'-(tetraliydro-2i?-pyran-4- yl)benzenesulfonamide [0735] Step 1 : Following the same procedure described in Example 474 (Step 3), 3- methoxybenzene sulfonyl chloride was used to prepare 3 -methoxybenzenesulfony 1 fluoride.
[0736] Step 2: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-chloro-iV-(tetrahydro-2/i'-pyran-4-yl)benzenesulfonamide and 3-methoxybenzene sulfonyl fluoride were used to prepare 2-chloro-5 - [(3 -methoxypheny Dsulfony 1] -iV-ftetrahy dro- 2H~-pyran-4-yl)benzenesulfonamide. MS (ES) m/z 444.0.
Example 607: 2-chIoro-5- [(l-methyl-LH-indol-5-yl)sulfonyl] -iV-(tetrahy dro-2H-pyran-4- yl)benzenesulfonamide
[0737] In an analogous manner to Example 597,
[0738] Step 3: 5-bromo-2-chloro-iV-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide was used to prepare 2-chloro-5-[(l-methyl-liJr-indol-5-yl')sulfonyl]-N-(tetrahydro-2iJr-pyran-4- yDbenzenesulfonamide. MS (ES) m/z 467.0.
Example 608: 5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-2- (trifluoromethyl)benzenesulfonamide
[0739] A mixture of 5-Berizenesulfonyl-2~trifluoromethyl-benzenesulfinic acid (0.47 g, 1.35 mmol), prepared in the same manner as described in step 5 of Example 570, N- Chlorosuccinimide (0.18 g, 1.36 mmol), and triethylamine (0.38 mL, 2.7 mmol) in 20 mL methylene chloride was stirred under nitrogen for thirty minutes at room temperature. Tetrahydro-2H-pyran-4-amine (0.14 g, 1.35 mmol) was slowly syringed into the flask and the reaction was stirred under nitrogen overnight at room temperature. The solvent was removed under reduced pressure and then the residue was partitioned between methylene chloride and 2 N HCl. The organic layer was separated and the aqueous layer extracted three times with methylene chloride. The combined extracts were dried (anhydrous MgSO4), filtered and the solvent removed under reduced pressure to produce 0.51 g of a dark brown solid. The solid was taken up in methylene chloride and purified on a Horizon™ Flash Collector (Column: Biotage Si 25+M) using a linear gradient of 5% methylene chloride-hexane to 100% methylene chloride as the eluent. Isolation of the main component gave the title compound 5-(phenylsulfonyl)-N- (tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide (55.1 mg, 10%) as a white solid, mp 155-158 °C.
MS (ES) m/z 448.0;
Anal. Calcd for C18H18F3NO5S2: C, 48.10; H, 4.04; N, 3.12. Found: C, 48.12; H, 3.81; N, 2.88.
Example 609: 2,4-Diisopropyl-iV-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide [0740] Step a) 2,4-Diisopropyl-l-(phenylsulfonyl)benzene
[0741] A stirred solution of 1,3-diisopropylbenzene (16.25 g, 100 mmol) and benzenesulfonyl chloride (8.8 g, 50 mmol) was cooled to -20 0C and treated slowly under nitrogen with solid anhydrous aluminum chloride (8.O g, 60 mmol). After stirring neat for 4 hours at room temperature, the mixture was poured slowly into ice water and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and filtered through a short column of silica gel. The filtrate was evaporated in vacuo to yield a crude oil. The crude oil was purified by preparative liquid chromatography on a Biotage® 40 Mi column of pre-packed silica gel (90 g) (multiple runs), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford 2,4-diisopropyl- 1 -(phenylsulfonvPbenzene (5.07 g, 33%), as a clear oil which crystallized on standing to a homogeneous, amorphous solid, m.p. 105-107 °C; MS (-ESI), m/z: 301 [M-FfT;
HRMS: calcd for C18H22O2S, 302.13405; found (EI, M+.), 302.1332; HPLC purity 100% at 210-370 ran, 10.5 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. [0742] Step b) 2,4-Diisopropyl-5-(phenylsulfonyl)benzenesulfonyl chloride [0743] 2,4-Diisopropyl-l-(phenylsulfonyl)benzene (3.01 g, 10 mmol) was heated with stirring at 60 °C for 30 minutes under nitrogen with chlorosulfonic acid (6.7 mL, 11.7 g, 100 mmol). The mixture was cooled to room temperature, poured slowly into a cold solution of IN hydrochloric acid, and extracted with ethyl acetate (2x.). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated in vacuo to a crude oil. The crude oil was crystallized from diethyl ether-hexane to afford 2,4-diisopropyl-5-(phenylsulfonvDbenzenesulfonyl chloride (2.92 g, 73%) as a colorless, crystalline solid, which was utilized in subsequent reactions. [0744] Step c) 2,4-Diisoρroρyl-N-(2-phenylethyl)-5- (phenylsulfonyl)benzenesulfonamide
[0745] A stirred solution of 2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) in dichloromethane (10 mL) was treated dropwise under nitrogen with a solution of phenethylamine (0.12 g, 1.0 mmol) in dichloromethane. After stirring for one hour at room temperature or until the reaction was complete, the mixture was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min. After evaporation of the solvent under vacuum, the title compound, 2,4-diisopropyl-iV-(2- phenylethyiy5-(phenylsulfonyl)benzenesulfonamide (0.22 g, 90%), was obtained as a homogeneous, colorless, crystalline solid, m.p. 156-158 °C; MS (-ESI), m/z: 483.9.1 [M-H]";
HRMS: calcd for C26H31NO4S2 + H+, 486.17673; found (ESI, [M+H]+), 486.1773; HPLC purity 100% at 210-370 nm, 10.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 610: 2,4-Diisopropyl-5-(phenylsulfonyl)-iV-(tetrahydro-2jHr-pyran-4- yl)benzenesulfonamide
[0746] The title compound was prepared from 2,4-diisopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and tetrahydro-pyran-4-ylamine (0.10 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert- butyl ether in hexane at a flow rate of 50 mL/min, to afford 2,4-diisopropyl-5-(phenylsulfonyl> iV-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide (0.20 g, 87%), as a homogeneous, colorless, crystalline solid, m.p. 159-160 °C; MS (ΕSI), m/z: 464.0 [M-H]";
HRMS: calcd for C23H31NO5S2 + H+, 466.17164; found (ESI, M+H), 466.1722; HPLC purity 100% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 611: 2,4~Diisopropyl~5-(phenyIsulfonyl)-iV-(tetrahydro-2/Z-pyran-4- ylmethyl)benzenesulfonamide
[0747] The title compound was prepared from 2,4-diisopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and (tetrahydro-pyran-4- yl)methylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl fert-butyl ether in hexane at a flow rate of 50 rnL/min, to afford 2,4-diisopropyl-5-(phenylsulfonyl)-A/-(tetrahvdro-2iJ'-pyran-4-ylmethyl)benzenesulfonamide (0.22 g, 93%), as a homogeneous, colorless, crystalline solid, m.p. 148-150 °C; MS (+ESI), m/z: 480 [M+H]+; MS (-ESI), m/z: 478 [M-H]";
HPLC purity 100% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 612: 2,4-Diisopropyl-5-(phenylsulfonyl)-iV-[2-(tetrahydro-2iϊ-pyran-4- y l)ethyl] benzenesulf onamide
[0748] The title compound was prepared from 2,4-diisopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and 2-(tetrahydro-pyran-4- yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford 2,4-diisopropyl-5-fphenylsulfonylVN-[2-(tetrahydro-27i-pyran-4-yDethyl1benzenesulfonamide (0.23 g, 91%), as a homogeneous, colorless, crystalline solid, m.p. 90-92 °C; MS (+ESI), m/z: 494 [M+H]+; MS (-ESI), m/z: 492 [M-H]";
HPLC purity 100% at 210-370 nm, 10.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 613: Λf-CyclopentyI-2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide [0749] The title compound was prepared from 2,4-diisopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and cyclopentylamine (0.09 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford N-cy clopentyl-2 ,4-diisopropy 1-5 - (phenylsulfonyl)benzenesulfonamide (0.17 g, 76%), as a homogeneous, colorless, crystalline solid, m.p. 179-181 0C; MS (+ESI), m/z: 450 [M+H]+; MS (-ESI), m/z: 448 [M-H]";
HPLC purity 100% at 210-370 nm, 10.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min.
Example 614: 2,4-Diisopropyl-5-(phenylsulfonyl)-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0750] The title compound was prepared from 2,4-diisopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and 2-(pyridin-2-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert- butyl ether in hexane at a flow rate of 50 mL/min, to afford 2,4-diisopropyl-5-(phenylsulfonyl)- A/-(2-pyridin-2-ylethyDbenzenesulfonamide (0.21 g, 84%), as a homogeneous, colorless, crystalline solid, m.p. 189-191 0C; MS (+ESI), m/z: 487 [M+H]+; MS (-ESI), m/z: 485 [M-H]";
HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=θ.5/ACN+MeOH) for lOmin, hold 4min.
Example 615: Λ^-[3-(liϊ-Imidazol-l-yl)propyl]-2,4-diisopropyl-5- (phenylsulfonyl)benzenesulfonamide
[0751] The title compound was prepared from 2,4-diisopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and 3-(lH-imidazol-l- yl)propylamine (0.13 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-4% methanol in dichloromethane at a flow rate of 50 mL/min, to afford N- [3- (lH'-imidazol-l-yl')propyl1-2,4-diisopiOpyl-5-('phenylsulfonyl)ben2enesulfonamide (0.07 g, 27%), as a homogeneous, colorless, crystalline solid, m.p. 203-205 °C; MS (-ESI), m/z: 488.2 [M-H]";
HPLC purity 100% at 210-370 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 616: 2,4-Diisopropyl-5-(phenylsulfonyl)-iV-(2-pyridin-3- ylethyl)benzenesulfonamide
[0752] The title compound was prepared from 2,4-diisopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and 2-(pyridin-3-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by preparative liquid chromatography on a Biotage " 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%- 100% methyl tert- butyl ether in hexane at a flow rate of 50 mL/min, to afford 2,4-diisopropyl-5-('phenylsulfonylV iV-(2-pyridin-3-ylethyl)benzenesulfonamide (0.15 g, 60%), as a homogeneous, colorless, crystalline solid, m.p. 163-165 0C; MS (-ESI), m/z: 485.2 [M-H]";
HPLC purity 100% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 617: 2,4-Diisopropyl-5-(phenylsulfonyl)-iV-(2-pyridin-4- ylethyl)benzenesulfonamide
[0753] The title compound was prepared from 2,4-diisopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and 2-(pyridin-4-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by preparative liquid chromatography on a Biotage11 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%- 100% methyl tert- butyl ether in hexane at a flow rate of 50 mL/min, to afford 2,4-diisopropyl-5-(phenylsulfonyl> iV-('2-pyridin-4-ylethyl)benzenesulfonamide ("0.12 g, 49%), as a homogeneous, colorless, crystalline solid, m.p. 178-180 °C;
MS (-ESI), m/z: 485.1 [M-H]";
HPLC purity 100% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 618: A'-(2,3-Dihydro-lJfir-inden-2-yl)-2,4-diisopropyl-5- (phenylsulfonyl)benzenesulfonamide
[0754] The title compound was prepared from 2,4-diisopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.20 g, 0.5 mmol) and indan-2-ylamine (0.13 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 609, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford N-(2,3-dihvdro-lH~-inden-2-yl)-2,4-diisopropyl- 5-fphenylsulfonyl*)benzenesulfonamide (0.22 g, 90%), as a homogeneous, colorless, crystalline solid, m.p. 215-217 0C; MS (-ESI), m/z: 496.1 [M-H]";
HPLC purity 100% at 210-370 nm, 11.0 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min.
Example 619: 5-[(4-FIuorophenyl)sulfonyl]-2,4-diisopropyl-iV-(2- phenylethyl)benzenesulfonamide
[0755] Step a) l-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropylbenzene [0756] A stirred solution of 1,3-diisopropylbenzene (16.25 g, 100 mmol) and 4- fluorobenzenesulfonyl chloride (9.73 g, 50 mmol) was cooled to -20 °C and treated slowly under nitrogen with solid anhydrous aluminum chloride (8.0 g, 60 mmol). After stirring neat for 4 hours at room temperature, the mixture was poured slowly into ice water and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and filtered through a short column of silica gel. The filtrate was evaporated in vacuo to yield a crude oil. The crude oil was purified by preparative liquid chromatography on a Biotage® 40 Mi column of pre-packed silica gel (90 g) (multiple runs), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 ■ mL/min, to afford l-["(4-fluorophenyl)sulfonyl1-2,4-diisopropylbenzene (9.71 g, 60%), as a clear oil which crystallized on standing to a homogeneous, amorphous solid, m.p. 75-80 °C; MS (EI), m/z: 320 [M]+;
HRMS: calcd for C18H21FO2S, 320.12463; found (ESI, M+.), 320.1237; HPLC purity 100% at 210-370 nm, 10.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
[0757] Step b) 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropylbenzenesulfonyl chloride
[0758] l-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropylbenzene (3.20 g, 10 mmol) was heated with stirring at 60 0C for 30 minutes under nitrogen with chlorosulfonic acid (6.7 mL, 11.7 g, 100 mmol). The mixture was cooled to room temperature, poured slowly into a cold solution of IN hydrochloric acid, and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated in vacuo to a crude oil. The crude oil was crystallized from diethyl ether-hexane to afford 5-[(4-fluorophenyDsulfonyl]-2,4-diisopropylbenzenesulfonyl chloride (3.11 g, 74%) as a colorless, crystalline solid, which was utilized in subsequent reactions.
[0759] Step c) 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2- phenylethyl)benzenesulfonamide
[0760] A stirred solution of 5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) in dichloromethane (10 mL) was treated dropwise under nitrogen with a solution of phenethylamine (0.12 g, 1.0 mmol) in dichloromethane. After stirring for one hour at room temperature or until the reaction was complete, the mixture was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min. After evaporation of the solvent under vacuum, the title compound, 5-r(4-fluorophenyl')sulfonyl]-2,4-diisopropyl-N-f2-phenylethyl)benzenesulfonamide (0.24 g, 95%), was obtained as a homogeneous, colorless, crystalline solid, m.p. 154-156 °C; MS (-ESI), m/z: 502 [M-H]";
HPLC purity 100% at 210-370 nm, 10.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. ExampIe 620: 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-iV-(tetrahydro-2Jϊ-pyran-4- yl)benzenesulfonamide
[0761] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyi]-2,4- diisopropylbenzenesulfonyl chloride (0.32 g, 0.75 mmol) and tetrahydro-pyran-4-ylamine (0.15 g, 1.5 mmol) according to the procedure and in the same manner as described in Example 619, step c. The crude product was purified by preparative liquid chromatography on a Biotage ' 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford 5- [(4-fluoropheny Dsulfonyll -2,4- diisopropyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide (0.31 g, 86%), as a homogeneous, colorless, crystalline solid, m.p. 183-186 0C; MS (-ESI), m/z: 481.8 [M-H]";
HPLC purity 100% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 621: iV-CyclopentyI-5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropylbenzenesulfonamide
[0762] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and cyclopentylamine (0.09 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 619, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford N-cyclopen1yl-5-[(4-fluorophenvDsulfonyl]-2,4- diisopropylbenzenesulfonamide (0.20 g, 85%), as a homogeneous, colorless, crystalline solid, m.p. 202-205 °C; MS (-ESI), m/z: 465.7 [M-H]";
HPLC purity 100% at 210-370 nm, 10.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 622: 2-chIoro-5-[(4-fluorophenyl)sulfonyl]-Λr-(tetrahydro-2fi-pyran-4- yl)benzenesulfonamide
[0763] Step 1 : Following the same procedure described in Example 474 (Step 3), 4- fluorobenzene sulfonyl chloride was used to prepare 4-fluorobenzenesulfonyl fluoride. [0764] Step 2: Following the same procedure described in Example 474 (Step 4), 5- bromo-2-chloro-iV-(tetrahydro-2H"-pyran-4-yl)benzenesulfonamide and 4-fluorobenzene sulfonyl fluoride were used to prepare 2-chloro-5-r(4-fluorophenyDsulfonvn-iV-('tetrahvdro-2i:/-pyran-4- yDbenzenesulfonamide. MS (ES) m/z 432.0.
Example 623: tert-hntyl 4-({[2-chloro-5-(phenylsulfonyl)phenyl] sulfonyl} amino)piperidine- 1-carboxylate
[0765] In an analogous manner to Example 334,
[0766] Step 3: 4-aminopiperidine-l- carboxylic acid tert-butyl ester was used to prepare tert-butyM-dβ-chloro-S-rphenylsulfonvDphenyllsulfonyljamino'jpiperidine-l-carboxylate. MS (ES) m/z 513.1.
Example 624: 2-chloro-5-(phenylsulfonyl)-iV-piperidin-4-ylbenzenesulfonamide
[0767] tert-butyl 4-({ [2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl} amino)piperidine-l - carboxylate (0.65 g, 1.26 mmol) was stirred in HCl 4 M in dioxane (5 rnL) for 1 hr. The mixture was neutralized with a saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, filtered, and concentrated to give 2-chloro-5-('phenylsulfonyl')-A/'-piperidin-4-ylbenzenesulfonamide (0.37 g, 70%). MS (ES) m/z 412.9.
Example 625: tert-butyl 4-[4-({4-isopropyl-3-[(tetrahydro-2/2r-pyran-4- ylamino)sulfonyl]phenyl}sulfonyl)phenyl]piperazine-l-carboxylate
[0768] In an analogous manner to Example 547, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-tetrahydro-2H-pyran-4-ylbenzenesulfonamide, piperazine-1 -carboxylic acid tert- butyl ester, and dimethylacetamide as solvent were used to prepare tert-butyl 4-[4-f {4-isopropyl- 3-["(tetrahvdro-2H-pyran-4-ylamino)sulfonyl]phenyllsulfonyl) phenyllpiperazine-l-carboxylate. MS (ESI +) m/z 608;
HPLC purity 97.2% at 210-370 nm, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. Example 626: 5-({4-c/s-3,5-dimethyIpiperazin-l-ylphenyl}sulfonyl)-2-isopropyI-Λr- (tetrahydro-2JHr-pyran-4-yl)benzenesulfonamide
[0769] In an analogous manner to Example 547, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-iV-tetrahydro-2H-pyran-4-ylbenzenesulfonamide, cw-2,6-dimethylpiperazine, and dimethylacetamide as solvent were used to prepare 5 -( (4-cis-3 , 5 -dimethy lpiperazin- 1 - ylphenyUsulfonyl)-2-isopropyl-N-(tetrahvdro-2H-pyran-4-yl)benzenesulfonamide. MS (ESI +) m/z 536;
HPLC purity 100% at 210-370 ran, 7.2 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 627: 5-({4-/rαM5-2,5-dimethylpiperazin-l-ylphenyl}sulfonyl)-2-isopropyl-A'- (tetrahydro-2H-pyran-4~yl)benzenesulfonamide
[0770] In an analogous manner to Example 547, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-tetrahydro-2iϊ-pyran-4-ylbenzenesulfonamide, c/>s-2,6-dimethylpiperazine:> and dimethylacetamide as solvent were used to prepare 5-({4-trans-2,5-dimethylpiperazin-l- ylphenyUsulfonylV2-isopropyl-N-('tetrahvdro-2H-pyran-4-yl)benzenesulfonamide. MS (ESI +) m/z 536;
HPLC purity 100% at 210-370 nm, 7.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 628: 2-isopropyl-5-[(4-piperazin-l-ylphenyl)sulfonyl]-iV-(tetrahydro-2Jϊ-pyraii-4- yl)benzenesulfonamide
[0771] To a stirred slurry of tert-butyl 4-[4-({4-isopropyl-3-[(tetrahydro-2H-pyran-4- ylamino)sulfonyl]phenyl}sulfonyl) phenyl]piperazine-l-carboxylate (50 mg, 0.08 mmol) in anhydrous tetrahydrofuran (1 mL) was added a 2.0 M HCl solution in tetrahydrofuran (0.5 mL). After 16 hours the starting material was still present and an additional 0.5 mL of the HCl solution was added and the slurry was stirred at room temperature for an additional 12 h where upon a predominately single product was observed. An aqueous solution of 2 M HCl was added and the aqueous phase was extracted with ethyl acetate (2 x 1 mL). The aqueous phase was then neutralized with a saturated aqueous solution of sodium bicarbonate until it was basic as determined by pH strip. The aqueous phase was then extracted with ethyl acetate (3 x 1 mL) and the combined organic phases were dried (MgSO4), filtered and concentrated to afford 2c isopropy 1-5 - ["(4-piperazin- 1 -ylpheny Psulfonyl] -N-(tetrahydro-2H-pyran-4- yPbenzenesulfonamide (31 mg, 75 %).
MS (ES -) m/z 506.1;
HPLC purity 100% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 629: 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyI-Λ'-(tetrahydro-2i3r-pyran-4- ylmethyl)benzenesulfonamide
[0772] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and (tetrahydro-pyran-4-yl)methylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 619, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert- butyl ether in hexane at a flow rate of 50 mL/min, to afford 5-[(4-fluorophenyl)sulfonyll-2,4- diisopropyl-N-(tetrahydro-2iJr-pyran-4-ylmethyπbenzenesulfonamide (0.22 g, 87%), as a homogeneous, colorless, crystalline solid, m.p. 200-202 0C; MS (-ESI), m/z: 496.1 [M-H]";
HPLC purity 100% at 210-370 nm, 10.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 630 : 5- [(4-Fluorophenyl)sulf onyl] -2,4-diisopropyl-TV- [2-(tetrahy dro~2/ϊ-py ran-4- yl)ethyl]benzenesulfonamide
[0773] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and 2-(tetrahydro-pyran-4-yl)ethylamine (0.13 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 619, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 30%-70% methyl tert- butyl ether in hexane at a flow rate of 50 mL/min, to afford 5-r(4-fluorophenyl)sulfonyll-2,4- diisopropyl-N-["2-(tetrahvdro-2H-pyran-4-yl)ethyl]benzenesulfonamide (0.18 g, 69%), as a homogeneous, colorless, crystalline solid, m.p. 141-143 0C; MS (-ESI), m/z: 510.2 [M-H]'; HPLC purity 100% at 210-370 nm, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 631: 5-[(4-FIuorophenyl)sulfonyI]-2,4-diisopropyl-ΛL(2-pyridin-2- ylethyl)benzenesulfonamide
[0774] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and 2-(pyridin-2-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 619, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford 5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide (0.22 g, 86%), as a homogeneous, colorless, crystalline solid, m.p. 159-161 0C; MS (-ESI), m/z: 503.1 [M-H]";
HPLC purity 100% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 632: 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-iV-(2-pyridin-3- ylethyl)benzenesulfonamide
[0775] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and 2-(pyridin-3-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner described in Example 619, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-hutyl ether in hexane at a flow rate of 50 mL/min, to afford 5-[(4-fluorophenyl*)sulfonyl]-2,4- diisopropyl-A/-(2-pyridin-3-ylethvDben2enesulfonamide (0.18 g, 71%), as a homogeneous, colorless, crystalline solid, m.p. 148-150 °C; MS (-ESI), m/z: 503.1 [M-H]';
HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 633: 5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-iV-(2-pyridin-4- ylethyl)benzenesulfonamide
[0776] The title compound was prepared from 5-[(4-fluorophenyi)sulfonyl]-2,4- diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and 2-(pyridin-4-yl)ethylamine (0.12 g, 1.0 mmol) according to the procedure and in the same manner described in Example 619, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%- 100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford 5-[(4-fluorophenyl)sulfonyl'l-2,4- diisopropyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide (0.14 g, 55%), as a homogeneous, colorless, crystalline solid, m.p. 210-211 0C; MS (-ESI), m/z: 503.1 [M-H]";
HPLC purity 100% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 634: Λr-(2,3-Dihydro-ljHr-inden-2-yl)-5-[(4-fluorophenyl)sulfonyI]-2,4- diisopropylbenzenesulfonamide
[0777] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2,4- diisopropylbenzenesulfonyl chloride (0.21 g, 0.5 mmol) and indan-2-ylamine (0.13 g, 1.0 mmol) according to the procedure and in the same manner as described in Example 619, step c. The crude product was purified by preparative liquid chromatography on a Biotage 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 0%-25% methyl fert-butyl ether in hexane at a flow rate of 50 mL/min, to afford N-(2.3-dihvdro-lH-inden-2-ylV5-|"('4- fluorophenyl)sulfonyll-2,4-diisopropylbenzenesulfonamide (0.23 g, 89%), as a homogeneous, colorless, crystalline solid, m.p. 202-204 °C; MS (-ESI), m/z: 514.1 [M-H]";
HPLC purity 100% at 210-370 nm, 11.1 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 635 : 1 -{ [2-chloro-5-(pheny lsulfony l)phenyl] sulf onyl} -4-py rrolidin-1 -ylpiperidine
[0778] In an analogous manner to Example 334,
[0779] Step 3: 4-pyrrolidin-l-yl-piperidine was used to prepare l-{[2-chloro-5- (phenylsulfonγl)phenvnsulfonyl} -4-pyrrolidin- 1 -ylpiperidine. MS (ESI) m/z 469.
Example 636: 4-[2-(4-{[2-chIoro-5-(phenylsulfonyl)phenyl]sulfonyI}piperazin~l- yl)ethy 1] morpholine
[0780] In an analogous manner to Example 334,
[0781] Step 3: 4-(2-piperazin-l-ylethyl)-morpholine was used to prepare 4-[2-(4-{[2- chloro-5-(phenylsulfonyl)phenyl1sulfonyl}piperazin-l-yl)ethyllmorpholine. MS (ESI) m/z 514.
Example 637: l-(l,3-benzodioxol-5-y!methyl)-4-{[2-chloro-5- (phenylsulfonyl)phenyl]sulfonyl}piperazine
[0782] In an analogous manner to Example 334,
[0783] Step 3: l-benzo[l,3]dioxol-5-ylmethyl-piperazine was used to prepare 1-(1,3- benzodioxol-5-ylmethyl')-4-{r2-chloro-5-(phenylsulfonyl)phenyl1sulfonyUpiperazine. MS (ESI) m/z 535.
Example 638: fert-butyl (l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}pyrrolidin-3- yl)carbamate
[0784] In an analogous manner to Example 334,
[0785] Step 3: pyrrolidin-3-yl-carbamic acid tert-butyl ester was used to prepare tert- butyl ( 1 - { [2-chloro-5-(phenylsulfony Dphenyl] sulfonyl } pyrrolidin-3 -vDcarbamate . MS (ESI) m/z 501.
Example 639: tert-butyl (l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperidin-4- yl)carbamate
[0786] In an analogous manner to Example 334,
[0787] Step 3 : piperidin-4-yl-carbamic acid tert-butyl ester was used to prepare tert- butyl ri-{r2-chloro-5-(phenylsulfonyl)phenyl]sulfonyljpiperidin-4-yDcarbamate. MS (ESI) m/z 515.
Example 640: 2-chloro-5-(phenylsulfonyl)-iV-(2-pyridin-3-ylethyl)benzenesuIfonamide
[0788] In an analogous manner to Example 334, [0789] Step 3: 2~pyridin-3-yl-ethylarnine was used to prepare 2-chloro-5- (phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide. MS (ESI) m/z 437.
Example 641 : 2-chloro-5-(phenyIsulfonyl)-iV-(2-pyridin-4-ylethyl)benzenesulfonamide
[0790] In an analogous manner to Example 334,
[0791] Step 3: 2-pyridin-4-yl-ethylamine was used to prepare 2-chloro-5- (phenylsulfonylVA/'-(2-pyridin-4-yletliyl>)benzenesulfonamide. MS (ESI) m/z 437.
Example 642: 2-chloro-iV-[3-(4-methylpiperazin-l-yl)propyl]-5- (phenylsulfonyl)benzenesulfonamide
[0792] In an analogous manner to Example 334,
[0793] Step 3: 3-(4-methylpiperazin-l-yl)-propylamine was used to prepare 2-chloro- N-[3-(4-methylpiperazin-l-yl)propyll-5-(phenylsulfonyl)benzenesulfonamide. MS (ESI) m/z 472.
Example 643: 2-chloro-iV-(2-cyanoethyl)-5-(phenylsulfonyl)benzenesulfonamide
[0794] In an analogous manner to Example 334,
[0795] Step 3 : 3-aminopropionitrile was used to prepare 2-chloro-A/"-(2-cvanoethyiy5- (phenylsulfonyDbenzenesulfonamide. MS (ESI) m/z 385.
Example 644: l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}-ΛVV-diethylpyrrolidin-3- amine
[0796] In an analogous manner to Example 334,
[0797] Step 3: diethylpyrrolidin-3-yl-amine was used to prepare l-{r2-chloro-5- (phenylsulfonyl)pb.enyllsulfonyl}-N,A/-diethylpyrrolidin-3-amine. MS (ESI) m/z 457.
Example 645: ethyl l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperidine-3- carboxylate [0798] In an analogous manner to Example 334,
[0799] Step 3: piperidine-3-carboxylic acid ethyl ester was used to prepare ethyl 1-{|"2- chloro-5-(phenylsulfonyl)phenyllsulfonyl)piperidine-3-carboxylate. MS (ESI) m/z All.
Example 646: 2-chloro-iV-methyI-5-(phenylsulfonyl)-iV-(2-pyridin-2- ylethyl)benzenesulfonamide
[0800] In an analogous manner to Example 334,
[0801] Step 3 : methyl-(2-pyridin-2-yl-ethyl)-amine was used to prepare 2-chloro-JV- methyl-5-(phenylsulfonyD-iV-(2-pyridin-2-ylethyl)benzenesulfonamide. MS (ESI) m/z 451.
Example 647: 2-chloro-5-(phenylsulfonyl)-JV-[l-(trifluoroacetyl)piperidin-4- yl]benzenesulfonamide
[0802] To a stirred solution of 2-chloro-5-(phenylsulfonyl)-N-piperidin-4- ylbenzenesulfonamide (0.09 g, 0.22 mmol) in dichloromethane (2 mL) was added triethylamine (0.1 mL, 0.72 mmol) and trifluoroacetic anhydride (0.09 g, 0.42 mmol). The resulting solution was stirred for 1 hr and concentrated. The crude mixture was flash column separated using 10- 50% ethyl acetate/ hexane to give 2-chloro-5-("phenylsulfonyl)-N-["l-(trifluoroacetyl)piperidin-4- yl~|benzenesulfonamide (0.04 g, 36%). MS (ESI) m/z 511.
Example 648: 2-chIoro-ΛL[l-(2,2-dimethyIpropanoyI)piperidin-4-yI]-5- (phenylsulfonyl)benzenesulfonamide
[0803] In an analogous manner to Example 647, trimethylacetyl chloride was used to prepare 2-chloro-N-ri-(2,2-dimethylpropanoyl)piperidin-4-yl1-5- ("phenylsulfonvDbenzenesulfonamide. MS (ESI) m/z 499.
Example 649: 7V-(tert-butyl)-4-({[2-chloro-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxamide [0804] In an analogous manner to Example 647, tert-butyl isocyanate was used to prepare N-(tert-butylV4-({r2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxamide. MS (ESI) m/z 512.
Example 650: 2-chloro-Λr-[l-(morphoIin-4-ylcarbonyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide
[0805] In an analogous manner to Example 647, morpholine-4-carbonyl chloride was used to prepare 2-chloro-iV- [ 1 -(morpholin-4-y lcarbony l)piperidin-4-vn -5 - (phenylsulfonvDbenzenesulfonamide. MS (ESI) m/z 528.
Example 651 : 2-chloro-Λ'-(l-cyanopiperidm-4-yl)-5-(phenylsulfonyl)benzenesulfonamide
[0806] In an analogous manner to Example 647, cyanogens bromide was used to prepare 2-chloro-JV-( 1 -cyanopiperidin-4-yl V 5 -(pheny lsulfonyDbenzenesulfonamide . MS (ESI) m/z 440.
Example 652: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[2-(l-oxidopyridin-3- yl)ethyl]benzenesulfonamide
[0807] 100 mg of 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-3- ylethyl)benzenesulfonamide was added to 4 mL of 50% hydrogen peroxide/acetic acid and the reaction was heated at 100 0C for four hours. The reaction was poured onto saturated bicarbonate solution and extracted with dichloromethane. The organic layer was washed with sodium dithionite solution. The organic layer was dried with magnesium sulfate and concentrated. Crude material was purified by flash chromatography using 10% methanol/dichloromethane to give 5- [Y 4-fluorophenyl)sulfony 1] -2-isopropy 1-N- \2-( 1 - oxidopyridin-3- yl)ethyl]benzenesulfonamide. MS (ES+) m/z 479 MS (ES-) m/z All.
Example 653: l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}-4-[(2,5-dimethyl-lJH-pyrrol- l-yl)methyl]piperidine [0808] In an analogous manner to Example 647, 4-(2,5-dimethylpyrrol-l -ylmethyl)- piperidine was used to prepare l-{|"2-chloro-5-(phenylsulfonyl)phenyllsulfonyl|-4-[(2,5- dimethy 1- 1 i7-pyrrol- 1 -vDmethyllpiperidine . MS (ES) m/z 507.0.
Example 654: methyl Λr-{[2-chloro-5-(phenylsuIfonyl)phenyl]sulfonyl}-2-methylalaninate
[0809] To a stirred solution of methyl alpha-aminoisobutyrate hydrochloride (1.3 g, 8.53 mmol) in a saturated aqueous sodium bicarbonate solution was added 5-benzenesulfonyl-2- chlorobenzenesulfonyl chloride (1.5 g, 4.27 mmol) dissolved in acetonitrile (10 mL). The resulting solution was stirred vigorously 1 hr and extracted several times with ethyl acetate. The combined organic layers were washed with ammonium chloride solution and concentrated. Flash column separation using 10-50% ethyl acetate /hexane gave methyl iV-{[2-chloro-5- (pheny lsulfony Dphenyl] sulfonyl } -2-methylalaninate (0.96 g, 52%) MS (ESI) m/z 432.
Example 655: 2-chloro-Λ^2-hydroxy-l,l-dimethylethyl)-5- (phenylsulfonyl)benzenesulfonamide
[0810] To a stirred solution of methyl N- { [2-chloro-5-
(phenylsulfonyl)phenyl]sulfonyl}-2-methylalaninate (1.20 g, 2.78 mmol) in THF (16 mL) at -78 °C was added diisobutylaluminum hydride 1.0 M in toluene (16.0 mL, 16.0 mmol) dropwise over 10 minutes. The resulting solution was stirred for 6 hours at -78°C, quenched with 0.5 M HCl solution and extracted several times with ethyl acetate. The combined organic layer was dried over magnesium sulfate, and concentrated to give 2-chloro-iV-(2-hydroxy-l,l- dimethylethyl)-5-(phenylsulfonyl)benzenesulfonamide (0.64 g, 57%). MS (ES-) m/z 402.0;
HPLC purity 100% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C16H18ClNO5S2 + H+, 404.03877; found (ESI, [M+H]+), 404.0384.
Example 656: 2-chloro-A'-[l-(4-fluorobenzoyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide [0811] In an analogous manner to example 462, 2-chloro-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 4-fluorobenzoyl chloride were used to prepare 2-chloro- iV-[l-(4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 534.9;
HPLC purity 100% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H22ClFN2O5S2 + H+, 537.07154; found (ESI, [M+H]+), 537.0699.
Example 657: 2-chloro-iV-[l-(4-cyanobenzoyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide
[0812] In an analogous manner to example 462, 2-chloro-5-(phenylsulfonyl)-N- piperidin-4-ylbenzenesulfonamide and 4-cyanobenzoyl chloride were used to prepare 2-chloro- iV-[l-(4-cyanobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 541.9;
HPLC purity 100% at 210-370 nm, 8.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H22ClN3O5S2 + H+, 544.07622; found (ESI, [M+H]+), 544.075.
Example 658: 2-chloro-5-(phenylsulfonyl)-Λ'-{l-[4-(trifluoromethyl)benzoyl]piperidin-4- yl}benzenesulfonamide
[0813] In an analogous manner to example 462, 2-chloro-5-(phenylsulfony I)-N- piperidin-4-ylbenzenesulfonamide and 4-trifluoromethylbenzoyl chloride were used to prepare 2- chloro-5-(phenylsulfonyl)-N-{l-[4-(trifluoromethyl)benzoyl]piperidin-4-yl}benzenesulfonamide. MS (ES-) m/z 584.9;
HPLC purity 94.5% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min.
Example 660: 5-(phenyIsulfonyl)-iV-(2-pyridiii-3-ylethyl)-2- (trifluoromethoxy)benzenesulfonamide
[0814] Step 1 : l-bromo-4-trifluoromethoxybenzene (0.50 g, 2.07 mmol) was added to chlorosulfonic acid (2 mL, 29.0 mmol) at room temperature. The resulting mixture was stirred 2 hours, poured over ice, and extracted several times with ethyl acetate. The combined organic layer was washed with water, dried over magnesium sulfate and concentrated to give 5-bromo-2- trifluoromethoxybenzene sulfonyl chloride (0.45 g, 64%)
[0815] Step 2: In an analogous manner to example 435, 5-bromo-2- trifluoromethoxybenzene sulfonyl chloride and 3-(2-aminoethyl)pyridine were used to prepare 5- bromo-N-(2-pyridin-3-ylethyl)-2-(trifluoromethoxy)benzenesulfonamide.
[0816] Step 3: Following the same procedure described on example 474 (Step 4), 5- bromo-N-(2-pyridin-3-ylethyl)-2-(tiifluoromethoxy)benzenesulfonamide and benzene sulfonyl fluoride were used to prepare 5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)-2- (trifluoromethoxy)benzenesulfonamide. MS (ES-) m/z 485.0;
HPLC purity 92.5% at 210-370 nm, 8.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H17F3N2O5S2 + H+, 487.06037; found (ESI, [M+H]+), 487.0615.
Example 662: 5-(phenylsulfonyl)-JV~(tetrahydro-2iϊ-pyraii-4-yl)-2- (trifluoromethoxy)benzenesulfonamide
[0817] In an analogous manner to Example 660,
Step 2: 5-bromo-2-trifluoromethoxybenzene sulfonyl chloride and tetrahydro-pyran-4- ylamine was used to prepare 5-bromo-N-(tetrahydro-2/f-pyran-4-yl)-2- (trifluoromethoxy)benzenesulfonamide
[0818] Step 3: 5-bromo-N-(tetrahydro-2H-pyran-4-yl)-2-
(trifluoromethoxy)benzenesulfonamide and benzene sulfonyl fluoride were used to prepare 5- (phenylsulfonyl)-N-(tetrahydro-2/i'-pyran-4-yl)-2-(trifluoromethoxy)benzenesulfonamide. MS (ES-) m/z 464.0;
HPLC purity 95.2% at 210-370 nm, 8.8 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C18Hi8F3NO6S2 + H+, 466.06004; found (ESI, [M+H]+), 466.0606.
Example 663: 2-chloro-iV-(cyanomethyl)-5-(phenylsuIfonyl)benzenesulfonamide
[0819] In an analogous manner to example 654, 2-chloro-5~(phenylsulfonyl)- benzenesulfonyl chloride and aminoacetonitrile HCl were used to prepare 2-chloro-vV- (cyanomethyl)-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 369.0;
HPLC purity 88.5% at 210-370 nm, 7.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 664: Λ^-(2-cyanoethyl)-5-[(4-fluorophenyl)suIfonyl]-2- isopropylbenzenesulfonamide
[0820] In an analogous manner to example 435, 5-(4-fluoro-benzenesulfonyl)-2- isopropyl-benzenesulfonyl chloride and aminopropionitrile were used to prepare N-(2- cyanoethyl)-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide. MS (ES-) m/z 409.1;
HPLC purity 99.0% at 210-370 nm, 8.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C18H19FN2O4S2 + H+, 411.08430; found (ESI, [M+H]+), 411.0841.
Example 665: 2-methyI-iV-(3-oxo-3-pyrrolidm-l-ylpropyl)-5- (phenylsulfonyl)benzenesulfonamide
[0821] To a solution of methyl N- { [2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-beta- alaninate (1.3 g, 3.3 mmol) in water (10 mL) and tetrahydrofuran (10 mL) was added lithium hydroxide monohydrate (0.67 g, 16 mmol). The resulting mixture was stirred overnight at room temperature. The mixture was then washed with ether and the organic phase was discarded. The aqueous phase was treated with 4 N HCl to pH 1 and then extracted with ethyl acetate. The ethyl acetate extract was dried (MgSO4), filtered, and concentrated to provide the desired 3-(5- benzenesulfonyl-2-methyl-benzenesulfonylamino)-propionic acid (1.2 g, 3.1 mmol). The 3-(5- benzenesulfonyl-2-methyl-benzenesulfonylamino)-propionic acid (1.2 g, 3.1 mmol) was dissolved in dichloromethane (40 mL) containing dimethylformamide (3 drops) and then treated with oxalyl chloride (1.0 mL, 11 mmol). The resulting solution was stirred at room temperature for 2 h and then concentrated to dryness. The crude 3-(5-benzenesulfonyl-2-methyl- benzenesulfonylamino)-propionyl chloride was dissolved in dichloromethane and used without further purification. To a solution of crude 3-(5-benzenesulfonyl-2-methyl- benzenesulfonylamino)-propionyl chloride (0.10 g, 0.25 mmol) in dichloromethane (1 mL) was added pyrrolidine (22 mg, 0.31 mmol) and triethylamine (55 μL, 0.39 mmol). The resulting solution was stirred overnight at ambient temperature, and then diluted with ethyl acetate and washed with saturated aqueous ammonium chloride, sodium bicarbonate, and brine. The organic phase was dried (MgSO4), concentrated, and purified by flash column chromatography to provide 2-methyl-iV-(3-oxo-3-pyrrolidin-l -ylpropyl)-5-(phenylsulfonyl)benzenesulfonamide (48 mg).
MS (ES+) m/z 437.1;
HPLC purity 91.3% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 666: Λ^-(tert-butyl)-iV3-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-β- alaninamide
[0822] In an analogous manner to Example 665, crude 3-(5-benzenesulfonyl-2-methyl- benzenesulfonylamino)-propionyl chloride (0.10 g, 0.25 mmol), t-butylamine (23 mg, 0.31 mmol) and triethylamine (55 μL, 0.39 mmol) in dichloromethane (1 mL) were used to prepare N- (tert-butyl)-N3-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-β-alaninamide (21 mg). MS (ES+) m/z 439.1;
HPLC purity 86.3% at 210-370 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min.
Example 667: iV3-{[2-methyl-5-(phenylsulfonyl)phenyl]suIfonyl}-iV-(l,2,3,4- tetrahydronaphthalen-l-yl)-β-alaninamide
[0823] In an analogous manner to Example 665, crude 3-(5-benzenesulfonyl-2-methyl- benzenesulfonylamino)-propionyl chloride (0.10 g, 0.25 mmol), 1,2,3,4-tetrahydro-l- naphthylamine (46 mg, 0.31 mmol) and triethylamine (55 μL, 0.39 mmol) in dichloromethane (1 mL) were used to prepare N3-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-N-(l,2,3,4- tetrahydronaphthalen-l-yl)-β-alaninamide (63 mg). MS (ES-) m/z 511.0;
HPLC purity 87.0% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min.
Example 668: iV-methyl-Λ'3-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-iV-phenyl-β- alaninamide [0824] In an analogous manner to Example 665, crude 3-(5-benzenesulfonyl-2-methyl- benzenesulfonylamino)-propionyl chloride (0.10 g, 0.25 mmol), iV-methylaniline (34 mg, 0.31 mmol) and triethylamine (55 μL, 0.39 mmol) in dichloromethane (1 mL) were used to prepare iV- methyl-N3"! [2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-Λ/-phenyl-β-alaninamide (34 mg). MS (ES+) m/z 473.1;
HPLC purity 82.7% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 669: 2-methyI-Λ'-[3-(6-methyl-3,4-dihydroquinoIin-l(2ir)-yl)-3-oxopropyl]-5- (phenylsulfonyl)benzenesulfonamide
[0825] In an analogous manner to Example 665, crude 3-(5~benzenesulfonyl-2-methyl- benzenesulfonylamino)-propionyl chloride (0.10 g, 0.25 mmol), 6-methy 1-1, 2,3,4- tetrahydroquinoline (46 mg, 0.31 mmol) and triethylamine (55 μL, 0.39 mmol) in dichloromethane (1 mL) were used to prepare 2-methyl-iV-[3-(6-methyl-3,4-dihydroquinolin- 1 (2/i)-yl)-3-oxopropyl]-5-(phenylsulfonyl)benzenesulfonamide (29 mg). MS (ES+) m/z 513.1;
HPLC purity 91.0% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 670: 2-isopropyl-5-(phenylsulfonyI)-JV-(tetrahydro-2/f-pyran-4- yl)benzenesulfonamide
[0826] In an analogous manner to Step 3, Example 295:
5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and tetrahydro-pyran-4-ylamine were used to prepare 2-isopropyl-5-(phenylsulfonyl)-N-(te1xahydro-2H-pyran-4- yl)benzenesulfonamide MS (ES-) m/z 422.1;
HPLC purity 99.5% at 210-370 nm, 8.9 min.; Xterra RPl 8, 3.5u, 15O x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H25NO5S2 + H+, 424.12469; found (ESI, [M+H]+), 424.127.
Example 671 : 2-isopropyl-5-(phenylsulfonyl)-iV-(2-pyridin-2-ylethyl)benzenesulfonamide
[0827] In an analogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 2-pyridin-2-yl-ethylamine were used to prepare 2-isopropyl-5-(phenylsulfonyl)-N-(2-pyridin-2- y lethy l)benzenesulfonamide . MS (ES+) m/z 445.0;
HPLC purity 99.5% at 210-370 nm, 9.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H24N2O4S2 + H+, 445.12502; found (ESI, [M+H]+)5 445.1251.
Example 672: 2-isopropyl-5-(phenylsulfonyl)-iV-(2-pyridin-3-ylethyl)benzenesulfonamide
[0828] In an analogous manner to Step 3, Example 295:
5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 2-pyridin-3-yl-ethylamine were used to prepare 2-isopropyl-5-(phenylsulfonyl)-N-(2-pyridin-3- y lethy l)benzenesulfonamide . MS (ES+) m/z 445.0;
HPLC purity 99.6% at 210-370 nm, 8.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 673: 2-chloro-iV-(2-hydroxyethyl)-5-(phenylsulfonyl)benzenesulfonamide [0829] In an analogous manner to example 654, 2-chloro-5-(phenylsulfonyl)- benzenesulfonyl chloride and ethanolamine were used to prepare 2-chloro-N-(2-hydroxyethyl)-5- (phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 373.9;
HPLC purity 99.6% at 210-370 nm, 7.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. HRMS: calcd for C14H14ClNO5S2 + H+, 376.00747; found (ESI, [M+H]+), 376.0079.
Example 674: 2-chloro-JV-(2-hydroxy-l-methylethyl)-5- (phenylsulfonyl)benzenesulfonamide
[0830] In an analogous manner to example 654, 2-chloro-5-(phenylsulfonyl)- benzenesulfonyl chloride and alanol were used to prepare 2-chloro-7V-(2-hydroxy-l- methylethyl)-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 388.0;
HPLC purity 96.9% at 210-370 nm, 7.6 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C15H16ClNO5S2 + H+, 390.02312; found (ESI-FTMS, [M+H]1+), 390.02353.
Example 675: 2-chloro-iV-[2-hydroxy-l-(hydroxymethyl)ethyl]-5- (phenylsulfonyl)benzenesulfonamide
[0831] In an analogous manner to example 654, 2-chloro-5-(phenylsulfonyl)- benzenesulfonyl chloride and serinol were used to prepare 2-chloro-iV-[2~hydroxy-l- (hydroxymethyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide.
MS (ES-) m/z 403.9;
HPLC purity 95.9% at 210-370 nm, 6.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C15H16ClNO6S2 + H+, 406.01803; found (ESI-FTMS, [M+H]1+), 406.01897.
Example 676: 2-chloro-iV-[(lR*,2R*)-2-hydroxy-l-methyl-2-phenylethyl]-5- (phenylsulfonyl)benzenesulfonamide
[0832] In an analogous manner to example 654, 2-chloro-5-(phenylsulfonyl)- benzenesulfonyl chloride and norephedrine were used to prepare 2-chloro-N-[(li?*,2i?*)-2- hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 463.9;
HPLC purity 100% at 210-370 nm, 9.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H20ClNO5S2 + Na+, 488.03636; found (ESI-FTMS, [M+Na]1+), 488.0366.
Example 677: 5-(phenylsuIfonyl)-N-(2-pyridin-3-ylethyl)-2- (trifluoromethyl)benzenesulfbnamide
[0833] Step 1: To a stirred solution of aluminum chloride (9.56 g, 71.7 mmol) in benzene (30 mL) was added 4-chloro-3-nitrobenzenesulfonyl chloride (15.3 g, 59.75 mmol). The resulting mixture was stirred overnight at room temperature, poured over ice, and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated to give 5-(phenylsulfonyl)-2-chloro-nitrobenzene. (14.9 g, 84%). [0834] Step 2: To a stirred solution of 5-(phenylsulfonyl)-2-chloro-nitrobenzene (13.8g, 41.66 mmol) in dimethylacetamide (85 mL) was added copper powder (15.9 g, 250 mmol), activated charcoal (6.9 g), and difluorodibromomethane (7.6 mL, 83.32 mmol). The resulting solution was stirred at 100°C for 3 hours. The mixture was allowed to cool to room temperature and filtered through celite with ethyl acetate. The filtrate was partitioned between ammonium chloride solution (sat) and ethyl acetate. The aqueous layer was extracted a second time with ethyl acetate. The combined organic layers were washed with water several times, washed with brine, dried over magnesium sulfate and concentrated. Flash column separation using 0%-20% ethyl acetate/hexane gradient gave 5-(phenylsulfonyl)-2-trifluoromethyl-nitrobenzene (5.6 g, 41%).
[0835] Step 3 : To a stirred solution of 5-(phenylsulfonyl)-2-trifluoromethyl- nitrobenzene (4.14 g, 12.5 mmol) in methanol (90 mL) was added water (4 mL) and Tin (II) Chloride (11.85 g, 62.85 mmol). The resulting solution was heated to 700C for 3 days. The solution was allowed to cool to room temperature and quenched with sodium bicarbonate solution (sat) and extracted several times with ethyl acetate. The combined organic layer was washed with brine, dried over magnesium sulfate and concentrated to give 5-(phenylsulfonyl)-2- trifluoromethylaniline (3.6 g, 95%).
[0836] Step 4: To a stirred solution of 5-(phenylsulfonyl)-2-trifluoromethylaniline (3.6 g, 11.95 mmol) in acetonitrile (85 mL) at 0°C was added concentrated acetic acid (8.5 mL) and concentrated hydrochloric acid (8.5 mL). To this solution was added sodium nitrite (0.99 g, 14.34 mmol) dissolved in water (1.5 mL) in a dropwise fashion. The resulting solution was stirred for 20 minutes, followed by bubbling in sulfur dioxide over 10 minutes. Immediately upon completion of sulfur dioxide addition, copper (II) chloride dihydride (2.0 g, 12.0 mmol) dissolved in water (2 mL) was added all at once. The mixture was allowed to warm to room temperature and stirred overnight. The reaction was diluted with water and extracted with ethyl acetate several times. The combined organic layer was washed with ammonium chloride solution (sat.), water, and brine. The organic phase was dried over magnesium sulfate, and concentrated. Flash column separation using 10%-30% ethyl acetate/hexane gradient gave 2- trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride (1.7 g, 37%).
[0837] Step 5: Following the same procedure described on example 435, 2- trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 3-(2-aminoethyl)pyridine were used to prepare 5-(phenylsulfonyl)-iV-(2-pyridin-3-ylethyl)-2-
(trifluoromethyl)benzenesulfonamide.
MS (ES-) m/z 468.9;
HPLC purity 100% at 210-370 ran, 8.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C20H17F3N2O4S2 + H+, 471.06546; found (ESI-FTMS, [M+H]1+), 471.06448.
Example 678: l-Methoxy-4-(phenylsulfonyI)benzene
[0838] Step a
A stirred solution of benzene (10 mL, 100 mmol) and 4-methoxybenzenesulfonyl chloride (4.12 g, 20 mmol) was cooled to -40 °C and treated slowly under nitrogen with solid anhydrous aluminum chloride (3.2 g, 24 mmol). After stirring neat for 4 hours at room temperature, the mixture was slowly poured into cold IN hydrochloric acid and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and filtered through a short column of silica gel. The filtrate was evaporated in vacuo to yield l-methoxy-4-(phenylsulfonyl)benzene (4.96 g, 100%) as a homogeneous oil which solidified on standing.
[0839] Step b
2-Methoxy-5-(phenylsulfonyl)benzenesulfonyl chloride l-methoxy-4-(phenylsulfonyl)benzene (4.96 g, 20 mmol) was stirred for 30 minutes under nitrogen with chlorosulfonic acid (13.2 mL, 23.2 g, 200 mmol). The mixture was cooled to room temperature, poured slowly into a cold solution of IN hydrochloric acid, and extracted with ethyl acetate (2x). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated in vacuo to a crude oil. The crude oil was crystallized from diethyl ether-hexane to afford 2- methoxy-5-(phenylsulfonyl)benzenesulfonyl chloride (5.12 g, 74%) as a colorless solid, which was utilized in subsequent reactions.
[0840] Step c
2-Methoxy-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide
A stirred solution of 2-methoxy-5-(phenylsulfonyl)benzenesulfonyl chloride (0.35 g, 1.0 mmol) in dichloromethane (10 mL) was treated dropwise under nitrogen with a solution of 2- (pyridin-3-yl)ethanamine (0.24 g, 2.0 mmol) in dichloromethane. The reaction was stirred for 18 hours at room temperature. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (90 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford, after crystallization from ethyl acetate-diethyl ether-hexane, 2-methoxy-5-(phenylsulfonyl)-N-(2- pyridin-3-ylethyl)benzenesulfonamide (0.26 g, 60%), as a homogeneous, colorless, crystalline solid, m.p. 181-183 0C;
MS (+ESI), m/z: 433.1 [M+H]+;
HRMS: calcd for C20H20N2O5S2 + H+, 433.08864; found (ESI, [M+H]+), 433.0907;
HPLC purity 100% at 210-370 run, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 679: iV-(2-cyanoethyl)-5-(phenyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide [0841] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and aminopropionitrile were used to prepare JV-(2-cyanoethyl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 417.0;
HPLC purity 95.3% at 210-370 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C16H13F3N2O4S2 + H+, 419.03416; found (ESI, [M+H]*), 419.0344.
Example 680: 5-(phenylsulfonyl)-2-(trifluoromethyl)-iV-{l-[4- (trifluoromethyl)benzoyl]piperidin-4-yI}benzenesulfonamide
[0842] Step 1 : In an analogous manner to example 462, piperidin-4-yl-carbamic acid tert-butyl ester and 4-trifluoromethylbenzoyl chloride were used to prepare [l-(4- trifluoromethyl-benzoyl)-piperidin-4-yl]-carbamic acid tert-butyl ester.
[0843] Step 2: [l-(4-trifluoromethyl-benzoyl)-piperidin-4-yl]-carbamic acid tert-butyl ester (1.50 g, 4.0 mmol) was dissolved in HCl in 1,4-dioxane 4M solution (6 mL, 24 mmol). The resulting solution was stirred 2 hours and concentrated. The crude was partitioned between sodium bicarbonate solution (sat) and ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated to give l-(trifluoromethyl)benzoyl-4- aminopiperidine. [0844] Step 3: In an analogous manner to example 435, 2-trifluoromethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and l-(trifluoromethyl)benzoyl-4-aminopiperidine were used to prepare 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-{l-[4- (trifluoromethyl)benzoyl]piperidin-4-yl}benzenesulfonamide. MS (ES+) m/z 621.1;
HPLC purity 100% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H22F6N2O5S2 + H+, 621.09471; found (ESI, [M+H]+), 621.0933.
Example 681: iV-(2-hydroxyethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0845] In an analogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and ethanolamine were used to prepare iV-(2-h.ydroxyethyi)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 410.1;
HPLC purity 100% at 210-370 nm, 7.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C15Hi4F3NO5S2 + H+, 410.03382; found (ESI, [M+H]+), 410.0352.
Example 682: iV-(2-hydroxy-2-phenylethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0846] In an analogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 2-phenylethanolamine were used to prepare N-(2-hydroxy-2- phenylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 484.0;
HPLC purity 100% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 683: iV-(2-hydroxy-l-methylethyl)-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide [0847] In an analogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and alanol were used to prepare N-(2-hydroxy-l-methylethyl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 422.0;
HPLC purity 97.9% at 210-370 ran, 8.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C16H16F3NO5S2 + H+, 424.04947; found (ESI, [MfH]+), 424.0484.
Example 684: iV-[(li?*,2i?A)-2-hydroxy-l-methyl-2-phenyIethyl]-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0848] In an analogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and norephedrine were used to prepare N-[(li-*,2i?*)-2-hydroxy-l- methyl-2-phenylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 498.0;
HPLC purity 98.0% at 210-370 ran, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 685: iV-[(lS,2R)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfbnamide
[0849] In an analogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and (15',2i?)-2-hydroxy-2-phenyl-l -methyl- 1-aminoethane were used to prepare N-[(lS',2i?)-2-hydroxy-l -methyl-2-phenylethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 498.0;
HPLC purity 96.6% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 686: iV-[(ljR,25)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0850] In an analogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and (li?,25)-2-hydroxy-2-phenyl-l-methyl-l-aminoethane were used to prepare N-[(li?,25)-2-hydroxy-l-methyl-2-phenylethyl]-5-(p]ienylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide.
MS (ES-) m/z 498.0;
HPLC purity 97.6% at 210-370 nm, 9.4 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 687: fert-butyl 4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate
[0851] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 4-ammopiperidine-l- carboxylic acid tert-butyl ester were used to prepare tert-butyl 4-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidine- 1-carboxylate. MS (ES-) m/z 547.0;
HPLC purity 97.4% at 210-370 nm, 10.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 688: 5-(phenylsuIfonyl)-iV-piperidin-4-yl-2-(trifluoromethyI)benzenesulfonamide
[0852] tert-butyl 4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate (1.57 g, 2.86 mmol) was dissolved in HCl in 1,4-dioxane 4M solution (8 mL, 32 mmol). The resulting solution was stirred overnight and concentrated. The crude was partitioned between sodium bicarbonate solution (sat) and ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated to give 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (1.1 g, 85%). MS (ES+) m/z 449.1;
HPLC purity 98.0% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C18H19F3N2O4S2 + H+, 449.08111; found (ESI, [M+H]+), 449.083.
Example 689: 2-Methoxy-5-(phenyIsuIfonyl)-Λr-(tetrahydro-2/jT-pyran-4- yl)benzenesulfonamide [0853] A stirred solution of 2-methoxy-5-(phenylsulfonyl)benzenesulfonyl chloride (0.35 g, 1.0 mmol) in dichloromethane (10 mL) was treated under nitrogen with tetrahydro-2/J- pyran-4-amine hydrochloride (0.27 g, 2.0 mmol) and a solution of diisopropylethylamine (0.39 g, 3.0 mmol) in dichloromethane. The reaction was stirred for 18 hours at room temperature. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (90 g), eluting with a gradient of 30%-70% methyl tert-bntyl ether in hexane at a flow rate of 50 niL/min, to afford, after crystallization from ethyl acetate- diethyl ether-hexane, 2-methoxy-5-(phenylsulfonyl)-iV-(tetrahydro-2//'-pyran-4- yl)benzenesulfonaniide (0.29 g, 70%), as a homogeneous, colorless, crystalline solid, m.p. 176- 178 0C;
MS (+ESI), m/z: 412.1 [M+H]+;
HRMS: calcd for C18H21NO6S2 + H+, 412.08830; found (ESI, [M+H]+), 412.0899; HPLC purity 100% at 210-370 nm, 7.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 rnL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 690: 4-[({5-[(4-fluorophenyl)suIfonyI]-2-isopropylphenyl}sulfonyl)ammo]-N-l- naphthylpiperidine-1-carbothioamide
[0854] To a solution of 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4- ylbenzenesulfonamide (example 520) (75 mg, 0.17 mmol) in dichloromethane (4.0 mL) was added triethylamine (36 μL, 0.25 mmol) followed by 1-naphthyl isothiocyanate (37 mg, 0.2 mmol). The reaction was mixed on an orbital shaker overnight at room temperature. The following day the reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 4- [( { 5 - [(4-fluoropheny l)sulfonyl]-2-isopropy lphenyl } sulfonyl)amino] -N- 1 - naphthylpiperidine-1-carbothioamide (42 mg, 40%). MS (ES+) m/z 626; HRMS: calcd. for C31H32FN3O4S3 + H+, 626.1617: found (ESI, [m+H]+), 626.1589.
Example 691: N-(2-fluorophenyl)-4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidine-l-carbothioamide
[0855] In an analogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and 2-fluorophenyl isothiocyanate were used to prepare N-(2-fluorophenyl)-4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidine-l-carbothioamide.
MS (ES+) m/z 594.1;
HRMS: calcd. for C27H29F2N3O4S3 + H+, 594.1366: found (ESI, [m+H]4"), 594.137.
Example 692: 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(2- methylphenyl)piperidine-l-carbothioamide
[0856] In an analogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]~2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and o-toluyl isothiocyanate were used to prepare 4- [( { 5- [(4-fluoroplieny l)sulfony 1] -2-isopropy lpheny 1 } sulfony l)amino] -N-(2- methy lpheny l)piperidine- 1 -carbothioamide . MS (ES+) m/z 590; HRMS: calcd. for C28H32FN3O4S3 + H+, 590.1617: found (ESI3 [m+H]+), 590.1628.
Example 693: ethyl ({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-l-yl}carbonothioyl)carbamate
[0857] In an analogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and ethyl isothiocyanatoformate were used to prepare ethyl ({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropy lpheny 1} sulfony l)amino]piperidin- 1 -yl} carbonothioyl)carbamate. MS (ES+) m/z 572; HRMS: calcd. for C24H30FN3O6S3 + H+, 572.1359: found (ESI, [m+H]+)3 572.1353.
Example 694: N-butyl-4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidine-l-carbothioamide
[0858] In an analogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and 1 -butyl isothiocyanate were used to prepare N-butyl-4- [( { 5- [(4-fluoropheny l)sulfony 1] -2- isopropy lpheny 1 } sulfony l)amino]piperidine- 1 - carbothioamide. MS (ES+) m/z 556.2; HRMS: calcd. for C25H34FN3O4S3 + H+, 556.1773: found (ESI, [m+H]+), 556.1765. Example 695: 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(4- methoxyphenyl)piperidine-l-carbothioamide
[0859] In an analogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and 4-isothiocyanatoanisole were used to prepare 4- [( { 5 - [(4-fluoropheny l)sulfony 1] -2-isopropylpheny 1} sulfony l)amino] -N-(4- methoxypheny l)piperidine- 1 -carbothioamide . MS (ES+) m/z 606.1; HRMS: calcd. for C28H32FN3O5S3 + H+, 606.1566: found (ESI, [m+H]+), 606.1456.
Example 696: methyl 4-[({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-l-yl}carbonothioyl)amino]benzoate
[0860] In an analogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and 4-isothiocyanato-benzoic acid methyl ester were used to prepare methyl 4-[({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-l-yl}carbonothioyl)amino]benzoate. MS (ES-) m/z 632.1; HRMS: calcd. for C29H32FN3O6S3 + H+, 634.1516: found (ESI, [m+H]+), 634.1478.
Example 697: methyl N-({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-l-yl}carbonothioyl)glycinate
[0861] In an analogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and 2-isothiocyanatoacetic methyl ester were used to prepare methyl N-({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-l-yl}carbonothioyl)glycinate. MS (ES-) m/z 570; HRMS: calcd. for C24H30FN3O6S3 + H+, 572.1359: found (ESI, [m+H]+), 572.1348.
Example 698 : 4- [({5- [(4-fluorophenyl)sulfony 1] -2-isopropylphenyl} sulf onyl)amino] -N-(2~ morpholin-4-ylethyl)piperidine-l-carbothioamide
[0862] In an analogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and 2-(4-morpholino)ethyl isothiocyanate were used to prepare methyl N-({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl } sulfonyl)amino]piperidin- 1 -yl} carbonothioyl)glycinate. MS (ES-) m/z 611.
Example 699: 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(3- nitrophenyl)piperidine-l-carbothioamide
[0863] In an analogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and 3-nitrophenyl isothiocyanate were used to prepare 4- [( { 5- [(4-fluorophenyl)sulfony 1] -2-isopropy lpheny 1 } sulfony l)amino] -N-(3 - nitrophenyl)piperidine- 1 -carbothioamide. MS (ES-) m/z 619; HRMS: calcd. for C27H29FN4O6S3 + H+, 621.1312: found (ESI, [m+H]+), 621.1219.
Example 700: 3-[({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-l-yl}carbonothioyl)amino]benzoic acid
[0864] In an analogous manner to example 690, 5- [(4-fluoropheny tysulfonyl] -2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and 3-carboxyphenyl isothiocyanate were used to prepare 3 - [( {4- [( { 5- [(4-fluoropheny l)sulfony l]-2- isopropy lpheny 1 } sulfony l)amino]piperidin- 1 - yl}carbonothioyl)amino]benzoic acid. MS (ES-) m/z 618; HRMS: calcd. for C28H30FN3O6S3 + H+, 620.1359: found (ESI, [m+H]+), 620.1364.
Example 701 : 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N- pyridin-3- ylpiperidine-l-carbothioamide
[0865] In an analogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and 3-pyridyl isothiocyanate were used to prepare 4- [( { 5- [(4-fluoropheny l)sulfony 1] -2-isopropy lphenyl} sulfony l)amino] -N-pyridin-3 - y lpiperidine- 1 -carbothioamide . MS (ES+) m/z 577.1; HRMS: calcd. for C26H29FN4O4S3 + H+, 577.1413: found (ESI, [m+H]+), 577.1396. Example 702: N-[l-(2-chlorobenzoyl)piperidin-4-yl]-5-(phenyIsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0866] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-chlorobenzoyl chloride were used to prepare N-[I- (2-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 587.0;
HPLC purity 93.6% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H22ClF3N2O5S2 + H+, 587.06835; found (ESI, [M+H]+), 587.0666.
Example 703: iV-[l-(2-methoxybenzoyl)piperidin-4-yI]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0867] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-methoxybenzoyl chloride were used to prepare N-[I- (2-methoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 583.1;
HPLC purity 96.8% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min.
Example 704: JV-[l-(3-chIorobeiizoyl)piperidin-4-yl] -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0868] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 3-chlorobenzoyl chloride were used to prepare N-[I- (3-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 587.0;
HPLC purity 98.4% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H22ClF3N2O5S2 + H+, 587.06835; found (ESI, [M+H]+), 587.0674.
Example 705: ΛL[l-(3,4-difluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide [0869] In an analogous manner to example 462, 5-(phenylsurfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 3,4-difluorobenzoyl chloride were used to prepare N- [ 1 -(3 ,4-difluorobenzoy l)piperidin-4-y 1] -5 -(phenylsulfony l)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 589.1;
HPLC purity 98.3% at 210-370 ran, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H21F5N2O5S2 + H+, 589.08848; found (ESI5 [M+H]+), 589.0875.
Example 706: iV-[l-(3,5-difluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0870] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 3,5-difluorobenzoyl chloride were used to prepare N- [l-(3,5-difluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 589.1;
HPLC purity 99.0% at 210-370 ran, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H21F5N2O5S2 + H+, 589.08848; found (ESI, [M+FfJ+), 589.0884.
Example 707: iV-[l-(2,6-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesιilfonamide
[0871] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2,6-dimethoxybenzoyl chloride were used to prepare N-[l-(2,6-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 613.1;
HPLC purity 98.3% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. HRMS: calcd for C27H27F3N2O7S2 + H+, 613.12845; found (ESI, [M+H]+), 613.1266. ExampIe 708: iV-[l-(2,4-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0872] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2,4-dimethoxybenzoyl chloride were used to prepare N-[l-(2,4-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 613.1;
HPLC purity 95.9% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 rnL/min, 85/15-5/95 (Ammon. Form. Buff. Pb=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 709: 5-(phenylsulfonyl)-iV-{l-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}-2- (trifluoromethyl)benzenesulfonamide
[0873] In an analogous manner to example 462, 5-(phenylsulfonyl)-JV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 4-trifluoromethoxybenzoyl chloride were used to prepare 5-(phenylsulfonyl)-N-{l-[4-(trifluoromethoxy)benzoyl]piperidin-4-yl}-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 637.1;
HPLC purity 98.6% at 210-370 nm, 10.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H22F6N2O6S2 + H+, 637.08962; found (ESI, [M+H]+), 637.0912.
Example 710: N- {1- [2-fluoro-4-(trifluoromethy l)benzoy 1] piperidin-4-y 1} -5-(phenylsulfonyl)- 2-(trifluoromethyl)benzenesulfonamide
[0874] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-fluoro-4-trifluoromethylbenzoyl chloride were used to prepare N-{ l-[2-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide . MS (ES+) m/z 639.1;
HPLC purity 98.9% at 210-370 nm, 10.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H2JF7N2O5S2 + H+, 639.08528; found (ESI, [M+H]+), 639.0881. Example 711: Λr-{l-[3-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)- 2-(trifluoromethyl)benzenesulfonamide
[0875] In an analogous manner to example 462, 5-(phenylsulfonyl)-/V~piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 3-fluoro-4-trifluoromethylbenzoyl chloride were used to prepare N- { l-[3-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 639.1;
HPLC purity 98.2% at 210-370 ran, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H21F7N2O5S2 + H+, 639.08528; found (ESI, [M+H]+), 639.0863.
Example 712: Λ^-[l-(3,4-dichlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0876] In an analogous manner to example 462, 5-(phenylsulfonyl)-JV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 3,4-dichlorobenzoyl chloride were used to prepare JV- [ 1 -(3 ,4-dichlorobenzoy l)piperidin-4-y 1] -5 -(phenylsulfony l)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 621.9;
HPLC purity 98.2% at 210-370 nm, 10.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H21Cl2F3N2O5S2 + H+, 621.02938; found (ESI, [M+H]+), 621.0306.
Example 713: JV-[l~(4-chlorobenzoyl)piperidm-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0877] In an analogous manner to example 462, 5-(phenylsulfonyi)-JV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 4-chlorobenzoyl chloride were used to prepare TV-[I- (4-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 587.0;
HPLC purity 98.2% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H22ClF3N2O5S2 + H+, 587.06835; found (ESI, [M+H]+), 587.0698. ExampIe 714: iV-(l-isonicotinoylpiperidin-4-yl)-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0878] In an analogous manner to example 462, 5-(phenylsulfonyi)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and pyridine-4-carbonyl chloride were used to prepare N- (l-isonicotinoylpiperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 554.1;
HPLC purity 99.4% at 210-370 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H22F3N3O5S2 + H+, 554.10257; found (ESI, [M+H]+), 554.1038.
Example 715: iV-[l-(2-chloro-6-methoxyisonicotinoyI)piperidin-4-yl]-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0879] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-chloro-6-methoxypyridine-4-carbonyl chloride were used to prepare N-[l-(2-chloro-6-methoxyisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 618.1;
HPLC purity 98.5% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H23ClF3N3O6S2 + H+, 618.07416; found (ESI, [M+H]+), 618.0737.
Example 716: iV-[l-(2-chloro-4-fluorobenzoyl)piperidm-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0880] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-chloro-4-fluorobenzoyl chloride were used to prepare N-[l-(2-chloro-4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 605.0;
HPLC purity 98.7% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H21ClF4N2O5S2 + H+, 605.05893; found (ESI, [M+H]+), 605.0582. Example 717: 5-(phenylsulfonyl)-Λr-[l-(2,4,6-trifluorobenzoyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide
[0881] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piperidm-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2,4,6-trifluorobenzoyl chloride were used to prepare 5- (phenylsulfonyl)-iV-[l-(2,4,6-trifluorobenzoyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 607.0;
HPLC purity 93.5% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H20F6N2O5S2 + H+, 607.07906; found (ESI, [M+H]+), 607.0799.
Example 718: iV-[l-(4-tert-butylbenzoyl)piperidin-4-yI]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0882] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 4-tert-butylbenzoyl chloride were used to prepare iV- [l-(4-tert-butylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 609.1;
HPLC purity 98.0% at 210-370 nm, 10.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C29H31F3N2O5S2 + H+, 609.16992; found (ESI, [M+H]+), 609.1714.
Example 719: iV-(4-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}phenyl)acetamide
[0883] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 4-Ν-acetamidebenzoyl chloride were used to prepare N-(4- { [4-( { [5 -(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)piperidin- 1 - yl]carbonyl}phenyl)acetamide. MS (ES+) m/z 610.1;
HPLC purity 96.7% at 210-370 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C27H26F3N3O6S2 + H+, 610.12879; found (ESI, [M+H]+), 610.1293. Example 720: iV-[(15)-l-benzyl-2-hydroxyethyl]-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0884] In an analogous manner to example 435, 2-trifluoromethyl~5-(phenylsulfonyl)- benzenesulfonyl chloride and L-phenylalaninol were used to prepare N-[(liS)-l-benzyl-2- hydroxyethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 500.0;
HPLC purity 99.1% at 210-370 nm, 9.2 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H20F3NO5S2 + H+, 500.08077; found (ESI, [M+H]+), 500.0791.
Example 721 : iV-[(15)-2-hydroxy-l-(lJΪ-indol-3-ylmethyl)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0885] In an analogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and L-tryptophanol were used to prepare iV-[(ljS)-2-hydroxy-l-(lH- indol-3-ylmethyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 539.0;
HPLC purity 97.2% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H21F3N2O5S2 + H+, 539.09167; found (ESI, [M+H]+), 539.0943.
Example 722: iV-[l-(2-hydroxy-2-methylpropyl)piperidin-4-yl]-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0886] To a stirred mixture of 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (0.075 g, 0.167 mmol) in ethanol (2 mL) was added 2,2- Dimethyl-oxirane (0.05 g, 0.69mmol) and the resulting mixture was heated to reflux overnight. The crude mixture was concentrated and flash column separation using 50% to 100% ethyl acetate/hexane gradient gave N-[l-(2-hydroxy-2-methylpropyl)piperidin-4-yl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (0.06 g, 70%). MS (ES-) m/z 519.0;
HPLC purity 96.8% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H27F3N2O5S2 + H+, 521.13862; found (ESI, [M+H]+), 521.1403.
Example 723: iV-[2-(l-oxidopyrid[in-3-yl)ethyl]-5-(phenyIsuIfonyI)-2- (trifluoromethyl)benzenesulfonamide
[0887] To a stirred solution of 5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)-2- (trifluoromethyl)benzenesulfonamide (0.10 g, 0.21mmol) in concentrated acetic acid (2 mL) was added 30% hydrogen peroxide solution (2 mL) and the resulting solution was heated to reflux for three hours. The solution was allowed to cool, poured into sodium bicarbonate solution (sat), and extracted with ethyl acetate. The organic layer was washed with sodium dithionite solution (sat), and brine. The organic layer was concentrated and flash column separation using 0%-10% methanol/methylene chloride gradient gave iV-[2-(l-oxidopyridin-3-yl)ethyl]-5-(phenylsulfonyl)- 2-(trifluoromethyl)benzenesulfonamide (0.015 g, 15%). MS (ES-) m/z 485.0;
HPLC purity 98.8% at 210-370 nm, 7.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H17F3N2O5S2 + H+, 487.06037; found (ESI, [M+H]+), 487.0619.
Example 724: 5-(phenylsulfonyl)-2-(trifluoromethyl)-iV-(l-{[4- (trifluoromethyl)phenyl]carbonothioyl}piperidin-4-yl)benzenesulfonamide
[0888] To a stirred solution of 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-{l-[4- (trifluoromethyl)benzoyl]piperidin-4-yl}benzenesulfonamide (0.10 g, 0.16 mmol) in toluene (1 mL) was added Lawesson's reagent (0.06 g, 0.15 mmol) and the resulting solution was stirred overnight at reflux. The solution was allowed to cool, partitioned between ethyl acetate and ammonium chloride solution (sat.). The organic layer was concentrated and flash column separation using 0% to 20% ethyl acetate/hexane gradient gave 5-(phenylsulfonyl)-2- (trifluoromethy \)-N-{ 1 - { [4-(trifluoromethy l)pheny 1] carbonothioyl } piperidin-4- yl)benzenesulfonamide (0.053 g, 56%). MS (ES+) m/z 637.1;
HPLC purity 100% at 210-370 nm, 10.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H22F6N2O4S3 + H+, 637.07186; found (ESI, [M+H]+), 637.0749. Example 725: iV-[(lS)-2-hydroxy-l-methylethyl]-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0889] In an analogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and S-2-amino-l-propanol were used to prepare JV-[(lS)-2-hydroxy-l- methylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 424.1;
HPLC purity 95.1% at 210-370 ran, 8.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C16Hi6F3NO5S2 + H+, 424.04947; found (ESI, [M+H]+), 424.0497.
Example 726: iV-[(lR)-2-hydroxy-l-methylethyl]-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0890] In an analogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and R-2-amino-l-propanol were used to prepare 7V-[(li?)-2-hydroxy-l- methylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 424.0;
HPLC purity 98.2% at 210-370 ran, 8.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C16H16F3NO5S2 + H+, 424.04947; found (ESI, [M+H]+), 424.0505.
Example 727: 5-[(4-fluorophenyl)sulfonyl]-iV-(2-hydroxy-2-pyridin-2-ylethyl)-2- isopropylbenzenesulfonamide
[0891] In an analogous manner to Step 3, Example 317:
2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-l- pyridin-2-yl-ethanol were used to prepare 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin- 2-ylethyl)-2-isopropylbenzenesulfonamide. MS (ES+) m/z 419 Λ;
HPLC purity Checked by AN LC/MS. MW confirmed.; Luna C8(2), 5u, 4.6x250mm column, 0.5 mL/min, Water/MeOH 20 min gradient.
HPLC purity 96.1% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H23FN2O5S2 + H+, 479.11052; found (ESI, [M+H]+), 479.1099. Example 728: ΛL(2-hydroxy-2-pyridin-2-ylethyl)-2-isopropyl-5-(phenylsulfonyI)benzene- sulfonamide
[0892] In an analogous manner to Step 3, Example 295:
5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 2-amino-l-pyridin-2-yl- ethanol were used to prepare N-(2-hydroxy-2-pyridin-2-ylethyl)-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 461.2;
HPLC purity Checked by AN LC/MS. MW confirmed by MS.; Luna C8(2), 5u, 4.6x250mm column, 0.5 mL/min, prep conditions.
HPLC purity 100% at 210-370 nm, 8.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H24N2O5S2 + H+, 461.11994; found (ESI5 [M+H]+), 461.118.
Example 729: iV-(2-hydroxy-2-pyridin-2-ylethyI)-2,4-dimethyl-5- (phenylsulfonyl)benzenesulfonamide
[0893] In an analogous manner to Step 3, Example 295:
5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 2-amino-l-pyridin-2-yl- ethanol were used to prepare N-(2-hydroxy-2-pyridin-2-ylethyl)-2,4-dimethyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 447.1;
HPLC purity Checked by AN LC/MS. MW confirmed by MS.; Luna C8 (2), 5u, 4.6x250mni column, 0.5 mL/min, MeOH /water 20min gradient.
HPLC purity 100% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H22N2O5S2 + H+, 447.10429; found (ESI, [M+H]+ ), 447.1033.
Example 730: 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-[4- (trifluoromethyl)phenyl]piperidine-l-carbothioamide
[0894] In an analogous manner to example 690, 5-[(4-fluorophenyl)sulfonyl]-2- isopropyl-N-piperidin-4-ylbenzenesulfonamide and 4-(trifluoromethyl)phenyl isothiocyanate were used to prepare 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-
[4- (trifluoromethyl)phenyl]piperidine- 1 -carbothioamide.
MS (ES+) m/z 644.1;
HRMS: calcd. for C28H29F4N3O4S3 + H+, 644.1335: found (ESI, [m+H]+), 644.1406.
Example 731 : 5-[(4-fluorophenyl)sulfonyl]-iV-(2-hydroxy-2-pyridin-3-yIethyl)-2- isopropylbenzenesulfonamide
[0895] In an analogous manner to Step 3, Example 317:
2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-l- pyridin-3-yl-ethanol were used to prepare 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin- 3-ylethyl)-2-isopropylbenzenesulfonamide. MS (ES+) m/z 479.1;
HPLC purity 96.7% at 210-370 nm, 8.4 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H23FN2O5S2 + H+, 479.11052; found (ESI, (M+H]+), 479.1088.
Example 732: 5-[(4-fluoroplienyl)sulfonyl]-Λ'-(2-hydroxy-2-phenylethyl)-2- isopropylbenzenesulfonamide
[0896] In an analogous manner to Step 3, Example 317:
2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-l- phenyl-ethanol were used to prepare 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-phenylethyl)- 2-isopropylbenzenesulfonamide . MS (ES-) m/z 476.1;
HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H24FNO5S2 + NH4 +, 495.14182; found (ESI, [M+NH4]"1"), 495.1433.
Example 733: 5-[(4-fluorophenyl)sulfonyl]-iV-(2-hydroxy-l-methylethyl)-2- isopropylbenzenesulfonamide
[0897] In an analogous manner to Step 3, Example 317: 2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-l- propanol were used to prepare 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-l-methylethyl)-2- isopropy lbenzenesulfonamide . MS (ES-) m/z 414.0;
HPLC purity 98.1% at 210-370 ran, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C18H22FNO5S2 + H+, 416.09962; found (ESI5 [M+H]+), 416.0975.
Example 734 : 5- [(4-fluoropheny l)sulf ony 1] -N- [1 -(hydroxy methy l)-2-methylp ropy 1] -2- isopropylbenzenesulfonamide
[0898] In an analogous manner to Step 3, Example 317:
2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-3- methyl-butan-1-ol were used to prepare 5-[(4-fluorophenyl)sulfonyl]-iV-[l-(hydroxymethyl)-2- methylpropyl]-2-isopropylbenzenesulfonamide. MS (ES+) m/z 444.1;
HPLC purity 96.4% at 210-370 ran, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H26FNO5S2 + H+, 444.13092; found (ESI, [M+H]4), 444.1322.
Example 735: iV-(2-hydroxy-2-pyridin-3-ylethyl)-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide
[0899] In an analogous manner to Step 3, Example 295:
5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 2-amino-l-pyridin-3-yl- ethanol were used to prepare Λ/-(2-hydroxy-2-pyridin-3-ylethyl)-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 461.1;
HPLC purity 100% at 210-370 ran, 8.1 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H24N2O5S2 + H+, 461.11994; found (ESI, [M+H]+), 461.1203.
Example 736: iY-(2-hydroxy-2-phenylethyl)-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide
[0900] In an analogous manner to Step 3, Example 295:
5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 2-amino-l-phenyl-ethanol were used to prepare N-(2-hydroxy-2-phenylethyl)-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES-) m/z 458.1;
HPLC purity 97.2% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H25NO5S2 + NH4 +, 477.15124; found (ESI, [M+NH4]+), 477.1512.
Example 737: iV-(2-hydroxy-2-pyridin-3-ylethyl)-2,4-dimethyl-5- (phenylsulfonyl)benzenesulfonamide
[0901] In an analogous manner to Step 3, Example 295:
5-Benzenesulfonyl-2,4-dimethyl-benzenesulfonyl chloride and 2-amino-l-pyridin-3-yl- ethanol were used to prepare N-(2-hydroxy-2-pyridin-3-ylethyl)-2,4-dimethyl-5- (phenylsulfonyl)benzenesulfonamide. MS (ES+) m/z 447.1;
HPLC purity 100% at 210-370 nm, 7.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H22N2O5S2 + H+, 447.10429; found (ESI, [M+H]+), 447.1032.
Example 738: 5-[(4-fluorophenyl)sulfonyI]-JV-(2-hydroxybutyl)-2- isopropylbenzenesulfonamide
[0902] In an analogous manner to Step 3, Example 317:
2- Isopropyl -5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 1-aminobutan- 2-ol were used to prepare 5-[(4-fluorophenyl)sulfonyl]-iV-(2-hydroxybutyl)-2- isopropylbenzenesulfonamide. MS (ES-) m/z 428.1;
HPLC purity 100% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C19H24FNO5S2 + H+, 430.11527; found (ESI, [M+H]+), 430.1147. Example 739: N-[2-(liy-Imidazol-l-yl)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0903] [2-(lH-Imidazol-l-yl)ethyl]amine dihydrochloride (97.3 mg, 0.529 mmol) was dissolved in 1 mL of water containing 169.3 mg (1.6 mmol) of sodium carbonate. Acetonitrile (4 mL) was then added. To this mixture 5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonyl chloride (201.8 mg, 0.524 mmol), prepared in Example 677, in 10 mL of acetonitrile was added dropwise over 1.5 h. After the addition the reaction was stirred at room temperature for 19 h (overnight). The reaction was filtered and the filtrate concentrated under reduced pressure to give 255.4 mg of a yellow oil. Purification of the oil on 50 g of silica gel (230-400 mesh) using 50% ethyl acetate-methylene chloride and then 5% methanol-methylene chloride as the eluents gave N-[2-(l/i-imidazol-l-yl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (78.4 mg, 33%) as a white solid. MS (ES) m/z 460.0;
HRMS: calcd for C18H16F3N3O4S2 + H+, 460.06071; found (ESI, [M+H]+), 460.0605; Anal. Calcd for C18H16F3N3O4S2: C, 47.05; H, 3.51; N, 9.15. Found: C, 47.04; H, 3.14; N, 9.03.
Example 740: 5-[(4-fluorophenyl)sulfonyl]-7V-(2-hydroxy-2-pyridin-3-ylethyl)-2- methylbenzenesulfonamide
[0904] In an analogous manner to Step 3, Example 298:
2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-l-pyridin- 3-yl-ethanol were used to prepare 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-3- ylethyl)-2-methylbenzenesulfonamide. MS (ES+) m/z 451.1;
HPLC purity 100% at 210-370 nm, 7.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H19FN2O5S2 + H+, 451.07922; found (ESI, [M+H]+), 451.0803.
Example 741 : iV-(2-hydroxy-2-py ridin-3-ylethyl)-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0905] In an analogous manner to Step 3, Example 677: 5-Benzenesulfonyl-2-trifluoromethyl-benzenesulfonyl chloride and 2-amino-l-pyridin-3- yl-ethanol were used to prepare N-(2-hydroxy-2-pyridin-3-ylethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 487.1;
HPLC purity 98.0% at 210-370 ran, 7.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H17F3N2O5S2 + H+, 487.06037; found (ESI, [M+H]+), 487.0612.
Example 742: tert-Butyl [2-({[5-(phenylsuIfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)ethyl] carbamate
[0906] 5-(Phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonyl chloride (2.1471 g, 5.58 mmol), prepared in Example 677, in 25 mL of methylene chloride was added under nitrogen dropwise over 15 minutes to a solution of N-(2-aminoethyl)carbamic acid tert-butyl ester (883 ML, 5.58 mmol) and triethylamine (2.33 mL, 16.7 mmol) in 50 mL of methylene chloride at room temperature. After the addition the reaction was stirred at room temperature for 5.5 h. The reaction was extracted with 2 N HCl, dried (anhydrous magnesium sulfate) and the solvent removed under reduced pressure to give 2.71 g of a white solid. Purification of the solid on 300 g of silica gel (230-400 mesh) using 100% methylene chloride to 15% ethyl acetate-methylene chloride as the eluent gave tert-butyl [2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate (2.05 g, 72%) as a white solid. MS (ESI) m/z 507.
Example 743 : 5- [(3-methoxy phenyl)sulf ony 1] -/V-(tetrahy dro-2H-py ran-4-yl)-2- (trifluoroniethyl)benzenesulfonamide
[0907] Step 1 : : Following the same procedure described on example 677 (Step 2), 2- chloro-5-fluoronitrobenzene was used to prepare 2-nitro-4-fluorobenzotrifluoride.
[0908] Step 2: To a stirred solution of 2-nitro-4-fluorobenzotrifluoride (1.6 g, 7.65 mmol) in dimethylformamide (20 mL) was added 3-methoxybenzenethiol (1 mL, 8.0 mmol) and potassium carbonate (2.1 g, 15.3 mmol). The resulting mixture was stirred at room temperature 2 hours, diluted with water and extracted with ethyl acetate. The organic layer was washed several times with water, dried over magnesium sulfate and concentrated. The crude mixture was dissolved in methylene chloride (25 mL) and mCPBA (3.5 g 77%, 15.7 mmol) was added. The resulting mixture was stirred at room temperature for 30 minutes, washed with sodium dithionite solution and with sodium bicarbonate solution (sat). The organic layer was dried over magnesium sulfate and concentrated. Flash column separation using 0%-20% ethyl acetate/hexane gradient gave 5-(3-methoxyphenylsulfonyl)-2-trifluoromethyl-nitrobenzene (1.84 g, 65%).
[0909] Step 3: Following the same procedure described on example 677 (Step 3), 5-(3- methoxyphenylsulfonyl)-2-trifluoromethyl-nitrobenzene was used to prepare 5-(3- methoxyphenylsulfonyl)-2-trifluoromethylaniline.
[0910] Step 4: Following the same procedure described on example 677 (Step 4), 5-(3- methoxyphenylsulfonyl)-2-trifluoromethylaniline, was used to prepare 2-trifluoromethyl-5-(3- methoxylphenylsulfonyl)- benzenesulfonyl chloride.
[0911] Step 5: In an analogous manner to example 435, 2-trifluoromethyl-5-(3- methoxylphenylsulfonyl)- benzenesulfonyl chloride and tetrahydrofurfurylamine were used to prepare 5-[(3-methoxyphenyl)sulfonyl]-iV-(tetrahydro-2H-pyran-4-yl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 478.0;
HPLC purity 97.2% at 210-370 nm, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 744: 5-[(3-hydroxyphenyl)sulfonyl]-iV-(tetrahydro-2fl-pyran-4-yl)-2- (trifluoromethyl)benzenesulfonamide
[0912] To a stirred solution of 5-[(3-methoxyphenyl)sulfonyl]-iV-(tetrahydro-2H-pyran- 4-yl)-2-(trifluoromethyl)benzenesulfonamide (0.08g, 0.17 mmol) in methylene chloride (2 mL) was added cyclohexene (2 drops) and boron tribromide solution IM in methylene chloride (0.6 mL, 0.6 mmol) at O0C. The resulting solution was stirred 1 hour, quenched with methanol, and washed with sodium bicarbonate solution (sat). The organic layer was concentrated and the crude solid was triturated in methylene chloride to give 5-[(3-hydroxyphenyl)sulfonyl]-iV- (tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide (0.04 g, 51%). MS (ES-) m/z 464.0;
HPLC purity 95.7% at 210-370 nm, 8.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C18H18F3NO6S2 + H+, 466.06004; found (ESI, [M+H]+), 466.0625. Example 745: iV-(2-cyanoethyl)-5-[(3-methoxyphenyl)sulfonyl]-2- (trifluoromethyl)benzenesulfonamide
[0913] In an analogous manner to example 435, 2-trifluoromethyl-5-(3- methoxylphenylsulfonyl)- benzenesulfonyl chloride and aminopropionitrile were used to prepare iV-(2-cyanoetriyl)-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 447.0;
HPLC purity 97.9% at 210-370 ran, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C17Hi5F3N2O5S2 + H+, 449.04472; found (ESI, [M+H]+), 449.0448.
Example 746 : N- [ l-(4-tert-butylbenzoyl)piperidin-4-yI] -5- [(3-methoxypheny l)sulf ony 1] -2- (trifluoromethyl)benzenesulfonamide
[0914] Step 1 : Following the same procedure described on example 462, piperidin-4-yl- carbamic acid tert-butyl ester and 4-tertbutylbenzoyl chloride were used to prepare [l-(4-tert- butyl-benzoyl)-piperidin-4-yl]-carbamic acid tert-butyl ester.
[0915] Step 2: Following the same procedure described on example 688, [l-(4-tert- butyl-benzoyl)-piperidin-4-yl]-carbamic acid tert-butyl ester was used to prepare (4-amino- piperidin-l-yl)-(4-tert-butyl-phenyl)-methanone.
[0916] Step 3: Following the same procedure described on example 435, 2- trifluoromethyl-5-(3-methoxylphenylsulfonyl)- benzenesulfonyl chloride and (4-amino- piperidin-l-yl)-(4-tert-butyl-phenyl)-methanone were used to prepare iV-[l-(4-tert- buty lbenzoy l)piperidin-4-yl] -5 - [(3 -methoxypheny l)sulfony 1] -2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 639.2;
HPLC purity 96.2% at 210-370 nm, 10.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C30H33F3N2O6S2 + H+, 639.18049; found (ESI, [M+H]+), 639.1804.
Example 747: 5-[(3-methoxyphenyl)sulfonyl]-7V-(2-pyridin-3-ylethyl)-2- (trifluoromethyl)benzenesulfonamide [0917] In an analogous manner to example 435, 2-trifluoromethyl-5-(3- methoxylphenylsulfonyl)- benzenesulfonyl chloride and 3~(2-aminoethyl)pyridine were used to prepare 5-[(3-methoxyphenyl)sulfonyl]-N-(2-pyridin-3-ylethyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 501.1;
HPLC purity 100% at 210-370 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H19F3N2O5S2 + H+, 501.07602; found (ESI, [M+H]"1"), 501.0756.
Example 748: Λ'-{l-[(4-terϊ!-butylphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0918] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 4-tert-butylbenzenesulfonyl chloride were used to prepare N-{l-[(4-tert-butylphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 645.1;
HPLC purity 94.7% at 210-370 nm, 10.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C28H31F3N2O6S3 + H+, 645.13691; found (ESI, [M+H]+)5 645.1376.
Example 749: 5-(phenylsulfonyl)-2-(trifluoromethyl)-JV-{l-[4- (trifluoromethyl)benzyl] piperidin-4-ylJbenzenesulfonamide
[0919] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 4-trifluoromethylben2yl bromide were used to prepare 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-{l-[4-(trifluoromethyl)benzyl]piperidin-4- y 1 } benzenesulfonamide . MS (ES+) m/z 607.1;
HPLC purity 96.8% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H24F6N2O4S2 + H+, 607.11544; found (ESI, [M+H]+), 607.1147. Example 750: Λr-[l-(cyanomethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfbnamide
[0920] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and bromoacetonitrile were used to prepare N-[I- (cyanomethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 488.1;
HPLC purity 96.7% at 210-370 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 rnL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H20F3N3O4S2 + H+, 488.09201; found (ESI, [M+H]+), 488.0933.
Example 751 : Λr-[l-(2-oxo-2-phenylethyl)piperidin-4-yl]-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0921] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2'-bromoacetophenone were used to prepare N-[I -(2- oxo-2-phenylethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 567.1;
HPLC purity 92.6% at 210-370 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H25F3N2O5S2 + H+, 567.12297; found (ESI, [M+H]+), 567.1232.
Example 752: 5-[(3-chlorophenyl)sulfonyl]~iV-(2-cyanoethyl)-2- (trifluoromethyl)benzenesulfonamide
[0922] In an analogous manner to example 743
Step 2: 3-chlorobenzenethiol and 2-nitro-4-fluorobenzotrifluoride were used to prepare 5- (3 -chloropheny lsulfonyl)-2-trifluoromethy 1-nitrobenzene .
[0923] Step 3 : Following the same procedure described on example 677 (Step 3), 5-(3- chlorophenylsulfonyl)-2-trifluoromethyl-nitrobenzene was used to prepare 5-(3- chlorophenylsulfonyl)-2-trifluoromethylaniline.
[0924] Step 4: Following the same procedure described on example 677 (Step 4), 5-(3- chlorophenylsulfonyl)-2-trifluoromethylaniline, was used to prepare 2-trifluoromethyl-5-(3- chlorophenylsulfonyl)- benzenesulfonyl chloride. [0925] Step 5: In an analogous manner to example 435, 2-trifluoromethyl-5-(3~ chlorophenylsulfonyl)- benzenesulfonyl chloride and propionitrile were used to prepare 5-[(3- chlorophenyl)sulfonyl]-N-(2-cyanoethyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 450.9;
HPLC purity 100% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 753: iV-[l-(4-te^-butylbenzoyl)piperidm-4-yl]-5-[(3-chIorophenyI)sulfonyl]-2- (trifluoromethyl)benzenesulfonamide
[0926] Step 1 : Following the same procedure described on example 462, piperidin-4-yl- carbamic acid tert-butyl ester and 4-tertbutylbenzoyl chloride were used to prepare [l-(4-tert- butyl-benzoyl)-piperidin-4-yl]-carbamic acid tert-butyl ester.
[0927] Step 2: Following the same procedure described on example 688, [l-(4-tert- butyl-benzoyl)-piperidin-4-yl]-carbamic acid tert-butyl ester was used to prepare (4-amino- piperidin- 1 -y l)-(4-tert-buty l-phenyl)-methanone .
[0928] Step 3: Following the same procedure described on example 435, 2- trifluoromethyl-5-(3-chlorophenylsulfonyl)- benzenesulfonyl chloride and (4-amino-piperidin-l- yl)-(4-tert-butyl-phenyl)-methanone were used to prepare iV-[l-(4-te/-t-butylbenzoyl)piperidin-4- yl]-5-[(3-chlorophenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 643.2;
HPLC purity 99.3% at 210-370 nm, 11.0 min.; Xterra RP18, 3.5u, 15O x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C29H30ClF3N2O5S2 + H+, 643.13095; found (ESI, [MfH]+), 643.1304.
Example 754: 5-[(3-chlorophenyl)sulfonyl]-iV-(tetrahydro-2jHr-pyran-4-yl)-2- (trifluoromethyl)benzenesulfonamide
[0929] In an analogous manner to example 435, 2-trifluoromethyl-5-(3- chlorophenylsulfonyl)- benzenesulfonyl chloride and tetrahydrofurfurylamine were used to prepare 5-[(3-chlorophenyl)sulfonyl]-N-(tetrahydro-2H"-pyran-4-yl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 481.9; HPLC purity 100% at 210-370 nm, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min5 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 755: 5-[(3-chlorophenyl)sulfonyI]-Λr-(2-pyridin-3-ylethyl)-2- (trifluoromethyl)benzenesulfonamide
[0930] In an analogous manner to example 435, 2-trifluoromethyl-5-(3- chlorophenylsulfonyl)- benzenesulfonyl chloride and 3-(2-aminoethyl)pyridine were used to prepare 5-[(3-chlorophenyl)sulfonyl]-iV-(2-pyridin-3-ylethyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 505.1;
HPLC purity 94.1% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H16ClF3N2O4S2 + H+, 505.02649; found (ESI, [M+H]+), 505.0247.
Example 756 : 5- [(4-fluorophenyl)sulf onyl] -JV-(2-hy droxy-2-py ridin-2-ylethyl)-2- methylbenzenesulfonamide
[0931] In an analogous manner to Step 3, Example 298:
2-Methyl-5-(4-fluoro-benzenesulfonyl)-benzenesulfonyl chloride and 2-amino-l-pyridin- 2-yl-ethanol were used to prepare 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-2- ylethyl)-2-methylbenzenesulfonamide. MS (ES+) m/z 451.1;
HPLC purity 100% at 210-370 nm, 7.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H19FN2O5S2 + H+, 451.07922; found (ESI, [M+H]+), 451.0801.
Example 757: Λ^2-hydroxy-2-pyridin~2-ylethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0932] In an analogous manner to Step 3, Example 677:
5-Benzenesulfonyl-2-trifluoromethyl-benzenesulfonyl chloride and 2-amino-l-pyridin-2- yl-ethanol were used to prepare N-(2-hydroxy-2-pyridin-2-ylethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 487.1; HPLC purity 100% at 210-370 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H17F3N2O5S2 + H+, 487.06037; found (ESI, [M+H]+), 487.0581.
Example 758: 5-(phenylsulfonyl)-iV-{l-[2-(trifluoromethoxy)benzoyl]piperidin-4-yI}-2- (trifluoromethyl)benzenesulf<mamide
[0933] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-trifluoromethoxybenzoyl chloride were used to prepare 5-(phenylsulfonyl)-N-{l-[2-(trifluoromethoxy)benzoyl]piperidin-4-yl}-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 637.1;
HPLC purity 96.0% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H22F6N2O6S2 + H+, 637.08962; found (ESI5 [M+H]+), 637.0891.
Example 759: iV-(4-tert-butylphenyl)-4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxamide
[0934] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 4-tertbutylphenylisocyanate were used to prepare N- (4-tert-butylphenyl)-4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)piperidine-l -carboxamide. MS (ES+) m/z 624.2;
HPLC purity 97.0% at 210-370 nm, 10.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C29H32F3N3O5S2 + H+, 624.18082; found (ESI, [MfH]+), 624.1806.
Example 760: iV-(l-benzoylpiperidin-4-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0935] Step 1 : In an analogous manner to example 462, piperidin-4-yl-carbamic acid tert-butyl ester and benzoyl chloride were used to prepare (l-benzoyl-piperidin-4-yl)-carbaniic acid tert-butyl ester.
[0936] Step 2: In an analogous manner to example 680, (l-benzoyl-piperidin-4-yl)- carbamic acid tert-butyl ester was used to give l-benzoyl-4-aminopiperidine. [0937] Step 3: In an analogous manner to example 435, 2-trifluoromethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and l-benzoyl-4-aminopiperidine were used to prepare iV-(l-benzoylpiperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 553.1;
HPLC purity 98.6% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H23F3N2O5S2 + H+, 553.10732; found (ESI, [M+H]+), 553.1075.
Example 761: iV-[l-(4-ter^-butylbenzoyI)pyrrolidin-3-yl]-5-(phenylsulfonyI)-2- (trifluoromethyl)benzenesulfonamide
[0938] Step 1 : In an analogous manner to example 462, 3-aminopyrrolidine-l- carboxylic acid tert-butyl ester and 4-tertbutylbenzoyl chloride were used to prepare [l-(4-tert- butyl-benzoyl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester.
[0939] Step 2: In an analogous manner to example 680, [l-(4-tert-butyl-benzoyl)- pyrrolidin-3-yl]-carbamic acid tert-butyl ester was used to give l-(4-tertbutylbenzoyl)-3- aminopyrrolidine.
[0940] Step 3: In an analogous manner to example 435, 2-trifluoromethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and l-(4-tertbutylbenzoyl)-3-aminopyrrolidine were used to prepare Λ/-[l-(4-tert-butylbenzoyl)pyrrolidin-3-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 595.1;
HPLC purity 96.2% at 210-370 nm, 10.3 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C28H29F3N2O5S2 + H+, 595.15427; found (ESI, [M+H]+), 595.1547.
Example 762: N-(2-Aminoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride
[0941] Approximately 100 mL of a saturated solution of anhydrous hydrogen chloride in ethyl acetate was added under nitrogen to a solution of tert-butyl [2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate (2.00 g, 3.93 mmol), prepared in Example 742, in 100 mL of ethyl acetate at room temperature. After the addition the reaction was stirred for 5 h. The solid was collected by filtration, rinsed with ethyl acetate and dried under reduced pressure to give N-(2-aminoethyl)-5~(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride (1.6270 g, 93%) as a white solid. MS (ES+) m/z 409.1; HRMS: calcd for C15H15F3N2O4S2 + H+, 409.04981; found (ESI5 [M+H]+)5 409.049.
Example 763: 5-(phenylsulfonyl)-2-(trifluoromethyl)-iV-{l-[4- (trifluoromethyl)phenyl]piperidin-4-yl}benzenesulfonamide
[0942] To a stirred solution of 5-(phenylsulfonyl)-N-piperidin-4-yl-2~ (trifluoromethyl)benzenesulfonamide (0.09 g, 0.2 mmol) in dimethylformamide (1 niL) was added potassium carbonate (0.06 g, 0.43 mmol) and 4-fluorobenzotrifluoride (0.06 g, 0.37 mmol). The resulting solution was heated to 100°C for three days and concentrated. The crude mixture was dissolved in methylene chloride, washed with ammonium chloride solution (sat.) and concentrated. Flash column separation using 0%-30% ethyl acetate/hexane gradient gave 5- (phenylsulfonyl)-2-(trifluoromethyl)-iV-{l-[4-(trifluoromethyl)phenyl]piperidin-4- yljbenzenesulfonamide (0.032 g, 28%). MS (ES+) m/z 593.1;
HPLC purity 98.1% at 210-370 nm, 11.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H22F6N2O4S2 + H+, 593.09979; found (ESI, [M+H]+), 593.1013.
Example 764: iV-[l-(4-te^-butylbenzoyl)piperidin-4-yl]-5-[(3-hydroxyphenyl)sulfonyl]-2- (trifluoromethyl)benzenesulfonamide
[0943] In an analogous manner to example 744, N-[l-(4-tert-butylbenzoyl)piperidin-4- yl]-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide was used to prepare N-[I -(4-tert-buty lbenzoy l)piperidin-4-yl] -5 - [(3 -hydroxypheny l)sulfony 1] -2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 625.2;
HPLC purity 97.0% at 210-370 nm, 10.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C29H31F3N2O6S2 + H+, 625.16484; found (ESI, [M+H]+), 625.1625. Example 765: 5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-ylmethyI)-2- (trifluoromethyl)benzenesulfonamide
[0944] A stirred solution of 5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonyl chloride (0.101 g, 0.26 mmol) prepared in same matter as example 677, was taken up in dichloromethane (2 ml). 1.2 eq of 4-Aminomethyltetrahydropyran and 1.5 eq. trietylamine was syringed into the reaction vial and was allowed to stir overnight at room temperature. The product was transferred onto a 4 g Isco RediSep® Normal Phase column and was purified by automated flash chromatography using a gradient of 20% to 100% hexane/ethyl acetate. Isolation of the main component gave the title compound of 5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran- 4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide (29 mg, 23.8%) as a white solid. MS (ES+) m/z 464.0;
HPLC purity 98.9% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C19H20F3NO5S2 + H+, 464.08077; found (ESI, [M+H]+), 464.079.
Example 766: N-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0945] In an analogous manner to example 765, 5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonyl chloride and 2-morpholinoethanamine was used to prepare the title compound of N-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (99 mg, 78.8%) as a white solid. MS (ES+) m/z 479.1;
HPLC purity 100% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C19H21F3N2O5S2 + H+, 479.09167; found (ESI, [M+H]+), 479.0921.
Example 767: N-(3-morpholin-4-ylpropyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0946] In an analogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and N-(3-Aminopropyl)-morpholine was used to prepare the title compound N-(3-moφholin-4-ylpropyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (72 mg, 55.7%) as a white solid. MS (ES+) m/z 493.1;
HPLC purity 93.8% at 210-370 ran, 6.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. HRMS: calcd for C20H23F3N2O5S2 + H+, 493.10732; found (ESI, [M+H]+), 493.1053;
Example 768: N-(3-methoxypropyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0947] In an analogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and 3-methoxypropylamine was used to prepare the title compound N-(3 -methoxypropy l)-5 -(pheny lsulfonyl)-2-(trifluoromethy l)benzenesulfonamide (75 mg, 65.3%) as a white solid. MS (ES+) m/z 438.1;
HPLC purity 100% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C17H18F3NO5S2 + H+, 438.06512; found (ESI, [M+H]+), 438.064.
Example 769: N-[l-(hydroxymethyl)-2-methylpropyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0948] In an analogous manner to example 765, 5-(phenylsulfonyl)~2-
(trifluoromethyl)benzenesulfonyl chloride and 2-amino-3-methylbutanol was used to prepare the title compound N-[I -(hydroxymethyl)-2-methylpropyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (27.5 mg, 23%) as a white solid. MS (ES+) m/z 452;
HPLC purity 89.5% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for Ci8H20F3NO5S2 + H+, 452.08077; found (ESI, [M+H]+), 452.0813.
Example 770: N-[2-({[5-(Phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)ethyl]benzamide
[0949] Benzoyl chloride (39 μL, 0.336 mmol) was added under nitrogen to a mixture of N-(2-aminoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (150.7 mg, 0.339 mmole), prepared in Example 762, and triethylamine (57 μL, 0.409 mmol) in 20 mL of methylene chloride at room temperature. After the addition the reaction was stirred at room temperature for approximately 24 h. An additional 57 μL (0.409 mmol) of triethylamine and 20 μL (0.172 mmol) of benzoyl chloride were added and the reaction was stirred for 4 h at room temperature. The reaction was extracted with 2 N HCl. The organic layer was separated and the aqueous layer was extracted three times with 10 % methanol-methylene chloride. The combined organic extracts were dried (anhydrous magnesium sulfate) and the solvent removed under reduced pressure to give 183 mg of a solid. Purification of the solid on a 12 g Redi Sep Flash Column (silica gel) using a gradient of 100% methylene chloride to 20% ethyl acetate- methylene chloride as the eluent gave N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (106.2 mg, 61%) as a white solid. MS (ESI+) m/z 513;
HRMS: calcd for C22H19F3N2O5S2 + H+, 513.07602; found (ESI, [M+H]+), 513.0763; Anal. Calcd for C22H19F3N2O5S2: C, 51.56; H, 3.74; N, 5.47. Found: C, 51.53; H, 3.58; N, 5.40.
Example 771: 5-(phenylsuIfonyl)-N-(2-pyridin-4-ylethyl)-2- (trifluoromethyl)benzenesulfonamide
[0950] In an analogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and 2-(pyridine-4-yl)ethanamine was used to prepare the title compound 5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)-2- (trifluoromethyl)benzenesulfonamide (40.4 mg, 38%) as a white solid. MS (ES+) m/z 471.1;
HPLC purity 100% at 210-370 nm, 8.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H17F3N2O4S2 + H+, 471.06546; found (ESI, [MfH]+), 471.0663.
Example 772 : N-(2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzeuesulfonamide
[0951] In an analogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and 2-aminoindan was used to prepare the title compound N-(2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (56.2 mg, 44%) as a white solid. MS (ES-) m/z 480.0; HPLC purity 91.5% at 210-370 nm, 10.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 773: N-[(2R)-2-hydroxy-2-phenyIethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0952] In an analogous manner to example 765, 5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonyl chloride and (R)-2-amino-l-phenylethanol was used to prepare the title compound N-[(2R)-2-hydroxy-2-phenylethyl]~5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (24.6 mg, 19%) as a white solid. MS (ES-) m/z 484.0;
HPLC purity 100% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 774: N-[(2S)-2-hydroxy-2-phenylethyl]-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0953] In an analogous manner to example 765, 5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonyl chloride and (>S)-2-ammo-l-phenylethanol was used to prepare the title compound iV-[(25)-2-hydroxy-2-phenylethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (45.5 mg, 36%) as a white solid. MS (ES-) m/z 484.0;
HPLC purity 100% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 775: 4-Methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide
[0954] In an analogous manner as described in Example 770, replacing benzoyl chloride with 4-methyl-benzoyl chloride and using a gradient of 100% methylene chloride to 50% ethyl acetate-methylene chloride as the eluent gave 4-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (105.1 mg, 59%) as a white solid. MS (ES+) m/z 527.1;
HRMS: calcd for C23H21F3N2O5S2 + H+, 527.09167; found (ESI, [M+H]+), 527.0905; Anal. Calcd for C23H2JF3N2O5S2: C, 52.46; H, 4.02; N, 5.32. Found: C, 52.28; H, 4.05; N, 5.12. Example 776: 4-tert-Butyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide
[0955] In an analogous manner as described in Example 775, and replacing 4-methyl- benzoyl chloride with 4-tert-butyl-benzoyl chloride, gave 4~tert-butyl-N-[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (134.2 mg, 70%) as a white solid. MS (ES+) m/z 569.2;
HRMS: calcd for C26H27F3N2O5S2 + H+, 569.13862; found (ESI, [M+H]+), 569.1392; Anal. Calcd for C26H27F3N2O5S2: C, 54.92; H, 4.79; N, 4.93. Found: C5 54.89; H, 4.74; N, 4.77.
Example 777: 4-Fluoro-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide
[0956] In an analogous manner as described in Example 775, and replacing 4-methyl- benzoyl chloride with 4-fluoro-benzoyl chloride, gave 4-fluoro-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (96.8 mg, 54%) as a white solid. MS (ES+) m/z 531.0;
HRMS: calcd for C22H18F4N2O5S2 + H+, 531.06660; found (ESI, [M+H]+), 531.0664; Anal. Calcd for C22H18F4N2O5S2: C, 49.81; H3 3.42; N, 5.28. Found: C, 49.71; H, 3.42; N, 5.09.
Example 778: 4-Chloro-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide
[0957] In an analogous manner as described in Example 775, and replacing 4-methyl- benzoyl chloride with 4-chloro-benzoyl chloride, gave 4-chloro-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (131.2 mg, 71%) as a white solid. MS (ES+) m/z 547.0;
HRMS: calcd for C22H18ClF3N2O5S2 + H+, 547.03705; found (ESI, [M+H]+), 547.0378; Anal. Calcd for C22H18ClF3N2O5S2: C, 48.31; H, 3.32; N, 5.12. Found: C, 48.15; H, 3.38; N, 4.95.
Example 779: 4-Bromo-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulf onyl} amino)ethyl]benzamide [0958] In an analogous manner as described in Example 775, and replacing 4-methyl- benzoyl chloride with 4-bromo-benzoyl chloride, gave 4-bromo-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (149.3 mg, 74%) as a white solid. MS (ESI+) m/z 591;
HRMS: calcd for C22H18BrF3N2O5S2 + H+, 590.98653; found (ESI, [MH-H]+), 590.9851; Anal. Calcd for C22H18BrF3N2O5S2: C, 44.68; H, 3.07; N5 4.74. Found: C, 44.57; H, 3.32; N, 4.55.
Example 780: 4-Methoxy-N-[2-({[5-(phenylsuIfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide
[0959] In an analogous manner as described in Example 775, and replacing 4-methyl- benzoyl chloride with 4-methoxy-benzoyl chloride, gave 4-methoxy-N-[2-({[5-(phenylsulfonyl)~ 2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (163.5 mg, 89%) as a white solid. MS (ES+) m/z 543.1;
HRMS: calcd for C23H21F3N2O6S2 + H+, 543.08659; found (ESI, [M+H]+), 543.0869; Anal. Calcd for C23H21F3N2O6S2: C, 50.92; H, 3.90; N, 5.16. Found: C, 51.11; H, 3.71; N, 4.94.
Example 781: N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]- 4-(trifluoromethyl)benzamide
[0960] In an analogous manner as described in Example 775, and replacing 4-methyl- benzoyl chloride with 4-trifluoromethyl-benzoyl chloride, gave N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4-(trifluoromethyl)benzamide (118.8 mg, 60%) as a white solid. MS (ES+) m/z 581.0;
HRMS: calcd for C23H18F6N2O5S2 + H+, 581.06341; found (ESI, [M+H]+), 581.0607; Anal. Calcd for C23H18F6N2O5S2: C, 47.59; H, 3.13; N, 4.83. Found: C, 47.45; H, 2.84; N3 4.63.
Example 782: N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]- 4-(trifluoromethoxy)benzamide
[0961] In an analogous manner as described in Example 775, and replacing 4-methyl- benzoyl chloride with 4-trifluoromethoxy-benzoyl chloride, gave N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4-(trifluoromethoxy)benzamide (122.8 mg, 60%) as a white solid.
MS (ES+) m/z 597.0;
HRMS: calcd for C23H18F6N2O6S2 + H+, 597.05832; found (ESI, [M+H]+)5 597.0574;
Anal. Calcd for C23Hi8F6N2O6S2: C, 46.31; H, 3.04; N, 4.70. Found: C, 46.24; H, 2.59; N, 4.49.
Example 783: N-[2-({[5-(Phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulf onyl} amino)ethyl] isonicotinamide
[0962] Isonicotinoyl chloride (61.5 mg, 0.345 mmol) was added under nitrogen to a mixture of N-(2-aminoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (150.1 mg, 0.337 mmol), prepared in Example 762, and triethylamine (141 IEIL, 1.01 mmol) in 20 mL of methylene chloride at room temperature. After the addition the reaction was stirred at room temperature for approximately 24 h. The reaction was partitioned with water. The organic layer was separated and the aqueous layer was extracted three times with methylene chloride. The combined extracts were dried (anhydrous magnesium sulfate) and the solvent removed under reduced pressure to give 186.8 mg of a solid. Purification of the solid on a 12 g Redi Sep Flash Column (silica gel) using a gradient of 100% methylene chloride to 20% methanol-methylene chloride as the eluent gave N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]isonicotinamide (153.5 mg, 89%) as a white solid. MS (ES+) m/z 514.1;
HRMS: calcd for C21H18F3N3O5S2 + H+, 514.07127; found (ESI, [M+H]"1"), 514.0713; Anal. Calcd for C21H18F3N3O5S2: C, 49.12; H3 3.53; N, 8.18. Found: C, 48.98; H, 2.94; N, 8.04.
Example 784: N-[(lR)-l-(hydroxymethyl)propyI]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0963] In an analogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and (S)-(+)-2-amino-l-butanol was used to prepare the title compound N-[(lR)-l-(hydroxymethyl)propyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (74.6 mg, 65%) as a white solid. MS (ES+) m/z 438.0;
HPLC purity 100% at 210-370 nm, 8.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C17H18F3NO5S2 + H+, 438.06512; found (ESI, [M+H]+), 438.0621.
Example 785: Λr-(2-hydroxyethyI)-5-[(3-methoxyphenyl)sulfonyl]-2- (trifluoromethyl)benzenesulfonamide
[0964] In an analogous manner to example 654, 2-txifluoromethyl-5-(3- methoxylphenylsulfonyl)- benzenesulfonyl chloride and ethanolamine were used to prepare N- (2-hydroxyethyl)-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 438.0;
HPLC purity 100% at 210-370 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 rnL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. HRMS: calcd for C16H16F3NO6S2 + H+, 440.04439; found (ESI, [M+H]+), 440.0446.
Example 786: tert-butyl (35)-3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate
[0965] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and S-3-aminopiperidine-l- carboxylic acid tert-butyl ester were used to prepare fert-butyl (3S)-3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)pheny 1] sulfony 1 } amino)piperidine- 1 -carboxy late . MS (ES-) m/z 547.0;
HPLC purity 96.6% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H27F3N2O6S2 + H+, 549.13354; found (ESI, [M+H]+), 549.1335.
Example 787: tert-butyl (3U)-3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate
[0966] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and R-3-aminopiperidine-l- carboxylic acid fert-butyl ester were used to prepare tert-butyl (3i?)-3-({[5-(phenylsulfonyl)-2- (trifluoromethy l)pheny 1] sulfonyl } amino)piperidine- 1 -carboxy late . MS (ES-) m/z 547.0;
HPLC purity 97.3% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H27F3N2O6S2 + H+, 549.13354; found (ESI, [M+H]*), 549.1335.
Example 788: iV-[l-(2-hydroxyethyl)piperidin-4-yl]-5-(phenyIsulfonyI)-2- (trifluoromethyl)benzenesulfonamide
[0967] To a stirred solution of 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (0.09 g, 0.20 mmol) in 1,4-dioxane (1 mL) was added 2- bromoethanol (0.05, 0.40 mmol) and triethylamine (0.1 mL, 0.7 mmol). The resulting solution was heated 1500C in a microwave for 10 minutes and concentrated. Flash column separation using 0%-5% methanol/methylene chloride gradient gave N-[l-(2-hydroxyethyl)piperidin-4-yl]- 5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. (0.03 g, 30%). MS (ES+) m/z 493.1;
HPLC purity 98.3% at 210-370 ran, 6.8 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H23F3N2O5S2 + H+, 493.10732; found (ESI, [M+H]+), 493.1083.
Example 789: tert-butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2- methylphenyl}sulfonyl)amino]piperidine-l-carboxylate
[0968] To a solution of 5-(4-fluoro-benzenesulfonyl)-2-methyl-benzenesulfonyl chloride (1.0 g, 2.87 mmol) in dichloromethane (20.0 mL) was added triethylamine (0.80 mL, 5.73 mmol) followed by 4-amino-l-Boc-piperidne (0.69 g, 3.44 mmol). The reaction was stirred overnight at room temperature under nitrogen. The following day the reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of tert-butyl 4-[({5-[(4- fluorophenyl)sulfonyl]-2- methylphenyl}sulfonyl)amino]piperidine-l-carboxylate (1.42 g, 97%). MS (ES-) m/z 511.0.
Example 790: 5-(phenylsulfonyl)-iV-[(3S)-piperidin-3-yl]-2- (trifluoromethyl)benzenesulfonamide
[0969] In an analogous manner to example 688, tert-butyl (35)-3-({[5-(phenylsulfonyl)- 2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate was used to prepare 5- (pheny lsulfony I)-N- [(35)-piperidin-3 -y 1] -2-(trifluoromethy l)benzenesulfonamide . MS (ES+) m/z 449.1;
HPLC purity 97.1% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C18H19F3N2O4S2 + H+, 449.08111; found (ESI, [M+H]"1"), 449.0825.
Example 791: 5-(phenylsulfonyl)-iV-[(3R)-piperidin-3-yl]-2- (trifluoromethyl)benzenesulfonamide
[0970] In an analogous manner to example 688, tert-huty\ (3i?)-3-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidine-l -carboxylate was used to prepare 5-(pheny lsulfony I)-N- [(3i?)-piperidin-3 -y 1] -2-(trifluoromethy l)benzenesulfonamide . MS (ES+) m/z 449.1;
HPLC purity 96.9% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C18H19F3N2O4S2 + H+, 449.08111 ; found (ESI, [M+H]+), 449.0822.
Example 792: 5-[(l,2-dimethyl-lZT-indol-5-yl)sulfonyl]-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide
[0971] Step 1 : To a stirred solution of 4-fluoro-2-bromobenzotrifluoride (2.0 g, 8.23 mmol) in THF (50 mL) at -78 °C was added nButyl lithium 2.5M in hexane (4.0 mL, 10.0 mmol) dropwise over 5 minutes. The resulting solution was stirred for 15minutes, then sulfur dioxide was bubbled in over 20 minutes, and the solution as concentrated. The crude mixture was taken up in methylene chloride (50 mL) and N-Chlorosuccinimide (1.1 g, 8.23 mmol) was added. The resulting solution was stirred room temperature for 1.5hrs, washed with ammonium chloride solution (sat.) and concentrated. Flash column separation using 0%-30% ethyl acetate/hexane gradient gave 5-fluoro-2-trifluoromethylbenzenesulfonyl chloride (0.55 g, 25%).
[0972] Step 2: In an analogous manner to example 435, 5-fluoro-2- trifluoromethylbenzenesulfonyl chloride and 4-aminopiperidine-l- carboxylic acid tert-butyl ester were used to prepare tert-butyl 4-({[5-fluoro-2- (trifluoromethy l)pheny 1] sulfony 1} amino)piperidine- 1 -carboxylate .
[0973] Step 3: To a stirred solution of 5-bromo-2-methyl-indole (5.0 g, 23.5 mmol) in DMF (50 mL) at 00C was added sodium hydride (1.13 g(60%), 28.05 mmol) and the resulting solution was stirred for 5 minutes. Methyl iodide (3.3mL, 52.8 mmol) was added and the reaction was allowed to warm to room temperature. After lhr, the reaction was quenched with ammonium chloride solution (sat), and extracted several times with ethyl acetate. The combined organic layers were washed with brine, dried over magnesium sulfate, and concentrated. Flash column separation using 0%-10% ethyl acetate/hexane gradient gave crude l,2-dimethyl-5- bromoindole. This material was dissolved in THF (30 mL) and chilled to -780C. nButyl lithium 2.5M in hexane (4.0 mL, 10.0 mmol) was added dropwise. After 10 minutes sulfur dioxide was bubbled into the reaction mixture for 15 minutes. The mixture was allowed to warm to room temperature and concentrated to give l,2-dimethylindole-5-sulfinic acid lithium salt. HRMS: calcd for C21H25F3N2O6S2 + H+, 523.11789; found (ESI, [M+H-C4H8]+), 467.0601. C4H8.
[0974] Step 4: To a stirred solution of l,2-dimethylindole-5-sulfinic acid lithium salt (0.10 g, 0.54 mmol) in dimethylformamide (1 mL), fert-butyl 4-({[5-fluoro-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate (0.115 g, 0.27 mmol) was added and the resulting solution was heated to 80°C overnight and concentrated. The crude material was taken up in ethyl acetate, washed with sodium bicarbonate solution (sat) and concentrated. Flash column separation using 0%-40% ethyl acetate/hexane gradient gave tert- butyl 4-({[5-(l,2-dimethyl-lH-indol-5-yl)sulfonyl)-2- (trifluoromethy l)pheny 1] sulfony 1 } amino)piperidine- 1 -carboxy late .
[0975] Step 5: In an analogous manner to example 688, tert-butyl 4-({[5-(l,2-dimethyl- lH-indol-5-yl)sulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate was used to prepare 5-[(l,2-dimethyl-l/f-indol-5-yl)sulfonyl]-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 516.1;
HPLC purity 100% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H24F3N3O4S2 + H+, 516.12331; found (ESI, [M+H]+), 516.1237.
Example 793: tert-Butyl methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate
[0976] 5-(Phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonyl chloride (2.6940 g, 7.00 mmol), prepared in Example 677, in 25 mL of methylene chloride was added under nitrogen dropwise over 30 minutes to a solution of N-(2-aminoethyl)-N-methyl carbamic acid tert-butyl ester (1.25 mL, 6.99 mmol) and triethylamine (2.93 mL, 21.0 mmol) in 50 mL of methylene chloride at room temperature. After the addition the reaction was stirred at room temperature for 7 h. The reaction was extracted with 2 N HCl. The organic layer was separated and the aqueous layer was extracted three times with methylene chloride. The combined extracts were dried (anhydrous magnesium sulfate) and the solvent removed under reduced pressure to give 2.98 g of a yellow foam. Purification of the foam on 500 g of silica gel (230-400 mesh) using 10% ethyl acetate-methylene chloride to 20% ethyl acetate-methylene chloride as the eluent gave tert- butyl methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate (862.1 mg, 24%) as a yellow foam. MS (ES) m/z 521.0.
Example 794: tert-butyl (3S)-3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l-carboxylate
[0977] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and S-3-aminopyrrolidine-l- carboxylic acid tert-butyl ester were used to prepare tert-butyl (3>S)-3-({[5-(phenylsulfonyl)-2- (trifluoromethy l)pheny 1] sulfony 1} amino)pyrrolidine- 1 -carboxy late . MS (ES-) m/z 533.0;
HPLC purity 97.3% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 795: tert-butyl (3R)-3-({[5-(phenylsuIfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l-carboxylate
[0978] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and R-3-aminopyrrolidine-l- carboxylic acid tert-butyl ester were used to prepare tert-butyl (3i?)-3-({[5-(phenylsulfonyl)-2- (trifluoromethy l)pheny 1] sulfony 1 } amino)pyrrolidine- 1 -carboxy late.
HPLC purity 97.6% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. MS (ES-) m/z 533.0. Exaraple 796: 5-(phenylsulfonyl)-iV-[(3S)-pyrroIidin-3-yl]-2- (trifluoromethyl)benzenesulfonamide
[0979] In an analogous manner to example 688, tert-butyl (35)-3-({[5-(phenylsulfonyl)- 2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l-carboxylate was used to prepare 5- (phenylsulfonyl)-N-[(3)S)-pyrrolidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 434.7;
HPLC purity 97.2% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C17H17F3N2O4S2 + H+, 435.06546; found (ESI, [M+H]+), 435.0656.
Example 797: 5-(phenylsulfonyl)-iV-[(3R)-pyrrolidin-3-yl]-2- (trifluoromethyl)benzenesulfonamide
[0980] In an analogous manner to example 688, fert-butyl (3i?)-3-({[5- (phenylsulfonyl)-2-(trifluoromethyl)p]ienyl]sulfonyl}amino)pyrrolidine-l-carboxylate was used to prepare 5-(phenylsulfonyl)-iV-[(3i?)-pyrrolidin-3-yl]-2-(trifluorometliyl)benzenesulfonamide. MS (ES+) m/z 434.7;
HPLC purity 96.9% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C17H17F3N2O4S2 + H+, 435.06546; found (ESI5 [M+H]+), 435.0658.
Example 798: 2-methyl-5-(phenyIsulfonyl)-N-(tetrahydro-2H-thiopyran-4- yl)benzenesulfonamide
[0981] Step 1 : To a solution of tetrahydrothiopyran-4-one (3.0 g, 25.82 mmol) and 2,4- dimethoxybenzylamine (4.3 g, 25.82 mmol) in dichloroethane was added sodium triacetoxyborohydride (7.7 g, 36.15 mmol). The reaction was stirred overnight at room temperature under nitrogen. The reaction was quenched with a saturated aqueous bicarbonate solution and extracted. Dried with magnesium sulfate and concentrated down to give (2,4- dimethoxy-benzyl)-(tetrahydro-thiopyran-4-yl)-amine (6.7 g, 97%).
[0982] Step 2: To a solution of 5-benzenesulfonyl-2-methyl-benzenesulfonyl chloride (0.30 g, 0.90 mmol) in dichloromethane (12 niL) was added triethylamine (0.38 μL, 2.72 mmol) followed by (2,4-dimethoxy-benzyl)-(tetrahydro-thiopyran-4-yl)-amine (0.49 g, 1.81 mmol). The reaction was stirred overnight at room temperature under nitrogen. The following day the reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 5-benzenesulfonyl-N-(254-dimethoxy-benzyl)-2-methyl-N-(tetrahydro-thiopyran-4-yl)- benzenesulfonamide .
[0983] Step 3: 5-Benzenesulfonyl-N-(2,4-dimethoxy-ben2yl)-2-methyl-N-(tetrahydro- thiopyran-4-yl)-benzenesulfonamide was taken up in 5 mL of 6% trifluoroacetic acid/dichloromethane and was stirred overnight at room temperature under nitrogen. The reaction was extracted with water. The organic layer was washed with saturated solution of sodium bicarbonate and dried with magnesium sulfate. The reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 2-methyl-5-(phenylsulfonyl)- N-(tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide (0.31 g, 84%). MS (ES+) m/z 411.7; HRMS: calcd. for C18H21NO4S3 + H+, 412.0711: found (ESI, [M+H]+), 412.0681.
Example 799: N-[2-(Methylamino)ethyl]-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride
[0984] Approximately 100 mL of a saturated solution of anhydrous hydrogen chloride in ethyl acetate was added to a solution of tert-butyl methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate (2.8555 g, 5.46 mmol), prepared in Example 793, in 100 mL of ethyl acetate at room temperature. After the addition the reaction was stirred for 6 h. The solid was collected by filtration, rinsed with ethyl acetate and dried under reduced pressure to give N-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride (2.2506 g, 90%) as a white solid. MS (ES-) m/z 420.6; HRMS: calcd for C16H17F3N2O4S2 + H+, 423.06546; found (ESI, [M+H]+), 423.0543.
Example 800: JV-[l-(4-benzoylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0985] A solution of 4-benzoyl-benzoyl chloride (34 mg, 0.14 mmol) in dichloromethane (1 mL) was added to a stirred dichloromethane solution of Example 688 (62 mg, 0.14 mmol) and triethylamine (0.28 mmol). The reaction was concentrated to dryness and immediately purified by flash column chromatography using an ethyl acetate hexane gradient
(20-50%) resulting in the isolation of iV-[l-(4-benzoylbenzoyl)piperidin-4-yl]-5-
(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (72 mg, 79%).
MS (ES+) m/z 656.6;
HPLC purity 93.4% at 210-370 ran, 10.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C32H27F3N2O6S2 + H+, 657.13354; found (ESI, [M+H]"1"), 657.1337.
Example 801 : iV-[l-(3-benzoylbenzoyI)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[0986] A solution of 3 -benzoyl-benzoyl chloride (34 mg, 0.14 mmol) in dichloromethane (1 mL) was added to a stirred dichloromethane solution of Example 688 (62 mg, 0.14 mmol) and triethylamine (0.28 mmol). The reaction was concentrated to dryness and immediately purified by flash column chromatography using an ethyl acetate hexane gradient (20-50%) resulting in the isolation of iV-[l-(3-benzoylbenzoyl)piperidin-4-yl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (67 mg, 71%). MS (ES+) m/z 656.7;
HPLC purity 95.1% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C32H27F3N2O6S2 + H+, 657.13354; found (ESI, [M+H]+), 657.1326.
Example 802: l-Isopropyl-4-(phenylsulfonyl)benzene
[0987] Step a
The title compound was prepared from 4-isopropylbenzenesulfonyl chloride (8.75 g, 40.0 mmol), benzene (20.0 mL, 200 mmol), and aluminum chloride (6.4 g, 48.0 mmol) according to the procedure and in the same manner as described in Example 678, step a. l-Isopropyl-4- (phenylsulfonyl)benzene (10.32g, 99%) was obtained as a homogeneous oil which solidified on standing.
[0988] Step b
2-Isopropyl-5-(phenyIsulfonyl)benzenesulfonyl chloride l-Isopropyl-4-(phenylsulfonyl)benzene (10.4 g, 40.0 mmol) was heated with stirring at 60 0C for one hour under nitrogen with chlorosulfonic acid (26.5 mL, 400 mmol). The mixture was cooled to room temperature, poured slowly into a cold solution of 2N hydrochloric acid, and extracted with ethyl acetate (2x.). The organic phase was washed with a saturated, aqueous sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated in vacuo to yield 2-isopropyl-5-(phenylsulfonyl)benzenesulfonyl chloride (3.3 g, 24%) as a homogeneous, colorless, crystalline solid. [0989] Step c
N-(l-Benzoylpiperidin-4-yl)-2-isopropyI-5-(phenylsulfonyI)benzenesulfonamide A stirred solution of 2-isopropyl-5-(phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol) in dichloromethane (10 mL) was treated under nitrogen with (4-aminopiperidin-l- yl)(phenyl)methanone hydrochloride (0.18 g, 0.75 mmol) and a solution of diisopropylethylamine (0.26 g, 2.0 mmol) in dichloromethane. The reaction was stirred from 2- 18 hours at room temperature. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%- 100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford, after crystallization from diethyl ether-hexane, JV-(I -benzoylpiperidin-4-yi)-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide (0.26 g, 76%), as a homogeneous, colorless, crystalline solid, m.p. 225 °C; MS (+ESI), m/z: 526.7 [MH-H]+;
HRMS: calcd for C27H30N2O5S2 + H+, 527.16689; found (ESI, [M+H]+), 527.1677; HPLC purity 100% at 210-370 nm, 9.5 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 803: 2-Isopropyl-iV-[l-(2-methoxybenzoyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide
[0990] The title compound was prepared from 2-isopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yi)(2- methoxyphenyl)methanone hydrochloride (0.20 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 75%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min to afford 2-isopropyl-iV-[l-(2- methoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide (0.21 g, 75%), as a homogeneous, amorphous solid, m.p. 160-162 0C;
MS (+ESI), m/z: 556.7 [M+H]+;
HRMS: calcd for C28H32N2O6S2 + H+, 557.17745; found (ESI5 [M+H]+), 557.1782;
HPLC purity 99.3% at 210-370 nm, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 804: JV-[l-(3-Fluorobenzoyl)piperidin-4-yl]-2-isopropyI-5- (phenylsulfonyl)benzenesulfonamide
[0991] The title compound was prepared from 2-isopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin~l-yl)(3- fluorophenyl)methanone hydrochloride (0.19 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%- 100% methyl terf-butyl ether in hexane at a flow rate of 50 mL/min to afford, after crystallization from diethyl ether- hexane, N-[I -(3-fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-
(phenylsulfonyl)benzenesulfonamide (0.16 g, 59%), as a homogeneous, colorless, crystalline solid, m.p. 215-218 °C; MS (+ESI), m/z: 544.7 [M+H]+;
HRMS: calcd for C27H29FN2O5S2 + H+, 545.15747; found (ESI, [M+H]+), 545.158; HPLC purity 100% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 805: JV-[l-(4-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide
[0992] The title compound was prepared from 2-isopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(4- fluorophenyl)methanone hydrochloride (0.19 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%- 100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min to afford, after crystallization from diethyl ether- hexane, N-[I -(4-fTuorobenzoyi)piperidin-4-yi]-2-isopropyl-5-
(phenylsulfonyl)benzenesulfonamide (0.18 g, 64%), as a homogeneous, colorless, crystalline solid, m.p. 218-220 °C;
MS (+ESI), m/z: 544.7 [M+H]+;
HRMS: calcd for C27H29FN2O5S2 + H+, 545.15747; found (ESI, [M+H]+), 545.1559;
HPLC purity 100% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 806: iV-[l-(2-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide
[0993] The title compound was prepared from 2-isopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(2- fluorophenyl)methanone hydrochloride (0.19 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by preparative liquid chromatography on a Biotage 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%- 100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min to afford, after crystallization from diethyl ether- hexane, N-[I -(2-fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-
(phenylsulfonyl)benzenesulfonamide (0.18 g, 68%), as a homogeneous, colorless, crystalline solid, m.p. 210-212 °C; MS (+ESI)5 m/z: 544.7 [M+H]+;
HRMS: calcd for C27H29FN2O5S2 + H+, 545.15747; found (ESI, [M+H]+), 545.1573; HPLC purity 100% at 210-370 nm, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 807: 2-Isopropyl-5-(phenylsulfonyl)-iV-{l-[4-(trifluoromethyl)benzoyl]piperidin-4- yl} benzenesulfonamide
[0994] The title compound was prepared from 2-isopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(4- (trifiuoromethyl)phenyl)methanone hydrochloride (0.23 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 25%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min to afford 2- isopropyl-5-(phenylsulfonyl)-N-{l-[4-(trifluoromethyl)benzoyl]piperidin-4- yl}benzenesulfonamide (0.24 g, 79%), as a homogeneous, amorphous solid, m.p. 140-142 °C; MS (+ESI), m/z: 594.7 [M+H]+;
HRMS: calcd for C28H29F3N2O5S2 + H+, 595.15427; found (ESI, [M+H]+), 595.1538; HPLC purity 99.3% at 210-370 nm, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 808: 2-Isopropyl-iV-[l-(l-naphthoyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide
[0995] The title compound was prepared from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l- yl)(naphthalen-l-yl)methanone hydrochloride (0.22 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by preparative liquid chromatography on a Biotage3 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%- 100% methyl tert- butyl ether in hexane at a flow rate of 50 mL/min to afford 2-isopropyl-iV-[l-(l- naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide (0.27 g, 92%), as a homogeneous, amorphous solid, m.p. 163-165 °C; MS (+ESI), m/z: 576.7 [M+H]+;
HRMS: calcd for C31H32N2O5S2 + H+, 577.18254; found (ESI, [M+H]+), 577.1828; HPLC purity 99.0% at 210-370 nm, 10.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 809: 2-Isopropyl-ΛL[l-(2-naphthoyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide
[0996] The title compound was prepared from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l- yl)(naphthalen-2-yl)methanone hydrochloride (0.22 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by preparative liquid chromatography on a Biotage®
40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 25%- 100% methyl tert- butyl ether in hexane at a flow rate of 50 mL/min to afford 2-isopropyl-N-[l-(2- naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide (0.24 g, 84%), as a homogeneous, amorphous solid, m.p. 130-132 0C;
MS (+ESI), m/z: 576.7 [M+H]+;
HRMS: calcd for C31H32N2O5S2 + H+, 577.18254; found (ESI, [M+H]+), 577.183;
HPLC purity 99.7% at 210-370 nm, 10.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 810: iV-[l-(3-Cyanobenzoyl)piperidin-4-yl]-2-isopropyl~5- (phenylsulfonyl)benzenesulfonamide
[0997] The title compound was prepared from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), 3-(4-aminopiperidine-l- carbonyl)benzonitrile hydrochloride (0.20 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min to afford JV-[I -(3-cyanobenzoyl)piperidin-4-yl]-2- isopropyl-5-(phenylsulfonyl)benzenesulfonamide (0.19 g, 69%), as a homogeneous, amorphous solid, m.p. 120-122 °C; MS (+ESI), m/z: 551.7 [M+H]+;
HRMS: calcd for C28H29N3O5S2 + H+, 552.16214; found (ESI, [M+H]+), 552.1634; HPLC purity 100% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 811: iV~[l-(4-Cyanobenzoyl)piperidm-4-yI]-2-isopropyI-5- (phenylsulfonyl)benzenesulfonamide
[0998] The title compound was prepared from 2-isopropyl-5- (phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), 4-(4-aminopiperidine-l- carbonyl)benzonitrile hydrochloride (0.20 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 25%- 100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min to afford iV-[l-(4-cyanobenzoyl)piperidin-4-yl]-2- isopropyl-5-(phenylsulfonyl)benzenesulfonamide (0.21 g, 77%), as a homogeneous, amorphous solid, m.p. 136-138 0C;
MS (+ESI)5 m/z: 551.7 [M+H]+;
HRMS: calcd for C28H29N3O5S2 + H+, 552.16214; found (ESI, [M+H]+)5 552.1635;
HPLC purity 100% at 210-370 ran, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 812: iV-[l-(4-te^-Butylbenzoyl)piperidin-4-yl]-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide
[0999] The title compound was prepared from 2-isopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(4-tert- butylphenyl)methanone hydrochloride (0.22 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 10%- 100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min to afford, after crystallization from diethyl ether- hexane, N-[l-(4-tert-butylbenzoyl)piperidin-4-yl]-2-isopropyl-5-
(phenylsulfonyl)benzenesulfonamide (0.28 g, 95%), as a homogeneous, colorless, crystalline solid, m.p. 150-152 0C; MS (+ESI), m/z: 582.8 [M+H]+;
HRMS: calcd for C31H38N2O5S2 + H+, 583.22949; found (ESI, [M+H]+), 583.2277; HPLC purity 99.4% at 210-370 nm, 10.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 813: N-[l-(2-Ethoxy-l-naphthoyI)piperidin-4-yl]-2-isopropyl-5- (phenylsulfonyl)benzenesulfonamide
[1000] The title compound was prepared from 2-isopropyl-5-
(phenylsulfonyl)benzenesulfonyl chloride (0.18 g, 0.5 mmol), (4-aminopiperidin-l-yl)(2- ethoxynaphthalen-l-yl)methanone hydrochloride (0.25 g, 0.75 mmol), and diisopropylethylamine (0.26 g, 2.0 mmol) according to the procedure and in the same manner as described in Example 802, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (45 g), eluting with a gradient of 10%-100% methyl terf-butyl ether in hexane at a flow rate of 50 mL/min to afford, after crystallization from diethyl ether-hexane, iV-[l-(2-ethoxy-l-naphthoyl)piperidin-4-yl]-2- isopropyl-5-(phenylsulfonyl)benzenesulfonamide (0.28 g, 89%), as a homogeneous, colorless, crystalline solid, m.p. 164-166 0C;
MS (+ESI), m/z: 620.8 [M+H]+;
HRMS: calcd for C33H36N2O6S2 + H+, 621.20875; found (ESI, [M+H]+), 621.2089;
HPLC purity 100% at 210-370 ran, 10.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 814: 5-[(4-hydroxyphenyl)sulfonyl]-iV-(2-pyridin-3-ylethyl)-2- (trifluoromethyl)benzenesulfonamide
[1001] Step 1 : Following the same procedure described on example 677 (Step 2), 2- chloro-5-fluoronitrobenzene was used to prepare 2-nitro-4-fluorobenzotrifluoride.
[1002] Step 2: In an analogous manner to example 743 (Step 2), 4- methoxybenzenethiol was used to prepare 5-(4-methoxyphenylsulfonyl)-2-trifluoromethyl- nitrobenzene.
[1003] Step 3: In an analogous manner to example 677 (Step 3), 5-(4- methoxyphenylsulfonyl)-2-trifluoromethyl-nitrobenzene was used to prepare 5-(4- methoxyphenylsulfonyl)-2-trifluoromethylaniline.
[1004] Step 4: In an analogous manner to example 677 (Step 4), 5-(4- methoxyphenylsulfonyl)-2-trifluoromethylaniline was used to prepare 2-trifluoromethyl-5-(4- methoxyphenylsulfonyl)-benzenesulfonyl chloride.
[1005] Step 5: In an analogous manner to example 435, 2-trifluoromethyl-5-(4- methoxyphenylsulfonyl)-benzenesulfonyl chloride and 3-(2-aminoethyl)pyridine were used to prepare 5-[(4-methoxyphenyl)sulfonyl]-Λ/-(2-pyridin-3-ylethyl)-2- (trifluoromethyl)benzenesulfonamide.
[1006] Step 6: In an analogous manner to example 744, 5-[(4- methoxyphenyl)sulfonyl]-iV-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide, was used to prepare 5-[(4-hydroxyphenyl)sulfonyl]-iV-(2-pyridin-3-yletliyl)-2-
(trifluoromethyl)benzenesulfonamide.
MS (ES+) m/z 486.6;
HPLC purity 95.7% at 210-370 run, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C20H17F3N2O5S2 + H+, 487.06037; found (ESI, [M+H]+), 487.0609.
Example 815: 5-[(4-fluorophenyl)suIfonyl]-2-isopropyl-N-(tetrahydro-2H-thiopyran-4- yl)benzenesulfonamide
[1007] Step 1 : To a solution of tetrahydrothiopyran (3.0 g, 25.82 mmol) and 2,4- dimethoxyben∑ylamine (4.3 g, 25.82 mmol) in dicliloromethane (100 mL) was added sodium triacetoxyborohydride (7.7 g, 36.15 mmol). The reaction was stirred overnight at room temperature under nitrogen. The reaction was quenched with a saturated aqueous bicarbonate solution and extracted. Dried with magnesium sulfate and concentrated to give N-(2,4- dimethoxybenzyl)tetrahydro-2H-thiopyran-4-amine (6.7 g, 97%).
[1008] Step 2: To a solution of 5-(4-fluorophenylsulfonyl)-2-isopropylbenzene-l- sulfonyl chloride (350 mg, 0.93 mmol) in dichloromethane 10 mL) was added triethylamine (388 μL, 2.79 mmol) followed by N-(2,4-dimethoxybenzyl)tetrahydro-2H-thiopyran-4-amine (497 mg, 1.86 mmol). The reaction was stirred overnight at room temperature. The following day the reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N-(2,4-dimethoxybenzyl)-5-(4-fluorophenylsulfonyl)-2-isopropyl-N-(tetrahydro-2H-thiopyran- 4-yl)benzenesulfonamide (504 mg, 89%).
[1009] Step 3: N-(254-dimethoxybenzyl)-5-(4-fluorophenylsulfonyl)-2-isopropyl-N- (tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide (504 mg, 0.83 mmol) was dissolved in 6% trifluoroacetic acid/dichloromethane (6 mL) and stirred overnight at room temperature under nitrogen. Saturated bicarbonate solution was added and the reaction was extracted. Dried with magnesium sulfate and concentrated onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-thiopyran-4- yl)benzenesulfonamide (350 mg, 92%). MS (ES+) m/z 456. Example 816: 5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2- (trifluoromethyl)benzenesulfonamide
[1010] Step 1 : l-chloro-4-(4-fluorophenylsulfonyl)-2-nitrobenzene (L31023-148). A mixture of 4-chloro-3-nitrobenzenesulfonyl chloride (25.13 g, 98.1 mmol), fluorobenzene (50 ml, 533 mmol) and aluminum chloride (15.71 g, 118 mmol) refluxed under nitrogen overnight. The next morning the reaction was allowed to cool to R.T. and then was transferred to a 1 L beaker where the reaction was mixed with ice for ten minutes. The contents of the beaker was partitioned between ethyl acetate and water. The ethyl acetate layer was separated, dried (anhydrous MgSO4) and the solvent removed under reduced pressure to give l-chloro-4-(4- fluorophenylsulfonyl)-2 -nitrobenzene (29.12 g, 93.9%).
[1011] Step 2: 4-(4-fluorophenylsulfonyl)-2-nitro-l-(trifluoromethyl)benzene (L31023- 152). To a flame dried flask the l-chloro-4-(4-fluorophenylsulfonyl)-2-nitrobenzene (29.12 g, 92.3 mmol) prepared in the previous step was taken up in 200 mL of anh. N,N- Dimethylformamide and was allowed stir under nitrogen at ice bath temperature. To the stirring reaction at ice bath temp., copper nanopowder (25.24 g , 0.4 mol) and activated carbon (13.67 g, 1.1 mol) was added to the reaction stirred for five minutes to which dibromodifluoromethane (19.8 ml, 0.2 mol) was slowly syringed into the reaction. After the complete addition of the dibromodifluoromethane, the reaction was heated to 100° C for five hours and then allowed to cool to R.T.. The contents of the flask was filtered though a plug of celite and the filtrate was then partitioned between ethyl acetate and ammonium chloride / water once. The organic layer was washed twice more with water. The ethyl acetate layer was separated, dried (anhydrous MgSO4) and the solvent removed under reduced pressure to give 4-(4-fluorophenylsulfonyl)-2- nitro-l-(trifluoromethyl)benzene (24.3 g, 75.3%).
[1012] Step 3 : 5-(4-fluorophenylsulfonyl)-2-(trifluoromethyl)aniline (L31023-153). A mixture of 4-(4-fluorophenylsulfonyl)-2-nitro-l-(trifluoromethyl)benzene (24.3 g, 69.6 mmol) and tin(II) chloride (65.9 g , 0.4 mol) was taken up in 1 : 16 water / methanol was refluxed for three days. The reaction was concentrated and then was partitioned between ethyl acetate and 2N hydrochloric acid. The ethyl acetate layer was separated, dried (anhydrous MgSO4) and the solvent removed under reduced pressure to give 25.6 g of a brown solid. The solid was purified on the Isco using a 330 g column and a gradient of hexane/ methylene chloride to give 5-(4- fluorophenylsulfonyl)-2-(trifluoromethyl)aniline. [1013] Step 4: 5-(4-fluorophenylsulfonyl)-2-(trifluoromethyl)benzene-l-sulfonyl chloride (L31023-160). 5-(4-fluoroρhenylsulfonyl)-2-(trifluoromethyl)aniline(3.79 g, 11.9 mmol) prepared in the previous step was taken up in 100 ml of acetonitrile and was cooled to ice bath temperature. To the chilled flask, 10 ml of acetic acid, 10 ml of hydrochloric acid and then sodium nitrite (0.98 g, 14.2 mmol) taken up in 2 ml of water were slowly syringed into the flask. The mixture was allowed to stir at ice bath temperature for one hour. Sulfur dioxide was then bubbled into the flask for fifteen minutes and then copper(II) chloride dihydrate taken up in 2 ml of water was syringed into the flask and was allowed to stir at ice bath temp, for three hours. The mixture was allowed to warm to room temp, and then was partitioned between ethyl acetate and water. The ethyl acetate layer was separated, dried (anhydrous MgSO4) and the solvent removed under reduced pressure to provide an orange oil which was purified on the Isco using a 330 g column and a gradient of hexane/ methylene chloride to give 5-(4-fluorophenylsulfonyl)-2- (trifluoromethyl)benzene-l-sulfonyl chloride (2.2234 g, 46.5 %).
[1014] Step 5: 5-[(4-fluorophenyl)sulfbnyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2- (trifluoromethyl)benzenesulfonamide). A mixture of sodium carbonate (0.1601 g, 1.5 mmol) in 1 ml of water and 2-(lH-imidazol-l-yl) ethyl amine (0.092, 0.5 mmol) in 3 ml of acetonitrile was treated with the mixture of 5-(4-fluorophenylsulfonyl)-2-(trifluoromethyl)benzene-l-sulfonyl chloride and 5-(2-fluorophenylsulfonyl)-2-(trifluoromethyl)benzene-l-sulfonyl chloride (0.2514 g, 0.6 mmol) prepared in the previous step in 10 ml of acetonitrile. The reaction was allowed to stir overnight at R. T. and then was partitioned between ethyl acetate and 2N hydrochloric acid. The ethyl acetate layer was separated, dried (anhydrous MgSO4) and the solvent removed under reduced pressure to give approximately 50 mg of the isomeric mixture that was dissolved in 3 mL of methanol / acetonitrile. 200 DL of the resulting solution was repetitively injected onto the Supercritical Fluid Chromatography (SFC) instrument, and the baseline resolved isomers were separately collected using the conditions described below to give the title compound 5-[(4- fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2-(trifluoromethyl)benzenesulfonamide (31.2 mg, 10%) as a white solid.
SFC Instrument: Berger MultiGram Prep SFC
Column: Ethylpyridine; IQDm; 250 mm L x 20 mm ID
Column temperature: 35°C
SFC Modifier: 15% MeOH with 0.2% DEA /85% CO2
Flow rate: 50 mL/min Outlet Pressure: 100 bar
Detector: UV at 220 ran
MS (ES+) m/z 477.6;
HPLC purity analytical SFc purity check after prep SFC separation of regioisomers peak 1 = 97.5% peak 2 = 96.8% minor impurities are of unknown composition; Ethyl pyridine 4.6 x 250 mm column, 2 mL/min, 15% MeOH / 85% CO2. HPLC purity 100% at 210-370 ran, 7.1 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C18H15F4N3O4S2 + H+5 478.05129; found (ESI, [M+H]+), 478.0507.
Example 817: 5-[(4-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)-2- (trifluoromethyl)benzenesulfonamide
[1015] In an analogous manner to example 765, a mixture of 5-[(4- fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2- (trifluoromethyl)benzenesulfonamide)and 5-(2-fluorophenylsulfonyl)-2-
(trifluoromethyl)benzene-l-sulfonyl chloride and 4-Aminotetrahydropyran to give approximately 85 mg of the isomeric mixture that was dissolved in 2.5 mL of methanol/acetonitrile. 250 μL of the resulting solution was repetitively injected onto the Supercritical Fluid Chromatography (SFC) instrument, and the baseline resolved isomers were separately collected using the conditions described below to give the title compound of 5-[(4-fluorophenyl)sulfonyl]-N~ (tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide (22.2 mg, 8%) as a white solid.
SFC Instrument: Berger MultiGram Prep SFC
Column: Ethylpyridine; 10 μm; 250 mm L x 20 mm ID
Column temperature: 35°C
SFC Modifier: 15% MeOH /85% CO2
Flow rate: 50 mL/min
Outlet Pressure: 100 bar
Detector: UV at 220 nm
MS (ES-) m/z 465.6; HPLC purity The peak purity is checked by analytical SFC: peak 1 - >99.9% peak 2 - >99.9%;
Ethyl Pyridine (4.6x250mm) column, 2mL/min, 15% MeOH /85%CO2.
HPLC purity 100% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 rnL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 818: tert-butyl 4-({[5-[(4-fluorophenyl)sulfonyl]-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate
[1016] In an analogous manner to example 765, a mixture of 5-[(4- fluorophenyl)sulfonyl]-N-[2-( lH-imidazol- 1 -yl)ethyl]-2-(trifluoromethyl)benzenesulfonamide) and 5-(2-fluorophenylsulfonyl)-2-(trifluoromethyl)benzene-l-sulfonyl chloride and 4-Amino- piperidine-1-carboxylic acid tert-butyl to give approximately 40 mg of the isomeric mixture that was dissolved in 2 mL of methanol/acetonitrile. 250 μL of the resulting solution was repetitively injected onto the Supercritical Fluid Chromatography (SFC) instrument, and the baseline resolved isomers were separately collected using the conditions described below to give the title compound tert-butyl 4-({[5-[(4-fluorophenyl)sulfonyl]-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate (27.6 mg, 8%) as a white solid.
SFC Instrument: Berger MultiGram Prep SFC
Column: Ethylpyridine; 10 μm; 250 mm L x 20 mm ID
Column temperature: 35°C
SFC Modifier: 15% MeOH/85% CO2
Flow rate: 50 rnL/min
Outlet Pressure : 100 bar
Detector: UV at 220 nm
MS (ESI-) m/z 565;
HPLC purity The purity was checked by analytical SFC: peak 1 - >99.9% peak 2 - >99.9%; Ethyl Pyridine (4.6x250mm) column, 2mL/min, 15% MeOH / 85% CO2. HPLC purity 100% at 210-370 nm, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H26F4N2O6S2 + H+, 567.12412; found (ESI, [M+H-C4H8]+), 511.0644. Example 819: N-Methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)ethyl]benzamide
[1017] Benzoyl chloride (38 μL, 0.327 mmol) was added under nitrogen to a solution ofN-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2-(1xifluoromethyl)benzenesulfonamide hydrochloride (150.8 mg, 0.329 mmol), prepared in Example 799, and triethylamine (229 μL, 1.64 mmol) in 20 mL of methylene chloride at room temperature. After the addition the reaction was stirred at room temperature for 19 h. The reaction was extracted two times with 2 N HCl, dried (anhydrous magnesium sulfate) and the solvent removed under reduced pressure to give 184.1 mg of a solid. Purification of the solid on a 12 g Redi Sep Fash Column (silica gel) using a gradient of 100% methylene chloride to 40% ethyl acetate-methylene chloride as the eluent gave N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl] sulfonyl} amino)ethyl]benzamide (156.3 mg, 91%) as a white solid. MS (ES+) m/z 526.6;
HRMS: calcd for C23H21F3N2O5S2 + H+, 527.09167; found (ESI, [M+H]+), 527.0908; Anal. Calcd for C23H21F3N2O5S2 . 0.20 CH2Cl2: C, 51.27; H, 3.97; N, 5.15. Found: C, 52.54; H, 3.87; N, 5.17.
Example 820: iV-(2-cyanoethyl)-5-[(4-methoxyphenyl)sulfonyl]-2- (trifluoromethyl)benzenesulfonamide
[1018] Step 1 : Following the same procedure described on example 677 (Step 2), 2- chloro-5-fluoronitrobenzene was used to prepare 2-nitro-4-fluorobenzotrifluoride.
[1019] Step 2: In an analogous manner to example 743 (Step 2), 4- methoxybenzenethiol was used to prepare 5-(4-methoxyphenylsulfonyl)-2-trifluoromethyl- nitrobenzene.
[1020] Step 3: In an analogous manner to example 677 (Step 3), 5-(4- methoxyphenylsulfonyl)-2-trifluoromethyl-nitrobenzene was used to prepare 5-(4- methoxyphenylsulfonyl)-2-trifluoromethylaniline.
[1021] Step 4: In an analogous manner to example 677 (Step 4), 5-(4- methoxyphenylsulfonyl)-2-trifluoromethylaniline was used to prepare 2-trifluoromethyl-5-(4- methoxyphenylsulfony l)-benzenesulfonyl chloride . [1022] Step 5: In an analogous manner to example 435, 2-trifluoromethyl-5-(4- methoxyphenylsulfonyl)-benzenesulfonyl chloride and aminopropionitrile were used to prepare iV-(2-cyanoethyl)-5-[(4-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 448.6;
HPLC purity 94.6% at 210-370 nm, 8.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HUMS: calcd for C17H15F3N2O5S2 + H+, 449.04472; found (ESI, [M+H]+), 449.0429.
Example 821: iV-(2-cyanoethyl)-5-[(4-hydroxyphenyI)sulfonyI]-2- (trifluoromethyl)benzenesulfonamide
[1023] In an analogous manner to example 744, iV-(2-cyanoethyl)-5-[(4- methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide was used to prepare N-(2- cyanoethyl)-5-[(4-liydroxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide MS (ES-) m/z 432.5;
HPLC purity 85.6% at 210-370 nm, 7.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Prrf.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C16H13F3N2O5S2 + H+, 435.02907; found (ESI, [M+H]"1"), 435.0308.
Example 822: 4-Methoxy-N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide
[1024] In an analogous manner as described in Example 819, and replacing benzoyl chloride with 4-methoxy-benzoyl chloride, gave 4-methoxy-N-methyl-N-[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (176.5 mg, 97%) as a white solid. MS (ES+) m/z 556.6;
HRMS: calcd for C24H23F3N2O6S2 + H+, 557.10224; found (ESI, [M+H]+), 557.1029; Anal. Calcd for C24H23F3N2O6S2: C3 51.79; H, 4.17; N, 5.03. Found: C, 52.03; H, 4.13; N, 4.74.
Example 823: N-(2-hydroxy-2,3-dihydro-lH-inden-l-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1025] In an analogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and l-amino-2,3-dihydro-lH-inden-2-ol was used to prepare the title compound N-(2-hydroxy-2,3-dihydro-lH-inden-l-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide (150.2 mg, 57%) as a white solid.
MS (ES-) m/z 495.7;
HPLC purity 94.4% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C22H18F3NO5S2 + H+, 498.06512; found (ESI, [M+H]+), 498.0664.
Example 824: 5-[(2-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)-2- (trifluoromethyl)benzenesulfbnamide
[1026] In an analogous manner to example 765, 5-[(4-fluorophenyl)sulfonyl]-N-[2- (lH-imidazol-l-yl)ethyl]-2-(trifluoromethyl)benzenesulfonamide)and 5-(2- fluorophenylsulfonyl)-2-(trifluoromethyl)benzene-l-sulfonyl chloride and 4- aminotetrahydropyran to give approximately 85 mg of the isomeric mixture that was dissolved in 2.5 mL of methanol/acetonitrile. 250 μL of the resulting solution was repetitively injected onto the Supercritical Fluid Chromatography (SFC) instrument, and the baseline resolved isomers were separately collected using the conditions described below to give the title compound 5-[(4- fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide (22.2 mg, 8%) as a white solid.
SFC Instrument: Berger MultiGram Prep SFC
Column: Ethylpyridine; lOμm; 250 mm L x 20 mm ID
Column temperature: 35°C
SFC Modifier: 15% MeOH /85% CO2
Flow rate: 50 mL/min
Outlet Pressure: 100 bar
Detector: UV at 220 nm
MS (ES+) m/z 467.6;
HPLC purity 100% at 210-370 nm, 8.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 825: 5-(phenylsulfonyl)-iV-[l-(phenylsulfonyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide [1027] In an analogous manner to Example 462, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and benzenesulfonyl chloride were used to prepare 5- (phenylsulfonyl)-N-[l-(phenylsulfonyl)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 588.5;
HPLC purity 98.0% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H23F3N2O6S3 + H+, 589.07431; found (ESI, [M+H]+), 589.0731.
Example 826: iV-{2-[(anilinocarbonyl)(methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1028] To a stirred suspension of iV-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride (0.16 g, 0.35 mmol) from Example 799 in a solution of phenyl isocyanate (42 mg, 0.35 mmol) in CH2Cl2 (8 mL) under N2 at room temperature was added diisopropylethylamine (70 μL, 52 mg, 0.40 mmol). The mixture was stirred at room temperature for 18 hours. It was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to give 0.18 g (95%) of N-{2- [(anilinocarbonyl)(methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 541.6; HRMS: calcd for C23H22F3N3O5S2 + H+, 542.10257; found (ESI, [M+H]+), 542.1027.
Example 827: iV-(2-{methyl[(pyridin-3-ylamino)carbonyl]amino}ethyI)-5-(phenylsulfonyl)- 2-(trifluoromethyl)benzenesulfonamide
[1029] In an analogous manner to Example 826, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and pyridine-3 -isocyanate were used to prepare iV-(2-{methyl[(pyridin-3- ylamino)carbonyl]amino}ethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 543.2; HRMS: calcd for C22H21F3N4O5S2 + H+, 543.09782; found (ESI, [M+H]+), 543.0983.
Example 828: 7V-{2-[{[(2,4-dimethoxyphenyl)amino]carbonyl}(methyl)amino]ethyl}-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide [1030] In an analogous manner to example 826, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and 2,4-dimethoxyphenyl isocyanate were used to prepare' N-{2-[{ [(2,4- dimethoxyphenyl)amino]carbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 601.6; HRMS: calcd for C25H26F3N3O7S2 + H+, 602.12370; found (ESI, DMH-H]+), 602.1265.
Example 829: N-{2-[[(ter^-butylamino)carbonyl](methyl)amino]ethyI}-5-(phenylsulfonyI)-2- (trifluoromethyl)benzenesulfonamide
[1031] In an analogous manner to Example 826, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and 4-(tert-butyl)phenyl isocyanate were used to prepare N-{2-[[(tert- butylamino)carbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 521.7; HRMS: calcd for C21H26F3N3O5S2 + H+, 522.13387; found (ESI, [M+H]+), 522.1318.
Example 830: Λ^-{2-[{[(4-methoxyphenyl)amino]carbonyl}(methyl)ainmo]ethyl}-5- (phenylsulfonyI)-2-(trifluoromethyl)benzenesuIfonamide
[1032] In an analogous manner to Example 826, iV-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and 4-methoxyphenyl isocyanate were used to prepare N- {2- [{[(4- methoxyphenyl)amino]carbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 571.6; HRMS: calcd for C24H24F3N3O6S2 + H+, 572.11314; found (ESI5 [M+H]+), 572.1152.
Example 831: Λr-{2-[[(butyIamino)carbonyl](methyl)amino]ethyl}-5-(phenyIsuIfonyI)-2- (trifluoromethyl)benzenesulfonamide
[1033] In an analogous manner to Example 826, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and butyl isocyanate were used to prepare 7V-{2-[[(butylammo)carbonyl](methyl)amino]ethyl}-5-
(phenylsulfonyl)-2-(trifluorometb.yl)benzenesulfonamide.
MS (ES+) m/z 521.7;
HRMS: calcd for C21H26F3N3O5S2 + H+, 522.13387; found (ESI, [M+H]"1"), 522.1337.
Example 832: iV-{2-[{[(2,4-difluorophenyl)amino]carbonyI}(methyl)amino]ethyl}-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide
[1034] In an analogous manner to Example 826, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and 2,4-difluorophenyl isocyanate were used to prepare N-{2-[{[(2,4- difluorophenyl)amino]carbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 577.6; HRMS: calcd for C23H20F5N3O5S2 + H+, 578.08373; found (ESI, [M+H]+), 578.0847.
Example 833: iV-methyl-iV-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l-carboxamide
[1035] To a stirred suspension of iV-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride (0.16 g, 0.35 mmol) from Example 799 in a solution of 1-pyrrolidinecarbonyl chloride (39 μL, 47 mg, 0.35 mmol) in CH2Cl2 (8 mL) under N2 at room temperature was added diisopropylethylamine (0.26 mL, 0.19 g, 1.5 mmol). The mixture was stirred at room temperature for 18 hours. It was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to give 0.16 g (85%) of iV-methyl- N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l- carboxamide. MS (ES+) m/z 519.7.
Example 834: iV-{2-[[(diethylamino)carbonyl](methyl)amino]ethyl}-5-(plienylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1036] In an analogous manner to Example 833, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and diethylcarbamoyl chloride were used to prepare N- {2- [[(diethylamino)carbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide.
MS (ES+) m/z 521.8;
HRMS: calcd for C21H26F3N3O5S2 + H+, 522.13387; found (ESI, [M+H]+), 522.1322.
Example 835: iV-methyl-Λ-[2-({[5-(phenylsulfonyI)-2- (trifluoromethyI)phenyl]sulfonyl}amino)ethyl]morpholine-4-carboxamide
[1037] In an analogous manner to Example 833, iV-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and 4-morpholinylcarbonyl chloride were used to prepare iV-methyl-Λ/-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]morpholine-4-carboxamide. MS (ES+) m/z 535.7; HRMS: calcd for C21H24F3N3O6S2 + H+, 536.11314; found (ESI, [M+Hf), 536.1124.
Example 836: iV-[2-(methyl{[methyl(phenyl)amino]carbonyl}amino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide
[1038] In an analogous manner to Example 833, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and N-methyl-N-phenyl carbamoyl chloride were used to prepare N- [2- (methyl{[methyl(phenyl)amino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 555.7; HRMS: calcd for C24H24F3N3O5S2 + H+, 556.11822; found (ESI, [M+H]*), 556.1173.
Example 837: N-Methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-2-furamide
[1039] In an analogous manner as described in Example 819, and replacing benzoyl chloride with furan-2-carbonyl chloride, gave N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-2-furamide (156.3 mg, 93%) as a white solid. MS (ES+) m/z 516.6;
HRMS: calcd for C21H19F3N2O6S2 + H+, 517.07094; found (ESI, [M+H]+), 517.072; Anal. Calcd for C21H19F3N2O6S2: C, 48.83; H, 3.71; N, 5.42. Found: C, 49.02; H, 3.44; N, 5.31. Example 838: 4-tert-Butyl-N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide
[1040] In an analogous manner as described in Example 819, and replacing benzoyl chloride with 4-fert-butyl-benzoyl chloride, gave 4-tert-butyl-N-methyl-N-[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (184.0 mg, 97%) as a white solid. MS (ESI+) m/z 583;
HRMS: calcd for C27H29F3N2O5S2 + H+, 583.15427; found (ESI, [M+H]+), 583.1552; Anal. Calcd for C27H29F3N2O5S2: C, 55.66; H, 5.02; N, 4.81. Found: C, 55.63; H, 4.90; N, 4.54.
Example 839: N-Methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyI]sulfonyl}amino)ethyl]-2-(trifluoromethoxy)benzainide
[1041] In an analogous manner as described in Example 819, and replacing benzoyl chloride with 2-trifluoromethoxy-benzoyl chloride, gave N-methyl-N-[2-({[5-(phenylsulfonyl)- 2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-2-(trifluoromethoxy)benzamide (184.1 mg, 92%) as a white solid foam. MS (ESI+) m/z 611;
HRMS: calcd for C24H20F6N2O6S2 + H+, 611.07397; found (ESI, [M+H]+), 611.0728; Anal. Calcd for C24H20F6N2O6S2: C, 47.21; H, 3.30; N, 4.59. Found: C5 47.51; H, 2.90; N3 4.43.
Example 840: 5-(phenylsulfonyl)-Λ'-pyrrolidiii-3-yl-2-(trifluoromethyl)benzenesulfonamide
[1042] Step 1 : Following the same procedure described on example 435, 2- trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 3-aminopyrrolidine-l- carboxylic acid tert-butyl ester were used to prepare tert-butyl-3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)pyrrolidine- 1 -carboxylate.
[1043] Step 2: Following the same procedure described on example 688, tert-butyl-3- ( { [5-(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfonyl } amino)pyrrolidine- 1 -carboxylate was used to prepare 5-(phenylsulfonyl)-Λ/-pyrrolidin-3-yl-2-(trifluoromethyl)benzenesulfonamide. MS (ESI+) m/z 435;
HPLC purity 94.2% at 210-370 nm, 6.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C17H17F3N2O4S2 + H+, 435.06546; found (ESI5 [M+H]+), 435.0666.
Example 841: N-[(2R*,4SA,6S*)-2,6-dimethyltetrahydro-2H-pyran-4-yl]-5-[(4- fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide
[1044] Step 1 : 2,6-Dimethyl-gamma-pyrone (5.0 g, 40.28 mmol) was hydrogenated with palladium on carbon (250 mg) in ethanol (50 mL) at 50 psi. The reaction was filtered through Celite® and washed with ethanol. The filtrate was concentrated to give (2R,6S)-2,6- dimethyldihydro-2H-pyran-4(3H)-one (5.1 g, 99%).
[1045] Step 2: To a solution of (2R,6S)-2,6-dimethyldihydro-2H-pyran-4(3H)-one (5.1 g, 39.79 mmol) in dichloromethane (50 mL) and 2,4-dimethoxybenzylamine (6.7 g, 39.79 mmol) was added sodium triacetoxyborohydride (11.8g, 55.70 mmol). The reaction was stirred overnight at room temperature under nitrogen. Added saturated bicarbonate solution and extracted. Dried with magnesium sulfate and concentrated to give (2R,4S,6S)-N-(2,4- dimethoxybenzyl)-2,6-dimethyltetrahydro-2H-pyran-4-amine (10.8 g, 97%).
[1046] Step 3: To a solution of 5-(4-fluorophenylsulfonyl)-2-methylbenzene-l- sulfonyl chloride (150 mg, 0.43 mmol) in dichloromethane (5.0 mL) was added triethylamine (137 uL, 0.25 mmol) followed by (2R,4S,6S)-N-(2,4-dimethoxyben2yl)-2,6-dimethyltetrahydro- 2H-pyran-4-amine (132 mg, 0.47 mmol). The reaction was stirred overnight at room temperature. The following day the reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N-(2,4-dimethoxybenzyl)-N-((2R,4s,6S)-2,6- dimethyltetrahydro-2H-pyran-4-yl)-5-(4-fluorophenylsulfonyl)-2-methylbenzenesulfonamide (96 mg, 38%).
[1047] Step 4: N-(2,4-dimethoxybenzyl)-N-((2R,4S,6S)-2,6-dimethyltetrahydro-2H- pyran-4-yl)-5-(4-fluorophenylsulfonyl)-2-methylbenzenesulfonamide (96 mg, 0.16 mmol) was dissolved in 6% trifluoroacetic acid/dichloromethane (6 mL) and stirred overnight at room temperature under nitrogen. Saturated bicarbonate solution was added and the reaction was extracted. Dried with magnesium sulfate and concentrated onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N-[(2R*,4S*,6S*)-2,6-dimethyltetrahydro-2H-pyran-4-yl]-5-[(4- fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide (33 mg, 46%). MS (ES-) m/z 440;
HRMS: calcd for C20H24FNO5S2 + H+, 442.115821; found (ESI3 [M+H]+), 442.1147.
Example 842: 5-{[4-(methylamino)phenyl]sulfonyl}-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide
[1048] Step 1 : A stirred solution of tert-butyl 4-({ [5-[(4-fluorophenyl)sulfonyl]-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate (0.10 g, 0.18 mmol) in 33% methylamine in ethanol (0.5 mL) was microwave irradiated for 15 minutes at 160°C. The resulting solution was washed with ammonium chloride solution (sat.) and extracted with ethyl acetate. The organic layer was concentrated to give tert-butyl 4-({[5-[(4- methylaminophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate.
[1049] Step 2: Following the same procedure described on example 688, tert-butyl 4- ({[5-[(4-methylaminophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate was used to prepare 5-{[4-(methylamino)phenyl]sulfonyl}-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide. MS (ESI+) m/z 478;
HPLC purity 100% at 210-370 nm, 7.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C19H22F3N3O4S2 + H+, 478.10766; found (ESI, [M+H]+), 478.1064.
Example 843 : 5- { [4-(dimethylamino)phenyl] sulf ony l}-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide
[1050] Step 1 : Following the same procedure described on example 842, dimethylamine in THF and tert-butyl 4-({[5-[(4-fluorophenyl)sulfonyl]-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate was used to prepare tert-butyl 4-({[5-[(4-dimethylaminophenyl)sulfonyl]-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate.
[1051] Step 2: Following the same procedure described on example 688, tert-butyl 4- ({[5-[(4-dimethylaminophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine- 1 -carboxylate was used to prepare 5-{[4-(dimethylamino)phenyl]sulfonyl}-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide. MS (ESI+) m/z 492;
HPLC purity 97.1% at 210-370 nm, 7.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H24F3N3O4S2 + H+, 492.12331; found (ESI, [M+H]+), 492.1243.
Example 844: 5-({4-[(2-hydroxyethyl)amino]phenyl}sulfonyl)-JV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide
[1052] Step 1: Following the same procedure described on example 842, ethanolamine in THF and tert-butyl 4-({[5-[(4-fluorophenyl)sulfonyl]-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate was used to prepare 4-({[5- [(4-[(2-hydroxyethyl)amino]phenyl)sulfonyl]~2- (trifluoromethyl)phenyl]sulfonyl} amino)piperidine-l -carboxylate.
[1053] Step 2: Following the same procedure described on example 688, 4-({[5-[(4-[(2- hydroxyethyl)amino]phenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate was used to prepare 5-({4-[(2-hydroxyethyl)amino]phenyl}sulfonyl)-N-piperidin-4- yl-2-(trifluoromethyl)benzenesulfonamide. MS (ESI+) m/z 508;
HPLC purity 95.1% at 210-370 nm, 6.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H24F3N3O5S2 + H+, 508.11822; found (ESI, [M+H]+), 508.1198.
Example 845: 5-[(2-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2- (trifluoromethyl)benzenesulfonamide
[1054] To a mixture of sodium carbonate (0.1601 g, 1.5 mmol) in 1 ml of water and 2- (lH-imidazol-1-yl) ethyl amine (0.092, 0.5 mmol) in 3 ml of acetonitrile was stirred at R.T. as the mixture of 5-(4-fluorophenylsulfonyl)-2-(trifluoromethyl)benzene-l-sulfonyl chloride and 5- (2-fluorophenylsulfonyl)-2-(trifluoromethyl)benzene-l-sulfonyl chloride (0.2514 g, 0.6 mmol) prepared in Example 816 Step 4 was taken up in 10 ml of acetonitrile was slowly added to the reaction with an addition funnel. The reaction was allowed to stir overnight at room temperature, and then was partitioned between ethyl acetate and 2N hydrochloric acid. The ethyl acetate layer was separated, dried (anhydrous MgSO4) and the solvent removed under reduced pressure to give approximately 50 mg of the isomeric mixture that was dissolved in 3 mL of methanol/acetonitrile. 200 μL of tlie resulting solution was repetitively injected onto the Supercritical Fluid Chromatography (SFC) instrument, and the baseline resolved isomers were separately collected using the conditions described below to give the title compound 5-[(2- fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2-(trifluoromethyl)benzenesulfonamide (19.8 mg, 7%) as a white solid. MS (ESI+) m/z 478;
HPLC purity 97.8% at 210-370 nm, 6.8 min.; XterraRP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C18H15F4N3O4S2 + H+, 478.05129; found (ESI5 [M+EQ+), 478.0506.
Example 846: N-methyl-N-[2-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cyclohexanecarboxamide
[1055] A stirred mixture of tert-butyl methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate (0.1062 g, 0.25 mmol) prepared in the same manner as Example 799 in dichloromethane (2 ml). 1.1 eq of cyclohexanecarbonyl chloride (35 μL, 0.26 mmol) and 1.5 eq. N,N-Diisoprpylethylamine was syringed into the reaction vial and was allowed to stir overnight at room temperature. The product was transferred onto a 4 g Isco RediSep® Normal Phase column and was purified by automated flash chromatography using a gradient of 20% to 100% hexane/ethyl acetate. Isolation of the main component gave the title compound N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cyclohexanecarboxamide (58.3 mg, 44%) as a white solid. MS (ESI+) m/z 533;
HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H27F3N2O5S2 + H+, 533.13862; found (ESI, [M+H]+), 533.138.
Example 847: 3-Fluoro-N-methyl-N-[2-({[5-(phenylsuIfonyl)-2- (trifluoromethyl)phenyl]sulfonyI}amino)ethyl]-4-(trifluoromethyl)benzamide
[1056] In an analogous manner as described in Example 819, and replacing benzoyl chloride with 3-fluoro-4-trifluoromethyl-benzoyl chloride, gave 3-fluoro-N-methyl-N-[2-({[5- (phenylsulfonyl)-2-(1rifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4-(trifluoromethyl)ben^
(168.1 mg, 84%) as a white solid.
MS (ESI+) m/z 613;
HRMS: calcd for C24H19F7N2O5S2 + H+, 613.06964; found (ESI, [M+H]+), 613.0691;
Anal. Calcd for C24H19F7N2O5S2: C, 47.06; H, 3.13; N, 4.57. Found: C5 46.83; H, 3.00; N, 4.34.
Example 848: Methyl 4-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)benzoate
[1057] In an analogous manner as described in Example 819, and replacing benzoyl chloride with 4-chlorocarbonyl-benzoic acid methyl ester, gave methyl 4-({methyl[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)benzoate (155.8 mg, 81%) as a white solid. MS (ESI+) m/z 585;
HRMS: calcd for C25H23F3N2O7S2 + H+, 585.09715; found (ESI, [M+H]+), 585.0983; Anal. Calcd for C25H23F3N2O7S2: C, 51.37; H, 3.97; N, 4.79. Found: C, 51.13; H, 3.74; N, 4.63.
Example 849: N-Methyl-N-[2-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide
[1058] In an analogous manner as described in Example 819, and replacing benzoyl chloride with nicotinoyl chloride, extracting with water instead of 2 N HCl, and using 100% methylene chloride to 5% methanol-methylene chloride as the eluent, gave N-methyl-N-[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide (166.6 mg, 97%) as a white solid foam. MS (ESI+) m/z 528;
HRMS: calcd for C22H20F3N3O5S2 + H+, 528.08692; found (ESI, [M+H]"1"), 528.0885; Anal. Calcd for C22H20F3N3O5S2: C, 50.09; H, 3.82; N, 7.97. Found: C, 49.99; H, 3.59; N, 7.72.
Example 850: N-Methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethy l)phenyl] sulf onyl} amino)ethy 1] is onicotinamide
[1059] In an analogous manner as described in Example 849, and replacing nicotinoyl chloride with isonicotinoyl chloride gave N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]isonicotinamide (151.1 mg, 88%) as a white solid. MS (ESI+) m/z 528;
HRMS: calcd for C22H20F3N3O5S2 + H+, 528.08692; found (ESI, [M+H]+), 528.0889;
Anal. Calcd for C22H20F3N3O5S2 . 0.70 CH2Cl2: C, 46.45; H, 3.67; N5 7.16. Found: C, 46.71; H,
3.46; N, 7.18.
Example 851: 2-Chloro-N-methyl-N-[2-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide
[1060] In an analogous manner as described in Example 849, and replacing nicotinoyl chloride with 2-chloro-nicotinoyl chloride gave 2-chloro-N-methyl-N-[2-({[5-(phenylsulfonyl)- 2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide (168.4 mg, 91%) as a white solid foam.
MS (ESI+) m/z 562;
HRMS: calcd for C22H19ClF3N3O5S2 + H+, 562.04795; found (ESI, [M+H]+), 562.0471; Anal. Calcd for C22H19ClF3N3O5S2 . 0.40 CH2Cl2: C, 45.15; H, 3.35; N, 7.05. Found: C, 46.48; H, 3.19; N, 7.32.
Example 852: N,2,2-trimethyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]propanamide
[1061] In an analogous manner to example 846, tert-butyl methyl[2-({ [5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)ethyl] carbamate and trimethylacetyl chloride was used to prepare the title compound N,2,2-trimethyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]propanamide (102 mg, 81%) as a white solid. MS (ES+) m/z 506.7;
HPLC purity 98.6% at 210-370 nm, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H25F3N2O5S2 + H+, 507.12297; found (ESI, [M+H]+), 507.1238.
Example 853: 3-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]sulfonyl}benzoic acid
[1062] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 3-(chlorosulfonyl)benzoic acid were used to prepare 3- { [4-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}ammo)piperidin-l - yl]sulfonyl}benzoic acid.
HPLC purity 97.1% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H23F3N2O8S3 + H+, 633.06414; found (ESI, [M+H]+), 633.0627.
Example 854: 4-{[4-({[5-(phenyIsulfonyl)-2-
(trifluo romethy I)phenyl] sulf ony 1} amino)piperidin-l -y 1] sulf ony 1} benzoic acid
[1063] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 4-(chlorosulfonyl)benzoic acid were used to prepare 4- { [4-( { [5-(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulf ony 1 } amino)piperidin- 1 - yl] sulf ony 1} benzoic acid. MS (ES+) m/z 632.5;
HPLC purity 100% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 855: 3-({[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonothioyl}amino)benzoic acid
[1064] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 3-carboxyphenyl isothiocyanate were used to prepare 3-({[4-({[5 -(pheny lsulfony l)-2-(trifluoromethy l)phenyl] sulfony 1 } amino)piperidin- 1 - yl]carbonothioyl}amino)benzoic acid. MS (ES+) m/z 627.5;
HPLC purity 98.4% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H24F3N3O6S3 + H+, 628.08521; found (ESI, [M+H]+), 628.0853.
Example 856: iV-[l-(2-chloro-6-methylisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1065] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piperidm-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-chloro-6-methylpyridine-4-carbonyl chloride were used to prepare N-[l-(2-chloro-6-methylisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide.
MS (ES-) m/z 599.5;
HPLC purity 95.5% at 210-370 ran, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C25H23ClF3N3O5S2 + H+, 602.07925; found (ESI, [M+H]+), 602.0812.
Example 857: A'-[l-(2,6-dichloroisonicotinoyI)piperidin-4-yI]-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1066] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2,6-dichloropyridine-4-carbonyl chloride were used to prepare N-[l-(2,6-dichloroisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (tfifluoromethyl)benzenesulfonamide. MS (ES+) m/z 621.5;
HPLC purity 91.5% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H20Cl2F3N3O5S2 + H+, 622.02463; found (ESI, [M+H]+), 622.0237.
Example 858: N-(l,l-dioxidotetrahydro-2H-thiopyran-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide
[1067] Step 1 : To a solution of tetrahydrothiopyran (3.0 g, 25.82 mmol) and 2,4- dimethoxybenzylamine (4.3 g, 25.82 mmol) in dichloromethane (100 mL) was added sodium triacetoxyborohydride (7.7 g, 36.15 mmol). The reaction was stirred overnight at room temperature under nitrogen. Added saturated bicarbonate solution and extracted. Dried with magnesium sulfate and concentrated to give N-(2,4-dimethoxybenzyl)tetrahydro-2H-thiopyran- 4-amine (6.7 g, 97%).
[1068] Step 2: To a solution of 5-(4-fluorophenylsulfonyl)-2-isopropylbenzene-l- sulfonyl chloride (350 mg, 0.93 mmol) in dichloromethane 10 mL) was added triethylamine (388 μL, 2.79 mmol) followed by N-(2,4-dimethoxybenzyl)tetrahydro-2H-thiopyran-4-amine (497 mg, 1.86 mmol). The reaction was stirred overnight at room temperature. The following day the reaction was concentrated down onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N-(2,4-dimethoxybenzyl)-5-(4-fluorophenylsulfonyl)-2-isopropyl-N-(tetrahydro-2H-thiopyran- 4-yl)benzenesulfonamide (504 mg, 89%).
[1069] Step 3: N-(2,4-dimethoxybenzyl)-5-(4-fluorophenylsulfonyl)-2-isopropyl-N- (tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide (504 mg, 0.83 mmol) was dissolved in 6% trifluoroacetic acid/dichloromethane (6 mL) and stirred overnight at room temperature under nitrogen. Saturated bicarbonate solution was added and the reaction was extracted. Dried with magnesium sulfate and concentrated onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-thiopyran-4- yl)benzenesulfonamide (350 mg, 92%).
[1070] Step 4: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-thiopyran- 4- yl)benzenesulfonamide (150 mg, 0.32 mmol) was dissolved in dichloromethane (8 mL) and 3- chloroperoxybenzoic acid (154 mg, 0.69 mmol) was added. The reaction was stirred overnight at room temperature and was then concentrated onto silica gel and purified using automated chromatography with a gradient mobile phase consisting of ethyl acetate and hexane resulting in the isolation of N-( 1 , 1 -dioxidotetrahydro-2H-thiopyran-4-y l)-5 - [(4-fluorophenyl)sulfonyl] -2- isopropylbenzenesulfonamide (80 mg, 50%). MS (ES-) m/z 487.6.
Example 859: 5-(Phenylsulfonyl)-2-propyl-iV-(2-pyridin-4-ylethyl)benzenesulfonamide
[1071] The title compound was prepared from 5-phenylsulfonyl-2-propyl- benzenesulfonyl chloride (0.36 g, 1.0 mmol) and 2-(pyridin-4-yl)ethanamine (0.25 g, .2.0 mmol) according to the procedure and in the same manner as described in Example 550, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (90 g), eluting with a gradient of 50%-100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford 5-(phenylsulfonyl)-2-propyl-N-[2-(tetrahydro-2i7- pyran-4-yl)ethyl]benzenesulfonamide (0.26 g, 58%), as a homogeneous, amorphous solid, m.p. 155-157 °C;
MS (+ESI), m/z: 444.1 [M+H]+;
HRMS: calcd for C22H24N2O4S2 + H+, 445.12502; found (ESI, [M+H]+), 445.1229; HPLC purity 100% at 210-370 nm, 8.5 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example δθO^-Isopropyl-iV-t^iϊ^jSS^-S-methyl-S-azabicyclop^.lloct-S-yll-S- (phenylsulfonyl)benzenesulfonamide monohydrochloride
[1072] A stirred solution of 2-isopropyl-5-(phenylsulfonyl)benzenesulfonyl chloride (0.36 g, 1.0 mmol) in 3:1 dichloromethane-acetonitrile (10 mL) was treated under nitrogen with enrfo-S-methyl-δ-azabicyclop^.lJoctan-S-amine dihydrochloride (0.42 g, 2.0 mmol) and diisopropylethylamine (0.52 g, 4.0 mmol). The reaction was stirred for 18 hours at room temperature. The crude product was purified by reverse phase preparative liquid chromatography on a Gilson® semi-prep column, eluting with a gradient of 10%- 100% water in acetonitrile at a flow rate of 2 niL/min, to afford, after concentration of the solvent and extraction with ethyl acetate (3x), an oil. The oil was dissolved in ethanol-dioxane and treated with a solution of IN hydrogen chloride in diethyl ether. Filtration of the solid afforded 2-isopropyl-N- [(Ii?*, 5S* )-8-methy 1-8-azabicyclo [3.2.1 ] oct-3 -y 1] -5 -(phenylsulfony l)benzenesulfonamide monohydrochloride (0.10 g, 20%), as a homogeneous, cream-colored, amorphous solid, m.p. 90
MS (+ESI), m/z: 462.8 [M+H]+;
HRMS: calcd for C23H30N2O4S2 + H+, 463.17197; found (ESI, [M+H]+), 463.171;
HPLC purity 98.7% at 210-370 ran, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Amman. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 861 : 5-{[2-(methylamino)phenyl]suIfonyI}-iV-piperidin-4-yI-2- (trifluoromethyl)benzenesulfonamide
[1073] Step 1 : Following the same procedure described on example 677 Step 1 , 4- chloro-3-nitrobenzenesulfonyl chloride and fluorobenzene was used to prepare 5-(2- fluorophenylsulfonyl)-2-chloro-nitrobenzene.
[1074] Step 2: Following the same procedure described on example 677 Step 2, 5-(2- fluorophenylsulfonyl)-2-chloro-nitrobenzene was used to prepare 5-(2-fluorophenylsulfonyl)-2- trifluoromethyl-nitrobenzene.
[1075] Step 3: Following the same procedure described on example 677 Step 3, 5-(2- fluorophenylsulfonyl)-2-trifluoromethyl-nitrobenzene was used to prepare 5-(2- fluorophenylsulfonyl)-2-trifluoromethylaniline. [1076] Step 4: Following the same procedure described on example 677 Step 4, 5-(2- fluorophenylsulfonyl)-2-trifluoromethylaniline was used to prepare 2-trifluoromethyl-5~(2- fluorophenylsulfonyl)- benzenesulfonyl chloride.
[1077] Step 5: Following the same procedure described on example 435, 2- trifluoromethyl-5-(2-fluorophenylsulfonyl)- benzenesulfonyl chloride and 4-aminopiperidine-l- carboxylic acid tert-butyl ester were used to prepare tert-butyl 4-({[5-(2-fluorophenylsulfonyl)- 2-(trifluoromethyl)pheny 1] sulfony 1 } amino)piperidine- 1 -carboxy late .
[1078] Step 6: Following the same procedure described on example 842 Step 1, tert- butyl 4-({[5-(2-fluorophenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate was used to prepare tert-butyl 4-({[5-(2-methylaminophenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate.
[1079] Step 7: Following the same procedure described on example 842 Step 2: tert- butyl 4-({ [5-(2-methylaminophenylsulfonyi)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l -carboxylate was used to prepare 5-{[2- (methylamino)phenyl]sulfonyl}-iV-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 477.7;
HPLC purity 100% at 210-370 nm, 7.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C19H22F3N3O4S2 + H+, 478.10766; found (ESI5 [MH-H]+), 478.1078.
Example 862: 5-{[2-(dimethylamino)phenyϊ]sulfonyl}-JV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide
[1080] Step 1 : Following the same procedure described on example 842 Step 1, tert- butyl 4-({ [5-(2-fluorophenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l - carboxylate and dimethylamine were used to prepare tert-butyl 4-({[5-(2- dimethylaminophenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate.
[1081] Step 2: Following the same procedure described on example 842 Step 2, tert- butyl 4-({ [5-(2-dimethylaminophenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l -carboxylate was used to prepare 5-{[2- (dimethylamino)phenyl]sulfonyl}-Λ/-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 491.7;
HPLC purity 95.8% at 210-370 nm, 7.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 863: 5-(phenylsulfonyl)-iV-[2-(2H-tetrazol-5-yl)ethyl]-2- (trifluoromethyl)benzenesulfonamide
[1082] To a stirred solution of trimethylaluminum 2M in toluene (0.13mL, 0.26 mmol) and trimethylsilylazide (0.03 g, 0.26 mmol) in toluene (1 mL) at 0°C was added N-(2- cyanoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (0.09 g, 0.22 mmol). The resulting solution was heated to 80°C overnight, cooled to 0°C, quenched with 6N HCl solution and extracted with ethyl acetate. The organic layer was concentrated and the resulting solid was triturated in ethyl acetate to give 5-(phenylsulfonyl)-N-[2-(2H-tetrazol-5-yl)ethyl]-2- (trifluoromethyl)benzenesulfonamide. (0.045 g, 45%). MS (ES+) m/z 461.6;
HPLC purity 100% at 210-370 nm, 7.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C16H14F3N5O4S2 + H+, 462.05121; found (ESI, [M+H]+), 462.049.
Example 864: 2-ethyl-N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]butanamide
[1083] In an analogous manner to example 846, tert-butyl methyl [2-({ [5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate and 2-Ethylbutyryl chloride was used to prepare the title compound 2-ethyl-N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]butanamide (47.8 mg, 36.1%) as a white solid. MS (ES+) m/z 520.6;
HPLC purity 100% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=θ.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H27F3N2O5S2 + H+, 521.13862; found (ESI, [M+HJ+), 521.1391.
Example 865: butyl methyl[2-({[5-(phenylsulfonyI)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate [1084] In an analogous manner to example 846, tert-butyl methyl[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)ethyl]carbamate and butyl chloroformate was used to prepare the title compound butyl methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate (39.7 mg, 32%) as a white solid. MS (ES+) m/z 522.6;
HPLC purity 100% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C2IH25F3N2O6S2 + H+, 523.11789; found (ESI, [M+H]+), 523.1178.
Example 866: tert-butyl 4-[({methyl[2-({[5-(phenyIsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l- carboxylate
[1085] Step 1 : To a mixture of N,N'-carbonyldiimidazole (143.0 mg, 0.8819 mmol) and 4-amino-l-BOC-piperidine (160.6 mg, 0.80 mmol) was added dichloromethane (10 mL). The reaction was stirred at room temperature under N2 for 18 hours. The solution was washed with H2O (3 x) and dried over MgSO4. The solvent was evaporated to give 224.7 mg (95%) of intermediate tert-butyl 4-[(l/i-imidazol-l -ylcarbonyl)amino]piperidine-l -carboxylate.
[1086] Step 2: To a stirred suspension of iV-[2-(methylamino)ethyl]-5-(phenylsulfonyl)- 2-(trifluoromethyl)benzenesulfonamide hydrochloride (0.16 g, 0.35 mmol) from Example 799 in a solution of tert-butyl 4- [(lH-imidazol-l-ylcarbonyl)amino]piperidine-l -carboxylate (0.11 g, 0.37 mmol) in CH2Cl2 (5 mL) under N2 at room temperature was added diisopropylethylamine (64 μL, 47 mg, 0.37 mmol). The mixture was stirred at room temperature for 3 days. The solution was washed 3 times with water. It was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to give 0.18 g (80%) of tert-butyl 4- [({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfony 1 } amino)ethyl] amino } carbonyl)amino]piperidine- 1 -carboxylate. MS (ES-) m/z 646.7; HRMS: calcd for C27H35F3N4O7S2 + H+, 649.19720; found (ESI, [M+H]+), 649.1979.
Example 867: 2,2-dimethylpropyl methyl[2-({[5-(phenyϊsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} ammo)ethyl] carbamate [1087] In an analogous manner to example 846, tert-butyl methyl[2-({ [5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate and neopentyl chloroformate was used to prepare the title compound 2,2-dimethylpropyl methyl[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl] carbamate (86.2 mg, 67%) as a white solid. MS (ES+) m/z 536.8;
HPLC purity 99.0% at 210-370 run, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amman. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H27F3N2O6S2 + H+, 537.13354; found (ESI, [M+H]+), 537.1332.
Example 868: JV-[(l-hydroxycyclohexyl)methyl]-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1088] In an analogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 1-aminomethyl-l-cyclohexanol hydrochloride were used to prepare N- [( 1 -hydroxycyclohexyl)methyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES) m/z 475.1;
HPLC purity 97.6% at 210-370 nm, 9.7 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 869: 5-({2-[(2-hydroxyethyl)amino]phenyl}sulfonyl)-JV~piperidin-4-yl-2~ (trifluoromethyl)benzenesulfonamide
[1089] Step 1 : Following the same procedure described on example 842 Step 1, tert- butyl 4-( { [5-(2-fluorophenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)piperidine- 1 - carboxylate and ethanolamine were used to prepare tert-butyl 4-({[5-([2- hydroxyethyl)amino]pheny lsulfonyl)-2-(trifluoromethy l)pheny 1] sulfonyl } amino)piperidine- 1 - carboxylate.
[1090] Step 2: Following the same procedure described on example 842 Step 2, tert- butyl 4-({ [5-([2-hydroxyethyl)amino]phenylsulfonyl)-2-
(trifluoromethyl)phenyl] sulfonyl} amino)piperidine-l -carboxylate was used to prepare 5-({2-[(2- hydroxyethyl)amino]phenyl}sulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide. MS (ES) m/z 507.8;
HPLC purity 94.9% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H24F3N3O5S2 + H+, 508.11822; found (ESI, [M+H]+), 508.119.
Example 870: isobutyl methyl[2-({[5-(phenylsulfonyl)~2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate
[1091] In an analogous manner to example 846, tert-butyl methyl[2-({[5- (phenylsulfoiiyl)-2-(ti-ifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate and isobutyl chloroformate was used to prepare the title compound isobutyl methyl[2-({[5-(phenylsulfonyl)- 2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate (57.7 mg, 46%) as a white solid. MS (ES+) m/z 522.9;
HPLC purity 99.1% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Pfr=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H25F3N2O6S2 + H+, 523.11789; found (ESI, [M+FTJ+), 523.1175.
Example 871: 3-(trifluoromethyl)phenyl methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethy l)phenyl] sulfony 1} amino)ethyl] carbamate
[1092] In an analogous manner to example 846, tert-butyl methyl[2-({ [5- (pheny lsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)ethyl] carbamate and 3 - (Trifluoromethyl)phenyl chloroformate was used to prepare the title compound 3- (trifluoromethyl)phenyl methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate (77.8 mg, 53%) as a white solid. MS (ES+) m/z 610.9;
HPLC purity 98.1% at 210-370 nm, 10.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H20F6N2O6S2 + H+, 611.07397; found (ESI, [M+H]+), 611.0731.
Example 872: 4-fluorophenyI methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate
[1093] In an analogous manner to example 846, tert-butyl methyl[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate and 4-Fluorophenyl chloroformate was used to prepare the title compound 4-fluorophenyl methyl[2-({[5-
(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate (85.6 mg, 62.4%) as a white solid.
MS (ES+) m/z 560.7;
HPLC purity 98.1% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C23H20F4N2O6S2 + H+, 561.07717; found (ESI, [M+H]+), 561.0757.
Example 873: 4-bromophenyl methyl [2-({ [5-(phenylsulf onyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)ethyl] carbamate
[1094] In an analogous manner to example 846, tert-butyl methyl[2-({ [5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)ethyl] carbamate and 4-Bromophenyl chloroformate was used to prepare the title compound 4-bromophenyl methyl[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)ethyl] carbamate (66.7mg, 39%) as a white solid. MS (ES+) m/z 620.6;
HPLC purity 97.0% at 210-370 nm, 10.4 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H20BrF3N2O6S2 + H+, 620.99710; found (ESI, [M+H]+), 620.9971.
Example 874: 5-[(4-Fluorophenyl)sulfonyl]-2-propyI-7V-(2-pyridin-3- ylethyl)benzenesulfonamide
[1095] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2- propylbenzenesulfonyl chloride (0.38 g, 1.0 mmol) and 2-(pyridin-3-yl)ethanamine (0.25 g, .2.0 mmol) according to the procedure and in the same manner as described in Example 559, step c. The crude product was purified by preparative liquid chromatography on a Biotage® 40 Si column of pre-packed silica gel (90 g), eluting with a gradient of 50%- 100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford, after crystallization from ethyl acetate- diethyl ether-hexane, 5-[(4-fluorophenyl)sulfonyl]-2-propyl-iV-(2-pyridin-3- ylethyl)benzenesulfonamide (0.27 g, 59%), as a homogeneous, colorless, crystalline solid, m.p. 111-113 0C; MS (+ESI), m/z: 462.8 [M+H]+; HRMS: calcd for C22H23FN2O4S2 + H+, 463.11560; found (ESI, [M+H]+), 463.1161; HPLC purity 100% at 210-370 run, 8.9 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 875: 5-[(4-Fluorophenyl)sulfonyl]-2-propyl-JV-(2-pyridin-4- ylethyl)benzenesulfonamide
[1096] The title compound was prepared from 5-[(4-fluorophenyl)sulfonyl]-2- propylbenzenesulfonyl chloride (0.38 g, 1.0 mmol) and 2-(pyridin-4-yl)ethanamine (0.25 g, .2.0 mmol) according to the procedure and in the same manner as described in Example 559, step c. The crude product was purified by preparative liquid chromatography on a Biotage' 40 Si column of pre-packed silica gel (90 g), eluting with a gradient of 50%- 100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford, after crystallization from ethyl acetate- diethyl ether-hexane, 5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-(2-pyridin-4- ylethyl)benzenesulfonamide (0.29 g, 63%), as a homogeneous, colorless, crystalline solid, m.p. 160-162 0C;
MS (+ESI), m/z: 462.8 [M+H]+;
HRMS: calcd for C22H23FN2O4S2 + H+, 463.11560; found (ESI, [MfH]+), 463.1139; HPLC purity 100% at 210-370 nm, 8.6 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 876: 5-(Phenylsulfonyl)-2-propyl-Λ7-(2-pyridin-3-ylethyl)benzenesulfonamide
[1097] The title compound was prepared from 5-phenylsulfonyl-2-propyl- benzenesulfonyl chloride (0.36 g, 1.0 mmol) and 2-(pyridin-3-yl)ethanamine (0.25 g, .2.0 mmol) according to the procedure and in the same manner as described in Example 550, step c. The crude product was purified by preparative liquid chromatography on a Biotage 40 Si column of pre-packed silica gel (90 g), eluting with a gradient of 50%- 100% methyl tert-butyl ether in hexane at a flow rate of 50 mL/min, to afford 5-(phenylsulfonyl)-2-propyl-N-(2-pyridin-3- ylethyl)benzenesulfonamide (0.30 g, 68%), as a white foam; MS (+ESI), m/z: 444.8 [M+H]+;
HRMS: calcd for C22H24N2O4S2 + H+, 445.12502; found (ESI, [M+H]+), 445.1261; HPLC purity 98.1% at 210-370 nm, 8.6 min; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min. Example 877: 4-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzoic acid
[1098] In an analogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 4-(2-aminoethyl)benzoic acid"were used to prepare 4-[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzoic acid. MS (ESI-) m/z 512;
HPLC purity 100% at 210-370 nm, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H18F3NO6S2 + H+, 514.06004; found (ESI, [M+H]+), 514.0597.
Example 878: 4-oxo-4-[4-({[5-(phenylsuIfonyI)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]butanoic acid
[1099] A stirred solution of 5-(phenylsulfonyl)-iV-piperidin-4-yl-2-
(trifluoromethyl)benzenesulfonamide (0.10 g, 0.22 mmol) and succinic anhydride (0.023 g, 0.23 mmol) in EtOH (1 mL) was microwave irradiated for 10 minutes at 150°C. The resulting solution was concentrated and flash column separation using 0-10% methanol/methylene chloride gradient gave 4-oxo-4-[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]butanoic acid. (0.04 g, 33%). MS (ESI+) m/z 549;
HPLC purity 100% at 210-370 nm, 8.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H23F3N2O7S2 + H+, 549.09715; found (ESI, [M+H]+), 549.095.
Example 879: [4-({[5-(phenyIsuIfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin- l-yl] acetic acid
[1100] A stirred solution of 5-(phenylsulfonyl)-N-piperidin-4-yl-2-
(trifluoromethyl)benzenesulfonamide (0.14 g, 0.30 mmol) and tert-butylbromoacetate (0.06 g, 0.30 mmol) and triethylamine (0.1 mL, 0.7 mmol) in THF (1 mL) was microwave irradiated for 10 minutes at 120°C. The resulting solution was concentrated and flash column separation using 0-50% ethyl acetate/hexane gradient gave a crude solid. The solid was dissolved in 4N HCl in dioxane solution (1 mL) and stirred overnight. The solution was concentrated and trituration with ethyl acetate gave [4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl] acetic acid. (0.09 g, 59%). HPLC purity 100% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H21F3N2O6S2 + H+, 507.08659; found (ESI, [M+H]+), 507.0854.
Example 880: 2-[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide
[1101] A stirred solution of 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (0.10 g, 0.21mmol) and bromoacetamide (0.03 g, 0.20 mmol) and triethylamine (0.1 mL, 0.7 mmol) in THF (1 mL) was microwave irradiated for 10 minutes at 1200C. The resulting solution was partitioned between sodium bicarbonate solution (sat.) and ethyl acetate. The organic layer was concentrated and flash column separation using 0- 10% methanol/methylene chloride gradient gave 2-[4-({[5-(phenylsulfonyl)~2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide. (0.06 g, 57%). HPLC purity 98.6% at 210-370 nm, 6.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H22F3N3O5S2 + H+, 506.10257; found (ESI, [M+H]*), 506.103.
Example 881: iV-(2-{methyl[(piperidin-4-yIamino)carbonyl]amino}ethyl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide
[1102] To a solution of tert-butyl 4-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l-carboxylate (166.0 mg, 0.2559 mmol) from Example 866 in CH2Cl2 ( 3 mL) was added EtOAc saturated with HCl (3 mL). This mixture stood at room temperature 18 hours but solid had not formed. It was concentrated to 1 mL. EtOH (1 mL) was added. The oil/gel almost completely dissolved. The solvent was evaporated from this mixture. The residue crystallized as it stood at room temperature overnight to give 140.6 mg (94%) of N-(2-{methyl[(piperidin-4- ylamino)carbonyl]amino}ethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 548.8; HRMS: calcd for C22H27F3N4O5S2 + H+, 549.14477; found (ESI, [M+H]4), 549.1453. Example 882: ethyl iV-({methyl[2-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)ethyl] amino} carbonyl)glycinate
[1103] In an analogous manner to Example 826, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and ethyl isocyanatoacetate were used to prepare ethyl N-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethy l)pheny 1] sulfonyl } amino)ethy 1] amino } carbonyl)gly cinate . MS (ES+) m/z 551.8; HRMS: calcd for C21H24F3N3O7S2 + H+, 552.10805; found (ESI, [M+H]+), 552.1089.
Example 883: 3-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}sulfonyl)benzoic acid
[1104] To a stirred suspension of iV-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride (111 mg, 0.242 mmol) from Example 799 in a solution of 3-(chlorosulfonyl)benzoic acid (53.3 mg, 0.242 mmol) in CH2Cl2 (5 mL) under N2 at room temperature was added diisopropylethylamine (0.127 mL, 94.2 mg, 0.729 mmol). The mixture was stirred at room temperature for 3 days. It was washed twice with 2N HCl. The solution of crude was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to give 109 mg (75%) of 3-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}sulfonyl)benzoic acid. MS (ES+) m/z 606.7; HRMS: calcd for C23H21F3N2O8S3 + H+, 607.04849; found (ESI, [M+H]+), 607.0455.
Example 884: 5-[(4-fluorophenyl)sulfonyl]-2-isopropyI-N-(2-piperidin-3- ylethyl)benzenesulfonamide
[1105] 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-3- ylethyl)benzenesulfonamide (Example 534) (0.20 g, 0.43 mmol) was hydrogenated with palladium on carbon (70 mg) in ethanol (30 mL) at 50 psi. The reaction was filtered through Celite® and washed with ethanol. The filtrate was concentrated to give 5-[(4- fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-3- ylethyl)benzenesulfonamide (0.17 g, 84%). MS (ES+) m/z 468.8. Example 885: 5-(phenylsulfonyl)-iV-[l-(2iϊ-tetrazol-5-yImethyI)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide
[1106] Step 1 : A solution of 5-(phenylsulfonyl)-iV-piperidm-4-yl-2-
(trifluoromethyl)benzenesulfonamide (0.15 g, 0.34 mmol) and bromoacetonitrile (0.04 g, 0.34 mmol) and triethylamine (0.1 mL, 0.7 mmol) in THP (1 mL) was stirred overnight at room temperature. The mixture was concentrated and flash column separation using 0-50% ethyl acetate/hexane gradient gave crude 2-[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetonitrile. (0.10 g, 62%).
[1107] Step 2: Following the same procedure described on example 863, 2-[4-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetonitrile was used to prepare 5-(phenylsulfonyl)-iV-[l -(2H"-tetrazol-5-ylmethyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 530.8;
ΗPLC purity 90.7% at 210-370 rnn, 6.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOΗ) for lOmin, hold 4min. HRMS: calcd for C20H21F3N6O4S2 + H+, 531.10905; found (ESI, [M+H]+), 531.1094.
Example 886: 4-oxo-4-[3-({[5-(phenylsulfonyl)-2~ (trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l-yl]butanoic acid
[1108] In an analogous manner to example 878, 5-(phenylsulfonyl)-iV-pyrrolidin-3-yl- 2-(trifluoromethyl)benzenesulfonamide and succinic anhydride were used to prepare 4-oxo-4-[3- ({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l -yl]butanoic acid. MS (ES+) m/z 534.7;
HPLC purity 96.4% at 210-370 nm, 7.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 887: tert-butyl 4-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)piperazine-l-carboxylate
[1109] Step 1 : Li an analogous manner to Example 866, step 1, N5N'- carbonyldiimidazole and 1-tert-butyl piperazinecarboxylate were used to prepare the intermediate tert-buty 14-( 1 H-imidazol- 1 -y lcarbony l)piperazine- 1 -carboxy late . [1110] Step 2: To a solution of tert-butyl 4-(lH-imidazol-l-ylcarbonyl)piperazine-l- carboxylate (119 mg, 0.425 mmol) stirring in acetonitrile (0.79 mL) at room temperature under N2 was added iodomethane (0.10 mL, 0.23 g, 1.6 mmol). The solution stirred at room temperature 18 hours. The acetonitrile and excess iodomethane were evaporated at reduced pressure. N-[2- (methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride (172 mg, 0.375 mmol) from Example 799, CH2Cl2 (5.25 mL) and diisopropylethylamine (74 μL, 55 mg, 0.42 mmol) were added. The mixture was stirred at room temperature for 3 days. It was washed with dilute aqueous HCl (0.22 mL, 2N, 0.44 mmol diluted to < IM). An emulsion formed. The layers separated with the addition of 2N NaOH. The organic phase was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to give 133 mg (56%) of tert-butyl 4-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)piperazine-l-carboxylate. MS (ES+) m/z 634.8; HRMS: calcd for C26H33F3N4O7S2 + H+, 635.18155; found (ESI, [M+H]+), 635.1817.
Example 888: N-{ {methyl [2-({[5-(pheny lsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)glycine
[1111] To a solution of ethyl N-({methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}ammo)ethyl]amino}carbonyl)glycinate (2.472 mg, 0.4481 mmol) from Example 882 in EtOH (6.5 mL) was added lithium hydroxide hydrate (94 mg, 2.24 mmol) in water (0.8 mL). The solution was stirred at room temperature for 2 h. The EtOH was evaporated. The residue was partitioned with EtOAc and 2N HCl. The EtOAc was washed once with water and dried over MgSO4. Evaporation gave 236.7 mg (100%) of iV-({methyl[2-({[5- (pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)ethy 1] amino } carbony l)glycine . MS (ES+) m/z 523.7; HRMS: calcd for C19H20F3N3O7S2 + H+, 524.07675; found (ESI, [M+H]*), 524.0753.
Example 889: iV-{[5-(phenylsulfonyI)-2-(trifluoromethyI)phenyl]sulfonyI}- D -alanine
[1112] Step 1 : Following the same procedure described on example 654, 2- trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and beta-alanine tertbutyl ester hydrochloride were used to prepare 3-(5-benzenesulfonyl-2-trifluoromethyl- benzenesulfonylamino)-propionic acid tert-butyl ester. [1113] Step 2: Following the same procedure described on example 688, 3-(5- benzenesulfonyl-2-trifluoromethyl-benzenesulfonylamino)-propionic acid tert-butyl ester was used to prepare iV-{[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}-D-alanine. MS (ES-) m/z 435.7;
HPLC purity 100% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C16H14F3NO6S2 + H+, 438.02874; found (ESI5 [M+H]+), 438.0272.
Example 890: 3-[4-({[5-(phenyIsulfonyI)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]propanoic acid
[1114] In an analogous manner to example 879, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and tert-butyl 3-bromopropionate were used to prepare 3- [4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]propanoic acid.
HPLC purity 97.6% at 210-370 nm, 6.8 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H23F3N2O6S2 + H+, 521.10224; found (ESI5 [M+H]+), 521.1035.
Example 891: 3-[4-({[5-(phenyIsuIfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]benzoic acid
[1115] To a stirred solution of 5-(phenylsulfonyl)-N-piperidin-4-yl-2-
(trifluoromethyl)benzenesulfonamide (0.13 g, 0.29mmol) in methylene chloride (2 mL) under a drying tube was added 3-(tertbutoxycarbonyl)-phenylboronic acid (0.08g, 0.35 mmol), triethylamine (0.15 mL, 1.0 mmol) and copper II acetate (0.10 g, 0.58 mmol). The resulting solution was stirred room temperature for 2 days. The reaction mixture was washed with ammonium chloride solution (sat.), concentrated, and flash column separated using a 0-30% ethyl acetate/hexane gradient. The resulting material was dissolved in 4N HCl in dioxane solution (1 mL) and stirred overnight. The solution was concentrated and trituration with methylene chloride to give 3-[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]benzoic acid. (0.026 g, 16%). HPLC purity 100% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HElMS: calcd for C25H23F3N2O6S2 + H+, 569.10224; found (ESI, [M+H]+), 569.1034.
Example 893: 4-({[5-(phenyIsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)butanoic acid
[1116] Step 1 : Following the same procedure described on example 654, 2- trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 4-amino-N-butyric acid tert- butyl ester hydrochloride were used to prepare 3-(5-Benzenesulfonyl-2-trifluoromethyl- benzenesulfonylamino)-butyric acid tert-butyl ester.
[1117] Step 2: Following the same procedure described on example 688, 3-(5- Benzenesulfonyl-2-trifluoromethyl-benzenesulfonylamino)-butyric acid tert-butyl ester was used to prepare 4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)butanoic acid. HPLC purity 99.1% at 210-370 run, 8.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C17H16F3NO6S2 + H+, 452.04439; found (ESI, [M+H]+), 452.0446.
Example 894: 5-oxo-5-[4-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)piperidin-l-yl]pentanoic acid
[1118] In an analogous manner to example 878, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and glutaric anhydride were used to prepare 5-oxo-5-[4- ({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]pentanoic acid. HPLC purity 100% at 210-370 nm, 8.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H25F3N2O7S2 + H+, 563.11280; found (ESI, [M+H]^), 563.1128.
Example 895: 5-oxo-5~[3-({[5-(phenylsulfonyI)-2- (trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l-yl]pentanoic acid
[1119] In an analogous manner to example 878, 5-(phenylsulfonyl)-N-pyrrolidin-3-yl- 2-(trifluoromethyl)benzenesulfonamide and glutaric anhydride were used to prepare 5-oxo-5-[3- ({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l-yl]pentanoic acid. HPLC purity 93.7% at 210-370 nm, 8.0 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H23F3N2O7S2 + H+, 549.09715; found (ESI, [M+H]+), 549.0967. Example 896: tert-butyl 4-[({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidine-l-carboxylate
[1120] In an analogous manner to example 435, 5-(phenylsulfonyl)-7V"-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 4-aminomethyl-l -(tert-butoxycarbonyl)piperidine were used to prepare fert-butyl 4-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidine-l-carboxylate. MS (ES-) m/z 560.7;
HPLC purity 97.9% at 210-370 nm, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H29F3N2O6S2 + H+, 563.14919; found (ESI, [M+H]+), 563.1487.
Example 897: 4-{methyl[2-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyI]sulfonyI}amino)ethyl]amino}-4-oxobutanoic acid
[1121] To a stirred suspension of N-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride (0.10 g, 0.22 mmol) from Example 799 in a solution of succinic anhydride (34 mg, 0.34 mmol) in toluene (3 mL) under N2 at room temperature was added diisopropylethylamine (0.076 mL, 56 mg, 0.44 mmol). The mixture was stirred at 1050C for 3 hours. An oil had formed which after cooling didn't dissolve with the addition of EtOAc saturated with HCl. The solution was decanted from the oil and saved. The oil was dissolved in methanol. The organic solutions were combined and washed with 2N HCl and water. It was loaded directly onto a Isco silica gel column and eluted with a gradient of hexane and ethyl acetate to give 45 mg (40%) of
4-{methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfonyl } amino)ethyl] amino } -4-oxobutanoic acid. MS (ES-) m/z 520.7; HRMS: calcd for C20H21F3N2O7S2 + H+, 523.08150; found (ESI, [M+H]+), 523.0803.
Example 898: 7V-methyWV-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperazine-l-carboxamide
[1122] To a solution of tert-butyl 4-({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)piperazine-l-carboxylate (81 mg, 0.13 mmol) from Example 887 in EtOH (1 mL) was added EtOAc saturated with HCl (1 mL). This mixture stood at room temperature 18 hours but solid had not formed. The solvent was evaporated after 4 days. The residue was dissolved in EtOH and transferred to another vial. No solid formed The solvent was evaporated and dried to give 48 mg (66%) of N-methyl-N-[2-({[5-
(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperazine-l-carboxamide.
MS (ES+) m/z 534.8;
HRMS: calcd for C21H25F3N4O5S2 + H+, 535.12912; found (ESI, [M+H]+), 535.1285.
Example 899: 5-(phenylsulfonyl)-Λf-(piperidin-4-ylmethyl)-2- (trifluoromethyl)benzenesulfonamide
[1123] In an analogous manner to example 688, tert-butyl 4-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidine-l-carboxylate was used to prepare 5- (phenylsulfonyl)-N-(piperidin-4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 460.8;
HPLC purity 98.3% at 210-370 nm, 7.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff.
Figure imgf000337_0001
for lOmin, hold 4min. HRMS: calcd for C19H2IF3N2O4S2 + H+, 463.09676; found (ESI, [M+H]+), 463.0958.
Example 900: N-(l-hydroxy-2,3-dihydro-lH-inden-2-yl)-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1124] In an analogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride and 2-amino-2,3-dihydro-lH-inden-l-ol was used to prepare the title compound N-(l-hydroxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (105.7 mg, 54.3%) as a white solid. MS (ES-) m/z 495.7;
HPLC purity 97.7% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H18F3NO5S2 + H+ - H+, 497.05785; found (ESI, [M+H-H20]+), 480.0508.
Example 901: tert-butyl [frø«s-4-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)cyclohexyl]carbamate
[1125] Step 1 : To a stirred solution of trans- 1,4-cyclohexanediamine (0.50 g, 4.4 mmol) in ethyl ether (25 mL) was added BOC anhydride (0.96 g, 4.4 mmol) and the resulting solution was stirred room temperature overnight. The mixture was filtered to give (4-aminocyclohexyl)- carbamic acid tert-butyl ester. (0.90 g, 82%).
[1126] Step 2: Following the same procedure described on example 435, 2- trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and (4-aminocyclohexyl)-carbamic acid tert-butyl ester were used to prepare tert-butyl [7røra'-4-({[5-(phenylsulfonyl)-2- (trifluoromethy l)ρhenyl] sulfonyl } amino)cy clohexyl] carbamate . MS (ES-) m/z 560.7;
HPLC purity 94.5% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H29F3N2O6S2 + H+, 563.14919; found (ESI, [M+H]4"), 563.1474.
Example 902: 4-oxo-4-{4-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin-l-yl}butanoic acid
[1127] In an analogous manner to example 878, 5-(jphenylsulfonyl)-iV-(piperidin-4- ylmethyl)-2-(trifluoromethyl)benzenesulfonamide and succinic anhydride were used to prepare 4-OXO-4- {4- [( { [5 -(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl } amino)methy l]piperidin- l-yl}butanoic acid. MS (ES-) m/z 560.7;
HPLC purity 90.6% at 210-370 nm, 8.2 min.; Xterra RPl 8, 3.5u, 15O x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Pb=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H25F3N2O7S2 + H+, 563.11280; found (ESI, [M+H]+), 563.1136.
Example 903: 5-oxo-5-{4-[({[5-(phenylsuIfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin-l-yl}pentanoic acid
[1128] In an analogous manner to example 878, 5-(phenylsulfonyl)-N-(piperidin-4- ylmethyl)-2-(trifluoromethyl)benzenesulfonamide and glutaric anhydride were used to prepare 5- oxo-5-{4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methylJpiperidin-l- yl}pentanoic acid. MS (ES+) m/z 576.8;
HPLC purity 100% at 210-370 nm, 8.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H27F3N2O7S2 + H+, 577.12845; found (ESI, [M+H]+), 577.1257. 86
/Λ.J.VJLAUJ.OUO - 338 -
Example 904: 3-({4-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin-l-yl}sulfonyl)benzoic acid
[1129] In an analogous manner to example 462, 5-(phenylsulfonyl)~JV-(piperidin-4- ylmethyl)-2-(trifluoromethyl)benzenesulfonamide and 3-(chlorosulfonyl)benzoic acid were used to prepare 3-({4-[({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin-l-yl}sulfonyl)benzoic acid. MS (ES+) m/z 646.7;
HPLC purity 92.6% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H25F3N2O8S3 + H+, 647.07979; found (ESI, [M+H]+), 647.0802.
Example 905: iV-{2-[(2-hydroxyethyl)(methyl)ammo]ethyl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1130] To a stirred suspension of N-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride (65 mg, 0.14 mmol) from Example 799 in a solution of 2-bromoethanol (11 μL, 19 mg, 0.16 mmol) in CH3CN (2 mL) under N2 at room temperature was added diisopropylethylamine (49 μL, 36 mg, 0.28 mmol). The mixture was stirred under N2 at 740C for 18 hours. The solvent was evaporated. The residue was partitioned with CH2Cl2 and water and washed twice with water. It was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to give 40 mg (61%) of 7V-{2-[(2- hydroxyethyl)(methyl)amino]ethyl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 466.8; HRMS: calcd for C18H21F3N2O5S2 + H+5 467.09167; found (ESI, [M+H]+), 467.0922.
Example 906: methyl iV-methyl-iV-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulf onyl} amino)ethyl] glycinate
[1131] To a stirred suspension of 7V-[2-(methylamino)ethyl]-5-(ρhenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride (12 mg, 0.26 mmol) from Example 799 in CH2Cl2 (3.5 mL) under N2 at room temperature was added methyl bromoacetate (26 μL, 43 mg, 0.28 mmol) and diisopropylethylamine (83 μL, 62 mg, 0.48 mmol). The mixture was stirred at room temperatue for 2 days. . It was washed twice with water and loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to give 0.11 g (85%) of methyl
N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycinate.
MS (ES-) m/z 492.7;
HRMS: calcd for C19H21F3N2O6S2 + H+, 495.08659; found (ESI3 [M+H]+), 495.0846.
Example 907: ethyl iV-methyl-Λ^[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-β-alaninate
[1132] To a stirred suspension of N-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride (0.15 g, 0.33 mmol) from Example 799 in CHCl3 (15 mL) under N2 at room temperature was added ethyl acrylate (48 μL, 44 mg, 0.44 mmol) and diisopropylethylamine (70 μL, 52 mg, 0.40 mmol). The mixture was stirred at 570C for 18 hours. Ethyl acrylate (46 μL, 42 mg, 0.42 mmol) and diisopropylethylamine (90 μL, 67 mg, 0.52 mmol) were added. The mixture was stirred at 570C for 2 days. It was washed with water and concentrated to 5 mL. This was loaded directly onto a Isco silica gel column and eluted with a gradient of hexane and ethyl acetate to give 0.15 g (88%) of ethyl N-methyl-N-[2- ({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-β-alaninate. MS (ES+) m/z 522.8; HRMS: calcd for C21H25F3N2O6S2 + H+, 523.11789; found (ESI, [M+H]+), 523.1188.
Example 908: tert-bntyl 2-[2-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l-carboxylate
[1133] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 2-(aminoethyl)-l-N-BOC-pyrrolidine were used to prepare tert- butyl 2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l- carboxylate. MS (ES-) m/z 560.8;
HPLC purity 100% at 210-370 nm, 10.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 909: tert-butyl 4-({[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate
[1134] In an analogous manner to Example 300: 5-benzenesulfonyl-2-ethyl-benzenesulfonyl chloride and 4-amino-piperidine-l- carboxylic acid tert-butyl ester were used to prepare tert-butyl 4-({[2-ethyl-5- (phenylsulfonyl)phenyl]sulfonyl} amino)piperidine- 1 -carboxylate. MS (ES-) m/z 507.1;
HPLC purity 100% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H32N2O6S2 + H+, 509.17745; found (ESI, [M+H]+), 509.1793.
Example 910: tert-butyl 4-({[2,3-dimethyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l -carboxylate
[1135] In an analogous manner to Example 347:
5-Benzenesulfony 1-2,3 -dimethyl-benzenesulfonyl chloride and 4-amino-piperidine-l- carboxylic acid tert-butyl ester were used to prepare tert-butyl 4-({[2,3-dimethyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate. MS (ES-) m/z 507.1;
HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H32N2O6S2 + H+, 509.17745; found (ESI, [M+H]+), 509.1761.
Example 911: tert-butyl 4-({[2,4-dimethyI-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate
[1136] In an analogous manner to Step 3, Example 295:
5-Benzenesulfony 1-2,4-dimethyl-benzenesulfonyl chloride and 4-amino-piperidine-l- carboxylic acid tert-butyl ester were used to prepare tert-butyl 4-({[2,4-dimethyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate. MS (ES-) m/z 507.1;
HPLC purity 100% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H32N2O6S2 + H+, 509.17745; found (ESI, [M+H]+), 509.1798.
Example 912: tert-butyl 4-({[2-isopropyl-5- W 2
- 341 -
(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate
[1137] In an analogous manner to Step 3, Example 295:
5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 4-amino-piperidine-l- carboxylic acid tert-butyl ester were used to prepare tør/-butyl 4-({[2-isopropyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate. MS (ES-) m/z 521.1;
HPLC purity 100% at 210-370 ran, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Pb=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H34N2O6S2 + H+, 523.19310; found (ESI, [M+H]+)3 523.1921.
Example 913: 5-(phenyIsulfonyI)-iV-(2-pyrrolidin-2-ylethyI)-2- (trifluoromethyl)benzenesulfonamide
[1138] In an analogous manner to example 688, tert-butyl 2-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l-carboxylate was used to prepare 5- (phenylsulfonyl)-Λ/-(2-pyrrolidin-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 462.8;
HPLC purity 100% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C19H21F3N2O4S2 + H+, 463.09676; found (ESI, [M+H]+), 463.0961.
Example 914: iV-{l-[(4-hydroxyphenyl)sulfonyl]piperidin-4-yl}-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1139] Step 1 : Following the same procedure described on example 462, 5- (phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 4- methoxybenzene sulfonyl chloride were used to prepare 7V-{l-[(4- methoxyphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide .
[1140] Step 2: Following the same procedure described on example 744, N-{l-[(4- methoxyphenyl)sulfonyl]piperidin-4-yl } -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide was used to prepare 7V-{l-[(4- hydroxyphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 604.7;
MS (ES) m/z 604.7;
HPLC purity 100% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C24H23F3N2O7S3 + H+, 605.06922; found (ESI, [M+H]4), 605.0696.
Example 915: tert-bntyl 4-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}piperidine-l-carboxylate [1141] To a stirred solution of 1 -BOC-piperidine-4-carboxylic acid (0.08g, 0.34 mmol) in methylene chloride (2 mL) was added triethylamine (0.1 mL, 0.7 mmol) and carbonyldiimidazole (0.06 g, 0.34 mmol). The resulting solution was stirred at room temperature for 20 minutes. To the mixture was added 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (0.15 g, 0.34 mmol). The resulting solution was stirred lhr, washed with ammonium chloride solution (sat), and concentrated. Flash column separation using 0%-50% ethyl acetate/hexane gradient gave tert-butyl 4-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)piperidin- 1 -yl]carbonyl}piperidine- 1 -carboxylate. (0.13 g, 70%).
MS (ES-) m/z 657.8;
HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C29H36F3N3O7S2 + H+, 660.20195; found (ESI, [M+H]+), 660.2032.
Example 916: A'-[l-(ΛVV-dimethyIglycyI)piperidin-4-yl]-5-(phenyIsulfonyI)-2- (trifluoromethyl)benzenesulfonaniide
[1142] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and dimethylaminoaceyl chloride hydrochloride were used to prepare N-[l-(iV,N-dimethylglycyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 533.8;
HPLC purity 100% at 210-370 nm, 7.1 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H26F3N3O5S2 + H+, 534.13387; found (ESI, [M+H]+), 534.1341. Example 917: iV-{l-[4-(dimethylamino)benzoyl]piperidm-4-yl}-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1143] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-pipeπdin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 4-(dimethylamino)beπzoyl chloride were used to prepare 7V-{1 -[4-(dimethylamino)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 595.8;
HPLC purity 95.8% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C27H28F3N3O5S2 + H+, 596.14952; found (ESI5 [M+Hj+), 596.1509.
Example 918: {2-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-l-yl}acetic acid
[1144] In an analogous mariner to example 879, 5-(phenylsulfonyl)-/V-(2-pyrrolidin-2- ylethyl)-2-(trifluoromethyl)benzenesulfonamide and tert-butylbromoacetate were used to prepare {2- [2-( { [5 -(phenylsulfonyl)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)ethy l]pyrrolidin- 1 - yl} acetic acid. MS (ES+) m/z 520.8;
HPLC purity 100% at 210-370 nm, 7.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H23F3N2O6S2 + H+, 521.10224; found (ESI, [M+H]+), 521.1031.
Example 919: 4-oxo-4-{2-[2-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-l-yl}butanoic acid
[1145] In an analogous manner to example 878, 5-(phenylsulfonyl)-iV-(2-pyrrolidin-2- ylethyl)-2-(trifluoromethyl)benzenesulfonamide and succinic anhydride were used to prepare 4- oxo-4-{2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-l- yljbutanoic acid. MS (ES+) m/z 562.7;
HPLC purity 100% at 210-370 nm, 8.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Figure imgf000345_0001
HRMS: calcd for C23H25F3N2O7S2 + H+, 563.11280; found (ESI, [IVB-H]+), 563.1114.
Example 920: 3-({2-[2-({[5-(phenylsulfonyI)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-l-yl}sulfonyl)benzoic acid
[1146] In an analogous manner to example 462, 5~(phenylsulfonyl)-iV-(2-pyrrolidm-2- ylethyl)-2-(trifluoromethyl)benzenesulfonamide and and 3-(chlorosulfonyl)benzoic acid were used to prepare 3-({2-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfonyl} amino)ethy l]pyrrolidin- 1 -y 1 } sulfony l)benzoic acid. MS (ES+) m/z 646.7;
HPLC purity 95.2% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H25F3N2O8S3 + H+, 647.07979; found (ESI, [M+H]+), 647.0803.
Example 921 : 2-ethyl-5-(phenylsulfonyl)-Λr-piperidin-4-ylbenzenesulfonamide
[1147] Example 909 (550 mg, 1.1 mmol) was dissolved in dry dioxane and a 4M hydrogenechloride solution in dioxane (2 mL) was added and the reaction was stirred at room temperature until the starting material was consumed as evidence by LCMS analysis. The resulting white precipitate was isolated by suction filtration and then recrystalized in hot ethanol resulting in the isolation of 2-ethyl-5-(phenylsulfonyl)-iV-piperidrn-4-ylbenzenesulfonamide (270 mg, 55%)
MS (ES+) m/z 408.8;
HPLC purity 100% at 210-370 nm, 6.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C19H24N2O4S2 + H+, 409.12502; found (ESI, [M+H]+), 409.1242.
Example 922: 2,3-dimethyl-5-(phenylsulfonyl)-Λr-piperidin-4-ylbenzenesulfonamide
[1148] In an analogous manner to Example 921:
Example 910 was treated with a solution of hydrogen chloride in dioxane to provide 2,3- dimethyl-5-(phenylsulfonyl)-iV-piperidin-4-ylbenzenesulfonamide. MS (ES+) m/z 408.8;
HPLC purity 100% at 210-370 nm, 6.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for Ci9H24N2O4S2 + H+, 409.12502; found (ESI, [M+H]+)5 409.1246.
Example 923: 2,4-dimethyI-5-(phenylsulfonyI)-A'-piperidin-4-ylbenzenesulfonamide
[1149] In an analogous manner to Example 921 :
Example 911 was treated with a solution of hydrogen chloride in dioxane to provide 2,4- dimethyl-5-(phenylsulfonyl)-iV-piperidin-4-ylbenzenesulfonamide. MS (ES+) m/z 408.8;
HPLC purity 100% at 210-370 nm, 6.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C19H24N2O4S2 + H+, 409.12502; found (ESI, [M+H]+), 409.1241.
Example 924: 2-isopropyl-5-(phenylsuIfonyl)-iV-piperidin-4-ylbenzenesulfonamide
[1150] In an analogous manner to Example 921 :
Example 912 was treated with a solution of hydrogen chloride in dioxane to provide 2- isopropyl-5-(phenylsulfonyl)-iV-piperidin-4-ylbenzenesulfonamide. MS (ES+) m/z 422.9;
HPLC purity 100% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H26N2O4S2 + H+, 423.14067; found (ESI, [M+Hf), 423.1404.
Example 925: 5-(phenylsulfonyl)-iV-piperidin-4-yl-2-propylbenzenesuIfonamide
[1151] In an analogous manner as Example 909, 5-benzenesulfonyl-2-propyl- benzenesulfonyl chloride and 4-amino-piperidine-l-carboxylic acid tert-butyl ester were used to prepare tert-butyl 4-({[2-propyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate.
[1152] In an analogous manner to Example 921 : tert-butyl 4-({[2-propyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate was treated with a solution of hydrogen chloride in dioxane to provide 5-
(phenylsulfonyl)-N-piperidin-4-yl-2-propylbenzenesulfonamide.
MS (ES+) m/z 422.9;
HPLC purity 100% at 210-370 nm, 7.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H26N2O4S2 + H+, 423.14067; found (ESI, [M+H]"1), 423.1412.
Example 926: tert-butyl (3S)-3-[({methyl[2-({[5-(phenyIsuIfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]pyrrolidine-l- carboxylate
[1153] Step 1 :In an analogous manner to Example 866, Step 1, N5N'- carbonyldiimidazole and (S)-N-BOC-3-aminopyrrolidine were used to prepare the intermediate fert-butyl (3S)-3 - [( 1 H-imidazol- 1 -ylcarbonyl)amino]pyrrolidine- 1 -carboxylate .
Step 2: In an analogous manner to Example 866, Step 2, JV-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and tert-butyl (3S)-3- [(I H-imidazol- l-ylcarbonyl)amino]pyrrolidine-l -carboxylate were used to prepare tert-butyl (35)-3-[({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl} amino)ethyl]amino} carbonyl)amino]pyrrolidine- 1 -carboxylate. MS (ES-) m/∑ 632.8; ΗRMS: calcd for C26H33F3N4O7S2 + H+, 635.18155; found (ESI, [M+H]+), 635.1805.
Example 927: tert-butyl methyI[3-({[5-(phenylsuIfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)propyl]carbamate
[1154] In an analogous manner to example 765, 5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonyl chloride and N-(3-Aminopropyl)-N-methylcarbamic acid tert- butyl was used to prepare the title compound tert-butyl methyl[3-({[5-(ρhenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)propyl]carbamate (1.827 g, 84%) as a white solid. MS (ES) m/z 536.8;
HPLC purity 97.1% at 210-370 nm, 9.9 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H27F3N2O6S2 + H+, 537.13354; found (ESI, [M+H-C4H8]+), 481.0687.
Example 928: Λ^-[2-(4-aminophenyl)ethyl]-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide [1155] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 4-(2-aminoethyl)phenylamine were used to prepare 7V-[2-(4- aminophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 484.8;
HPLC purity 98.7% at 210-370 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C2IH19F3N2O4S2 + H+, 485.08111; found (ESI, [M+H]+), 485.0799.
Example 929: N-[3-(methyIamino)propyl]-5-(phenyI$uIfonyI)-2- (trifluoroniethyl)benzenesulfonamide
[1156] Tert-butyl methyl[3-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)propyl]carbamate (1.49 g, 2.77 mmol) prepared in example 927 was taken up in 25 ml of hydrochloric saturated ethyl acetate. The hydrochloric salt of the title compound N-[3-(methylamino)propyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (1.29 g, 98%) crashed out of solution as a white solid. MS (ES-) m/z 434.7;
HPLC purity 98.4% at 210-370 nm, 6.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOrnin, hold 4min. HRMS: calcd for C17H19F3N2O4S2 + H+, 437.08111; found (ESI, [M+H]+), 437.0803.
Example 930: 5-(phenylsulfonyl)-Λ'-[l-(piperidin-4-ylcarbonyI)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide
[1157] To a stirred solution of tert-butyl 4- { [4-( { [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin- 1 -yl]carbonyl}ρiperidine- 1 -carboxylate (0.10 g, 0.15 mmol) in ethyl acetate (2 mL) was bubbled HCl gas. The resulting solution was stirred at room temperature overnight, and concentrated. Trituration in ethyl ether gave 5- (pheny lsulfonyl)-iV- [ 1 -(piperidin-4-y lcarbony l)piperidin-4-yl] -2- (trifluoromethyl)benzenesulfonamide. (0.085 g, 85%). MS (ES+) m/z 559.8;
HPLC purity 100% at 210-370 nm, 7.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H28F3N3O5S2 + H+, 560.14952; found (ESI, [MMH]+), 560.1478.
Example 931: tert-butyl 4-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidine-l-carboxylate
[1158] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyi)- benzenesulfonyl chloride and 4-(aminoethyl)piperidine-l-carboxylic acid tert-butyl ester were used to prepare tert-butyl 4-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)ethyl]piperidine- 1 -carboxylate. MS (ES) m/z 574.8;
HPLC purity 100% at 210-370 nm, 10.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 932: methyl 3-({[2-isopropyl-5-
(phenylsulfonyl)phenyl] sulfonyl} amino)cy clohexanecarboxylate [1159] In an analogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and methyl 3- aminocyclohexanecarboxylate were used to prepare methyl 3-({[2-isopropyl-5-
(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate.
MS (ES) m/z 479.9;
HPLC purity 100% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C23H29NO6S2 + H+, 480.15091; found (HRMS, [M+H]+), 480.1512.
Example 933: methyl 4-({[2-isopropyl-5-
(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate [1160] In an analogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and methyl 4- aminocyclohexanecarboxylate were used to prepare methyl 4-({[2-isopropyl-5-
(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate.
MS (ES) m/z 479.8;
HPLC purity 94.0% at 210-370 nm, 9.7 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H29NO6S2 + H+, 480.15091; found (ESI3 [M+H]+), 480.1503.
Example 934: methyl tfrø«s-4-[({[2-isopropyl-5-
(phenylsulfonyl)phenyl]sulfonyl}amino)methyl]cyclohexanecarboxylate [1161] In an analogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and methyl trans-4-
(aminomethyl)-l-cyclohexanecarboxylate were used to prepare methyl /r<my-4-[({[2-isopropyl-
5-(phenylsulfonyl)phenyl]sulfonyl}amino)methyl]cyclohexanecarboxylate.
MS (ES+) m/z 493.9;
HPLC purity 96.2% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C24H3iNO6S2 + H+, 494.16656; found (ESI, [M+H]+), 494.1669.
Example 935: 2-isopropyl-5-(phenyIsulfonyl)-iV-(2,2,6,6-tetramethylpiperidin-4- yl)benzenesulfonamide
[1162] In an analogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 4-amino-2,2,6,6- tetramethylpiperidine were used to prepare 2-isopropyl-5-(phenylsulfonyl)-N-(2,2,6,6- tetramethylpiperidin-4-yl)benzenesulfonamide.
MS (ES) m/z 478.9;
HPLC purity 97.9% at 210-370 nm, 7.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C24H34N2O4S2 + H+, 479.20327; found (ESI, [M+H]+)5 479.2044.
Example 936: 2-isopropyI-5-(phenylsulfonyl)-Λ'-(pyridin-4-yImethyl)benzenesulfonamide
[1163] In an analogous manner to Step 3, Example 295:
5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and 4-aminomethylpyridine were used to prepare 2-isopropyl-5-(phenylsulfonyl)-iV-(pyridin-4- ylmethy l)benzenesulfonamide . MS (ES) m/z 430.8; HPLC purity 100% at 210-370 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C2]H22N2O4S2 + H+, 431.10937; found (ESI, [M+H]+), 431.1076.
Example 937: Λ'-[2-(methyl{[(3S)-pyrroIidin-3-ylammo]carbonyI}amino)ethyI]-5- (phenylsulfonyI)-2-(trifluoromethyl)benzenesulfonamide
[1164] To a solution of tert-butyl (35)-3-[({methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)ethyl] amino } carbonyl)amino]pyrrolidine- 1 -carboxylate (0.17 g, 0.27 mmol) from Example 926 in EtOAc (1 niL) was added EtOAc saturated with HCl. This mixture stood at room temperature for 18 hours but solid had not formed. The solvent was evaporated. The residue was dissolved in EtOH. No solid formed. The solvent was evaporated. The residue was dried at 1000C for 0.75 hours to give 0.14 g (88%) of N-[2-(methyl{[(35)- pyrrolidin-3-ylamino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride. MS (ES+) m/z 534.8; HRMS: calcd for C21H25F3N4O5S2 + H+, 535.12912; found (HRMS, [M+H]+), 535.1287.
Example 938: methyl 3-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]sulfonyl}benzoate
[1165] To a stirred solution of acyl chloride (0.1 mL, 1.4 mmol) in methanol (2 niL) was added 3 - { [4-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl } amino)piperidin- 1 - yljsulfonyl} benzoic acid (0.10 g, 0.16 mmol). The resulting solution was heated to 50°C overnight and concentrated. Flash column separation using 0-10% methanol/methylene chloride gradient gave methyl 3-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]sύlfonyl}benzoate. (0.075 g, 74%). MS (ES+) m/z 646.8;
HPLC purity 100% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H25F3N2O8S3 + H+, 647.07979; found (HRMS, [M+H]+), 647.0825.
Example 939: iV-[2-(4-methoxyphenyl)ethyl]-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide [1166] In an analogous manner to example 435, 2-trifluoromethyl-5-(ρhenylsulfonyl)- benzenesulfonyl chloride and 2-(4-methoxyphenyl)ethylamine were used to prepare N-[2-(4- methoxyphenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 499.8;
HPLC purity 100% at 210-370 run, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H20F3NO5S2 + H+, 500.08077; found (HRMS, [M+H]+), 500.0799.
Example 940: 5-(phenyIsuIfonyl)-JV-(2-piperidin-4-yIethyl)-2- (trifluoromethyl)benzenesulfonamide
[1167] In an analogous manner to example 930, tert-bnty\ 4-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidine-l-carboxylate was used to prepare 5- (phenylsulfonyl)-N-(2-piperidin-4-ylethyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 476.8;
HPLC purity 97.8% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H23F3N2O4S2 + H+, 477.11241; found (HRMS, [M+H]+), 477.1128.
Example 941: {4-[({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl] sulf ony 1} amino)methyl] piperidin-1 -yl} acetic acid
[1168] In an analogous manner to example 879, 5-(phenylsulfonyl)-7V-(piperidin-4- ylmethyl)-2-(trifluoromethyl)benzenesulfonamide and tert-butylbromoacetate were used to prepare {4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin- 1-yl} acetic acid. MS (ES+) m/z 520.8;
HPLC purity 97.4% at 210-370 nm, 6.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 942: iV-(4-aminobenzyl)-5-(phenyIsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide [1169] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 4-aminomethylphenylamine were used to prepare N-(4- aminobenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 470.8;
HPLC purity 98.1% at 210-370 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Bicarb Buff. Ph=9.5/ACN+MeOH) for lOmin, hold 4min.
Example 943: JV-[2-(4-hydroxyphenyI)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1170] In an analogous manner to example 744, iV-[2-(4-methoxyphenyl)etliyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide was used to prepare N-[2-(4- hydroxyphenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 483.7;
HPLC purity 100% at 210-370 nm, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H18F3NO5S2 + H+, 486.06512; found (HRMS, [M+H]+), 486.065.
Example 944: {4-[2-({[5-(phenylsulfonyI)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidin-l-yl}acetic acid
[1171] In an analogous manner to example 879, 5-(phenylsulfonyl)-iV-(2-piperidin-4- ylethyl)-2-(trifluoromethyl)benzenesulfonamide and tert-butylbromoacetate were used to prepare {4-[2-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)ethyl]piperidin- 1 - yl} acetic acid. MS (ES+) m/z 534.8;
HPLC purity 100% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H25F3N2O6S2 + H+, 535.11789; found (ESI, [M+H]+), 535.1189.
Example 945: methyl 3-({[5-(phenylsulfonyI)-2- (trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate
[1172] In an analogous manner to Step 3, Example 677: 5-Benzenesulfonyl-2-trifluoromethyl-benzenesulfonyl chloride and methyl 3- aminocyclohexanecarboxylate were used to prepare methyl 3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate. MS (ES-) m/z 503.8;
HPLC purity 98.2% at 210-370 nm, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H22F3NO6S2 + H+, 506.09134; found (ESI, [M+H]+), 506.0894.
Example 946: methyl 4-({[5-(phenylsuIfonyI)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate [1173] In an analogous manner to Step 3, Example 677: 5-Benzenesulfonyl-2-trifluoromethyl-benzenesulfonyl chloride and methyl 4- aminocyclohexanecarboxylate were used to prepare methyl 4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate.
MS (ES-) m/z 503.8;
HPLC purity 90.5% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C21H22F3NO6S2 + H+, 506.09134; found (ESI, [M+H]+), 506.0928.
Example 947: methyl *ra«s-4-[({[5-(phenylsuIfonyl)-2- (trifluoromethyl)phenyl] sulfony 1} amino)methyl] cy clohexanecarboxylate
[1174] In an analogous manner to Step 3, Example 677:
5-Benzenesulfonyl-2-trifluoromethyl-benzenesulfonyl chloride and methyl trans-4- (aminomethy l)-l-cy clohexanecarboxylate were used to prepare methyl trans-4-[({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]cyclohexanecarboxylate. MS (ES-) m/z 517.8;
HPLC purity 98.1% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H24F3NO6S2 + H+, 520.10699; found (ESI, [M+H]+), 520.108.
Example 948: 5-(phenylsulfonyl)-Λ'-(2,2,6,6-tetramethylpiperidin-4-yl)-2- (trifluoromethyl)benzenesulfonamide
[1175] In an analogous manner to Step 3, Example 677:
5-Benzenesulfonyl-2-trifluoromethyl-benzenesulfonyl chloride and 4-amino-2,2,6,6- tetramethylpiperidine were used to prepare 5-(phenylsulfonyl)-N-(2,2,6,6-tetramethylpiperidin-4- yl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 504.9;
HPLC purity 98.0% at 210-370 urn, 7.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H27F3N2O4S2 + H+, 505.14371; found (ESI5 [M+H]+), 505.1442.
Example 949: 5-(phenyIsuIfonyl)-AL(pyridin-4-yImethyI)-2- (trifluoromethyl)benzenesulfonamide
[1176] In an analogous manner to Step 3, Example 677: 5-Benzenesulfonyl-2-trifluoromethyl-benzenesulfonyl chloride and 4- aminomethylpyridine were used to prepare 5-(phenylsulfonyl)-iV-(pyridin-4-ylmethyl)-2-
(trifluoromethyl)benzenesulfonamide.
MS (ES+) m/z 456.8;
HPLC purity 97.7% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C19H15F3N2O4S2 + H+, 457.04981; found (ESI, [M+H]+), 457.0482.
Example 950: methyl 4-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]benzoate
[1177] In an analogous manner to Step 3, Example 677: 5-Benzenesulfonyl-2-trifluoromethyl-benzenesulfonyl chloride and methyl 4- aminomethylbenzoate were used to prepare methyl 4-[({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)methyl]benzoate.
MS (ES) m/z 513.7;
HPLC purity 100% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/AOSB-MeOH) for lOmin, hold 4min.
HRMS: calcd for C22H18F3NO6S2 + H+, 514.06004; found (ESI, [MB-H]+), 514.0614. Example 951: methyl 4-[({[2-isopropyl-5-
(phenylsulfonyl)phenyl] sulfonyl} amino)methyl] benzoate
[1178] In an analogous manner to Step 3, Example 295: 5-Benzenesulfonyl-2-isopropyl-benzenesulfonyl chloride and methyl A- aminomethylbenzoate were used to prepare methyl 4-[({[2-isopropyl-5-
(phenylsulfonyl)phenyl] sulfonyl } amino)methyl]benzoate .
MS (ES-) rn/z 485.8;
HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C24H25NO6S2 + H+, 488.11961; found (ESI, [M+H]+)3 488.1208.
Example 952: 3-({[2-isopropyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid
[1179] Methyl 3-({[2-isopropyl-5-
(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate (example 932, 100 mg, 0.2 mmol) was dissolved in tetrahydrofuran (2 mL) and a 50% aqueous solution of sodium hydroxide (48 mg, 0.6 mmol) was added. The reaction mixture was stirred at room temperature for 18 h. The reaction was concentrated and then water (2 mL) was added followed by extraction with ethyl acetate (2 x 2 mL). The aqueous phase was acidified with 2N HCl and extracted with ethyl acetate which when evaporated under reduced pressure afforded 3-({[2- isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid (92 mg, 95%) as an amorphous white solid. MS (ES-) m/z 464.1;
HPLC purity 97.9% at 210-370 nm, 9.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H27NO6S2 + H+, 466.13526; found (ESI, [M+H]4"), 466.1344.
Example 953: 4-({[2-isopropyI-5-
(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid [1180] In an analogous manner to Example 952: methyl 4-( { [2-isopropy l-(phenylsulfony l)pheny 1] sulfony 1 } amino)cyclohexanecarboxylate (example 933) and 50% sodium hydroxide were used to prepare 4-({ [2-isopropy 1-5- (phenylsulfonyl)phenyl] sulfony 1 } amino)cyclohexanecarboxy Hc acid. MS (ES-) m/z 464.1;
HPLC purity 94.3% at 210-370 nm, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H27NO6S2 + H+, 466.13526; found (ESI, [M+H]+), 466.1345.
Example 954: tfrα«s-4-[({[2-isopropyI-5- (phenylsulfonyl)phenyl]sulfonyl}amino)methyl]cyclohexanecarboxylic acid
[1181] In an analogous manner to Example 952:
Methyl trans-4-[({[2-isopτopyl-5-
(phenylsulfonyl)phenyl]sulfonyl}amino)methyl]cyclohexanecarboxylate (example 934) and 50% sodium hydroxide were used to prepare trαrø-4-[({[2-isopropyl-5- (phenylsulfony^phenyljsulfonyljamino^ethyljcyclohexanecarboxy lie acid. MS (ES-) m/z 478.1;
HPLC purity 97.8% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 955: tert-butyl 4-[({methyl[3-({[5-(phenyIsuIfonyl)-2-
(trifluoromethy I)phenyl] sulf onyl} amino)propyl] amino} carbony l)amino] piperidine-1 - carboxylate
[1182] A mixture of N-[3-(methylamino)propyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (202.5 mg, 0.43 mmol) prepared example 929 in dichloromethane (15 ml). Tert-butyl 4-(lH-imidazole-l-carboxamido)piperidine-l- carboxylate( 109.4 mg, 0.37 mmol) and 1.5 eq. of N,N-Diisoprpylethylamine was syringed into the reaction vial and was allowed to stir overnight at room temperature. The product was transferred onto a 40 g Isco RediSep® Normal Phase column and was purified by automated flash chromatography using a gradient of 20% to 100% hexane/ethyl acetate. Isolation of the main component gave the title compound tert-butyl 4-[({methyl[3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfony 1 } amino)propyl] amino } carbony l)amino]piperidine- 1 -carboxylate (217.2 mg, 77%) as a white solid. MS (ES-) m/z 661.2;
HPLC purity 98.2% at 210-370 nm, 9.8 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C28H37F3N4O7S2 + H+, 663.21285; found (ESI5 [M+H]+)5 663.2208.
Example 956: 3-{4-[({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin-l-yl}benzoic acid
[1183] In an analogous manner to example 891, 5-(phenylsulfonyl)-7V-(piperidin-4- ylmethyl)-2-(trifluoromethyl)benzenesulfonamide and 3-(tertbutoxycarbonyl)-phenylboronic acid were used to prepare 3-{4-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidm-l-yl}benzoic acid. MS (ES+) m/z 583.1;
HPLC purity 100% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C26H25F3N2O6S2 + H+, 583.11789; found (ESI, [M+H]+), 583.1181.
Example 957: 3-{4-[2-({[5-(phenylsuIfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidin-l-yl}benzoic acid
[1184] In an analogous manner to example 891, 5-(phenylsulfonyl)-iV-(2-piperidin-4- ylethyl)-2-(rrifluoromethyl)benzenesulfonamide and 3-(tertbutoxycarbonyl)-phenylboronic acid were used to prepare 3-{4-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidin-l-yl}benzoic acid. MS (ES+) m/z 597.1;
HPLC purity 97.4% at 210-370 nm, 10.0 min.; Xterra RPl 8, 3.5u, 15O x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C27H27F3N2O6S2 + H+, 597.13354; found (ESI, [M+HJ+), 597.1345.
Example 958: N-{l-[(6-chloropyridin-3-yl)carbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1185] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 6-chloronicotinyl chloride were used to prepare N- {I- [(6-chloropyridin-3-yl)carbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide.
MS (ES) m/z 588.0;
HPLC purity 100% at 210-370 nm, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 959: AL(/rα«5-4-aminocyclohexyI)-5-(phenyIsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1186] In an analogous manner to example 930, tert-butyl [trans-4-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexyl] carbamate was used to prepare iV-(trαrø-4-aminocyclohexyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 463.1;
HPLC purity 100% at 210-370 nm, 8.3 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Bicarb Buff. Ph=9.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C19H21F3N2O4S2 + H+, 463.09676; found (ESI, [M+H]+), 463.0959.
Example 960: JV-[2-(4-bromophenyl)ethyl]-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1187] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 2-(4-bromophenyl)ethylamine were used to prepare iV-[2-(4- bromophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 546.0;
HPLC purity 100% at 210-370 nm, 10.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 961: ^rt-butyliV-methyI-iV-[2-({[5-(plienylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-β-alaninate
[1188] To a stirred suspension of iV-[2-(methylamino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride (0.13 g, 0.28 mmol) from Example 799 in EtOH (8.9 mL) was added fert-butyl acrylate (0.14 mL, 0.13 g, 0.97 mmol) and diisopropylethylamine (59 μL, 44 mg, 0.34 mmol). The mixture was stirred 6 h at 760C under N2. The solvent was evaporated and the residue was partitioned with water and CH2Cl2. The organic layer was washed with water. The solvent was evaporated. The residue was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to give
0.10 g (64%) of tert-butyl N-methyl-N-[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfony 1} amino)ethyl]- β -alaninate .
MS (ESI+) m/z 551;
HRMS: calcd for C23H29F3N2O6S2 + H+, 551.14919; found (ESI, [M+H]+), 551.1503.
Example 962: ter^butylN-methyl-iV-[2-({[5-(phenylsuIfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycinate
[1189] In an analogous manner to Example 906, iV-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and tert-butyl bromoacetate were used to prepare tert-butyl N-methyl-iV-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycinate. MS (ES-) m/z 534.8; HRMS: calcd for C22H27F3N2O6S2 + H+, 537.13354; found (ESI, [M+H]+), 537.1312.
Example 963: 3-[({4-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]phenyl}amino)sulfonyl]benzoic acid
[1190] In an analogous manner to example 462, N-(4-aminobenzyl)-5-(phenylsulfonyl)- 2-(trifluoromethyl)benzenesulfonamide and and 3-(chlorosulfonyl)benzoic acid were used to prepare 3-[({4-[({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)methyl]phenyl}amino)sulfonyl]benzoic acid. HPLC purity 86.4% at 210-370 nm, 7.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C27H21F3N2O8S3 + H+, 655.04849; found (ESI, [MH-H]+), 655.0472.
Example 964: N-(4-bromobenzyl)-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1191] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 4-bromobenzyl amine were used to prepare 7V-(4-bromobenzyl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 531.6;
HPLC purity 97.6% at 210-370 nm, 10.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HPLC purity 97.6% at 210-370 nm, 10.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 965: tert-butyl 4-{2-oxo-2-[4-({[5-(phenylsuIfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]ethyl}piperidine-l-carboxylate
[1192] In an analogous manner to example 915, 5-(phenylsulfonyl)-JV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and l-BOC-piperidin-4-ylacetic acid were used to prepare tert-butyl 4-{2-oxo-2-[4-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfony 1} amino)piperidin- 1 -yl] ethyl }piperidine- 1 -carboxylate . HPLC purity 97.7% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C30H38F3N3O7S2 + H+, 674.21760; found (ESI, [M+H]+), 674.2167.
Example 966: Λr-[2-(4-cyanophenyl)ethyI]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1193] In an analogous manner to example 376, N-[2-(4-bromophenyl)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide was used to prepare N-[2-(4- cyanophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. HPLC purity 100% at 210-370 nm, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H17F3N2O4S2 + H+, 495.06546; found (ESI, [M+H]+), 495.0669.
Example 967: 3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid
[1194] In an analogous manner to Example 952:
Methyl 3-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate (example 945) and 50% sodium hydroxide were used to prepare 3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxy lie acid. HPLC purity 98.5% at 210-370 nm, 8.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H20F3NO6S2 + H+, 492.07569; found (ESI, [M+H]+), 492.075.
Example 968: 4-({[5-(phenylsuIfonyl)-2-
(trifluoromethyl)phenyl] sulfonyl} amino)cyclohexanecarboxylic acid
[1195] In an analogous manner to Example 952:
Methyl 4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl] sulfonyl }amino)cyclohexanecarboxy late (example 946) and 50% sodium hydroxide were used to prepare 4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl }amino)cyclohexanecarboxy lie acid. HPLC purity 90.5% at 210-370 nm, 8.9 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C20H20F3NO6S2 + H+, 492.07569; found (ESI, [M+H]+), 492.0756.
Example 969: #γms-4-[({[5-(phenyIsulfonyl)-2-
(trifluoromethyl)phenyl] sulfonyl} amino)methyl] cyclohexanecarboxylic acid
[1196] In an analogous manner to Example 952:
HPLC purity 98.4% at 210-370 nm, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H22F3NO6S2 + H+, 506.09134; found (ESI5 [M+H]+), 506.089.
Example 970: 5-(phenylsulfonyl)-iV-[l-(piperidin-4-ylacetyl)piperidm-4-yl]-2- (trifluoromethyl)benzenesulfonamide
[1197] In an analogous manner to example 930, tert-butyl 4-{2-oxo-2-[4-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]ethyl}piperidine-l- carboxylate was used to prepare 5-(phenylsulfonyl)-iV-[l-(piperidin-4-ylacetyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 573.9;
HPLC purity 98.0% at 210-370 nm, 7.3 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H30F3N3O5S2 + H+, 574.16517; found (ESI, [M+H]+), 574.1636. Example 971 : N-(3-{methyl[(piperidm-4-ylammo)carbonyl]amino}propyl)-5- (phenyIsulfonyl)-2-(trifluoromethyI)benzenesuIfonamide
[1198] Tert-butyl 4-[({methyl[3-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfonyl} amino)propyl] amino } carbonyl)amino]piperidine- 1 -carboxylate (156.3 mg, 0.23 mmol) prepared in example 955 was taken up in 25 ml of hydrochloric saturated ethyl acetate. The hydrochloric salt of the title compound N-(3-{methyl[(piperidin-4- ylamino)carbonyl]amino}propyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (134.4 mg, 97%) crashed out of solution as a white solid. MS (ES+) m/z 562.9;
HPLC purity 98.4% at 210-370 urn, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H29F3N4O5S2 + H+, 563.16042; found (ESI, [M+H]+), 563.1581.
Example 972: 4-[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]benzoic acid
[1199] In an analogous manner to example 891, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 4-(tertbutoxycarbonyl)-phenylboronic acid were used to prepare 4-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]benzoic acid. HRMS: calcd for C25H23F3N2O6S2 + H+, 569.10224; found (ESI, [M+H]+), 569.0995.
Example 973: methyl 4-[2-({[5-(phenylsulfonyI)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzoate
[1200] Step 1 : Following the same procedure described on example 938, 4-(2- aminoethyl)benzoic acid was used to prepare 4-(2-aminoethyl)benzoic acid methyl ester.
[1201] Step 2: Following the same procedure described on example 435, 2- trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 4-(2-aminoethyl)benzoic acid methyl ester were used to prepare methyl 4-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzoate. W
- 363 -
HPLC purity 92.4% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H20F3NO6S2 + H+, 528.07569; found (ESI, [M+H]+), 528.0778.
Example 974: tert-butyl 4-({methyl[3-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)propyl]amino}carbonyl)piperazine-l-carboxylate
[1202] In an analogous manner to example 955, tert-butyl methyl[3-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)propyl]carbamate (149.5 mg, 0.32mmol) prepare in example 927 and tert-butyl 4-(lH-imidazole-l-carboxamido)piperidine-l- carboxylate (78.1 mg, 0.28mmol) was used to prepare the title compound tert-butyl A- ({methyl[3-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny l]sulfonyl } amino)propyl] amino } carbony l)piρerazine- 1 -carboxylate (161.3 mg, 89%) as a white solid.
HPLC purity 96.8% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=θ.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C27H35F3N4O7S2 + H+, 649.19720; found (ESI, [M+H]+), 649.1952.
Example 975: N-methyI-N-[3-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)propyl]piperazine-l-carboxamide
[1203] Tert-butyl 4-({methyl[3-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)propyl]amino}carbonyl)piperazine-l-carboxylate (133.1 mg, 0.2mmol) prepared in example 974 was taken up in 25 ml of hydrochloric saturated ethyl acetate. The hydrochloric salt of the title compound N-methyl-N-[3-({[5-(phenylsulfonyl)- 2-(trifluoromethyl)phenyl]sulfonyl}amino)propyl]piperazine-l-carboxamide (118.7 mg, 98%) crashed out of solution as a yellow oil. MS (ES+) m/z 549.0;
HPLC purity 98.2% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Bicarb Buff. Ph=9.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H27F3N4O5S2 + H+, 549.14477; found (ESI, [M+H]+), 549.1434.
Example 976: 4'-[({[5-(phenyIsulfonyl)-2- (trifluoromethyI)phenyl]suIfonyl}amino)methyl]biphenyl-3-carboxyIic acid [1204] Step 1 : To a stirred solution of N-(4-bromobenzyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (0.15 g, 0.28 mmol) in glyme (3.5 mL) was added 3-(tert- butoxycarbonylphenyl) boronic acid (0.094 g, 0.42 mmol), Pd(PPh3)4 (0.03 g, 0.03 mmol), and sodium carbonate (0.09 g, 0.84 mmol) predissolved in water (0.6 mL). The resulting solution was heated to reflux for 2.5hr, allowed to cool and extracted several times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and concentrated. Flash column separation using 0%-30% ethyl acetate/hexane gradient gave 4'-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-3-carboxylic acid tert-butyl ester.
[1205] Step 2: In an analogous manner to example 930, 4'-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-3-carboxylic acid tert-butyl ester was used to prepare 4'-[({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-3-carboxy lie acid. MS (ES-) m/z 573.9;
HPLC purity 100% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C27H20F3NO6S2 + H+, 576.07569; found (ESI, [M+H]+), 576.0751.
Example 977: Λ^-{l-[(2,5-dichloropyridin-3-yl)carbonyl]piperidin-4-yl}-5-(phenyIsulfonyl)- 2-(trifluoromethyl)benzenesulfonamide
[1206] In an analogous manner to example 435, 5-(phenylsulfonyl)-JV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2,5-dichloropyridine-3-carbonyl chloride were used to prepare N-{\ -[(2,5-dichloropyridin-3-yl)carbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 621.9;
HPLC purity 96.3% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H20Cl2F3N3O5S2 + H+, 622.02463; found (ESI, [M+H]+), 622.0225.
Example 978: Λr-[l-(2-chloroisonicotinoyI)piperidin-4-yI]-5-(phenylsuIfonyI)-2- (trifluoromethyl)benzenesulfonamide
[1207] In an analogous manner to example 435, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-chloropyridine-4-carbonyl chloride were used to W 2
- 365 -
prepare N-[l-(2-chloroisonicotinoyl)ρiperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide.
MS (ES+) m/z 588.0;
HPLC purity 97.7% at 210-370 run, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C24H21ClF3N3O5S2 + H+, 588.06360; found (ESI, [M+H]+), 588.0627.
Example 979: 4'-[({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]suIfonyl}amino)methyl]biphenyl-4-carboxylic acid [1208] In an analogous manner to example 976, iV-(4-bromobenzyl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide and 4-(tert-butoxycarbonylphenyl) boronic acid were used to prepare 4'-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-4-carboxylic acid. MS (ES-) m/z 573.9;
HPLC purity 100% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 980: 4-{4-[({methyl[2-({[5-(phenyIsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidin-l-yl}-4- oxobutanoic acid
[1209] In an analogous manner to Example 897, N-(2-{niethyl[(piperidin-4- ylamino)carbonyl]amino}ethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 881 and succinic anhydride were used to prepare crude product which was recrystallized from ethyl acetate/ethanol to give 4-{4-[({methyl[2-({[5- (phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidin-l-yl}-4- oxobutanoic acid. MS (ES+) m/z 649.0; HRMS: calcd for C26H31F3N4O8S2 + H+, 649.16082; found (ESI5 [MfH]+), 649.1613.
Example 981: 7V-methyl-iV-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycine [1210] To a solution of tert-butyl N-methyl-N-[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycinate (87.9 mg, 0.164 mmol) from Example 962 in EtOAc (0.3 mL) was added EtOAc saturated with HCl (0.5 mL). The solution stood for 3 days and was then concentrated. ΝMR showed the reaction was incomplete. The mixture was dissolved in EtOAc saturated with HCl. The solution stood for 3 days and the solvent was removed by pipette. The solid was washed with EtOAc and dried to give 70.9 mg (90%) of N- methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]glycine hydrochloride. MS (ES-) m/z 478.9; HRMS: calcd for C18H19F3N2O6S2 + H+, 481.07094; found (ESI, [M+H]+)5 481.0704.
Example 982: iV-methyl-iV-[2-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]- β-alanine
[1211] In an analogous manner to example 981 , tert-butyl N-methyl-N-[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]- β-alaninate (99 mg, 0.18 mg) from Example 961 was dissolved in EtOAc (0.5 mL) saturated with HCl. After 3 days the solvent was removed by pipette. The solid was washed with EtOAc and dried to give 72 mg (81 %) of N-methyl-N-[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]- β-alanine hydrochloride. MS (ES+) m/z 495.0; HRMS: calcd for C19H21F3N2O6S2 + H+, 495.08659; found (ESI, [M+H]+)5 495.088.
Example 983: 4-(bromomethyl)-iV-methyl-iV-[2-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide
[1212] In an analogous manner to Example 833, N-[2-(methylamino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and 4-bromomethyl benzoyl bromide were reacted as described in the example. After 2.5 hours the reaction mixture was washed once with water. It was loaded directly onto a silica gel column and eluted with a gradient of hexane and ethyl acetate to give 4-(bromomethyl)-N-methyl-N-[2-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide. MS (ES+) m/z 618.9; HRMS: calcd for C24H22BrF3N2O5S2 + H+, 619.01783; found (ESI5 [M+H]+), 619.0162. W 2
- 367 -
Example 984: 5-(phenylsulfonyI)-iV-{2-[4-(2iy-tetrazoI-5-yl)phenyl]ethyl}-2- (trifluoromethyl)benzenesulfonamide
[1213] In an analogous manner to example 863, N-[2-(4-cyanophenyl)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide was used to prepare 5- (phenylsulfonyl)-iV-{2-[4-(2/f-tetrazol-5-yl)phenyl]ethyl}-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 538.0;
HPLC purity 95.7% at 210-370 nm, 8.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HEMS: calcd for C22H18F3N5O4S2 + H+, 538.08251; found (ESI, [M+H]+), 538.0812.
Example 985: iV-{l-[(3-cyanophenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyI)-2- (trifluoromethyl)benzenesulfonamide
[1214] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-piρeridin-4-yl~2- (trifluoromethyl)benzenesulfonamide and 3-cyanobenzenesulfonyl chloride were used to prepare 7V-{l-[(3-cyanophenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 613.9;
HPLC purity 98.4% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 986: iV-[l-(3-cyanophenyl)piperidm-4-yI]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1215] Step 1 : A solution of 4-aminopiperidine (0.50 g, 5.0 mmol) and 3- fluorobenzonitrile (0.60 g, 5.0 mmol) in dimethylacetamide (5 mL) was heated 200°C in a microwave for 20 minutes and partitioned between sodium bicarbonate solution (sat) and ethyl acetate. The organic layer was washed several times with water and concentrated. Flash column separation using 0%-10% methanol/methylene chloride gradient gave 3-(4-aminopiperidin-l-yl)- benzonitrile.
[1216] Step 2: In an analogous manner to example 435, 2-trifluoromethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and 3-(4-aminopiperidin-l-yl)-benzonitrile were used to prepare N-[l-(3-cyanophenyl)piperidm-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide .
HRMS: calcd for C25H22F3N3O4S2 + H+, 550.10766; found (ESI, [M+H]+), 550.1066; HPLC purity 100% at 210-370 nm, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 987: iV-(2-{4-[(methylsulfonyl)amino]phenyl}ethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1217] In an analogous manner to example 435, iV-[2-(4-aminophenyl)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide and methane sulfonyl chloride were used to prepare N-(2-{4-[(methylsulfonyl)amino]ρhenyl}ethyl)-5-(ρhenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide.
HRMS: calcd for C22H21F3N2O6S3 + H+, 563.05866; found (ESI, [M+H]+), 563.0579; HPLC purity 92.4% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 988: tert-butyl [3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)propyl]carbamate
[1218] In an analogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride (768.9mg, 2mmol) and tert-Butyl JV-(3- aminopropyl)carbamate (525 μL, 3mmol) was used to prepare the title compound tert-butyl [3- ({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)propyl]carbamate (1.0331 g 99%) as a white foam. MS (ES-) m/z 521.0;
HPLC purity 98.2% at 210-370 nm, 9.6 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H25F3N2O6S2 + H+, 523.11789; found (ESI, [M+H-tboc]+), 467.0599.
Example 989: tert-bntyl 4-[methyl({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l- carboxylate [1219] Step 1 : In an analogous manner to Example 866, Step I3 N3N'- carbonyldiimidazole and 4-N-methylamino-l-BOC-piperidine were used to prepare the intermediate tert-butyl 4-[( lH-imidazol- 1 -ylcarbonyl)(methyl)amino]piperidine- 1 -carboxylate.
[1220] Step 2: In an analogous manner to Example 887, Step 2, iV-[2- (methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)beiτzenesulfonamide hydrochloride from Example 799 and tert-butyl 4-[(lH-imidazol-l-ylcarbonyl)(methyl)amino]piperidine-l- carboxylate were used to prepare tert-butyl 4-[methyl({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l-carboxylate. MS (ES-) m/z 661.1; HRMS: calcd for C28H37F3N4O7S2 + H+, 663.21285; found (ESI, [M+H]+), 663.2126.
Example 990: tert-butyl (3i?)-3-[({methyl[2-({[5-(phenylsuIfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]pyrrolidine-l- carboxylate
[1221] Step 1 :In an analogous manner to Example 866, Step 1, N3N'- carbonyldiimidazole and (i?)-N-BOC-3-aminopyrrolidine were used to prepare the intermediate tert-butyl (3i?)-3-[(lϋT-imidazol- 1 -ylcarbonyl)amino]pyrrolidine- 1 -carboxylate.
[1222] Step 2: In an analogous manner to Example 866, Step 2, N-[2-
(methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and tert-butyl (3i?)-3-[(li-r-imidazol-l-ylcarbonyl)amino]pyrrolidine-l- carboxylate were used to prepare tert-butyl (3i?)-3-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)ethyl]amino} carbonyl)amino]pyrrolidine- 1 -carboxylate. MS (ES-) m/z 633.0; HRMS: calcd for C26H33F3N4O7S2 + H+3 635.18155; found (ESI3 [M+H]+)3 635.1808.
Example 991 : N-(5-methoxy-2,3-dihy dro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1223] In an analogous manner to example 765, 5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonyl chloride (709.4 mg, l.Smmol) and 5-methoxy-2,3-dihydro-lH- inden-2-amine (361.1 mg, 2.2mmol) was used to prepare the title compound N-(5-methoxy-2,3- dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (723.5 mg, 77%) as a yellow solid. MS (ESI+) m/z 512;
HPLC purity 99.2% at 210-370 ran, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H20F3NO5S2 + H+, 512.08077; found (ESI, [M+H]+), 512.0795.
Example 992: 4-{methyl[3-({[5-(phenyIsuIfonyl)-2-
(trifluoromethyI)phenyI]sulfonyl}amino)propyl]amino}-4-oxobutanoic acid [1224] A mixture of N-[3-(methylamino)propyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (150.9 mg, 0.32 mmol) prepared example 929 in toluene (10 ml). Succinic anhydride (44.2 mg, 0.44 mmol) and 2 eq. of N,N-Diisoprpylethylamine was syringed into the reaction flask and was allowed to stir overnight at room temperature. The product was transferred onto a 12 g Isco RediSep® Normal Phase column and was purified by automated flash chromatography using a gradient of 20% to 100% hexane/ethyl acetate. Isolation of the main component gave the title compound of 4-{methyl[3-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)propyl]amino}-4-oxobutanoic acid (121.3 mg, 71%) as an amorphous solid. MS (ES+) m/z 536.9;
HPLC purity 93.3% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C2IH23F3N2O7S2 + H+, 537.09715; found (ESI, [M+H]+), 537.0928.
Example 993: N-(3-aminopropyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1225] Tert-butyl [3-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)propyl]carbamate (800 mg, 1.53 mmol) prepared in example 988 was taken up in 25 ml of hydrochloric saturated ethyl acetate. The hydrochloric salt of the title compound N-(3-aminopropyl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide (697.3 mg, 99%) crashed out of solution as a white solid. MS (ES+) m/z 423.0;
HPLC purity 100% at 210-370 nm, 6.6 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C16HnF3N2O4S2 + H+, 423.06546; found (ESI, [M+H]+), 423.0655. Example 994: iV-(3-bromobenzyl)-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1226] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 3-bromobenzylamine were used to prepare iV-(3-bromobenzyl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 531.8;
HPLC purity 98.0% at 210-370 nm, 10.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 995: 5-(phenylsulfonyl)-Λ'-(l-{[3-(2Jfir-tetrazoI-5-yI)phenyl]sulfonyl}piperidin-4- yl)-2-(trifluoromethyl)benzenesulfonamide
[1227] In an analogous manner to example 863, 7V-{l-[(3- cyanophenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide was used to prepare 5-(phenylsulfonyl)-N-(l-{[3-(2H- tetrazol-5-yl)phenyl]sulfonyl}piperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 657.0;
HPLC purity 93.4% at 210-370 nm, 8.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min.
Example 996: 3'-[({[5-(phenylsulfonyl)-2-
(trifluoromethy l)phenyl] sulfonyl} amino)methyl] biphenyl-3-carboxylic acid
[1228] In an analogous manner to example 976, N-(3-bromobenzyl)-5- (pheny lsulfonyl)-2-(trifluoromethy l)benzenesulfonamide and 3 -(tert-butoxy carbonylphenyl) boronic acid were used to prepare 3'-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-3-carboxy lie acid. MS (ES-) m/z 573.9;
HPLC purity 100% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: caled for C27H20F3NO6S2 + H+, 576.07569; found (ESI, [M+H]+), 576.0735. Example 997: 3'~[({[5-(phenylsulfonyI)-2-
(trifluoromethyl)phenyl] sulfonyl} amino)methyl] biphenyl-4-carboxyIic acid
[1229] In an analogous manner to example 976, N-(3-bromobenzyl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide and 4-(tert-butoxycarbonylphenyl) boronic acid were used to prepare 3'-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-4-carboxy lie acid. MS (ES-) m/z 573.9;
HPLC purity 100% at 210-370 nm, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: caled for C27H20F3NO6S2 + H+, 576.07569; found (ESI, [M+H]+), 576.076.
Example 998: iV-[2-(4-{[amino(immo)methyl]amino}phenyl)ethyl]-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1230] A mixture of iV-[2-(4-aminoρhenyl)ethyl]-5-(ρhenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (0.12 g, 0.25 mmol) and 3,5-dimethylpyrazole-l- carboxamidine nitrate (0.05 g, 0.25 mmol) were heated neat at 170°C for lOminutes. The resulting mixture was allowed to cool and flash column separation using 0%-10% methanol/methylene chloride gradient gave iV-[2-(4- {[amino(imino)methyl]amino}phenyl)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. (0.036 g, 28%). MS (ES+) m/z 527.0;
HPLC purity 100% at 210-370 nm, 7.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H2]F3N4O4S2 + H+, 527.10291; found (ESI, [M+H]+), 527.1037.
Example 999: 5-[(4-methoxyphenyI)sulfonyl]-iV-piperidm-4-yl-2- (trifluoromethyl)benzenesulfonamide
[1231] Step 1 : In an analogous manner to example 820, 2-trifluoromethyl-5-(4- methoxyphenylsulfonyl)-benzenesulfonyl chloride and 4-aminopiperidine-l- carboxylic acid fert-butyl ester were used to prepare tert-bntyl 4-({[5-(4-methoxyphenylsulfonyl)-2- (trifluoromethyl)pheny 1] sulfonyl } amino)piperidine- 1 -carboxy late . [1232] Step 2: In an analogous manner to example 930, tert-bntyl 4-({[5-(4- methoxyphenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate was used to prepare 5-[(4-methoxyphenyl)sulfonyl]-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 479.0;
HPLC purity 95.9% at 210-370 nm, 7.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1000: Λ'-[l-(iV-methylgIycyI)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1233] Step 1 : In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin- 4-yl-2-(trifluoromethyl)benzenesulfonamide and chloroacetyl chloride were used to prepare N- [l-(chloroacetyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide.
[1234] Step 2: To a stirred solution of N-[l-(chloroacetyl)piperidin-4-yl]-5- (phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (0.08 g, 0.15 mmol) in THF (1 mL) was added 33% methylamine in ethanol (0.1 mL) and the resulting solution was stirred overnight at room temperature. The mixture was concentrated and flash column separation using 0%-10% methanol/methylene chloride gradient gave N-[l-(iV-methylglycyl)piperidin-4-yl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. (0.05 g, 61%). MS (ES+) m/z 520.0;
HPLC purity 100% at 210-370 nm, 6.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H24F3N3O5S2 + H+, 520.11822; found (ESI, [M+H]+), 520.1174.
Example 1001 : 5-(phenylsuIfonyl)-iV-[l-(pyrrolidm-l-yIacetyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide
[1235] In an analogous manner to example 1000, N-[l-(chloroacetyl)piperidin-4-yl]-5- (phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide and pyrrolidine were used to prepare 5-(phenylsulfonyl)-iV-[l-(pyrrolidin-l-ylacetyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 560.0; HPLC purity 100% at 210-370 nm, 7.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1002: AL[l-(morpholin-4-ylacetyl)piperidin-4-yI]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1236] In an analogous manner to example 1000, N-[I -(chloroacetyl)piperidin-4-yl]-5- (phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide and morpholine were used to prepare iV-[l-(morpholin-4-ylacetyl)pipeπdin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 576.0;
HPLC purity 100% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H28F3N3O6S2 + H+, 576.14444; found (ESI, [M+H]+), 576.1428.
Example 1003: 2-[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]propanamide
[1237] In an analogous manner to example 880, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-bromopropionamide were used to prepare 2-[4-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]propanamide. MS (ES+) m/z 520.0;
HPLC purity 100% at 210-370 nm, 6.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H24F3N3O5S2 + H+, 520.11822; found (ESI, [M+H]+), 520.1199.
Example 1004: N-(5-hydroxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluorometliyl)benzenesulfonamide
[1238] To a flame dried flask N-(5-methoxy-2,3-dihydro-lH-inden-2-yl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (262.3 mg, 0.51 mmol) was taken up in 5 ml of dichloromethane and cooled to -78° C. 1.0M Boron tribromide (3 ml, 3 mmol) in dichloromethane was syringed into the flask and then was allowed to warm to room temperature. The reaction was quenched with water, partioned between dichloromethane, dried with magnesium sulfate, and the solvent was removed under reduced pressure. The product was transferred onto a 4 g Isco RediSep® Normal Phase column and was purified by automated flash chromatography using a gradient of 20% to 100% hexane/ethyl acetate. Isolation of the main component gave the title compound N-(5-hydroxy-2,3-dihydro-lH-inden-2~yl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (232.9 nig, 91%) as a white solid. MS (ES+) m/z 497.9;
[1239] HPLC purity 100% at 210-370 run, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. FOIΌI. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H18F3NO5S2 + H+, 498.06512; found (ESI, [M+HJ+), 498.0631.
Example 1005 : 5-(pheny lsulf onyl)-iV- [1 -(piperazin-1 -ylacety l)piperidin-4-yl] -2- (trifluoromethyl)benzenesulfonamide
[1240] Step 1 : In an analogous manner to example 1000, N-[l-(chloroacetyl)piperidin- 4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide and piperazine-1-carboxylic acid tert-butyl ester were used to prepare 5-(phenylsulfony I)-N- [l-(piperazin-l-y lacetyl-4-tert- butylcarboxylate)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonamide.
[1241] Step 2: In an analogous manner to example 930, 5-(phenylsulfonyl)-N-[l- (piperazin- 1 -ylacetyl-4-ter/-butylcarboxylate)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide was used to prepare 5-(phenylsulfonyl)-N-[l-(piperazin-l- ylacetyl)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 572.9;
HPLC purity 100% at 210-370 nm, 7.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min.
Example 1006: dimethyl [4-({methyl[2-({[5-(phenylsuIfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)benzyl]phosphonate [1242] A solution of 4-(bromomethyl)-N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide (0.311 g, 0.503 mmol) from Example 983 in trimethylphosphite (2.0 mL) was stirred at HO0C for 6 h. The mixture was partitioned with 2Ν HCl and EtOAc. The organic layer was washed with water and loaded directly onto a silica gel column and eluted with a gradient Of CH2Cl2 and CH3OH to give 86.1 mg (26%) of dimethyl [4-( {methyl [2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)pheny 1] sulfonyl } amino)ethyl] amino } carbony l)benzy l]phosphonate . MS (ES+) m/z 649.0;
HRMS: calcd for C26H28F3N2O8PS2 + H+, 649.10496; found (ESI, [M+H]+), 649.1035.
Example 1007: iV-[2-(methyI{[methyl(piperidm-4-yl)amino]carbonyl}amino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesuIfonamide
[1243] In an analogous manner to Example 937, tert-buty\ 4-[methyl({methyl[2-({[5- (phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl} amino)ethyl] amino } carbonyl)amino]piperidine- 1 -carboxylate from Example 989 was treated in EtOAc with HCl to give iV-[2-(methyl{[methyl(piperidin-4- yl)amino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride. MS (ES+) m/z 563.2; HRMS: calcd for C23H29F3N4O5S2 + H+, 563.16042; found (ESI, [M+H]+), 563.1605.
Example 1008 : N- [2-(methy I { [(3i?)-py rrolidin-3-ylamino] carbonyl} amino)ethyl] -5- (phenyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide
[1244] In an analogous manner to Example 937, fert-butyl (3iζ)-3-[({methyl[2-({ [5- (phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]pyrrolidine-l-carboxylate from Example 990 was treated in EtOAc with HCl. The solvent was removed by pipette from the solid that formed. The solid was washed with EtOAc and dried to give N-[2-(methyl{[(3i?)- pyrrolidin-3-ylamino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide hydrochloride. MS (ES+) m/z 535.1; HRMS: calcd for C21H25F3N4O5S2 + H+, 535.12912; found (ESI, [M+H]+), 535.129.
Example 1009: tert-bniyl (3R)-3~ [({methyl [2-({[5-(pheny Isulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidme-l- carboxylate
[1245] Step 1 : In an analogous manner to Example 866, Stepl, N,N'- carbonyldiimidazole and (R)-l-BOC-3-amino-piperidine were used to prepare the intermediate tert-buty 1 (3i?)-3 - [( 1 /f-imidazol- 1 -ylcarbony l)amino]piperidine- 1 -carboxylate. [1246] Step 2: In an analogous manner to Example 866, Step2, JV-[2- (methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and tert-butyl (3i?)-3-[(lH"-imidazol-l-ylcarbonyl)amino]piperidine-l- carboxylate were used to prepare tert-butyl (3i?)-3-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l-carboxylate. MS (ES-) m/z 647.2; HRMS: calcd for C27H35F3N4O7S2 + H+, 649.19720; found (ESI, [M+H]+), 649.1984.
Example 1010: tert-bntyl (3S)-3-[({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l- carboxylate
[1247] Step 1 : In an analogous manner to Example 866, Stepl, N,N'- carbonyldiimidazole and (S)-l-BOC-3-amino-piperidine were used to prepare the intermediate ter/-butyl (3S)-3 - [( 1 H-imidazol- 1 -y lcarbonyl)amino]piperidine- 1 -carboxylate.
[1248] Step 2: In an analogous manner to Example 866, Step2, N-[2-
(methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 799 and tøf-butyl (36)-3-[(l/f-imidazol-l-ylcarbonyl)amino]piperidine-l- carboxylate were used to prepare tert-butyl (3.S)-3-[({methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l-carboxylate. MS (ES+) m/z 649.2; HRMS: calcd for C27H35F3N4O7S2 + H+, 649.19720; found (ESI, [M+H]+), 649.1954.
Example 1011: tert-butyl (25)-2-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidm-l-yl]carbonyl}pyrrolidine-l-carboxylate [1249] In an analogous manner to example 915, N-(fer/~butoxycarbonyl)-L-proline and 5-(phenylsulfonyl)-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide were used to prepare tert-butyl (2<S)-2-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l -carboxylate . MS (ES-) m/z 644.2;
HPLC purity 100% at 210-370 nm, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. HRMS: calcd for C28H34F3N3O7S2 + H+, 646.18630; found (ESI, [M+H]+), 646.188. Example 1012: 5-(phenylsulfonyl)-iV-(l-L-prolylpiperidin-4-yl)-2- (trifluoromethyl)benzenesulfonamide
[1250] In an analogous manner to example 930, tert-butyl (2S)-2-{ [4-({ [5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin- 1 -yl]carbonyl}pyrrolidine- 1-carboxylate was used to prepare 5-(phenylsulfonyl)-N-(l-L-prolylpiperidin-4-yl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 546.1;
HPLC purity 100% at 210-370 nm, 7.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H26F3N3O5S2 + H+, 546.13387; found (ESI, [M+H]+), 546.1358.
Example 1013: JV-(*ra«s-4-hydroxycyclohexyI)-5-(phenylsulfonyI)-2- (trifluoromethyl)benzenesulfonamide
[1251] In an analogous manner to example 654, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and trans-4-aminocyclohexanol were used to prepare N-(trans-4- hydroxycyclohexyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 462.1;
HPLC purity 93.3% at 210-370 nm, 8.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1014: tert-hntyl (2R)-2-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxylate
[1252] In an analogous manner to example 915, N-(tert-butoxycarbonyl)-D-proline and 5-(phenylsulfonyl)-iV-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide were used to prepare tert-butyl (2i?)-2-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl] sulfonyl} amino)piperidin- 1 -yl]carbonyl}pyrrolidine- 1 -carboxylate. MS (ES-) m/z 644.2;
HPLC purity 100% at 210-370 nm, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C28H34F3N3O7S2 + H+, 646.18630; found (ESI, [M+H]+), 646.1856. Example 1015: 5-(phenyIsuIfonyl)-iV-(l-D-prolyIpiperidin-4-yl)-2- (trifluoromethyl)benzenesulfonamide
[1253] In an analogous manner to example 930, tert-butyl (2i?)-2-{[4-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine- 1-carboxylate was used to prepare 5-(phenylsulfonyl)-N-(l-D-prolylpiperidin-4-yl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 546.1;
HPLC purity 97.7% at 210-370 ran, 7.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H26F3N3O5S2 + H+, 546.13387; found (ESI, [M+H]*), 546.1329.
Example 1016: iV-[4-(dimethyIamino)benzyI]-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1254] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 4-dimethylaminobenzylamine were used to prepare iV-[4-(dimethylamino)benzyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 498.9;
HPLC purity 97.6% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C22H21F3N2O4S2 + H+, 499.09676; found (ESI, [M+H]+), 499.0995.
Example 1017: 5-(phenyIsulfonyl)-iV-{l - [(6-py rrolidin-1 -ylpy ridin-3-yI)carbonyl] piperidin- 4-yl}-2-(trifluoromethyl)benzenesulfonamide
[1255] Step 1 : In an analogous manner to example 435, piperidin-4-yl-carbamic acid tert-butyl ester and 2-chloropyridine-5-carbonyl chloride were used to prepare [l-(6-Chloro- pyridine-3-carbonyl)-piperidin-4-yl]-carbamic acid tert-butyl ester.
[1256] Step 2: To a stirred solution of [l-(6-Chloro-pyridine-3-carbonyl)-piperidin-4- yl]-carbamic acid tert-butyl ester (0.50 g, 1.47 mmol) in THF (1 mL) was added pyrrolidine (0.5 mL, 6.0 mmol) and the resulting solution was 160°C in a microwave for 30 minutes and concentrated. Flash column separation using 0%-5% methanol/methylene chloride gradient gave [l-(6-Pyrrolidin-l-yl-pyridine-3-carbonyl)-piperidin-4-yl]-carbamic acid tert-butyl ester. [1257] Step 3: In an analogous manner to example 930, [l-(6-Pyrrolidin-l-yl-pyridme- 3-carbonyl)~piperidm-4-yl]-carbamic acid tert-butyl ester was used to prepare (4-Amino- piperidin- 1 -yl)-(6-pyrrolidin- 1 -y l-pyridin-3 -yl)-methanone .
[1258] Step 4: In an analogous manner to example 435, 2-trifluoromethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and (4-Amino-piperidin-l-yl)-(6-pyrrolidin-l-yl- pyridin-3-yl)-methanone were used to prepare 5-(phenylsulfonyl)-N-{l-[(6-pyrrolidin-l- ylpyridin-3-yl)carbonyl]piperidin-4-yl}-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 623.0;
HPLC purity 92.8% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1018: iV-(l-{[6-(dimethylamino)pyridm-3-yl]carbonyl}piperidin-4-yl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide
[1259] In an analogous manner to example 1017,
Step 2: [l-(6-Chloro-pyridine-3-carbonyl)-piperidin-4-yl]-carbamic acid tert-butyl ester and dimethylamine in THF were used to prepare [l-(6-Dimethylamino-pyridine-3-carbonyl)- piperidin-4-yl]-carbamic acid tert-butyl ester.
[1260] Step 3: In an analogous manner to example 930, [l-(6-Dimethylamino-pyridine- 3-carbonyl)-piperidin-4-yl]-carbamic acid tert-butyl ester was used to prepare
(4-Amino-piperidin-l-yl)-(6-dimethylamino-pyridin-3-yl)-methanone.
[1261] Step 4: In an analogous manner to example 435, 2-trifluoromethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and (4-Amino-piperidin-l-yl)-(6-dimethylamino- pyridin-3-yl)-methanone were used to prepare N-(l-{[6-(dimethylamino)pyridin-3- yl]carbonyl}piperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 597.0;
HPLC purity 100% at 210-370 nm, 8.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1019: iV-[l-(2-morpholin-4-ylethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1262] To a stirred solution of 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (0.10 g, 0.223 mmol) in ethanol (1 niL) was added triethylamine (0.1 mL, 0.72 mmol) and 4-(2-chloroethyl)-morpholine hydrochloride (0.042 g,
0.223 mmol) and heated 12O0C in a microwave for 10 minutes and concentrated. Flash column separation using 0%-10% methanol/methylene chloride gradient gave N-[l-(2-morpholin-4- ylethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. (0.074 g,
59%).
MS (ES+) m/z 562.0;
HPLC purity 100% at 210-370 nm, 12.1 min.; XTerra MS C18, 5u, 3xl50mm column, 0.5 mL/min, FA / MeOH gradient.
HRMS: calcd for C24H30F3N3O5S2 + H+, 562.16517; found (ESI, [M+H]+), 562.1645.
Example 1020: Λr-{l-[(6-oxo-l-{[5-(phenyIsulfonyl)-2-(trifluoromethyl)phenyl]suIfonyI}-l,6- dihydropyridin-3-yl)carbonyl]piperidin-4-yl}-5-(phenylsuIfonyl)-2-
(trifluoromethyl)benzenesulfonamide
[1263] In an analogous manner to example 1017,
Step 2: [l-(6-Chloro-pyridine-3-carbonyl)-piperidin-4-yl]-carbamic acid tert-butyl ester and potassium tørtbutoxide in THF were used to prepare [l-(6-tert-Butoxy-pyridine-3-carbonyl)- piperidin-4-yl]-carbamic acid tert-butyl ester.
[1264] Step 3: In an analogous manner to example 930, [l-(6-tert-Butoxy-pyridine-3- carbonyl)-piperidin-4-yl]-carbamic acid tert-butyl ester was used to prepare
5-(4-Amino-piperidine- 1 -carbonyl)- 1 H-pyridin-2-one.
[1265] Step 4: In an analogous manner to example 435, 2-trifluorornethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and 5-(4-Amino-piperidine-l -carbonyl)- 1 H-pyridin- 2-one were used to prepare 7V-{l-[(6-oxo-l-{[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}-l,6-dihydropyridin-3-yl)carbonyl]piperidin-4-yl}-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 917.9;
HPLC purity 85.0% at 210-370 nm, 19.9 min.; XTerra MS C18, 5u, 3xl50mm column, 0.5mL/min, formic acid / MeOH gradient.
Example 1021: iV-(2,4-dimethoxybenzyI)-5-(phenylsulfbnyl)-2- (trifluoromethyl)benzenesulfonamide [1266] In an analogous manner to example 435, 2-txifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 2,4-dimethoxybenzylamine were used to prepare JV-(2,4- dimethoxybenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 513.9;
HPLC purity 100.0% at 210-370 urn, 18.7 min.; Xterra MS C18, 5u, 150 x 3.0 mm column, 0.5 mL/min, FA / MeOH grad.
Example 1022: iV-[2-(methyI{[(3i?)-piperidin-3-ylamino]carbonyl}amino)ethyl]-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesuIfonamide
[1267] In an analogous manner to Example 937, fert-butyl (3i?)-3-[({methyl[2-({[5- (phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l-carboxylate from Example 1009 was used to prepare N-[2-(methyl{[(3i?)-piperidin-3- ylamino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride. MS (ES+) m/z 549.0; HRMS: calcd for C22H27F3N4O5S2 + H+, 549.14477; found (ESI5 [M+H]+), 549.1461.
Example 1023: iV-[2-(methyl{[(3A-»)-piperidin-3-ylammo]carbonyI}amino)ethyl]-5- (phenyIsulfonyl)-2-(trifluoromethyl)benzenesulfonamide
[1268] In an analogous manner to Example 937, fert-butyl (35)-3-[({methyl[2-({ [5- (phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l-carboxylate from Example 1010 was used to prepare N-[2-(methyl{[(35)-piperidin-3- ylamino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride. MS (ES+) m/z 549.1; HRMS: calcd for C22H27F3N4O5S2 + H+, 549.14477; found (ESI, [M+H]+), 549.1456.
Example 1024: Λ^-{l-[(6-phenylpyridin-3-yl)carbonyl]piperidin-4-yI}-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide [1269] Step 1 : In an analogous manner to example 435, ρiperidin-4-yl-carbamic acid tert-butyl ester and 2-chloropyridine-5-carbonyl chloride were used to prepare [l-(6-Chloro- pyridine-3-carbonyl)-piperidin-4-yl]-carbamic acid tert-butyl ester.
[1270] Step 2: In an analogous manner to example 976 step 1, [l-(6-Chloro-pyridine-3- carbonyl)-piperidin-4-yl]-carbamic acid tert-butyl ester and phenyl boronic acid were used to prepare tert-butyl { 1 -[(6-phenylpyridin-3-yl)carbonyl]piperidin-4-yl}cai-bamate.
[1271] Step 3: In an analogous manner to example 930, tert-butyl {l-[(6-phenylpyridin- 3 -yl)carbonyl]piperidin-4-yl} carbamate was used to prepare l-[(6-phenylpyridin-3- yl)carbony l]piperidin-4-amine .
[1272] Step 4: In an analogous manner to example 435, 2-trifluoromethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and l-[(6-ρhenylpyridin-3-yl)carbonyl]piperidm-4- amine were used to prepare N-{l-[(6-phenylpyridin-3-yl)carbonyl]piperidin-4-yl}-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 630.0;
HPLC purity 100.0% at 210-370 nm, 10.0 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C30H26F3N3O5S2 + H+, 630.13387; found (ESI, [M+H]+), 630.135.
Example 1025: Λr-{l-[(6-morphoIin-4-ylpyridin-3-yl)carbonyl]piperidin-4-yl}-5- (phenyIsulfonyI)-2-(trifluoromethyl)benzenesulfonamide
[1273] In an analogous manner to example 1017,
Step 2: [l-(6-chloro-pyridine-3-carbonyl)-piperidin-4-yl]-carbamic acid tert-butyl ester and morpholine in THF were used to prepare tert-butyl { l-[(6-morpholin-4-ylpyridin-3- yl)carbonyl]piperidin-4-yl } carbamate .
[1274] Step 3: In an analogous manner to example 930, tert-butyl {l-[(6-morpholin-4- ylpyridin-3-yl)carbonyl]piperidin-4-yl} carbamate was used to prepare l-[(6-morpholin-4-ylpyridin-3-yl)carbonyl]piperidin-4-amine.
[1275] Step 4: In an analogous manner to example 435, 2-trifluoromethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and l-[(6-morpholin-4-ylpyridin-3- yl)carbonyl]piperidin-4-amine were used to prepare N-{l-[(6-morpholm-4-ylpyridin-3- yl)carbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 639.1;
HPLC purity 98.3% at 210-370 nm, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C28H29F3N4O6S2 + H+, 639.15534; found (ESI, [M+H]+), 639.1536.
Example 1026: fert-butyl 4-[({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)carbonyl]piperidine-l-carboxylate
[1276] Step 1 : In an analogous manner to example 930, N-(2,4-dimethoxybenzyl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide and TFA were used to prepare 5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide.
[1277] Step 2: To a stirred solution of 1 -BOC-piperidine-4-carboxylic acid (0.08g, 0.34 mmol) in methylene chloride (3mL) was added DMAP (0.05 g, 0.37 mmol) and EDC (0.08g, 0.40 mmol). The resulting solution was stirred at room temperature for 20 minutes. To the mixture was added 5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (0.11 g, 0.30 mmol). The resulting solution was stirred lhr, washed with ammonium chloride solution (sat), and concentrated. Flash column separation using 0%-5% methanol/methylene chloride gradient gave tert-butyl 4-[({[5~(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)carbonyl]piperidine-l-carboxylate. (0.06 g, 34%). MS (ES-) m/z 575.0;
HPLC purity 100.0% at 210-370 nm, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1027 : N- { [5-(phenylsulf onyl)-2-(trifluoromethyl)phenyl] sulfonyl}piperidine-4- carboxamide
[1278] In an analogous manner to example 930, fert-butyl 4-[({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)carbonyl]piperidine-l-carboxylate was used to prepare iV-{[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}piperidine-4-carboxamide. MS (ES-) m/z 475.0;
HPLC purity 100.0% at 210-370 nm, 6.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C19H19F3N2O5S2 + H+, 477.07602; found (ESI, [M+H]+), 477.0748. Example 1028: methyl {[2-({[5-(phenylsulfonyl)-2-(trifluoromethyI)phenyl]sulfonyl}amino)- 2,3-dihydro-lH-inden-5-yl]oxy}acetate
[1279] In an analogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride (151.2 mg, 0.5 mmol) and methyl 2-(2-amino-2,3- dihydro-lH-inden-5-yloxy)acetate (155.3 mg, 0.6 mmol) was used to prepare the title compound methyl {[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)-2,3-dihydro-lH- inden-5-yl]oxy} acetate (176.2 mg, 62%) as a white solid. MS (ES+) m/z 569.8;
BPLC purity 97.1% at 210-370 run, 10.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C25H22F3NO7S2 + H+, 570.08625; found (ESI, [M+H]+), 570.085.
Example 1029 : 5-(phenylsulfonyl)-iV- [l-(2-pyrroIidin-l-ylisonicotinoyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide
[1280] Step 1 : In an analogous manner to example 435, piperidin-4-yl-carbamic acid fert-butyl ester and 2-chloropyridine-4-carbonyl chloride were used to prepare tert-butyl [l-(2- chloroisonicotinoyl)piperidin-4-yl]carbamate.
[1281] Step 2: In an analogous manner to example 1017 step 2, tert-butyl [l-(2- chloroisonicotinoyl)piperidin-4-yl]carbamate and pyrrolidine in THF were used to prepare tert- butyl [l-(2-pyrrolidin-l-ylisomcotinoyl)piperidin-4-yl]carbamate.
[1282] Step 3: In an analogous manner to example 930. tert-butyl [l-(2-pyrrolidin-l- ylisonicotinoyl)piperidin-4-yl]carbamate was used to prepare
1 -(2-pyrrolidin- 1 -ylisonicotinoyl)piperidin-4-amine.
[1283] Step 4: In an analogous manner to example 435, 2-trifluoromethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and l-(2-pyrrolidin-l-ylisonicotinoyl)piperidin-4- amine were used to prepare 5-(phenylsulfonyl)-N-[l-(2-pyrrolidin-l-ylisonicotinoyl)piperidin-4- yl]-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 623.1;
HPLC purity 98.5% at 210-370 nm, 8.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C28H29F3N4O5S2 + H+, 623.16042; found (ESI, [M+H]+), 623.1596. Example 1030 : N- [(6-chIoropy ridin-3-y l)m ethyl] -5-(pheny lsulf onyI)-2- (trifluoromethyl)benzenesulfonamide
[1284] In an analogous manner to example 435, 2-trifluoromethyl-5-(phenylsulfonyl)- benzenesulfonyl chloride and 5-(aminomethyl)-2-chloropyridine were used to prepare N-[(6- chloropyridin-3-yl)methyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 490.8;
HPLC purity 98.4% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C19H14ClF3N2O4S2 + H+, 491.01083; found (ESI, [M+H]+), 491.0101.
Example 1031 : {[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyI]sulfonyl}amino)-2,3- dihydro-lH-inden-5-yl]oxy}acetic acid
[1285] Methyl { [2-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)- 2,3 -dihydro-lH-inden-5-yl]oxy} acetate (125.3mg, 0.2mmol) prepare in example 1028 was taken up in 12.5 ml of a solution of 2:2:1 tetrahydrofuran:methanol:water. To the stirring solution 2N sodium hydroxide (220 μL, 0.44 mmol) was syringed into the reaction flask and allowed to stir overnight at room temperature. 2N Hydrochloric acid (230 μL, 0.46 mmol) was syringed into the reaction flask that allowed the title compound {[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)-2,3-dihydro-lH-inden-5-yl]oxy}acetic acid (117 mg, 96%) to crash out of solution as a white solid. MS (ES+) m/z 556.0;
HPLC purity 100.0% at 210-370 nm, 9.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H20F3NO7S2 + H+, 556.07060; found (ESI, [M+H]+), 556.0712.
Example 1032: 5-(phenyIsulfonyl)-Λr-[(6-pyrroIidin-l-ylpyridin-3-yl)methyI]-2- (trifluoromethyl)benzenesulfonamide
[1286] In an analogous manner to example 1017 step 2, N-[(6-chloropyridin-3- yl)methyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide and pyrrolidine were used to prepare 5-(phenylsulfonyl)-iV-[(6-pyrrolidin- 1 -ylpyridin-3-yl)methyl]-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 526.0;
HPLC purity 95.8% at 210-370 nm, 7.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1033: Λr-[(6-morpholin-4-ylpyridin-3-yI)methyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1287] In an analogous manner to example 1017 step 2, iV-[(6-chloropyridin-3- yl)methyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide and morpholine were used to prepare iV-[(6-morpliolin-4-ylpyridin-3-yl)methyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 542.0;
HPLC purity 100.0% at 210-370 nm, 8.9 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H22F3N3O5S2 + H+5 542.10257; found (ESI, [M+H]4), 542.1033.
Example 1034: 5-[(3-bromophenyl)sulfonyl]-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonainide
[1288] To a stirred solution of 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide (0.80 g, 1.78 mmol) in cone, sulfuric acid (13mL) and water (2 niL) was added NBS (0.32 g, 1.80 mmol) portionwise and the resulting solution was stirred overnight at room temperature. The solution was neutralized with aquous sodium hydroxide to pH ~8 and extracted several times with ethyl acetate. The combined organic layers were dried over magnesium sulfate and concentrated. Achiral preparative super-critical fluid chromatography using 15%methanol/85% CO2 with 0.2% dimethylethylamine gave 5-[(3- bromophenyl)sulfonyl]-iV-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide. (0.52 g, 55%). MS (ES+) m/z 526.8;
HPLC purity 100.0% at 210-370 nm, 8.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C18Hj8BrF3N2O4S2 + H+, 526.99162; found (ESI3 [M+H]+), 526.9941.
Example 1035: _V-[(lfi*, 5S*)-8-Methyl-8-azabicyclo[3.2.1]oct-3-yl]-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide [1289] A stirred solution of 5-(phenylsulfonyl)-2-(tπfluoromethyl)benzenesulfonyl chloride (0.38 g, 1.0 mmol) in 3:1 dichloromethane-acetonitrile (10 niL) was treated under nitrogen with e«(io-8-methyl-8-azabicyclo[3.2.1]octan-3-amine dihydrochloride (0.42 g, 2.0 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.52 g, 4.0 mmol). The reaction was stirred for 18 hours at room temperature. The crude product was purified by reverse phase preparative liquid chromatography on an Xterra MSCl 8, 50 x 250 mm prep column, eluting with a mixture of 60:40 water-methanol containing 0.1% formic acid at a flow rate of 100 mL/min, to afford, after concentration of the solvent and extraction with ethyl acetate (3x), an oil. The oil was crystallized from diethyl ether to afford N-[( IR*, δS^-S-meslkyl-S-εaabicycloiS.lΛjoct-S-yϊl-S- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide_(0.09 g, 20%), as a homogeneous, colorless, crystalline solid, m.p. 154-57 °C; MS (-ESI), m/z: 486.9 [M-H]";
HRMS: calcd for C21H23F3N2O4S2 + H+, 489.11241; found (ESI, [M+H]+), 489.1109; HPLC purity 99.5% at 210-370 nm, 7.2 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4 min.
Example 1036: [4-({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)phenyl] sulf ony 1} amino)ethyl] amino} carbonyl)benzyl] phosphonic acid
[1290] To a stirring solution of dimethyl [4-({methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)benzyl]phosphonate (0.282 g, 0.435 mmol) from Example 1006 in CH2Cl2 (5 mL) under N2 at room temperature was added iodotrimethylsilane (0.13 mL, 0.18 g, 0.91 mmol). The mixture was stirred 2 days. The solvent and volatile components were evaporated. The residue was dissolved in CH3OH (3 mL) and stirred overnight. Evaporation of the CH3OH gave 0.06 g (22%) of [4-({methyl[2-({[5- (phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)benzyl]phosphonic acid. MS (ES+) m/z 620.8; HRMS: calcd for C24H24F3N2O8PS2 + H+, 621.07365; found (ESI, [M+H]+), 621.0723.
Example 1037: methyl 2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyI]sulfonyI}amino)indane-5-carboxylate [1291] In an analogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride (98.3 mg, 0.33 mmol) and methyl 2-amino-2,3- dihydro-lH-indene-5-carboxylate (74.7 mg, 0.39 mmol) was used to prepare the title compound methyl 2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)indane-5-carboxylate (79.1 mg, 45%) as a white solid. MS (ES-) m/z 537.7;
HPLC purity 100.0% at 210-370 nm, 10.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C24H20F3NO6S2 + H+, 540.07569; found (ESI, [M+H]+), 540.0762.
Example 1038: (22?)-2-[4-({[5-(phenylsulfonyI)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]propanamide
[1292] In an analogous manner to example 880, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-bromopropionamide were used to prepare 2-[4-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]propanamide. This was chiral separated using column AD-H at 30% isopropyl alcohol to give (2i?)-2-[4-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]propanamide. MS (ES+) m/z 520.0;
HPLC purity 100.0% at 210-370 nm, 7.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph-3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H24F3N3O5S2 + H+, 520.11822; found (ESI, [M+H]+), 520.1199.
Example 1039: (2S)-2-[4-({[5-(phenyIsuIfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]propanamide
[1293] In an analogous manner to example 880, 5-(phenylsulfonyl)-iV-piperidm-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-bromopropionamide were used to prepare 2-[4-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]propanamide. This was chiral separated using column AD-H at 30% isopropyl alcohol to give (25)-2-[4-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin- 1 -yl]propanamide. MS (ES+) m/z 520.1;
HPLC purity 100.0% at 210-370 nm, 7.0 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C21H24F3N3O5S2 + H+, 520.11822; found (ESI, [M+H]+), 520.118.
Example 1040: iV-{l-[(6-oxo-l,6-dihydropyridin-3-yl)carbonyI]piperidin-4-yI}-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide
[1294] In an analogous manner to example 1017,
Step 2: [l-(6-Chloro-pyridine-3-carbonyl)-piperidin-4-yl]-carbamic acid fert-butyl ester and potassium tertbutoxide in THF were used to prepare [l-(6-tert-Butoxy-pyridine-3-carbonyl)- piperidin-4-yl]-carbamic acid tert-butyl ester.
[1295] Step 3: In an analogous manner to example 435, 2-trifluoromethyl-5- (phenylsulfonyl)- benzenesulfonyl chloride and 5-(4-Amino-piperidine-l-carbonyl)-lH-pyridin- 2-one were used to prepare iV-{l-[(6-fert-butoxypyridin-3-yl)carbonyl]piperidin-4-yl}-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide.
[1296] Step 4: In an analogous manner to example 930, N- { 1 -[(6-tert-butoxypyridin-3- yl)carbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide was used to prepare N- {1 -[(6-oxo- 1 ,6-dihydropyridin-3 -yl)carbonyl]piperidin-4-yl} -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 569.8;
HPLC purity 98.4% at 210-370 nm, 7.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1041: N-[l-(l-acetyl-L-prolyl)piperidm-4-yl]-5-(phenylsulfonyl)-2- (trifluoroniethyl)benzenesulfonamide
[1297] In an analogous manner to example 1026 step 2, 5-(phenylsulfonyl)-N- piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and N-aceyl-L-proline was used to prepare N-[I-(I -acetyl-L-prolyl)piperidin-4-y 1] -5-(pheny lsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 587.9;
HPLC purity 100.0% at 210-370 nm, 8.2 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1042: tert-butyl (55)-2-oxo-5-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxylate [1298] In an analogous manner to example 1026 step 2, 5-(phenylsulfony I)-N- piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 5-oxo-pyrrolidine-l ,2-dicarboxylic acid 1-tert-butyl ester were used to prepare tert-butyl (5.S)-2-oxo-5-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)piperidin- 1 -yl]carbonyl}pyiτolidine- 1 -carboxylate. MS (ES-) m/z 658.0;
HPLC purity 96.6% at 210-370 ran, 9.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Pb=3.5/ACΝ+MeOH) for lOmin, hold 4min.
Example 1043: ΛL[l-(5-oxo-L-prolyl)piperidin-4-yl]-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonainide
[1299] In an analogous manner to example 930, tert-butyl (55)-2-oxo-5-{ [4-({ [5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine- 1 -carboxylate was used to prepare N-[l-(5-oxo-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 559.8;
HPLC purity 100.0% at 210-370 nm, 7.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Pb=3.5/ACΝ+MeOH) for lOmin, hold 4min.
Example 1044: N-(l-hydroxy-6-methoxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1300] In an analogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride (151.7mg, 0.5 mmol) and 2-amino-6-methoxy-2,3- dihydro-lH-inden-1-ol (104.4 mg, 0.6 mmol) was used to prepare the title compound N-(I- hydroxy-6-methoxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide (171.6 mg, 65%) as a white solid. HPLC purity 98.0% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C23H20F3NO6S2 - H+, 526.06114; found (ESI, [+MH-H2O]+), 510.0851.
Example 1045: tert-butyl 4-[methyl({[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l- carboxylate [1301] In an analogous manner to Example 887, Step 2, iV-2-(aminoethyl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 762 and tert-butyl 4-[(li7-imidazol-l-ylcarbonyl)(methyl)amino]piperidine-l-carboxylat from Example 989, Stepl, were used to prepare tert-butyl 4-[methyl({[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)ethyl]amino} carbonyl)amino]piperidine- 1 -carboxylate. MS (ES-) m/z 647.0; HRMS: calcd for C27H35F3N4O7S2 + H+, 649.19720; found (ESI, [M+H]+), 649.1974.
Example 1046: tert-butyl 4-[({[2-({[5-(phenylsulfonyI)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l- carboxylate
[1302] In an analogous manner to Example 866, Step 2, iV-2-(aminoethyl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride from Example 762 and tert-butyl 4- [(l//-imidazol-l-ylcarbonyl)amino]piperidine-l -carboxylate from Example 866, Step2, were used to prepare tert-butyl 4-[({[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy^phenyljsulfonyllamii^ethyyaminojcarbony^aminojpiperidine-l-carboxylate. MS (ESI-) m/z 633; HRMS: calcd for C26H33F3N4O7S2 + H+, 635.18155; found (ESI, [MH-H]+), 635.1825.
Example 1047: Λ'-[l-(l-methyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1303] In an analogous manner to example 1026 step 2, 5-(phenylsulfonyl)-iV- piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and N-methyl-L-proline were used to prepare iV-[l-(l-methyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 560.2;
HRMS: calcd for C24H28F3N3O5S2 + H+, 560.14952; found (ESI, [M+H]+), 560.1518; HPLC purity 100.0% at 210-370 nm, 7.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1048: 5-(phenylsulfonyl)-ΛL[l-(pyridin-3-yIcarbonyI)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide [1304] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and pyridine-3-carbonyl chloride were used to prepare 5- (pheny lsulfony I)-N- [ 1 -(pyridin-3 -ylcarbony l)piperidin-4-y 1] -2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 554.0;
HRMS: calcd for C24H22F3N3O5S2 + H+, 554.10257; found (ESI, [MH-H]+), 554.1022; HPLC purity 93.8% at 210-370 ran, 8.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1049: 5-(phenyIsulfonyl)-iV-[l-(pyridm-2-ylcarbonyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide
[1305] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and pyridine-2-carbonyl chloride were used to prepare 5- (phenylsulfony I)-N- [ 1 -(pyridin-2-ylcarbonyl)piperidin-4-yl] -2- (trifluoromethyl)benzenesulfonamide. MS (ES) m/z 554.0;
HRMS: calcd for C24H22F3N3O5S2 + H+, 554.10257; found (ESI, [M+H]+), 554.1008; HPLC purity 94.8% at 210-370 nm, 8.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1050: iV-{l-[4-(methyIthio)benzoyI]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1306] In an analogous manner to example 1026 step 2, 5-(phenylsulfonyl)-N-piperidin- 4-yl-2-(trifluoromethyl)benzenesulfonamide and 4-methylsulfanyl-benzoic acid were used to prepare N-{l-[4-(methylthio)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 598.9;
HRMS: calcd for C26H25F3N2O5S3 + H+, 599.09504; found (ESI, [M+H]+), 599.0963; HPLC purity 100.0% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1051 : 5-(phenylsulfonyl)-2-(trifluoromethyl)-iV-(l-{[6-(trifluoromethyI)pyridin-3- yl]carbonyl}piperidin-4-yl)benzenesulfonamide
[1307] In an analogous manner to example 462, 5-(phenylsurfonyi)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 6-trifluoromethyl-nicotinoyl chloride were used to prepare 5-(phenylsulfonyl)-2-(trifluoromethyl)-N-(l -{ [6-(trifluoromethyl)pyridin-3- yl]carbonyl}piperidin-4-yl)benzenesulfonamide. MS (ES+) m/z 621.9;
HRMS: calcd for C25H21F6N3O5S2 + H+, 622.08996; found (ESI5 [M+H]+), 622.0897; HPLC purity 100.0% at 210-370 nm, 9.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1052: Λ-{l-[4-(methylsulfinyl)benzoyl]piperidin-4-yl}-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1308] To a stirred solution of N-{l-[4-(methylthio)benzoyl]piperidin-4-yl}-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide (0.08g, 0.137 mmol) in methylene chloride (1 mL) was added mCPBA (0.31 g 77%, 0.137 mmol) and the resulting mixture was stirred at room temperature for 30min. The solution was washed with with sodium bicarbonate solution (sat) and concentrated. Flash column separation using 50%- 100% ethyl acetate/hexane gradient gave N-{ l-[4-(methylsulfinyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. (0.058g, 69%). MS (ES+) m/z 614.9;
HRMS: calcd for C26H25F3N2O6S3 + H+, 615.08996; found (ESI, [M+H]+), 615.0925; HPLC purity 96.3% at 210-370 nm, 8.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1053: iV-{l-[3-(methylthio)propanoyl]piperidin-4-yl}-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1309] In an analogous manner to example 1026 step 2, 5-(phenylsulfony I)-N- piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and 3-methylsulfanyl-propionic acid were used to prepare N-{l-[3-(methylthio)propanoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. HRMS: calcd for C22H25F3N2O5S3 + H+, 551.09504; found (ESI, [M+H]"1"), 551.0927; HPLC purity 99.1% at 210-370 nm, 9.2 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1054: 7V-{l-[3-(methylsulfinyl)propanoyl]piperidin-4-yl}-5-(phenylsulfonyI)-2- (trifluoromethyl)benzenesulfonamide
[1310] In an analogous manner to example 1052, N-{ 1 -[3- (methylthio)propanoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide was used to prepare 7V-{l-[3- (methylsulfinyl)propanoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluorometliyl)benzenesulfonamide.
HRMS: calcd for C22H25F3N2O6S3 + H+, 567.08996; found (ESI, [M+H]4), 567.0894; HPLC purity 100.0% at 210-370 nm, 7.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1055: tert-butyl (4R)-4-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}-l,3-thiazolidine-3- carboxylate
[1311] In an analogous manner to example 1026 step 2, 5-(phenylsulfonyl)-Λ/- piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and R-thiazolidine-3,4-dicarboxylic acid 3-tert-butyl ester were used to prepare tert-butyl (4i-)-4-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethy l)pheny 1] sulfony 1 } amino)piperidin- 1 -y 1] carbony 1 } - 1 , 3 -thiazolidine-3 - carboxylate. MS (ES-) m/z 661.9;
HRMS: calcd for C27H32F3N3O7S3 + H+, 664.14272; found (ESI, [M+H]+), 664.1432; HPLC purity 100.0% at 210-370 nm, 9.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1056: 5-(pheny lsulfonyl)-iV- {1 - [(4R)-1 ,3-thiazolidin-4-ylcarbonyl] piperidin-4-y 1}- 2-(trifluoromethyl)benzenesulfonamide
[1312] In an analogous manner to example 930, tert-butyl (4i?)-4-{[4-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}-l,3- thiazolidine-3-carboxylate was used to prepare 5-(phenylsulfonyl)-iV-{l-[(4i-)-l33-thiazolidin-4- y lcarbonyl]piperidin-4-yl } -2-(trifluoromethy l)benzenesulfonamide . MS (ES+) m/z 563.8;
HPLC purity 100.0% at 210-370 nm, 8.6 min.; Xterra RP18, 3.5u, 15O x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1057: tert-butyl (3ϋT)-3-{[4-({[5-(phenylsulfonyI)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxylate
[1313] In an analogous manner to example 1026 step 2, 5-(phenylsulfonyl)-iV- piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and R-pyrrolidine-l,3-dicarboxylic acid 1-tert-butyl ester were used to prepare tert-butyl (3i?)-3-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxylate. HRMS: calcd for C28H34F3N3O7S2 + H+, 646.18630; found (ESI, [MfH]+), 646.189; HPLC purity 100.0% at 210-370 nm, 9.8 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1058: tert-butyl (3S)-3-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxylate
[1314] In an analogous manner to example 1026 step 2, 5-(phenylsulfonyl)-N- piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and S-pyrrolidine-l,3-dicarboxylic acid 1- tert-butyl ester were used to prepare fert-butyl (3ιS)-3-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxylate. HRMS: calcd for C28H34F3N3O7S2 + H+, 646.18630; found (ESI, [M+H]+), 646.1891; HPLC purity 100.0% at 210-370 nm, 9.8 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1059 : 5-(pheny Isulf onyl)-iV- {1 - [(3J? )-py rrolidin-3-ylcarbonyl] piperidin-4-yI}-2- (trifluoromethyl)benzenesulfonamide
[1315] In an analogous manner to example 930, tert-butyl (3R)-3-{[4-({[5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine- 1-carboxylate was used to prepare 5-(phenylsulfonyl)-N-{l-[(3i?)-pyrrolidin-3- ylcarbonyl]piperidin-4-yl}-2-(trifluoromethyl)benzenesulfonamide. HRMS: calcd for C23H26F3N3O5S2 + H+, 546.13387; found (ESI, [M+H]+), 546.1336; HPLC purity 95.7% at 210-370 nm, 7.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1060: 5-(phenyIsulfonyl)-iV-{l-[(3iS)-pyrrolidin-3-ylcarbonyl]piperidin-4-yl}-2- (trifluoromethyl)benzenesulfonamide
[1316] In an analogous manner to example 930, tert-butyl (35)-3-{ [4-({ [5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine- 1-carboxylate was used to prepare 5-(phenylsulfonyl)-iV-{l-[(3>S)-pyrrolidin-3- ylcarbonyl]piperidin-4-yl}-2-(trifluoromethyl)benzenesulfonamide. HRMS: calcd for C23H26F3N3O5S2 + H+, 546.13387; found (ESI, [M+H]+), 546.1344; HPLC purity 90.4% at 210-370 nm, 7.3 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1061: tert-butyl (4R)-4-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}-l,3-thiazolidine-3- carboxylate 1-oxide
[1317] In an analogous manner to example 1052, tert-butyl (4i?)-4- { [4-({ [5- (phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin- 1 -yljcarbonyl} - 1,3- thiazolidine-3-carboxylate was used to prepare tert-butyl (4i?)-4-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl} amino)piperidin-l -yl]carbonyl} - 1 ,3-thiazolidine-3-carboxylate 1-oxide.
MS (ES+) m/z 679.9;
HPLC purity 100.0% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1062: 2-{[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)-2,3- dihydro-lH-inden-5-yl]oxy}acetamide
[1318] In an analogous manner to example 765, 5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonyl chloride (181.4 mg, 0.6 mmol) and 2-(2-amino-2,3-dihydro- lH-inden-5-yloxy)acetamide (145.7 mg, 0.6 mmol) was used to prepare the title compound 2- {[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)-2,3-diliydro-lH-inden-5- yl]oxy}acetamide (97.3 mg, 30%) as a yellow solid.
MS (ES+) m/z 554.8;
HPLC purity 95.0% at 210-370 nm, 9.1 min.; Xterra RP 18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
HRMS: calcd for C24H2JF3N2O6S2 + H+, 555.08659; found (ESI, [M+HJ+), 555.0836.
Example 1063: methyl [4-({[5-(phenylsulfonyI)-2- (trifluoromethyl)phenyl] sulfonyl} amino)piperidin-l-yl] acetate
[1319] In an analogous manner to example 938, [4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetic acid was used to prepare methyl [4-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)piρeridin- 1 -yl]acetate. MS (ES+) m/z 520.8;
HPLC purity 96.3% at 210-370 nm, 6.9 min.; column, Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1064: iV-(l-{[(3if)-l-acetylpyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide
[1320] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-{ 1 -[(3R)- pyrrolidin-3-ylcarbonyl]piperidin-4-yl} -2-(trifluoromethyl)benzenesulfonamide and acyl chloride were used to prepare Λ/-(l-{[(3i?)-l-acetylpyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 587.8;
HPLC purity 95.1% at 210-370 nm, 8.2 min.; column, Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1065: iV-(l-{[(31S)-l-acetylpyrrolidin-3-yl]carbonyl}piperidm-4-yl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide
[1321] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-{ 1 -[(3S)- pyrrolidin-3-ylcarbonyl]piperidin-4-yl} -2-(trifluoromethyl)benzenesulfonamide and acyl chloride were used to prepare iV-(l-{[(3JS)-l-acetylpyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 587.8;
HPLC purity 100% at 210-370 nm, 8.2 min.; column, Xterra RP18, 3.5u, 150 x 4.6 mm column,
1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1066: 4-{[3-({[l-(før£-butoxycarbonyl)piperidin-4~yI]amino}sulfonyl)-4- (trifluoromethyl)phenyl]sulfonyl}benzoic acid
[1322] Step 1 : To a stirred solution of tert-butyl 4-({ [5-[(4-fluorophenyl)sulfonyl]-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate (0.10 g, 0.18 mmol) in DMSO (1 mL) was added sodium cyanide (0.02 g, 0.35 mmol) and the resulting solution was heated to 120°C overnight. The solution was allowed to cool to room temperature, extracted with ethyl acetate and washed several times with water. The organic phase was concentrated. Flash column separation using 0%-30% ethyl acetate/hexane gradient gave 4-({[5-[(4-cyanophenyl)sulfonyl]- 2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate.
[1323] Step 2: To a stirred solution of 4-({ [5-[(4-cyanophenyl)sulfonyl]-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate (0.10 g, 0.17 mmol) in glyme (1 mL) was added 2.5M KOH solution (0.5 mL) and the resulting solution was refluxed overnight. The solution was allowed to cool, neutralized with 2N HCl solution, and extracted with ethyl acetate. The organic phase was concentrated. Flash column separation using 0%-10% methanol/methylene chloride gradient gave 4-{[3-({[l-(feτt-butoxycarbonyl)piperidin-4- yl]amino}sulfonyl)-4-(trifluoromethyl)phenyl]sulfonyl}benzoic acid. (0.05 g, 47%). MS (ES-) m/z 590.8;
HPLC purity 85.3% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1067: Λ^-[l-(l-isobutyryl-L-proIyl)piperidin-4-yI]-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1324] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and isobutyryl chloride were used to prepare N-[I-(I -isobutyry 1-L-proly l)piperidin-4-yl] -5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 615.8; HPLC purity 100.0% at 210-370 nm, 9.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 US2006/018886
ΛiYiiυj.o«j - 400 -
mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C27H32F3N3O6S2 + H+, 616.17574; found (ESI5 [M+H]+), 616.1791.
Example 1068: iV-{l-[l-(2,2-dimethylpropanoyl)-L-prolyl]piperidin-4-yl}-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide
[1325] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-(l-L- ρrolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and 2,2-dimethyl-proρionyl chloride were used to prepare iV-{l-[l-(2,2-dimethylpropanoyl)-L-prolyl]piperidin-4-yl}-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 629.8;
HPLC purity 95.8% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, holcUmin. HRMS: calcd for C28H34F3N3O6S2 + H+, 630.19139; found (ESI, [M+H]+X 630.1919.
Example 1069: iV-{l-[l-(3,3-dimethylbutanoyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)- 2-(trifluoromethyl)benzenesulfoπamide
[1326] In an analogous manner to example 462, 5-(phenylsulfonyl)-7V-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and 3,3-dimethyl-butyryl chloride were used to prepare iV-{l-[l-(3,3-dimethylbutanoyl)-L-prolyl]piperidin-4-yl}-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 643.9;
HPLC purity 94.6% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold4min.
Example 1070: iV-{l-[l-(cyclohexylcarbonyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)beπzenesuifonamide
[1327] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and cyclohexanecarbonyl chloride were used to prepare JV-{1 -[I -(cyclohexylcarbonyl)-L-prolyl]piperidin-4-yl} -5-(phenylsulfonyl)- 2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 655.9; HPLC purity 100.0% at 210-370 nm, 8.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1071: ΛL{l-[l-(morpholin-4-ylcarbonyI)-L-prolyl]piperidin-4-yl}-5- (phenylsuIfonyl)-2-(trifluoromethyI)benzenesulfonamide
[1328] In an analogous manner to example 462, 5-(phenylsulfonyl)-Λr-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and moφholine-4-carbonyl chloride were used to prepare N-{l-[l-(morpholin-4-ylcarbonyl)-L-prolyl]piperidin-4-yl}-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 658.8;
HPLC purity 100.0% at 210-370 urn, 9.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C28H35F3N4O6S2 + H+, 645.20229; found (ESI, [M+H]+), 645.2024.
Example 1072: (2S)-iV-(te^-butyl)-2-{[4-({[5-(phenyIsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l- carboxamide
[1329] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-(l -L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and tert-butylisocyanate were used to prepare (25)-iV-(fert-butyl)-2-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)pheny 1] sulfonyl } amino)piperidin- 1 -yl] carbony 1} pyrrolidine- 1 -carboxamide. MS (ES+) m/z 644.9;
HPLC purity 100.0% at 210-370 ran, 10.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C28H35F3N4O6S2 + H+, 645.20229; found (ESI, [M+H]+), 645.2048.
Example 1074: (2S)-iV-phenyl-2-{[4-({[5-(phenyIsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l- carboxamide
[1330] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and phenylisocyanate were used to prepare (2S)-iV-phenyl-2-{ [4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l -carboxamide. MS (ES+) m/z 664.8;
HPLC purity 100.0% at 210-370 nm, 9.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1075: Λ^-{l-[l-(methylsulfonyl)-L-prolyl]piperidin-4-yI}-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1331] In an analogous manner to example 462, 5-(ρhenylsulfonyl)-N-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and methane sulfonyl chloride were used to prepare JV- {1 -[I -(methylsulfonyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 623.8;
HRMS: calcd for C24H2SF3N3O7S3 + H+, 624.11142; found (ESI, [M+H]+), 624.1116; HPLC purity 100.0% at 210-370 nm, 8.5 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 niL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1076: iV-[l-(l -benzoyI-L-proIyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1332] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and benzoyl chloride were used to prepare N-[l-(l-benzoyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 649.8;
HPLC purity 94.7% at 210-370 nm, 9.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C30H30F3N3O6S2 + H+, 650.16009; found (ESI, [M+H]+), 650.1616.
Example 1077: 7V-(l-{l-[4-(dimethylamino)benzoyl]-L-prolyl}piperidin-4-yl)-5- (phenyIsulfonyI)-2-(trifluoromethyI)benzenesuIfbnamide
[1333] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and 4-demethylaminobenzoyl chloride were used to prepare N-(l-{l-[4-(dimethylamino)benzoyl]-L-prolyl}piperidin-4-yl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 692.9;
HPLC purity 94.2% at 210-370 nm, 9.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. HRMS: calcd for C32H35F3N4O6S2 + H+, 693.20229; found (ESI, [M+H]4), 693.2034.
Example 1078: AL[l-(l-isonicotinoyI-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1334] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and isonicotinoyl chloride were used to prepare iV-[l-(l-isonicotinoyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 650.8;
HRMS: calcd for C29H29F3N4O6S2 + H+, 651.15534; found (ESI, [M+H]+), 651.1552; HPLC purity 100.0% at 210-370 nm, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1079: iV-(l-{l-[(6-chloropyridin-3-yl)carbonyl]-L-prolyl}piperidin-4-yl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide
[1335] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and 6-chloro-nicotinoyl chloride were used to prepare N-(l-{ l-[(6-chloropyridin-3-yl)carbonyl]-L-prolyl}piperidin-4-yl)-5- (phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 684.8;
HPLC purity 100.0% at 210-370 nm, 9.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1080: 4-[((25)-2-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidin-l- yl)sulfonyl]benzoic acid
[1336] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and 4-(chlorosulfonyl)benzoic acid were used to prepare 4-[((2£)-2-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)piperidin- 1 -yl]carbonyl}pyrrolidin- 1 - yl)sulfonyl]benzoic acid.
MS (ES+) m/z 729.8;
HPLC purity 100.0% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1081 : iV-[l-(i\yV-dimethylglycyl-L-proIyl)piperidin-4-yl]-5-(phenyϊsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1337] In an analogous manner to example 462, 5-(phenylsulfonyl)-iV-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and dimethylamino-acetyl chloride were used to prepare iV-[l-(ΛζN-dimethylglycyl-L-prolyl)pipeπdin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 630.9;
HPLC purity 87.6% at 210-370 nm, 7.4 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1082: 2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)indane-5- carboxylic acid
[1338] Methyl 2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)indane-5-carboxylate (478.2mg, 0.9 mmol) prepare in example 1037 was taken up in 25 ml of a solution of 2:2:1 tetrahydrofuran:methanol: water. To the stirring solution 2N sodium hydroxide (880 μL, 1.76 mmol) was syringed into the reaction flask and allowed to stir overnight at room temperature. 2N Hydrochloric acid (900 μL, 1.8 mmol) was syringed into the reaction flask that caused a white solid to crash out of solution. The solid was collected by filtration and the product was transferred onto a 12 g Isco RediSep® Normal Phase column and was purified by automated flash chromatography using a gradient of 20% to 100% hexane/ethyl acetate. Isolation of the main component gave the title compound 2- ({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)indane-5-carboxylic acid (122.2 mg, 26%) as a white solid. MS (ES-) m/z 525.7;
HPLC purity 97.2% at 210-370 nm, 9.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1083: 7V-methyl-2-[4-({[5-(phenyIsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide
[1339] In an analogous manner to example 880, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-chloro-N-methyl-acetamide were used to prepare N- methyl-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]acetamide. MS (ES+) m/z 519.8;
HPLC purity 100.0% at 210-370 nm, 7.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1084: JV-[I-(I -benzyl-L-prolyI)piperidin-4-yl]-5-(phenylsuIfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1340] In an analogous manner to example 880, 5-(phenylsulfonyl)-N-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and benzyl bromide were used to prepare N-[l-(l-ben2yl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 635.9;
HPLC purity 100.0% at 210-370 nm, 8.1 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min.
Example 1085: ΛyV-dimethyl-2-[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide
[1341] In an analogous manner to example 880, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-chloro-Ν,Ν-dimethyl-acetamide were used to prepare NrN-dimethyl-2-[4-( { [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide. MS (ES+) m/z 533.9;
HPLC purity 96.6% at 210-370 nm, 6.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACΝ+MeOH) for lOmin, hold 4min. Example 1086: iV-isopropyl-2-[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide
[1342] In an analogous manner to example 880, 5-(phenylsulfonyl)-N-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-chloro-N-isopropyl-acetamide were used to prepare N-isopropyl-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yljacetamide. MS (ES-) m/z 547.8;
HPLC purity 95.1% at 210-370 nm, 7.6 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1087: iV-[l-(2-morphoHn-4-yl-2-oxoethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1343] In an analogous manner to example 880, 5-(phenylsulfonyl)-iV-piperidin-4-yl-2- (trifluoromethyl)benzenesulfonamide and 2-chloro-l-morpholin-4-yl-ethanone were used to prepare Λ/-[l-(2-morpholin-4-yl-2-oxoethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 575.8;
HPLC purity 98.2% at 210-370 nm, 7.0 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1088: iV-{l-[l-(cyclohexylmethyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1344] To a stirred solution of 5-(phenylsulfonyl)-iV-(l -L-prolylpiperidin-4-yl)-2- (trifluoromethyl)benzenesulfonamide (0.09 g, 0.16 mmol) and cyclohexanecarbaldehyde (0.02 g, 0.16 mmol) in methanol (1 mL) was added triacetoxy sodium borohydride (0.05 g, 0.22 mmol) and the resulting solution was stirred overnight at room temperature. The crude mixture was concentrated. Flash column separation using 0%-10% methanol/methylene chloride gradient gave N- { 1 -[I -(cyclohexylmethyl)-L-prolyl]piperidin-4-yl) -5-(phenylsulfony l)-2- (trifluoromethyl)benzenesulfonamide. (0.025 g, 25%). MS (ES+) m/z 641.9;
HPLC purity 100.0% at 210-370 nm, 8.9 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example l089: iV-{l-[l-(3,3-dimethylbutyI)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluororaethyl)benzenesulfonamide
[1345] In an analogous manner to example 1088, 5-(phenylsulfonyl)-7V-(l-L- prolylpiρeridin-4-y l)-2-(trifluoromethy l)benzenesulfonamide and 3 ,3 -dimethyl-butyraldehyde were used to prepare iV-{l-[l-(3,3-dimethylbutyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 630.0;
HPLC purity 100.0% at 210-370 nm, 8.8 min.; Xterra RPl 8, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1090: 5-(phenyϊsuIfonyI)-iV-[l-(l,3-thiazol-4-ylcarbonyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide
[1346] In an analogous manner to examplelO26 step 2, 5-(phenylsulfonyl)-N-piperidin- 4-yl-2-(trifluoromethyl)benzenesulfonamide and thiazole-4-carboxylic acid were used to prepare 5-(phenylsulfonyl)-iV-[l-(l,3-thiazol-4-ylcarbonyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 559.6;
HPLC purity 98.5% at 210-370 nm, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1091: (2S)-iV-ethyI-2-{[4-({[5-(phenyIsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l- carboxamide
[1347] In an analogous manner to example 462, 5-(phenylsulfonyl)-7V-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and ethylisocyanate were used to prepare (25)-N-ethyl-2-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxamide. MS (ES+) m/z 616.8;
HPLC purity 100.0% at 210-370 nm, 8.6 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min. Example 1092: (2S)-ΛyV-dimethyl-2-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l- carboxamide
[1348] In an analogous manner to example 462, 5-(phenylsulfonyl)-N-(l-L- prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide and dimethylaminocarbonyl chloride were used to prepare (25)-N,iV-dimethyl-2-{[4-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxamide. MS (ES+) m/z 616.8;
HPLC purity 100.0% at 210-370 ran, 8.7 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1093: iY-[l-(liϊ-imidazol-l-ylacetyl)piperidin-4-yl]-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1349] In an analogous manner to example 1026 step 2, 5-(phenylsulfonyl)-iV- piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and imidazol-1-yl-acetic acid were used to prepare N-[I -( 1/i-imidazol- 1 -ylacetyl)piperidin-4-yl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES+) m/z 556.8;
HPLC purity 99.2% at 210-370 nm, 7.3 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Ammon. Form. Buff.
Figure imgf000409_0001
for lOmin, hold 4min.
Example 1094: iV-(5-bromo-2,3-dihydro-lJH-inden-2-yl)-5-(phenyIsulfonyl)-2- (trifluoromethyl)benzenesulfonamide
[1350] To a stirred suspension of 5-bromoindan-2 -amine hydrobromide (2.80 g, 9.56 mmol) in a solution of 5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonyl chloride (3.67 g, 9.54 mmol) from Example 677 in CH2Cl2 (75 mL) under N2 at room temperature was added diisopropylethylamine (5.00 mL, 3.71 g, 28.7 mmol). The mixture was stirred at room temperature for 1.5 hours. It was washed once with 2N HCl, twice with water and once with brine. The solvent was evaporated. The residue was dissolved again in CH2Cl2 (18 mL) The solution was loaded directly onto a silica gel column and eluted with a gradient of hexane and CH2Cl2 to give 4.11 g (77%) of N-(5-bromo-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide. MS (ES-) m/z 557.6.
Example 1095: tert-butyl (2S)-2-{[4-({[5-[(3-cyanophenyl)sulfonyl]-2- (trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxylate
[1351] Step 1 : In an analogous manner to example 1026 step 2, 5-[(3- bromophenyl)sulfonyl]-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide and N-(te7t- butoxycarbonyl)-L-proline were used to prepare tert-butyl (2JS)-2-{[4-({[5-[(3- bromophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin- 1 - yl]carbonyl}pyrrolidine-l-carboxylate.
[1352] Step 2: In an analogous manner to example 376, tert-butyl (2S)-2-{ [4-({ [5-[(3- bromophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]carbonyl}pyrrolidine-l-carboxylate was used to prepare tert-butyl (2£)-2-{[4-({[5-[(3- cyanophenyl)sulfonyl]-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin- 1 - yljcarbonyljpyrrolidine-l-carboxylate. MS (ES+) m/z 670.7
HPLC purity 98.8% at 210-370 nm, 11.2 min.; Xterra RP18, 3.5u, 150 x 4.6 mm column, 1.2 mL/min, 85/15-5/95 (Amnion. Form. Buff. Ph=3.5/ACN+MeOH) for lOmin, hold 4min.
Example 1096: Fluorescence Polarization Binding Assay
[1353] The affinity of test compounds for SFPvP-I was determined using a fluorescence polarization binding assay. According to the assay design, a probe compound was bound to SFRP-I . The fluorescence anisotropy value of the probe compound is increased upon binding to SFRP-I. Upon the addition of a test compound, the fluorescence anisotropy value for the probe compound decreased due to competitive displacement of the probe by the test compound. The decrease in anisotropy as a function of increasing concentration of the test compound provides a direct measure of the test compound's binding affinity for SFRP-I .
[1354] To determine IC50 values, fluorescence polarization experiments were conducted in a 384-well format according to the following procedures. A 20 mM stock solution of the probe compound was prepared in 100 % DMSO and dispensed in 10 μL aliquots for long- term storage at -20 0C. The binding assay buffer was prepared by combining stock solutions of Tris-Cl, NacL, glycerol, and NP40 at final concentrations of 25 mM Tris-Cl pH 7.4, 0.5 M NaCl, 5% glycerol and 0.002 % NP40. Master stock solutions of the test compounds were prepared in 100 % DMSO at final concentrations of 20 niM. Typically the working stock solutions of the test compounds were prepared by serially diluting the 20 mM master stock solution to 5 mM, 2.5 mM, 1.25 mM, 0.625 mM, 0.3125 mM, 0.156 mM, 78 μM, 39 μM, 19.5 μM, 9.8 μM, 4.9 μM, 2.44 μM, 1.22 μM, 0.31 μM, 76 nM, and 19 nM in DMSO. The working stock solutions of the test compounds were further diluted by combining 6 μl of the solutions with 24 μL of Milli-Q purity water, resulting in working stock solutions (10x compound stocks) in 20 % DMSO.
[1355] The assay controls were prepared as follows. A 2 μL aliquot of the 20 mM fluorescence probe compound was diluted 1000-fold in 100 % DMSO to a final concentration of 20 μM. 6 μL of the 20 μM probe was combined with 5.4 mL of the assay buffer, mixed well, and 18 μL of the resulting solution was dispensed into 384-well plates.
[1356] SFRP-1/probe complex was prepared by combining 11 μL of 20 μM probe compound with 9.9 mL of the assay buffer and SFRP-I stock solution to final concentrations of 22 nM probe compound and 50 nM SFRP-1. 18 μL of the SFRP-1/probe complex was dispensed into the 384-well plates.
[1357] 2 μL aliquots of the test compounds from the 10x working stock solutions were removed and dispensed into the plate containing the SFRP-1/probe complex and the resultant solutions were mixed by pipetting up and down once. The final concentratons of SFRP-I and probe in the assay solutions were 45 nM and 20 nM, respectively. In a typical experiment, each plate was used to test 14 compounds.
[1358] The plate was incubated in the dark for 15 minutes. The fluorescence of the SFRP-1/probe complexs was read in the Tecan Ultra plate reader at excitation and emission maxima of 485 and 535 nm. The plate reader settings were as follows:
Mode: Fluorescence Polarization Plate definition: Matrical3841v.pdf (pdf stands for Plate Definition File) Excitation 485nm (bandwidth 20nm) Emission 535nm (bandwidth 30nm) G-factor: 1.03 # flashes / well: 10 integration time: lOOus time btwn move, flash: 60ms Z-position: 10730 um
Analysis of Results [1359] Fluorescence anisotropy results from the emission of polarized light in the parallel and perpendicular directions when a fluorophore is excited with vertically polarized light. The anisotropy of the probe in the free and bound state was determined using the following equation: r = i(π)-i(±)*i(π)+ 2i(±) where I(II) and 1(1) are the parallel and perpendicular emission intensities, respectively.
[1360] Monitoring the anisotropy changes of the probe compound revealed that it bound saturably to SFRP-I with a KD of 20-30 nM. The binding affinity was independently verified using a tryptophan fluorescence quenching assay.
[1361] The decrease in the anisotropy of the probe upon addition of the competing test compound was fitted to a sigmoidal dose response curve of the equation shown below:
(Top - Bottom)
Y = Bottom + ■
(1 + 10 X-LagIC50 \ * Hillslope
where "X" is the logarithm of concentration, "Y" is the anisotropy, and "Bottom" and "Top" correspond to the anisotropy values of the free and SFRP-I -bound probe prior to the addition of the test compound, respectively.
[1362] For automated IC50 determinations, the equation shown above was used in the program GraphPad Prism. The "Hillslope" was kept constant at 1. The value for "Bottom" was fixed, but was determined by the blank (probe-only) wells in the plate. The values for "Top" and "IC50" were determined by the data fit. The value for "Top" was typically close to 120, equivalent to approximately 50 % bound probe, and the value for "Bottom" was around 30, due to free probe. If the test compound interfered with the probe in the fluorescence assay at high concentrations, the range for the fitted data was limited to the lower concentration range. The data obtained from the experiments are shown in the table below.
Figure imgf000412_0001
Figure imgf000413_0001
6018886
-413-
Figure imgf000414_0001
Λ.iViXUXOUJ -414-
Figure imgf000415_0001
Figure imgf000416_0001
018886
-416-
Figure imgf000417_0001
Figure imgf000418_0001
2006/018886
-418-
Figure imgf000419_0001
Figure imgf000420_0001
Figure imgf000421_0001
Figure imgf000422_0001
Figure imgf000423_0001
Figure imgf000424_0001
Figure imgf000424_0002
Figure imgf000425_0001
Figure imgf000426_0001
Figure imgf000427_0001
Figure imgf000428_0001
Figure imgf000429_0001
Example 1097: Cell-based Assay for in vitro Measurement of SFRP-1/SARP2 Antagonist Activity
[1363] The following cell-based assay can be used to identify inhibitors of SFRP-I . Materials and Methods
Cells
[1364] The osteosarcoma cell line, U2OS (ATCC, HTB 96), was passaged twice a week with growth medium (McCoy's 5 A medium containing 10% (v/v) fetal calf serum, 2mM GlutaMAX-1, and 1% (v/v) Penicillin- Streptomycin). The cells were maintained in vented flasks at 370C inside a 5% CU2/95% humidified air incubator. One day prior to transfection, the cells were plated with growth medium at 25,000 cells/well into 96-well plates and incubated at 37 °C overnight.
Routine Co-Tr ansfection
[1365] The growth medium was removed, and the cells were washed once with OPTIMEM I (Gibco-BRL) medium (100 μL/well) to remove the serum and antibiotics. The wash medium was removed, and the cells were re-fed with OPTI-MEM I medium (100 μL/well). For each well of cells to be transfected, the following DNA' s were diluted together in 25 μL OPTI-MEM I medium: 0.1 μg 16x TCF-tk-Luciferase reporter, 0.02 μg Wnt 3, Wnt3A, Wnt 1 or empty vector (Upstate Biotechnology), 0.075 μg hSFRP-1 or empty vector (pcDNA3.1, Invitrogen), and 0.025 μg CMV-βgal (Clonetech). For each well of cells to be transfected, lμl of Lipofectamine 2000 reagent (Invitrogen) was diluted in 25 μl OPTI-MEM I medium and incubated at room temperature for 5 minutes. The diluted DNA' s were then combined with the diluted Lipofectamine 2000 (LF2000), and the mixture was incubated at room temperature for 20 minutes. Fifty μL of the DNA-LF 2000 mixture was added to each well, and the plate(s) were incubated at 37 °C in a 5% CO2/95% humidified air incubator for 4 hours. The cells were washed once with 150 μL/well of experimental medium (phenol red-free RPMI Medium 1640 containing 2% fetal bovine serum, 2mM GlutaMAX-1, and 1% Penicillin-Streptomycin). Finally, the cells were treated overnight at 37 °C with 200 μL/well of experimental medium containing either vehicle (typically DMSO) or diluted compound in replicates of 8 wells/compound.
Dosing
[1366] Initial single dose screening of test compounds was done at 10 μM .
[1367] Dose-response experiments were initially performed with the compounds in log increases of concentration from 1-10,000 nM. From these dose-response curves, ECso values were generated.
Assay
[1368] After treatment, the cells were washed twice with 150 μL/well of PBS without calcium or magnesium and were lysed with 50 μL/well of IX cell culture lysis reagent (Promega Corporation) on a shaker at room temperature for 30 minutes. Thirty μL aliquots of the cell lysates were transferred to 96-well luminometer plates, and luciferase activity was measured in a MicroLumat PLUS luminometer (EG&G Berthold), or a Victor (PerkinElmer Life Sciences) using 100 μL/well of luciferase substrate (Promega Corporation). Following the injection of substrate, luciferase activity was measured for 10 seconds after a 1.6 second delay. Similarly, 10 μL aliquots of the cell lysates were transferred to separate 96-well luminometer plates, and 50 μL of Galacton chemiluminescent substrate (Tropix) was added to each well. The plates were covered and incubated on a rotary shaker at room temperature for one hour, βgal activity was measured in a MicroLumat PLUS luminometer or Victor using 100 μL/well of Light Emission Accelerator (Tropix). Following the injection of the accelerator, βgal activity was measured for 10 seconds after a 1.6 second delay. The luciferase and βgal activity data were transferred from the luminometer to a PC and analyzed using the SAS/Excel program. After the luciferase activity was normalized to βgal, the SAS/Excel program was used to determine the mean and standard deviation of each treatment, to analyze the data for statistical significance, and to determine EC5O values (see the Table below).
Large-Scale Co-Transfection
[1369] As an alternative to co-transfection in a 96 well plate, the U2OS cells were transfected in T225 flasks and the transfected cells were frozen. The frozen cells were thawed and plated on a 96 well plate and the assay was carried out as detailed above. The growth medium was removed from the T225 flasks, and the cells were washed once with OPTI-MEM I medium (approx. 25 ml/flask) to remove the serum and antibiotics. The wash medium was removed, and the cells were re-fed with OPTI-MEM I medium (59 ml/flask). For each T225 flask of cells to be transfected, the following DNA' s were diluted together in 5.9 ml OPTI-MEM I medium: 70.3 μg 16x TCF-tk-Luciferase reporter, 14.06 μg WNT3, 3A or Wntl or empty vector, 52.8 μg hSFRP-1 or empty vector, and 17.58 μg CMV-βgal. Separately, for each flask of cells to be transfected, 354 μL of Lipofectamine 2000 reagent (Invitrogen) was diluted in 5.9 mL OPTI-MEM I medium and incubated at room temperature for 5 minutes. The diluted DNA' s were then combined with the diluted Lipofectamine 2000 (LF2000), and the mixture was incubated at room temperature for 20 minutes. 11.8 mL of the DNA-LF 2000 mixture was added to each flask, and the flask(s) were incubated at 37 0C in a 5% CO2 /95% humidified air incubator for 4 hours. The medium was removed, and the cells were washed once with approximately 25 mL/flask of phenol red-free RPMI Medium 1640, then re-fed with 50 mL/flask of experimental medium (phenol red-free RPMI Medium 1640 containing 2% fetal bovine serum, 2 mM GlutaMAX-1, and 1% Penicillin- Streptomycin) and incubated at 37 0C overnight.
Freezing Cells
[1370] The transfected cells were washed twice with 25 mL/flask/wash of PBS without calcium or magnesium. Three ml of Trypsin-EDTA (0.05% Trypsin, 0.53 mM EDTA-4Na) was added to each flask, and the flasks were incubated at room temperature for approximately 5 minutes until the cells were rounded and detached from the surface of the flask(s). The cells were resuspended in 10 mL/flask of phenol red-free RPMI 1640 containing 10% fetal bovine serum and were pipetted up and down several times until a single cell suspension was formed. The resuspended cells were pooled and a 10 μL aliquot was removed and diluted at 1:10 in PBS. The diluted cells were counted using a hemacytometer to determine the total number of cells in the pool. The cells were transferred to sterile centrifuge tubes and pelletted at 1500 rpm in a Sorvall RC-3B refrigerated centrifuge at 4 0C for 5 minutes. The supernatant was aspirated and the cells were resuspended in cold, phenol red-free RPMI 1640 medium containing 50% FBS to a cell density of 2.5E+7 cells/ml. An equal volume of cold, 2x freezing medium (phenol red-free RPMI 1640 medium containing 50% FBS and 15% DMSO) was added slowly, dropwise to the resuspended cells with gentle mixing, resulting in a final cell density of 1.25E+7 cells/mL. The resuspended cells were placed on ice and aliquoted into sterile cryogenic vials. The vials were transferred to aNalgene Cryo 1°C freezing container (Nalgene catalog # 5100-0001) containing 250 mL isopropyl alcohol. The sealed container was placed in a -80 0C freezer overnight to freeze the cells at a cooling rate of -1 °C/minute. The frozen cells were then transferred to a - 150 °C freezer for long-term storage.
Benchtop Assay for Single Dose Confirmation of HTS Hits
[1371] Early in the morning, a vial of frozen transfected cells was thawed, and the cells were resuspended in phenol red-free RPMI 1640 medium to a final cell density of 150,000 cells/ml. The resuspended cells were then plated in white, 96-well polystyrene tissue culture treated CulturPlatesTM (Packard cat. # 6005180) at a volume of 100 μL of cell suspension/well (i.e. 15,000 cells/well). The plates were incubated at 37 °C inside a 5% CO2/95% humidified air incubator for 6 hours or until the cells were attached and started to spread. Test compounds were then added to the wells (1 well/compound) and the plates were incubated at 37 0C overnight. After the overnight incubation, luciferase activity was measured using the Luc-Screen Luciferase Assay System (Tropix). Fifty μL of Luc-Screen buffer 1, warmed to room temperature, was added directly to the cells in the 96-well plates. Fifty μL of Luc-Screen buffer 2, warmed to room temperature, was then added, and the plates were incubated in the dark, at room temperature, for 10 minutes. The plates were transferred to a Packard Top Count Microplate Scintillation and Luminescence Counter (Packard), and the light emission was measured for 10 seconds after a 2 minute delay.
[1372] The luciferase activity data was transferred to a PC and analyzed using the SAS/Excel program as described above. Analysis of Results
[1373] The luciferase data was analyzed using the SAS/Excel program. For the initial single dose experiment, if the compound treatment resulted in increased reporter activity and was specific to SFRP-I inhibition, then the results were reported as fold induction over SFRP-I control (see the Table below). Compounds
[1374] A known inhibitor of GSK-3β, a key enzyme involved in the Wnt signaling pathway, served as an internal control for measurement of the cellular response to Wnt signaling. The inhibition of GSK-3 results in stabilization of β-catenin, leading to up-regulation of LEF/TCF regulated reporter genes.
Figure imgf000433_0001
Figure imgf000434_0001
Figure imgf000435_0001
Figure imgf000436_0001
Figure imgf000437_0001
Figure imgf000438_0001
Figure imgf000439_0001
Figure imgf000440_0001
Figure imgf000441_0001
Figure imgf000442_0001
Figure imgf000443_0001
Figure imgf000444_0001
Figure imgf000445_0001
Figure imgf000445_0002
Figure imgf000446_0001
Figure imgf000447_0001
Figure imgf000448_0001
Figure imgf000449_0001
Figure imgf000450_0001
Figure imgf000451_0001
Figure imgf000452_0001
Figure imgf000453_0001
Figure imgf000454_0001
Figure imgf000455_0001
[1375] The entire disclosure of each patent, patent application, and publication cited or described in this document is hereby incorporated by reference.

Claims

We Claim:
1. A compound of Formula ( 1 ) :
Figure imgf000456_0001
(1) or a pharmaceutically acceptable salt thereof, wherein
R1 Is
Figure imgf000456_0002
and each R1 group is optionally substituted with up to three R8 groups;
Y is O, S, or NR9;
R8 is alkyl, arylalkyl, perfluoroalkyl, alkenyl, arylalkenyl, alkynyl, arylalkynyl, cycloalkyl, all<ylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, aryl, alkylaryl, heteroaryl, alkoxy, perfluoroalkoxy, arylalkoxy, alkylcarbonyl, arylcarbonyl, halogen, cyano, azido, hydroxyl, carboxy, alkoxycarbonyl, alkylamino, dialkylamino, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, alkylcarbonylalkylamino, hydroxyalkylamino, nitro, alkylcarbonyloxime, alkylsulfonyl, alkylsulfinyl, alkylthio, perfluoroalkylthio, arylthio, tertiary alkylcarbinol, tertiary alkylcycloalkylcarbinol, or tertiary arylalkylcarbinol;
R9 is hydrogen, alkyl, aryl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, or spirocycloalkyl;
X is oxygen or an electron pair; R2 is hydrogen, alkyl, alkoxy, cycloalkyl, perfluoroalkyl, perfluoroalkylalkyl, perfluoroalkoxy, dialkylamino, or halogen;
R4 is hydrogen, halogen, alkyl, cycloalkyl, alkoxy, perfluoroalkyl, or perfluoroalkoxy; or R2 and R4, together with the carbon atoms to which they are attached, form a cycloalkyl ring of 5 to 7 carbon atoms that is optionally substituted with 1 to 3 R groups; each R is, independently, hydrogen, alkyl, arylalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, spirocycloalkyl, aryl, arylalkyl, or alkoxyalkyl;
R5, and R6 are, independently, hydrogen, alkyl, aryl, alkoxy, halogen, or perfluoroalkyl;
R3 and R7 are each, independently, hydrogen or an optionally substituted alkyl, cycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, heteroarylalkyl, alkylaryl, alkylheteroaryl, alkenyl, alkynyl, fused cycloalkylaryl, fused heterocycloalkylaryl, cycloalkylcarbonyl, or heterocycloalkylcarbonyl group; or R3 and R7, together with the nitrogen atom to which they are attached, form a five or six membered heterocycloalkyl ring optionally substituted with 1 to 5 substituents selected from alkyl, aryl, heterocycloalkyl, heterocycloalkylalkyl, alkylamino, dialkylamino, alkoxycarbonyl, alkylcarbonyl, alkylaminocarbonylalkyl, and heterocycloalkylcarbonylalkyl; provided that the compound is not
2-methyl-N-(2-phenylethyl)-5-(phenylsulfonyl)-benzenesulfonamide;
2-methyl-N-(2-phenylmethyl)-5-(phenylsulfonyl)-benzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-cyclohexyl-2-methylbenzenesulfonamide;
N-benzyl-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-cUorophenyl)sulfonyl]-N-(2-furylmethyl)-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-benzenesulfonamide;
5-[(4-bromophenyl)sulfonyl]-2-methylbenzenesulfonamide;
2-methyl-5-[(4-nitrophenyl)sulfonyl]-benzenesulfonamide;
5-[(2,4-dinitrophenyl)sulfonyl]-2-methyl-benzenesulfonamide; or
5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(3-pyridinylmethyl)-benzenesulfonamide.
2. The compound of claim 1 wherein the alkyl, cycloalkyl, alkylheterocycloalkyl, heteroarylalkyl, alkylaryl, alkylheteroaryl, alkenyl, alkynyl, fused cycloalkylaryl, fused heterocycloalkylaryl, cycloalkylcarbonyl, and heterocycloalkylcarbonyl groups groups of R3 and R7 are each independently, optionally substituted with 1 to 5 substituents selected from alkyl, perfluoroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, fused cycloalkylaryl, alkoxy, aminocarbonylalkoxy, alkoxycarbonylalkoxy, carboxyalkoxy, cycloalkyloxy, aryloxy, amino, alkylamino, dialkylamino, alkoxycarbonylamino, carboxy, cyano, halogen, oxo, hydroxyl, alkylcarbonyl, carboxyalkylcarbonyl, arylaniinocarbonyl, heterocycloalkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, fused cycloalkylarylaminocarbonyl, and fused heterocycloalkylarylcarbonyl.
3. The compound of claim 2 wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl substituents on the alkyl groups of R3 and R7 are independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, spirocycloalkyl, perfluoroalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, dimethylphosphonatealkyl, phosphonic acid alkyl, arylalkyl, cycloalkylalkyl, alkoxy, perfluoroalkoxy, arylalkoxy, benzoxy, aryl, heteroaryl, carboxyaryl, arylcarbonyl, alkylcarbonyl, perfluoroalkylcarbonyl, alkoxycarbonyl, carboxyalkylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, aryloxythiocarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocycloalkylcarbonyl, heterocycloalkylthiocarbonyl, arylthiocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, dialkylaminoarylcarbonyl, dialkylaminoalkylcarbonyl, alkylthiocarbonyl, arylaminocarbonyl, heteroarylcarbonyl, heteroarylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, arylsulfonylarylsulfonyl, carboxyarylsulfonyl, nitro, amino, dialkylamino, alkylcarbonylamino, alkylsulfonylamino, carboxyarylsulfonylamino, hydroxy, carboxy, sulfonamide, alkylthio, halogen, cyano, guanidine, and oxo, and the nitrogen atoms in the heteroaryl substituents are optionally substituted with an oxygen atom.
4. The compound of claim 1 wherein the heterocycloalkyl groups of R3 and R7 are independently, optionally substituted with 1 to 5 substituents selected from alkyl, hydroxyalkyl, cyanoalkyl, carboxyalkyl, aminocarbonylalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heterocycloalkylcarbonylalkyl, arylalkyl, heteroarylalkyl, arylcarbonylalkyl, alkylcarbonyl, cyano, alkylester, alkylamide, cycloalkylamide, aryl, arylester, alkylcarbonyl, perfluoroalkylcarbonyl, aminocarbonyl, arylaminocarbonyl, arylaminothiocarbonyl, cyanoalkoxycarbonyl, cycloalkylcarbonyl, arylcarbonyl, arylthiocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, heteroarylcarbonyl, heterocycloalkylcarbonyl, cyanoarylcarbonyl, arylalkylcarbonyl, alkoxycarbonyl, alkoxyalkylcarbonyl, alkylthioalkylcarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, heterocycloalkylallcylcarbonyl, heterocycloalkylalkylaminothiocarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, heteroarylalkylcarbonyl, carboxyalkylcarbonyl, alkoxycarbonylaminothiocarbonyl, alkoxycarbonylalkylaminothiocarbonyl, alkylthiocarbonylallcylcarbonyl, alkylsulfonyl, arylsulfonyl, alkylaminoarylsulfonyl, and heteroarylsulfonyl.
5. The compound of claim 4 wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl substituents on the heterocycloalkyl groups of R3 and R7 are independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, spirocycloalkyl, perfluoroalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, dimethylphosphonatealkyl, phosphonic acid alkyl, arylalkyl, cycloalkylalkyl, alkoxy, perfluoroalkoxy, arylalkoxy, benzoxy, aryl, heteroaryl, carboxyaryl, arylcarbonyl, alkylcarbonyl, perfluoroalkylcarbonyl, alkoxycarbonyl, carboxyalkylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, aryloxythiocarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocycloalkylcarbonyl, heterocycloalkylthiocarbonyl, arylthiocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, dialkylaminoarylcarbonyl, dialkylaminoalkylcarbonyl, alkylthiocarbonyl, arylaminocarbonyl, heteroarylcarbonyl, heteroarylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, arylsulfonylarylsulfonyl, carboxyarylsulfonyl, nitro, amino, dialkylamino, alkylcarbonylamino, alkylsulfonylamino, carboxyarylsulfonylamino, hydroxy, carboxy, sulfonamide, alkylthio, halogen, cyano, guanidine, and oxo, and the nitrogen atoms in the heteroaryl substituents are optionally substituted with an oxygen atom.
6. The compound of claim 2 wherein the amino substituents on the alkyl groups of R3 and R7 are independently, optionally substituted with 1 or 2 substituents selected from alkyl, hydroxyalkyl, carboxyalkyl, cycloalkyl, alkoxycarbonylalkyl, aryl, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl, cycloalkylcarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, alkoxycarbonylalkylaminocarbonyl, carboxyalkylcarbonyl, carboxyalkylaminocarbonyl, carboxyalkylcarbonylheterocycloalkylaminocarbonyl, arylaminocarbonyl, arylcarbonyl, heteroarylaminocarbonyl, heterocycloalkylcarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, heterocycloalkylaminocarbonyl, heterocycloallcylthiocarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, and ary loxythiocarbony 1.
7. The compound of claim 6 wherein the cycloalkyl, heterocycloalkyl, aryl, and heteroaryl substituents on the amino substituents on the alkyl groups of R3 and R7 are independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, spirocycloalkyl, perfluoroalkyl, haloalkyl, cyanoalkyl, carboxyalkyl, dimethylphosphonatealkyl, phosphonic acid alkyl, arylalkyl, cycloalkylalkyl, alkoxy, perfluoroalkoxy, arylalkoxy, benzoxy, aryl, heteroaryl, carboxyaryl, arylcarbonyl, alkylcarbonyl, perfluoroalkylcarbonyl, alkoxycarbonyl, carboxyalkylcarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, aryloxythiocarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocycloalkylcarbonyl, heterocycloalkylthiocarbonyl, arylthiocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, dialkylaminoarylcarbonyl, dialkylaminoalkylcarbonyl, alkylthiocarbonyl, arylaminocarbonyl, heteroarylcarbonyl, heteroarylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, aminosulfonyl, alkylsulfonyl, arylsulfonyl, arylsulfonylarylsulfonyl, carboxyarylsulfonyl, nitro, amino, dialkylamino, alkylcarbonylamino, alkylsulfonylamino, carboxyarylsulfonylamino, hydroxy, carboxy, sulfonamide, alkylthio, halogen, cyano, guanidine, and oxo, and the nitrogen atoms in the heteroaryl substituents are optionally substituted with an oxygen atom.
8. The compound of claim 1 wherein the alkyl group substituents on the heterocycloalkyl ring formed from R3 and R7, together with the nitrogen atom to which they are attached are each independently, optionally substituted with 1 to 5 substituents selected from aryl, heteroaryl optionally substituted with one to three alkyl groups, aminoalkyl, heterocycloalkyl, fused heterocycloalkylaryl, and heterocycloalkylcarbonyl.
9. The compound of claim 1 wherein R1 is aryl.
10. The compound of claim 1 wherein each R8 is, independently, alkyl, alkylaryl, alkylheteroaryl, alkylamino, dialkylamino, carboxy, alkylcarbonyl, alkoxy, perfluoroalkoxy, halogen, or cyano.
11. The compound of claim 1 wherein X is oxygen.
12. The compound of claim 1 wherein R4, R5, and R6 are each hydrogen.
13. The compound of claim 1 wherein R4 is methyl and R5 and R6 are each hydrogen, or R5 is ' methyl and R4 and R6 are each hydrogen, or R6 is methyl and R4 and R5 are each hydrogen.
14. The compound of claim 1 wherein R2 is methyl, ethyl, isopropyl, propyl, Cl, methoxy, trifluoromethyl, or trifluoromethoxy.
15. The compound of claim 14 wherein R2 is methyl, isopropyl, trifluoromethyl, or trifluoromethoxy.
16. The compound of claim 15 wherein R2 is isopropyl or trifluoromethyl.
17. The compound of claim 1 wherein R3 and R7, together with the nitrogen atoms to which they are attached, form an optionally substituted 5 or 6 membered heterocycloalkyl group.
18. The compound of claim 17 wherein R3 and R7, together with the nitrogen atoms to which they are attached, form an optionally substituted piperazinyl group.
19. The compound of claim 1 wherein R7 is hydrogen and R3 is alkyl, cycloalkyl,
Figure imgf000462_0001
wherein the carbon atoms of each alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group are optionally substituted with up to four R13 groups;
R13 is hydrogen, F3 Cl, Br, alkyl, alkoxy, aryl, nitro, aminosulfonyl, arylalkoxy, perfluoroalkyl, perfluoroalkoxy, amino, alkylamino, dialkylamino, hydroxy, carboxy, cycloalkyl, carboxyalkyl, carboxyalkoxy, alkoxycarbonyl, aminocarbonylalkyl, alkoxycarbonylalkoxy,aminocarbonylalkoxy, alkylaminocarbonylalkyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, heterocycloalkylcarbonyl, heterocycloalkylaminocarbonyl, alkylaminocarbonylalkoxy, dialkylaminocarbonylalkyl, dialkylaminocarbonylalkoxy, heterocycloalkylcarbonylalkyl, heterocycloalkylaminocarbonylalkoxy, heterocycloalkylcarbonylalkoxy, cycloalkylaminoalkyl, heterocycloalkylaminoalkyl, aminoalkylaminoalkylarylamionalkyl, heteroarylaminoalkylarylalkylammoalkyl, heteroarylalkylaminoalkyl, alkylaminoalkylamino, dialkylaminoalkylaminoarylamino, heteroarylaminoarylalkylamino, heteroarylalkylamino, or cyano; each R12 is alkyl, aryl, alkylamino, dialkylamino, alkoxy, hydroxyl, amino, arylamino, diarylamino, aryl(alkyl)amino, or aryloxy; each R14 is hydrogen, alkyl, aryl, cycloalkyl, alkylcarbonyl, arylcarbonyl, aryloxycarbonyl, alkylsulfonyl, arylsulfonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, heterocycloalkylcarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, heterocycloalkylthiocarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, alkoxythiocarbonyl, alkoxycarbonylaminothiocarbonyl, cycloalkylcarbonyl, aminocarbonyl, alkoxycarbonyl, cycloalkylaminocarbonyl, heterocycloalkylaminocarbonyl, cycloalkylsulfonyl, heterocycloalkylsulfonyl, heteroarylsulfonyl, or aryloxythiocarbonyl;
R15 is hydrogen, alkyl, aryl, cycloalkyl, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminothiocarbonyl, dialkylaminothiocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, heterocycloalkylcarbonyl, arylaminothiocarbonyl, heteroarylaminothiocarbonyl, heterocycloalkylthiocarbonyl, heterocycloalkylalkylaminothiocarbonyl, heteroarylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, aryltbiocarbonyl, alkoxythiocarbonyl, or aryloxythiocarbonyl;
R16, Rn and R18 are each, independently, hydrogen, alkyl, aryl or cycloalkyl; m is 0, 1 , or 2; p is O, I, or 2; q is 1 or 2; s is 1 or 2; and
W is NR9, O, or S.
20. The compound of claim 19 wherein the alkyl, aryl and cycloalkyl groups of R13, R14 and R15 are each, independently, optionally substituted with 1 to 5 substituents selected from alkyl, cycloalkyl, heterocycloalkyl, perfluoroalkyl, aryl, heteroaryl, alkoxy, aryloxy, cycloalkyloxy, amino, alkylamino, dialkylamino, carboxy, cyano, oxo, hydroxyl, alkylcarbonyl, alkoxycarbonyl, arylcarbonyl, alkoxycarbonylamino, alkylcarbonylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthio, alkyloxothio, and alkoxycarbonylalkylamino.
21. The compound of claim 19 wherein the arylsulfonyl, arylcarbonyl and heteroarylcarbonyl groups ofR13, R14 and R15 are each, independently, optionally substituted with 1 to 5 substituents selected from hydrogen, halogen, hydroxyl, alkyl, cycloalkyl, perfluoroalkyl, aryl, alkoxy, heterocycloalkyl, heteroaryl, cycloalkyloxy, aryloxy, amino, alkylamino, diallcylamino, alkylthio, alkyloxothio, carboxy, cyano, oxo, alkylcarbonyl, arylcarbonyl,alkoxycarbonyl, alkylcarbonylamino, aminocarbonyl, alkylaminocarbonyl, and dialkylaminocarbonyl.
22. The compound of claim 19 wherein the heterocycloalkyl groups of R13, R14 and R15 are each, independently, optionally substituted with 1 to 5 substituents selected from hydrogen, hydroxyl, alkyl, cycloalkyl, perfluoroalkyl, aryl, heterocycloalkyl, heteroaryl, heteroarylcarbonyl, heteroarylalkylcarbonyl, alkylcarbonyl, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, arylcarbonyl, heteroarylcarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl, heterocycloalkylcarbonylalkyl, carboxyalkylcarbonyl, and arylaminocarbonyl.
23. The compound of claim 19 wherein the alkylcarbonyl groups OfR13, R14 and R15 are each, independently, optionally substituted with 1 to 5 substituents selected from amino, alkylamino, dialkylamino, cycloalkyl, heterocycloalkyl, perfluoroalkyl, aryl, heteroaryl, alkoxy, aryloxy, cycloalkyloxy, carboxy, cyano, oxo, hydroxyl, alkylcarbonyl, alkoxycarbonyl, arylcarbonyl, and alkoxycarbonylamino.
24. The compound of claim 19 wherein the amino groups of the alkylamino and hetercycloalkylamino groups OfR13, R14 and R15 are each, independently, optionally substituted with a substituent selected from hydrogen, alkyl, cycloalkyl, and aryl.
25. The compound of claim 1 wherein R7 is hydrogen and R3 is heteroarylethyl, heteroarylpropyl, arylethyl, heterocycloalkyl, heterocycloalkylethyl, heterocycloalkylpropyl, heterocycloalkylmethyl, heterocyclalkylamino, cycloalkyl, fused cycloalkylaryl, aminoalkyl, or alkoxyalkyl.
26. The compound of claim 25 wherein R7 is hydrogen and R3 is heteroarylethyl, heteroarylpropyl, heterocyclalkylamino, fused cycloalkylaryl, or phenylethyl.
27. The compound of claim 26 wherein R7 is hydrogen and R3 is pyridinylethyl, imidazolylethyl, imidazolylpropyl, heterocyclalkylamino, fused cycloalkylaryl, or phenylethyl.
28. The compound of claim 1 which is N-(2-phenylethyl)-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(2-chlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; iV-[2-(2-methoxyphenyl)ethyl]-3-(phenylsulfonyl)ben2;enesulfonamide; iV-[2-(3-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; 7V-[2-(3,4-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-bromophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-fluorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide; N-[2-(4-chlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N- [2-(4-methoxyphenyl)ethyl] -3 -(phenylsulfonyl)benzenesulfonamide;
N-[2-(4-methylphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-{2-[4-(aminosulfonyl)phenyl]ethyl}-3-(ρhenylsulfonyl)benzenesulfonamide;
N-{2-[3,4-bis(benzyloxy)phenyl]ethyl}-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(4-nitrophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(l,3-benzodioxol-5-yl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
3 -(pheny lsulfony I)-N- { 2-[3 -(trifluoromethyl)phenyl] ethyl } benzenesulfonamide;
N- [2-(3 -chloropheny l)ethy 1] -3 -(phenylsulfonyl)benzenesulfonamide;
N-[2-(2,4-dichlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(2,6-dichlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(2,5-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3,4-dichlorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3,5-dimethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(4-ethoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3-fluorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(2-fluorophenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N- [2-(3 -ethoxy-4-methoxyphenyl)ethy 1] -3 -(pheny lsulfony l)benzenesulfonamide; N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-(4-methoxybenzyl)-3-(phenylsulfonyl)beiizenesulfonamide;
N- [2-(2-bromo-4,5-dimethoxyphenyl)ethyl] -3 -(phenylsulfonyl)benzenesulfonamide;
N-[2-(5-bromo-2-methoxyphenyl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N3- { [3 -(pheny lsulfony l)pheny 1] sulfony 1} -beta-alaninamide ; methyl N-{[3-(phenylsulfonyl)phenyl]sulfonyl}-beta-alaninate;
N-(2-cyanoethyl)-3-(phenylsulfonyl)benzenesulfonamide;
3-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
N-(3-morpholin-4-ylpropyl)-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-(l-methylpyrrolidin-2-yl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
3-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide;
3-(phenylsulfonyl)-N-(2-piperidin- 1 -ylethyl)benzenesulfonamide;
N-[2-(lH"-imidazol-4-yl)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-[2-({[3-(phenylsulfonyl)phenyl]sulfonyl}amino)ethyl]acetamide;
N-(2-morpholin-4-ylethyl)-3-(phenylsulfonyl)benzenesulfonamide;
N- [3 -(2-oxopyrrolidin- 1 -y l)propy 1] -3 -(phenylsulfonyl)benzenesulfonamide ;
N- [2-(diethylamino)ethy 1] -3 -(pheny lsulfony l)benzenesulfonamide;
N-[2-(dimethylamino)ethyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-(3 -methoxypropyl)-3 -(phenylsulfony l)benzenesulfonamide ;
N- [3 -(dimethylamino)propyl] -3 -(pheny lsulfony l)benzenesulfonamide;
N-(2-methoxyethyl)-3-(phenylsulfonyl)benzenesulfonamide;
N-[3-(diethylamino)propyl]-3-(phenylsulfonyl)benzenesulfonamide;
N- [3 -( 1 i7-imidazol- 1 -y l)propy 1] -3 -(phenylsulfony l)benzenesulfonamide;
3-(phenylsulfonyl)-N-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide;
N-[3-(4-methylpiperazin-l-yl)propyl]-3-(phenylsulfonyl)benzenesulfonamide;
N-{[3-(phenylsulfonyl)phenyl]sulfonyl}-beta-alanine;
N-2,3-dihydro-l//-inden-2-yl-3-(phenylsulfonyl)benzenesulfonamide;
N-[(15',2i?)-2-phenylcyclopropyl]-3-(phenylsulfonyl)benzenesulfonamide;
N- [(2i?)-2 -pheny lpropyl] -3 -(phenylsulfony l)benzenesulfonamide ; or
N- [(25)-2-phenylpropyl] -3 -(pheny lsulfony l)benzenesulfonamide .
29. The compound of claim 1 which is 5-[(4-fluorophenyl)sulfonyl]-2-methyl-iV-(2-phenylethyl)benzenesulfonamide;
N-[2-(2-chlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-[2-(2-metlioxyphenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-iV-[2-(3-methoxyphenyl)ethyl]-2-methylbeiizenesulfonamide;
N- [2-(3 ,4-dimethoxypheny l)ethy 1] -5 - [(4-fluorophenyl)sulfonyl] -2-methy lbenzenesulfonamide ; jV-[2-(4-bromophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbeiizenesulfonamide;
N-[2-(4-fluorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[2-(4-chlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-[2-(4-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[2-(4-methylphenyl)ethyl]beiizenesulfonamide; iV-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
N-{2-[3,4-bis(benzyloxy)phenyl]ethyl}-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-iV-[2-(4-nitrophenyl)ethyl]benzenesulfonamide;
N-[2-(l,3-benzodioxol-5-yl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-iV-{2-[3-
(trifluoromethyl)phenyl]ethyl}benzenesulfonamide; iV-[2-(3-chlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[2-(2,4-dichlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
Λ/"-[2-(2,6-dichlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
Λ/-[2-(2,5-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[2-(3,4-dichlorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[2-(355-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[2-(4-ethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide; iV-[2-(3-fluorophenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N- [2-(2-fluoropheny l)ethy 1] -5 - [(4-fluoropheny l)sulfony 1] -2-methy lbenzenesulfonamide;
Λ/-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methy lbenzenesulfonamide ;
N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methy lbenzenesulfonamide ;
5-[(4-fluorophenyl)sulfonyl]-N-(4-methoxybenzyl)-2-methylbenzenesulfonamide; iV-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methy lbenzenesulfonamide ;
N-[2-(5-bromo-2-methoxyphenyl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- methy lbenzenesulfonamide ;
2-Methyl-N- (2-phenylethyl)-5-(phenylsulfonyl) benzene sulfonamide;
N- [2-(2-chloropheny l)ethy 1] -2-methy 1-5 -(pheny lsulfony l)benzenesulfonamide ;
7V-[2-(2-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(3-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
7V-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(4-bromophenyl)ethyl]-2-metb.yl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(4-fluorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N- [2-(4-chloropheny l)ethy 1] -2-methy 1-5 -(pheny lsulfony l)benzenesulfonamide ;
N-[2-(4-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[2-(4-methylphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; iV-{2-[3,4-bis(benzyloxy)phenyl]ethyl}-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[2-(4-nitrophenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(l,3-benzodioxol-5-yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-{2-[3-(trifluoromethyl)phenyl]ethyl}benzenesulfonamide;
N-[2-(3-chlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(2,4-dichlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
Λ/-[2-(2,6-dichlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(2,5-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(3,4-dichlorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3,5-diniethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
7V-[2-(4-ethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3-fluorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(2-fluorophenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
7V-[2-(4-ethoxy-3-methoxyplienyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-(4-methoxybenzyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; N-[2-(5-bromo-2-metihιoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2-phenylethyl)benzenesulfonamide;
N-[2-(2-chlorophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-[2-(2-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-[2-(3-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-iV-[2-(3,4-dimethoxyphenyl)ethyl]-2-methylbenzenesulfonamide; jV-[2-(4-bromophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-chloropb.enyl)sulfonyl]-N-[2-(4-fluorophenyl)ethyl]-2-methylbenzenesulfonamide; iV-[2-(4-chlorophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-[2-(4-methoxyphenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[2-(4-methylphenyl)ethyl]benzenesulfonamide;
N-{2-[4-(aminosulfonyl)phenyl]ethyl}-5-[(4-chlorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-[2-(4-nitrophenyl)ethyl]benzenesulfonamide;
7V-[2-(l,3-benzodioxol-5-yl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-iV-{2-[3-
(trifluoromethyl)phenyl]ethyl}benzenesulfonamide;
Λ/-[2-(3-chlorophenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-iV-[2-(2,4-dichlorophenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-iV-[2-(2,6-dichlorophenyl)ethyl]-2-met]iylbenzenesulfonamide;
5-[(4-cWorophenyl)sulfonyl]-N-[2-(2,5-dimethoxyphenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-A/-[2-(3,4-dichlorophenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-cMorophenyl)sulfonyl]-N-[2-(3,5-dimethoxyphenyl)etiiyl]-2-meth.ylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-[2-(4-ethoxyphenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-[2-(3-fluorophenyl)ethyl]-2-methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-iV-[2-(2-fluoropb.enyl)ethyl]-2-methylbenzenesulfonamide;
5- [(4-chloropheny l)sulfony 1] -N- [2-(3 -ethoxy-4-methoxyphenyl)ethyl] -2- methy lbenzenesulfonamide ;
5-[(4-chlorophenyl)sulfonyl]-N-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-2- methylbenzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-iV-(4-methoxybenzyl)-2-niethylbenzenesulfonamide; N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2- methylbenzenesulfonamide ;
N-[2-(5-bromo-2-methoxyphenyl)ethyl]-5-[(4-chlorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
2-methyl-5-[(4-methylphenyl)sulfonyl]-N-(2-phenylethyl)benzenesulfonamide;
N-[2-(2-chlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(2-methoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(3-methoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide; iV-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(4-bromophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]beiizenesulfonamide;
N-[2-(4-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(4-chlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(4-methoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
2-methy l-N- [2-(4-methy lpheny l)ethy 1] -5 - [(4-methy lpheny l)sulfony ljbenzenesulfonamide;
N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-methyl-5-[(4- methylphenyl)sulfonyl]benzenesulfonamide;
2-methyl-5-[(4-methylphenyl)sulfonyl]-iV-[2-(4-nitroplienyl)ethyl]benzenesulfonamide;
N-[2-(l,3-benzodioxol-5-yl)etiiyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]betizenesulfonamide;
2-methyl-5-[(4-methylphenyl)sulfonyl]-iV-{2-[3-
(trifluoromethyl)phenyl] ethyl } benzenesulfonamide ;
N-[2-(3-chlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(2,4-dicMorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(2,6-dϊcWorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(2,5-dimethoxyphenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(3,4-dichlorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(3,5-dimethoxyphenyl)ethyl]-2-metiiyl-5-[(4-me1±ιylphenyl)sulfonyl]benzenesulfonamide;
N- [2-(4-ethoxyphenyl)ethy 1] -2-methy 1-5- [(4-methy lpheny l)sulfony ljbenzenesulfonamide ; iV-[2-(3-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(2-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-[2-(2-bromo-4,5-dimethoxyphenyl)ethyl]-2-methyl-5-[(4- methylphenyl)sulfonyl]benzenesulfonamide; Λ/-[2-(5-bromo-2-methoxyphenyl)ethyl]-2-methyl-5-[(4- methylphenyl)sulfonyl]benzenesulfonamide;
2-ethyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-N-[2-(2-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-N-[2-(3-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3,4-dimethoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide;
N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-N-[2-(3-fluorophenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-iV-[2-(2-fluorophenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3-ethoxy-4-methoxyplienyl)eth.yl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(4-ethoxy-3-methoxyphenyl)ethyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide;
2-methoxy-iV-(2-phenyletliyl)-5-(phenylsulfonyl)benzenesulfonaniide;
2-methoxy-iV-[2-(2-methoxyphenyl)ethyl]-5-(phenylsulfonyl)benzenesulfonaniide;
2-methoxy-iV- [2-(3 -methoxyphenyl)ethy 1] -5-(phenylsulfonyl)benzenesulfonamide ;
N- [2-(3 ,4-dimethoxypheny l)ethyl] -2-methoxy-5 -(pheny lsulfony l)benzenesulfonamide ;
N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(3-fluorophenyl)ethyl]-2-methoxy-5-(ph.enylsulfonyl)benzenesulfonamide;
N-[2-(2-fluorophenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide;
Λ/-[2-(3-ethoxy-4-methoxyphenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide; iV-[2-(4-ethoxy-3-meth.oxyphenyl)ethyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-iV-(3-phenylpropyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-iV-(3-phenylpropyl)-5-(phenylsulfonyl)benzenesulfonamide;
N-2,3-dihydro-lH-inden-2-yl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
2-metihιyl-iV-[(15r 52i?)-2-phenylcyclopropyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[(2i?)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-2,3-dihydro-lH-inden-2-yl-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-iV-[(15',2i?)-2-p]ienylcyclopropyl]benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-iV-[(2i?)-2-phenylpropyl]benzenesulfonamide;
N-23-dihydro-lH-inden-2-yl-2-methyl-5-[(4-methylpb.enyl)sulfonyl]benzenesulfonamide;
2-methyl-5-[(4-methylphenyl)sulfonyl]-N-[(15',2i?)-2-phenylcyclopropyl]benzenesulfonaniide;
2-methyl-5-[(4-methylphenyl)sulfonyl]-iV-[(2i?)-2-phenylpropyl]benzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-23-dihydro-lH-inden-2-yl-2-methylbenzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-iV-[(15',2i?)-2-phenylcyclopropyl]benzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-iV-[(2i?)-2-phenylpropyl]benzenesulfonaniide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-iV-[(25)-2-phenylpropyl]benzenesulfonamide;
2-methyl-N-[(2,S)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-[(4-methylphenyl)sulfonyl]-Λ/'-[(25)-2-phenylpropyl]benzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-iV-[(2)S)-2-phenylpropyl]benzenesulfonamide;
N-2,3-dihydro-lH"-inden-2-yl-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-N-[(l>S',2i?)-2-phenylcyclopropyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-N-[(2J??)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-2,3-dihydro-lH-inden-2-yl-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide;
2-methoxy-N-[(15',2i?)-2-phenylcyclopropyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-methoxy-N-[(2i?)-2-phenylpropyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-isopropyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-N-(2-phenylethyl)-3-(phenylsulfonyl)benzenesulfonamide;
2-chloro-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-(2-hydroxy-2-methylpropyl)-Ν-(2-phenylethyl)-5- (phenylsulfonyl)benzenesulfonamide;
N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-L-phenylalaninamide; methyl N- { [2 -methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-D-phenylalaninate;
N-(2,3 -dihydro- 1 H-inden- 1 -yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(2-fluorophenyl)ethyl]-3-[(4-methylphenyl)sulfonyl]-5,6,7,8-tetrahydronaphthalene-l- sulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-iV-[(2i?)-2-phenylpropyl]benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-iV-[(2iS)-2-phenylpropyl]benzenesulfonamide;
N-(2-phenylethyl)-5-(phenylsulfonyl)-2-propylbenzenesulfonamide;
5-(phenylsulfonyl)-2-propylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-(2-phenylethyl)-2-propylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-propylbenzenesulfonamide;
N-(2-phenylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)-benzenesulfonamide;
2,4-diisopropyl-iV-(2-ph.enylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
N-(2,3-dihydro-lH-inden-2-yl)-2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-iV-(2-phenylethyl)benzenesulfonamide; or N-(2,3-dihydro-lH-inden-2-yl)-5-[(4-fluoroρlienyl)sulfonyl]-2,4- diisopropy lbenzenesulfonamide .
30. The compound of claim 1 which is
N-(2-hydroxy-2-phenylethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-phenylethyl)-2-methylbenzenesulfonamide; 2-ethyl-5-[(4-fluorophenyl)sulfonyl]-iV-(2-hydroxy-2-phenylethyl)benzenesulfonamide; Λ/r-(2-hydroxy-2-phenylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide; trans-iV-(2-hydroxy-l-methyl-2-phenylethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-iV-[trans-2-hydroxy-l-methyl-2-phenylethyl]-2- methylbenzenesulfonamide;
2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-[(trans)-2-hydroxy-l-methyl-2- phenylethyl]benzenesulfonamide; iV-[(trans)-2-hydroxy-l-methyl-2-phenylethyl]-2,4-dimethyl-5- (phenylsulfonyl)benzenesulfonamide;
N- [( 1 S * ,2 S * )-2-hydroxy cy clohexyl]-2-methy 1-5 -(pheny lsulfony l)benzenesulfonamide or 5-[(4-fluorophenyl)sulfonyl]-iV-(2-hydroxyethyl)-2-isopropylbenzenesulfonamide.
31. The compound of claim 1 which is
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(3-moφholin-4-ylpropyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methyl-5-(phenylsulfonyl)-Λ/-(2-pyridin-4-ylethyl)benzenesulfonamide; 2-ethyl-5-(phenylsulfonyl)-iV-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methoxy-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-methoxy-5-(phenylsulfonyl)-iV-(2-pyridin-4-ylethyl)benzenesulfonamide; 5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide; 2,4-dimethyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide; 2,3-dimethyl-5-(phenylsulfonyl)--V-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-methyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5- { [4-( 1 -cyclohexyl- 1 -hydroxyethy l)pheny 1] sulfony 1 } -2-methy l-iV-(2-pyridin-2- ylethyl)benzenesulfonamide;
5- { [4-( 1 -hydroxy- 1 -pheny lethyl)phenyl] sulfony 1} -2-methy l-iV-(2-pyridin-2- ylethyl)benzenesulfonamide;
5- { [4-( 1 -hydroxy- 1 -methyl-2 -pheny lethyl)phenyl]sulfonyl} -2-methy l-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
5-[(3-cyanophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-methyl-5-(l-naphthylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-hydroxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3,5-difluorophenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2-ylethyl)berizenesulfonamide;
5-[(4-ethylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-acetylphenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(2-ethoxyphenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(2,5-dimethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(2,3-dimethoxyphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(2,4-dimethoxyphenyl)sulfonyl]-2-metihιyl-N-(2-pyridin-2-yleώyl)benzenesulfonamide;
2-methyl-N-(2-pyridin-2-ylethyl)-5-(pyridin-3-ylsulfonyl)benzenesulfonamide;
5-(lH-indol-5-ylsulfonyl)-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4-cyanophenyl)sulfonyl]-2-methyl-7V-(2-pyridin-2-ylethyl)benzenesulfonamide;
5- { [3 -(ethy lsulfony l)phenyl] sulfony 1 } -2-methyl-JV-(2-pyridin-2-y lethy l)benzenesulfonamide ;
2-methyl-5-[(2-methylphenyl)sulfonyl]-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(2-ethylphenyl)sulfonyl]-2-methyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-(biphenyl-2-ylsulfonyl)-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-(biphenyl-4-ylsulfonyl)-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-(biphenyl-3-ylsulfonyl)-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4-tert-butylphenyl)sulfonyl]-2-isopropyl-Ν-(2-pyridin-2- ylethyl)benzenesulfonamide;
5-[(4-tert-butylphenyl)sulfonyl]-2-methyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
5-[(3,5-dimethylphenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-chlorophenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide; 2-isopropyl-5-[(3-methoxyphenyl)sulfonyl]-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-isopropyl-5-[(2-methoxyphenyl)sulfonyl]-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3,5-difluorophenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-cyclohexyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-cyclohexyl-5-[(4-fluorophenyl)sulfonyl]-N-(2-pyridin-2-yleth.yl)benzenesulfonamide;
2-te7Y-butyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
256-dimethyl-3-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-{ [5-(dimethylamino)- 1 -naphthyljsulfonyl} -2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide;
5-[(3-cliloro-5-cyanophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide
2-methyl-3-(phenylsulfonyl)-iV-(2-pyridm-2-ylethyl)benzenesulfonamide;
5- [(3 , 5 -dichloropheny l)sulfony 1] -2-isopropy l-iV-(2-pyridin-2-y lethy l)benzenesulfonamide;
2-isopropyl-iV-(2-pyridin-2-ylethyl)-5-{[3-
(trifluoromethoxy)pheny 1] sulf ony 1 } benzene sulfonamide ;
5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-iV-(2-pyridin-2- ylethyl)benzenesulfonamide ;
2-isopropyl-iV-(2-pyridm-2-ylethyl)-5-{[3-
(trifluoromethyl)phenyl]sulfonyl}benzenesulfonamide;
5-[(5-chloro-2-methoxyphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
2-isopropyl-iV-(2-pyridin-2-ylethyl)-5-(quinolin-8-ylsulfonyl)benzenesulfonamide;
5-[(2,5-dichloro-3-thienyl)sulfonyl]-2-isopropyl-Λ/-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(5-chloro-l,3-dimethyl-lH-pyrazol-4-yl)sulfonyl]-2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
2-isopropyl-5-[(l-methyl-l/f-imidazol-4-yl)sulfonyl]-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
5-[(3-chloro-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4,4-dimethyl-2-oxo-l ,4-dihydro-2H-3, 1 -benzoxazin-6-yl)sulfonyl]-2-isopropyl-N-(2-pyridin-
2-y lethy l)benzenesulfonamide ;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-4- ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-3- ylethyl)benzenesulfonamide;
5-[(3-cyanophenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-yletliyl)benzenesulfonamide; 5-(lH-indol-5-ylsulfonyl)-2-isopropyl-iV-(2-ρyridin-2-ylethyl)benzenesulfonaniide;
5-(phenylsulfonyl)-2-propyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-propyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-(phenylsulfonyl)-Ν-(2-pyridin-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide;
2-isopropyl-5-(phenylsulfinyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-bromo-2-methylphenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(2-chloro-6-methylphenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-isopropyl-5-[(3-methylphenyl)sulfonyl]-iV-(2-pyridin-2-yletliyl)benzenesulfonaiiiide;
2-isopropyl-5-[(i?)-pb.enylsulfinyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-isopropyl-5-[(5)-phenylsulfinyl]-iV-(2-pyridin-2-yletb.yl)benzenesulfonamide;
2-bromo-5-(phenylsulfonyl)-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-cyano-2-methylphenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(3-acetyl-2-methylphenyl)sulfonyl]-2-isopropyl-iV-(2-pyridm-2-ylethyl)benzenesulfonamide;
5-[(3-chloro-4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4-fluoro-2-me1iιylphenyl)sulfonyl]-2-isopropyl-iV-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-isopropyl-5-[(l-methyl-lH-indol-5-yl)sulfonyl]-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-isopropyl-5- { [2-methyl-4-(methylammo)plienyl]sulfonyl} -N-(2-pyridin-2- ylethyl)benzenesulfonamide;
5 - { [3 -chloro-4-(methy lamino)pheny 1] sulfonyl} -2-isopropy l-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
2,4-diisopropyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2,4-diisopropyl-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide;
2,4-diisopropyl-5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-pyridin-3-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide;
2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide;
2-chloro-5-(phenylsulfonyl)-N-(2-pyridin-4-ylethyl)benzenesulfonamide; or
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-Ν-[2-(l-oxidopyridin-3- yl)ethyl]benzenesulfonamide.
32. The compound of claim 1 which is
5- [(4-fluoropheny l)sulfonyl] -N- [2-( 1 /i-imidazol-4-y l)ethy 1] -2-methy lbenzenesulfonamide ; 5- [(4-fluorophenyl)sulfony 1] -N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -2-methy lbenzenesulfonamide;
N-[2-(l/J-imidazol-4-yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(li/'-imidazol-l-yl)propyl]-2-niethyl-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-N-[2-(lH"-imidazol-4-yl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-ethy 1-N- [3 -( 1 H-imidazol- 1 -yl)propy 1] -5-(phenylsulfony l)benzenesulfonamide ;
N-[2-(li7-imidazol-4-yl)etliyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide;
5-[(4-chlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
5-[(4-azidophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
Ν-[2-(lH-indol-3-yl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(l/f-imidazol-l-yl)propyl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
2-ethy 1-5- [(4-fluorophenyl)sulfonyl] -N- [2-( 1 H-imidazol- 1 -yl)ethy l]benzenesulfonamide ;
2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-[3-(li7-imidazol-l-yl)propyl]benzenesulfonamide;
5-({4-[ethyl(methyl)amino]phenyl}sulfonyl)-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -y l)propyl] -2-methy 1-5 - [(4-pyrrolidin- 1 - ylphenyl)sulfonyl]benzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -4-methy 1-3 -(pheny lsulfiny l)benzenesulfonamide;
5 - [(4-fluoropheny l)sulfony I]-N- [2-( 1 H-imidazol- 1 -y l)ethyl] -2-methy lbenzenesulfonamide ;
N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-{[4-
(methy lamino)pheny 1] sulfony 1 } benzenesulfonamide ;
5- { [4-(ethylamino)phenyl] sulfony 1} -N- [3 -( 1 H-imidazol- 1 -y l)propyl] -2- methylbenzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -yl)propyl] -2-methy 1-5- [(4-piperidin- 1 - ylphenyl)sulfonyl]benzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-[(4-morpholin-4- ylphenyl)sulfonyl]benzenesulfonamide;
N- [2-( 1 H-imidazol- 1 -y l)ethy 1] -2-methy l-5-(phenylsulfonyl)benzenesulfonamide ;
N- [3 -( 1 H-imidazol- 1 -y l)propyl] -5 - [(4-methoxypheny l)sulfonyl] -2-methy lbenzenesulfonamide ;
N- [3 -( 1 H-imidazol- 1 -y l)propyl] -5 - [(2-methoxypheny l)sulfonyl] -2-methy lbenzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-4-methyl-3-(phenylsulfonyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2-isopropylbenzenesulfonamide; 5- [(4-fluoropheny l)sulfony 1] -N- [3 -( 1 H-imidazol- 1 -y l)propyl] -2-isopropy lbenzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -5 - [(3 -methoxypheny l)sulfony 1] -2-methy lbenzenesulfonamide ;
N-[2-(l/f-imidazol-l-yl)ethyl]-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(lϋf-imidazol-l-yl)propyl]-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH"-imidazol-l-yl)ethyl]-2,4-dimethylbenzenesulfonamide;
5- [(4-fluoropheny l)sulfony 1] -N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -2 ,4-dimethy lbenzenesulfonamide ;
2-chloro-N-[3-(lH"-imidazol-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-5-[(4-isopropylphenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[3-(l/i-imidazol-l-yl)propyl]-2-methyl-5-(2-naphthylsulfonyl)benzenesulfonamide;
5-[(3,4-dichlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
5-[(3-chlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
5-[(3,5-dimethylphenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
5-[(3,5-dichlorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
5-[(2,5-dichlorophenyl)sulfonyl]-N-[3-(li7-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -2-methy 1-5 -(pheny lsulfinyl)benzenesulfonamide ;
N-[2-(lH-imidazol-l-yl)ethyl]-2,3-dimethyl-5-(phenylsulfonyl)benzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -yl)propyl] -2,3 -dimethyl-5-(phenylsulfony l)benzenesulfonamide ;
5-{[4-(cyclohexylamino)phenyl]sulfonyl}-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide;
5-( {4- [(2-cyanoethy l)amino]pheny 1 } sulfony I)-N- [3 -( 1 H-imidazol- 1 -yl)propy 1] -2- methylbenzenesulfonamide;
5-[(4-{[(15,25)-l-(hydroxymethyl)-2-methylbutyl]amino}phenyl)sulfonyl]-N-[3-(lH-imidazol- l-yl)propyl]-2-methylbenzenesulfonamide;
N-[3-(lH"-imidazol-l-yl)propyl]-2-methyl-5-({4-[(l- phenylethyl)amino]phenyl}sulfonyl)benzenesulfonamide;
5-[(2,3-dichlorophenyl)sulfonyl]-N-[3-(l/i-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
N- [3 -( 1 /f-imidazol- 1 -y l)propyl] -2-methy 1-5 -(2-thieny lsulfony l)benzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-2-memyl-5-[(2-methyl-3-furyl)sulfonyl]benzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-2-methyl-5-{[4-(tetrahydro-2H-pyran-4- ylamino)phenyl]sulfonyl}benzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -y l)propyl] -5-({4-[(3 -isopropoxypropyl)amino]pheny 1 } sulfony l)-2- methylbenzenesulfonamide; 5-( {4- [(cyclopropylmethy l)amino]pheny 1 } sulfony I)-N- [3 -( 1 H-imidazol- 1 -y l)proρy 1] -2- methylbenzenesulfonamide;
5-({4-[(li?,2i-,41S)-bicyclo[2.2.1]hept-2-ylamino]phenyl}sulfonyl)-N-[3-(lH"-imidazol-l- yl)propyl]-2-methylbenzenesulfonamide;
5 - { [4-(benzylamino)phenyl] sulfony 1} -N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -2- methylbenzenesulfonamide;
5-[(4-{[(l^-l-cyclohexylethyl]amino}phenyl)sulfonyl]-N-[3-(lH'-imidazol-l-yl)piOpyl]-2- methylbenzenesulfonamide;
5-[(4-{[(li?)-l-cyclohexylethyl]amino}phenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide ;
5-( {4- [(2-hydroxybutyl)amino]phenyl } sulfony I)-N- [3 -( 1 H-imidazol- 1 -y l)propyl] -2- methylbenzenesulfonamide;
N-[3-(lH-imidazol-l-yl)propyl]-2-memyl-5-[(4-{[4-
(trifluoromethyl)benzyl]amino}phenyl)sulfonyl]benzenesulfonamide;
5-[(2-chlorophenyl)sulfonyl]-N-[3-(l/f-imidazol-l-yl)propyl]-2 -methylbenzenesulfonamide;
Ν-(tert-butyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
5- [(4-tert-butylphenyl)sulfony 1] -N- [3 -( 1 H-imidazol- 1 -yl)propy 1] -2- isopropylbenzenesulfonamide;
5-[(4-tert-butylphenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2- methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-4-yl)ethyl]-2-isopropylbenzenesulfonamide;
5-( {4- [(2-cyanoethyl)amino]pheny 1 } sulfony I)-N- [2-( 1 H-imidazol- 1 -y l)ethyl] -2- isopropylbenzenesulfonamide;
N-[2-(lH-imidazol-l-yl)ethyl]-2-isopropyl-5-{[4-
(methylamino)phenyl] sulfonyl} benzenesulfonamide;
5-({4-[(2-hydroxybutyl)amino]phenyl}sulfonyl)-N-[2-(lH-imidazol-l-yl)ethyl]-2- isopropylbenzenesulfonamide;
5-[(4-{[(25)-l-(hydroxymethyl)-2-methylbutyl]amino}phenyl)sulfonyl]-N-[2-(lH-imidazol-l- yl)ethyl]-2-isopropylbenzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -y l)propy 1] -2-methy 1-3 -(phenylsulfonyl)benzenesulfonamide;
N-[3-(lH-Imidazol-l-yl)propyl]-5-(phenylsulfonyl)-2-propylbenzenesulfonamide;
5-[(4-Fluorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-propylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[2-(2-methyl-lH-iniidazol-l- yl)ethyl]benzenesulfbnamide;
N-[2-(2-ethyl-lH-imidazol-l-yl)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[2-(2-isopropyl-lH-imidazol-l- yl)ethyl]benzenesulfonamide or
N- [3 -( 1 H-Imidazol- 1 -yl)propyl] -2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide.
33. The compound of claim 1 which is
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[2-(l-methylpyrrolidin-2-yl)ethyl]benzenesulfonamide;
5 - [(4-fluoropheny l)sulfony 1] -2-methy l-N-(2-piperidin- 1 -y lethyl)benzenesulfonamide ;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-morpholin-4-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[3-(2-oxopyrrolidin-l-yl)propyl]benzenesulfonamide;
N-[3-(dimethylamino)propyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-(2-methoxyethyl)-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[3-(4-methylpiperazin-l- yl)propyl]benzenesulfonamide;
2-methyl-N-(3-moφholin-4-ylpropyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[2-(l-methylpyrrolidin-2-yl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-(2-piperidin-l-ylethyl)benzenesulfonamide;
2-methyl-N-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[3-(2-oxopyrrolidin-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-(3 -pyrrolidin- 1 -ylpropyl)benzenesulfonamide;
2-methy 1-N- [3 -(4-methy lpiperazin- 1 -yl)propyl] -5-(phenylsulfony l)benzenesulfonamide ;
2-ethyl-N-(2-moφholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-5-(phenylsulfonyl)-N-(3-pyrrolidin-l-ylpropyl)benzenesulfonamide;
2-methoxy-N-(2-morpholin-4-ylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
2-methoxy-5 -(phenylsulfony l)-N-(3 -pyrrolidin- 1 -y lpropyl)benzenesulfonamide ;
5-[(4-chlorophenyl)sulfonyl]-2-methyl-N-(2-morpholin-4-ylethyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-tetrahydro-2/i'-pyran-4-ylbenzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide; 2-etliyl-5-(phenylsulfonyl)-iV-tetrahydro-2/i'-pyran-4-ylbenzenesulfonaniide;
2-ethyl-5-(phenylsulfonyl)-N-(2-tetrahydro-2//-pyran-4-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-iV-tetrahydro-2H-pyran-4-ylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(2-tetrahydro-2H-pyran-4-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-Λ/-tetrahydro-2H-pyran-4-ylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-tetxahydro-2H-pyran-4- ylethyl)benzenesulfonamide;
2,4-dimethyl-5-(phenylsulfonyl)-N-tetrahydro-2H"-pyran-4-ylbenzenesulfonamide;
2,4-dimethyl-5-(phenylsulfonyl)-N-(2-te1xahydro-2H-pyran-4-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-N-(tetrahydro-2H'-pyran-4-yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2,4-dimethyl-iV-[2-(tetrahydro-2H'-pyran-4- yl)ethyl]benzenesulfonamide;
2-chloro-N-(2-morpholin-4-ylethyl)-5-(pb.enylsulfonyl)benzenesulfonamide;
2,3-dimethyl-5-(phenylsulfonyl)-Λ/'-(tetrahydro-2H-pyran-4-yl)benzenesulfonaniide;
2,3-dimethyl-5-(phenylsulfonyl)-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzenesulfonamide;
2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-(tetrahydro-2H"-pyran-4- yl)benzenesulfonamide;
2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-[2-(tetrahydro-2H-pyran-4- yl)ethyl]benzenesulfonamide;
2-chloro-5-(phenylsulfonyl)-iV-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
5-[(4-bromophenyl)sulfonyl]-2-methyl-iV-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
5-[(4-cyanophenyl)sulfonyl]-2-methyl-N-(tetrahydro-27f-pyran-4-yl)benzenesulfonamide;
N- [3 -( 1 H-imidazol- 1 -y l)propyl] -2-methyl-5 -(pyridin-2-ylsulfony l)benzenesulfonamide;
5-[(2,4-dicUorophenyl)sulfonyl]-N-[3-(lH-imidazol-l-yl)propyl]-2-methylbenzenesulfonamide;
5-[(4-acetylphenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
5-[(4-bromophenyl)sulfonyl]-2-methyl-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-(tetrahydro-2i7-pyran-4-ylmethyl)benzenesulfonamide;
2-ethyl-5-[(4-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide;
2,4-dimethyl-5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesύlfonamide;
Ν-(2,2-dimethylpropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; 5-({4-[(lE)-N-hydroxyethanimidoyl]phenyl}sulfonyl)-2-methyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
5-[(4-acetylphenyl)sulfonyl]-2-methyl-iV-(2-pyridm-2-ylethyl)benzenesulfonaniide;
5- { [4-( 1 -hydroxy- 1 -methylethyl)phenyl]sulfonyl} -2-methy l-JV-(2-pyridin~2- y lethyl)benzenesulfonamide ;
2-methyl-5-(phenylsulfonyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)benzenesulfonamide;
N-(l-benzylpiperidm-4-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-(l-benzylpyrrolidin-3-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; ethyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate;
5-[(4-tert-butylphenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
5-[(4-tert-butylphenyl)sulfonyl]-2-methyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide; tert-butyl 4-( { [2-methyl-5-(phenylsulfonyl)pheny l]sulfonyl} amino)piperidine- 1 - carboxylate;
2-methyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-[l-(phenylsulfonyl)piperidin-4- yl]benzenesulfonamide;
N-[l-(2-furoyl)piperidin-4-yl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[l-(2-methoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
N-[l-(3-methoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
N-[l-(3,4-dimethoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-{l-[3-(trifluoromethyl)benzoyl]piperidin-4- yl}benzenesulfonamide;
N-[l-(4-chlorobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
N-[l-(4-methoxybenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[l-(4-methylbenzoyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide;
N-[l-(methoxyacetyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[l-(phenylacetyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
N- [ 1 -(cyclohexy lcarbonyl)piperidin-4-yl] -2-methy 1-5 - (phenylsulfony l)benzenesulfonamide;
2,6-dimethyl-3-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
N-[l-(cyclopropylcarbonyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
N-[I -(4-cyanobenzoyl)piperidin-4-y 1] -2-methy 1-5- (phenylsulfony l)benzenesulfonamide ;
N-[l-(3-cyanobenzoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; 2-methyl-N-[l-(methylsulfonyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide;;
N-(l-acetylpiperidin-4-yl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide
N-(4-{[4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidin-l- y 1] carbony 1} phenyl)acetamide ;
2-methyl-N-{ 1 -[(1 -methyl- lH-imidazol-4-yl)sulfonyl]piperidin-4-yl} -5-
(pheny lsulfony l)benzenesulfonamide ;
2-methyl-5-(phenylsulfonyl)-N-[l-(2-thienylsulfonyl)piperidin-4- yl]benzenesulfonamide;
N-( 1 - { [5 -(dimethy lamino)- 1 -naphthy 1] sulfonyl } piperidin-4-y l)-2-methy 1-5 -
(phenylsulfonyl)benzenesulfonamide;
N- [ 1 -( 1 ,3 -benzodioxol-5-ylcarbony l)piperidin-4-y 1] -2-methy 1-5 -
(phenylsulfonyl)benzenesulfonamide;
N-[I -(isoxazol-5 -y lcarbony l)piperidin-4-y 1] -2-methy 1-5- (phenylsulfony l)benzenesulfonamide ;
N-[l-(N,N-dimethylglycyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide; prop-2-yn-l-yl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine- 1- carboxylate; methyl 4-( { [2-methy l-5-(pheny lsulfony l)phenyl] sulfonyl} amino)piperidine- 1 - carboxylate;
2-methoxyphenyl 4-({[2-methyl-5- (phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate;
N-(tert-butyl)-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine- 1- carboxamide;
N-cyclohexy l-4-( { [2-methy 1-5 -(phenylsulfony l)pheny 1] sulfonyl} amino)piperidine- 1 - carboxamide;
2-methyl-iV-(2-morpholin-4-ylethyl)-3-(phenylsulfonyl)benzenesulfonamide;
2-methyl-N-[l-(2-naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-[l-(2-thienylcarbonyl)piperidin-4- yl]benzenesulfonamide; isobutyl 4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate;
N- { 1 -[4-(dimethylamino)benzoyl]piperidin-4-yl} -2-methy 1-5-
(pheny lsulfony l)benzenesulfonamide ; ;
4-fiuorophenyl 4-( { [2-methyl-5-(pheny lsulfony l)phenyl] sulfonyl} amino)piperidine- 1 - carboxylate
N-ethyl-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l- carboxamide;
2-methyl-N-[l-(morpholin-4-ylcarbonyl)piperidin-4-yl]-5- (phenylsulfonyl)benzenesulfonamide; N,N-dimethyl-4-({[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}ammo)piperidine-l- carboxamide;
N-[l-(3,3-dimethylbutanoyl)piperidin-4-yl]-2-methyl-5- (phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-[l-(pyridin-3-ylcarbonyl)piperidin-4- yl]benzenesulfonamide; tert-butyl 4- [( { 5- [(4-fluorophenyl)sulfony 1] -2- isopropy lphenyl } sulfony l)amino]piperidine- 1 - carboxylate;
N-(I -{ [5-(dimethylamino)-l -naphthyl]sulfonyl}piperidin-4-yl)-5-[(4- fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[l-(methoxyacetyl)piperidin-4- yljbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-piperidin-4-ylbenzenesulfonamide;
N-(l-benzylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide; ethyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropy lphenyl} sulfony l)amino]piperidine-l- carboxylate;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-l- ylethyl)benzenesulfonamide; tert-butyl 4-{[(2-isopropyl-5-{[4-
(methy lamino)pheny 1] sulfony 1} phenyl)sulfonyl] amino } piperidine- 1 -carboxylate;
N-(l-acetylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide;
N-[l-(cyclopropylcarbonyl)piperidin-4-yl]-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide;
N-[I -(4-cyanobenzoyl)piperidin-4-y 1] -5- [(4-fluorophenyl)sulfonyl] -2- isopropylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(te1xahydrofuran-2- ylmethyl)benzenesulfonamide;
5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2H"-pyran-4- yl)benzenesulfonamide;
5-( {4- [(2-cyanoethyl)amino]phenyl} sulfonyl)-2-isopropyl-N-(tetrahydro-2H-pyran-4- y lmethyl)benzenesulfonamide ;
5-({4-[(2-cyanoethyl)amino]phenyl}sulfonyl)-2-isopropyl-iV-[2-(tetrahydro-2H"-pyran-4- yl)ethyl]benzenesulfonamide;
Ν-CS'^'-dihydroxy-S-oxo-SΗ-spirop-benzofuran-l^'-xanthenl-S-y^^-tCfS-^- fluorophenyl)sulfonyl] -2-isopropy lphenyl} sulfony l)amino]piperidine- 1 - carbothioamide;
2-isopropyl-5-[(2-methylphenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; 5-[(3-chloro-2-methylphenyl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-iV'-(tetrahydro-2/i-pyran-4- y lmethyl)benzenesulfonamide ;
5- { [4-(dimethylamino)phenyl] sulfonyl} -2-isopropyl-Λ/-(tetrahydro-2/Z'-pyran-4- yl)benzenesulfonamide;
5- { [4-(dimethylamino)phenyl]sulfonyl} -2-isopropyl-iV-(tetrahydro-2if-pyran-4- ylmethyl)benzenesulfonamide;
5-{[4-(dimethylamino)phenyl]sulfonyl}-2-isopropyl-Λ/-[2-(tetrahydro-2H-pyran-4- yl)ethyl]benzenesulfonamide;
2-isopropyl-5- { [4-(4-methylpiperazin- 1 -yl)phenyl] sulfonyl} -7V-(tetrahydro-2H"-pyran-4- yl)benzenesulfonamide;
2-isopropyl-5- { [4-(4-methylpiperazin- 1 -yl)phenyl]sulfonyl} -N-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide;
2-isopropyl-5-{[4-(4-methylpiperazin-l-yl)phenyl]sulfonyl}-N-[2-(tetrahydro-2H'-pyran-4- yl)ethyl]benzenesulfonamide;
5-(phenylsulfonyl)-2-propyl-N-(tetrahydro-2i/-pyran-4-yl)benzenesulfonamide;
5-(phenylsulfonyl)-2-propyl-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide;
5 -(pheny lsulfony l)-2-propy l-N- [2-(tetrahy dro-2H-pyran-4-yl)ethyl]benzenesulfonamide ; tert-butyl 4-( { [5 -(pheny lsulfony l)-2-propylphenyl] sulfonyl} amino)piperidine- 1 -carboxylate ;
5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-(tetrahydro-2H-pyran-4-ylmethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-propyl-N-[2-(tetrahydro-2H-pyran-4- yl)ethyl]benzenesulfonamide ; tert-Butyl 4-[({5-[(4-fluorophenyl)sulfonyl]-2-propylphenyl}sulfonyl)amino]piperidine-l- carboxylate;
2-isopropyl-5-{[4-(methylamino)phenyl]sulfonyl}-N-piperidin-4- ylbenzenesulfonamide;
5-[(5-chloro-l,3-dimethyl-lH-pyrazol-4-yl)sulfonyl]-2-isopropyl-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-[l-(niθφholm-4-ylcarbonyl)piperidin- 4- yl]benzenesulfonamide; 4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N,N- dimethylpiperidine-
1-carboxamide;
N-(I -benzylpiperidin-4-yl)-5- [(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-piperidin-4-ylbenzenesulfonamide;
5 -( { 4- [(2-cy anoethyl)(methyl)amino]pheny 1 } sulfony l)-2-isopropy l-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
5-({4-[(2-cyanoethyl)(methyl)amino]phenyl}sulfonyl)-2-isopropyl-N-(tetrahydro-2H-pyran-4- ylmethyl)benzenesulfonamide;
N-(l-acetylpiperidin-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
N-[I -(4-cyanobenzoy l)piperidin-4-y 1] -5 - [(4-fiuoropheny l)sulfony 1] -2- methylbenzenesulfonamide ;
4- [( { 5- [(4-fluoropheny l)sulfony 1] -2-methy lpheny 1} sulfony l)amino] -N3N- dimethy lpiperidine- 1 - carboxamide;
5-[(4-fluorophenyl)sulfonyl]-N-[l-(methoxyacetyl)piperidin-4-yl]-2- methylbenzenesulfonamide;
2-isopropyl-5 - [(3 -methoxyphenyl)sulfony 1] -N-(tetrahydro-2/i-pyran-4-y l)benzenesulfonamide;
5-{[4-(dimethylamino)-2-methylphenyl]sulfonyl}-2-isopropyl-N-(2-pyridin-2- ylethyl)benzenesulfonamide;
2-(dimethylamino)-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-methyl-N-[l-(morpholin-4-ylcarbonyl)piperidin-4- yl]benzenesulfonamide;
2-chloro-5-[(3-methylphenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
2-chloro-5-[(3-methoxyphenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
2-cUoro-5-[(l-meώyl-lH-indol-5-yl)sulfonyl]-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethyl)benzenesulfonamide;
2,4-diisopropyl-5-(phenylsulfonyl)-Λ/'-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
2,4-diisopropyl-5-(phenylsulfonyl)-iV-(tetrahydro-2H"-pyran-4-ylmethyl)benzenesulfonamide;
2,4-diisopropyl-5-(phenylsulfonyl)-N-[2-(tetrahydro-2H"-pyran-4-yl)ethyl]benzenesulfonamide;
5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(tetrahydro-2H"-pyran-4-yl)benzenesulfonamide;
2-chloro-5-[(4-fluorophenyl)sulfonyl]-iV-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide; tert-butyl 4-({[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate 2-chloro-5-(phenylsulfonyl)-iV-piperidin-4-ylbenzenesulfonaniide;; tert-butyl 4-[4-({4-isopropyl-3-[(tetrahydro-2H*-pyran-4- ylamino)sulfonyl]pheny 1} sulfonyl)phenyl]piperazine- 1 -carboxylate
5-( {A-cis-3 ,5-dimethylpiperazin- 1 -ylphenyl} sulfonyl)-2-isopropy l-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide ;
5-({4-trαn>s'-2,5-dimeth.ylpiperazin-l-ylplienyl}sulfonyl)-2-isopropyl-iV-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide;
2-isopropyl-5-[(4-piperazin-l-ylphenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4- yl)benzenesulfonamide ;
5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-(tetrab.ydro-2H"-pyran-4- ylmethyl)benzenesulfonamide;
5-[(4-Fluorophenyl)sulfonyl]-2,4-diisopropyl-N-[2-(tetrahydro-2H"-pyran-4- yl)ethy ljbenzenesulfonamide ;
2-chloro-N-[3-(4-methylpiperazin-l-yl)propyl]-5-(phenylsulfonyl)benzenesulfonamide; l-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}-Λ/",Λ/-diethylpyrrolidin-3-amine; ethyl 1 - { [2-chloro-5 -(pheny lsulfony l)pheny 1] sulfony 1 } piperidine-3 -carboxylate;
2-chloro-5-(phenylsulfonyl)-iV-[l-(trifluoroacetyl)piperidin-4-yl]benzenesulfonamide;
2-chloro-N-[l-(2,2-dimethylpropanoyl)piperidin-4-yl]-5-φhenylsulfonyl)benzenesulfonamide;
N-(tert-butyl)-4-( { [2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl} amino)piperidine- 1 - carboxamide;
2-cWoro-N-[l-(morpholin-4-ylcarbonyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide; or
2-chloro-iV-(l-cyanopiperidin-4-yl)-5-(phenylsulfonyl)benzenesulfonamide.
34. The compound of claim 1 which is
Λ^-({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)-beta-alaninamide; methyl N-({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)-beta-alaninate;
N-(2-cyanoethyl)-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-{2-[({5-[(4-fluorophenyl)sulfonyl]-2-methylphenyl}sulfonyl)amino]ethyl}acetamide;
N-[2-(diethylamino)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
N-[2-(dimethylamino)ethyl]-5-[(4-fluorophenyl)sulfonyl]-2-methylbenzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-Λ/-(3-methoxypropyl)-2-methylbenzenesulfonamide; N- [3 -(diethy lamino)propyl] -5 - [(4-fluoropheny l)sulfony l]-2-methy lbenzenesulfonamide ;
N- ({5-[(4-fluorophenyl) sulfonyl]-2-methylphenyl} sulfonyl)-beta-alanine; iV3-{[2-metliyl-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-alaninamide; methyl N-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-alaninate;
N-[2-(diethylamino)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(dimethylamino)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; iV-(3-methoxypropyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[3-(dimethylamino)propyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide; iV-(2-methoxyethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N- [3 -(diethy lamino)propy 1] -2-methy 1-5 -(pheny lsulfony l)benzenesulfonamide; methyl iV-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-alaninate;
2-ethyl-iV-(3-methoxypropyl)-5-(phenylsulfonyl)benzenesulfonamide; iV-[3-(dimethylamino)propyl]-2-ethyl-5-(phenylsulfonyl)benzenesulfonamide;
2-ethyl-N-(2-methoxyethyl)-5-(phenylsulfonyl)benzenesulfonamide;
N- [3 -(diethy lamino) propyl]-2-ethyl-5- (phenylsulfonyl) benzene sulfonamide; methyl N-{[2-methoxy-5-(phenylsulfonyl)phenyl]sulfonyl}-beta-alaninate;
2-methoxy-N-(3-methoxypropyl)-5-(phenylsulfonyl)benzenesulfonamide;
7V-[3-(dimethylamiiio)propyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide;
2-methoxy-N-(2-methoxyethyl)-5-(phenylsulfonyl)benzenesulfonamide; iV-[3-(diethylamino)propyl]-2-methoxy-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-Ν-propylbenzenesulfonamide;
N-( 1 -ethylpropyl)-2-methyl-5-(phenylsulfony l)benzenesulfonamide;
N-cyclobutyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-cyclopentyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-cyclohexyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide;
N-(2-hydroxy- 1 , 1 -dimethylethyl)-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-cyclopropyl-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-cyclopropyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide;
N-cyclobutyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide;
N-cyclopentyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide;
N-cyclohexyl-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide; N-cyclopentyl-5-(phenylsulfonyl)-2-propylbenzenesulfonamide; N-cyclopentyl-5-[(4-fluorophenyl)sulfonyl]-2-propylbenzenesulfonamide; N-cyclopentyl-2,4-diisopropyl-5-(phenylsulfonyl)benzenesulfonamide; N-cyclopentyl-5-[(4-fluorophenyl)sulfonyl]-2,4-diisopropylbenzenesulfonamide; 2-chloro-N-(2-cyanoethyl)-5-(phenylsulfonyl)benzenesulfonamide; or methyl Λ/-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}-2-methylalaninate.
35. The compound of claim 1 which is iV-[2-(3,4-dimethoxyphenyl)ethyl]-Λζ2-dimethyl-5-(phenylsulfonyl)benzenesulfonamide;
N-allyl-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-5-(phenylsulfonyl)-N-prop-2- ynylbenzenesulfonamide;
N-[2-(2-fluorophenyl)ethyl]-N,2-dimethyl-5-[(4-methylphenyl)sulfonyl]benzenesulfonamide;
N-allyl-N- [2-(2-fluorophenyl) ethyl]-2-methyl-5- [(4-methylphenyl) sulfonyl] benzene sulfonamide; iV-[2-(2-fluorophenyl)ethyl]-2-methyl-5-[(4-methylphenyl)sulfonyl]-N-ρrop-2- ynylbenzenesulfonamide;
Λζ,2-dimethyl-N-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
1 - { [2-methyl-5-(phenylsulfonyl)phenyl] sulfonyl} -4-(2-oxo-2-pyrrolidin-l -y lethyl)piperazine;
Nr/V-diethyl-N-[2-(4-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]amine;
4-[2-(4-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]morpholine; l-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-4-(2-pyrrolidin-l-ylethyl)piperazine;
4-[3-(4-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)propyl]morpholine;
2-ethyl-iV-methyl-iV-(2-phenylethyl)-5-(phenylsulfonyl)benzenesulfonamide;
1 - { [2-ethyl-5-(phenylsulfonyl)phenyl] sulfonyl} -4-(2-oxo-2-pyrrolidin- 1 -ylethyl)piperazine;
N,N-diethyl-N-[2-(4-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]amine;
4-[2-(4-{[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]morpholine;
1 - { [2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl} -4-(2-pyrrolidin- 1 -ylethyl)piperazine;
4- [3 -(4- { [2-ethyl-5 -(pheny lsulfony l)phenyl] sulfonyl }piperazin- 1 -y l)propyl]morpholine ;
N-[I -(cyclopropy lcarbony l)piperidin-4-yl]-N-( { 5 - [(4-fluoropheny l)sulfonyl] -2- methylphenyl}sulfonyl)cyclopropanecarboxamide;
1 -{ [2-chloro-5-(phenylsulfonyl)phenyl] sulfonyl } -4-pyrrolidin- 1 -ylpiperidine; 4-[2-(4-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperazin-l-yl)ethyl]morpholine; l-(l,3-benzodioxol-5-ylmethyl)-4-{[2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperazine;
Figure imgf000490_0001
tert-butyl (1 -{ [2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl}piperidin-4-yl)carbamate; 2-chloro-iV-methyl-5-(phenylsulfonyl)-iV-(2-pyridin-2-ylethyl)benzenesulfonamide; or 1 - { [2-chloro-5-(phenylsulfonyl)phenyl]sulfonyl} -4-[(2,5-dimethyl- 1/f-pyiτol- 1 - yl)methyl]piperidine.
36. The compound of claim 1 which is
2-chloro-N-(2-hydroxy- 1 , 1 -dimethylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-N-(cyanomethyl)-5-(phenylsulfonyl)benzenesulfonamide; N-(2-cyanoethyl)-5-[(4-fluorophenyl)sulfonyl]-2-isopropylbenzenesulfonamide; 2-methyl-N-(3-oxo-3-pyrrolidin-l-ylpropyl)-5-(phenylsulfonyl)benzenesulfonamide; N-(tert-butyl)-Λ'3-{[2-methyl-5-(phenylsulfonyl)phenyl]sulfonyl}-β-alamnamide; ^-{P-methyl-S-Cphenylsulfony^phenyηsulfonylJ-iV-Cl^^^-tetrahydronaphthalen-l-yO-β- alaninamide;
N-methyl-A^-IP-methyl-S-Cphenylsulfony^phenyllsulfonylJ-N-phenyl-P-alaninamide; 2-methyl-N-[3-(6-methyl-3,4-dihydroquinolin-l(2H)-yl)-3-oxopropyl]-5- (phenylsulfonyl)benzenesulfonamide;
2-chloro-N-(2-hydroxyethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-iV-(2-hydroxy-l-methylethyl)-5-(phenylsulfonyl)benzenesulfonamide; 2-chloro-N-[2-hydroxy-l-(hydroxymethyl)ethyl]-5-(phenylsulfonyl)benzenesulfonamide; iV-(2-cyanoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; iV-(2-hydroxyethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; iV-(2-hydroxy-l-methylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; N- [( 1 iS)-2-hy droxy- 1 -methy lethy 1] -5 -(pheny lsulfony l)-2-(trifluoromethy l)benzenesulfonamide ; JV-[(li?)-2-hydroxy-l-methylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-l-methylethyl)-2-isopropylbenzenesulfonamide; 5- [(4-fluoropheny l)sulfony 1] -N- [ 1 -(hy droxymethyl)-2-methy lpropyl] -2- isopropylbenzenesulfonamide; 5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxybutyl)-2-isopropylbenzenesulfonamide; N-(2-cyanoethyl)-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide;
5-[(3-chlorophenyl)sulfonyl]-N-(2-cyanoethyl)-2-(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-(te1xahydro-2H-pyran-4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide;
N-(2-moφholin-4-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-(3-morpholin-4-ylpropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-(3-methoxypropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N- [ 1 -(hy droxymethy l)-2-methy lpropy 1] -5 -(phenylsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
N-[(lR)-l-(hydroxymethyl)propyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-(2-hydroxyethyl)-5-[(3-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide;
N-(2-cyanoethyl)-5-[(4-methoxyphenyl)sulfonyl]-2-(trifluoromethyl)benzenesulfonamide;
N-(2-cyanoethy l)-5 - [(4-hy droxypheny l)sulfony 1] -2-(trifluoromethy l)benzenesulfonamide;
Λ/"-[(l-hydroxycyclohexyl)methyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopropyl-N-(2-piperidin-3- ylethyl)benzenesulfonamide;
N-{[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}-β-alanine;
4-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)butanoic acid; tert-butyl 4- [( { [5 -(phenylsulfony l)-2-(trifluoromethyl)phenyl] sulfonyl } amino)methyl]piperidine-
1-carboxylate;
5-(phenylsulfonyl)-N-(piperidin-4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide; tert-butyl [trans-4-( { [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexyl]carbamate;
4-oxo-4-{4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin- l-yl}butanoic acid;
5-oxo-5-{4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]piperidin- l-yl}pentanoic acid;
3-({4-[({[5-(phenylsulfonyl)-2-(1xifluoroniethyl)phenyl]sulfonyl}amino)methyl]piperidin-l- yl}sulfonyl)benzoic acid; fert-butyl 2-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)etb.yl]pyrrolidme-l-carboxylate;
5-(phenylsulfonyl)-N-(2-pyrrolidm-2-ylethyl)-2-(trifluoromethyl)benzenesulfonamide;
{2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-l- yl} acetic acid; 4-oxo-4-{2-[2-({[5-(phenylsulfonyl)-2-(1xifluoromethyl)phenyl]sulfonyl}aniino)ethyl]pyrrolidin- l-yl}butanoic acid;
3-({2-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidin-l- yl}sulfonyl)benzoic acid; tert-butyl 4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidme-
1-carboxylate; methyl 3 -( { [2-isopropy 1-5 -(pheny lsulfony l)phenyl] sulfony 1 } amino)cy clohexanecarboxy late; methyl 4-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate; methyl trans-4-[({ [2-isopropy 1-5-
(phenylsulfonyl)phenyl]sulfonyl}amino)methyl]cyclohexanecarboxylate;
5-(phenylsulfonyl)-7V-(2-piperidin-4-ylethyl)-2-(trifluoromethyl)benzenesulfonamide;
{4- [( { [5-(pheny lsulfony l)-2-(trifluoromethyl)phenyl]sulfonyl} amino)methyl]piperidin- 1 - yl} acetic acid;
{4-[2-( { [5-(phenylsulfonyl)-2-(trifluoromethy l)phenyl] sulfonyl} amino)ethyl]piperidin- 1 - yl} acetic acid; methyl 3-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate; methyl 4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylate; methyl trans-4-[({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)methyl]cyclohexanecarboxylate;
3-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid;
4-({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid; trans-4-[({ [2-isopropyl-5-
(phenylsulfonyl)phenyl]sulfonyl}amino)methyl]cyclohexanecarboxy lie acid;
3-{4-[({[5 -(pheny lsulfony l)-2-(trifluoromethyl)pheny 1] sulfonyl} amino)methyl]piperidin- 1 - yl}benzoic acid;
3-{4-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperidin-l- yl} benzoic acid; iV-(trα«5-4-aminocyclohexyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid;
4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)cyclohexanecarboxylic acid; tmns-4~[({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)methyl]cyclohexanecarboxylic acid;
N-(frαn5-4-hydroxycyclohexyl)-5-φhenylsulfonyl)-2-(1xifluoromethyl)benzenesulfonainide; tert-butyl 4-[({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl) amino)carbonyl]piperidine-l -carboxylate; or
N- { [5 -(pheny lsulf ony l)-2-(trifluoromethy l)pheny 1] sulfony 1} piperidine-4-carboxamide .
37. The compound of claim 1 which is
5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)-2-(trifluoromethoxy)benzenesulfonamide;
2-isopropyl-5-(phenylsulfonyl)-iV-(tetrahydro-2H'-pyran-4-yl)benzenesulfonamide;
5-(ρhenylsulfonyl)-iV-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide;
2-Methoxy-5-(phenylsulfonyl)-N-(tetrahydro-2H-pyran-4-yl)benzenesulfonamide;
5-[(3-methoxyphenyl)sulfonyl]-iV-(tetrah.ydro-2H-pyran-4-yl)-2-
(trifluoromethyl)benzenesulfonamide;
5-[(3-hydroxyphenyl)sulfonyl]-iV-(tetrahydro-2H-pyran-4-yl)-2-
(trifluoromethyl)benzenesulfonamide;
5-[(3-chlorophenyl)sulfonyl]-iV-(tetrahydro-2H-pyran-4-yl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-[(3)S)-piperidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-[(3i?)-piperidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide;
5-[(l,2-dimethyl-liϊ-indol-5-yl)sulfonyl3-iV-piperidin-4-yl-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-[(3iS)-pyrrolidm-3-yl]-2-(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfon.yl)-ΛT-[(3i?)-pyrrolidin-3-yl]-2-(trifluoromethyl)benzenesulfonamide;
2-methyl-5-(phenylsulfonyl)-N-(tetrahydro-2H-thiopyran-4-yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-2-isopiOpyl-N-(tetrahydro-2H-thiopyran-4- yl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)-2-
(trifluoromethyl)benzenesulfonamide;
5-[(2-fluorophenyl)sulfonyl]-N-(tetrahydro-2H-pyran-4-yl)-2-
(trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-N-pyrrolidin-3-yl-2-(trifluoromethyl)benzenesulfonamide;
N-[(2R*,4S*,6S*)-2,6-dimethyltetrahydro-2H-pyran-4-yl]-5-[(4- fluorophenyl)sulfonyl]-2- methylbenzenesulfonamide;
5 - { [4-(methy lamino)pheny 1] sulfony 1 } -N-piperidm-4-yl-2-(trifluoromethy l)benzenesulfonamide ;
5- { [4-(dimethylamino)phenyl] sulfonyl} -JV-piperidin-4-yl-2-
(trifluoromethyl)benzenesulfonamide;
5-({4-[(2-hydroxyethyl)amino]phenyl}sulfonyl)-iV-piperidin-4-yl-2-
(trifluoromethyl)benzenesulfonamide;
N-( 1 , 1 -dioxidotetrahydro-2H-thiopyran-4-yl)-5-[(4-fluorophenyl)sulfonyl]-2- isopropylbenzenesulfonamide;
5- { [2-(methylamino)phenyl]sulfonyl} -iV-piperidin-4-yl-2-(trifluorometb.yl)benzenesulfonamide;
5-{[2-(dimethylamino)phenyl]sulfonyl}-N-piperidin-4-yl-2-
(trifluoromethyl)benzenesulfonamide;
5-({2-[(2-hydroxyethyl)amino]phenyl}sulfonyl)-iV-piperidin-4-yl-2-
(trifluoromethyl)benzenesulfonamide;
2-ethyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide;
2,3-dimethyl-5-(phenylsulfonyl)-N-piperidin-4-ylbenzenesulfonamide;
2,4-dimethyl-5-(phenylsulfonyl)-iV-piperidin-4-ylbenzenesulfonamide;
2-isopropyl-5-(phenylsulfonyl)-iV-piperidin-4-ylbenzenesulfonamide;
5-(phenylsulfonyl)-N-piperidin-4-yl-2-propylbenzenesulfonamide;
2-isopropyl-5-(phenylsulfonyl)-N-(2,256,6-tetramethylpiperidin-4-yl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-(2,2,6,6-tetramethylpiperidin-4-yl)-2-
(trifluoromethyl)benzenesulfonamide;
5-[(4-methoxyphenyl)sulfonyl]-iV-piperidm-4-yl-2-(trifluoromethyl)benzenesulfonamide; or
5-[(3-bromophenyl)sulfonyl]-N-piperidin-4-yl-2-(trifluoromethyl)benzenesulfonamide.
38. The compound of claim 1 which is
2-chloro-N-[l-(4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
2-chloro-iV-[l-(4-cyanobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
2-chloro-5-(phenylsulfonyl)-iV-{l-[4-(trifluoromethyl)benzoyl]piperidin-4- yl}benzenesulfonamide; 5-(phenylsulfonyl)-2-(trifluoromethyl)-iV-{l-[4-(trifluoromethyl)benzoyl]piperidiii-4- y 1 } benzenesulfonamide ;
N-[l-(2-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(2-methoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N- [ 1 -(3 -chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N- [ 1 -(3 ,4-difluorobenzoy l)piperidin-4-y 1] -5 -(pheny lsulfony l)-2-
(trifluoromethyl)benzenesulfonamide; iV-[l-(3,5-difluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(2,6-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(2,4-dimethoxybenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(pheny lsulfony V)-N- { 1 -[4-(trifluoromethoxy)benzoyl]piperidm-4-yl} -2-
(trifluoromethyl)benzenesulfonamide; iV-{l-[2-fluoro-4-(trifluorometliyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{l-[3-fluoro-4-(trifluoromethyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N- [ 1 -(3 ,4-dichlorobenzoy l)piperidin-4-y 1] -5 -(phenylsulfony l)-2-
(trifluoromethyl)benzenesulfonamide
N-[l-(4-chlorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(l-isonicotinoylpiperidin-4-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[l-(2-chloro-6-methoxyisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; iV-[l-(2-chloro-4-fluorobenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethy l)benzenesulfonamide ;
5-(phenylsulfonyl)-iV-[l-(2,4,6-trifluorobenzoyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide;
ΛL[l-(4-tert-butylbenzoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N~(4- { [4-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)pheny ljsulfonyl} amino)piperidin- 1 - yl]carbonyl}phenyl)acetamide;
5-(phenylsιdf(myl)-2<triJauorome1hyl)-JV-1 (l-{[4-
(trifluoromethyl)phenyl]carbonothioyl}piperidin-4-yl)benzenesulfonamide;
Λ/-[l-(4-tert-butylbenzoyl)piρeridin-4-yl]-5-[(3-methoxyphenyl)sulfonyl]-2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(4-tert-butylbenzoyl)piperidin-4-yl]-5-[(3-chlorophenyl)sulfonyl]-2-
(trifluoromethyl)benzenesulfonamide;
5 -(phenylsulfony I)-N- { 1 -[2-(trifluoromethoxy)benzoy l]piperidin-4-yl} -2-
(trifluoromethyl)benzenesulfonamide;
N-(l-benzoylpiperidin-4-yl)-5-(phenylsulfonyl)-2-(1xifluorome1iiyl)benzenesvιlfonamide; iV-[l-(4-rert-butylbenzoyl)pyrrolidm-3-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonainide;
N-[l-(4-fcrif-butylbenzoyl)piperidin-4-yl3-5-[(3-hydroxyphenyl)sulfonyl]-2-
(trifluorometbyl)benzenesulfonamide; iV-[l-(4-benzoylbenzoyl)piρeridin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(3-benzoylbenzoyl)piρeridin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
1 -Isopropyl-4-(phenylsulfonyl)benzene ;
2-Isopropy l-N-[ 1 -(2-methoxybenzoy l)piperidin-4-yl] -5 -(phenylsulfony l)benzenesulfonamide; iV-[l-(3-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
A/-[l-(4-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[l-(2-Fluorobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
2-Isopropyl-5-(phenylsulfonyl)-iV-{l-[4-(trifluoromethyl)benzoyl]piperidin-4- yl}benzenesulfonamide;
2-Isopropyl-N-[l-(l-naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
2-Isopropyl-N-[l-(2-naphthoyl)piperidin-4-yl]-5-(phenylsulfonyl)benzenesulfonamide;
Λr-[l-(3-Cyanobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; iV-[l-(4-Cyanobenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesuIfonamide;
Λr-[l-(4-te^Butylbenzoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
N- [ 1 -(2-Ethoxy- 1 -naphthoyl)piperidin-4-yl]-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide; iV-[l-(2-chloro-6-methyIisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; iV-[l-(2,6-dichloroisonicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N- {I -[4-(dimethy lamino)benzoy l]piperidin-4-y 1} -5-(phenylsulfony l)-2-
(trifluoromethyl)benzenesulfonamide; iV-{l-[(6-chloropyridin-3-yl)carbonyl]piperidin-4~yl}-5-(plienylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; iV-fl-^^-dichloropyridin-S-y^carbonyllpiperidin^-y^-S-Cphenylsulfonyl)^-
(trifluoromethyl)benzenesulfonamide; iV-[l-(2-chloroisoπicotinoyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(triflιxoromethyl)benzenesυlfonamide;
5-(pheny lsulfony I)-JV- { 1 -[(6-pyrrolidin- 1 -ylpyridin-3 -y l)carbony l]piperidin-4-yl } -2-
(trifluoromethyl)benzenesulfonamide;
7V-(l-{[6-(dimethylamino)pyridin-3-yl]carbonyl}piperidin-4-yl)-5-(phenyIsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N"{l"[(6-oxo-l-{[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}-l,6-dihydropyridin-3- yl)carbonyl]piρeridin-4-yl}-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; iV-{l-[(6-phenylpyridin-3-yl)carbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{l-[(6-niorpliolin-4-ylpyridin-3-yl)carbonyl]piperidm-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-[l-(2-pyrrolidin-l-ylisonicotinoyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide;
N-{ l-[(6-oxo-l 56-dihydropyridin-3-yl)carbonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-iV-[l-(pyridin-3-ylcarbonyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-jV-[l-(pyridin-2-ylcarbonyl)piperidin-4-yl]-2- (trifluoromethyl)benzenesulfonamide;
Λ^{l-[4-(methylthio)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5 -(phenylsulfony l)~2-(trifluoromethyl)-N-( 1 - { [6-(trifluoromethy l)pyridin-3 - yl]carbonyl}piperidin-4-yl)benzenesulfonamide; iV-{l-[4-(methylsulfinyl)benzoyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide ; or
5-(phenylsulfony I)-N- [1 -( 1 ,3 -thiazol-4-ylcarbonyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide.
39. The compound of claim 1 which is tert-bvttyl 4-( { [5-(phenylsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)piρeridine- 1 - carboxylate; rert-butyl (3S)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidine-l- carboxylate; tert-buty 1 (3i?)-3 -( { [5-(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfonyl} amino)piperidine- 1 - carboxylate; tert-butyl 4-[({5-[(4-fluoroρhenyl)sulfonyl]-2- methylρhenyl}sulfonyl)amino]piperidine-l- carboxylate; tert-bu1yl (35)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l- carboxylate; tgrt-butyl (3i?)-3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidine-l- carboxylate; tert-buryl 4-({[5-[(4-fluorophenyl)sulfonyl]-2-
(trifluoromethyl)phen.y 1] sulfonyl} amino)ρiperidine- 1 -carboxylate; ter^butyl 4-({[2-ethyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate; fert-butyl 4-({[2,3-dimethyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate; tert-butyl 4-( { [2 ,4-dimethy 1-5 -(pheny lsulfony l)pheny 1] sulfonyl} amino)piperidine- 1 -carboxylate; tert-butyl 4-({[2-isopropyl-5-(ρhenylsulfonyl)phenyl]sulfonyl}amino)piperidine-l-carboxylate; or
4- { [3-( { [1 -(tert-butoxycarbonyl)piperidin-4-yl]amino} sulfonyl)-4-
(trifluoromethyl)phenyl]sulfonyl}benzoic acid.
40. The compound of claim 1 which is
4-0X0-4- [4-( { [5 -(pheny lsulfonyl)-2-(trifluoromethy l)phenyl] sulfony 1 } amino)piperidin- 1 - yl]butanoic acid;
4-oxo-4-[3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l- yljbutanoic acid;
5-oxo-5-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]pentanoic acid;
5-oxo-5-[3-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)pyrrolidin-l- yljpentanoic acid;
N-[l-(iV,N-dimethylglycyl)piperidm-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl 4-{2-oxo-2-[4-({ [5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfonyl } amino)piperidin- 1 -yl] ethyl} piperidine- 1 -carboxylate;
5-(phenylsulfonyl)-N-[l-(piperidin-4-ylacetyl)piperidin-4-yl]~2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(N-methylglycyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-[l-(pyrrolidin-l-ylacetyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide;
N-[l-(morpholin-4-ylacetyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-[l-(piperazin-l-ylacetyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide;
N- { 1 - [3 -(methy lthio)propanoy l]piperidin-4-y 1 } -5-(phenylsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
N- { 1 - [3 -(methy lsulfiny l)proρanoy l]piperidin-4-y 1} -5 -(pheny lsulfony l)-2-
(trifluoromethyl)benzenesulfonamide; or
N-[I-(I H-imidazol- 1 -ylacetyl)piperidin-4-yl] -5-(pheny lsulfony l)-2-
(trifluoromethyl)benzenesulfonamide.
41. The compound of claim 1 which is 4- [( { 5 - [(4-fluoropheny l)sulfony 1] -2-isopropy lpheny 1 } sulfony l)amino]-N- 1 - naphthy lpiperidine-
1 -carbothioamide;
N-(2-fluorophenyl)-4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl} sulfony l)amino]piperidine- 1 -carbothioamide;
4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(2- methylphenyl)piperidine- 1 -carbothioamide; ethyl ({4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl}sulfonyl)amino]piperidin-l- yl} carbonothioyl)carbamate;
N-butyl-4-[({5-[(4-fluorophenyl)sulfonyl]-2- isopropylphenyl} sulfony l)amino]piperidine-l- carbothioamide;
4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(4- methoxyphenyl)piperidine- 1 -carbothioamide; methyl 4-[( { 4- [( { 5- [(4-fluoropheny l)sulfony 1] -2- isopropylphenyl} sulfony l)amino]piperidm- 1 - yl} carbonothioyl)amino]benzoate; methyl N-( { 4- [( { 5- [(4-fluoropheny l)sulfony 1] -2- isopropylphenyl } sulfony l)ammo]piperidin~ 1 - yl} carbonothioyl)glycinate;
4-[({5-[(4-fluorophenyl)sulfonyl]-2 -isopropylphenyl} sulfony l)amino]-N-(2- morpholin-4- ylethyl)piperidine- 1 -carbothioamide;
4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-(3- nitrophenyl)piperidine-l-carbothioamide;
3 - [( {4- [( { 5-[(4-fluorophenyl)sulfony 1] -2- isopropylphenyl } sulfony l)amino]piperidin- 1 - yl}carbonothioyl)amino]benzoic acid;
4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-pyridin-3- ylpiperidine-
1 -carbothioamide;
4-[({5-[(4-fluorophenyl)sulfonyl]-2-isopropylphenyl}sulfonyl)amino]-N-[4-
(trifluoromethyl)pheny ljpiperidine- 1 -carbothioamide ;
N-(4-tert-butylphenyl)-4-( { [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl} amino)piperidine-l -carboxamide; or
3-({[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]carbonothioyl}amino)benzoic acid.
42. The compound of claim 1 which is tert-butyl 4-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl] carbony 1} piperidine- 1 -carboxy late ;
5-(phenylsulfonyl)-N-[l-(piperidin-4-ylcarbonyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl (2S)-2- { [4-( { [5-(phenylsulfonyl)-2-(trifluoromethy l)phenyl] sulfonyl} amino)piperidin-
1 -y 1] carbony 1 } pyrrolidine- 1 -carboxy late;
5-(plienylsulfonyl)-iV-(l-L-prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide; tert-butyl (2i?)-2-{[4-({[5-(phenylsulfonyl)-2-(trifluorometliyl)phenyl]sulfonyl}amino)piperidin-
1 -y 1] carbony 1 } pyrrolidine- 1 -carboxy late;
5-(phenylsulfonyl)-iV-(l-D-prolylpiperidin-4-yl)-2-(trifluoromethyl)benzenesulfonamide;
N-[I-(I -acetyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl (55)-2-oxo-5-{ [4-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxylate;
N-[l-(5-oxo-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[I-(I -methy 1-L-proly l)piperidin-4-y 1] -5 -(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl (4/?)-4-{[4-({[5-(phenylsulfonyl)-2-(1xifluoromethyl)phenyl]sulfonyl}amino)piperidin- l-yl]carbonyl}-l,3-thiazolidine-3-carboxylate;
5-(phenylsulfonyl)-N-{ 1 -[(4R)-1 ,3-thiazolidin-4-ylcarbonyl]piperidin-4-yl}-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl (3i?)-3-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)plienyl]sulfonyl}amino)piperidin- l-yycarbonyllpyrrolidine-l-carboxylate; tert-butyl (3iS)-3-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-
1 -y 1] carbony 1 } pyrrolidine- 1 -carboxy late;
5-(phenylsulfonyl)-N-{l-[(3i?)-pyrrolidin-3-ylcarbonyl]piperidin-4-yl}-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfony I)-N- { 1 -[(35)-pyrrolidin-3 -ylcarbonyl]piperidin-4-yl} -2-
(trifluoromethyl)benzenesulfonamide; tert-butyl (4i?)-4- { [4-( { [5 -(phenylsulfony l)-2-(trifluoromethy l)pheny 1] sulfonyl } amino)piperidin- l-yl]carbonyl}-l,3-thiazolidine-3-carboxylate 1-oxide;
N-(I - { [(3R)- 1 -acetylpyrrolidin-3 -yl]carbonyl }piperidin-4-yl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide;
N-(l-{[(35^-l-acetylpyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; iV-[l-(l-isobutyryl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)berizenesulfonamide;
JV-(I -[I -(2,2-dimethylproρanoyl)-L-prolyl]piperidin-4-yl} -5-(phenylsulfonyl)-2-
(trifluoromethyl)beiizenesulfonamide; iV-{l-[l-(3,3-dimetb.ylbutanoyl)-L-prolyl]piperidin-4-yl}-5-(ph.enylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
JV-(I -[I -(cyclohexylcarbonyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N- { 1 -[I -(morpholin-4-ylcarbonyl)-L-prolyl]piρeridin-4-yl) -5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
(2S)-JV-(tert-butyl)-2-{[4-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl] sulfonyl} amino)piperidin- 1 -yl]carbonyl} pyrrolidine- 1 -carboxamide;
(2S)-N-phenyl-2-{[4-({[5-(phenylsulfonyl)-2-(1riiluoromethyl)phenyl]sulfonyl}amino)ρiper^^^
1 -yl]carbony 1} pyrrolidine- 1 -carboxamide;
N-{l-[l-(methylsulfonyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
JV-[I -(I -benzoyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)beri2enesulfonamide; iV-(l-{l-[4-(dime1hylamino)benzoyl]-L-prolyl}piperidiri-4-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
JV-[I -(I -isonicotinoyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
JV-(l-{l-[(6-chloropyridin-3-yl)carbonyl]-L-prolyl}piperidin-4-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
4-[((25)-2- { [4-( { [5 -(pheny lsulf onyl)-2-(trifluoromethy l)phenyl] sulfonyl} amino)piperidm- 1 - yljcarbonyllpyrrolidin-l-y^sulfonyllbenzoic acid;
JV-[l-(iV,Λr-dimethylglycyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; N-[I-(I -benzyl-L-prolyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-{l-[l-(cyclohexylmethyl)-L-prolyl]piperidin-4-yl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-ll-Cl-CS^-dimethylbuty^-L-proly^piperidin^-yll-S-Cphenylsulfonyl)^-
(trifluoromethyl)benzenesulfonamide;
(2£)-N-ethyl-2- { [4-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)piperidin- 1 - yl] carbonyl } pyrrolidine- 1 -carboxamide;
(2S)-N,N-dimethyl-2-{ [4-({ [5-(phenylsulfonyl)-2-
(1xifluoromethyl)phenyl]sulfonyl}arnino)piperidin-l-yl]carbonyl}pyrrolidine-l-carboxarnide; or tert-butyl (2S)-2-{ [4-({ [5-[(3-cyanophenyl)sulfonyl]-2-
(trifluoromethy l)pheny 1] sulfonyl} amino)piperidin- 1 -yl] carbonyl} pyrrolidine- 1 -carboxy late .
43. The compound of claim 1 which is
N-[l-(2-hydroxy-2-methylpropyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-2-(trifluoromethyl)-N-{l-[4-(trifluoromethyl)benzyl]piperidin-4- yl } benzenesulfonamide ;
N-[l-(cyanomethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[I -(2-oxo-2-pheny lethy l)piperidin-4-yl] -5-(pheny lsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-2-(trifluoromethyl)-N- { 1 - [4-(trifluoromethyl)phenyl]piperidin-4- y 1} benzenesulfonamide ;
N-[l-(2-hydroxyethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
2-Isoρroρyl-N-[(li?*,5S*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-5-
(phenylsulfonyl)benzenesulfonamide monohydrochloride;
[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetic acid;
2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l-yl]acetamide;
5-(phenylsulfonyl)-N-[l-(2H'-tetrazol-5-ylmethyl)piperidin-4-yl]-2-
(trifluoromethyl)benzenesulfonamide; 3 ■* [4-( { [5 -(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)piperidin- 1 -yl]propanoic acid;
3 - [4-( { [5 -(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)piperidin- 1 -y ljbenzoic acid;
4-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidm-l-yl]benzoic acid;
N-[l-(3-cyanophenyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-(trifluoiOmethyl)benzenesulfonamide;
2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]propanamide;
N-[l-(2-morpholin-4-ylethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[(1R*, 5S*)-8-Methyl-8-azabicyclo[3.2.1 ]oct-3-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
(2R)-2- [4-( { [5 -(pheny lsulfony l)-2-(trifluoromethy l)phenyl] sulfony 1} amino)piperidin- 1 - yl]propanamide;
(2»S)-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]propananiide; methyl [4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]acetate; iV-methy 1-2- [4-( { [5-(phenylsulfony l)-2-(trifluoromethy l)phenyl] sulfonyl } amino)piperidin- 1 - yl]acetamide;
N,N-dimethyl-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yl]acetamide;
N-isopropyl-2-[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yljacetamide; or
N-[l-(2-morpholin-4-yl-2-oxoethyl)piperidin-4-yl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide.
44. The compound of claim 1 which is
Λ/-{l-[(4-tert-butylphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; 5-(phenylsulfonyl)-Λ/-[l-(phenylsulfonyl)piperidin-4-yl]-2-(trifluoromethyl)benzenesulfonamide; 3-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)piperidin-l- yljsulfonyl} benzoic acid;
4- { [4-( { [5-(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1 } amino)piperidin- 1 - yl]sulfonyl}benzoic acid;
N-{l-[(4-hydroxyphenyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; methyl 3-{[4-({[5-(phenylsulfonyl)-2-(trifluoromethyl)plienyl]sulfonyl}ammo)piperidin-l- y 1] sulfony 1 } benzoate; iV-{l-[(3-cyanopb.enyl)sulfonyl]piperidin-4-yl}-5-(phenylsulfonyl)-2- (trifluoromethy l)benzenesulfonamide ; or
5-(phenylsulfonyl)-Λ/-(l-{[3-(2H-tetrazol-5-yl)phenyl]sulfonyl}piperidin-4-yl)-2- (trifluoromethyl)benzenesulfonamide.
45. The compound of claim 1 which is
5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)-2-(trifluoromethoxy)benzenesulfonamide;
2-isopropyl-5-(phenylsulfonyl)-N-(2-pyridin-2-ylethyl)benzenesulfonamide;
2-isopropyl-5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide; l-Methoxy-4-(phenylsulfonyl)benzene; iV-[2-(l-oxidopyridm-3-yl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-2-ylethyl)-2- isopropylbenzenesulfonamide;
N-(2-hydroxy-2-pyridin-2-ylethyl)-2-isopropyl-5-(phenylsulfonyl)benzene-sulfonamide; iV-(2-hydroxy-2-pyridin-2-ylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-(2-hydroxy-2-pyridin-3-ylethyl)-2- isopropylbenzenesulfonamide;
N-(2-hydroxy-2-pyridin-3-ylethyl)-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
N-(2-hydroxy-2-pyridin-3-ylethyl)-2,4-dimethyl-5-(phenylsulfonyl)benzenesulfonamide;
N-[2-(lH-Imidazol-l-yl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-iV-(2-hydroxy-2-pyridin-3-ylethyl)-2-methylbenzenesulfonamide;
N-(2-hydroxy-2-pyridin-3-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; 5-[(3-methoxyphenyl)sulfonyl]-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide;
5-[(3-chlorophenyl)sulfonyl]-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-7V-(2-hydroxy-2-pyridin-2-ylethyl)-2-methylbenzenesulfonamide;
N-(2-hydroxy-2-pyridin-2-ylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-Ν-(2-pyridin-4-ylethyl)-2-(trifluoromethyl)benzenesulfonamide;
5-[(4-hydroxyphenyl)sulfonyl]-N-(2-pyridin-3-ylethyl)-2-(trifluoromethyl)benzenesulfonamide;
5-[(4-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2-
(trifluoromethyl)benzenesulfonamide;
5-[(2-fluorophenyl)sulfonyl]-N-[2-(lH-imidazol-l-yl)ethyl]-2-
(trifluoromethyl)benzenesulfonamide;
5-(Phenylsulfonyl)-2-propyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide;
5-(phenylsulfonyl)-N-[2-(2H-tetrazol-5-yl)ethyl]-2-(trifluoromethyl)benzenesulfonamide;
5-[(4-Fluorophenyl)sulfonyl]-2-proρyl-N-(2-pyridin-3-ylethyl)benzenesulfonamide;
5-[(4-Fluorophenyl)sulfonyl]-2-propyl-N-(2-pyridin-4-ylethyl)benzenesulfonamide;
5-(Phenylsulfonyl)-2-propyl-N-(2-pyridin-3-ylethyl)benzenesulfonamide;
2-isopropyl-5-(phenylsulfonyl)-N-(pyridin-4-ylmethyl)benzenesulfonamide;
5-φhenylsulfonyl)-iV-(pyridin-4-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[(6-chloropyridin-3-yl)methyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
5-(phenylsulfonyl)-Λ/-[(6-pyrrolidin-l-ylpyridin-3-yl)methyl]-2-
(trifluoromethyl)benzenesulfonamide; or iV-[(6-morpholin-4-ylpyridin-3-yl)methyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide.
46. The compound of claim 1 which is
2-chloro-N-[( 1 i?* ,2i?*)-2-hydroxy- 1 -methyl-2-phenylethyl]-5-
(phenylsulfonyl)benzenesulfonamide;
N-(2-hydroxy-2-phenylethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
7V-[(li?*,2i?*)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; iy-[(15,2i?)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
7V-[(li?,25)-2-hydroxy-l-methyl-2-phenylethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide;
N- [( 1 S)- 1 -benzy l-2-hydroxyethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[(15)-2-hydroxy-l-(lH-indol-3-ylmethyl)ethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
5-[(4-fluoropb.enyl)sulfonyl]-N-(2-hydroxy-2-phenylethyl)-2-isopropylbenzenesulfonamide;
N-(2-hydroxy-2-phenylethyl)-2-isopropyl-5-(phenylsulfonyl)benzenesulfonamide;
Ν-[(2R)-2-hydroxy-2-phenylethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[(2S)-2-hydroxy-2-phenylethyl]-5-(jphenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
4-[2-({[5-(pb.enylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzoic acid;
N-[2-(4-ammophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[2-(4-methoxyphenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-(4-aminobenzyl)-5-(phenylsulfonyl)-2-(trifluorometliyl)benzenesulfonamide;
N-[2-(4-hydroxyphenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; methyl 4-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]benzoate; methyl 4-[({[2-isopropyl-5-(phenylsulfonyl)phenyl]sulfonyl}amino)methyl]benzoate;
N-[2-(4-bromophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
3-[({4-[({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)methyl]phenyl}amino)sulfonyl]benzoic acid;
N-(4-bromobenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[2-(4-cyanophenyl)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; methyl 4-[2-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)ethyl]benzoate;
4'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-3- carboxylic acid;
4'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-4- carboxylic acid;
5-(ρhenylsulfonyl)-N-{2-[4-(2H-tetrazol-5-yl)ρhenyl]ethyl}-2-
(trifluoromethyl)benzenesulfonamide;
N-(2-{4-[(methylsulfonyl)amino]phenyl}ethyl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(3-bromobenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
3'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-3- carboxylic acid; 3'-[({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)methyl]biphenyl-4- carboxylic acid;
N-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide;
N-[4-(dimethylamino)benzyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; or N-(2,4-dimethoxybenzyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide.
47. The compound of claim 1 which is tert-Butyl [2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate;
N-(2-Aminoethyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride;
N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
4-Methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl] sulfonyl} amino)ethyl]benzamide;
4-tert-Butyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
4-Fluoro-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
4-Chloro-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
4-Bromo-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
4-Methoxy-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
N- [2-( { [5-(Pheny lsulfonyl)-2-(trifluoromethy l)pheny 1] sulfonyl } amino)ethyl] -4-
(trifluoromethyl)benzamide;
N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4-
(trifluoromethoxy)benzamide ;
N-[2-({[5-(Phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]isonicotinamide; tert-Butyl methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate;
N-[2-(Methylamino)ethyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride; N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfony 1 } amino)ethy l]benzamide ;
4-Methoxy~N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; iV-{2-[(anilinocarbonyl)(methyl)amino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(2- {methyl [(pyridin-3 -y lamino)carbony 1] amino } ethy l)-5 -(pheny lsulfony l)-2-
(txifluoromethyl)benzenesulfonamide; iV-{2-[{[(2,4-dimethoxyphenyl)amino]carbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
7V-{2-[[(tert-butylamino)carbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamϊde;
N- {2- [ { [(4-methoxypheny l)amino] carbony 1 } (methy l)amino] ethy 1} -5 -(pheny lsulfony l)-2-
(trifluoromethy l)benzenesulfonamide ; ;
N-{2-[[(butylamino)carbonyl](methyl)amino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide
N-{2-[{[(2,4-difluorophenyl)amino]carbonyl}(methyl)amino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]pyrrolidine-l-carboxamide;
N- {2-[[(diethylamino)carbonyl] (methyl)amino]ethyl} -5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]morpholine-4-carboxamide;
N-[2-(methyl{[methyl(phenyl)amino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
Ν-Methy 1-Ν- [2-( { [5 -(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfonyl } amino)ethy l]-2- furamide;
4-tert-Butyl-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide;
N-Methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-2-
(trifluoromethoxy)benzamide; N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]cyclohexanecarboxamide; 3-Fluoro-N-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-4-(trifluoromethyl)benzamide; Methyl 4-({methyl[2-({[5-(ρhenylsulfonyl)-2-
(Mfluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)benzoate; N-Methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide; N-Methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)pb.enyl]sulfonyl}amino)etb.yl]isonicotinamide; 2-Chloro-N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]nicotinamide; N,2,2-trimethyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)ρhenyl]sulfonyl}ainmo)etb.yl]propanainide; 2-ethyl-N-methyl-N-[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl] sulfonyl} amino)ethy l]butanamide ; butyl methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate; fert-butyl 4-[({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)amino]piperidine-l-carboxylate; 2,2-dimethylpropyl methyl[2-( { [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate; isobutyl methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbaniate; 3-(trifluoromethyl)phenyl methyl[2-({ [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate; 4-fluorophenyl methyl[2-({[5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate; 4-bromophenyl methyl[2-( { [5-(phenylsulfonyl)-2- (trifluoromethyl)phenyl]sulfonyl}amino)ethyl]carbamate; N-(2-{methyl[(piperidin-4-ylamino)carbonyl]amino}ethyl)-5-(phenylsulfonyl)-2- (trifluoromethyl)benzenesulfonamide; ethyl N-({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)glycinate;
3-({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}sulfonyl)benzoic acid; tert-butyl 4-({methyl[2-({ [5-(ρhenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)piperazine-l-carboxylate;
N-({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]amino}carbonyl)glycine;
4-{methyl[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}ammo)ethyl]amino}-4- oxobutanoic acid;
N-methyl-iV-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]piperazine-l-carboxamide;
N-{2-[(2-hydroxyethyl)(methyl)aniino]ethyl}-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; methyl N-methyl-iV-[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfony 1 } amino)ethy 1] gly cinate; ethyl N-methyl-N-[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-D- alaninate; tert-butyl (35)-3-[({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl} amino)ethyl]amino } carbonyl)amino]pyrrolidine- 1 -carboxylate; tert-butyl methyl[3-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)propyl]carbamate;
N-[3-(methylamino)propyl]-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-[2-(methyl{[(3S)-pyrrolidin-3-ylamino]carbonyl}ammo)ethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl 4-[({methyl[3-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)propyl]amino}carbonyl)amino]piperidine-l- carboxylate; tert-butyl N-methyl-N-[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]-β-alaninate; tert-butyl iV-methyl-iV-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfony 1 } amino)ethy 1] gly cinate; N-(3-{methyl[(piperidin-4-ylamino)carbonyl]amino}propyl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl 4-({methyl[3-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)propyl]amino}carbonyl)piperaziiie-l-carboxylate;
N-methyl-N-[3-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl} amino)propyl]piperazine- 1 -carboxamide;
4-{4-[({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfony 1 } amino)ethy 1] amino } carbony l)amino]piperidin- 1 -y 1} -4- oxobutanoic acid; iV-methy \-N- [2-( { [5 -(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)ethy 1] glycine ; iV-methy 1-JV- [2-( { [5-(pheny lsulfony l)-2-(trifluoromethy l)pheny 1] sulfony 1} amino)ethy 1] - β - alanine;
4-(bromomethyl)-Λ/-methyl-N-[2-({[5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl}amino)ethyl]benzamide; tert-butyl [3-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl} amino)propyl]carbamate; tert-butyl 4-[methyl({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfonyl } amino)ethy 1] amino } carbony l)amino]piperidine- 1 -carboxy late; tert-butyl (3i?)-3-[({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethyl)phenyl]sulfonyl} amino)ethyl] amino} carbony l)amino]pyrrolidine- 1 -carboxylate;
4- {methyl [3 -( { [5-(phenylsulfonyl)-2-(trifluoromethyl)pheny 1] sulfonyl } amino)propyl] amino } -A- oxobutanoic acid;
N-(3-aminopropyl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide; dimethyl [4-({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfonyl } amino)ethy 1] amino } carbony l)benzyl]phosphonate; iV-[2-(methyl{[methyl(piperidin-4-yl)amino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[2-(methyl{[(3i?)-pyrrolidin-3-ylamino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; tert-butyl (3i?)-3-[({methyl[2-({ [5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfonyl } amino)ethy 1] amino } carbony l)amino]piperidine- 1 -carboxylate ; tert-butyl (35)-3-[({methyl[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfonyl } amino)ethy 1] amino } carbony l)amino]piperidine- 1 -carboxylate ; N-[2-(methyl{[(3i?)-piperidin-3-ylamino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-[2-(methyl{[(3ιS)-piperidin-3-ylamino]carbonyl}amino)ethyl]-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
^-({methyip-CitS-Cphenylsulfonyl)^-
(trifluoromethyl)phenyl]sulfonyl}amino)eth.yl]amino}carbonyl)benzyl]phosphonic acid; tert-butyl 4-[methyl({[2-({[5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfony 1 } amino)ethy 1] amino } carbony l)amino]piperidine- 1 -carboxy late ; or tert-butyl 4-[({ [2-({ [5-(phenylsulfonyl)-2-
(trifluoromethy l)pheny 1] sulfony 1 } amino)ethyl] amino } carbony l)amino]piperidine- 1 -carboxy late .
48. The compound of claim 1 which is
N-(2,3 -dihydro- 1 H-inden-2-yl)-5-(phenylsulfonyl)-2-(trifluoromethyl)benzenesulfonamide;
N-(2-hydroxy-2,3-dihydro- 1 H-inden- 1 -yl)-5-(phenylsulfony l)-2-
(trifluoromethyl)benzenesulfonamide;
N-(l-hydroxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(5-methoxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
N-(5-hydroxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide; methyl {[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)-2,3-dihydro-lH- inden-5-yl]oxy } acetate;
{ [2-( { [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl] sulfonyl} amino)-2,3 -dihydro- 1 H-inden-5- yl]oxy} acetic acid; methyl 2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)indane-5-carboxylate;
N-(l-hydroxy-6-methoxy-2,3-dihydro-lH-inden-2-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide;
2-{[2-({[5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)-2,3-dihydro-lH-inden-
5-yl]oxy}acetamide; 2-({ [5-(phenylsulfonyl)-2-(trifluoromethyl)phenyl]sulfonyl}amino)indane-5-carboxylic acid; or
N-(5-bromo-2,3-dihydro-lH~inden-2-yl)-5-(phenylsulfonyl)-2-
(trifluoromethyl)benzenesulfonamide.
49. A pharmaceutical composition comprising at least one compound of any one of claims 1 to 48 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, diluents, or carriers.
50. A method for treating a patient suffering from osteoporosis, arthritis, chronic obstructive pulmonary disease, cartilage defects, bone fractures, or leiomyoma comprising administering to the patient a therapeutically effective amount of at least one compound of Formula (1):
Figure imgf000514_0001
or a pharmaceutically acceptable salt thereof, wherein
R1 Is
Figure imgf000514_0002
and each Ri group is optionally substituted with up to three R8 groups;
Y is O, S3 Or NR9;
R8 is alkyl, arylalkyl, perfluoroalkyl, alkenyl, arylalkenyl, alkynyl, arylalkynyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, aryl, alkylaryl, heteroaryl, alkoxy, perfluoroalkoxy, arylalkoxy, alkylcarbonyl, arylcarbonyl, halogen, cyano, azido, hydroxyl, carboxy, alkoxycarbonyl, alkylamino, dialkylamino, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylamino, alkylcarbonylalkylamino, hydroxyalkylamino, nitro, alkylcarbonyloxime, alkylsulfonyl, alkylsulfinyl, alkylthio, perfluoroalkylthio, arylthio, tertiary alkylcarbinol, tertiary alkylcycloalkylcarbinol, or tertiary arylalkylcarbinol;
Rg is hydrogen, alkyl, aryl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, or spirocycloalkyl;
X is oxygen or an electron pair;
R2 is hydrogen, alkyl, alkoxy, cycloalkyl, perfluoroalkyl, perfluoroalkylalkyl, perfluoroalkoxy, dialkylamino, or halogen;
R4 is hydrogen, halogen, alkyl, cycloalkyl, alkoxy, perfluoroalkyl, or perfluoroalkoxy; or R2 and R4, together with the carbon atoms to which they are attached, form a cycloalkyl ring of 5 to 7 carbon atoms that is optionally substituted with 1 to 3 R groups; each R is, independently, hydrogen, alkyl, arylalkyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, spirocycloalkyl, aryl, arylalkyl, or alkoxyalkyl;
R5, and R6 are, independently, hydrogen, alkyl, aryl, alkoxy, halogen, or perfluoroalkyl;
R3 and R7 are each, independently, hydrogen or an optionally substituted alkyl, cycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, heteroarylalkyl, alkylaryl, alkylheteroaryl, alkenyl, alkynyl, fused cycloalkylaryl, fused heterocycloalkylaryl, cycloalkylcarbonyl, or heterocycloalkylcarbonyl group; or R3 and R7, together with the nitrogen atom to which they are attached, form a five or six membered heterocycloalkyl ring optionally substituted with 1 to 5 substituents selected from alkyl, aryl, heterocycloalkyl, heterocycloalkylalkyl, alkylamino, dialkylamino, alkoxycarbonyl, alkylcarbonyl, alkylaminocarbonylalkyl, and heterocycloalkylcarbonylalkyl.
51. The method of claim 50 wherein the patient suffers from osteoporosis or arthritis.
52. Use of a compound having Formula (1)
Figure imgf000516_0001
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7,and X are as defined in claim 50, in the preparation of a medicament for treating a patient suffering from osteoporosis, arthritis, chronic obstructive pulmonary disease, cartilage defects, bone fractures, or leiomyoma.
PCT/US2006/018886 2005-05-13 2006-05-12 Diarylsulfone sulfonamides and use therof WO2006124875A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2008511473A JP2008540579A (en) 2005-05-13 2006-05-12 Diarylsulfonesulfonamides and uses thereof
BRPI0610009-0A BRPI0610009A2 (en) 2005-05-13 2006-05-12 compound, pharmaceutical composition, method for treating a patient suffering from osteoporosis, arthritis, chronic obstructive pulmonary disease, cartilage defects, bone fractures, or leiomyoma, use of a compound having the formula (1)
CA002607326A CA2607326A1 (en) 2005-05-13 2006-05-12 Diarylsulfone sulfonamides and use therof
AU2006247334A AU2006247334A1 (en) 2005-05-13 2006-05-12 Diarylsulfone sulfonamides and use therof
EP06770422A EP1879859A2 (en) 2005-05-13 2006-05-12 Diarylsulfone sulfonamides and use therof
IL187269A IL187269A0 (en) 2005-05-13 2007-11-08 Diarylsulfone sulfonamides and uses thereof
NO20075781A NO20075781L (en) 2005-05-13 2007-11-12 Diarylsulfone sulfonamides and their use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68108005P 2005-05-13 2005-05-13
US60/681,080 2005-05-13
US11/432,788 2006-05-10
US11/432,788 US20060276464A1 (en) 2005-05-13 2006-05-10 Diarylsulfone sulfonamides and use thereof

Publications (2)

Publication Number Publication Date
WO2006124875A2 true WO2006124875A2 (en) 2006-11-23
WO2006124875A3 WO2006124875A3 (en) 2007-01-18

Family

ID=37103195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/018886 WO2006124875A2 (en) 2005-05-13 2006-05-12 Diarylsulfone sulfonamides and use therof

Country Status (17)

Country Link
US (1) US20060276464A1 (en)
EP (1) EP1879859A2 (en)
JP (1) JP2008540579A (en)
KR (1) KR20080012361A (en)
AR (1) AR057296A1 (en)
AU (1) AU2006247334A1 (en)
BR (1) BRPI0610009A2 (en)
CA (1) CA2607326A1 (en)
CR (1) CR9507A (en)
GT (1) GT200600199A (en)
IL (1) IL187269A0 (en)
NO (1) NO20075781L (en)
PE (1) PE20061451A1 (en)
RU (1) RU2007141346A (en)
SV (1) SV2007002526A (en)
TW (1) TW200719897A (en)
WO (1) WO2006124875A2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008060999A1 (en) * 2006-11-10 2008-05-22 Wyeth Piperidinyl arylsulfone derivatives as modulators of secreted frizzled related protein-1
WO2008061016A1 (en) * 2006-11-10 2008-05-22 Wyeth N-substituted piperidinyl 4 -arylsulfonamides as modulators of the secreted frizzled related protein- 1
WO2008061006A1 (en) * 2006-11-10 2008-05-22 Wyeth Substituted indan-2-yl, tetrahydronaphthalen-2-yl, or dihydr0-2h-chr0men-3-yl arylsulfonamides and methods of their use
EP1964834A1 (en) * 2007-03-01 2008-09-03 Bayer Schering Pharma Aktiengesellschaft Sulphonyltryptophanols
WO2009064938A1 (en) * 2007-11-16 2009-05-22 Abbott Laboratories Method of treating arthritis
WO2009071947A2 (en) 2007-12-05 2009-06-11 Lectus Therapeutics Limited Potassium ion channel modulators & uses thereof
US8153793B2 (en) 2005-09-27 2012-04-10 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
EP2471363A1 (en) 2010-12-30 2012-07-04 Bayer CropScience AG Use of aryl-, heteroaryl- and benzylsulfonamide carboxylic acids, -carboxylic acid esters, -carboxylic acid amides and -carbonitriles and/or its salts for increasing stress tolerance in plants
WO2018108627A1 (en) 2016-12-12 2018-06-21 Bayer Cropscience Aktiengesellschaft Use of substituted indolinylmethyl sulfonamides, or the salts thereof for increasing the stress tolerance of plants
US10065926B2 (en) 2013-10-04 2018-09-04 Bayer Cropscience Aktiengesellschaft Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants
WO2019025153A1 (en) 2017-07-31 2019-02-07 Bayer Cropscience Aktiengesellschaft Use of substituted n-sulfonyl-n'-aryl diaminoalkanes and n-sulfonyl-n'-heteroaryl diaminoalkanes or salts thereof for increasing the stress tolerance in plants
US10501423B2 (en) 2017-10-30 2019-12-10 Neuropore Therapies, Inc. Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
KR20200141718A (en) 2019-06-11 2020-12-21 (주)부흥산업사 Manufacturing method of piperidinyl sulfonyl sulfonamide
US11412730B2 (en) 2015-06-30 2022-08-16 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Method for the cryopreservation of cells for therapeutic purposes

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255117A1 (en) * 2007-03-01 2008-10-16 Lars Wortmann Sulfonyltryptophanols
EP1985612A1 (en) * 2007-04-26 2008-10-29 Bayer Schering Pharma Aktiengesellschaft Arymethylen substituted N-Acyl-gamma-aminoalcohols
US8853250B2 (en) * 2007-07-13 2014-10-07 Icagen, Inc. Sodium channel inhibitors
WO2012036512A2 (en) * 2010-09-16 2012-03-22 연세대학교 산학협력단 Use of a compound for inducing differentiation of mesenchymal stem cells into cartilage cells
CN112898178A (en) * 2021-01-25 2021-06-04 蚌埠产品质量监督检验研究院 Preparation method of N-Boc-trans-1, 4-cyclohexanediamine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1164829A (en) * 1965-10-23 1969-09-24 Tanabe Seiyaku Co Pharmacological Compositions and use thereof
DE19920790A1 (en) * 1999-05-06 2000-11-09 Bayer Ag Bis-sulfonamides with anti-HCMV activity
WO2002072570A2 (en) * 2001-03-13 2002-09-19 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
WO2005000244A2 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912131A (en) * 1987-06-18 1990-03-27 Merck Frosst Canada, Inc. 4,7-diacyloxybenzofuran derivatives
US20080166356A9 (en) * 1999-09-13 2008-07-10 Peter Bodine Pharmaceutical compositions and methods of using secreted frizzled related protein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1164829A (en) * 1965-10-23 1969-09-24 Tanabe Seiyaku Co Pharmacological Compositions and use thereof
DE19920790A1 (en) * 1999-05-06 2000-11-09 Bayer Ag Bis-sulfonamides with anti-HCMV activity
WO2002072570A2 (en) * 2001-03-13 2002-09-19 Schering Corporation Non-imidazole compounds as histamine h3 antagonists
WO2005000244A2 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A.V. TARASOV ET AL: "New 6-Arylsulfonyl-1,2-Benzoisothiazol-3(2H)-o ne 1,1-dioxides" CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 39, no. 1, 2003, pages 119-122, XP001247598 *
CHANG GI CHO ET AL: "Synthesis and Characterization of poly(arylene ether sulfone) copolymers" POLYMER PREPRINTS, vol. 44, no. 2, 2003, pages 649-650, XP001247597 *
G.PAPPALARDO: "Azione degli idrati alcalini sugli o-amino-difenildisolfuri simmetrici e sintesi di fenotiazine sulfonamidiche" GAZZETTA CHIMICA ITALIANA, vol. 90, 1960, pages 648-659, XP009074103 *
H.HORSTMANN: "Chemische Struktur und diuretische Wirkung in der Reihe der 4-Chlor-3-sulfonamido-benzolsulfonamide" ARZNEIMITTEL FORSCHUNG, vol. 17, no. 6, 1967, pages 653-659, XP009074175 *
H.KORNOWSKI ET AL: "Méthyl-4 oxadiazines-1,2,4 diones-3,5" CHIMIE THERAPEUTIQUE, vol. 5, no. 6, 1966, pages 353-355, XP009074104 *
R.CREMLYN: "Chlorosulfonation of some Diphenyl Derivatives" PHOSPHORUS AND SULFUR, vol. 12, 1982, pages 341-352, XP001247192 *
V.CECCHETTI ET AL: "o-Chlorobenzenesulfonamidic derivatives" J.MED.CHEM., vol. 36, 1993, pages 157-161, XP009074112 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153793B2 (en) 2005-09-27 2012-04-10 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
US8993763B2 (en) 2005-09-27 2015-03-31 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
US9440938B2 (en) 2005-09-27 2016-09-13 Shionogi & Co., Ltd. Sulfonamide derivative having PGD2 receptor antagonistic activity
WO2008061016A1 (en) * 2006-11-10 2008-05-22 Wyeth N-substituted piperidinyl 4 -arylsulfonamides as modulators of the secreted frizzled related protein- 1
WO2008061006A1 (en) * 2006-11-10 2008-05-22 Wyeth Substituted indan-2-yl, tetrahydronaphthalen-2-yl, or dihydr0-2h-chr0men-3-yl arylsulfonamides and methods of their use
WO2008060999A1 (en) * 2006-11-10 2008-05-22 Wyeth Piperidinyl arylsulfone derivatives as modulators of secreted frizzled related protein-1
EP1964834A1 (en) * 2007-03-01 2008-09-03 Bayer Schering Pharma Aktiengesellschaft Sulphonyltryptophanols
WO2008104597A3 (en) * 2007-03-01 2008-12-24 Bayer Schering Pharma Ag Sulfonyltryptophanols
WO2008104597A2 (en) * 2007-03-01 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Sulfonyltryptophanols
WO2009064938A1 (en) * 2007-11-16 2009-05-22 Abbott Laboratories Method of treating arthritis
WO2009071947A2 (en) 2007-12-05 2009-06-11 Lectus Therapeutics Limited Potassium ion channel modulators & uses thereof
WO2009071947A3 (en) * 2007-12-05 2010-03-11 Lectus Therapeutics Limited Potassium ion channel modulators and uses thereof
US8466201B2 (en) 2007-12-05 2013-06-18 Ramot At Tel-Aviv University Ltd. Potassium ion channel modulators and uses thereof
WO2012089721A1 (en) 2010-12-30 2012-07-05 Bayer Cropscience Ag Use of substituted spirocyclic sulfonamidocarboxylic acids, carboxylic esters thereof, carboxamides thereof and carbonitriles thereof or salts thereof for enhancement of stress tolerance in plants
WO2012089722A2 (en) 2010-12-30 2012-07-05 Bayer Cropscience Ag Use of open-chain carboxylic acids, carbonic esters, carboxamides and carbonitriles of aryl, heteroaryl and benzylsulfonamide or the salts thereof for improving the stress tolerance in plants
EP2471363A1 (en) 2010-12-30 2012-07-04 Bayer CropScience AG Use of aryl-, heteroaryl- and benzylsulfonamide carboxylic acids, -carboxylic acid esters, -carboxylic acid amides and -carbonitriles and/or its salts for increasing stress tolerance in plants
US10065926B2 (en) 2013-10-04 2018-09-04 Bayer Cropscience Aktiengesellschaft Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants
US11412730B2 (en) 2015-06-30 2022-08-16 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Method for the cryopreservation of cells for therapeutic purposes
WO2018108627A1 (en) 2016-12-12 2018-06-21 Bayer Cropscience Aktiengesellschaft Use of substituted indolinylmethyl sulfonamides, or the salts thereof for increasing the stress tolerance of plants
WO2019025153A1 (en) 2017-07-31 2019-02-07 Bayer Cropscience Aktiengesellschaft Use of substituted n-sulfonyl-n'-aryl diaminoalkanes and n-sulfonyl-n'-heteroaryl diaminoalkanes or salts thereof for increasing the stress tolerance in plants
US10501423B2 (en) 2017-10-30 2019-12-10 Neuropore Therapies, Inc. Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
US11008294B2 (en) 2017-10-30 2021-05-18 Neuropore Therapies, Inc. Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
US11708338B2 (en) 2017-10-30 2023-07-25 Neuropore Therapies, Inc. Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
KR20200141718A (en) 2019-06-11 2020-12-21 (주)부흥산업사 Manufacturing method of piperidinyl sulfonyl sulfonamide

Also Published As

Publication number Publication date
TW200719897A (en) 2007-06-01
GT200600199A (en) 2007-02-23
PE20061451A1 (en) 2007-01-22
CA2607326A1 (en) 2006-11-23
WO2006124875A3 (en) 2007-01-18
JP2008540579A (en) 2008-11-20
RU2007141346A (en) 2009-06-20
SV2007002526A (en) 2007-12-12
NO20075781L (en) 2008-02-05
IL187269A0 (en) 2008-02-09
AR057296A1 (en) 2007-11-28
KR20080012361A (en) 2008-02-11
US20060276464A1 (en) 2006-12-07
AU2006247334A1 (en) 2006-11-23
BRPI0610009A2 (en) 2010-05-18
CR9507A (en) 2008-01-10
EP1879859A2 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
WO2006124875A2 (en) Diarylsulfone sulfonamides and use therof
US7632838B2 (en) 11-beta HSD1 inhibitors
JP5215975B2 (en) Acylated indanylamine and its use as a medicament
CN100406007C (en) Asthma and allergic inflammation modulators
DE69503647T2 (en) AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULATING AGENTS
US6143744A (en) Sulfamide-metalloprotease inhibitors
CA2125730C (en) Novel sulfonylamino pyrimidines
RU2234497C2 (en) Sulfonylaminocarboxylic acid sulfur-substituted n-arylamides, method for their preparing (variants), pharmaceutical composition and method for treatment
CA2458533C (en) Imidazole derivates as anti-inflammatory agents
AU730127B2 (en) Sulfamide-metalloprotease inhibitors
KR101462393B1 (en) Inhibitors of c-fms kinase
JP5216341B2 (en) Novel oxadiazole derivatives and thiadiazole derivatives having angiogenesis inhibitory activity
JP4057244B2 (en) Cell adhesion inhibitory anti-inflammatory and immunosuppressive compounds
AU2005317870A1 (en) Pyridine carboxamide derivatives for use as anticancer agents
HU225696B1 (en) N-hydroxycarboxamide derivatives, pharmaceutical compositions containing them, process for the preparation thereof
NO323156B1 (en) Benzophenones and Related Compounds, Use of These Compounds for the Preparation of Medicines for the Treatment of HIV Infections, Pharmaceutical Preparations Containing Such, and These Compounds for Use as a Medication
WO2008061016A1 (en) N-substituted piperidinyl 4 -arylsulfonamides as modulators of the secreted frizzled related protein- 1
BG65426B1 (en) Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp)
CN103772239A (en) Novel amide and amidine derivatives and uses thereof
WO2002055484A1 (en) Biaryl compound, process for producing the same, and agent
DE102004047272A1 (en) Inhibitors of soluble adenylate cyclase
WO2008060998A1 (en) Indole sulfonamides as sfrp-1 modulators
CA2485298C (en) Substituted pyrazolyl compounds for the treatment of inflammation
CN101208299A (en) Diarylsulfone sulfonamides and use therof
WO2008061029A1 (en) Aryl sulfonamide derivatives and methods of their use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680023300.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006770422

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2607326

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006247334

Country of ref document: AU

Ref document number: 8624/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 187269

Country of ref document: IL

Ref document number: 563258

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: CR2007-009507

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2008511473

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/014240

Country of ref document: MX

Ref document number: 12007502529

Country of ref document: PH

Ref document number: 07119461

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006247334

Country of ref document: AU

Date of ref document: 20060512

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007141346

Country of ref document: RU

Ref document number: 1020077029176

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0610009

Country of ref document: BR

Kind code of ref document: A2